PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 30817703-4 2019 The variant of ITPA (inosine triphosphatase), which dephosphorylates inosine triphosphate to inosine monophosphate, is a protective factor for RBV-induced anemia. Ribavirin 143-146 inosine triphosphatase Homo sapiens 15-19 30817703-11 2019 Multiple regression analysis revealed that ITPA genotype and erythrocyte RTP concentrations were major factors associated with reduced Hb levels in RBV therapy for CHC. Ribavirin 148-151 inosine triphosphatase Homo sapiens 43-47 30817703-13 2019 CONCLUSIONS: The increased tolerability to RTP concentrations in erythrocytes in the ITPA variant rs1127354 plays a role in preventing RBV-induced severe anemia in this ITPA variant. Ribavirin 135-138 inosine triphosphatase Homo sapiens 85-89 30817703-13 2019 CONCLUSIONS: The increased tolerability to RTP concentrations in erythrocytes in the ITPA variant rs1127354 plays a role in preventing RBV-induced severe anemia in this ITPA variant. Ribavirin 135-138 inosine triphosphatase Homo sapiens 169-173 31001628-8 2019 Interestingly, ORF2 was detected in plasma from mice that tested negative for HEV RNA in plasma but positive for HEV RNA in stool and was detected after viral clearance in mice that were treated with ribavirin. Ribavirin 200-209 OFD1, centriole and centriolar satellite protein Mus musculus 15-19 31926499-5 2019 This study aimed to assess the relation between NOS2A gene haplotypes and HCV treatment response in pegylated interferon alpha /ribavirin (PEG-IFN /RBV) in chronic HCV patients (CHC) in an attempt to find a predictor biomarker to detect poor responders to therapy. Ribavirin 128-137 nitric oxide synthase 2 Homo sapiens 48-53 31366399-7 2019 RESULTS: We found that PB1-216G viruses had greater mutation potential, and were more sensitive to ribavirin than PB1-216S viruses. Ribavirin 99-108 submaxillary gland androgen regulated protein 3A Homo sapiens 23-26 31926499-5 2019 This study aimed to assess the relation between NOS2A gene haplotypes and HCV treatment response in pegylated interferon alpha /ribavirin (PEG-IFN /RBV) in chronic HCV patients (CHC) in an attempt to find a predictor biomarker to detect poor responders to therapy. Ribavirin 148-151 nitric oxide synthase 2 Homo sapiens 48-53 31143073-14 2019 CONCLUSION: In an all-comers HCV GT1 population, 12 or 24-wk of OBV/PTV/r + DSV +/- RBV is highly effective and tolerable and results in better mental and physical health following treatment. Ribavirin 84-87 beta-1,4-galactosyltransferase 1 Homo sapiens 33-36 31000196-0 2019 Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation. Ribavirin 0-9 mitogen-activated protein kinase 1 Mus musculus 107-110 31000196-0 2019 Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation. Ribavirin 0-9 eukaryotic translation initiation factor 4E Mus musculus 121-126 31000196-2 2019 In this work, we demonstrate that eIF4E inhibition using both ribavirin and siRNA targets NPC cells and enhances the efficacy of 5-fluorouracil (5-FU). Ribavirin 62-71 eukaryotic translation initiation factor 4E Mus musculus 34-39 31081724-11 2019 Based on these findings, ribavirin-induced anti-RR autoantibody seems to be associated with a more frequent nonresponse to IFN-alpha/ribavirin therapy with a significant higher HCV viral load. Ribavirin 25-34 interferon alpha 1 Homo sapiens 123-132 31000196-7 2019 Ribavirin acts on NPC cells via inhibiting eIF4E/Akt signaling, and the suppression of eIF4E by ribavirin are not the consequence of inhibition of eIF4E upstream signaling: Mnk and mTOR. Ribavirin 0-9 eukaryotic translation initiation factor 4E Mus musculus 43-48 31000196-7 2019 Ribavirin acts on NPC cells via inhibiting eIF4E/Akt signaling, and the suppression of eIF4E by ribavirin are not the consequence of inhibition of eIF4E upstream signaling: Mnk and mTOR. Ribavirin 0-9 thymoma viral proto-oncogene 1 Mus musculus 49-52 31000196-7 2019 Ribavirin acts on NPC cells via inhibiting eIF4E/Akt signaling, and the suppression of eIF4E by ribavirin are not the consequence of inhibition of eIF4E upstream signaling: Mnk and mTOR. Ribavirin 96-105 eukaryotic translation initiation factor 4E Mus musculus 87-92 31000196-7 2019 Ribavirin acts on NPC cells via inhibiting eIF4E/Akt signaling, and the suppression of eIF4E by ribavirin are not the consequence of inhibition of eIF4E upstream signaling: Mnk and mTOR. Ribavirin 96-105 eukaryotic translation initiation factor 4E Mus musculus 87-92 30929914-6 2019 We identify eIF4E as a therapeutically actionable targets by showing that ribavirin, an anti-viral drug, phenocopies the effects of eIF4E knockdown in NPC. Ribavirin 74-83 eukaryotic translation initiation factor 4E Mus musculus 12-17 30929914-6 2019 We identify eIF4E as a therapeutically actionable targets by showing that ribavirin, an anti-viral drug, phenocopies the effects of eIF4E knockdown in NPC. Ribavirin 74-83 eukaryotic translation initiation factor 4E Mus musculus 132-137 30929914-7 2019 We further demonstrate that ribavirin acts on chemoresistant NPC cells through suppressing eIF4E activity and oncogenic protein translation. Ribavirin 28-37 eukaryotic translation initiation factor 4E Mus musculus 91-96 31383827-2 2019 HCV mutation in NS5A-ISDR/PKR-BD region improved the outcome in HCV monoinfection treated with Peg-IFN/RBV. Ribavirin 103-106 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 26-29 30716294-4 2019 Our data indicate that ENT1 participates in uptake of ribavirin by BeWo cells, fresh human placental villous fragments and microvillous plasma membrane (MVM) vesicles while activity of CNTs (probably CNT2) was only observed in BeWo cells. Ribavirin 54-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 23-27 30716294-7 2019 In summary, our data show that ribavirin placental pharmacokinetics are largely controlled by ENT1 activity and independent of ABCB1, ABCG2, and ABCC2 efflux pumps. Ribavirin 31-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-98 31360020-3 2019 Methods: Between September 2016 and June 2017, data from the 359 participants who completed treatment with SOF/VEL (+- RBV) for 12-24 weeks were analyzed. Ribavirin 119-122 small integral membrane protein 1 (Vel blood group) Homo sapiens 107-114 31360020-9 2019 Conclusions: In Myanmar, generic and pan-genotypic SOF/VEL +- RBV is a highly effective and safe treatment for HCV, regardless of the HCV genotype, and therefore, the requirement for the baseline genotype can be eliminated. Ribavirin 62-65 small integral membrane protein 1 (Vel blood group) Homo sapiens 55-58 30422370-7 2019 Genotype 2/3 (G2/3) (n = 57) received peg-interferon+ribavirin. Ribavirin 53-62 crystallin gamma E, pseudogene Homo sapiens 0-18 31383827-5 2019 The aim of the study is to determine the role of HCV NS5A-ISDR/PKR-BD mutation and SNP IL-28 polymorphism on the successfulness of Peg-IFN/RBV therapy in HCV-HIV coinfection. Ribavirin 139-142 interferon lambda 3 Homo sapiens 87-92 30739792-2 2019 In this work, we demonstrate that eIF4E inhibition in ovarian cancer can be achieved by ribavirin, a FDA-approved antiviral drug. Ribavirin 88-97 eukaryotic translation initiation factor 4E Homo sapiens 34-39 30739792-4 2019 Mechanistically, ribavirin suppresses Akt/mTOR and eIF4E/p70S6K signaling pathways in ovarian cancer cells. Ribavirin 17-26 AKT serine/threonine kinase 1 Homo sapiens 38-41 30739792-4 2019 Mechanistically, ribavirin suppresses Akt/mTOR and eIF4E/p70S6K signaling pathways in ovarian cancer cells. Ribavirin 17-26 mechanistic target of rapamycin kinase Homo sapiens 42-46 30739792-4 2019 Mechanistically, ribavirin suppresses Akt/mTOR and eIF4E/p70S6K signaling pathways in ovarian cancer cells. Ribavirin 17-26 eukaryotic translation initiation factor 4E Homo sapiens 51-56 30739792-4 2019 Mechanistically, ribavirin suppresses Akt/mTOR and eIF4E/p70S6K signaling pathways in ovarian cancer cells. Ribavirin 17-26 ribosomal protein S6 kinase B1 Homo sapiens 57-63 30739792-5 2019 We confirm that eIF4E is the critical molecular target of ribavirin, and furthermore that this is dependent on phosphorylation at S209. Ribavirin 58-67 eukaryotic translation initiation factor 4E Homo sapiens 16-21 30739792-7 2019 Interestingly, the sensitivity to ribavirin varies among a panel of ovarian cancer cell lines, mostly likely due to their differential expression level of eIF4E and dependency to eIF4E inhibition. Ribavirin 34-43 eukaryotic translation initiation factor 4E Homo sapiens 155-160 30739792-7 2019 Interestingly, the sensitivity to ribavirin varies among a panel of ovarian cancer cell lines, mostly likely due to their differential expression level of eIF4E and dependency to eIF4E inhibition. Ribavirin 34-43 eukaryotic translation initiation factor 4E Homo sapiens 179-184 30739792-10 2019 Additionally, ribavirin is a useful addition to ovarian cancer treatment, particularly to those with high dependency on eIF4E. Ribavirin 14-23 eukaryotic translation initiation factor 4E Homo sapiens 120-125 30763062-2 2019 Previously, we discovered a novel form of cancer drug resistance where the Glioma-associated protein 1 (GLI1) elevates UGT1A glucuronidation enzymes, thereby glucuronidating cytarabine and ribavirin, leading to resistance in leukemia patients. Ribavirin 189-198 GLI family zinc finger 1 Homo sapiens 75-102 30763062-2 2019 Previously, we discovered a novel form of cancer drug resistance where the Glioma-associated protein 1 (GLI1) elevates UGT1A glucuronidation enzymes, thereby glucuronidating cytarabine and ribavirin, leading to resistance in leukemia patients. Ribavirin 189-198 GLI family zinc finger 1 Homo sapiens 104-108 30763062-2 2019 Previously, we discovered a novel form of cancer drug resistance where the Glioma-associated protein 1 (GLI1) elevates UGT1A glucuronidation enzymes, thereby glucuronidating cytarabine and ribavirin, leading to resistance in leukemia patients. Ribavirin 189-198 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 119-124 30988680-0 2019 The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin. Ribavirin 147-156 interferon lambda 3 Homo sapiens 4-19 30450781-2 2019 In this phase 3b open-label study, we assessed changes in IFN-stimulated genes (ISGs) in non-cirrhotic treatment-naive or pegIFN/RBV-experienced HCV-GT1a-infected patients receiving paritaprevir/ritonavir/ombitasvir + dasabuvir + ribavirin (PrOD + R) for 12 weeks. Ribavirin 129-132 interferon alpha 1 Homo sapiens 58-61 30450781-2 2019 In this phase 3b open-label study, we assessed changes in IFN-stimulated genes (ISGs) in non-cirrhotic treatment-naive or pegIFN/RBV-experienced HCV-GT1a-infected patients receiving paritaprevir/ritonavir/ombitasvir + dasabuvir + ribavirin (PrOD + R) for 12 weeks. Ribavirin 230-239 interferon alpha 1 Homo sapiens 58-61 30478448-0 2019 Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Ribavirin 31-40 eukaryotic translation initiation factor 4E Homo sapiens 10-15 30478448-2 2019 Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment. Ribavirin 135-144 eukaryotic translation initiation factor 4E Homo sapiens 22-27 30478448-2 2019 Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment. Ribavirin 135-144 eukaryotic translation initiation factor 4E Homo sapiens 85-90 30478448-2 2019 Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment. Ribavirin 135-144 eukaryotic translation initiation factor 4E Homo sapiens 85-90 30478448-3 2019 We find that ribavirin treatment of actively dividing infant ALL cells on bone marrow stromal cells (BMSCs) at clinically achievable concentrations causes robust proliferation inhibition in proportion with EIF4E expression. Ribavirin 13-22 eukaryotic translation initiation factor 4E Homo sapiens 206-211 30478448-4 2019 Further, we find that ribavirin treatment of KMT2A-rearranged (KMT2A-R) infant ALL cells and the KMT2A-AFF1 cell line RS4:11 inhibits EIF4E, leading to decreases in oncogenic EIF4E-regulated cell growth and survival proteins. Ribavirin 22-31 eukaryotic translation initiation factor 4E Homo sapiens 134-139 30478448-4 2019 Further, we find that ribavirin treatment of KMT2A-rearranged (KMT2A-R) infant ALL cells and the KMT2A-AFF1 cell line RS4:11 inhibits EIF4E, leading to decreases in oncogenic EIF4E-regulated cell growth and survival proteins. Ribavirin 22-31 eukaryotic translation initiation factor 4E Homo sapiens 175-180 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 3-12 eukaryotic translation initiation factor 4E Homo sapiens 66-71 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 3-12 MYC proto-oncogene, bHLH transcription factor Homo sapiens 163-166 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 3-12 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 168-172 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 3-12 nibrin Homo sapiens 174-177 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 3-12 BCL2 apoptosis regulator Homo sapiens 179-183 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 3-12 baculoviral IAP repeat containing 5 Homo sapiens 188-193 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 135-144 eukaryotic translation initiation factor 4E Homo sapiens 66-71 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 135-144 MYC proto-oncogene, bHLH transcription factor Homo sapiens 163-166 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 135-144 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 168-172 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 135-144 nibrin Homo sapiens 174-177 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 135-144 BCL2 apoptosis regulator Homo sapiens 179-183 30478448-5 2019 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin 135-144 baculoviral IAP repeat containing 5 Homo sapiens 188-193 30478448-6 2019 Ribavirin-treated RS4:11 cells exhibit impaired EIF4E-dependent nuclear to cytoplasmic export and/or translation of the corresponding mRNAs, as well as reduced phosphorylation of the p-AKT1, p-EIF4EBP1, p-RPS6 and p-EIF4E signaling proteins. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 48-53 30478448-6 2019 Ribavirin-treated RS4:11 cells exhibit impaired EIF4E-dependent nuclear to cytoplasmic export and/or translation of the corresponding mRNAs, as well as reduced phosphorylation of the p-AKT1, p-EIF4EBP1, p-RPS6 and p-EIF4E signaling proteins. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 193-198 30478448-8 2019 Ribavirin causes nuclear EIF4E to re-localize to the cytoplasm in KMT2A-AFF1 infant ALL and RS4:11 cells, providing further evidence for EIF4E inhibition. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 25-30 30478448-8 2019 Ribavirin causes nuclear EIF4E to re-localize to the cytoplasm in KMT2A-AFF1 infant ALL and RS4:11 cells, providing further evidence for EIF4E inhibition. Ribavirin 0-9 lysine methyltransferase 2A Homo sapiens 66-76 30478448-8 2019 Ribavirin causes nuclear EIF4E to re-localize to the cytoplasm in KMT2A-AFF1 infant ALL and RS4:11 cells, providing further evidence for EIF4E inhibition. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 137-142 30478448-10 2019 Ribavirin cooperates with chemotherapy, particularly L-asparaginase, in reducing live KMT2A-AFF1 infant ALL cells in BMSC co-cultures. Ribavirin 0-9 asparaginase and isoaspartyl peptidase 1 Homo sapiens 53-67 30478448-10 2019 Ribavirin cooperates with chemotherapy, particularly L-asparaginase, in reducing live KMT2A-AFF1 infant ALL cells in BMSC co-cultures. Ribavirin 0-9 lysine methyltransferase 2A Homo sapiens 86-96 30478448-11 2019 This work establishes that EIF4E is broadly elevated across infant ALL and that clinically relevant ribavirin exposures have preclinical activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment. Ribavirin 100-109 eukaryotic translation initiation factor 4E Homo sapiens 170-175 30478448-11 2019 This work establishes that EIF4E is broadly elevated across infant ALL and that clinically relevant ribavirin exposures have preclinical activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment. Ribavirin 100-109 eukaryotic translation initiation factor 4E Homo sapiens 170-175 30478448-11 2019 This work establishes that EIF4E is broadly elevated across infant ALL and that clinically relevant ribavirin exposures have preclinical activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment. Ribavirin 238-247 eukaryotic translation initiation factor 4E Homo sapiens 27-32 30988680-1 2019 Background: The present study aimed to determine the frequency of the IL28B polymorphism rs8099917 in patients with genotype 1 hepatitis C virus (HCV) infection treated with pegylated-interferon-alpha2b (PEG-IFN-alpha2b) and ribavirin (RBV) and its treatment outcome. Ribavirin 225-234 interferon lambda 3 Homo sapiens 70-75 30988680-1 2019 Background: The present study aimed to determine the frequency of the IL28B polymorphism rs8099917 in patients with genotype 1 hepatitis C virus (HCV) infection treated with pegylated-interferon-alpha2b (PEG-IFN-alpha2b) and ribavirin (RBV) and its treatment outcome. Ribavirin 236-239 interferon lambda 3 Homo sapiens 70-75 30552141-0 2019 Ribavirin-induced down-regulation of CCAAT/enhancer-binding protein alpha leads to suppression of lipogenesis. Ribavirin 0-9 CCAAT enhancer binding protein alpha Homo sapiens 37-73 30446175-2 2019 Ribavirin aggregates/induces antigenic changes in IMPDH-2, an enzyme necessary for ribavirin action. Ribavirin 0-9 inosine monophosphate dehydrogenase 2 Homo sapiens 50-57 30446175-2 2019 Ribavirin aggregates/induces antigenic changes in IMPDH-2, an enzyme necessary for ribavirin action. Ribavirin 83-92 inosine monophosphate dehydrogenase 2 Homo sapiens 50-57 30552141-4 2019 Treatment with proteasome inhibitor attenuated RBV-induced down-regulation of C/EBPalpha, suggesting that RBV promoted degradation of C/EBPalpha protein via the ubiquitin-proteasome pathway. Ribavirin 47-50 CCAAT enhancer binding protein alpha Homo sapiens 78-88 30552141-1 2019 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) had the ability to suppress lipogenesis through down-regulation of retinoid X receptor alpha (RXRalpha) under the control of the intracellular GTP-level and AMP-activated protein kinase-related kinases, especially microtubule affinity regulating kinase 4 (MARK4). Ribavirin 51-60 retinoid X receptor alpha Homo sapiens 134-159 30552141-4 2019 Treatment with proteasome inhibitor attenuated RBV-induced down-regulation of C/EBPalpha, suggesting that RBV promoted degradation of C/EBPalpha protein via the ubiquitin-proteasome pathway. Ribavirin 47-50 CCAAT enhancer binding protein alpha Homo sapiens 134-144 30552141-4 2019 Treatment with proteasome inhibitor attenuated RBV-induced down-regulation of C/EBPalpha, suggesting that RBV promoted degradation of C/EBPalpha protein via the ubiquitin-proteasome pathway. Ribavirin 106-109 CCAAT enhancer binding protein alpha Homo sapiens 78-88 30552141-4 2019 Treatment with proteasome inhibitor attenuated RBV-induced down-regulation of C/EBPalpha, suggesting that RBV promoted degradation of C/EBPalpha protein via the ubiquitin-proteasome pathway. Ribavirin 106-109 CCAAT enhancer binding protein alpha Homo sapiens 134-144 30552141-1 2019 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) had the ability to suppress lipogenesis through down-regulation of retinoid X receptor alpha (RXRalpha) under the control of the intracellular GTP-level and AMP-activated protein kinase-related kinases, especially microtubule affinity regulating kinase 4 (MARK4). Ribavirin 51-60 retinoid X receptor alpha Homo sapiens 161-169 30552141-5 2019 Depletion of intracellular GTP through inosine monophosphate dehydrogenase inhibition by RBV led to down-regulation of C/EBPalpha. Ribavirin 89-92 CCAAT enhancer binding protein alpha Homo sapiens 119-129 30552141-1 2019 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) had the ability to suppress lipogenesis through down-regulation of retinoid X receptor alpha (RXRalpha) under the control of the intracellular GTP-level and AMP-activated protein kinase-related kinases, especially microtubule affinity regulating kinase 4 (MARK4). Ribavirin 51-60 microtubule affinity regulating kinase 4 Homo sapiens 323-328 30552141-6 2019 In contrast, down-regulation of C/EBPalpha by RBV was independent of RXRalpha and MARK4. Ribavirin 46-49 CCAAT enhancer binding protein alpha Homo sapiens 32-42 30552141-11 2019 These data suggest that down-regulation of C/EBPalpha by RBV leads to the reduction in GPAM expression, which contributes to the suppression of lipogenesis. Ribavirin 57-60 CCAAT enhancer binding protein alpha Homo sapiens 43-53 30552141-1 2019 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) had the ability to suppress lipogenesis through down-regulation of retinoid X receptor alpha (RXRalpha) under the control of the intracellular GTP-level and AMP-activated protein kinase-related kinases, especially microtubule affinity regulating kinase 4 (MARK4). Ribavirin 62-65 retinoid X receptor alpha Homo sapiens 134-159 30552141-1 2019 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) had the ability to suppress lipogenesis through down-regulation of retinoid X receptor alpha (RXRalpha) under the control of the intracellular GTP-level and AMP-activated protein kinase-related kinases, especially microtubule affinity regulating kinase 4 (MARK4). Ribavirin 62-65 retinoid X receptor alpha Homo sapiens 161-169 30552141-1 2019 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) had the ability to suppress lipogenesis through down-regulation of retinoid X receptor alpha (RXRalpha) under the control of the intracellular GTP-level and AMP-activated protein kinase-related kinases, especially microtubule affinity regulating kinase 4 (MARK4). Ribavirin 62-65 microtubule affinity regulating kinase 4 Homo sapiens 323-328 30141214-9 2018 Patients with GT1 and GT3 treated with sofosbuvir/ribavirin (SR) had 88% and 89% SVR12, respectively, but those GT6 treated with sofosbuvir/ledipasvir (SL) had only 77.6% SVR12. Ribavirin 50-59 beta-1,4-galactosyltransferase 1 Homo sapiens 14-17 30201505-2 2019 In chronic hepatitis, patients not responding to interferon/ribavirin treatment had high levels of an antagonist form of IP-10. Ribavirin 60-69 C-X-C motif chemokine ligand 10 Homo sapiens 121-126 31685739-1 2019 Recently, a clinical study using a Chronic Liver Disease Questionnaire (CLDQ) showed that ledipasvir/sofosbuvir (LDV/SOF)-treated patients" QOL was more favorable than that of IFN/ribavirin (RBV)-treated patients. Ribavirin 191-194 interferon alpha 1 Homo sapiens 176-189 30027841-1 2019 Genetic polymorphisms within the interferon lambda (IFN-lambda) chromosomal region, mainly rs12979860 of IFN-lambda4 gene (IFNL4), are known as associated with spontaneous hepatitis C virus (HCV) resolution and sustained viral response to therapy with pegylated interferon- alpha and ribavirin. Ribavirin 284-293 interferon lambda 3 Homo sapiens 105-116 30027841-1 2019 Genetic polymorphisms within the interferon lambda (IFN-lambda) chromosomal region, mainly rs12979860 of IFN-lambda4 gene (IFNL4), are known as associated with spontaneous hepatitis C virus (HCV) resolution and sustained viral response to therapy with pegylated interferon- alpha and ribavirin. Ribavirin 284-293 interferon lambda 4 (gene/pseudogene) Homo sapiens 123-128 30312466-9 2019 The RBV of l-Lys sulfate relative to l-Lys HCl was 106%, 119%, and 117% for effects on ADG, G:F, and plasma urea, respectively. Ribavirin 4-7 ADG Sus scrofa 87-90 30592759-7 2018 Serum concentrations of SEMA3C and SEMA6D significantly decreased after DAA and PEG IFN-alpha/ribavirin therapy, while the serum concentration of SEMA5A significantly increased after DAAs therapy. Ribavirin 94-103 semaphorin 3C Homo sapiens 24-30 30592759-7 2018 Serum concentrations of SEMA3C and SEMA6D significantly decreased after DAA and PEG IFN-alpha/ribavirin therapy, while the serum concentration of SEMA5A significantly increased after DAAs therapy. Ribavirin 94-103 semaphorin 6D Homo sapiens 35-41 30507970-8 2018 Increased IP-10 serum levels were associated with therapeutic non-response to antiviral treatment with pegylated-interferon and ribavirin. Ribavirin 128-137 C-X-C motif chemokine ligand 10 Homo sapiens 10-15 30454696-7 2018 We further showed that ribavirin acted on osteosarcoma largely via targeting eIF4E. Ribavirin 23-32 eukaryotic translation initiation factor 4E Homo sapiens 77-82 30454696-8 2018 In addition to eIF4E, ribavirin also modulated phosphorylation of Erk and expression of EZH2 and Snail without affecting Akt and mTOR. Ribavirin 22-31 snail family transcriptional repressor 1 Homo sapiens 97-102 30454696-8 2018 In addition to eIF4E, ribavirin also modulated phosphorylation of Erk and expression of EZH2 and Snail without affecting Akt and mTOR. Ribavirin 22-31 mitogen-activated protein kinase 1 Homo sapiens 66-69 30454696-9 2018 Lastly, we found that eIF4E expression and phosphorylation were elevated in osteosarcoma compared to normal cells, which might explain the selective anti-osteosarcoma activity of ribavirin. Ribavirin 179-188 eukaryotic translation initiation factor 4E Homo sapiens 22-27 30454696-10 2018 eIF4E depletion mimics the inhibitory effects of ribavirin, further confirm that eIF4E is the essential target of ribavirin in osteosarcoma. Ribavirin 49-58 eukaryotic translation initiation factor 4E Homo sapiens 0-5 30454696-8 2018 In addition to eIF4E, ribavirin also modulated phosphorylation of Erk and expression of EZH2 and Snail without affecting Akt and mTOR. Ribavirin 22-31 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 88-92 30454696-10 2018 eIF4E depletion mimics the inhibitory effects of ribavirin, further confirm that eIF4E is the essential target of ribavirin in osteosarcoma. Ribavirin 49-58 eukaryotic translation initiation factor 4E Homo sapiens 81-86 30454696-10 2018 eIF4E depletion mimics the inhibitory effects of ribavirin, further confirm that eIF4E is the essential target of ribavirin in osteosarcoma. Ribavirin 114-123 eukaryotic translation initiation factor 4E Homo sapiens 0-5 30454696-10 2018 eIF4E depletion mimics the inhibitory effects of ribavirin, further confirm that eIF4E is the essential target of ribavirin in osteosarcoma. Ribavirin 114-123 eukaryotic translation initiation factor 4E Homo sapiens 81-86 29959920-3 2018 We show that ribavirin, an anti-viral drug and pharmacological eIF4E inhibitor, effectively inhibits proliferation and decreases viability of paclitaxel-resistant cervical cancer and 5-FU-resistant colon cancer cells while is less toxic to human fibroblast cells. Ribavirin 13-22 eukaryotic translation initiation factor 4E Homo sapiens 63-68 30383478-0 2018 Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population. Ribavirin 76-85 interferon lambda 3 Homo sapiens 20-26 30516500-0 2018 CLINICAL-PATHOGENETICAL ROLE OF DYNAMICS OF CONCENTRATION OF INTERLEUKIN-6 DEPENDING ON POLYMORPHISM OF ITS GENE IN CONDUCTING ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C. The study included 83 patients with CHC who received antiviral therapy according to the EASL 2016 recommendations on a 12-week peg-IFN+SOF+RBV schedule. Ribavirin 322-325 interleukin 6 Homo sapiens 61-74 30516500-3 2018 In patients with CHC, the genotype CC of the polymorphism of the IL-6 gene was associated with fluctuations in the concentration of IL-6 in the blood within the reference range, which was prognostically favorable for the formation of SVR 24 for AVT according to the peg-IFNalpha + SOF + RBV. Ribavirin 287-290 interleukin 6 Homo sapiens 65-69 30516500-3 2018 In patients with CHC, the genotype CC of the polymorphism of the IL-6 gene was associated with fluctuations in the concentration of IL-6 in the blood within the reference range, which was prognostically favorable for the formation of SVR 24 for AVT according to the peg-IFNalpha + SOF + RBV. Ribavirin 287-290 interleukin 6 Homo sapiens 132-136 30516500-5 2018 The ineffectiveness of AVT according to the scheme peg-IFNalpha+SOF+RBV was associated with the presence of CG/GG genotypes and the highest concentration of IL-6 in the blood. Ribavirin 68-71 interleukin 6 Homo sapiens 157-161 30055200-5 2018 During a 48-week course of treatment with peg-IFN-a2a plus ribavirin, dynamic changes in the frequencies of CD8+CD28-PD1+ T cells were observed, associated with the virologic response. Ribavirin 59-68 CD8a molecule Homo sapiens 108-111 29959920-6 2018 We further confirm that the mechanism of the action of ribavirin in chemoresistant cancer cells is through suppressing eIF4E function. Ribavirin 55-64 eukaryotic translation initiation factor 4E Homo sapiens 119-124 29959920-7 2018 In addition, specific eIF4E knockdown via two independent siRNA mimics the effects of ribavirin in chemoresistant colon and cervical cancer cells. Ribavirin 86-95 eukaryotic translation initiation factor 4E Homo sapiens 22-27 29959920-8 2018 Cell cycle analysis indicate that ribavirin enhances the anti-proliferative effect of 5-FU by additionally arresting cells at G2/M phase via increasing cyclin B1, p-histone H3(Ser10) and Mad2 levels. Ribavirin 34-43 cyclin B1 Homo sapiens 152-161 29959920-8 2018 Cell cycle analysis indicate that ribavirin enhances the anti-proliferative effect of 5-FU by additionally arresting cells at G2/M phase via increasing cyclin B1, p-histone H3(Ser10) and Mad2 levels. Ribavirin 34-43 mitotic arrest deficient 2 like 1 Homo sapiens 187-191 30245117-8 2018 PATIENTS AND METHODS: The functional SNPs in PKR promoter region were detected using DNA sequencing in 40 HCV infected patients; 20 sustained virologic response (SVR) patients and 20 nonresponse (NR) patients after combined interferon/ribavirin therapy. Ribavirin 235-244 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 45-48 30045981-2 2018 Reduced ITPase activity was earlier reported to protect against ribavirin-induced hemolytic anemia and to diminish relapse following ribavirin and interferon therapy for hepatitis C virus (HCV) genotype 2 or 3 infections. Ribavirin 64-73 inosine triphosphatase Homo sapiens 8-14 30045981-2 2018 Reduced ITPase activity was earlier reported to protect against ribavirin-induced hemolytic anemia and to diminish relapse following ribavirin and interferon therapy for hepatitis C virus (HCV) genotype 2 or 3 infections. Ribavirin 133-142 inosine triphosphatase Homo sapiens 8-14 30045981-4 2018 The in vitro effect of reduced ITPase activity was assessed by means of transfection of hepatocytes (Huh7.5 cells) with a small interfering RNA (siRNA) directed against ITPA or a negative-control siRNA in the presence or absence of ribavirin in an HCV culture system. Ribavirin 232-241 inosine triphosphatase Homo sapiens 31-37 30045981-7 2018 Our results extend the understanding of the biological impact of reduced ITPase activity, demonstrate that RTP is a substrate of ITPase, and may point to personalized ribavirin dosage according to ITPA genotype in addition to novel antiviral strategies.IMPORTANCE This study highlights the multiple modes of action of ribavirin, including depletion of intracellular GTP and increased hepatitis C virus mutagenesis. Ribavirin 167-176 inosine triphosphatase Homo sapiens 73-79 30045981-7 2018 Our results extend the understanding of the biological impact of reduced ITPase activity, demonstrate that RTP is a substrate of ITPase, and may point to personalized ribavirin dosage according to ITPA genotype in addition to novel antiviral strategies.IMPORTANCE This study highlights the multiple modes of action of ribavirin, including depletion of intracellular GTP and increased hepatitis C virus mutagenesis. Ribavirin 318-327 inosine triphosphatase Homo sapiens 129-135 30045981-8 2018 In cell culture, reduced ITP pyrophosphatase (ITPase) enzyme activity affected the intracellular concentrations of ribavirin triphosphate (RTP) and augmented the impact of ribavirin on the mutation rate and virus production. Ribavirin 115-124 inosine triphosphatase Homo sapiens 25-44 30045981-8 2018 In cell culture, reduced ITP pyrophosphatase (ITPase) enzyme activity affected the intracellular concentrations of ribavirin triphosphate (RTP) and augmented the impact of ribavirin on the mutation rate and virus production. Ribavirin 115-124 inosine triphosphatase Homo sapiens 46-52 29958924-12 2018 Additionally, using the developed ELISA nsP1 assay, the inhibitory effects of sinefungin, aurintricarboxylic acid (ATA) and ribavirin were determined and the IC50 values were estimated to be 2.69 muM, 5.72 muM and 1.18 mM, respectively. Ribavirin 124-133 SH2 domain containing 3A Homo sapiens 40-44 30063745-14 2018 CONCLUSIONS: Our real-world results validate the efficacy of current GT3 IFN-free regimens suggesting that, among patients with severe disease, Peg/IFN/RBV experience and NS5A associated RASs are predictors of relapse. Ribavirin 152-155 interferon alpha 1 Homo sapiens 73-76 29660762-1 2018 BACKGROUND: Inosine triphosphate pyrophosphatase (ITPA) gene single nucleotide polymorphisms (SNPs), rs1127354 and rs7270101, may cause a functional impairment in ITPase enzyme, resulting anemia protection in patients with chronic hepatitis C virus (HCV) infection undergoing ribavirin (RBV)-dependent regimens. Ribavirin 276-285 inosine triphosphatase Homo sapiens 12-48 29660762-1 2018 BACKGROUND: Inosine triphosphate pyrophosphatase (ITPA) gene single nucleotide polymorphisms (SNPs), rs1127354 and rs7270101, may cause a functional impairment in ITPase enzyme, resulting anemia protection in patients with chronic hepatitis C virus (HCV) infection undergoing ribavirin (RBV)-dependent regimens. Ribavirin 276-285 inosine triphosphatase Homo sapiens 50-54 29660762-1 2018 BACKGROUND: Inosine triphosphate pyrophosphatase (ITPA) gene single nucleotide polymorphisms (SNPs), rs1127354 and rs7270101, may cause a functional impairment in ITPase enzyme, resulting anemia protection in patients with chronic hepatitis C virus (HCV) infection undergoing ribavirin (RBV)-dependent regimens. Ribavirin 287-290 inosine triphosphatase Homo sapiens 12-48 29660762-1 2018 BACKGROUND: Inosine triphosphate pyrophosphatase (ITPA) gene single nucleotide polymorphisms (SNPs), rs1127354 and rs7270101, may cause a functional impairment in ITPase enzyme, resulting anemia protection in patients with chronic hepatitis C virus (HCV) infection undergoing ribavirin (RBV)-dependent regimens. Ribavirin 287-290 inosine triphosphatase Homo sapiens 50-54 30145562-3 2018 OBJECTIVE: Report the virological response and safety of LDV/SOF with/without RBV for 12-24 weeks in treating HCV GT1 relapsers after SMV + SOF. Ribavirin 78-81 beta-1,4-galactosyltransferase 1 Homo sapiens 114-117 30145562-13 2018 CONCLUSIONS: Treatment with LDV/SOF with/without RBV for 12-24 weeks was very well tolerated and resulted in high SVR 12 rates (96%) in HCV GT1 relapsers to SMV + SOF treatment. Ribavirin 49-52 beta-1,4-galactosyltransferase 1 Homo sapiens 140-143 29861209-5 2018 RESULTS: Current RGT suggested 24 weeks of PegIFN/RBV for G1 naive patients with baseline LVL and RVR at treatment week 4 achieved an average treatment cost per SVR of $5090 +- 2400. Ribavirin 50-53 nuclear receptor subfamily 1 group D member 2 Homo sapiens 98-101 29861209-7 2018 In terms of G2 patients, according to current RGT of 16 weeks of treatment duration, PegIFN/RBV treatment with RVR achieved was of a very competitive cost per SVR ($3237 +- 488). Ribavirin 92-95 nuclear receptor subfamily 1 group D member 2 Homo sapiens 111-114 30127629-10 2018 Conclusion: Relapse with GZR and peginterferon/ribavirin is commonly associated with single RASs in NS3 that generally revert to WT, while breakthrough follows more complex patterns of viral resistance. Ribavirin 47-56 KRAS proto-oncogene, GTPase Homo sapiens 100-103 30116347-7 2018 In conclusion, the present meta-analysis indicated that treatment with peg IFN + ribavirin or interferon only is associated with a wide range of neuropsychiatric side effects, including fatigue, mood disorders, anxiety, irritability, emotional ability and agitation. Ribavirin 81-90 interferon alpha 1 Homo sapiens 75-78 29715527-2 2018 We assessed the correlation of five single nucleotide polymorphisms (SNPs) of CD81 (rs800136, rs2651842, rs2522012, rs800146, and rs708564) and SCARB1 rs10846744 polymorphisms with treatment responses in 395 treatment-naive patients with chronic HCV (CHC) genotype 1 treated with pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV). Ribavirin 311-320 CD81 molecule Homo sapiens 78-82 29288514-11 2018 CONCLUSION: A 12-week regimen of OBV/PTV/r +- DSV with or without RBV is highly effective with a favourable safety profile amongst GT4 and GT1 patients with CKD stages 4-5. Ribavirin 66-69 beta-1,4-galactosyltransferase 1 Homo sapiens 139-142 29580856-0 2018 Induction of inosine triphosphatase activity during ribavirin treatment for chronic hepatitis C. BACKGROUND: Ribavirin (RBV) is an antiviral agent and the primary component for chronic hepatitis C (CHC) therapy. Ribavirin 52-61 inosine triphosphatase Homo sapiens 13-35 29705128-2 2018 In chronic hepatitis C virus (HCV) infections, where the IFNL variants were first identified to be associated with response to interferon-alpha-ribavirin therapy, the available data clearly suggests that the causal variant could be the dinucleotide polymorphism rs368234815 that causes an open reading frame-shift in the IFNL4 gene resulting in expression of a functional IFN-lambda4, a new type III IFN. Ribavirin 144-153 interferon lambda 3 Homo sapiens 372-383 29580856-0 2018 Induction of inosine triphosphatase activity during ribavirin treatment for chronic hepatitis C. BACKGROUND: Ribavirin (RBV) is an antiviral agent and the primary component for chronic hepatitis C (CHC) therapy. Ribavirin 109-118 inosine triphosphatase Homo sapiens 13-35 29580856-0 2018 Induction of inosine triphosphatase activity during ribavirin treatment for chronic hepatitis C. BACKGROUND: Ribavirin (RBV) is an antiviral agent and the primary component for chronic hepatitis C (CHC) therapy. Ribavirin 120-123 inosine triphosphatase Homo sapiens 13-35 29580856-2 2018 Inosine triphosphatase (ITPA) activity has been associated with severity of RBV-induced anemia. Ribavirin 76-79 inosine triphosphatase Homo sapiens 0-22 29580856-2 2018 Inosine triphosphatase (ITPA) activity has been associated with severity of RBV-induced anemia. Ribavirin 76-79 inosine triphosphatase Homo sapiens 24-28 29580856-4 2018 The aim of this study was to measure the time-dependent change in ITPA activity over the RBV treatment. Ribavirin 89-92 inosine triphosphatase Homo sapiens 66-70 29580856-6 2018 RESULTS: The median value of ITPA activity at start of RBV treatment was 134.2 mumol/h/g hemoglobin (Hb; range, 26.3-251.0 mumol/h/g Hb). Ribavirin 55-58 inosine triphosphatase Homo sapiens 29-33 29580856-7 2018 The ITPA activity values at 4, 8, and 12 weeks during RBV treatment were 143.2, 202.2, and 225.7 mumol/h/g Hb, respectively, and these ITPA values were significantly elevated compared with the start of treatment (p < 0.001). Ribavirin 54-57 inosine triphosphatase Homo sapiens 4-8 29580856-7 2018 The ITPA activity values at 4, 8, and 12 weeks during RBV treatment were 143.2, 202.2, and 225.7 mumol/h/g Hb, respectively, and these ITPA values were significantly elevated compared with the start of treatment (p < 0.001). Ribavirin 54-57 inosine triphosphatase Homo sapiens 135-139 29580856-9 2018 CONCLUSION: Our findings indicate that ITPA activities are elevated with RBV therapy, and this elevation may be a risk of anemia in late therapeutic phase in patients that began with low ITPA activity. Ribavirin 73-76 inosine triphosphatase Homo sapiens 39-43 29580856-9 2018 CONCLUSION: Our findings indicate that ITPA activities are elevated with RBV therapy, and this elevation may be a risk of anemia in late therapeutic phase in patients that began with low ITPA activity. Ribavirin 73-76 inosine triphosphatase Homo sapiens 187-191 29086249-4 2018 We firstly inhibited eIF4E activity by ribavirin in two cell lines (Caki-1 and ACHN) representing RCC metastasis models. Ribavirin 39-48 eukaryotic translation initiation factor 4E Homo sapiens 21-26 30174840-8 2018 Of note, the sensitivity of esophageal cancer cells to ribavirin or eIF4E knockdown correlates well with the expression levels of eIF4E, demonstrating that esophageal cells with higher eIF4E expression are more sensitive to eIF4E inhibition. Ribavirin 55-64 eukaryotic translation initiation factor 4E Homo sapiens 130-135 30174840-8 2018 Of note, the sensitivity of esophageal cancer cells to ribavirin or eIF4E knockdown correlates well with the expression levels of eIF4E, demonstrating that esophageal cells with higher eIF4E expression are more sensitive to eIF4E inhibition. Ribavirin 55-64 eukaryotic translation initiation factor 4E Homo sapiens 130-135 30174840-8 2018 Of note, the sensitivity of esophageal cancer cells to ribavirin or eIF4E knockdown correlates well with the expression levels of eIF4E, demonstrating that esophageal cells with higher eIF4E expression are more sensitive to eIF4E inhibition. Ribavirin 55-64 eukaryotic translation initiation factor 4E Homo sapiens 130-135 30174840-9 2018 We further confirmed that the mechanism of action of ribavirin on esophageal cancer cells was through suppressing the Akt/mTOR/eIF4E and eIF4E-regulated pathways. Ribavirin 53-62 AKT serine/threonine kinase 1 Homo sapiens 118-121 30174840-9 2018 We further confirmed that the mechanism of action of ribavirin on esophageal cancer cells was through suppressing the Akt/mTOR/eIF4E and eIF4E-regulated pathways. Ribavirin 53-62 mechanistic target of rapamycin kinase Homo sapiens 122-126 30174840-9 2018 We further confirmed that the mechanism of action of ribavirin on esophageal cancer cells was through suppressing the Akt/mTOR/eIF4E and eIF4E-regulated pathways. Ribavirin 53-62 eukaryotic translation initiation factor 4E Homo sapiens 127-132 30174840-9 2018 We further confirmed that the mechanism of action of ribavirin on esophageal cancer cells was through suppressing the Akt/mTOR/eIF4E and eIF4E-regulated pathways. Ribavirin 53-62 eukaryotic translation initiation factor 4E Homo sapiens 137-142 29086249-6 2018 We further confirmed that the inhibitory effects of ribavirin were attributed to its ability in inhibiting eIF4E-regulated protein translation and activity. Ribavirin 52-61 eukaryotic translation initiation factor 4E Homo sapiens 107-112 29086249-7 2018 eIF4E inhibition using siRNA knockdown mimicked ribavirin"s effector in RCC cells. Ribavirin 48-57 eukaryotic translation initiation factor 4E Homo sapiens 0-5 29086249-8 2018 Importantly, eIF4E inhibition by both ribavirin and siRNA knockdown significantly sensitized RCC response to chemo- and immunotherapeutic agents in vitro as well as in vivo. Ribavirin 38-47 eukaryotic translation initiation factor 4E Homo sapiens 13-18 29509884-2 2018 Concerning previous anti-HCV therapies, pharmacogenetics had a significant impact, particularly considering the association of interleukin28B polymorphisms with dual-therapy (ribavirin + pegylated IFN) outcomes. Ribavirin 175-184 interferon lambda 3 Homo sapiens 127-141 30600949-7 2018 Circulating Th17 cells and serum IL17 levels were significantly decreased after successful Sofosbuvir-Ribavirin therapy (P < 0.0001). Ribavirin 102-111 interleukin 17A Homo sapiens 33-37 29851985-10 2018 CONCLUSIONS: Our study demonstrates that genetics of ITPA and IL28B may help identify patients protected from RBV-induced anemia when treated with IFN-free regimens. Ribavirin 110-113 interferon lambda 3 Homo sapiens 62-67 29920131-11 2018 We also found a significant difference in the relative expression of SOCS1 and SOCS3 in DAAs-treated and IFN/ribavirin (RBV)-treated and untreated individual. Ribavirin 120-123 suppressor of cytokine signaling 1 Homo sapiens 69-74 29920131-11 2018 We also found a significant difference in the relative expression of SOCS1 and SOCS3 in DAAs-treated and IFN/ribavirin (RBV)-treated and untreated individual. Ribavirin 120-123 suppressor of cytokine signaling 3 Homo sapiens 79-84 29920131-11 2018 We also found a significant difference in the relative expression of SOCS1 and SOCS3 in DAAs-treated and IFN/ribavirin (RBV)-treated and untreated individual. Ribavirin 120-123 interferon alpha 1 Homo sapiens 105-118 29851985-0 2018 Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. Ribavirin 76-85 interferon lambda 3 Homo sapiens 38-43 29851985-1 2018 BACKGROUND: Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Ribavirin 137-146 inosine triphosphatase Homo sapiens 56-60 29851985-1 2018 BACKGROUND: Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Ribavirin 137-146 interferon alpha 1 Homo sapiens 194-197 29851985-1 2018 BACKGROUND: Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Ribavirin 147-150 inosine triphosphatase Homo sapiens 56-60 29851985-1 2018 BACKGROUND: Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Ribavirin 147-150 interferon alpha 1 Homo sapiens 194-197 29851985-1 2018 BACKGROUND: Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Ribavirin 199-202 inosine triphosphatase Homo sapiens 56-60 29851985-1 2018 BACKGROUND: Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Ribavirin 199-202 interferon alpha 1 Homo sapiens 194-197 29851985-4 2018 RBV has been an important component of IFN-containing regimens, and is currently recommended in combination with several IFN-free regimens for treatment of harder to cure HCV infections. Ribavirin 0-3 interferon alpha 1 Homo sapiens 39-42 29805683-12 2018 The present study indicated that certain miRNAs (including miR-96, miR-145 and miR-183) and mRNAs (including NAT2, FBXO5, CCNB1, DEPDC1 and NTN4) may be associated with the effects of ribavirin on HCC. Ribavirin 184-193 microRNA 96 Homo sapiens 59-65 29805683-12 2018 The present study indicated that certain miRNAs (including miR-96, miR-145 and miR-183) and mRNAs (including NAT2, FBXO5, CCNB1, DEPDC1 and NTN4) may be associated with the effects of ribavirin on HCC. Ribavirin 184-193 microRNA 145 Homo sapiens 67-74 29805683-12 2018 The present study indicated that certain miRNAs (including miR-96, miR-145 and miR-183) and mRNAs (including NAT2, FBXO5, CCNB1, DEPDC1 and NTN4) may be associated with the effects of ribavirin on HCC. Ribavirin 184-193 microRNA 183 Homo sapiens 79-86 29805683-12 2018 The present study indicated that certain miRNAs (including miR-96, miR-145 and miR-183) and mRNAs (including NAT2, FBXO5, CCNB1, DEPDC1 and NTN4) may be associated with the effects of ribavirin on HCC. Ribavirin 184-193 N-acetyltransferase 2 Homo sapiens 109-113 29805683-12 2018 The present study indicated that certain miRNAs (including miR-96, miR-145 and miR-183) and mRNAs (including NAT2, FBXO5, CCNB1, DEPDC1 and NTN4) may be associated with the effects of ribavirin on HCC. Ribavirin 184-193 F-box protein 5 Homo sapiens 115-120 29805683-12 2018 The present study indicated that certain miRNAs (including miR-96, miR-145 and miR-183) and mRNAs (including NAT2, FBXO5, CCNB1, DEPDC1 and NTN4) may be associated with the effects of ribavirin on HCC. Ribavirin 184-193 cyclin B1 Homo sapiens 122-127 29805683-12 2018 The present study indicated that certain miRNAs (including miR-96, miR-145 and miR-183) and mRNAs (including NAT2, FBXO5, CCNB1, DEPDC1 and NTN4) may be associated with the effects of ribavirin on HCC. Ribavirin 184-193 DEP domain containing 1 Homo sapiens 129-135 29805683-12 2018 The present study indicated that certain miRNAs (including miR-96, miR-145 and miR-183) and mRNAs (including NAT2, FBXO5, CCNB1, DEPDC1 and NTN4) may be associated with the effects of ribavirin on HCC. Ribavirin 184-193 netrin 4 Homo sapiens 140-144 29851985-5 2018 AIM: To evaluate whether genetic variations that reduce ITPase activity impact RBV-induced anemia in IFN-free/RBV regimens. Ribavirin 79-82 interferon alpha 1 Homo sapiens 101-104 29851985-10 2018 CONCLUSIONS: Our study demonstrates that genetics of ITPA and IL28B may help identify patients protected from RBV-induced anemia when treated with IFN-free regimens. Ribavirin 110-113 inosine triphosphatase Homo sapiens 53-57 29851985-10 2018 CONCLUSIONS: Our study demonstrates that genetics of ITPA and IL28B may help identify patients protected from RBV-induced anemia when treated with IFN-free regimens. Ribavirin 110-113 interferon alpha 1 Homo sapiens 147-150 29851985-11 2018 Our work demonstrates for the first time that IL28B genetics may also have an impact on RBV-induced anemia. Ribavirin 88-91 interferon lambda 3 Homo sapiens 46-51 29540601-17 2018 Currently, off-label use of ribavirin (RBV) and polyethylene glycol-interferon (PEG-IFN) as antiviral therapy has shown promising results in both acute and chronic hepatitis E patients; however, the teratogenicity of RBV limits its use during pregnancy, while alpha IFN (IFN-alpha) increases the risk of transplant rejections. Ribavirin 28-37 interferon alpha 1 Homo sapiens 266-269 29272349-7 2018 By the end of treatment, patients receiving IFN-containing regimens experienced significant decreases in most PRO domains (-4.5 to -28.7 on a 0-100 scale), while subjects treated with IFN-free RBV-containing regimens had a modest impairment (-2.3 to -8.9) (P <= .01). Ribavirin 193-196 interferon alpha 1 Homo sapiens 184-187 29540601-17 2018 Currently, off-label use of ribavirin (RBV) and polyethylene glycol-interferon (PEG-IFN) as antiviral therapy has shown promising results in both acute and chronic hepatitis E patients; however, the teratogenicity of RBV limits its use during pregnancy, while alpha IFN (IFN-alpha) increases the risk of transplant rejections. Ribavirin 28-37 interferon alpha 1 Homo sapiens 271-280 29540601-17 2018 Currently, off-label use of ribavirin (RBV) and polyethylene glycol-interferon (PEG-IFN) as antiviral therapy has shown promising results in both acute and chronic hepatitis E patients; however, the teratogenicity of RBV limits its use during pregnancy, while alpha IFN (IFN-alpha) increases the risk of transplant rejections. Ribavirin 217-220 interferon alpha 1 Homo sapiens 84-87 29077864-0 2018 Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. Ribavirin 59-68 KRAS proto-oncogene, GTPase Homo sapiens 154-157 29664167-5 2018 Despite receiving treatment with ribavirin plus IFN, the case fatality rate was as high as 71% in the IFN-treatment group and exactly the same in patients who received supportive treatment only. Ribavirin 33-42 interferon alpha 1 Homo sapiens 102-105 29910570-1 2018 Background: In hepatitis C virus (HCV), infection viral and IL28B genotype along with many clinical and biochemical factors can influence response rates to pegylated interferon plus ribavirin (Peg-IFN-a/R) therapy and progression to chronic hepatitis C (CHC). Ribavirin 182-191 interferon lambda 3 Homo sapiens 60-65 30043870-0 2018 DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS? Ribavirin 73-82 insulin Homo sapiens 5-12 30043870-2 2018 Insulin resistance assessed by HOMA-IR is associated with low rates of sustained virological response, especially in HCV genotype 1 positive patients treated with peginterferon/ribavirin. Ribavirin 177-186 insulin Homo sapiens 0-7 30043870-4 2018 OBJECTIVE: To evaluate the impact of insulin resistance on sustained virological response in HCV genotype 3 patients treated with peginterferon/ribavirin. Ribavirin 144-153 insulin Homo sapiens 37-44 30043870-5 2018 METHODS: A retrospective multicenter study was performed to evaluate the impact of insulin resistance on sustained virological response in non-diabetic HCV genotype 3 positive patients treated with peginterferon and ribavirin. Ribavirin 216-225 insulin Homo sapiens 83-90 29152781-2 2018 MAGELLAN-1 Part 2 was a randomized, open-label, phase 3 study to evaluate the efficacy and safety of ribavirin (RBV)-free glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) in patients with chronic HCV and past VF on at least one NS3/4A protease and/or NS5A inhibitor-containing therapy. Ribavirin 101-110 ADP-ribosyltransferase 1 Homo sapiens 0-17 29077864-11 2018 Conclusions: Our findings support the concept of retreating with sofosbuvir + grazoprevir/elbasvir + ribavirin, for 16 weeks, genotype 1 or 4 DAA-experienced patients with proven NS5A or NS3 RASs. Ribavirin 101-110 KRAS proto-oncogene, GTPase Homo sapiens 187-190 29559835-2 2018 Currently, more than 90% of IFN-treated patients show a sustained virological response (SVR) when also treated with ribavirin and/or a protease inhibitor. Ribavirin 116-125 interferon alpha 1 Homo sapiens 28-31 29251333-6 2018 Dotted accumulations of gammaH2AX were found in the nuclei and increased levels of ATM and phosphorylated ATM protein expression were also observed following ribavirin treatment (10 microM of ribavirin, clinical relevant concentration) in both the malignant glioma cells, indicating double-strand breaks as one possible mechanism underlying the antitumor effect of ribavirin. Ribavirin 192-201 ATM serine/threonine kinase Homo sapiens 106-109 29293991-6 2018 Subjects receiving IFN-free RBV-containing regimens had significant but smaller PRO decreases, again similar in the OST and non-OST groups. Ribavirin 28-31 interferon alpha 1 Homo sapiens 19-23 29293991-7 2018 Finally, subjects treated with regimens free of both IFN and RBV (IFN/RBV-free) showed improvements in nearly all PROs during treatment, with improvements more pronounced in OST recipients. Ribavirin 61-64 interferon alpha 1 Homo sapiens 66-78 29181838-5 2018 RESULTS: In 34 632 persons treated with DAA and 23 475 treated with PEG/RBV, HBV-r rate per 1000 person-years was 30.04 (10.41, 49.67) and 25.42 (95% CI 17.23, 33.62) respectively (P = .8). Ribavirin 72-75 progestagen associated endometrial protein Homo sapiens 68-71 29271328-8 2018 This study illustrated that the carriage of IL28B rs12980275 AA had a positive effect on treatment response to pegIFN-alpha/RBV among Chinese CHC patients. Ribavirin 124-127 interferon lambda 3 Homo sapiens 44-49 29119253-0 2018 Higher expression of inhibitory CD158b and CD158e NK cell receptor and age predicts treatment response in children with chronic hepatitis C. Treatment with pegylated interferon-alpha and ribavirin (PEG-IFN/RBV) is the only choice for chronic hepatitis C (CHC) in children. Ribavirin 187-196 killer cell lectin like receptor D1 Homo sapiens 50-66 29251333-6 2018 Dotted accumulations of gammaH2AX were found in the nuclei and increased levels of ATM and phosphorylated ATM protein expression were also observed following ribavirin treatment (10 microM of ribavirin, clinical relevant concentration) in both the malignant glioma cells, indicating double-strand breaks as one possible mechanism underlying the antitumor effect of ribavirin. Ribavirin 158-167 ATM serine/threonine kinase Homo sapiens 83-86 29251333-6 2018 Dotted accumulations of gammaH2AX were found in the nuclei and increased levels of ATM and phosphorylated ATM protein expression were also observed following ribavirin treatment (10 microM of ribavirin, clinical relevant concentration) in both the malignant glioma cells, indicating double-strand breaks as one possible mechanism underlying the antitumor effect of ribavirin. Ribavirin 158-167 ATM serine/threonine kinase Homo sapiens 106-109 29251333-6 2018 Dotted accumulations of gammaH2AX were found in the nuclei and increased levels of ATM and phosphorylated ATM protein expression were also observed following ribavirin treatment (10 microM of ribavirin, clinical relevant concentration) in both the malignant glioma cells, indicating double-strand breaks as one possible mechanism underlying the antitumor effect of ribavirin. Ribavirin 192-201 ATM serine/threonine kinase Homo sapiens 83-86 29251333-6 2018 Dotted accumulations of gammaH2AX were found in the nuclei and increased levels of ATM and phosphorylated ATM protein expression were also observed following ribavirin treatment (10 microM of ribavirin, clinical relevant concentration) in both the malignant glioma cells, indicating double-strand breaks as one possible mechanism underlying the antitumor effect of ribavirin. Ribavirin 192-201 ATM serine/threonine kinase Homo sapiens 83-86 29251333-6 2018 Dotted accumulations of gammaH2AX were found in the nuclei and increased levels of ATM and phosphorylated ATM protein expression were also observed following ribavirin treatment (10 microM of ribavirin, clinical relevant concentration) in both the malignant glioma cells, indicating double-strand breaks as one possible mechanism underlying the antitumor effect of ribavirin. Ribavirin 192-201 ATM serine/threonine kinase Homo sapiens 106-109 29251333-9 2018 Additionally, analysis by FACS indicated that apoptosis was induced following ribavirin treatment and caspase cascade, downstream of the p53 pathway, which indicated the activation of both exogenous and endogenous apoptosis in both malignant glioma cell lines. Ribavirin 78-87 tumor protein p53 Homo sapiens 137-140 29487714-5 2018 We provide evidence that ribavirin has a significant impact on AT/RT cell growth and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E and/or EZH2 pathways. Ribavirin 25-34 eukaryotic translation initiation factor 4E Homo sapiens 167-172 29487714-5 2018 We provide evidence that ribavirin has a significant impact on AT/RT cell growth and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E and/or EZH2 pathways. Ribavirin 25-34 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 180-184 28573908-0 2018 The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data<sup/>. Ribavirin 20-29 eukaryotic translation initiation factor 4E Homo sapiens 4-9 29311405-12 2018 At multivariate analysis emerged that the addition of ribavirin to DAA, represented an independent predictor of increased Lp(a) (OR 3.982, 95% CI 1.206-13.144, p = 0.023). Ribavirin 54-63 lipoprotein(a) Homo sapiens 122-127 30354193-9 2018 RBV had the greatest antiviral effect in HUH-7 cells (EC50 = 2.575 microg/mL); IFN-alpha was most effective in A549 cells (EC50 = 4.235 IU/mL); and FAV in HUH-7 cells (EC50 = 20.00 mug/mL). Ribavirin 0-3 MIR7-3 host gene Homo sapiens 41-46 30354193-9 2018 RBV had the greatest antiviral effect in HUH-7 cells (EC50 = 2.575 microg/mL); IFN-alpha was most effective in A549 cells (EC50 = 4.235 IU/mL); and FAV in HUH-7 cells (EC50 = 20.00 mug/mL). Ribavirin 0-3 MIR7-3 host gene Homo sapiens 155-160 29112301-0 2018 Ribavirin augments doxorubicin"s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 115-120 29112301-2 2018 In this work, we demonstrate that targeting eIF4E by ribavirin sensitizes hepatocellular carcinoma (HCC) cell response to doxorubicin. Ribavirin 53-62 eukaryotic translation initiation factor 4E Homo sapiens 44-49 29112301-5 2018 Ribavirin suppresses phosphorylation of molecules involved in Akt/mTOR/eIF4E pathway. Ribavirin 0-9 AKT serine/threonine kinase 1 Homo sapiens 62-65 29112301-5 2018 Ribavirin suppresses phosphorylation of molecules involved in Akt/mTOR/eIF4E pathway. Ribavirin 0-9 mechanistic target of rapamycin kinase Homo sapiens 66-70 29112301-5 2018 Ribavirin suppresses phosphorylation of molecules involved in Akt/mTOR/eIF4E pathway. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 71-76 29112301-6 2018 Overexpression of the phosphomimetic form (S209D) but not the nonphosphorylatable form (S209A) eIF4E significantly reverses the inhibitory effects of ribavirin. Ribavirin 150-159 eukaryotic translation initiation factor 4E Homo sapiens 95-100 29112301-8 2018 In addition, eIF4E activation induced by doxorubicin in HCC cells is inhibited by ribavirin. Ribavirin 82-91 eukaryotic translation initiation factor 4E Homo sapiens 13-18 29284412-0 2017 CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV. Ribavirin 121-124 C-C motif chemokine ligand 4 Homo sapiens 0-4 29284412-10 2017 CONCLUSIONS: IL28B genotype is the predictor for NR in GT-1 CHC patients treated with PegIFN/RBV, while baseline serum level of CCL4 is the only predictor for NR in GT-1 CHC patients with favorable IL28B genotype. Ribavirin 93-96 interferon lambda 3 Homo sapiens 13-18 27760839-9 2017 During therapy, haemoglobin levels were not significantly modified, but recombinant erythropoietin (rEPO) dose significantly increased in patients treated with RBV. Ribavirin 160-163 erythropoietin Homo sapiens 84-98 29260001-6 2017 Differential dynamics of hepcidin during PEG-IFNalpha/RBV therapy in responders and non-responders might indicate the direct influence of viral eradication on iron homeostasis. Ribavirin 54-57 hepcidin antimicrobial peptide Homo sapiens 25-33 28688129-7 2017 In C-CREST Part C, SVR12 was achieved by 23/24 (96%) participants treated for 16 weeks with ribavirin (GT1, 2/2 [100%]; GT2, 13/14 [93%]; GT3, 8/8 [100%]). Ribavirin 92-101 beta-1,4-galactosyltransferase 1 Homo sapiens 103-111 29039469-0 2017 The association of LMP7 and TAP2 gene polymorphisms with treatment response to interferon/ribavirin in patients with genotype 1 chronic hepatitis C. Previous studies have highlighted the important role of genes related to antigen presentation in the spontaneous clearance of hepatitis C virus. Ribavirin 90-99 proteasome 20S subunit beta 8 Homo sapiens 19-23 29039469-0 2017 The association of LMP7 and TAP2 gene polymorphisms with treatment response to interferon/ribavirin in patients with genotype 1 chronic hepatitis C. Previous studies have highlighted the important role of genes related to antigen presentation in the spontaneous clearance of hepatitis C virus. Ribavirin 90-99 transporter 2, ATP binding cassette subfamily B member Homo sapiens 28-32 29039469-10 2017 The present study illustrated that the carriage of LMP7 rs2071543-AA and TAP2 rs1800454-AA had a negative effect on treatment response to pegIFN-alpha/RBV among genotype 1 patient with CHC in a Chinese Han population. Ribavirin 151-154 proteasome 20S subunit beta 8 Homo sapiens 51-55 29039469-10 2017 The present study illustrated that the carriage of LMP7 rs2071543-AA and TAP2 rs1800454-AA had a negative effect on treatment response to pegIFN-alpha/RBV among genotype 1 patient with CHC in a Chinese Han population. Ribavirin 151-154 transporter 2, ATP binding cassette subfamily B member Homo sapiens 73-77 29290908-8 2017 Majority (71%) of CP-B patients required a RBV dosage reduction during the treatment. Ribavirin 43-46 carboxypeptidase B1 Homo sapiens 18-22 29049978-2 2017 In this work, we report that ribavirin, a pharmacologic inhibitor of eIF4E function, effectively targets retinoblastoma and angiogenesis. Ribavirin 29-38 eukaryotic translation initiation factor 4E Homo sapiens 69-74 29049978-4 2017 Ribavirin also significantly inhibited angiogenesis via disrupting capillary network formation and suppressing VEGF-induced migration, proliferation and survival of human retinal endothelial cells. Ribavirin 0-9 vascular endothelial growth factor A Homo sapiens 111-115 29049978-6 2017 Mechanistically, ribavirin inhibited eIF4E function in retinoblastoma cells as shown by the decreased protein levels of Cyclin D1, c-Myc and VEGF without affecting their mRNA expression. Ribavirin 17-26 eukaryotic translation initiation factor 4E Homo sapiens 37-42 29049978-6 2017 Mechanistically, ribavirin inhibited eIF4E function in retinoblastoma cells as shown by the decreased protein levels of Cyclin D1, c-Myc and VEGF without affecting their mRNA expression. Ribavirin 17-26 cyclin D1 Homo sapiens 120-129 29049978-6 2017 Mechanistically, ribavirin inhibited eIF4E function in retinoblastoma cells as shown by the decreased protein levels of Cyclin D1, c-Myc and VEGF without affecting their mRNA expression. Ribavirin 17-26 MYC proto-oncogene, bHLH transcription factor Homo sapiens 131-136 29049978-6 2017 Mechanistically, ribavirin inhibited eIF4E function in retinoblastoma cells as shown by the decreased protein levels of Cyclin D1, c-Myc and VEGF without affecting their mRNA expression. Ribavirin 17-26 vascular endothelial growth factor A Homo sapiens 141-145 29049978-7 2017 Overexpression of the wildtype and phosphormimetic but not the nonphosphorylatable form of eIF4E significantly abolished the inhibitory effects of ribavirin, further demonstrating eIF4E as the target of ribavirin. Ribavirin 147-156 eukaryotic translation initiation factor 4E Homo sapiens 180-185 29049978-7 2017 Overexpression of the wildtype and phosphormimetic but not the nonphosphorylatable form of eIF4E significantly abolished the inhibitory effects of ribavirin, further demonstrating eIF4E as the target of ribavirin. Ribavirin 203-212 eukaryotic translation initiation factor 4E Homo sapiens 180-185 29049978-8 2017 Genetic knockdown of eIF4E using two independent siRNAs mirrored ribavirin"s effects, confirming the role of eIF4E in retinoblastoma growth, survival and response to chemotherapy. Ribavirin 65-74 eukaryotic translation initiation factor 4E Homo sapiens 21-26 27760839-9 2017 During therapy, haemoglobin levels were not significantly modified, but recombinant erythropoietin (rEPO) dose significantly increased in patients treated with RBV. Ribavirin 160-163 erythropoietin Rattus norvegicus 100-104 28128521-0 2017 ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin. Ribavirin 126-135 inosine triphosphatase Homo sapiens 0-4 28877086-9 2017 CONCLUSION: These real-life findings indicated a high efficacy of sofosbuvir+NS5A-inihbitors in retreating NS3-experienced patients and also NS5A-experienced patients by using a 24-week course ribavirin-containing regimen. Ribavirin 193-202 KRAS proto-oncogene, GTPase Homo sapiens 107-110 28128521-5 2017 The relationships among genetic polymorphisms of ITPA and the decline in hemoglobin levels from baseline, RBV dose reduction, and sustained virological response (SVR) rates were analyzed. Ribavirin 106-109 inosine triphosphatase Homo sapiens 49-53 29042578-3 2017 Treatment with interferon and ribavirin upregulated beta-defensin-1, but not other beta-defensin tested, with the extent and duration of upregulation associated with treatment response. Ribavirin 30-39 defensin beta 1 Homo sapiens 52-67 28992878-4 2017 RESULTS: PegIFN in combination with ribavirin remains an important and relevant option for some patients, achieving SVR rates of up to 79% in genotype 1 and 89% in genotype 2 or 3 infections, which increases for patients with favorable IL28B genotypes. Ribavirin 36-45 interferon lambda 3 Homo sapiens 236-241 28890388-0 2017 DHEA prevents ribavirin-induced anemia via inhibition of glucose-6-phosphate dehydrogenase. Ribavirin 14-23 glucose-6-phosphate dehydrogenase Homo sapiens 57-90 28128521-8 2017 The percentage of patients requiring RBV dose reduction was significantly lower for those with the ITPA CA/AA variation, a difference even more apparent when the pretreatment hemoglobin level was <12 g/dL. Ribavirin 37-40 inosine triphosphatase Homo sapiens 99-103 28128521-10 2017 CONCLUSIONS: Patients with the ITPA CA/AA genotype were less likely to develop anemia than those with the ITPA CC genotype and were more likely to complete SOF/RBV therapy. Ribavirin 160-163 inosine triphosphatase Homo sapiens 31-35 28128521-10 2017 CONCLUSIONS: Patients with the ITPA CA/AA genotype were less likely to develop anemia than those with the ITPA CC genotype and were more likely to complete SOF/RBV therapy. Ribavirin 160-163 inosine triphosphatase Homo sapiens 106-110 28128521-2 2017 Genetic variation leading to inosine triphosphatase (ITPA) deficiency is known to protect against RBV-induced hemolytic anemia. Ribavirin 98-101 inosine triphosphatase Homo sapiens 53-57 29062905-8 2017 CONCLUSIONS: The IFNL3 rs12979860 polymorphism may be considered a predictor for IFN/RBV effectiveness following liver transplantation. Ribavirin 85-88 interferon lambda 3 Homo sapiens 17-22 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 45-54 inosine triphosphatase Homo sapiens 0-4 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 45-54 inosine triphosphatase Homo sapiens 132-154 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 45-54 inosine triphosphatase Homo sapiens 156-160 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 45-54 inosine triphosphatase Homo sapiens 156-160 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 196-205 inosine triphosphatase Homo sapiens 0-4 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 196-205 inosine triphosphatase Homo sapiens 132-154 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 196-205 inosine triphosphatase Homo sapiens 156-160 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 196-205 inosine triphosphatase Homo sapiens 156-160 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 207-210 inosine triphosphatase Homo sapiens 0-4 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 207-210 inosine triphosphatase Homo sapiens 132-154 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 207-210 inosine triphosphatase Homo sapiens 156-160 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 207-210 inosine triphosphatase Homo sapiens 156-160 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 383-386 inosine triphosphatase Homo sapiens 0-4 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 383-386 inosine triphosphatase Homo sapiens 132-154 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 383-386 inosine triphosphatase Homo sapiens 156-160 28480960-0 2017 ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Inosine triphosphatase (ITPA) gene variants can protect against ribavirin (RBV)-induced anemia in patients treated for chronic hepatitis C. The aim of this study was to determine the relationship between genetic variants of ITPA polymorphism, anemia, RBV dose reduction, and treatment response in hepatitis C virus (HCV)-infected patients. Ribavirin 383-386 inosine triphosphatase Homo sapiens 156-160 28480960-8 2017 The ITPA gene polymorphism rs1127354 heterozygous genotype (CA) may influence Hb levels and protect against hemolytic anemia during RBV-containing regimens for HCV. Ribavirin 132-135 inosine triphosphatase Homo sapiens 4-8 28480960-10 2017 Patients with wild ITPA genotype (CC) experienced a more Hb drop and RBV dose reductions more frequently. Ribavirin 69-72 inosine triphosphatase Homo sapiens 19-23 29039351-6 2017 During therapeutic regimens combined with ribavirin, destructive thyroiditis with typical biphasic course is more common than in IFN-alpha monotherapy. Ribavirin 42-51 interferon alpha 1 Homo sapiens 129-138 28739427-1 2017 Single nucleotide polymorphisms (SNPs) near the interleukin-28B (IL28B), interferon lambda 4 (IFNL4) and the human leukocyte antigen (HLA) gene are associated with treatment responses in patients with chronic hepatitis C (CHC) virus infection treated with pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV). Ribavirin 287-296 interferon lambda 3 Homo sapiens 48-63 28739427-1 2017 Single nucleotide polymorphisms (SNPs) near the interleukin-28B (IL28B), interferon lambda 4 (IFNL4) and the human leukocyte antigen (HLA) gene are associated with treatment responses in patients with chronic hepatitis C (CHC) virus infection treated with pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV). Ribavirin 287-296 interferon lambda 3 Homo sapiens 65-70 28739427-1 2017 Single nucleotide polymorphisms (SNPs) near the interleukin-28B (IL28B), interferon lambda 4 (IFNL4) and the human leukocyte antigen (HLA) gene are associated with treatment responses in patients with chronic hepatitis C (CHC) virus infection treated with pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV). Ribavirin 287-296 interferon lambda 3 Homo sapiens 73-92 28739427-1 2017 Single nucleotide polymorphisms (SNPs) near the interleukin-28B (IL28B), interferon lambda 4 (IFNL4) and the human leukocyte antigen (HLA) gene are associated with treatment responses in patients with chronic hepatitis C (CHC) virus infection treated with pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV). Ribavirin 287-296 interferon lambda 3 Homo sapiens 94-99 28815296-1 2017 Autoantibodies against inosine-5"-monophosphate-dehydrogenase-2 (IMPDH2; "rods and rings" pattern) develop in chronic hepatitis C (CHC) patients under treatment with peg-interferon (IFN) and ribavirin (RBV), an inhibitor of IMPDH2. Ribavirin 191-200 inosine monophosphate dehydrogenase 2 Homo sapiens 65-71 28815296-1 2017 Autoantibodies against inosine-5"-monophosphate-dehydrogenase-2 (IMPDH2; "rods and rings" pattern) develop in chronic hepatitis C (CHC) patients under treatment with peg-interferon (IFN) and ribavirin (RBV), an inhibitor of IMPDH2. Ribavirin 202-205 inosine monophosphate dehydrogenase 2 Homo sapiens 65-71 29104462-0 2017 Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy. Ribavirin 116-125 interferon lambda 3 Homo sapiens 15-20 29104462-1 2017 BACKGROUND: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis. Ribavirin 144-153 interferon lambda 3 Homo sapiens 39-58 29104462-1 2017 BACKGROUND: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis. Ribavirin 144-153 interferon lambda 3 Homo sapiens 60-65 28543275-3 2017 The baseline haemoglobin and ITPA rs1127354 CA/AA have been found as predictors of anaemia at 4, 8 and 12 weeks of RBV therapy. Ribavirin 115-118 inosine triphosphatase Homo sapiens 29-33 28543275-5 2017 In conclusion, the ITPA variant rs1127354C>A significantly predict RBV-induced anaemia during the first 3 months of treatment and it is recommended to be assessed before RBV administration. Ribavirin 70-73 inosine triphosphatase Homo sapiens 19-23 28543275-5 2017 In conclusion, the ITPA variant rs1127354C>A significantly predict RBV-induced anaemia during the first 3 months of treatment and it is recommended to be assessed before RBV administration. Ribavirin 173-176 inosine triphosphatase Homo sapiens 19-23 28864377-0 2017 Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis. Ribavirin 15-24 eukaryotic translation initiation factor 4E Mus musculus 72-77 28815216-9 2017 Two previously identified ribavirin {1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide} resistance mutations, PB1 V43I and PB1 D27N, do not confer drug resistance in the PR8 background, and the PR8-PB1 V43I polymerase exhibits a normal baseline mutation rate. Ribavirin 26-35 polybromo 1 Homo sapiens 153-156 28815216-9 2017 Two previously identified ribavirin {1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide} resistance mutations, PB1 V43I and PB1 D27N, do not confer drug resistance in the PR8 background, and the PR8-PB1 V43I polymerase exhibits a normal baseline mutation rate. Ribavirin 26-35 polybromo 1 Homo sapiens 166-169 28815216-9 2017 Two previously identified ribavirin {1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide} resistance mutations, PB1 V43I and PB1 D27N, do not confer drug resistance in the PR8 background, and the PR8-PB1 V43I polymerase exhibits a normal baseline mutation rate. Ribavirin 26-35 polybromo 1 Homo sapiens 166-169 28797106-9 2017 Serum AFP levels decreased to similar levels between PEG-IFN/RBV and DCV/ASV groups following the achievement of viral eradication. Ribavirin 61-64 alpha fetoprotein Homo sapiens 6-9 28864377-0 2017 Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis. Ribavirin 15-24 catenin (cadherin associated protein), beta 1 Mus musculus 78-90 28864377-2 2017 Ribavirin, an anti-viral drug, has been identified as an eIF4E inhibitor. Ribavirin 0-9 eukaryotic translation initiation factor 4E Mus musculus 57-62 28864377-9 2017 Mechanistically, ribavirin suppressed eIF4E phosphorylation and overexpression of its wildtype and phosphor-mimetic form (S209D) but not of the non-phosphorylatable form (S209A), which rescued the inhibitory effects of ribavirin in thyroid cancer cells. Ribavirin 17-26 eukaryotic translation initiation factor 4E Mus musculus 38-43 28864377-10 2017 We further demonstrated that ribavirin suppressed phosphorylation and activities of beta-catenin and its subsequent gene transcriptional expression. Ribavirin 29-38 catenin (cadherin associated protein), beta 1 Mus musculus 84-96 28864377-11 2017 beta-Catenin overexpression rescued the effects of ribavirin in thyroid cancer cells. Ribavirin 51-60 catenin (cadherin associated protein), beta 1 Mus musculus 0-12 28864377-13 2017 The in vivo inhibitory effects of ribavirin on phosphorylation of eIF4E and beta-catenin were also observed in thyroid tumor. Ribavirin 34-43 eukaryotic translation initiation factor 4E Mus musculus 66-71 28864377-13 2017 The in vivo inhibitory effects of ribavirin on phosphorylation of eIF4E and beta-catenin were also observed in thyroid tumor. Ribavirin 34-43 catenin (cadherin associated protein), beta 1 Mus musculus 76-88 28864377-14 2017 CONCLUSIONS: Our data clearly demonstrate that ribavirin acts on thyroid cancer cells by inhibiting eIF4E/beta-catenin signaling. Ribavirin 47-56 eukaryotic translation initiation factor 4E Mus musculus 100-105 28864377-14 2017 CONCLUSIONS: Our data clearly demonstrate that ribavirin acts on thyroid cancer cells by inhibiting eIF4E/beta-catenin signaling. Ribavirin 47-56 catenin (cadherin associated protein), beta 1 Mus musculus 106-118 28864377-15 2017 Our findings suggest that ribavirin has the potential to be repurposed for thyroid cancer treatment and also highlight the therapeutic value of inhibiting eIF4E-beta-catenin in thyroid cancer. Ribavirin 26-35 eukaryotic translation initiation factor 4E Mus musculus 155-160 28864377-15 2017 Our findings suggest that ribavirin has the potential to be repurposed for thyroid cancer treatment and also highlight the therapeutic value of inhibiting eIF4E-beta-catenin in thyroid cancer. Ribavirin 26-35 catenin (cadherin associated protein), beta 1 Mus musculus 161-173 28777714-3 2017 Treatment of chronic HCV using combined pegylated interferon and ribavirin (PEG/RIBA) has long been the standard of care with modest response. Ribavirin 65-74 Ras like without CAAX 2 Homo sapiens 80-84 28109022-0 2017 Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy. Ribavirin 114-123 inosine triphosphatase Homo sapiens 40-62 28109022-0 2017 Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy. Ribavirin 151-160 inosine triphosphatase Homo sapiens 40-62 28109022-9 2017 CONCLUSIONS: Inosine triphosphatase polymorphism appeared to correlate with anemia incidence and RBV dose reduction during SOF/RBV therapy, but not the clinical outcome. Ribavirin 97-100 inosine triphosphatase Homo sapiens 13-35 28109022-9 2017 CONCLUSIONS: Inosine triphosphatase polymorphism appeared to correlate with anemia incidence and RBV dose reduction during SOF/RBV therapy, but not the clinical outcome. Ribavirin 127-130 inosine triphosphatase Homo sapiens 13-35 28109022-10 2017 Careful monitoring of Hb concentrations and prompt adjustment of RBV doses are required for successful treatment, particularly in patients harboring the ITPA CC genotype or age >= 65 years. Ribavirin 65-68 inosine triphosphatase Homo sapiens 153-157 28852525-0 2017 Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism. Ribavirin 52-61 interferon lambda 3 Homo sapiens 115-120 28852525-4 2017 The purpose of this study was to determine IL28B polymorphism and ITPA variation among hepatitis C genotype 1 patients who have undergone therapy with PEG-IFN and ribavirin and their association with sustained viral response (SVR). Ribavirin 163-172 interferon lambda 3 Homo sapiens 43-48 28852525-15 2017 Conclusion: Hepatitis C genotype 1 patients should be informed of the response rate for treatment with PEG-IFN and ribavirin in a population with favourable IL28B genotype before consideration of newer therapeutic options. Ribavirin 115-124 interferon lambda 3 Homo sapiens 157-162 28506030-9 2017 Conclusions: Simeprevir-based triple therapy with reduced doses of PEG-IFN and ribavirin was safe and effective for IFN ineligible patients infected with genotype 1b HCV. Ribavirin 79-88 interferon alpha 1 Homo sapiens 116-119 27822709-0 2017 ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection. Ribavirin 74-83 inosine triphosphatase Homo sapiens 0-4 28315743-0 2017 Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. Ribavirin 27-36 interferon lambda 3 Homo sapiens 137-142 28315743-2 2017 Naive treated patients, who are not eligible for IFN-free therapies, could be selected for standard dual treatment with pegylated (PEG)-IFN and ribavirin (RBV), through IFN lambda 3 gene polymorphisms and fibrosis stage evaluation. Ribavirin 144-153 interferon lambda 3 Homo sapiens 169-181 28315743-2 2017 Naive treated patients, who are not eligible for IFN-free therapies, could be selected for standard dual treatment with pegylated (PEG)-IFN and ribavirin (RBV), through IFN lambda 3 gene polymorphisms and fibrosis stage evaluation. Ribavirin 155-158 interferon lambda 3 Homo sapiens 169-181 28315743-6 2017 The RBV cutoff at 2weeks of 1800ng/mL, predictor of RVR, was determined (p=0.003; sensibility=60.4%, specificity=88.2%, positive predictive value=88.9%, negative predictive value=100%). Ribavirin 4-7 nuclear receptor subfamily 1 group D member 2 Homo sapiens 52-55 28315743-8 2017 Considering a pharmacogenetic-guided approach, dual therapy with PEG-IFN and RBV can be considered a reliable option for patients ineligible for IFN-free treatments, who are motivated and well informed about all the aspects related to PEG-IFN administration. Ribavirin 77-80 interferon alpha 1 Homo sapiens 145-148 28315743-8 2017 Considering a pharmacogenetic-guided approach, dual therapy with PEG-IFN and RBV can be considered a reliable option for patients ineligible for IFN-free treatments, who are motivated and well informed about all the aspects related to PEG-IFN administration. Ribavirin 77-80 interferon alpha 1 Homo sapiens 145-148 28243801-5 2017 Ribavirin significantly suppressed toll-like receptor 2 and 4 expression in the lung and decreased the level of IL-1beta, IL-6, TNF-alpha, and IFN-gamma in lung tissues of mice infected with influenza virus. Ribavirin 0-9 interleukin 1 beta Mus musculus 112-120 28243801-5 2017 Ribavirin significantly suppressed toll-like receptor 2 and 4 expression in the lung and decreased the level of IL-1beta, IL-6, TNF-alpha, and IFN-gamma in lung tissues of mice infected with influenza virus. Ribavirin 0-9 interleukin 6 Mus musculus 122-126 28243801-5 2017 Ribavirin significantly suppressed toll-like receptor 2 and 4 expression in the lung and decreased the level of IL-1beta, IL-6, TNF-alpha, and IFN-gamma in lung tissues of mice infected with influenza virus. Ribavirin 0-9 tumor necrosis factor Mus musculus 128-137 28243801-5 2017 Ribavirin significantly suppressed toll-like receptor 2 and 4 expression in the lung and decreased the level of IL-1beta, IL-6, TNF-alpha, and IFN-gamma in lung tissues of mice infected with influenza virus. Ribavirin 0-9 interferon gamma Mus musculus 143-152 29528582-0 2017 Interleukin-22 and Chemokine Interferon gamma -Inducible-10 (IP-10) Levels in Chronic Hepatitis C Patients and Treatment Response to Pegylated Interferon and Ribavirin Therapy. Ribavirin 158-167 C-X-C motif chemokine ligand 10 Homo sapiens 61-66 29404478-0 2017 Ribavirin suppresses hepatic lipogenesis through inosine monophosphate dehydrogenase inhibition: Involvement of adenosine monophosphate-activated protein kinase-related kinases and retinoid X receptor alpha. Ribavirin 0-9 retinoid X receptor alpha Homo sapiens 181-206 29404478-6 2017 In addition, RBV treatment led to the down-regulation of retinoid X receptor alpha (RXRalpha), a key nuclear receptor in various metabolic processes, including lipogenesis. Ribavirin 13-16 retinoid X receptor alpha Homo sapiens 57-82 29404478-6 2017 In addition, RBV treatment led to the down-regulation of retinoid X receptor alpha (RXRalpha), a key nuclear receptor in various metabolic processes, including lipogenesis. Ribavirin 13-16 retinoid X receptor alpha Homo sapiens 84-92 29404478-8 2017 Overexpression of RXRalpha attenuated the RBV action for suppression of lipogenic genes and intracellular neutral lipids, suggesting that down-regulation of RXRalpha was required for the suppression of lipogenesis in RBV action. Ribavirin 42-45 retinoid X receptor alpha Homo sapiens 18-26 29404478-8 2017 Overexpression of RXRalpha attenuated the RBV action for suppression of lipogenic genes and intracellular neutral lipids, suggesting that down-regulation of RXRalpha was required for the suppression of lipogenesis in RBV action. Ribavirin 42-45 retinoid X receptor alpha Homo sapiens 157-165 29404478-8 2017 Overexpression of RXRalpha attenuated the RBV action for suppression of lipogenic genes and intracellular neutral lipids, suggesting that down-regulation of RXRalpha was required for the suppression of lipogenesis in RBV action. Ribavirin 217-220 retinoid X receptor alpha Homo sapiens 18-26 29404478-8 2017 Overexpression of RXRalpha attenuated the RBV action for suppression of lipogenic genes and intracellular neutral lipids, suggesting that down-regulation of RXRalpha was required for the suppression of lipogenesis in RBV action. Ribavirin 217-220 retinoid X receptor alpha Homo sapiens 157-165 29404478-9 2017 Conclusion: We provide novel insights about RBV action in lipogenesis and its mechanisms involving inosine monophosphate dehydrogenase inhibition, adenosine monophosphate-activated protein kinase-related kinases, and down-regulation of RXRalpha. Ribavirin 44-47 retinoid X receptor alpha Homo sapiens 236-244 27735085-0 2017 Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-alpha and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. BACKGROUND: The aim of this study was to determine whether two polymorphisms of the human interferon lambda 4 (IFNL4) gene (rs12979860 and rs8099917) can predict sustained virologic response (SVR) following antiviral therapy in patients with inherited bleeding disorder and chronic hepatitis C (CHC). Ribavirin 95-104 interferon lambda 4 (gene/pseudogene) Homo sapiens 10-15 27735085-8 2017 CONCLUSION: These results demonstrate that polymorphisms of the IFNL4 gene are highly associated with SVR to PegIFN and RBV combination therapy in patients with a congenital bleeding disorder and CHC. Ribavirin 120-123 interferon lambda 4 (gene/pseudogene) Homo sapiens 64-69 28036111-7 2017 IFNL4 expression was associated with non-response to PEG-IFN/ribavirin therapy. Ribavirin 61-70 interferon lambda 3 Homo sapiens 0-5 28036111-7 2017 IFNL4 expression was associated with non-response to PEG-IFN/ribavirin therapy. Ribavirin 61-70 interferon alpha 1 Homo sapiens 0-3 29062331-1 2017 BACKGROUND: Many recent studies support the idea that osteopontin (OPN) can be used to predict the success of pegylated interferon (PEG IFN) alpha-2b/ribavirin therapy in chronic HCV patients. Ribavirin 150-159 secreted phosphoprotein 1 Homo sapiens 54-65 29062331-1 2017 BACKGROUND: Many recent studies support the idea that osteopontin (OPN) can be used to predict the success of pegylated interferon (PEG IFN) alpha-2b/ribavirin therapy in chronic HCV patients. Ribavirin 150-159 secreted phosphoprotein 1 Homo sapiens 67-70 29062331-10 2017 CONCLUSION: Osteopontin blood level can be considered as a reliable predictor to PEG IFN alpha2b plus ribavirin therapy in chronic HCV Saudi Patients. Ribavirin 102-111 secreted phosphoprotein 1 Homo sapiens 12-23 27822709-0 2017 ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection. Ribavirin 74-83 inosine triphosphatase Homo sapiens 164-186 27822709-0 2017 ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection. Ribavirin 266-275 inosine triphosphatase Homo sapiens 0-4 27822709-0 2017 ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection. Ribavirin 266-275 inosine triphosphatase Homo sapiens 164-186 27822709-0 2017 ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection. Ribavirin 266-275 inosine triphosphatase Homo sapiens 188-192 27822709-0 2017 ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection. Ribavirin 277-280 inosine triphosphatase Homo sapiens 0-4 27822709-0 2017 ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection. Ribavirin 277-280 inosine triphosphatase Homo sapiens 164-186 27822709-0 2017 ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection. Ribavirin 277-280 inosine triphosphatase Homo sapiens 188-192 27822709-11 2017 CONCLUSIONS: ITPA polymorphism influences hemoglobin levels and incidence of RBV dose reduction during sofosbuvir plus RBV therapy. Ribavirin 77-80 inosine triphosphatase Homo sapiens 13-17 27822709-11 2017 CONCLUSIONS: ITPA polymorphism influences hemoglobin levels and incidence of RBV dose reduction during sofosbuvir plus RBV therapy. Ribavirin 119-122 inosine triphosphatase Homo sapiens 13-17 29270489-17 2017 Most of the patients (n = 23; 56%) in the ribavirin group required an increase in the erythropoietin dose. Ribavirin 42-51 erythropoietin Homo sapiens 86-100 27941882-3 2017 Ribavirin, the only clinically approved drug known to target eIF4E, is an anti-viral molecule currently used in hepatitis C treatment. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 61-66 27941882-6 2017 Our work showed that ribavirin inhibits glioma cell growth and migration, and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E, EZH2 and ERK pathways. Ribavirin 21-30 eukaryotic translation initiation factor 4E Homo sapiens 160-165 27941882-6 2017 Our work showed that ribavirin inhibits glioma cell growth and migration, and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E, EZH2 and ERK pathways. Ribavirin 21-30 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 167-171 27941882-6 2017 Our work showed that ribavirin inhibits glioma cell growth and migration, and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E, EZH2 and ERK pathways. Ribavirin 21-30 mitogen-activated protein kinase 1 Homo sapiens 176-179 28040549-7 2017 Unlike IFN-free regimens, SOF plus IFN/ribavirin induced a transiently increased frequency of Foxp3+ CD25+ CD4+ T cells at EOT (5.0% at baseline to 6.1% at EOT; p=0.001). Ribavirin 39-48 CD4 molecule Homo sapiens 107-110 28579812-13 2017 Detailed analysis of the costs for GT 1 showed the treatment based on ritonavir boosted paritaprevir/ombitasvir + dasabuvir+-RBV with an average cost of $24,978 (RBV+) and $25,448 (RBV-) per patient was the most cost-effective. Ribavirin 125-128 beta-1,4-galactosyltransferase 1 Homo sapiens 35-39 28579812-13 2017 Detailed analysis of the costs for GT 1 showed the treatment based on ritonavir boosted paritaprevir/ombitasvir + dasabuvir+-RBV with an average cost of $24,978 (RBV+) and $25,448 (RBV-) per patient was the most cost-effective. Ribavirin 162-165 beta-1,4-galactosyltransferase 1 Homo sapiens 35-39 28040549-7 2017 Unlike IFN-free regimens, SOF plus IFN/ribavirin induced a transiently increased frequency of Foxp3+ CD25+ CD4+ T cells at EOT (5.0% at baseline to 6.1% at EOT; p=0.001). Ribavirin 39-48 forkhead box P3 Homo sapiens 94-99 28040549-7 2017 Unlike IFN-free regimens, SOF plus IFN/ribavirin induced a transiently increased frequency of Foxp3+ CD25+ CD4+ T cells at EOT (5.0% at baseline to 6.1% at EOT; p=0.001). Ribavirin 39-48 interferon stimulated exonuclease gene 20 Homo sapiens 101-105 28459367-0 2017 Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. Ribavirin 147-156 colony stimulating factor 3 Homo sapiens 25-30 28459367-10 2017 The antibiotic dapsone, the lipid-lowering agent fenofibrate, and the antiviral drug ribavirin are Food and Drug Administration- and European Medicines Agency-approved medicines that have potential to lower synthesis or effects of G(M)-CSF and thus deprive a glioblastoma of some of the growth promoting contributions of bone marrow and G(M)-CSF. Ribavirin 85-94 colony stimulating factor 2 Homo sapiens 231-239 28459367-10 2017 The antibiotic dapsone, the lipid-lowering agent fenofibrate, and the antiviral drug ribavirin are Food and Drug Administration- and European Medicines Agency-approved medicines that have potential to lower synthesis or effects of G(M)-CSF and thus deprive a glioblastoma of some of the growth promoting contributions of bone marrow and G(M)-CSF. Ribavirin 85-94 colony stimulating factor 2 Homo sapiens 337-345 28391873-0 2022 IL-10 and IL-28B gene variants as predictors of sustained response to peginterferon and ribavirin therapy in chronic HCV infection. Ribavirin 88-97 interleukin 10 Homo sapiens 0-5 28391873-0 2022 IL-10 and IL-28B gene variants as predictors of sustained response to peginterferon and ribavirin therapy in chronic HCV infection. Ribavirin 88-97 interferon lambda 3 Homo sapiens 10-16 28232517-2 2017 We determined the cumulative incidence of DM2 in subjects with chronic HCV infection who received concomitant pegylated interferon (Peg-IFN) and ribavirin. Ribavirin 145-154 immunoglobulin heavy diversity 1-14 (non-functional) Homo sapiens 42-45 28417642-0 2017 Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin. Ribavirin 123-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-38 28417642-9 2017 Results There was a strong direct correlation between expression of ENT1 in primary hepatocytes and ribavirin uptake at 24 hr. Ribavirin 100-109 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-72 28417642-12 2017 Conclusions In this study, we clearly demonstrate that ribavirin uptake in primary human hepatocytes is variable and correlates with ENT1 expression. Ribavirin 55-64 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-137 28417642-13 2017 This variation in ENT1 expression may account for differences in response rate in patients receiving ribavirin-based anti-hepatitis C virus therapy. Ribavirin 101-110 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-22 28496530-0 2017 Assessment of the Relation Between SNP in MxA Gene and the Responsiveness of Egyptian HCV Genotype 4 Patients to Pegylated Interferon and Ribavirin Treatment. Ribavirin 138-147 MX dynamin like GTPase 1 Homo sapiens 42-45 28496530-4 2017 The aim of the work was to assess the relation between the SNP in the MxA gene and its impact on treatment of chronic HCV patients with PegIFN and ribavirin. Ribavirin 147-156 MX dynamin like GTPase 1 Homo sapiens 70-73 28496530-9 2017 Our results call for additional large studies and/or meta-analysis of all currently available data to examine the role of MxA nt-88 SNP in predicting response to PegIFN and ribavirin in patients with IFN-alpha naive HCV genotype 4. Ribavirin 173-182 interferon alpha 1 Homo sapiens 200-209 27027531-0 2017 IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. AIM: Older patients with chronic hepatitis C have a lower virological response to interferon (IFN)-based treatments compared to younger patients. Ribavirin 72-81 interferon lambda 4 (gene/pseudogene) Homo sapiens 0-5 27896573-1 2017 The human immunodeficiency virus (HIV), hepatitis C virus (HCV), and the treatment of HCV with pegylated interferon and ribavirin (IFN/RBV) have been associated with neurocognitive and psychiatric abnormalities. Ribavirin 120-129 interferon alpha 1 Homo sapiens 131-134 28566078-2 2017 NS3 inhibitors (PI) with low genetic barrier have been approved to be used in the CHC genotype 1 infections, and in the treatment of compensated liver disease including cirrhosis together with pegile interferon and ribavirin. Ribavirin 215-224 KRAS proto-oncogene, GTPase Homo sapiens 0-3 27165046-2 2017 The objective of this analysis was to evaluate the effect of renal function as determined by creatinine clearance (CrCL) on the pharmacokinetics of the DAAs, ritonavir, and ribavirin in HCV genotype 1-infected patients with or without cirrhosis. Ribavirin 173-182 CRCL Homo sapiens 115-119 27165046-4 2017 The effect of CrCL on the AUC values of each DAA, ritonavir, and ribavirin was separately evaluated and adjusted for any significant patient-specific covariates including, age, sex, body weight, cirrhosis, and Asian race in multiple linear regression analysis. Ribavirin 65-74 CRCL Homo sapiens 14-18 27165046-10 2017 CrCL showed a significant relationship with the ribavirin AUC values, consistent with ribavirin"s renal excretion. Ribavirin 48-57 CRCL Homo sapiens 0-4 27165046-10 2017 CrCL showed a significant relationship with the ribavirin AUC values, consistent with ribavirin"s renal excretion. Ribavirin 86-95 CRCL Homo sapiens 0-4 28233734-7 2017 Prospective studies assessing the usefulness of RBV in the era of new IFN-free combinations are needed. Ribavirin 48-51 interferon alpha 1 Homo sapiens 70-73 27027531-0 2017 IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. AIM: Older patients with chronic hepatitis C have a lower virological response to interferon (IFN)-based treatments compared to younger patients. Ribavirin 72-81 interferon alpha 1 Homo sapiens 0-3 27693529-7 2017 Patients whose HCV infection failed to respond to boceprevir, peginterferon and ribavirin therapy developed mutations in NS3 at position T54A and R155K. Ribavirin 80-89 KRAS proto-oncogene, GTPase Homo sapiens 121-124 28187751-4 2017 RESULTS: In Panel 1 and Panel 2-Arm 1, 5/10 and 6/12 (50%) GT1a/GT1b + ribavirin patients achieved SVR12, versus 3/9 (33%) GT1b without ribavirin patients in Panel 2-Arm 2. Ribavirin 71-80 ADRM1 26S proteasome ubiquitin receptor Homo sapiens 32-37 27956135-3 2017 Single nucleotide polymorphisms in the gene encoding the inosine triphosphatase (ITPA) enzyme have been associated with protection against RBV-induced anemia and may mediate the effect of RBV treatment on endogenous purines. Ribavirin 139-142 inosine triphosphatase Homo sapiens 57-79 27956135-3 2017 Single nucleotide polymorphisms in the gene encoding the inosine triphosphatase (ITPA) enzyme have been associated with protection against RBV-induced anemia and may mediate the effect of RBV treatment on endogenous purines. Ribavirin 139-142 inosine triphosphatase Homo sapiens 81-85 27956135-3 2017 Single nucleotide polymorphisms in the gene encoding the inosine triphosphatase (ITPA) enzyme have been associated with protection against RBV-induced anemia and may mediate the effect of RBV treatment on endogenous purines. Ribavirin 188-191 inosine triphosphatase Homo sapiens 57-79 27956135-3 2017 Single nucleotide polymorphisms in the gene encoding the inosine triphosphatase (ITPA) enzyme have been associated with protection against RBV-induced anemia and may mediate the effect of RBV treatment on endogenous purines. Ribavirin 188-191 inosine triphosphatase Homo sapiens 81-85 26567007-0 2017 Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-alpha and ribavirin treatment: potential role as markers of response to antiviral therapy. Ribavirin 149-158 major histocompatibility complex, class I, A Homo sapiens 20-33 26567007-0 2017 Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-alpha and ribavirin treatment: potential role as markers of response to antiviral therapy. Ribavirin 149-158 major histocompatibility complex, class I, G Homo sapiens 38-43 27793650-2 2017 The aim of the study was to analyze the association of single nucleotide polymorphisms (SNPs) of IL-10 gene with severity of liver disease (degree of inflammation and stage of fibrosis) and outcome of pegylated interferon alpha and ribavirin combined therapy (sustained virological response (SVR) and relapse) in 196 Polish CHC patients infected with HCV genotype 1. Ribavirin 232-241 interleukin 10 Homo sapiens 97-102 28207300-2 2017 The equilibrative nucleoside transporter-1 codified by SLC29A1 gene has been associated with ribavirin uptake into hepatocytes and erythrocytes. Ribavirin 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 55-62 28207300-3 2017 rs760370A>G single nucleotide polymorphism (SNP) at the SLC29A1 gene may have a role in ribavirin-based regimen treatment response. Ribavirin 91-100 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 59-66 27932243-0 2017 Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma. Ribavirin 44-53 mechanistic target of rapamycin kinase Homo sapiens 14-18 28125694-5 2017 PATIENTS AND METHODS: Eighty-seven GT4 treatment-naive or -Interferon (IFN) ribavirin (RBV) experienced patients treated with sofosbuvir and simeprevir +/- ribavirin (RBV) were enrolled in this cohort study (41% severe fibrosis, 59% cirrhosis). Ribavirin 76-85 interferon alpha 1 Homo sapiens 71-74 27932243-0 2017 Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma. Ribavirin 44-53 eukaryotic translation initiation factor 4E Homo sapiens 19-24 27932243-3 2017 In this work, we show that ribavirin, an anti-viral drug, effectively augments sensitivity of OTSCC cells to paclitaxel via inhibiting mTOR/eIF4E signaling pathway. Ribavirin 27-36 mechanistic target of rapamycin kinase Homo sapiens 135-139 27932243-3 2017 In this work, we show that ribavirin, an anti-viral drug, effectively augments sensitivity of OTSCC cells to paclitaxel via inhibiting mTOR/eIF4E signaling pathway. Ribavirin 27-36 eukaryotic translation initiation factor 4E Homo sapiens 140-145 27932243-7 2017 Mechanistically, ribavirin significantly decreases mTOR/eIF4E signaling pathway in OTSCC cells via suppressing phosphorylation of Akt, mTOR, 4EBP1 and eIF4E. Ribavirin 17-26 mechanistic target of rapamycin kinase Homo sapiens 51-55 27932243-7 2017 Mechanistically, ribavirin significantly decreases mTOR/eIF4E signaling pathway in OTSCC cells via suppressing phosphorylation of Akt, mTOR, 4EBP1 and eIF4E. Ribavirin 17-26 eukaryotic translation initiation factor 4E Homo sapiens 56-61 27932243-7 2017 Mechanistically, ribavirin significantly decreases mTOR/eIF4E signaling pathway in OTSCC cells via suppressing phosphorylation of Akt, mTOR, 4EBP1 and eIF4E. Ribavirin 17-26 AKT serine/threonine kinase 1 Homo sapiens 130-133 27932243-7 2017 Mechanistically, ribavirin significantly decreases mTOR/eIF4E signaling pathway in OTSCC cells via suppressing phosphorylation of Akt, mTOR, 4EBP1 and eIF4E. Ribavirin 17-26 mechanistic target of rapamycin kinase Homo sapiens 135-139 27932243-7 2017 Mechanistically, ribavirin significantly decreases mTOR/eIF4E signaling pathway in OTSCC cells via suppressing phosphorylation of Akt, mTOR, 4EBP1 and eIF4E. Ribavirin 17-26 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 141-146 27932243-7 2017 Mechanistically, ribavirin significantly decreases mTOR/eIF4E signaling pathway in OTSCC cells via suppressing phosphorylation of Akt, mTOR, 4EBP1 and eIF4E. Ribavirin 17-26 eukaryotic translation initiation factor 4E Homo sapiens 151-156 27932243-8 2017 Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells. Ribavirin 142-151 eukaryotic translation initiation factor 4E Homo sapiens 47-52 27932243-8 2017 Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells. Ribavirin 142-151 eukaryotic translation initiation factor 4E Homo sapiens 54-59 27932243-8 2017 Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells. Ribavirin 142-151 eukaryotic translation initiation factor 4E Homo sapiens 54-59 27932243-8 2017 Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells. Ribavirin 142-151 eukaryotic translation initiation factor 4E Homo sapiens 54-59 27932243-8 2017 Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells. Ribavirin 216-225 eukaryotic translation initiation factor 4E Homo sapiens 47-52 27932243-8 2017 Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells. Ribavirin 216-225 eukaryotic translation initiation factor 4E Homo sapiens 54-59 27932243-8 2017 Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells. Ribavirin 216-225 eukaryotic translation initiation factor 4E Homo sapiens 54-59 27932243-8 2017 Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells. Ribavirin 216-225 eukaryotic translation initiation factor 4E Homo sapiens 54-59 27583701-0 2017 ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study). Ribavirin 109-118 inosine triphosphatase Homo sapiens 0-4 27583701-1 2017 BACKGROUND: We aimed to determine the impact of inosine triphosphatase (ITPA) deficiency on ribavirin (RBV)-induced anaemia in HIV-HCV-coinfected patients receiving a triple therapy including the haematotoxic direct-acting antiviral agent boceprevir (BOC). Ribavirin 92-101 inosine triphosphatase Homo sapiens 48-70 27583701-13 2017 CONCLUSIONS: ITPA deficiency and RBV Ctrough are still predictive of RBV-induced anaemia in HIV-HCV-coinfected patients treated with RBV combined with a first-generation direct antiviral agent. Ribavirin 69-72 inosine triphosphatase Homo sapiens 13-17 27583701-1 2017 BACKGROUND: We aimed to determine the impact of inosine triphosphatase (ITPA) deficiency on ribavirin (RBV)-induced anaemia in HIV-HCV-coinfected patients receiving a triple therapy including the haematotoxic direct-acting antiviral agent boceprevir (BOC). Ribavirin 92-101 inosine triphosphatase Homo sapiens 72-76 27583701-1 2017 BACKGROUND: We aimed to determine the impact of inosine triphosphatase (ITPA) deficiency on ribavirin (RBV)-induced anaemia in HIV-HCV-coinfected patients receiving a triple therapy including the haematotoxic direct-acting antiviral agent boceprevir (BOC). Ribavirin 103-106 inosine triphosphatase Homo sapiens 48-70 27583701-1 2017 BACKGROUND: We aimed to determine the impact of inosine triphosphatase (ITPA) deficiency on ribavirin (RBV)-induced anaemia in HIV-HCV-coinfected patients receiving a triple therapy including the haematotoxic direct-acting antiviral agent boceprevir (BOC). Ribavirin 103-106 inosine triphosphatase Homo sapiens 72-76 26521772-7 2017 Circulating CXCL10 levels, and the interleukin(IL)-28B gene polymorphisms, are associated with the success of the therapy both with DAAs or ribavirin and PEGylated interferon-alpha. Ribavirin 140-149 C-X-C motif chemokine ligand 10 Homo sapiens 12-18 28165327-8 2017 CONCLUSIONS: This study suggests that the polymorphisms in the ITPA gene influence the severity of anaemia during the first month of a DAA/RBV-based treatment in HCV-related cirrhosis. Ribavirin 139-142 inosine triphosphatase Homo sapiens 63-67 26521772-7 2017 Circulating CXCL10 levels, and the interleukin(IL)-28B gene polymorphisms, are associated with the success of the therapy both with DAAs or ribavirin and PEGylated interferon-alpha. Ribavirin 140-149 interferon lambda 3 Homo sapiens 35-54 29733167-5 2017 It was shown that in the case of treatment with Peg-IFN-alpha in combination with ribavirin, a significant decrease in the number of white blood cells, neutrophils and platelets prevailed in patients with HCV-monoinfected genotype 1b in the F0-F2 stages (2,8-8,6 kPa) at METAVIR. Ribavirin 82-91 interferon alpha 1 Homo sapiens 52-61 29040986-8 2017 Moreover, BMP-7 and CTGF were significantly lower at EOT than the baseline in the Sofosbuvir plus RBV group. Ribavirin 98-101 bone morphogenetic protein 7 Homo sapiens 10-15 29040986-8 2017 Moreover, BMP-7 and CTGF were significantly lower at EOT than the baseline in the Sofosbuvir plus RBV group. Ribavirin 98-101 cellular communication network factor 2 Homo sapiens 20-24 27818246-2 2017 Ribavirin-triggered oxidative stress, caspase activation, and apoptotic death in U251 human glioma cells were associated with the induction of autophagy, as confirmed by intracellular acidification, appearance of autophagic vesicles, conversion of microtubule associated protein 1 light chain 3 (LC3)-I to autophagosome-associated LC3-II, and degradation of autophagic target p62/sequestosome 1. Ribavirin 0-9 microtubule associated protein 1 light chain 3 alpha Homo sapiens 296-299 27818246-2 2017 Ribavirin-triggered oxidative stress, caspase activation, and apoptotic death in U251 human glioma cells were associated with the induction of autophagy, as confirmed by intracellular acidification, appearance of autophagic vesicles, conversion of microtubule associated protein 1 light chain 3 (LC3)-I to autophagosome-associated LC3-II, and degradation of autophagic target p62/sequestosome 1. Ribavirin 0-9 microtubule associated protein 1 light chain 3 alpha Homo sapiens 331-334 27818246-2 2017 Ribavirin-triggered oxidative stress, caspase activation, and apoptotic death in U251 human glioma cells were associated with the induction of autophagy, as confirmed by intracellular acidification, appearance of autophagic vesicles, conversion of microtubule associated protein 1 light chain 3 (LC3)-I to autophagosome-associated LC3-II, and degradation of autophagic target p62/sequestosome 1. Ribavirin 0-9 sequestosome 1 Homo sapiens 376-379 27818246-2 2017 Ribavirin-triggered oxidative stress, caspase activation, and apoptotic death in U251 human glioma cells were associated with the induction of autophagy, as confirmed by intracellular acidification, appearance of autophagic vesicles, conversion of microtubule associated protein 1 light chain 3 (LC3)-I to autophagosome-associated LC3-II, and degradation of autophagic target p62/sequestosome 1. Ribavirin 0-9 sequestosome 1 Homo sapiens 380-394 27818246-3 2017 Ribavirin downregulated the activity of autophagy-inhibiting mammalian target of rapamycin complex 1 (mTORC1), as indicated by a decrease in phosphorylation of the mTORC1 substrate ribosomal p70S6 kinase and reduction of the mTORC1-activating Src/Akt signaling. Ribavirin 0-9 CREB regulated transcription coactivator 1 Mus musculus 102-108 27818246-3 2017 Ribavirin downregulated the activity of autophagy-inhibiting mammalian target of rapamycin complex 1 (mTORC1), as indicated by a decrease in phosphorylation of the mTORC1 substrate ribosomal p70S6 kinase and reduction of the mTORC1-activating Src/Akt signaling. Ribavirin 0-9 CREB regulated transcription coactivator 1 Mus musculus 164-170 27818246-3 2017 Ribavirin downregulated the activity of autophagy-inhibiting mammalian target of rapamycin complex 1 (mTORC1), as indicated by a decrease in phosphorylation of the mTORC1 substrate ribosomal p70S6 kinase and reduction of the mTORC1-activating Src/Akt signaling. Ribavirin 0-9 CREB regulated transcription coactivator 1 Mus musculus 164-170 27818246-3 2017 Ribavirin downregulated the activity of autophagy-inhibiting mammalian target of rapamycin complex 1 (mTORC1), as indicated by a decrease in phosphorylation of the mTORC1 substrate ribosomal p70S6 kinase and reduction of the mTORC1-activating Src/Akt signaling. Ribavirin 0-9 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 243-246 27818246-3 2017 Ribavirin downregulated the activity of autophagy-inhibiting mammalian target of rapamycin complex 1 (mTORC1), as indicated by a decrease in phosphorylation of the mTORC1 substrate ribosomal p70S6 kinase and reduction of the mTORC1-activating Src/Akt signaling. Ribavirin 0-9 AKT serine/threonine kinase 1 Homo sapiens 247-250 27818246-5 2017 Autophagy suppression by ammonium chloride, bafilomycin A1, or RNA interference-mediated knockdown of LC3 sensitized glioma cells to ribavirin-induced apoptosis. Ribavirin 133-142 microtubule associated protein 1 light chain 3 alpha Homo sapiens 102-105 27818246-6 2017 Ribavirin also induced cytoprotective autophagy associated with Akt/mTORC1 inhibition in C6 rat glioma cells. Ribavirin 0-9 AKT serine/threonine kinase 1 Rattus norvegicus 64-67 27818246-6 2017 Ribavirin also induced cytoprotective autophagy associated with Akt/mTORC1 inhibition in C6 rat glioma cells. Ribavirin 0-9 CREB regulated transcription coactivator 1 Mus musculus 68-74 27818246-7 2017 Our data demonstrate that ribavirin-triggered Akt/mTORC1-dependent autophagy counteracts apoptotic death of glioma cells, indicating autophagy suppression as a plausible therapeutic strategy for sensitization of cancer cells to IMPDH inhibition. Ribavirin 26-35 AKT serine/threonine kinase 1 Homo sapiens 46-49 27818246-7 2017 Our data demonstrate that ribavirin-triggered Akt/mTORC1-dependent autophagy counteracts apoptotic death of glioma cells, indicating autophagy suppression as a plausible therapeutic strategy for sensitization of cancer cells to IMPDH inhibition. Ribavirin 26-35 CREB regulated transcription coactivator 1 Mus musculus 50-56 27349952-1 2017 Individuals with lower inosine triphosphatase (ITPA) enzyme activity have a reduced likelihood of experiencing hemolytic anemia during hepatitis C virus (HCV) treatment containing ribavirin (RBV). Ribavirin 180-189 inosine triphosphatase Homo sapiens 23-45 27349952-1 2017 Individuals with lower inosine triphosphatase (ITPA) enzyme activity have a reduced likelihood of experiencing hemolytic anemia during hepatitis C virus (HCV) treatment containing ribavirin (RBV). Ribavirin 180-189 inosine triphosphatase Homo sapiens 47-51 27349952-1 2017 Individuals with lower inosine triphosphatase (ITPA) enzyme activity have a reduced likelihood of experiencing hemolytic anemia during hepatitis C virus (HCV) treatment containing ribavirin (RBV). Ribavirin 191-194 inosine triphosphatase Homo sapiens 23-45 27349952-1 2017 Individuals with lower inosine triphosphatase (ITPA) enzyme activity have a reduced likelihood of experiencing hemolytic anemia during hepatitis C virus (HCV) treatment containing ribavirin (RBV). Ribavirin 191-194 inosine triphosphatase Homo sapiens 47-51 27349952-2 2017 Because ITPA degrades purines and RBV is a purine analogue, it is conceivable that ITPA activity may affect intracellular RBV concentrations. Ribavirin 34-37 inosine triphosphatase Homo sapiens 83-87 27349952-2 2017 Because ITPA degrades purines and RBV is a purine analogue, it is conceivable that ITPA activity may affect intracellular RBV concentrations. Ribavirin 122-125 inosine triphosphatase Homo sapiens 8-12 27349952-2 2017 Because ITPA degrades purines and RBV is a purine analogue, it is conceivable that ITPA activity may affect intracellular RBV concentrations. Ribavirin 122-125 inosine triphosphatase Homo sapiens 83-87 27349952-7 2017 Despite higher RBV-TP levels, individuals with variant ITPA phenotypes had less anemia. Ribavirin 15-18 inosine triphosphatase Homo sapiens 55-59 27349952-9 2017 This finding of higher RBV-TP concentrations in RBCs in ITPA variants was unexpected given that ITPA activity-deficient individuals have a reduced likelihood of RBV-induced anemia. Ribavirin 23-26 inosine triphosphatase Homo sapiens 56-60 27349952-9 2017 This finding of higher RBV-TP concentrations in RBCs in ITPA variants was unexpected given that ITPA activity-deficient individuals have a reduced likelihood of RBV-induced anemia. Ribavirin 23-26 inosine triphosphatase Homo sapiens 96-100 27349952-9 2017 This finding of higher RBV-TP concentrations in RBCs in ITPA variants was unexpected given that ITPA activity-deficient individuals have a reduced likelihood of RBV-induced anemia. Ribavirin 161-164 inosine triphosphatase Homo sapiens 56-60 27349952-9 2017 This finding of higher RBV-TP concentrations in RBCs in ITPA variants was unexpected given that ITPA activity-deficient individuals have a reduced likelihood of RBV-induced anemia. Ribavirin 161-164 inosine triphosphatase Homo sapiens 96-100 27349952-10 2017 It also refutes the hypothesis that the mechanism by which ITPA variants are protected against anemia is due to lower RBV-TP levels in RBCs. Ribavirin 118-121 inosine triphosphatase Homo sapiens 59-63 27833011-6 2017 Ribavirin treatment of uninfected larvae reduces the basal level of IFNgamma, but increases the level of IL-1beta mRNA expression. Ribavirin 0-9 interferon gamma Homo sapiens 68-76 27833011-6 2017 Ribavirin treatment of uninfected larvae reduces the basal level of IFNgamma, but increases the level of IL-1beta mRNA expression. Ribavirin 0-9 interleukin 1 beta Homo sapiens 105-113 27833011-7 2017 Furthermore, infecting larvae with NNV following ribavirin treatment reduces the expression levels of IFNgamma, IFN-I, Mx, and TNF-alpha genes, while the expression of IL-1beta is increased. Ribavirin 49-58 interferon gamma Homo sapiens 102-110 28083615-0 2016 Functional Polymorphism in the Interleukin 6 (IL6) Gene with Respect to Depression Induced in the Course of Interferon-alpha and Ribavirin Treatment in Chronic Hepatitis Patients. Ribavirin 129-138 interleukin 6 Homo sapiens 46-49 28083615-2 2016 The aim of the study was to explore the association between IL6 gene C-174G polymorphism and depressive symptom severity in the longitudinal study design following the course of pegylated interferon/ribavirin treatment in CHC patients. Ribavirin 199-208 interleukin 6 Homo sapiens 60-63 27541605-1 2016 AIM: Telaprevir (TVR) remarkably improves the efficacy of interferon treatment for chronic hepatitis C. Interleukin-28B (IL28B) genotype and interferon-gamma-inducible protein-10 (IP-10) level predict virologic response to peg-interferon (Peg-IFN)/ribavirin (RBV) therapy. Ribavirin 248-257 interferon lambda 3 Homo sapiens 104-119 28856281-0 2016 The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin. Ribavirin 146-155 keratin 88, pseudogene Homo sapiens 22-25 27541605-1 2016 AIM: Telaprevir (TVR) remarkably improves the efficacy of interferon treatment for chronic hepatitis C. Interleukin-28B (IL28B) genotype and interferon-gamma-inducible protein-10 (IP-10) level predict virologic response to peg-interferon (Peg-IFN)/ribavirin (RBV) therapy. Ribavirin 259-262 interferon lambda 3 Homo sapiens 104-119 26674359-7 2016 The frequency of Siglec-7pos NK cells was significantly higher at baseline in sustained virological responders to pegylated interferon-alpha/ribavirin treatment than in non-responders. Ribavirin 141-150 sialic acid binding Ig like lectin 7 Homo sapiens 17-25 27591011-4 2016 Three P1,P3-bis-thio-analogs of symmetrical di(nucleosid-5"-yl) triphosphates (NP3N) bearing adenosine, guanosine or ribavirin residues (6, 7 and 8, respectively), were obtained by direct condensation of corresponding base-protected nucleoside-5"-O-(2-thio-1,3,2-oxathiaphospholane) with anhydrous phosphoric acid in the presence of DBU. Ribavirin 117-126 crystallin gamma F, pseudogene Homo sapiens 6-11 28004016-0 2016 Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism. Ribavirin 22-31 killer cell lectin like receptor K1 Homo sapiens 97-120 27543394-0 2016 Influence of IL10 Gene polymorphisms on the sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy. Ribavirin 128-137 interleukin 10 Homo sapiens 13-17 26916827-0 2016 Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. AIM: Polymorphisms in the ITPA gene influence anemia during peg-interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with simeprevir, PEG-IFN, and RBV are not sufficiently known. Ribavirin 94-103 inosine triphosphatase Homo sapiens 177-181 26916827-0 2016 Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. AIM: Polymorphisms in the ITPA gene influence anemia during peg-interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with simeprevir, PEG-IFN, and RBV are not sufficiently known. Ribavirin 240-249 inosine triphosphatase Homo sapiens 177-181 26916827-0 2016 Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. AIM: Polymorphisms in the ITPA gene influence anemia during peg-interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with simeprevir, PEG-IFN, and RBV are not sufficiently known. Ribavirin 251-254 inosine triphosphatase Homo sapiens 177-181 26916827-0 2016 Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. AIM: Polymorphisms in the ITPA gene influence anemia during peg-interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with simeprevir, PEG-IFN, and RBV are not sufficiently known. Ribavirin 335-338 inosine triphosphatase Homo sapiens 177-181 26916827-5 2016 In simeprevir plus PEG-IFN/RBV-treated patients, decreases in hemoglobin levels were faster and greater, and the cumulative proportion of patients with ribavirin dose reduction was significantly greater in ITPA genotype CC patients than in CA/AA patients. Ribavirin 27-30 inosine triphosphatase Homo sapiens 206-210 26916827-5 2016 In simeprevir plus PEG-IFN/RBV-treated patients, decreases in hemoglobin levels were faster and greater, and the cumulative proportion of patients with ribavirin dose reduction was significantly greater in ITPA genotype CC patients than in CA/AA patients. Ribavirin 152-161 inosine triphosphatase Homo sapiens 206-210 27435935-6 2016 As subanalysis, serum total M2BP levels were measured in patients treated with pegylated-interferon and ribavirin. Ribavirin 104-113 galectin 3 binding protein Homo sapiens 28-32 27435935-11 2016 In patients treated with pegylated-interferon and ribavirin, total M2BP levels were positively correlated with fibrosis and HCC development. Ribavirin 50-59 galectin 3 binding protein Homo sapiens 67-71 27543394-2 2016 This meta-analysis aimed to derive a more precise estimation of the effects of IL10 gene polymorphisms (-1082G/A, -819C/T, -592C/A) and their haplotypes on SVR in CHC patients receiving pegylated interferon alpha (PEG-IFN-a) plus ribavirin. Ribavirin 230-239 interleukin 10 Homo sapiens 79-83 27857890-2 2016 The treatment typically involves a combination of interferon-alpha (IFN-alpha) and ribavirin (RBV) therapy; however, the use of IFN-alpha is well documented to be associated with thyroid disease, the most common autoimmune disorder associated with IFN-alpha. Ribavirin 83-92 interferon alpha 1 Homo sapiens 128-137 27770805-7 2016 ITPA status has been linked to altered outcomes for patients undergoing thiopurine or ribavirin therapy. Ribavirin 86-95 inosine triphosphatase Homo sapiens 0-4 27770805-8 2016 Thiopurine therapy can be toxic for patients with ITPA polymorphism, however, ITPA polymorphism is associated with improved outcomes for patients undergoing ribavirin treatment. Ribavirin 157-166 inosine triphosphatase Homo sapiens 78-82 27775635-3 2016 METHODS: We genotyped four SNPs from the candidate genes (HLA-DMA and DMB) in 336 patients who were treated with pegylated interferon-alpha and ribavirin (PEG IFN-alpha/RBV). Ribavirin 144-153 major histocompatibility complex, class II, DM alpha Homo sapiens 58-65 27444413-2 2016 The impact of RBV-free pan-genotypic regimen with SOF and velpatasvir (SOF/VEL) on patient-reported outcomes (PROs) of patients with genotype 2 and 3 has not been described. Ribavirin 14-17 small integral membrane protein 1 (Vel blood group) Homo sapiens 71-78 27444413-5 2016 The rates of nearly all adverse events were lower in the RBV-free SOF/VEL group (all P < .03). Ribavirin 57-60 small integral membrane protein 1 (Vel blood group) Homo sapiens 66-73 27444413-10 2016 Furthermore, the interferon- and ribavirin-free SOF/VEL regimen resulted in a rapid improvement of PROs in HCV GTs 2 and 3 patients during treatment and after achieving sustained virologic response. Ribavirin 33-42 small integral membrane protein 1 (Vel blood group) Homo sapiens 52-55 27146049-0 2016 Haoqin Qingdan Decoction () and ribavirin therapy downregulate CD14 and toll-like receptor 4 in febrile disease with dampness-heat syndrome in a mouse model. Ribavirin 32-41 CD14 antigen Mus musculus 63-67 27146049-0 2016 Haoqin Qingdan Decoction () and ribavirin therapy downregulate CD14 and toll-like receptor 4 in febrile disease with dampness-heat syndrome in a mouse model. Ribavirin 32-41 toll-like receptor 4 Mus musculus 72-92 27146049-10 2016 The CD14 and TLR4 expression levels in the lung tissues of HQD and ribavirin groups significantly delined compared with the model group (P<0.05 or P<0.01). Ribavirin 67-76 CD14 antigen Mus musculus 4-8 27146049-10 2016 The CD14 and TLR4 expression levels in the lung tissues of HQD and ribavirin groups significantly delined compared with the model group (P<0.05 or P<0.01). Ribavirin 67-76 toll-like receptor 4 Mus musculus 13-17 27146049-11 2016 CD14 was down-regulated more remarkably in the HQD group compared with the ribavirin group (P<0.05), whereas the converse was true with TLR4 (P<0.05). Ribavirin 75-84 CD14 antigen Mus musculus 0-4 27146049-13 2016 Both HQD and ribavirin can inhibit the expression of CD14 and TLR4 in FDDHS mice, while the effect of ribavirin might be much more violent. Ribavirin 13-22 CD14 antigen Mus musculus 53-57 27146049-13 2016 Both HQD and ribavirin can inhibit the expression of CD14 and TLR4 in FDDHS mice, while the effect of ribavirin might be much more violent. Ribavirin 13-22 toll-like receptor 4 Mus musculus 62-66 27476467-4 2016 AIM: We have shown that vWF-Ag is associated with portal hypertension and treatment response to PEG/RBV and we evaluated if vWF-Ag is a predictive marker for treatment response and safety in patients with triple therapy. Ribavirin 100-103 von Willebrand factor Homo sapiens 24-27 27456384-2 2016 We describe 2 open-label phase 2 studies investigating the efficacy and safety of ABT-493 plus ABT-530 with or without ribavirin (RBV) in GT1- or GT3-infected patients with compensated cirrhosis. Ribavirin 130-133 beta-1,4-galactosyltransferase 1 Homo sapiens 138-141 27861337-9 2016 The changes in IL-8 also differed significantly between LDV/SOF + RBV and LDV/SOF groups (P < 0.05). Ribavirin 66-69 C-X-C motif chemokine ligand 8 Homo sapiens 15-19 27328944-9 2016 Furthermore, induction of ISGs and the anti-HEV effect of IRF1 overlapped that of IFNalpha, but was potentiated by ribavirin. Ribavirin 115-124 interferon regulatory factor 1 Homo sapiens 58-62 27857890-2 2016 The treatment typically involves a combination of interferon-alpha (IFN-alpha) and ribavirin (RBV) therapy; however, the use of IFN-alpha is well documented to be associated with thyroid disease, the most common autoimmune disorder associated with IFN-alpha. Ribavirin 83-92 interferon alpha 1 Homo sapiens 128-137 27498543-0 2016 Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3? Ribavirin 55-64 interferon lambda 3 Homo sapiens 4-9 27498543-1 2016 Favourable genotypes of IFNL3 polymorphism CC for rs12979860 and TT for rs8099917 are strongly associated with the interferon/ribavirin treatment outcome in hepatitis C virus (HCV) patients with genotypes 1 and 4. Ribavirin 126-135 interferon lambda 3 Homo sapiens 24-29 27379616-3 2016 Ribavirin and Indinavir are known inhibitors of eIF4E activity. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 48-53 26991414-7 2016 RBV dosage affected SVR dose-dependently in patients with the IL28B non-TT genotype treated with SMV triple therapy. Ribavirin 0-3 interferon lambda 3 Homo sapiens 62-67 27196675-11 2016 In conclusion, LDV/SOF and SOF+RBV demonstrate a high barrier to resistance in Japanese patients with HCV GT1 and GT2 infection. Ribavirin 31-34 beta-1,4-galactosyltransferase 1 Homo sapiens 106-109 27379616-6 2016 RESULTS: In vitro analyses indicate that Ribavirin and Indinavir reduce viability of HeLa cells, induce apoptosis and decrease secretion of MMPs. Ribavirin 41-50 matrix metallopeptidase 2 Homo sapiens 140-144 27194214-0 2016 The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouse. Ribavirin 91-100 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 16-54 27660680-3 2016 There is a strong relationship between single nucleotide polymorphisms at or near the IL-28B gene and the sustained virological response with pegylated interferon plus ribavirin treatment for chronic hepatitis C. Pakistan is a resource limited country, with very low per capita income and there is no proper social security (health insurance) system. Ribavirin 168-177 interferon lambda 3 Homo sapiens 86-92 27590274-3 2016 The aim of this study is to analyze whether TRIM5 and TRIM22 polymorphisms are associated with liver fibrosis inflammation-related biomarkers and response to pegylated-interferon-alpha plus ribavirin (pegIFNalpha/RBV) therapy in HIV/hepatitis C virus (HCV) coinfected patients. Ribavirin 190-199 tripartite motif containing 5 Homo sapiens 44-49 27590274-3 2016 The aim of this study is to analyze whether TRIM5 and TRIM22 polymorphisms are associated with liver fibrosis inflammation-related biomarkers and response to pegylated-interferon-alpha plus ribavirin (pegIFNalpha/RBV) therapy in HIV/hepatitis C virus (HCV) coinfected patients. Ribavirin 213-216 tripartite motif containing 5 Homo sapiens 44-49 27590274-14 2016 CONCLUSIONS: TRIM5 and TRIM22 SNPs are associated to increased odds of significant liver fibrosis and SVR after pegIFNalpha/RBV therapy in HIV/HCV coinfected patients. Ribavirin 124-127 tripartite motif containing 5 Homo sapiens 13-18 27590274-14 2016 CONCLUSIONS: TRIM5 and TRIM22 SNPs are associated to increased odds of significant liver fibrosis and SVR after pegIFNalpha/RBV therapy in HIV/HCV coinfected patients. Ribavirin 124-127 tripartite motif containing 22 Homo sapiens 23-29 27194214-10 2016 The findings in the present study suggest that ENT1 plays a pivotal role in the distribution of ribavirin into tissues including the liver and pancreas, but affects only the rate, but not the extent, of ribavirin distribution into the fetus. Ribavirin 96-105 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 47-51 27194214-10 2016 The findings in the present study suggest that ENT1 plays a pivotal role in the distribution of ribavirin into tissues including the liver and pancreas, but affects only the rate, but not the extent, of ribavirin distribution into the fetus. Ribavirin 203-212 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 47-51 27194214-2 2016 The equilibrative nucleoside transporter 1 (ENT1) expressed in hepatocytes transports ribavirin into the liver, the site of efficacy of the drug. Ribavirin 86-95 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 4-42 27194214-2 2016 The equilibrative nucleoside transporter 1 (ENT1) expressed in hepatocytes transports ribavirin into the liver, the site of efficacy of the drug. Ribavirin 86-95 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 44-48 27194214-5 2016 ENT1 might play a role in the fetal distribution and therefore the fetal toxicity of ribavirin. Ribavirin 85-94 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 0-4 27194214-6 2016 The aim of the present study was to investigate the in vivo contribution of ENT1 to the tissue distribution of ribavirin. Ribavirin 111-120 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 76-80 27194214-7 2016 When compared with that in Ent1(+/+) mice, the ribavirin tissue to plasma concentration ratio (including phosphorylated metabolites) in Ent1(-/-) mice at 15 min and 6 h after intravenous [(3) H]-ribavirin (3 mg/kg) administration was consistently and significantly decreased in the liver and the pancreas. Ribavirin 47-56 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 136-140 27194214-8 2016 Likewise, when compared with the Ent1(+/+) mice, the fetal distribution of ribavirin at 15 min after administration was significantly reduced in Ent1(-/-) fetuses and placenta. Ribavirin 75-84 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 33-37 27194214-8 2016 Likewise, when compared with the Ent1(+/+) mice, the fetal distribution of ribavirin at 15 min after administration was significantly reduced in Ent1(-/-) fetuses and placenta. Ribavirin 75-84 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 145-149 26921346-4 2016 First, IFN-alpha exerts a rapid, antiproliferative and proapoptotic effect in vitro and in vivo, as early as after 2 d of pegylated IFN/ribavirin therapy in patients with chronic hepatitis C. Such activities result in the decline, at d 2, in circulating regulatory T cell frequency and specifically of the activated regulatory T cell subset. Ribavirin 136-145 interferon alpha 1 Homo sapiens 7-16 28856274-12 2016 CONCLUSIONS: In treatment-naive patients with genotype 3 HCV infection, low baseline platelet count and elevated GGT activity were significantly associated with poor response to PegIFNalpha and RBV. Ribavirin 194-197 gamma-glutamyltransferase 1 Homo sapiens 113-116 26921346-4 2016 First, IFN-alpha exerts a rapid, antiproliferative and proapoptotic effect in vitro and in vivo, as early as after 2 d of pegylated IFN/ribavirin therapy in patients with chronic hepatitis C. Such activities result in the decline, at d 2, in circulating regulatory T cell frequency and specifically of the activated regulatory T cell subset. Ribavirin 136-145 interferon alpha 1 Homo sapiens 7-10 27501049-10 2016 The importance of eIF4E KD to NSCLC phenotype was further corroborated with its inhibitor, ribavirin. Ribavirin 91-100 eukaryotic translation initiation factor 4E Homo sapiens 18-23 27904617-0 2016 The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. BACKGROUND: A dinucleotide variant rs368234815 in interferon lambda 4 (IFNL4) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. Ribavirin 98-107 interferon lambda 4 (gene/pseudogene) Homo sapiens 4-23 27904617-0 2016 The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. BACKGROUND: A dinucleotide variant rs368234815 in interferon lambda 4 (IFNL4) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. Ribavirin 98-107 interferon lambda 4 (gene/pseudogene) Homo sapiens 207-226 27904617-0 2016 The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. BACKGROUND: A dinucleotide variant rs368234815 in interferon lambda 4 (IFNL4) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. Ribavirin 98-107 interferon lambda 4 (gene/pseudogene) Homo sapiens 228-233 27904617-1 2016 This study aimed to assess the impact of IFNL4 rs368234815 polymorphism on treatment response to pegylated-IFN alpha (Peg-IFN-alpha) and ribavirin (RBV) in hemophilic patients with chronic hepatitis C (CHC). Ribavirin 137-146 interferon lambda 4 (gene/pseudogene) Homo sapiens 41-46 27904617-1 2016 This study aimed to assess the impact of IFNL4 rs368234815 polymorphism on treatment response to pegylated-IFN alpha (Peg-IFN-alpha) and ribavirin (RBV) in hemophilic patients with chronic hepatitis C (CHC). Ribavirin 148-151 interferon lambda 4 (gene/pseudogene) Homo sapiens 41-46 27272497-1 2016 Legalon SIL (SIL) is a chemically hydrophilized version of silibinin, an extract of milk thistle (Silybum marianum) seeds that has exhibited hepatoprotective and antiviral effectiveness against hepatitis C virus (HCV) in patients leading to viral clearance in combination with ribavirin. Ribavirin 277-286 STIL centriolar assembly protein Homo sapiens 8-11 27501049-12 2016 In summary, targeting eIF4E/eIF4GI reduces migration and EMT, both essential for metastasis, thereby underscoring the potential of TI targeting in NSCLC therapy, especially the already clinically employed agents (ribavirin/4EGI). Ribavirin 213-222 eukaryotic translation initiation factor 4E Homo sapiens 22-27 27501049-12 2016 In summary, targeting eIF4E/eIF4GI reduces migration and EMT, both essential for metastasis, thereby underscoring the potential of TI targeting in NSCLC therapy, especially the already clinically employed agents (ribavirin/4EGI). Ribavirin 213-222 eukaryotic translation initiation factor 4 gamma 1 Homo sapiens 28-34 26836972-2 2016 The aim was to analyze whether IL15 rs10833 is associated with liver disease severity and response to pegylated-interferon-alpha plus ribavirin (pegIFN-alpha/RBV) therapy in human immunodeficiency virus (HIV)-/HCV-co-infected patients. Ribavirin 134-143 interleukin 15 Homo sapiens 31-35 27547881-4 2016 Pharmacogenetics has identified ITPA and SLC28/29 genes to be closely related to RBV-induced anemia. Ribavirin 81-84 inosine triphosphatase Homo sapiens 32-36 26836972-2 2016 The aim was to analyze whether IL15 rs10833 is associated with liver disease severity and response to pegylated-interferon-alpha plus ribavirin (pegIFN-alpha/RBV) therapy in human immunodeficiency virus (HIV)-/HCV-co-infected patients. Ribavirin 158-161 interleukin 15 Homo sapiens 31-35 26836972-11 2016 CONCLUSIONS: The presence of IL15 rs10833 AA genotype in HIV-/HCV-co-infected patients was associated with advanced liver fibrosis, inflammation-related biomarkers and increased rates of SVR to pegIFN-alpha/RBV therapy. Ribavirin 207-210 interleukin 15 Homo sapiens 29-33 27149089-1 2016 OBJECTIVES: Ribavirin (RBV) induced anemia may be influenced by host genetic factors affecting RBV transport solute carrier (SLC) or metabolism inosine triphosphatase (ITPA), as already reported. Ribavirin 12-21 inosine triphosphatase Homo sapiens 168-172 27561198-0 2016 Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy. Ribavirin 135-144 scavenger receptor class B member 1 Homo sapiens 15-21 27149089-1 2016 OBJECTIVES: Ribavirin (RBV) induced anemia may be influenced by host genetic factors affecting RBV transport solute carrier (SLC) or metabolism inosine triphosphatase (ITPA), as already reported. Ribavirin 23-26 inosine triphosphatase Homo sapiens 168-172 27140229-0 2016 Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. Ribavirin 43-52 interferon lambda 3 Homo sapiens 56-61 27506143-1 2016 Hemolytic anemia is a major side effect of ribavirin antiviral treatment for chronic hepatitis C. Ribavirin dose reduction may compromise the antiviral response and erythropoietin can take several weeks to alleviate anemia. Ribavirin 43-52 erythropoietin Oryctolagus cuniculus 165-179 27140229-19 2016 CONCLUSION: In this small study, the interferon-free regimen of faldaprevir, deleobuvir and ribavirin resulted in high rates of virological breakthrough and low rates of SVR12 in IL28B non-CC genotype patients infected with genotype-1a HCV (http://www.clinicaltrials.gov NCT01132313). Ribavirin 92-101 interferon lambda 3 Homo sapiens 179-184 27376688-1 2016 BACKGROUND: Triple therapy with Pegylated-Interferon alpha (PEG-IFNalpha)/Ribavirin (RBV) and Boceprevir (Boc) or Telaprevir (Tel) significantly improved sustained virological response (SVR) rates for patients with genotype 1 HCV infection compared to PEG-IFNalpha/RBV alone (dual therapy). Ribavirin 74-83 interferon alpha 1 Homo sapiens 256-264 27128845-0 2016 Molecular assessment of vitamin D receptor polymorphism as a valid predictor to the response of interferon/ribavirin-based therapy in Egyptian patients with chronic hepatitis C. OBJECTIVE: The aim of this study was to find an association between serum concentration of vitamin D and vitamin D receptor (VDR) polymorphisms to achieve a sustained virological response (SVR). Ribavirin 107-116 vitamin D receptor Homo sapiens 24-42 27376688-1 2016 BACKGROUND: Triple therapy with Pegylated-Interferon alpha (PEG-IFNalpha)/Ribavirin (RBV) and Boceprevir (Boc) or Telaprevir (Tel) significantly improved sustained virological response (SVR) rates for patients with genotype 1 HCV infection compared to PEG-IFNalpha/RBV alone (dual therapy). Ribavirin 265-268 interferon alpha 1 Homo sapiens 64-72 26750805-0 2016 Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients. Ribavirin 111-120 Kruppel like factor 12 Homo sapiens 81-86 26750805-7 2016 RBV-induced anemia was independently correlated with SLC29A1 rs760370 AA genotype (OR, 2.90; 95% CI, 1.29-6.54, P = 0.010), and the severity of IFN-induced thrombocytopenia was related to GG genotype (OR, 4.98; 95% CI, 1.27-19.61; P = 0.021); the detected effects held true for HCV-2a patients but weakened in HCV-1b patients. Ribavirin 0-3 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-60 26750805-7 2016 RBV-induced anemia was independently correlated with SLC29A1 rs760370 AA genotype (OR, 2.90; 95% CI, 1.29-6.54, P = 0.010), and the severity of IFN-induced thrombocytopenia was related to GG genotype (OR, 4.98; 95% CI, 1.27-19.61; P = 0.021); the detected effects held true for HCV-2a patients but weakened in HCV-1b patients. Ribavirin 0-3 interferon alpha 1 Homo sapiens 144-147 27348632-0 2016 CD209 promoter polymorphisms associate with HCV infection and pegylated-interferon plus ribavirin treatment response. Ribavirin 88-97 CD209 molecule Homo sapiens 0-5 28144454-0 2016 Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. BACKGROUND: The current medical treatment for hepatitis C virus (HCV) infection is pegylated interferon plus ribavirin, but just 50% of genotype 1 HCV patients and about 80% of HCV genotype 3 patients are treated completely. Ribavirin 99-108 interferon lambda 3 Homo sapiens 8-12 28144454-0 2016 Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. BACKGROUND: The current medical treatment for hepatitis C virus (HCV) infection is pegylated interferon plus ribavirin, but just 50% of genotype 1 HCV patients and about 80% of HCV genotype 3 patients are treated completely. Ribavirin 264-273 interferon lambda 3 Homo sapiens 8-12 27180197-0 2016 Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis. Ribavirin 150-159 interferon lambda 4 (gene/pseudogene) Homo sapiens 20-25 27388623-5 2016 By multivariable regression including age, sex, HCV viral load, HCV genotype, liver fibrosis stage, prior treatments, immunosuppression and IL28b genotype, ribavirin levels consistently displayed significant influence on SVR and relapse without indication for a specific importance of higher concentrations early or late in the treatment course. Ribavirin 156-165 interferon lambda 3 Homo sapiens 140-145 27180197-1 2016 BACKGROUND AND AIMS: Many studies have been published on the association between IFNL4 rs368234815 single-nucleotide polymorphism (SNP) and sustained virological response (SVR) in chronic hepatitis C (CHC) patients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV). Ribavirin 277-286 interferon lambda 4 (gene/pseudogene) Homo sapiens 81-86 27180197-1 2016 BACKGROUND AND AIMS: Many studies have been published on the association between IFNL4 rs368234815 single-nucleotide polymorphism (SNP) and sustained virological response (SVR) in chronic hepatitis C (CHC) patients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV). Ribavirin 288-291 interferon lambda 4 (gene/pseudogene) Homo sapiens 81-86 27206440-0 2016 Repeated Panniculitis Induced by Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis C. Pegylated interferon alpha (PEG-IFN-alpha) is widely used to treat chronic hepatitis C in combination with ribavirin. Ribavirin 209-218 interferon alpha 2 Homo sapiens 43-62 27399090-5 2016 Already during treatment, IFN/RBV-free therapy improved physical health (PCS: 41.4 +- 9.7 vs. 47.0 +- 11.2; P < 0.01) and reduced fatigue (37.8 +- 14.0 vs. 31.9 +- 15.2; P = 0.01), whereas we observed a substantial worsening of both factors in patients treated with BOC/PEGIFN/RBV. Ribavirin 280-283 interferon alpha 1 Homo sapiens 26-29 27136459-0 2016 MBL2 Genetic Variants in HCV Infection Susceptibility, Spontaneous Viral Clearance and Pegylated Interferon Plus Ribavirin Treatment Response. Ribavirin 113-122 mannose binding lectin 2 Homo sapiens 0-4 27275462-2 2016 This study aimed to evaluate IFN-induced ophthalmological manifestations in patients receiving PEGylated interferon (PEG IFN) and ribavirin (RBV) and to assess the effect of IFN duration, response and systemic risk factors on the severity. Ribavirin 130-139 interferon alpha 1 Homo sapiens 29-32 27275462-2 2016 This study aimed to evaluate IFN-induced ophthalmological manifestations in patients receiving PEGylated interferon (PEG IFN) and ribavirin (RBV) and to assess the effect of IFN duration, response and systemic risk factors on the severity. Ribavirin 141-144 interferon alpha 1 Homo sapiens 29-32 27799970-0 2016 Polymorphism of IL-28B Gene (rs12979860) in HCV Genotype 1Patients Treated by Pegylated Interferon and Ribavirin. Ribavirin 103-112 interferon lambda 3 Homo sapiens 16-22 27799970-2 2016 The aim of this study was to detect the polymorphism of IL-28B gene (rs12979860) in HCV genotype 1 patients treated with pegylated Interferon and Ribavirin. Ribavirin 146-155 interferon lambda 3 Homo sapiens 56-62 27799970-8 2016 CONCLUSION: IL-28B polymorphism has an effective impact on the therapeutic response to ribavirin and peginterferon combination therapy in chronic HCV patients infected by different genotypes. Ribavirin 87-96 interferon lambda 3 Homo sapiens 12-18 26825765-8 2016 In 32 genotype-1 patients available for the IL28B genotype (rs8099917), SVR was achieved in more patients in the IL28B major allele group than in the minor allele group (15/17 vs 7/15, P = 0.021) after PEG-IFN/RBV combination therapy. Ribavirin 210-213 interferon lambda 3 Homo sapiens 113-118 26825765-10 2016 CONCLUSIONS: Overall, both therapies showed encouraging results, and were reasonably safe in children and adolescents with chronic hepatitis C. The IL28B genotype was useful for predicting the treatment response to PEG-IFN/RBV combination therapy in this cohort. Ribavirin 223-226 interferon lambda 3 Homo sapiens 148-153 27147735-16 2016 An HGFR candidate inhibitor currently being evaluated for cancer treatment showed potent antiviral activity and additive drug effects with ribavirin, which is used in the clinic to treat human LASV infection. Ribavirin 139-148 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 3-7 26945967-6 2016 Furthermore, we identified activated eIF4E, which is phosphorylated by MNK1, as a regulator of Sox2 expression after irradiation, and pharmacologic inhibition of eIF4E with CGP57380 and Ribavirin significantly weakened Sox2-mediated tumor cell repopulation. Ribavirin 186-195 eukaryotic translation initiation factor 4E Homo sapiens 162-167 27167219-5 2016 Conclusion: Ribavirin down-regulates IP-10, and may have an anti-viral effect differently regulated across IL28B genotypes. Ribavirin 12-21 C-X-C motif chemokine ligand 10 Homo sapiens 37-42 26470765-2 2016 Our purpose was to assess the combination of pretreatment IP-10 levels with IL28B SNPs as predictors of treatment response to pegylated interferon alpha-2a plus ribavirin in patients infected with genotype 1 hepatitis C virus in China. Ribavirin 161-170 C-X-C motif chemokine ligand 10 Homo sapiens 58-63 27167219-5 2016 Conclusion: Ribavirin down-regulates IP-10, and may have an anti-viral effect differently regulated across IL28B genotypes. Ribavirin 12-21 interferon lambda 3 Homo sapiens 107-112 26082258-1 2016 OBJECTIVES: Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Ribavirin 55-58 interferon alpha 1 Homo sapiens 195-205 27114554-13 2016 Indeed, m(7)G cap analogs or ribavirin prevents nuclear entry of eIF4E, which mirrors the trafficking phenotypes observed in patients with AML. Ribavirin 29-38 eukaryotic translation initiation factor 4E Homo sapiens 65-70 26805671-9 2016 Finally, six-week administration of ribavirin led to a strong reduction of viral replication in the serum and liver of GT 1 infected mice. Ribavirin 36-45 retinoic acid induced 1 Mus musculus 119-123 26082258-0 2016 Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Ribavirin 0-9 interferon alpha 1 Homo sapiens 19-27 27114554-7 2016 During clinical responses to the m(7)G-cap competitor ribavirin, eIF4E is mainly cytoplasmic. Ribavirin 54-63 eukaryotic translation initiation factor 4E Homo sapiens 65-70 27313635-0 2016 The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNalpha-2a/RBV Combination Therapy in Azerbaijani Patients. Ribavirin 140-143 interferon lambda 3 Homo sapiens 83-88 27313635-9 2016 CONCLUSIONS: The data of the present study suggest that amino acid substitutions at position 43, 70, 91, and 106 in the HCV-1b core protein are correlated with the response to the Peg-IFNalpha-2a/RBV treatment in Azerbaijani patients with chronic hepatitis C. Moreover, host genetic polymorphisms, such as those of the IL28B locus, might be useful for predicting the responsiveness to Peg-IFNalpha-2a/RBV combination therapy against HCV. Ribavirin 196-199 interferon lambda 3 Homo sapiens 319-324 27313635-9 2016 CONCLUSIONS: The data of the present study suggest that amino acid substitutions at position 43, 70, 91, and 106 in the HCV-1b core protein are correlated with the response to the Peg-IFNalpha-2a/RBV treatment in Azerbaijani patients with chronic hepatitis C. Moreover, host genetic polymorphisms, such as those of the IL28B locus, might be useful for predicting the responsiveness to Peg-IFNalpha-2a/RBV combination therapy against HCV. Ribavirin 401-404 interferon lambda 3 Homo sapiens 319-324 26082258-0 2016 Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Ribavirin 0-9 interferon alpha 1 Homo sapiens 95-105 26082258-1 2016 OBJECTIVES: Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Ribavirin 44-53 interferon alpha 1 Homo sapiens 195-205 26082258-1 2016 OBJECTIVES: Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Ribavirin 44-53 interferon alpha 1 Homo sapiens 207-210 26082258-1 2016 OBJECTIVES: Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Ribavirin 55-58 interferon alpha 1 Homo sapiens 207-210 26082258-2 2016 Here, we describe a new mechanism by which RBV modulates IFN-stimulated genes (ISGs) and contributes to restore hepatic immune responsiveness. Ribavirin 43-46 interferon alpha 1 Homo sapiens 57-60 26082258-5 2016 RESULTS: RBV decreases the mRNA levels of several abnormally preactivated ISGs in patients with HCV, who are non-responders to IFN therapy. Ribavirin 9-12 interferon alpha 1 Homo sapiens 127-130 26082258-6 2016 RBV increases G9a histone methyltransferase recruitment and histone-H3 lysine-9 dimethylation/trimethylation at selected ISG promoters in vitro and in vivo. Ribavirin 0-3 euchromatic histone lysine methyltransferase 2 Homo sapiens 14-43 26082258-7 2016 G9a pharmacological blockade abolishes RBV-induced ISG downregulation and severely impairs RBV ability to potentiate IFN antiviral action and induction of ISGs following HCV infection of primary human hepatocytes. Ribavirin 91-94 interferon alpha 1 Homo sapiens 117-120 26082258-8 2016 CONCLUSIONS: RBV-induced epigenetic changes, leading to decreased ISG expression, restore an IFN-responsive hepatic environment in patients with HCV, which may also prove useful in IFN-free regimens. Ribavirin 13-16 interferon alpha 1 Homo sapiens 93-96 26082258-8 2016 CONCLUSIONS: RBV-induced epigenetic changes, leading to decreased ISG expression, restore an IFN-responsive hepatic environment in patients with HCV, which may also prove useful in IFN-free regimens. Ribavirin 13-16 interferon alpha 1 Homo sapiens 181-184 26965318-0 2016 Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Chronic hepatitis C virus (HCV) infection had been associated with cytokine imbalance. Ribavirin 107-116 interferon gamma Homo sapiens 38-47 26725771-0 2016 Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C. BACKGROUND/PURPOSE: Recent studies have shown that serum vitamin D deficiency is a negative predictor of response to peginterferon plus ribavirin therapy for Caucasian patients with chronic hepatitis C (CHC). Ribavirin 89-98 vitamin D receptor Homo sapiens 15-33 26725771-0 2016 Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C. BACKGROUND/PURPOSE: Recent studies have shown that serum vitamin D deficiency is a negative predictor of response to peginterferon plus ribavirin therapy for Caucasian patients with chronic hepatitis C (CHC). Ribavirin 279-288 vitamin D receptor Homo sapiens 15-33 26952879-4 2016 As ribavirin is transported across the brush border membrane of the human jejunum by hCNT2, it shows saturable uptake in the intestine. Ribavirin 3-12 solute carrier family 28 member 2 Homo sapiens 85-90 26525407-5 2016 These data suggest that short-term treatment with IFN alfa combined with RBV decreases HIV expression, in part through inhibition of HIV transcription by TRIM22 and decrease in T-cell activation. Ribavirin 73-76 tripartite motif containing 22 Homo sapiens 154-160 27363047-8 2016 We conclude the importance of the detection of MCP-1 expression at the start of therapy as a factor for assessing the likelihood of HCV genotype 4 patients to achieving a sustained virological response to treatment with IFN-a2 in combination with ribavirin. Ribavirin 247-256 C-C motif chemokine ligand 2 Homo sapiens 47-52 27400472-10 2016 Levels of IL-6, IL-10 and IFN-gamma in mice treated with ribavirin or the combination of both ribavirin and Reduning were all significantly lower than in the untreated group, especially in the combination-treated group. Ribavirin 57-66 interleukin 6 Mus musculus 10-14 27400472-10 2016 Levels of IL-6, IL-10 and IFN-gamma in mice treated with ribavirin or the combination of both ribavirin and Reduning were all significantly lower than in the untreated group, especially in the combination-treated group. Ribavirin 57-66 interleukin 10 Mus musculus 16-21 27400472-10 2016 Levels of IL-6, IL-10 and IFN-gamma in mice treated with ribavirin or the combination of both ribavirin and Reduning were all significantly lower than in the untreated group, especially in the combination-treated group. Ribavirin 57-66 interferon gamma Mus musculus 26-35 27400472-10 2016 Levels of IL-6, IL-10 and IFN-gamma in mice treated with ribavirin or the combination of both ribavirin and Reduning were all significantly lower than in the untreated group, especially in the combination-treated group. Ribavirin 94-103 interleukin 6 Mus musculus 10-14 27400472-10 2016 Levels of IL-6, IL-10 and IFN-gamma in mice treated with ribavirin or the combination of both ribavirin and Reduning were all significantly lower than in the untreated group, especially in the combination-treated group. Ribavirin 94-103 interferon gamma Mus musculus 26-35 26787701-6 2016 Furthermore, different IFN-alpha subtypes were also able to block viral replication in combination with ribavirin. Ribavirin 104-113 interferon alpha 1 Homo sapiens 23-32 27095759-0 2016 [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-alpha-2b and ribavirin]. Ribavirin 21-30 interferon alpha 2 Homo sapiens 162-181 27095759-1 2016 OBJECTIVE: To investigate the association between the dose and plasma concentration of ribavirin (RBV) and sustained virologic response (SVR) during the anti-hepatitis C virus (HCV) treatment with pegylated interferon-alpha-2b (PEG-IFN-alpha-2b) and RBV. Ribavirin 87-96 interferon alpha 2 Homo sapiens 207-226 27095759-1 2016 OBJECTIVE: To investigate the association between the dose and plasma concentration of ribavirin (RBV) and sustained virologic response (SVR) during the anti-hepatitis C virus (HCV) treatment with pegylated interferon-alpha-2b (PEG-IFN-alpha-2b) and RBV. Ribavirin 98-101 interferon alpha 2 Homo sapiens 207-226 26965318-5 2016 Serial dynamic cytokine expression demonstrated that not only elevated IFN-gamma concentrations at specific time points but also the total IFN-gamma amount was strongly linked to non-response in peginterferon/ribavirin therapy. Ribavirin 209-218 interferon gamma Homo sapiens 71-80 26965318-5 2016 Serial dynamic cytokine expression demonstrated that not only elevated IFN-gamma concentrations at specific time points but also the total IFN-gamma amount was strongly linked to non-response in peginterferon/ribavirin therapy. Ribavirin 209-218 interferon gamma Homo sapiens 139-148 26499461-3 2016 The aim of this study was to determine whether CXCL12 polymorphisms are related so as to achieve sustained virological response (SVR) after HCV therapy with pegylated-interferon-alpha/ribavirin (pegIFN-alpha/ribavirin) in HIV/HCV-coinfected patients. Ribavirin 184-193 C-X-C motif chemokine ligand 12 Homo sapiens 47-53 26499461-3 2016 The aim of this study was to determine whether CXCL12 polymorphisms are related so as to achieve sustained virological response (SVR) after HCV therapy with pegylated-interferon-alpha/ribavirin (pegIFN-alpha/ribavirin) in HIV/HCV-coinfected patients. Ribavirin 208-217 C-X-C motif chemokine ligand 12 Homo sapiens 47-53 26499461-12 2016 In conclusion, in this study we found that the favorable CXCL12 rs1029153 T allele seems to be related so as to achieve an SVR in HIV/HCV-coinfected patients on pegIFN-alpha/ribavirin therapy. Ribavirin 174-183 C-X-C motif chemokine ligand 12 Homo sapiens 57-63 26489607-4 2016 We show that interferon (IFN)/ribavirin (RBV) induces let-7g expression through p38/AP-1 signaling. Ribavirin 41-44 mitogen-activated protein kinase 14 Homo sapiens 80-83 26289410-1 2016 AIM: Protease inhibitors with pegylated interferon (PEG IFN)/ribavirin improve a sustained virological response (SVR) rate to approximately 90% in chronic hepatitis C genotype 1b patients with IL28B rs8099917 genotype TT, but yield only approximately 50% in those with the unfavorable non-TT. Ribavirin 61-70 interferon lambda 3 Homo sapiens 193-198 26280154-3 2016 To examine the association between different IL28B variants and the relapse of HCV infection after combined therapy with ribavirin and pegylated interferon (pegIFN). Ribavirin 121-130 interferon lambda 3 Homo sapiens 45-50 26489607-9 2016 Interferon/ribavirin induces let-7g expression through p38/AP-1 signaling. Ribavirin 11-20 microRNA let-7g Homo sapiens 29-35 26489607-0 2016 MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication. Ribavirin 43-52 microRNA let-7g Homo sapiens 9-15 26489607-9 2016 Interferon/ribavirin induces let-7g expression through p38/AP-1 signaling. Ribavirin 11-20 mitogen-activated protein kinase 14 Homo sapiens 55-58 26489607-4 2016 We show that interferon (IFN)/ribavirin (RBV) induces let-7g expression through p38/AP-1 signaling. Ribavirin 30-39 microRNA let-7g Homo sapiens 54-60 26489607-11 2016 Let-7g additively cooperates with interferon/ribavirin to repress HCV replication. Ribavirin 45-54 microRNA let-7g Homo sapiens 0-6 26489607-4 2016 We show that interferon (IFN)/ribavirin (RBV) induces let-7g expression through p38/AP-1 signaling. Ribavirin 30-39 mitogen-activated protein kinase 14 Homo sapiens 80-83 26344576-0 2016 High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity. Ribavirin 69-78 C-X-C motif chemokine ligand 9 Homo sapiens 5-8 26489607-4 2016 We show that interferon (IFN)/ribavirin (RBV) induces let-7g expression through p38/AP-1 signaling. Ribavirin 41-44 microRNA let-7g Homo sapiens 54-60 26344576-0 2016 High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity. Ribavirin 69-78 C-X-C motif chemokine ligand 9 Homo sapiens 10-15 27263300-12 2016 CONCLUSION: Vitamin D receptor gene Bsm I polymorphism may be associated with the therapeutic response to antiviral therapy with pegylated interferon plus ribavirin in chronic hepatitis C patients. Ribavirin 155-164 vitamin D receptor Homo sapiens 12-30 26344576-1 2016 BACKGROUND & AIMS: Sustained virological response (SVR) following peginterferon (pegIFN) and ribavirin (RBV) treatment in hepatitis C virus (HCV)-infected patients has been linked with the IL28B genotype and lower peripheral levels of the CXCR3-binding chemokine IP-10 (CXCL10). Ribavirin 108-111 interferon lambda 3 Homo sapiens 193-198 26344576-1 2016 BACKGROUND & AIMS: Sustained virological response (SVR) following peginterferon (pegIFN) and ribavirin (RBV) treatment in hepatitis C virus (HCV)-infected patients has been linked with the IL28B genotype and lower peripheral levels of the CXCR3-binding chemokine IP-10 (CXCL10). Ribavirin 108-111 C-X-C motif chemokine receptor 3 Homo sapiens 243-248 26344576-1 2016 BACKGROUND & AIMS: Sustained virological response (SVR) following peginterferon (pegIFN) and ribavirin (RBV) treatment in hepatitis C virus (HCV)-infected patients has been linked with the IL28B genotype and lower peripheral levels of the CXCR3-binding chemokine IP-10 (CXCL10). Ribavirin 108-111 C-X-C motif chemokine ligand 10 Homo sapiens 267-272 26344576-1 2016 BACKGROUND & AIMS: Sustained virological response (SVR) following peginterferon (pegIFN) and ribavirin (RBV) treatment in hepatitis C virus (HCV)-infected patients has been linked with the IL28B genotype and lower peripheral levels of the CXCR3-binding chemokine IP-10 (CXCL10). Ribavirin 108-111 C-X-C motif chemokine ligand 10 Homo sapiens 274-280 26344576-9 2016 CONCLUSIONS: The associations of MIG with SVR status and IL28B genotype imply that higher MIG plasma levels could reflect a beneficial immunological state for response to pegIFN/RBV treatment. Ribavirin 178-181 C-X-C motif chemokine ligand 9 Homo sapiens 90-93 26945356-2 2016 Interferon (IFN)- and ribavirin (RBV)-containing regimens for CH-C have a negative impact on patient-reported outcomes (PROs) during treatment. Ribavirin 22-31 solute carrier family 4 member 1 (Diego blood group) Homo sapiens 62-66 26945356-2 2016 Interferon (IFN)- and ribavirin (RBV)-containing regimens for CH-C have a negative impact on patient-reported outcomes (PROs) during treatment. Ribavirin 33-36 solute carrier family 4 member 1 (Diego blood group) Homo sapiens 62-66 26945356-3 2016 The aim of this study was to assess the impact of IFN-free RBV-free sofosbuvir (SOF)-based regimens on PROs in CH-C patients of Asian ancestry. Ribavirin 59-62 interferon alpha 1 Homo sapiens 50-53 26945356-3 2016 The aim of this study was to assess the impact of IFN-free RBV-free sofosbuvir (SOF)-based regimens on PROs in CH-C patients of Asian ancestry. Ribavirin 59-62 solute carrier family 4 member 1 (Diego blood group) Homo sapiens 111-115 26945356-10 2016 During treatment, Asian CH-C patients experienced a decline in their PRO scores while receiving IFN and/or RBV-containing regimens (up to -19.6%, P < .001). Ribavirin 107-110 solute carrier family 4 member 1 (Diego blood group) Homo sapiens 24-28 26945356-15 2016 The use of IFN- and RBV-free LDV/SOF regimens leads to PRO improvement in Asian patients with CH-C during treatment. Ribavirin 20-23 solute carrier family 4 member 1 (Diego blood group) Homo sapiens 94-98 27148387-0 2016 The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C. BACKGROUND: It has been found that ITPase deficiency is caused by ITPA gene polymorphisms. Ribavirin 111-120 inosine triphosphatase Homo sapiens 4-8 27054010-7 2016 CONCLUSION: miR-122 might be a useful predictor for virological responses to treatment with PEG-interferon plus ribavirin therapy in patients with HCV. Ribavirin 112-121 microRNA 122 Homo sapiens 12-19 26913058-1 2016 The aim of this study was to assess the effect of insulin resistance on the development of HCC by non-cirrhotic chronic hepatitis C patients treated with pegylated interferon alpha-2b (PEG-IFNalpha2b) and ribavirin. Ribavirin 205-214 insulin Homo sapiens 50-57 26913058-10 2016 CONCLUSIONS: Insulin resistance has a strong impact on the development of HCC by non-cirrhotic patients who have PEG-IFNalpha2b and ribavirin treatment failure. Ribavirin 132-141 insulin Homo sapiens 13-20 27148387-0 2016 The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C. BACKGROUND: It has been found that ITPase deficiency is caused by ITPA gene polymorphisms. Ribavirin 111-120 dynein axonemal assembly factor 9 Homo sapiens 13-22 27148387-1 2016 It was observed that ITPA polymorphisms have impact on hematological changes, including hemoglobin (Hb)-decline during treatment of chronic hepatitis C (CHC) patients with pegylated-interferon (PEG-IFN) plus ribavirin (RBV). Ribavirin 208-217 inosine triphosphatase Homo sapiens 21-25 27148387-1 2016 It was observed that ITPA polymorphisms have impact on hematological changes, including hemoglobin (Hb)-decline during treatment of chronic hepatitis C (CHC) patients with pegylated-interferon (PEG-IFN) plus ribavirin (RBV). Ribavirin 219-222 inosine triphosphatase Homo sapiens 21-25 27148387-2 2016 OBJECTIVES: This study aimed to assess the effect of ITPA and C20orf194 polymorphisms on hematological changes at week 4 of treatment with PEG-IFN plus RBV in patients with CHC. Ribavirin 152-155 dynein axonemal assembly factor 9 Homo sapiens 62-71 26436610-10 2016 The change in miR-122 levels was similar across genotypes, and was comparable with or without RBV. Ribavirin 94-97 microRNA 122 Homo sapiens 14-21 26877604-10 2016 Ribavirin is a direct IMPDH2 inhibitor and is able to induce the formation of RR structures in vitro and in vivo. Ribavirin 0-9 inosine monophosphate dehydrogenase 2 Homo sapiens 22-28 26825683-4 2016 Despite this, these participants experienced significant PRO improvement during treatment with IFN-free RBV-free regimens (up to +8.0%, P < .001), similar to improvements in younger participants. Ribavirin 104-107 interferon alpha 1 Homo sapiens 95-98 26825683-5 2016 In contrast, participants aged 65 and older experienced substantial decline in PROs while receiving IFN- or RBV-containing regimens (up to -18.9% in IFN + SOF + RBV, -10.4% in IFN-free SOF+RBV, P < .001), and some were greater than in the younger group. Ribavirin 108-111 interferon alpha 1 Homo sapiens 149-152 26819511-3 2016 Until a few years ago the only treatment strategy was based on the combination of pegylated interferon and ribavirin (PEG/RBV). Ribavirin 107-116 progestagen associated endometrial protein Homo sapiens 118-125 26752952-10 2016 CONCLUSION: Our data show that TGF-beta1 serum levels decrease significantly at the EOT and remain decreased 6 months after the EOT mostly in chronic hepatitis C patients who achieve SVR after pegylated interferon-alpha and ribavirin combination treatment. Ribavirin 224-233 transforming growth factor beta 1 Homo sapiens 31-40 26731263-9 2016 The monophosphate form of the purine nucleoside analog ribavirin inhibited T. brucei GMPR activity, though mammalian GMPRs showed no or only a little inhibition by it. Ribavirin 55-64 guanosine monophosphate reductase Homo sapiens 85-89 27110259-0 2016 The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C. BACKGROUND: Hepatitis C Virus (HCV) is the major cause of liver failure in thalassemic patients. Ribavirin 80-89 interferon lambda 3 Homo sapiens 35-40 27110259-2 2016 OBJECTIVES: We aimed to assess the impact of polymorphisms near the IL28B gene on virological response in HCV - infected thalassemic patients, who were treated with PEG-IFN and RBV. Ribavirin 177-180 interferon lambda 3 Homo sapiens 68-73 27156327-3 2016 We showed previously the implication of low molecular mass polypeptide-7 (LMP-7) single nucleotide varia- tions in the response to combined pegylated IFN and ribavirin therapy in patients infected with HCV genotype 4. Ribavirin 158-167 proteasome 20S subunit beta 8 Homo sapiens 40-72 27293923-3 2016 Following successful therapy with sofosbuvir, simeprevir, and ribavirin, her insulin requirements decreased and her glycosylated hemoglobin (HgA1c) normalized despite weight gain. Ribavirin 62-71 insulin Homo sapiens 77-84 27215079-0 2016 Impact of TGF-beta1 Gene Polymorphism (rs1800469) on Treatment Response to Pegylated Interferon/Ribavirin in Iranian Patients with Hepatitis C. BACKGROUND: Hepatitis C virus as a major cause of chronic liver disease affects more than 170 million people worldwide. Ribavirin 96-105 transforming growth factor beta 1 Homo sapiens 10-19 27156327-3 2016 We showed previously the implication of low molecular mass polypeptide-7 (LMP-7) single nucleotide varia- tions in the response to combined pegylated IFN and ribavirin therapy in patients infected with HCV genotype 4. Ribavirin 158-167 proteasome 20S subunit beta 8 Homo sapiens 74-79 27156332-0 2016 Correlation Study Between IL-28B Gene Polymorphism (rs8099917SNP) and Sustained Virological Response in Iranian Patients with Chronic Hepatitis C. BACKGROUND: The current standard treatment for hepatitis C is a combination of pegylated interferon alpha and ribavirin (peg-IFNalpha/RBV). Ribavirin 257-266 interferon lambda 3 Homo sapiens 26-32 27156332-0 2016 Correlation Study Between IL-28B Gene Polymorphism (rs8099917SNP) and Sustained Virological Response in Iranian Patients with Chronic Hepatitis C. BACKGROUND: The current standard treatment for hepatitis C is a combination of pegylated interferon alpha and ribavirin (peg-IFNalpha/RBV). Ribavirin 281-284 interferon lambda 3 Homo sapiens 26-32 27525598-0 2016 Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population. Ribavirin 82-91 interferon lambda 3 Homo sapiens 27-33 26880169-0 2016 Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C. BACKGROUND: Ribavirin (RBV)-induced anemia is one of the major causes of dose reduction and discontinuation of therapy for chronic hepatitis C (CHC) patients. Ribavirin 34-43 inosine triphosphatase Homo sapiens 8-12 26880169-0 2016 Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C. BACKGROUND: Ribavirin (RBV)-induced anemia is one of the major causes of dose reduction and discontinuation of therapy for chronic hepatitis C (CHC) patients. Ribavirin 139-148 inosine triphosphatase Homo sapiens 8-12 26880169-0 2016 Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C. BACKGROUND: Ribavirin (RBV)-induced anemia is one of the major causes of dose reduction and discontinuation of therapy for chronic hepatitis C (CHC) patients. Ribavirin 150-153 inosine triphosphatase Homo sapiens 8-12 26880169-1 2016 We investigated the role of inosine triphosphate pyrophosphatase (ITPA) single nucleotide polymorphism (SNP) (rs1127354) in predicting RBV-induced anemia and thrombocytopenia among Egyptian patients with CHC genotype 4 infection. Ribavirin 135-138 inosine triphosphatase Homo sapiens 28-64 26880169-1 2016 We investigated the role of inosine triphosphate pyrophosphatase (ITPA) single nucleotide polymorphism (SNP) (rs1127354) in predicting RBV-induced anemia and thrombocytopenia among Egyptian patients with CHC genotype 4 infection. Ribavirin 135-138 inosine triphosphatase Homo sapiens 66-70 26880169-8 2016 CONCLUSION: Rs1127354 ITPA polymorphism was associated with RBV-induced anemia and thrombocytopenia in Egyptian patients with hepatitis C virus genotype 4 infection. Ribavirin 60-63 inosine triphosphatase Homo sapiens 22-26 26740864-8 2016 Changes in IL-8, MIP-1beta, and MCP-1 serum concentrations may be associated with efficacy of pegIFNalpha- and ribavirin-based therapies in patients coinfected by HCV and HIV. Ribavirin 111-120 C-X-C motif chemokine ligand 8 Homo sapiens 11-15 26740864-8 2016 Changes in IL-8, MIP-1beta, and MCP-1 serum concentrations may be associated with efficacy of pegIFNalpha- and ribavirin-based therapies in patients coinfected by HCV and HIV. Ribavirin 111-120 C-C motif chemokine ligand 4 Homo sapiens 17-26 26740864-8 2016 Changes in IL-8, MIP-1beta, and MCP-1 serum concentrations may be associated with efficacy of pegIFNalpha- and ribavirin-based therapies in patients coinfected by HCV and HIV. Ribavirin 111-120 C-C motif chemokine ligand 2 Homo sapiens 32-37 27170384-6 2016 In the setting of liver transplantation, with an accelerated course of hepatitis C, previous IFN-RBV treatments were poorly tolerated and attained low SVR rates. Ribavirin 97-100 interferon alpha 1 Homo sapiens 93-96 27525598-1 2016 BACKGROUND: A polymorphism upstream of interleukin (IL)-28B was recently identified to be associated with a 2-fold difference in sustained virologic response (SVR) to pegylated interferon-alpha and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic hepatitis C (CHC) virus genotype 1 (HCV-1) infection. Ribavirin 200-209 interferon lambda 3 Homo sapiens 41-61 27525598-12 2016 CONCLUSION: In treatment-naive HCV patients treated with pegylated interferon and ribavirin, a polymorphism upstream CC at the site rs12979860 of IL-28B is associated with increased sustained virologic response and effectively predicts treatment outcome. Ribavirin 82-91 interferon lambda 3 Homo sapiens 146-152 26684004-1 2015 BACKGROUND: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-alpha plus ribavirin combination therapy (PEG-IFNalpha/RBV). Ribavirin 218-227 interferon alpha 1 Homo sapiens 253-261 26684004-1 2015 BACKGROUND: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-alpha plus ribavirin combination therapy (PEG-IFNalpha/RBV). Ribavirin 262-265 interferon alpha 1 Homo sapiens 253-261 26650626-10 2015 CONCLUSIONS: The ITPA rs1127354 CC and rs6051702 AA genotypes may predict ribavirin-induced anemia during treatment with interferon-free, ribavirin-containing regimens. Ribavirin 74-83 inosine triphosphatase Homo sapiens 17-21 26670100-7 2015 Refined analysis showed that the effect of IL28B SNPs on sustained virological response was restricted to prior PegIFN/RBV relapse (OR = 3.80[1.82-8.92], P = 8x10(-4)). Ribavirin 119-122 interferon lambda 3 Homo sapiens 43-48 26650626-10 2015 CONCLUSIONS: The ITPA rs1127354 CC and rs6051702 AA genotypes may predict ribavirin-induced anemia during treatment with interferon-free, ribavirin-containing regimens. Ribavirin 138-147 inosine triphosphatase Homo sapiens 17-21 26644819-8 2015 CONCLUSION: We suggested that the elevation of AFP and DCP levels at 24 wk after the completion of IFN and ribavirin therapy were strongly associated with the incidence of HCC irrespective of virological response among Japanese LC-C patients. Ribavirin 107-116 alpha fetoprotein Homo sapiens 47-50 25857516-2 2015 Recently, genome-wide association studies (GWAS) have identified that the IL28B gene rs8099917 polymorphism was associated with the response to the pegylated-interferon alpha/ribavirin (PegIFNalpha/RBV) combination therapy in patients infected with HCV genotype 1. Ribavirin 175-184 interferon lambda 3 Homo sapiens 74-79 25857516-2 2015 Recently, genome-wide association studies (GWAS) have identified that the IL28B gene rs8099917 polymorphism was associated with the response to the pegylated-interferon alpha/ribavirin (PegIFNalpha/RBV) combination therapy in patients infected with HCV genotype 1. Ribavirin 198-201 interferon lambda 3 Homo sapiens 74-79 25857516-4 2015 The aims of this study were to analyze the correlation between IL28B gene rs8099917 (T/G) polymorphism and PegIFNalpha/RBV therapy outcome in the Turkish population. Ribavirin 119-122 interferon lambda 3 Homo sapiens 63-68 26280786-7 2015 In multivariate analysis, treatment with LDV/SOF + RBV was independently associated with reduction in apoE (beta = 5.31 mug/mL, P = 0.002) (compared to RBV-free LDV/SOF) (P < 0.05). Ribavirin 51-54 apolipoprotein E Homo sapiens 102-106 26280786-9 2015 Subgroup analysis revealed an increase in apoCII during treatment only in patients receiving LDV/SOF without RBV (+5.52 +- 11.92 mug/mL, P = 0.0007) but not in patients receiving LDV/SOF + RBV (P = 0.638). Ribavirin 109-112 apolipoprotein C2 Homo sapiens 42-48 26280786-9 2015 Subgroup analysis revealed an increase in apoCII during treatment only in patients receiving LDV/SOF without RBV (+5.52 +- 11.92 mug/mL, P = 0.0007) but not in patients receiving LDV/SOF + RBV (P = 0.638). Ribavirin 189-192 apolipoprotein C2 Homo sapiens 42-48 26557951-2 2015 RBV up-regulates type 1 and/or 2 cytokines to modulate the T helper (Th) 1/2 cell balance to Th1 dominance. Ribavirin 0-3 negative elongation factor complex member C/D Homo sapiens 93-96 26609346-11 2015 In addition, the interleukin-28B single nucleotide polymorphism and response to previous pegylated-IFN-alpha and ribavirin therapy were identified as independent factors for SVR. Ribavirin 113-122 interferon lambda 3 Homo sapiens 17-32 26614853-6 2015 The three IL28B gene polymorphisms (CC genotype of rs12979860, TT genotype of rs8099917, and AA genotype of rs12980275) were associated with the SVR (p=0.029, p=0.016, and p=0.028, respectively) in the study patients with chronic hepatitis C treated with the combination therapy of PEGIFN alpha and RBV. Ribavirin 299-302 interferon lambda 3 Homo sapiens 10-15 26557951-3 2015 Examination of co-stimulatory signaling indicated that RBV down-modulates inducible co-stimulator on Th cells, which contributes to differentiating naive Th cells into Th2 cells while reducing their interleukin-10 production. Ribavirin 55-58 interleukin 10 Homo sapiens 199-213 26557951-5 2015 These findings indicate that RBV mainly down-regulates the activity of Th2 cells, resulting in the maintenance of Th1 activity that contributes to abrogating HCV-infected hepatocytes. Ribavirin 29-32 negative elongation factor complex member C/D Homo sapiens 114-117 26314558-9 2015 In response to pegIFN/RBV treatment, GROalpha levels increased in Caucasian but not African-American patients from week 4 onwards. Ribavirin 22-25 C-X-C motif chemokine ligand 1 Homo sapiens 37-45 26314558-12 2015 The ethnic difference in GRO levels both pre-treatment and in response to pegIFN/RBV might be driven by a genetic polymorphism in GROalpha associated with higher plasma levels and more common in the African-American population. Ribavirin 81-84 C-X-C motif chemokine ligand 1 Homo sapiens 130-138 26249823-2 2015 The HCV NS3-Q80K polymorphism is associated with resistance to the recently approved NS3 inhibitor simeprevir (SMV) when combined with PEG-interferon and ribavirin (PEG-IFN/RBV) and alternative therapy should be considered for patients with baseline Q80K. Ribavirin 154-163 KRAS proto-oncogene, GTPase Homo sapiens 8-11 26249823-2 2015 The HCV NS3-Q80K polymorphism is associated with resistance to the recently approved NS3 inhibitor simeprevir (SMV) when combined with PEG-interferon and ribavirin (PEG-IFN/RBV) and alternative therapy should be considered for patients with baseline Q80K. Ribavirin 173-176 KRAS proto-oncogene, GTPase Homo sapiens 8-11 26249823-6 2015 Therefore, in clinical practice, an NS3-Q80K genotyping test prior to simeprevir plus PEG-IFN/RBV treatment is highly recommended. Ribavirin 94-97 KRAS proto-oncogene, GTPase Homo sapiens 36-39 25968438-1 2015 BACKGROUND: ITPA polymorphisms have been associated with protection against ribavirin-induced anemia in chronic hepatitis C (HCV) patients. Ribavirin 76-85 inosine triphosphatase Homo sapiens 12-16 25968438-2 2015 Here we determined the association of inosine triphosphate pyrophosphohydrolase (inosine triphosphatase or ITPase) enzyme activity with ITPA genotype in predicting ribavirin-induced anemia. Ribavirin 164-173 inosine triphosphatase Homo sapiens 136-140 25580859-3 2015 The duration of ribavirin/pegylated interferon (PEG IFN)-alpha-2b therapy was prolonged to 48 weeks in patients with unfavorable IL28B alleles showing adherence rates of less than 80% for either drug during the first 12 weeks even if RVR had been achieved, and in those in whom cEVR, but not RVR, was achieved; furthermore, to 72 weeks in those showing partial early viral response. Ribavirin 16-25 interferon lambda 3 Homo sapiens 129-134 26319013-5 2015 Successful eradication of HCV with interferon alfa and ribavirin was shown to improve some of these extrahepatic effects; sustained virological response is associated with resolution of complications of cryoglobulinemia, reduced levels of insulin resistance, reduced incidence of diabetes and stroke, and improved fatigue and cognitive functioning. Ribavirin 55-64 insulin Homo sapiens 239-246 25580859-3 2015 The duration of ribavirin/pegylated interferon (PEG IFN)-alpha-2b therapy was prolonged to 48 weeks in patients with unfavorable IL28B alleles showing adherence rates of less than 80% for either drug during the first 12 weeks even if RVR had been achieved, and in those in whom cEVR, but not RVR, was achieved; furthermore, to 72 weeks in those showing partial early viral response. Ribavirin 16-25 nuclear receptor subfamily 1 group D member 2 Homo sapiens 234-237 25580859-3 2015 The duration of ribavirin/pegylated interferon (PEG IFN)-alpha-2b therapy was prolonged to 48 weeks in patients with unfavorable IL28B alleles showing adherence rates of less than 80% for either drug during the first 12 weeks even if RVR had been achieved, and in those in whom cEVR, but not RVR, was achieved; furthermore, to 72 weeks in those showing partial early viral response. Ribavirin 16-25 nuclear receptor subfamily 1 group D member 2 Homo sapiens 292-295 26186989-3 2015 METHODS: We compared IFNL4-DeltaG/TT and rs4803217 for association with response to pegylated-IFN-alpha/ribavirin in the VIRAHEP-C and HALT-C trials, and spontaneous HCV clearance in the ALIVE, UHS and WIHS studies. Ribavirin 104-113 interferon lambda 4 (gene/pseudogene) Homo sapiens 21-26 25649470-0 2015 Interferon and ribavirin combination therapy are linked to severe indirect hyperbilirubinemia in patients with nt-211G > A variant of UGT1A1 gene. Ribavirin 15-24 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 137-143 26441325-1 2015 BACKGROUND/OBJECTIVE: Genetic polymorphisms in the inosine triphosphatase (ITPA) gene have been associated with the protection from early ribavirin(RBV)-induced hemolytic anemia among patients with chronic hepatitis C virus (HCV) infection. Ribavirin 138-147 inosine triphosphatase Homo sapiens 51-73 26438033-0 2015 Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis. Ribavirin 92-101 inosine triphosphatase Homo sapiens 21-25 26441325-1 2015 BACKGROUND/OBJECTIVE: Genetic polymorphisms in the inosine triphosphatase (ITPA) gene have been associated with the protection from early ribavirin(RBV)-induced hemolytic anemia among patients with chronic hepatitis C virus (HCV) infection. Ribavirin 138-147 inosine triphosphatase Homo sapiens 75-79 26438033-1 2015 BACKGROUND: There is growing evidence that variations in the gene encoding inosine triphosphate pyrophosphohydrolase (ITPase), known as inosine triphosphatase (ITPA), are related to hemolytic anemia, which is frequently observed among hepatitis C virus (HCV)-infected patients receiving ribavirin (RBV)-based therapy. Ribavirin 287-296 inosine triphosphatase Homo sapiens 118-124 26438033-1 2015 BACKGROUND: There is growing evidence that variations in the gene encoding inosine triphosphate pyrophosphohydrolase (ITPase), known as inosine triphosphatase (ITPA), are related to hemolytic anemia, which is frequently observed among hepatitis C virus (HCV)-infected patients receiving ribavirin (RBV)-based therapy. Ribavirin 287-296 inosine triphosphatase Homo sapiens 160-164 26441325-1 2015 BACKGROUND/OBJECTIVE: Genetic polymorphisms in the inosine triphosphatase (ITPA) gene have been associated with the protection from early ribavirin(RBV)-induced hemolytic anemia among patients with chronic hepatitis C virus (HCV) infection. Ribavirin 148-151 inosine triphosphatase Homo sapiens 51-73 26438033-1 2015 BACKGROUND: There is growing evidence that variations in the gene encoding inosine triphosphate pyrophosphohydrolase (ITPase), known as inosine triphosphatase (ITPA), are related to hemolytic anemia, which is frequently observed among hepatitis C virus (HCV)-infected patients receiving ribavirin (RBV)-based therapy. Ribavirin 298-301 inosine triphosphatase Homo sapiens 118-124 26441325-1 2015 BACKGROUND/OBJECTIVE: Genetic polymorphisms in the inosine triphosphatase (ITPA) gene have been associated with the protection from early ribavirin(RBV)-induced hemolytic anemia among patients with chronic hepatitis C virus (HCV) infection. Ribavirin 148-151 inosine triphosphatase Homo sapiens 75-79 26438033-1 2015 BACKGROUND: There is growing evidence that variations in the gene encoding inosine triphosphate pyrophosphohydrolase (ITPase), known as inosine triphosphatase (ITPA), are related to hemolytic anemia, which is frequently observed among hepatitis C virus (HCV)-infected patients receiving ribavirin (RBV)-based therapy. Ribavirin 298-301 inosine triphosphatase Homo sapiens 160-164 26438033-2 2015 We performed a meta-analysis of all eligible studies assessing ITPA gene polymorphisms related to RBV-induced hemolytic anemia in HCV-infected patients published in PubMed, Embase and the Cochrane library prior to the end of 2014. Ribavirin 98-101 inosine triphosphatase Homo sapiens 63-67 26441325-10 2015 CONCLUSION: Genetic variants in the ITPA gene protected against RBV treatment-induced anemia among Caucasian patients with chronic HCV infection. Ribavirin 64-67 inosine triphosphatase Homo sapiens 36-40 26438033-10 2015 CONCLUSIONS: ITPA polymorphisms increase the likelihood of developing hemolytic anemia for HCV-infected patients on RBV-based therapy, particularly rs1127354 CC and rs7270101 AA genotypes, suggesting the utility of screening for ITPA polymorphisms to avoid hematological toxicity and increase adherence to RBV-based therapy. Ribavirin 116-119 inosine triphosphatase Homo sapiens 13-17 26441325-11 2015 Patients with normal ITPase activity underwent more dose reductions of RBV and received erythropoietin more frequently. Ribavirin 71-74 inosine triphosphatase Homo sapiens 21-27 26438033-10 2015 CONCLUSIONS: ITPA polymorphisms increase the likelihood of developing hemolytic anemia for HCV-infected patients on RBV-based therapy, particularly rs1127354 CC and rs7270101 AA genotypes, suggesting the utility of screening for ITPA polymorphisms to avoid hematological toxicity and increase adherence to RBV-based therapy. Ribavirin 116-119 inosine triphosphatase Homo sapiens 229-233 26438033-10 2015 CONCLUSIONS: ITPA polymorphisms increase the likelihood of developing hemolytic anemia for HCV-infected patients on RBV-based therapy, particularly rs1127354 CC and rs7270101 AA genotypes, suggesting the utility of screening for ITPA polymorphisms to avoid hematological toxicity and increase adherence to RBV-based therapy. Ribavirin 306-309 inosine triphosphatase Homo sapiens 13-17 26485009-2 2015 IL28B SNPs were genotyped in 269 patients, 181 mono- and 88 co-infected, treated with pegylated interferon and ribavirin. Ribavirin 111-120 interferon lambda 3 Homo sapiens 0-5 26118427-11 2015 CONCLUSIONS: ALV plus RBV represents an effective IFN-free option for a proportion of patients with HCV genotype 2 or 3 infections, with high SVR rates for patients with early viral clearance. Ribavirin 22-25 interferon alpha 1 Homo sapiens 50-53 26284971-2 2015 In 2009 a genome-wide association study (GWAS) identified a single nucleotide polymorphism near the IL28B gene that was associated with treatment-induced viral clearance in chronic HCV infection treated with pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV). Ribavirin 249-258 interferon lambda 3 Homo sapiens 100-105 26284971-2 2015 In 2009 a genome-wide association study (GWAS) identified a single nucleotide polymorphism near the IL28B gene that was associated with treatment-induced viral clearance in chronic HCV infection treated with pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV). Ribavirin 260-263 interferon lambda 3 Homo sapiens 100-105 26096332-2 2015 Combined simeprevir (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological response (SVR) rates along with minimal adverse events (AEs) in patients with hepatitis C genotype 1 (HCV GT1). Ribavirin 74-77 beta-1,4-galactosyltransferase 1 Homo sapiens 223-226 26380828-5 2015 Other investigations demonstrated that inosine triphosphate pyrophosphatase genetic variants protect hepatitis C virus-genotype-1 CHC patients from ribavirin-induced anemia, and other studies that a polymorphism in the patatin-like phospholipase domain-containing protein 3 was associated with hepatic steatosis in CHC patients. Ribavirin 148-157 patatin like phospholipase domain containing 3 Homo sapiens 219-273 26317515-0 2015 Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. Ribavirin 0-9 mechanistic target of rapamycin kinase Homo sapiens 35-39 26526510-12 2015 CONCLUSION: Interleukin-28B polymorphism could be a possible predictor of response to pegylated interferon/ribavirin therapy (PEG-IFN/RBV). Ribavirin 107-116 interferon lambda 3 Homo sapiens 12-27 26526510-12 2015 CONCLUSION: Interleukin-28B polymorphism could be a possible predictor of response to pegylated interferon/ribavirin therapy (PEG-IFN/RBV). Ribavirin 134-137 interferon lambda 3 Homo sapiens 12-27 26248125-4 2015 The Q80K NS3-protease mutation affects sensibility to simeprevir + peg-interferon/ribavirin combinations. Ribavirin 82-91 KRAS proto-oncogene, GTPase Homo sapiens 9-12 26317515-2 2015 Previous studies reported that ribavirin could suppress eIF4E-controlled translation and reduce the synthesis of onco-proteins. Ribavirin 31-40 eukaryotic translation initiation factor 4E Homo sapiens 56-61 26177560-3 2015 In 2009, a genome wide association study (GWAS) revealed that genetic variants in close proximity to the IL28B (IFNL3) gene predicted greater likelihood of achieving sustained virological response (SVR) following treatment with pegylated IFN-alpha (peg INF-alpha) and ribavirin. Ribavirin 268-277 interferon lambda 3 Homo sapiens 105-110 26177560-3 2015 In 2009, a genome wide association study (GWAS) revealed that genetic variants in close proximity to the IL28B (IFNL3) gene predicted greater likelihood of achieving sustained virological response (SVR) following treatment with pegylated IFN-alpha (peg INF-alpha) and ribavirin. Ribavirin 268-277 interferon lambda 3 Homo sapiens 112-117 26177560-3 2015 In 2009, a genome wide association study (GWAS) revealed that genetic variants in close proximity to the IL28B (IFNL3) gene predicted greater likelihood of achieving sustained virological response (SVR) following treatment with pegylated IFN-alpha (peg INF-alpha) and ribavirin. Ribavirin 268-277 interferon alpha 1 Homo sapiens 238-247 26177560-3 2015 In 2009, a genome wide association study (GWAS) revealed that genetic variants in close proximity to the IL28B (IFNL3) gene predicted greater likelihood of achieving sustained virological response (SVR) following treatment with pegylated IFN-alpha (peg INF-alpha) and ribavirin. Ribavirin 268-277 interferon alpha 17 Homo sapiens 253-262 26177560-4 2015 IL28B (rs12979860 and rs8099917) single nucleotide polymorphisms (SNPs) have been recently found among the Pakistani population associated with response to chronic HCV infection INF-alpha + ribavirin therapy. Ribavirin 190-199 interferon lambda 3 Homo sapiens 0-5 26177560-4 2015 IL28B (rs12979860 and rs8099917) single nucleotide polymorphisms (SNPs) have been recently found among the Pakistani population associated with response to chronic HCV infection INF-alpha + ribavirin therapy. Ribavirin 190-199 interferon alpha 17 Homo sapiens 178-187 26135875-1 2015 Persons with hepatitis C virus (HCV) genotype 1a (GT1a) infections harboring a baseline Q80K polymorphism in nonstructural protein 3 (NS3) have a reduced virologic response to simeprevir in combination with pegylated interferon-alfa and ribavirin. Ribavirin 237-246 KRAS proto-oncogene, GTPase Homo sapiens 134-137 26317515-5 2015 7-Methyl-guanosine cap affinity assay further demonstrated that ribavirin remarkably increased the eIF4E binding to 4EBP1 and decreased the combination of eIF4E with eIF4G, consequently resulting in a major inhibition of eIF4F complex assembly. Ribavirin 64-73 eukaryotic translation initiation factor 4E Homo sapiens 99-104 26317515-5 2015 7-Methyl-guanosine cap affinity assay further demonstrated that ribavirin remarkably increased the eIF4E binding to 4EBP1 and decreased the combination of eIF4E with eIF4G, consequently resulting in a major inhibition of eIF4F complex assembly. Ribavirin 64-73 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 116-121 26317515-0 2015 Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 40-45 26317515-5 2015 7-Methyl-guanosine cap affinity assay further demonstrated that ribavirin remarkably increased the eIF4E binding to 4EBP1 and decreased the combination of eIF4E with eIF4G, consequently resulting in a major inhibition of eIF4F complex assembly. Ribavirin 64-73 eukaryotic translation initiation factor 4E Homo sapiens 155-160 26317515-0 2015 Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. Ribavirin 0-9 EPH receptor B2 Homo sapiens 47-50 26317515-5 2015 7-Methyl-guanosine cap affinity assay further demonstrated that ribavirin remarkably increased the eIF4E binding to 4EBP1 and decreased the combination of eIF4E with eIF4G, consequently resulting in a major inhibition of eIF4F complex assembly. Ribavirin 64-73 eukaryotic translation initiation factor 4 gamma 1 Homo sapiens 166-171 26317515-5 2015 7-Methyl-guanosine cap affinity assay further demonstrated that ribavirin remarkably increased the eIF4E binding to 4EBP1 and decreased the combination of eIF4E with eIF4G, consequently resulting in a major inhibition of eIF4F complex assembly. Ribavirin 64-73 eukaryotic translation initiation factor 4E Homo sapiens 221-226 26317515-0 2015 Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. Ribavirin 0-9 MAPK interacting serine/threonine kinase 1 Homo sapiens 51-55 26317515-0 2015 Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 56-61 26317515-0 2015 Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. Ribavirin 0-9 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 145-152 26032235-1 2015 BACKGROUND: The biological mechanism underlying the association between IFNL4/IFNL3 polymorphism and peginterferon/ribavirin (PR) response in HCV-1 is thought to involve differential intrahepatic interferon-stimulated gene expression. Ribavirin 115-124 interferon lambda 4 (gene/pseudogene) Homo sapiens 72-77 25958342-0 2015 The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C. BACKGROUND/AIMS: There is increasing evidence for the effect of rs12979860 IL28B polymorphism in response to the standard treatment PEG-IFN/RBV (i.e. combination of pegylated interferon and ribavirin) in chronic hepatitis C virus (HCV) infection. Ribavirin 289-292 interferon lambda 3 Homo sapiens 34-49 25958342-0 2015 The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C. BACKGROUND/AIMS: There is increasing evidence for the effect of rs12979860 IL28B polymorphism in response to the standard treatment PEG-IFN/RBV (i.e. combination of pegylated interferon and ribavirin) in chronic hepatitis C virus (HCV) infection. Ribavirin 339-348 interferon lambda 3 Homo sapiens 34-49 26279979-1 2015 In 2009, several groups reported that interleukin-28B (IL28B) genotypes are associated with the response to peginterferon plus ribavirin therapy for chronic hepatitis C virus (HCV) infection in a genome-wide association study, although the mechanism of this association is not yet well understood. Ribavirin 127-136 interferon lambda 3 Homo sapiens 55-60 26032235-1 2015 BACKGROUND: The biological mechanism underlying the association between IFNL4/IFNL3 polymorphism and peginterferon/ribavirin (PR) response in HCV-1 is thought to involve differential intrahepatic interferon-stimulated gene expression. Ribavirin 115-124 interferon lambda 3 Homo sapiens 78-83 25588648-0 2015 Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNalpha/RBV therapy. Ribavirin 110-113 vasoactive intestinal peptide receptor 1 Homo sapiens 35-39 26189761-2 2015 We undertook this study to investigate the distribution of IL28B SNP rs12979860 in Mexican patients with HCV infection and to assess its usefulness in predicting response to pegylated interferon-alpha and ribavirin (PegIFN-alpha/RVB) therapy. Ribavirin 205-214 interferon lambda 3 Homo sapiens 59-64 26060059-9 2015 IL28B rs8099917/rs12979860 is useful in the treatment of MC-positive HCV patients with PEG-IFN and ribavirin; the TT/CC genotype is associated with SVR, the TG/TC with non-SVR; TT/CC is also predictive of MC in HCV patients. Ribavirin 99-108 interferon lambda 3 Homo sapiens 0-5 25588648-1 2015 The identification of mutations in the HVR1 region of hepatitis type C virus (HCV) is time-consuming and expensive, and there is a need for a rapid, inexpensive method of screening for these mutations to predict the ineffectiveness of pegylated interferon alpha combined with ribavirin (PEG-IFNalpha/RBV) therapy. Ribavirin 276-285 vasoactive intestinal peptide receptor 1 Homo sapiens 39-43 25588648-1 2015 The identification of mutations in the HVR1 region of hepatitis type C virus (HCV) is time-consuming and expensive, and there is a need for a rapid, inexpensive method of screening for these mutations to predict the ineffectiveness of pegylated interferon alpha combined with ribavirin (PEG-IFNalpha/RBV) therapy. Ribavirin 300-303 vasoactive intestinal peptide receptor 1 Homo sapiens 39-43 25973761-0 2015 IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy. Ribavirin 114-123 C-X-C motif chemokine ligand 10 Homo sapiens 0-5 26209404-0 2015 Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population. Ribavirin 98-107 interferon lambda 3 Homo sapiens 18-23 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 187-196 interferon lambda 3 Homo sapiens 47-52 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 187-196 interferon alpha 1 Homo sapiens 47-50 26209404-0 2015 Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population. Ribavirin 98-107 inosine triphosphatase Homo sapiens 9-13 26115415-0 2015 The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C. The strong impact of interleukin 28B (IL28B) polymorphisms on sustained virological response (SVR) after peginterferon and ribavirin treatment in patients with chronic hepatitis C (CHC) is well-known. Ribavirin 312-321 interferon lambda 3 Homo sapiens 14-19 26638424-0 2015 [Change in Serum Levels of New Hepatic Fibrosis Marker "Mac-2 Binding Protein Glycosylation isomer (M2BPGi)" in Patients with Chronic Hepatitis C during the Treatment of Pegylated Interferon and Ribavirin]. Ribavirin 195-204 galectin 3 binding protein Homo sapiens 56-77 26218843-5 2015 Uni- and multivariable logistic regression analyses were used to evaluate the association between RBV concentration and SVR in GT 1/4 and GT 2/3 infections. Ribavirin 98-101 beta-1,4-galactosyltransferase 1 Homo sapiens 127-131 26218843-8 2015 Overall, median RBV concentration was 2.0 mg/L in GT 1/4, and 1.9 mg/L in GT 2/3, and did not change significantly across treatment phases. Ribavirin 16-19 beta-1,4-galactosyltransferase 1 Homo sapiens 50-54 26019032-0 2015 Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients. Ribavirin 98-107 CD4 molecule Homo sapiens 24-27 26130141-8 2015 In conclusion, 48-week treatment with Peg-IFN plus weight-based RBV provides a greater SVR rate than 24-week treatment in treatment-naive HCV-2 patients with unfavorable IL-28B genotypes who fail to achieve RVR. Ribavirin 64-67 interferon lambda 3 Homo sapiens 170-176 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 187-196 interferon alpha 1 Homo sapiens 85-88 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 187-196 interferon alpha 1 Homo sapiens 85-88 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 198-201 interferon lambda 3 Homo sapiens 47-52 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 198-201 interferon alpha 1 Homo sapiens 47-50 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 198-201 interferon alpha 1 Homo sapiens 85-88 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 198-201 interferon alpha 1 Homo sapiens 85-88 26154744-0 2015 Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C. Inosine triphosphatase (ITPA) single nucleotide polymorphisms (SNPs) are strongly associated with protection against ribavirin (RBV)-induced anaemia in European, American and Asian patients; however, there is a paucity of data for Brazilian patients. Ribavirin 279-288 inosine triphosphatase Homo sapiens 162-184 26154744-0 2015 Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C. Inosine triphosphatase (ITPA) single nucleotide polymorphisms (SNPs) are strongly associated with protection against ribavirin (RBV)-induced anaemia in European, American and Asian patients; however, there is a paucity of data for Brazilian patients. Ribavirin 290-293 inosine triphosphatase Homo sapiens 162-184 25717047-0 2015 Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon alpha Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection. Ribavirin 120-129 secreted phosphoprotein 1 Homo sapiens 0-25 26071337-0 2015 Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. Ribavirin 100-109 inosine triphosphatase Homo sapiens 8-12 26071337-0 2015 Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. Ribavirin 100-109 solute carrier family 28 member 2 Homo sapiens 17-24 26316472-7 2015 RBV obtained using 18F-FLT in males were found to have high correlation with measured weight (R2=0.61) and BMI (R2=0.70). Ribavirin 0-3 fms related receptor tyrosine kinase 1 Homo sapiens 23-26 26165495-6 2015 Ribavirin and MPA treatments induced only IMPDH2-based RR. Ribavirin 0-9 inosine monophosphate dehydrogenase 2 Homo sapiens 42-48 26165495-8 2015 Over 95% of NHA-CTPS1 transfected cells with DON treatment presented IMPDH2-based RR and almost 100% presented CTPS1-based RR; when treated with ribavirin, over 94% of transfected cells presented IMPDH2-based RR and 37% presented CTPS1-based RR, whereas 2% of untreated transfected cells presented IMPDH2-based RR and 28% presented CTPS1-based RR. Ribavirin 145-154 CTP synthase 1 Homo sapiens 16-21 26165495-8 2015 Over 95% of NHA-CTPS1 transfected cells with DON treatment presented IMPDH2-based RR and almost 100% presented CTPS1-based RR; when treated with ribavirin, over 94% of transfected cells presented IMPDH2-based RR and 37% presented CTPS1-based RR, whereas 2% of untreated transfected cells presented IMPDH2-based RR and 28% presented CTPS1-based RR. Ribavirin 145-154 inosine monophosphate dehydrogenase 2 Homo sapiens 196-202 26165495-8 2015 Over 95% of NHA-CTPS1 transfected cells with DON treatment presented IMPDH2-based RR and almost 100% presented CTPS1-based RR; when treated with ribavirin, over 94% of transfected cells presented IMPDH2-based RR and 37% presented CTPS1-based RR, whereas 2% of untreated transfected cells presented IMPDH2-based RR and 28% presented CTPS1-based RR. Ribavirin 145-154 inosine monophosphate dehydrogenase 2 Homo sapiens 196-202 25382001-2 2015 Interferon alpha (IFNalpha) sensitivity in liver and IL28B genotype has been identified as important determinants of HCV clearance in the setting of pegylated interferon/ribavirin treatment. Ribavirin 170-179 interferon alpha 1 Homo sapiens 18-26 25963122-1 2015 Aim: Pegylated-interferon/ribavirin/simeprevir (PEG-IFN/RBV/SMV) combination therapy is widely used for hepatitis C virus (HCV) treatment after liver transplantation (LT). Ribavirin 26-35 interferon alpha 1 Homo sapiens 52-55 25512630-0 2015 Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin. Ribavirin 136-145 C-X-C motif chemokine ligand 10 Homo sapiens 28-34 25512630-1 2015 UNLABELLED: We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Ribavirin 119-128 C-X-C motif chemokine ligand 10 Homo sapiens 45-51 25823618-0 2015 Hepatitis C therapy with interferon-alpha and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients. Ribavirin 46-55 CD4 molecule Homo sapiens 68-71 25382001-2 2015 Interferon alpha (IFNalpha) sensitivity in liver and IL28B genotype has been identified as important determinants of HCV clearance in the setting of pegylated interferon/ribavirin treatment. Ribavirin 170-179 interferon lambda 3 Homo sapiens 53-58 25535910-4 2015 An association was also observed between week 12 eGFR and ribavirin concentration only for patients on triple therapy (P = .002). Ribavirin 58-67 epidermal growth factor receptor Homo sapiens 49-53 25810373-7 2015 Indeed, UGT levels in AML patients treated with ribavirin and/or cytarabine were elevated at relapse relative to diagnosis. Ribavirin 48-57 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 8-11 25965701-0 2015 Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C. Hepatitis C virus (HCV) genotype 1 infections are significantly more difficult to eradicate with PEG-IFN/ribavirin therapy, compared to HCV genotype 2. Ribavirin 117-126 killer cell lectin like receptor K1 Homo sapiens 33-38 25965701-0 2015 Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C. Hepatitis C virus (HCV) genotype 1 infections are significantly more difficult to eradicate with PEG-IFN/ribavirin therapy, compared to HCV genotype 2. Ribavirin 264-273 killer cell lectin like receptor K1 Homo sapiens 33-38 25965701-8 2015 In conclusion, Decreased NKG2D expression on CD56+CD3+ lymphocytes in chronic HCV genotype 1 infection predicts inferior treatment response to PEG-IFN/ribavirin therapy compared to genotype 2. Ribavirin 151-160 killer cell lectin like receptor K1 Homo sapiens 25-30 24961662-1 2015 AIM: The efficacy and safety of simeprevir in combination with peginterferon-alpha-2b and ribavirin (PEG IFN-alpha-2b/RBV) were investigated in patients infected with hepatitis C virus (HCV) genotype 1 who were treatment-naive or had previously received interferon (IFN)-based therapy. Ribavirin 90-99 interferon alpha 1 Homo sapiens 105-108 25738706-1 2015 The aim of the present study was to demonstrate that ribavirin, a known inhibitor of eIF4E and inosine 5"-phosphate dehydrogenase (IMPDH), also inhibits histone methyltransferase zeste homolog 2 (EZH2). Ribavirin 53-62 eukaryotic translation initiation factor 4E Homo sapiens 85-90 25652367-0 2015 IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C. The aim of this study was to describe the genetic characteristics of Pakistani patients infected with hepatitis C virus (HCV) in relation to IL28B polymorphisms and its association to interferon and ribavirin treatment response. Ribavirin 322-331 interferon lambda 3 Homo sapiens 0-5 25738706-1 2015 The aim of the present study was to demonstrate that ribavirin, a known inhibitor of eIF4E and inosine 5"-phosphate dehydrogenase (IMPDH), also inhibits histone methyltransferase zeste homolog 2 (EZH2). Ribavirin 53-62 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 196-200 25738706-5 2015 Ribavirin decreased EZH2 expression, inhibited histone methyltransferase activity and decreased H3K27 trimethylation. Ribavirin 0-9 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 20-24 25738706-6 2015 Ribavirin induced variable growth inhibition in a number of cell lines and downregulation of the targets, EZH2, eIF4E and IMPDH1 and 2 by siRNA led to comparable growth inhibition while no significant further reduction in viability was observed when siRNA transfected cells were treated with ribavirin. Ribavirin 0-9 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 106-110 25738706-6 2015 Ribavirin induced variable growth inhibition in a number of cell lines and downregulation of the targets, EZH2, eIF4E and IMPDH1 and 2 by siRNA led to comparable growth inhibition while no significant further reduction in viability was observed when siRNA transfected cells were treated with ribavirin. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 112-117 25738706-6 2015 Ribavirin induced variable growth inhibition in a number of cell lines and downregulation of the targets, EZH2, eIF4E and IMPDH1 and 2 by siRNA led to comparable growth inhibition while no significant further reduction in viability was observed when siRNA transfected cells were treated with ribavirin. Ribavirin 0-9 inosine monophosphate dehydrogenase 1 Homo sapiens 122-134 25738706-6 2015 Ribavirin induced variable growth inhibition in a number of cell lines and downregulation of the targets, EZH2, eIF4E and IMPDH1 and 2 by siRNA led to comparable growth inhibition while no significant further reduction in viability was observed when siRNA transfected cells were treated with ribavirin. Ribavirin 292-301 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 106-110 25914454-3 2015 Currently, interferon (IFN)-based regimens can be used in dual-agent regimens with ribavirin, in triple-agent antiviral strategies with direct-acting antivirals (e.g., protease inhibitors telaprevir or boceprevir), or before transplant in compensated patients to reduce HCV viral load to prevent or reduce the risk of post-LT recurrence and complications; they cannot be used in patients with decompensated cirrhosis. Ribavirin 83-92 interferon alpha 1 Homo sapiens 11-21 25914454-3 2015 Currently, interferon (IFN)-based regimens can be used in dual-agent regimens with ribavirin, in triple-agent antiviral strategies with direct-acting antivirals (e.g., protease inhibitors telaprevir or boceprevir), or before transplant in compensated patients to reduce HCV viral load to prevent or reduce the risk of post-LT recurrence and complications; they cannot be used in patients with decompensated cirrhosis. Ribavirin 83-92 interferon alpha 1 Homo sapiens 23-26 25666200-0 2015 The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection. Ribavirin 85-94 major histocompatibility complex, class I, A Homo sapiens 9-14 25852275-8 2015 CONCLUSION: In response-guided Peg-IFNalpha/RBV combination therapy for chronically HCV G2-infected patients, the impact of the IFNL3 genotype on SVR was limited to non-RVR patients. Ribavirin 44-47 interferon lambda 3 Homo sapiens 128-133 25703417-1 2015 Hepatitis C virus (HCV) genotypes and genetic variants of interleukin 28B (IL28B) are significantly associated with interferon plus ribavirin treatment of HCV infection. Ribavirin 132-141 interferon lambda 3 Homo sapiens 75-80 25687192-1 2015 Although the single-nucleotide polymorphism (SNP) rs12979860 in the IL28B gene is a better predictor of sustained virological response to treatment of chronic hepatitis C (CHC) than other baseline factors, some CHC patients with the favorable C allele cannot achieve a sustained virological response when treated with peginterferon plus ribavirin. Ribavirin 337-346 interferon lambda 3 Homo sapiens 68-73 25666200-12 2015 Host HLA-A*02 allele expression is associated with SVR, highlighting the importance of considering HLA-A*02 as a predictor of the response to PEG-IFN/RBV treatment in the Chinese population with CHC. Ribavirin 150-153 major histocompatibility complex, class I, A Homo sapiens 5-10 25666200-12 2015 Host HLA-A*02 allele expression is associated with SVR, highlighting the importance of considering HLA-A*02 as a predictor of the response to PEG-IFN/RBV treatment in the Chinese population with CHC. Ribavirin 150-153 major histocompatibility complex, class I, A Homo sapiens 99-104 25583751-1 2015 OBJECTIVES: The equilibrative nucleoside transporter 1 (ENT1) is the main protein involved in ribavirin cellular uptake. Ribavirin 94-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 16-54 24849518-1 2015 AIM: Single nucleotide polymorphisms (SNP) near the interleukin-28B (IL28B) gene affect the outcome of 24-week telaprevir-based triple therapy with telaprevir, pegylated interferon-alpha and ribavirin for chronic hepatitis C virus (HCV) genotype 1b patients. Ribavirin 191-200 interferon lambda 3 Homo sapiens 69-74 25703417-9 2015 In conclusion, HCV genotypes and IL28B rs12979860 are predictive markers for the efficiency of interferon plus ribavirin combinational therapy of HCV infection. Ribavirin 111-120 interferon lambda 3 Homo sapiens 33-38 25650729-9 2015 CONCLUSIONS: Concentration-guided RBV dosing with darbepoetin support substantially improves tolerance and offers high adherence to a full peg-IFN and RBV treatment course in patients with post-transplant HCV relapse. Ribavirin 34-37 interferon alpha 1 Homo sapiens 143-146 25583751-1 2015 OBJECTIVES: The equilibrative nucleoside transporter 1 (ENT1) is the main protein involved in ribavirin cellular uptake. Ribavirin 94-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-60 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 64-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-28 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 64-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 64-73 interferon alpha 1 Homo sapiens 180-188 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 64-73 interferon alpha 1 Homo sapiens 223-231 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 193-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-28 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 193-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 193-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-28 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 193-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 25583751-3 2015 In this study, we investigated the role of the rs760370 SLC29A1 variant in ribavirin-induced anaemia in chronic hepatitis C patients treated with telaprevir-based triple therapy. Ribavirin 75-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-63 25583751-8 2015 CONCLUSIONS: In patients with chronic hepatitis C receiving telaprevir-based therapy, SNP rs760370A>G at the SLC29A1 gene influences the severity of ribavirin-induced anaemia, possibly mirroring the erythrocyte uptake of ribavirin. Ribavirin 152-161 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 112-119 25583751-8 2015 CONCLUSIONS: In patients with chronic hepatitis C receiving telaprevir-based therapy, SNP rs760370A>G at the SLC29A1 gene influences the severity of ribavirin-induced anaemia, possibly mirroring the erythrocyte uptake of ribavirin. Ribavirin 224-233 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 112-119 25920094-3 2015 Successive improvements in IFN-alpha-based therapy (dose finding, pegylation, addition of ribavirin) increased the rates of sustained virologic response, i.e. the rates of curing HCV infection. Ribavirin 90-99 interferon alpha 1 Homo sapiens 27-30 25766991-2 2015 OBJECTIVES: To analyze the association between Toll-like receptor-3 (TLR3) polymorphisms (rs3775291 and rs13126816) and virologic response to pegylated interferon-alpha plus ribavirin (pegIFNalpha/RBV) therapy in HIV/HCV coinfected patients. Ribavirin 197-200 toll like receptor 3 Homo sapiens 47-67 25766991-2 2015 OBJECTIVES: To analyze the association between Toll-like receptor-3 (TLR3) polymorphisms (rs3775291 and rs13126816) and virologic response to pegylated interferon-alpha plus ribavirin (pegIFNalpha/RBV) therapy in HIV/HCV coinfected patients. Ribavirin 197-200 toll like receptor 3 Homo sapiens 69-73 25877355-3 2015 After treated by interferon/ribavirin, miR-146a expression was decreased when HCV RNA became undetectable. Ribavirin 28-37 microRNA 146a Homo sapiens 39-47 25766991-2 2015 OBJECTIVES: To analyze the association between Toll-like receptor-3 (TLR3) polymorphisms (rs3775291 and rs13126816) and virologic response to pegylated interferon-alpha plus ribavirin (pegIFNalpha/RBV) therapy in HIV/HCV coinfected patients. Ribavirin 174-183 toll like receptor 3 Homo sapiens 47-67 25766991-2 2015 OBJECTIVES: To analyze the association between Toll-like receptor-3 (TLR3) polymorphisms (rs3775291 and rs13126816) and virologic response to pegylated interferon-alpha plus ribavirin (pegIFNalpha/RBV) therapy in HIV/HCV coinfected patients. Ribavirin 174-183 toll like receptor 3 Homo sapiens 69-73 25938745-1 2015 Single nucleotide polymorphisms (SNPs) of the IL28B locus are associated with a positive response to pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV) treatment of HCV-infected patients. Ribavirin 132-141 interferon lambda 3 Homo sapiens 46-51 25805936-0 2015 Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver. Ribavirin 85-94 hepcidin antimicrobial peptide Homo sapiens 0-8 25713999-8 2015 This rapid mechanism could be responsible for the development of early anemia.These results indicate for the first time the strong, significant, and independent role of VDR in the early development of ribavirin-induced anemia and confirm the ITPA function in the prediction of anemia at week 4. Ribavirin 201-210 vitamin D receptor Homo sapiens 169-172 25713999-0 2015 VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. Ribavirin 103-106 vitamin D receptor Homo sapiens 0-3 25834588-0 2015 An index to predict ribavirin-induced anemia in asian patients with chronic genotype 1 hepatitis C. BACKGROUND: Single-nucleotide polymorphisms (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene correlate with ribavirin (RBV)-induced anemia in patients with chronic hepatitis C (CHC) receiving combination therapy. Ribavirin 20-29 inosine triphosphatase Homo sapiens 157-193 25834588-0 2015 An index to predict ribavirin-induced anemia in asian patients with chronic genotype 1 hepatitis C. BACKGROUND: Single-nucleotide polymorphisms (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene correlate with ribavirin (RBV)-induced anemia in patients with chronic hepatitis C (CHC) receiving combination therapy. Ribavirin 221-230 inosine triphosphatase Homo sapiens 157-193 25834588-0 2015 An index to predict ribavirin-induced anemia in asian patients with chronic genotype 1 hepatitis C. BACKGROUND: Single-nucleotide polymorphisms (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene correlate with ribavirin (RBV)-induced anemia in patients with chronic hepatitis C (CHC) receiving combination therapy. Ribavirin 232-235 inosine triphosphatase Homo sapiens 157-193 25805936-15 2015 CONCLUSION: Decreased expression of hepcidin and ferroportin in SVR patients indicates the importance of hepatocytic iron retention for viral response during pegylated-interferon plus ribavirin treatment. Ribavirin 184-193 hepcidin antimicrobial peptide Homo sapiens 36-44 25500249-0 2015 The relationship between HLA-G and viral loads in non-responder HCV-infected patients after combined therapy with IFN-alpha2alpha and ribavirin. Ribavirin 134-143 major histocompatibility complex, class I, G Homo sapiens 25-30 25608710-2 2015 In this article, we report that a pharmacologic inhibitor of eIF4E function, ribavirin, safely and potently suppresses breast tumor formation. Ribavirin 77-86 eukaryotic translation initiation factor 4E Homo sapiens 61-66 25608710-6 2015 Our findings offer a preclinical rationale to explore broadening the clinical evaluation of ribavirin, currently being tested in patients with eIF4E-overexpressing leukemia, as a strategy to treat solid tumors such as metastatic breast cancer. Ribavirin 92-101 eukaryotic translation initiation factor 4E Homo sapiens 143-148 25515861-5 2015 Furthermore, rs2305482 genotype was associated with the doses of pegylated interferon (PEG-IFN) that could be tolerated in hepatitis C virus genotype 1-infected patients treated with PEG-IFN plus ribavirin, but not with treatment efficacy. Ribavirin 196-205 interferon alpha 1 Homo sapiens 91-94 25785448-11 2015 Higher levels of LBP at baseline were associated with non-response to peg-IFN/RBV treatment in both bivariate (OR: 0.19 95% CI: 0.06-0.31, p = 0.004) and multivariate analysis (OR: 1.43, 95% CI: 1.1-1.86, p = 0.07). Ribavirin 78-81 lipopolysaccharide binding protein Homo sapiens 17-20 25785448-12 2015 CONCLUSION: In HIV/HCV co-infected patients high baseline LBP levels are associated with non-response to peg-IFN/RBV therapy. Ribavirin 113-116 lipopolysaccharide binding protein Homo sapiens 58-61 25631788-5 2015 The results show that ribavirin administered orally in food to Atlantic salmon increased IFNgamma and CD4 transcripts in the in vivo assays and, in addition, increased IL-12, IL-15 and CD8 in the in vitro analyses, indicating that the treatment stimulates a Th1 type response in salmon. Ribavirin 22-31 LOC100169855 Salmo salar 102-105 26075078-0 2015 MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection. Ribavirin 115-124 MHC class I polypeptide-related sequence B Homo sapiens 0-27 26075078-2 2015 In the present study, the association between MHC class I-related chain B (MICB) genotypes and therapeutic response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy was investigated in hepatitis C virus (HCV)-infected patients. Ribavirin 145-154 MHC class I polypeptide-related sequence B Homo sapiens 46-73 26075078-2 2015 In the present study, the association between MHC class I-related chain B (MICB) genotypes and therapeutic response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy was investigated in hepatitis C virus (HCV)-infected patients. Ribavirin 145-154 MHC class I polypeptide-related sequence B Homo sapiens 75-79 26075078-2 2015 In the present study, the association between MHC class I-related chain B (MICB) genotypes and therapeutic response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy was investigated in hepatitis C virus (HCV)-infected patients. Ribavirin 164-167 MHC class I polypeptide-related sequence B Homo sapiens 46-73 26075078-11 2015 In conclusion, the MICB genotype is a strong predictive factor for virological response to PEG-IFN/RBV therapy in HCV patients. Ribavirin 99-102 MHC class I polypeptide-related sequence B Homo sapiens 19-23 25627660-8 2015 RSV-induced IDO activity was inhibited by palivizumab, UV inactivation, TL4R inhibition, and ribavirin. Ribavirin 93-102 indoleamine 2,3-dioxygenase 1 Homo sapiens 12-15 25287171-9 2015 CONCLUSIONS: The ITPA SNP rs1127354 is a useful predictor of ribavirin-induced anemia in Taiwanese patients and may be related to more severe decreases in platelet counts during the early stage of HCV combination therapy. Ribavirin 61-70 inosine triphosphatase Homo sapiens 17-21 25648321-9 2015 In conclusion, anti-apoptotic SNPs in the BCL2L1 gene were predictive of SVR to pegIFN/RBV treatment in HCV genotypes 1 and 3 infected individuals. Ribavirin 87-90 BCL2 like 1 Homo sapiens 42-48 25476473-8 2015 The IMPDH2 enzyme aggregated or modified shaped RR in those patients treated with ribavirin may become antigenic and induce an autoimmune response. Ribavirin 82-91 inosine monophosphate dehydrogenase 2 Homo sapiens 4-10 26030972-0 2015 ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C. The aim of this study was to clarify the association between the inosine triphosphate pyrophosphatase (ITPA) gene variants and PEG-IFNalpha/RBV combination treatment induced anemia in chronic hepatitis C (CHC) Ukrainian patients. Ribavirin 90-99 inosine triphosphatase Homo sapiens 0-4 26030972-0 2015 ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C. The aim of this study was to clarify the association between the inosine triphosphate pyrophosphatase (ITPA) gene variants and PEG-IFNalpha/RBV combination treatment induced anemia in chronic hepatitis C (CHC) Ukrainian patients. Ribavirin 310-313 inosine triphosphatase Homo sapiens 0-4 26030972-8 2015 Significant association of ITPA gene rs1127354 with protection against RB V-induced hemolytic anemia was found in Ukrainian patients with CHC infection. Ribavirin 71-75 inosine triphosphatase Homo sapiens 27-31 25391769-14 2015 Further studies are needed to determine the possible association between IL28B variants and response to pegylated-interferon-alpha plus ribavirin combination therapy among Filipino patients chronically infected with HBV. Ribavirin 136-145 interferon lambda 3 Homo sapiens 73-78 25470790-1 2015 BACKGROUND: IL28B genotype predicts response to treatment against HCV with pegylated interferon/ribavirin (PR) and impacts on the outcome of therapy including telaprevir (TVR). Ribavirin 96-105 interferon lambda 3 Homo sapiens 12-17 25661337-1 2015 Ribavirin is phosphorylated by adenosine kinase 1 (AK1) and cytosolic 5"-nucleotidase 2 and it is transported into cells by concentrative nucleoside transporters (CNT) 2/3, coded by SLC28A2/3 genes, and equilibrative nucleoside transporters (ENT) 1/2, coded by SLC29A1/2 genes. Ribavirin 0-9 adenylate kinase 1 Homo sapiens 31-49 25661337-1 2015 Ribavirin is phosphorylated by adenosine kinase 1 (AK1) and cytosolic 5"-nucleotidase 2 and it is transported into cells by concentrative nucleoside transporters (CNT) 2/3, coded by SLC28A2/3 genes, and equilibrative nucleoside transporters (ENT) 1/2, coded by SLC29A1/2 genes. Ribavirin 0-9 adenylate kinase 1 Homo sapiens 51-54 25661337-1 2015 Ribavirin is phosphorylated by adenosine kinase 1 (AK1) and cytosolic 5"-nucleotidase 2 and it is transported into cells by concentrative nucleoside transporters (CNT) 2/3, coded by SLC28A2/3 genes, and equilibrative nucleoside transporters (ENT) 1/2, coded by SLC29A1/2 genes. Ribavirin 0-9 solute carrier family 28 member 2 Homo sapiens 182-189 25661337-1 2015 Ribavirin is phosphorylated by adenosine kinase 1 (AK1) and cytosolic 5"-nucleotidase 2 and it is transported into cells by concentrative nucleoside transporters (CNT) 2/3, coded by SLC28A2/3 genes, and equilibrative nucleoside transporters (ENT) 1/2, coded by SLC29A1/2 genes. Ribavirin 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 261-268 25661337-5 2015 Concerning ribavirin pharmacokinetics, SLC28A2_rs11854488 TT was related to lower Ctrough levels; conversely patients with TC profile of SLC28A3_rs10868138 and SLC29A1_rs760370 GG genotype had higher ribavirin levels. Ribavirin 11-20 solute carrier family 28 member 2 Homo sapiens 39-46 25661337-5 2015 Concerning ribavirin pharmacokinetics, SLC28A2_rs11854488 TT was related to lower Ctrough levels; conversely patients with TC profile of SLC28A3_rs10868138 and SLC29A1_rs760370 GG genotype had higher ribavirin levels. Ribavirin 200-209 solute carrier family 28 member 2 Homo sapiens 39-46 25661339-3 2015 The aim of this retrospective study was the evaluation of the influence of some single nucleotide polymorphisms (SNPs) of genes (ABCB1, SLC28A2/3, SLC29A1) involved in TLV and RBV transport and their correlation with plasma TLV drug exposure at 1 month of therapy. Ribavirin 176-179 ATP binding cassette subfamily B member 1 Homo sapiens 129-134 25661339-3 2015 The aim of this retrospective study was the evaluation of the influence of some single nucleotide polymorphisms (SNPs) of genes (ABCB1, SLC28A2/3, SLC29A1) involved in TLV and RBV transport and their correlation with plasma TLV drug exposure at 1 month of therapy. Ribavirin 176-179 solute carrier family 28 member 2 Homo sapiens 136-145 25661339-3 2015 The aim of this retrospective study was the evaluation of the influence of some single nucleotide polymorphisms (SNPs) of genes (ABCB1, SLC28A2/3, SLC29A1) involved in TLV and RBV transport and their correlation with plasma TLV drug exposure at 1 month of therapy. Ribavirin 176-179 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-154 25236396-2 2015 The aim of this study was to examine the association of interleukin-7 receptor-alpha (IL7RA) polymorphisms with a sustained virologic response (SVR) after hepatitis C virus (HCV) therapy with pegylated interferon-alpha plus ribavirin (pegIFNalpha/ribavirin) in 177 human immunodeficiency virus (HIV)/HCV-coinfected patients. Ribavirin 224-233 interleukin 7 Homo sapiens 56-69 25236396-2 2015 The aim of this study was to examine the association of interleukin-7 receptor-alpha (IL7RA) polymorphisms with a sustained virologic response (SVR) after hepatitis C virus (HCV) therapy with pegylated interferon-alpha plus ribavirin (pegIFNalpha/ribavirin) in 177 human immunodeficiency virus (HIV)/HCV-coinfected patients. Ribavirin 224-233 interleukin 7 receptor Homo sapiens 86-91 25236396-2 2015 The aim of this study was to examine the association of interleukin-7 receptor-alpha (IL7RA) polymorphisms with a sustained virologic response (SVR) after hepatitis C virus (HCV) therapy with pegylated interferon-alpha plus ribavirin (pegIFNalpha/ribavirin) in 177 human immunodeficiency virus (HIV)/HCV-coinfected patients. Ribavirin 247-256 interleukin 7 Homo sapiens 56-69 25236396-2 2015 The aim of this study was to examine the association of interleukin-7 receptor-alpha (IL7RA) polymorphisms with a sustained virologic response (SVR) after hepatitis C virus (HCV) therapy with pegylated interferon-alpha plus ribavirin (pegIFNalpha/ribavirin) in 177 human immunodeficiency virus (HIV)/HCV-coinfected patients. Ribavirin 247-256 interleukin 7 receptor Homo sapiens 86-91 25236396-10 2015 IL7RA polymorphisms seem to play a significant role in the virological response to pegIFNalpha/ribavirin therapy in HIV/HCV-coinfected patients, in particular among patients infected with HCV GT2/3. Ribavirin 95-104 interleukin 7 receptor Homo sapiens 0-5 25422161-5 2015 eIF4E inhibition in MM cells [bone marrow (BM), lines] by siRNA and/or the anti-viral drug and competitive eIF4E inhibitor ribavirin (RBV) deleteriously affected MM cells in a similar manner to the overexpression of tetraspanins. Ribavirin 123-132 eukaryotic translation initiation factor 4E Homo sapiens 0-5 25422161-5 2015 eIF4E inhibition in MM cells [bone marrow (BM), lines] by siRNA and/or the anti-viral drug and competitive eIF4E inhibitor ribavirin (RBV) deleteriously affected MM cells in a similar manner to the overexpression of tetraspanins. Ribavirin 123-132 eukaryotic translation initiation factor 4E Homo sapiens 107-112 25422161-5 2015 eIF4E inhibition in MM cells [bone marrow (BM), lines] by siRNA and/or the anti-viral drug and competitive eIF4E inhibitor ribavirin (RBV) deleteriously affected MM cells in a similar manner to the overexpression of tetraspanins. Ribavirin 134-137 eukaryotic translation initiation factor 4E Homo sapiens 0-5 25422161-5 2015 eIF4E inhibition in MM cells [bone marrow (BM), lines] by siRNA and/or the anti-viral drug and competitive eIF4E inhibitor ribavirin (RBV) deleteriously affected MM cells in a similar manner to the overexpression of tetraspanins. Ribavirin 134-137 eukaryotic translation initiation factor 4E Homo sapiens 107-112 25422161-7 2015 Our results demonstrate that breach of proteostasis via eIF4E inhibition is an attractive therapeutic approach that may be relatively easily achieved by employing RBV, making this strategy readily translatable into the clinic. Ribavirin 163-166 eukaryotic translation initiation factor 4E Homo sapiens 56-61 24461080-2 2015 In this study, we aimed to determine the effect of SOCS3 induction on the cytokine response in patients receiving Pegylated interferon (PegIFN) and ribavirin (RBV) therapy. Ribavirin 148-157 suppressor of cytokine signaling 3 Homo sapiens 51-56 24461080-2 2015 In this study, we aimed to determine the effect of SOCS3 induction on the cytokine response in patients receiving Pegylated interferon (PegIFN) and ribavirin (RBV) therapy. Ribavirin 159-162 suppressor of cytokine signaling 3 Homo sapiens 51-56 25445343-1 2015 BACKGROUND: It has been suggested that HCV proteins, core, NS3/4A, NS4B, and NS5A, contribute to the resistance of HCV to IFN and ribavirin (RBV) treatments. Ribavirin 130-139 KRAS proto-oncogene, GTPase Homo sapiens 59-62 25445343-1 2015 BACKGROUND: It has been suggested that HCV proteins, core, NS3/4A, NS4B, and NS5A, contribute to the resistance of HCV to IFN and ribavirin (RBV) treatments. Ribavirin 141-144 KRAS proto-oncogene, GTPase Homo sapiens 59-62 25445343-1 2015 BACKGROUND: It has been suggested that HCV proteins, core, NS3/4A, NS4B, and NS5A, contribute to the resistance of HCV to IFN and ribavirin (RBV) treatments. Ribavirin 141-144 interferon alpha 1 Homo sapiens 122-125 25445343-9 2015 CONCLUSION: Our study suggests that the increase of amino acid variations within the NS3 protein of HCV 1a, 1b, 3a and 3b were associated with the response to Peg-IFN and RBV treatment in Thai patients. Ribavirin 171-174 KRAS proto-oncogene, GTPase Homo sapiens 85-88 25601894-6 2015 Microinjection of affinity-purified anti-IMPDH2 antibodies in live COS-7 cells treated with ribavirin, DON, or MPA showed mature forms of RR presented as stable and stationary structures in 71% of cells. Ribavirin 92-101 inosine monophosphate dehydrogenase 2 Homo sapiens 41-47 25131720-0 2015 The role of IL-28, IFN-gamma, and TNF-alpha in predicting response to pegylated interferon/ribavirin in chronic HCV patients. Ribavirin 91-100 tumor necrosis factor Homo sapiens 34-43 24930407-0 2015 Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism. Ribavirin 0-9 inosine triphosphatase Homo sapiens 104-108 24930407-7 2015 Decline of haemoglobin was significantly faster, and ribavirin was more extensively reduced in patients with ITPA SNP rs1127354 genotype CC than CA/AA. Ribavirin 53-62 inosine triphosphatase Homo sapiens 109-113 25624738-1 2015 The effectiveness of hepatitis C treatment has improved with the development of interferon (IFN), and it has drastically improved with the development of peg-interferon-alpha (PEG-IFN) in combination with ribavirin (RBV) and, more recently, with the addition of a protease inhibitor. Ribavirin 216-219 interferon alpha 1 Homo sapiens 180-183 25688301-1 2015 The long-term impact of pegylated-interferon plus ribavirin treatment outcome on CD4 T cell course in patients coinfected with human immunodeficiency virus and hepatitis C virus is largely unclear in the literature. Ribavirin 50-59 CD4 molecule Homo sapiens 81-84 25279449-1 2015 BACKGROUND: The combination of ribavirin and pegylated interferon-alpha is considered the standard of care for HCV-2/3 genotypes. Ribavirin 31-40 BMP binding endothelial regulator Homo sapiens 111-116 25279449-5 2015 METHODS: A total of 112 HCV-2/3 patients treated with interferon plus ribavirin were retrospectively studied; allelic discrimination was performed by real-time PCR. Ribavirin 70-79 BMP binding endothelial regulator Homo sapiens 24-29 25011570-3 2015 The CNT1- and ENT1-mediated ribavirin uptake showed concentration dependency with the following kinetics parameters: Km 26.3 muM and Vmax 426.2 fmol/min/oocyte for CNT1; Km 70.5 muM and Vmax 134.3 fmol/min/oocyte for ENT1. Ribavirin 28-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 217-221 24641916-0 2015 Association of interleukin-10 polymorphisms with chronic hepatitis C virus infection in a case-control study and its effect on the response to combined pegylated interferon/ribavirin therapy. Ribavirin 173-182 interleukin 10 Homo sapiens 15-29 25011570-6 2015 Real-time polymerase chain reaction analysis of CNT1 and ENT1 expressions in the hepatocytes showed that ENT1 mRNA expression was closely correlated with ribavirin uptake (R = 0.95, P = 0.003) while CNT1 was not. Ribavirin 154-163 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-109 25011570-7 2015 The findings indicated that ENT1 was the major transporter controlling the hepatic uptake of ribavirin. Ribavirin 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 28-32 24641916-4 2015 Further, a significant increase in risk was also revealed for the CC genotype of IL-10 -592A/C in response-relapse patients or non-responder patients compared to sustained virological response patients, suggesting a role of the GG genotype of IL-10 -1082A/G and CC genotype of IL-10 -592A/C in the treatment outcome of combined Peg-IFN/ribavirin therapy. Ribavirin 336-345 interleukin 10 Homo sapiens 243-248 24641916-4 2015 Further, a significant increase in risk was also revealed for the CC genotype of IL-10 -592A/C in response-relapse patients or non-responder patients compared to sustained virological response patients, suggesting a role of the GG genotype of IL-10 -1082A/G and CC genotype of IL-10 -592A/C in the treatment outcome of combined Peg-IFN/ribavirin therapy. Ribavirin 336-345 interleukin 10 Homo sapiens 243-248 25011570-0 2015 Contribution of CNT1 and ENT1 to ribavirin uptake in human hepatocytes. Ribavirin 33-42 solute carrier family 28 member 1 Homo sapiens 16-20 25011570-0 2015 Contribution of CNT1 and ENT1 to ribavirin uptake in human hepatocytes. Ribavirin 33-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 25-29 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 76-85 solute carrier family 28 member 1 Homo sapiens 42-46 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 76-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-55 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 76-85 solute carrier family 28 member 1 Homo sapiens 145-149 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 76-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 110-119 solute carrier family 28 member 1 Homo sapiens 42-46 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 110-119 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-55 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 110-119 solute carrier family 28 member 1 Homo sapiens 145-149 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 110-119 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 25011570-3 2015 The CNT1- and ENT1-mediated ribavirin uptake showed concentration dependency with the following kinetics parameters: Km 26.3 muM and Vmax 426.2 fmol/min/oocyte for CNT1; Km 70.5 muM and Vmax 134.3 fmol/min/oocyte for ENT1. Ribavirin 28-37 solute carrier family 28 member 1 Homo sapiens 4-8 25011570-3 2015 The CNT1- and ENT1-mediated ribavirin uptake showed concentration dependency with the following kinetics parameters: Km 26.3 muM and Vmax 426.2 fmol/min/oocyte for CNT1; Km 70.5 muM and Vmax 134.3 fmol/min/oocyte for ENT1. Ribavirin 28-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-18 25011570-3 2015 The CNT1- and ENT1-mediated ribavirin uptake showed concentration dependency with the following kinetics parameters: Km 26.3 muM and Vmax 426.2 fmol/min/oocyte for CNT1; Km 70.5 muM and Vmax 134.3 fmol/min/oocyte for ENT1. Ribavirin 28-37 solute carrier family 28 member 1 Homo sapiens 164-168 25011570-5 2015 Estimation of the contributions of CNT1 and ENT1 to the hepatic uptake of ribavirin by using a relative activity factor method indicated that the relative contribution of ENT1 to the ribavirin uptake was 82.8 +- 3.9%. Ribavirin 74-83 solute carrier family 28 member 1 Homo sapiens 35-39 25011570-5 2015 Estimation of the contributions of CNT1 and ENT1 to the hepatic uptake of ribavirin by using a relative activity factor method indicated that the relative contribution of ENT1 to the ribavirin uptake was 82.8 +- 3.9%. Ribavirin 74-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 25011570-5 2015 Estimation of the contributions of CNT1 and ENT1 to the hepatic uptake of ribavirin by using a relative activity factor method indicated that the relative contribution of ENT1 to the ribavirin uptake was 82.8 +- 3.9%. Ribavirin 74-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 171-175 25011570-5 2015 Estimation of the contributions of CNT1 and ENT1 to the hepatic uptake of ribavirin by using a relative activity factor method indicated that the relative contribution of ENT1 to the ribavirin uptake was 82.8 +- 3.9%. Ribavirin 183-192 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 171-175 24641916-1 2015 We conducted a case-control study involving 150 genotype 3 chronic hepatitis C virus (HCV) patients and 150 healthy controls to investigate the association of polymorphisms in the interleukin-10 (IL-10) gene with chronic HCV infection and the association of these polymorphic variants with the combination of pegylated interferon (Peg-IFN) and ribavirin therapy response. Ribavirin 344-353 interleukin 10 Homo sapiens 180-194 24641916-1 2015 We conducted a case-control study involving 150 genotype 3 chronic hepatitis C virus (HCV) patients and 150 healthy controls to investigate the association of polymorphisms in the interleukin-10 (IL-10) gene with chronic HCV infection and the association of these polymorphic variants with the combination of pegylated interferon (Peg-IFN) and ribavirin therapy response. Ribavirin 344-353 interleukin 10 Homo sapiens 196-201 24641916-4 2015 Further, a significant increase in risk was also revealed for the CC genotype of IL-10 -592A/C in response-relapse patients or non-responder patients compared to sustained virological response patients, suggesting a role of the GG genotype of IL-10 -1082A/G and CC genotype of IL-10 -592A/C in the treatment outcome of combined Peg-IFN/ribavirin therapy. Ribavirin 336-345 interleukin 10 Homo sapiens 81-86 25821463-2 2015 To investigate the relationship between insulin resistance and viral load decay in nondiabetic and noncirrhotic genotype 1 chronic HCV patients during peginterferon and ribavirin treatment and the possible influence of BMI and leptin as metabolic confounders. Ribavirin 169-178 insulin Homo sapiens 40-47 25425688-0 2015 A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. Ribavirin 19-28 eukaryotic translation initiation factor 4E Homo sapiens 135-140 26078754-1 2015 Pegylated interferon-alpha and ribavirin (PEG-IFN/RBV) is widely used to treat chronic hepatitis C virus infection with notorious adverse reactions since the broad expression of IFN-alpha receptors on all nucleated cells. Ribavirin 31-40 interferon alpha 1 Homo sapiens 178-187 26078754-1 2015 Pegylated interferon-alpha and ribavirin (PEG-IFN/RBV) is widely used to treat chronic hepatitis C virus infection with notorious adverse reactions since the broad expression of IFN-alpha receptors on all nucleated cells. Ribavirin 50-53 interferon alpha 1 Homo sapiens 178-187 26078754-3 2015 In addition, single nucleotide polymorphisms (SNPs) near the human IFN-lambda3 gene, IL-28B, correlate strongly with the ability to achieve a sustained virological response (SVR) to therapy with pegylated IFN-alpha plus ribavirin in patients infected with chronic hepatitis C. Furthermore, we also discuss the most recent findings: IFN-lambda4 predicts treatment outcomes of HCV infection. Ribavirin 220-229 interferon lambda 3 Homo sapiens 67-78 26078754-3 2015 In addition, single nucleotide polymorphisms (SNPs) near the human IFN-lambda3 gene, IL-28B, correlate strongly with the ability to achieve a sustained virological response (SVR) to therapy with pegylated IFN-alpha plus ribavirin in patients infected with chronic hepatitis C. Furthermore, we also discuss the most recent findings: IFN-lambda4 predicts treatment outcomes of HCV infection. Ribavirin 220-229 interferon lambda 3 Homo sapiens 85-91 24606027-11 2015 CONCLUSION: PEG IFN/RBV therapy in CHC patients could improve NK activity by increasing the frequency of CD56(bright) NK cells in SVR patients. Ribavirin 20-23 neural cell adhesion molecule 1 Homo sapiens 105-109 26666596-0 2015 Impact of Body Weight Reduction via Diet and Exercise on the Anti-Viral Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Insulin Resistance: A Randomized Controlled Pilot Trial. Ribavirin 109-118 insulin Homo sapiens 156-163 25510279-7 2015 Finally, recent clinical work targeting eIF4E in acute myeloid leukemia patients with ribavirin is discussed. Ribavirin 86-95 eukaryotic translation initiation factor 4E Homo sapiens 40-45 25811035-1 2015 Recent studies have demonstrated that polymorphisms near the interleukin-28B (IL-28B) gene could predict the response to Peg-IFN-a/RBV combination therapy in HCV-infected patients. Ribavirin 131-134 interferon lambda 3 Homo sapiens 61-76 25462177-5 2015 METHODS: One hundred and fifty HCV genotype 3 patients were assessed to study the correlation of IL28B with a therapeutic regimen of PEG-IFN alpha plus ribavirin. Ribavirin 152-161 interferon lambda 3 Homo sapiens 97-102 24995561-3 2015 The aim of this study was to investigate whether the SNP of IL28B (rs8099917) and amino acid substitutions in the NS5A region in patients with HCV genotype 2 affect the response to IFN and ribavirin combination therapy. Ribavirin 189-198 interferon lambda 3 Homo sapiens 60-65 25811035-1 2015 Recent studies have demonstrated that polymorphisms near the interleukin-28B (IL-28B) gene could predict the response to Peg-IFN-a/RBV combination therapy in HCV-infected patients. Ribavirin 131-134 interferon lambda 3 Homo sapiens 78-84 25339775-4 2015 We found that HCV replication in persistently infected cultures induces an autophagy response that impairs RBV uptake by preventing the expression of equilibrative nucleoside transporter 1 (ENT1). Ribavirin 107-110 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 190-194 25529083-2 2015 Second wave direct acting antivirals such as sofosbuvir, simeprevir and daclatasvir can be combined with pegylated interferon alpha and ribavirin (PEG-IFN/RBV) as triple therapy in patients with hepatitis C virus (HCV) infection. Ribavirin 136-145 interferon alpha 1 Homo sapiens 151-154 25529083-4 2015 A PEG-IFN/RBV-based regimen with simeprevir or daclatasvir is based on response-guided therapy and its efficacy depends on predictors of response to IFN. Ribavirin 10-13 interferon alpha 1 Homo sapiens 149-152 25569669-1 2015 Combination treatment of pegylated interferon (PEG-IFN) plus ribavirin for renal transplant recipients (RTRs) with hepatitis C virus (HCV) infection remains controversial, as it has been associated with a high risk of rejection, resulting in graft loss and a reduction in patient survival.We present a special case of an elderly RTR who experienced treatment of HCV infection 8 years after renal transplant. Ribavirin 61-70 nuclear receptor subfamily 6 group A member 1 Homo sapiens 104-107 26279293-0 2015 ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. Ribavirin 50-59 inosine triphosphatase Homo sapiens 0-4 25742144-9 2015 In a real life setting, the importance of RVR and IL28B SNPs was confirmed as predictive of SVR to identify patients with a higher likelihood of SVR to Peg-INF?+RBV, and also to designate a deferred therapy for patients with a low likelihood of SVR for whom it is preferable to wait for more successful options. Ribavirin 161-164 interferon lambda 3 Homo sapiens 50-55 26279293-0 2015 ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. Ribavirin 50-59 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-16 26279293-5 2015 Here, we investigated haemoglobin levels and the best-known functional SNPs in ITPA and SLC29A1 genes in 22 patients treated with triple therapy with BOC/Peg-IFN/RBV. Ribavirin 162-165 inosine triphosphatase Homo sapiens 79-83 26279293-5 2015 Here, we investigated haemoglobin levels and the best-known functional SNPs in ITPA and SLC29A1 genes in 22 patients treated with triple therapy with BOC/Peg-IFN/RBV. Ribavirin 162-165 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 26279293-6 2015 The identification of ITPA protective and SLC29A1 risk genotypes still appears to be a current methodology in RBV dosing during hepatitis C virus therapy with DAAs. Ribavirin 110-113 inosine triphosphatase Homo sapiens 22-26 26279293-6 2015 The identification of ITPA protective and SLC29A1 risk genotypes still appears to be a current methodology in RBV dosing during hepatitis C virus therapy with DAAs. Ribavirin 110-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-49 25477336-5 2014 This form was discovered while developing means to target a specific oncogene, the eukaryotic translation initiation factor 4E (eIF4E), with its inhibitor ribavirin. Ribavirin 155-164 eukaryotic translation initiation factor 4E Homo sapiens 83-126 26021070-1 2015 The identification of the single nucleotide polymorphisms (SNP) at rs8099917 and rs12979860 loci of IL-28B gene is presently necessary for patients with the genotype HCV-1 to predict sustained viral response (SVR) in case of combined antiviral therapy with interferon and ribavirin. Ribavirin 272-281 interferon lambda 3 Homo sapiens 100-106 27442378-3 2015 The next two decades saw a series of incremental improvements of the IFN therapies by extending the duration of therapy, using IFN in combination with oral ribavirin, using pegylated IFN with ribavirin, and most recently adding oral compounds that inhibit the HCV replication (directly acting antivirals - DAAs) to that regimen. Ribavirin 156-165 interferon alpha 1 Homo sapiens 69-72 27442378-3 2015 The next two decades saw a series of incremental improvements of the IFN therapies by extending the duration of therapy, using IFN in combination with oral ribavirin, using pegylated IFN with ribavirin, and most recently adding oral compounds that inhibit the HCV replication (directly acting antivirals - DAAs) to that regimen. Ribavirin 192-201 interferon alpha 1 Homo sapiens 69-72 25477336-5 2014 This form was discovered while developing means to target a specific oncogene, the eukaryotic translation initiation factor 4E (eIF4E), with its inhibitor ribavirin. Ribavirin 155-164 eukaryotic translation initiation factor 4E Homo sapiens 128-133 25477336-10 2014 Inhibition of Gli1 reduced UGT1As, eliminated drug glucuronides, and renewed sensitivity to ribavirin and Ara-C. Ribavirin 92-101 GLI family zinc finger 1 Homo sapiens 14-18 25664085-0 2014 Soluble TRAIL levels decreased in chronic hepatitis C treatment with pegylated interferon alpha plus ribavirin: association with viral responses. Ribavirin 101-110 TNF superfamily member 10 Homo sapiens 8-13 25548485-6 2014 In particular, patients who received combined peginterferon alfa-2b and ribavirin had significantly higher mean VAS scores than those receiving peginterferon alfa-2a or no IFN treatment. Ribavirin 72-81 interferon alpha 1 Homo sapiens 172-175 25664085-10 2014 IFN binds to its receptor on the infected hepatocyte surface during Peg-IFNalpha and ribavirin treatment. Ribavirin 85-94 interferon alpha 1 Homo sapiens 0-3 25664085-12 2014 We suggest that the decreased level of circulating sTRAIL may reflect increased binding to its ligand expressed on hepatocyte and decreased TRAIL production under the influence of Peg-IFNalpha plus ribavirin treatment. Ribavirin 198-207 TNF superfamily member 10 Homo sapiens 52-57 25453340-5 2014 In the current study, we have examined the activity of cidofovir, brincidofovir, and ribavirin against disseminated Ad5 infection in the immunosuppressed Syrian hamster model. Ribavirin 85-94 Alzheimer disease, familial, type 5 Homo sapiens 116-119 25255161-0 2014 Ribavirin enhances myeloid-derived suppressor cell differentiation through CXCL9/10 downregulation. Ribavirin 0-9 C-X-C motif chemokine ligand 9 Homo sapiens 75-80 27785282-2 2014 We aimed to evaluate the treatment response of chronic HCV infection patients to pegile interferon (pegIFN) and ribavirin treatment with regard to IL28B rs12979860 C/T polymorphism. Ribavirin 112-121 interferon lambda 3 Homo sapiens 147-152 25255161-6 2014 We observed a significant down-regulation of chemokine (C-X-C motif) ligand 9 (CXCL9) and CXCL10 mRNA in ribavirin-generated MDSCs, when compared with control. Ribavirin 105-114 C-X-C motif chemokine ligand 9 Homo sapiens 45-77 25255161-6 2014 We observed a significant down-regulation of chemokine (C-X-C motif) ligand 9 (CXCL9) and CXCL10 mRNA in ribavirin-generated MDSCs, when compared with control. Ribavirin 105-114 C-X-C motif chemokine ligand 9 Homo sapiens 79-84 25255161-6 2014 We observed a significant down-regulation of chemokine (C-X-C motif) ligand 9 (CXCL9) and CXCL10 mRNA in ribavirin-generated MDSCs, when compared with control. Ribavirin 105-114 C-X-C motif chemokine ligand 10 Homo sapiens 90-96 25255161-7 2014 Peripheral blood mononuclear cells from clinical chronic hepatitis C patients subjected to ribavirin therapy also displayed a similar suppression in CXCL9/10 mRNA expression. Ribavirin 91-100 C-X-C motif chemokine ligand 9 Homo sapiens 149-154 25255161-8 2014 Administration of recombinant CXCL9/10 proteins clearly counteracted the effect of ribavirin on MDSCs. Ribavirin 83-92 C-X-C motif chemokine ligand 9 Homo sapiens 30-35 25255161-9 2014 In summary, this study showed that ribavirin enhanced human MDSCs differentiation in vitro, which may be attribute to the down-regulation of CXCL9/10 expression. Ribavirin 35-44 C-X-C motif chemokine ligand 9 Homo sapiens 141-146 24910341-8 2014 CONCLUSIONS: IL28B genotype and (TA)n of rs72258881 may independently affect virological outcomes of peginterferon-alpha and ribavirin as host factors, even in response-guided therapy. Ribavirin 125-134 interferon lambda 3 Homo sapiens 13-18 24362944-0 2014 Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. BACKGROUND: Older patients with chronic hepatitis C have a lower virological response to interferon (IFN) treatment compared to younger patients. Ribavirin 88-97 interferon lambda 4 (gene/pseudogene) Homo sapiens 24-29 25326107-1 2014 Treatment of hepatitis C virus (HCV) with pegylated interferon and ribavirin (IFN/RBV) can be associated with neuropsychiatric side effects, which may necessitate dose reductions or treatment discontinuation. Ribavirin 67-76 interferon alpha 1 Homo sapiens 78-81 25393884-6 2014 The exposure of activated microglia to RBV led to: decrease in the level of NO as a result of decreased cell number, lower average cell surface, the reduction of membrane ruffling, the suppression of interleukin-6 release and promoted interleukin-10 production. Ribavirin 39-42 interleukin 6 Homo sapiens 200-213 25393884-6 2014 The exposure of activated microglia to RBV led to: decrease in the level of NO as a result of decreased cell number, lower average cell surface, the reduction of membrane ruffling, the suppression of interleukin-6 release and promoted interleukin-10 production. Ribavirin 39-42 interleukin 10 Homo sapiens 235-249 25364409-10 2014 Of the extracted genes, PDGFRA demonstrated the strongest positive correlation between gene expression level and ribavirin sensitivity. Ribavirin 113-122 platelet derived growth factor receptor alpha Homo sapiens 24-30 24033816-5 2014 Consequently, serum creatinine and cystatin C significantly rose during PEG IFN/RBV/TVR treatment. Ribavirin 80-83 cystatin C Homo sapiens 35-45 25393304-7 2014 Prediction of SVR with high accuracy (71-96%) was possible in genotype 1, 2, 3 and 4 infected patients who received PEG-IFN/ribavirin combination therapy by selection of beneficial IL28B rs12979860 C/C and/or ss469415590 TT/TT genotypes (p<0.001). Ribavirin 124-133 interferon lambda 3 Homo sapiens 181-186 25364884-1 2014 BACKGROUND: The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN. Ribavirin 64-73 interferon alpha 1 Homo sapiens 28-31 25364884-1 2014 BACKGROUND: The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN. Ribavirin 64-73 interferon alpha 1 Homo sapiens 206-209 25193851-7 2014 The in cellulo anti-HCV activity of hLF was additive to both Ribavirin and Interferon-alpha-2b. Ribavirin 61-70 HLF transcription factor, PAR bZIP family member Homo sapiens 36-39 25171028-4 2014 Our aim was to evaluate treatment outcome and host/viral factors on SVR in HCV-4 patients treated with pegylated interferon and ribavirin (PEG IFN+RBV) in a systematic and quantitative manner. Ribavirin 128-137 interferon alpha 1 Homo sapiens 143-150 25598789-4 2014 OBJECTIVES: The aim of this case-control study was to assess hepcidin mRNA expression in liver tissue of patients with CHC in terms of iron metabolism parameters, hemochromatosis (HFE) gene mutations, disease activity, and efficacy of antiviral treatment with pegylated interferon and ribavirin. Ribavirin 285-294 hepcidin antimicrobial peptide Homo sapiens 61-69 25473172-4 2014 Ribavirin (RBV) monotherapy has been shown to decrease inflammation in liver of patients with chronic hepatitis C. Sustained virological response (SVR) is significantly higher when IFN is combined with RBV in chronic HCV (cHCV) infection. Ribavirin 0-9 interferon alpha 1 Homo sapiens 181-184 25473172-4 2014 Ribavirin (RBV) monotherapy has been shown to decrease inflammation in liver of patients with chronic hepatitis C. Sustained virological response (SVR) is significantly higher when IFN is combined with RBV in chronic HCV (cHCV) infection. Ribavirin 11-14 interferon alpha 1 Homo sapiens 181-184 25473172-9 2014 Ribavirin-induced hemolysis floods the hepatocytes and KCs with heme, which is metabolized and detoxified by heme oxygenase-1 (HMOX1) to carbon monoxide (CO), biliverdin and free iron (which induces ferritin). Ribavirin 0-9 heme oxygenase 1 Homo sapiens 109-125 25473172-9 2014 Ribavirin-induced hemolysis floods the hepatocytes and KCs with heme, which is metabolized and detoxified by heme oxygenase-1 (HMOX1) to carbon monoxide (CO), biliverdin and free iron (which induces ferritin). Ribavirin 0-9 heme oxygenase 1 Homo sapiens 127-132 24372894-7 2014 Among the patients treated with PEG-IFN/RBV/telaprevir, low pretreatment concentrations of serum IP-10 were associated with a very rapid virological response, defined as undetectable HCV RNA at week 2 after the start of therapy. Ribavirin 40-43 C-X-C motif chemokine ligand 10 Homo sapiens 97-102 24372894-8 2014 CONCLUSION: Pretreatment serum IP-10 concentrations are associated with treatment efficacy in PEG-IFN/RBV and with early viral kinetics of hepatitis C virus in PEG-IFN/RBV/telaprevir therapy. Ribavirin 102-105 C-X-C motif chemokine ligand 10 Homo sapiens 31-36 24372894-8 2014 CONCLUSION: Pretreatment serum IP-10 concentrations are associated with treatment efficacy in PEG-IFN/RBV and with early viral kinetics of hepatitis C virus in PEG-IFN/RBV/telaprevir therapy. Ribavirin 168-171 C-X-C motif chemokine ligand 10 Homo sapiens 31-36 25469117-10 2014 The genotypes of IL28B rs8099917, rs12979860, rs7248668, MxA rs2071430, and MxA rs17000900 were strong SVR predictors for PEG-IFN/ ribavirin -treated HCV patients in Han Chinese population. Ribavirin 131-140 interferon lambda 3 Homo sapiens 17-22 25469117-10 2014 The genotypes of IL28B rs8099917, rs12979860, rs7248668, MxA rs2071430, and MxA rs17000900 were strong SVR predictors for PEG-IFN/ ribavirin -treated HCV patients in Han Chinese population. Ribavirin 131-140 MX dynamin like GTPase 1 Homo sapiens 76-79 25757280-4 2014 In this study, the therapeutic index of recombinant human interferon alpha 2b anti-HPIV was 1476.63, the therapeutic index of recombinant human interferon alpha 2b anti-RSV was 141.37, the therapeutic index of recombinant human interferon alpha 2b anti-coronavirus was more than 2820.76, and the antiviral effect of recombinant human interferon alpha 2b was better than ribavirin (RBV). Ribavirin 370-379 interferon alpha 2 Homo sapiens 144-163 25218243-10 2014 CONCLUSIONS: The presence of homozygous for the minor allele of CXCL9 rs10336, CXCL10 rs3921 and CXCL11 rs4619915 was related to higher likelihoods of achieving the HCV clearance after pegIFNalpha/ribavirin therapy in HIV infected patients coinfected with HCV GT1/4. Ribavirin 197-206 C-X-C motif chemokine ligand 9 Homo sapiens 64-69 25218243-10 2014 CONCLUSIONS: The presence of homozygous for the minor allele of CXCL9 rs10336, CXCL10 rs3921 and CXCL11 rs4619915 was related to higher likelihoods of achieving the HCV clearance after pegIFNalpha/ribavirin therapy in HIV infected patients coinfected with HCV GT1/4. Ribavirin 197-206 C-X-C motif chemokine ligand 10 Homo sapiens 79-85 25218243-10 2014 CONCLUSIONS: The presence of homozygous for the minor allele of CXCL9 rs10336, CXCL10 rs3921 and CXCL11 rs4619915 was related to higher likelihoods of achieving the HCV clearance after pegIFNalpha/ribavirin therapy in HIV infected patients coinfected with HCV GT1/4. Ribavirin 197-206 C-X-C motif chemokine ligand 11 Homo sapiens 97-103 25657752-0 2014 Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus. Ribavirin 91-100 interferon lambda 3 Homo sapiens 0-15 25757280-4 2014 In this study, the therapeutic index of recombinant human interferon alpha 2b anti-HPIV was 1476.63, the therapeutic index of recombinant human interferon alpha 2b anti-RSV was 141.37, the therapeutic index of recombinant human interferon alpha 2b anti-coronavirus was more than 2820.76, and the antiviral effect of recombinant human interferon alpha 2b was better than ribavirin (RBV). Ribavirin 370-379 interferon alpha 2 Homo sapiens 144-163 25757280-4 2014 In this study, the therapeutic index of recombinant human interferon alpha 2b anti-HPIV was 1476.63, the therapeutic index of recombinant human interferon alpha 2b anti-RSV was 141.37, the therapeutic index of recombinant human interferon alpha 2b anti-coronavirus was more than 2820.76, and the antiviral effect of recombinant human interferon alpha 2b was better than ribavirin (RBV). Ribavirin 370-379 interferon alpha 2 Homo sapiens 144-163 25757280-4 2014 In this study, the therapeutic index of recombinant human interferon alpha 2b anti-HPIV was 1476.63, the therapeutic index of recombinant human interferon alpha 2b anti-RSV was 141.37, the therapeutic index of recombinant human interferon alpha 2b anti-coronavirus was more than 2820.76, and the antiviral effect of recombinant human interferon alpha 2b was better than ribavirin (RBV). Ribavirin 381-384 interferon alpha 2 Homo sapiens 144-163 25757280-4 2014 In this study, the therapeutic index of recombinant human interferon alpha 2b anti-HPIV was 1476.63, the therapeutic index of recombinant human interferon alpha 2b anti-RSV was 141.37, the therapeutic index of recombinant human interferon alpha 2b anti-coronavirus was more than 2820.76, and the antiviral effect of recombinant human interferon alpha 2b was better than ribavirin (RBV). Ribavirin 381-384 interferon alpha 2 Homo sapiens 144-163 25757280-4 2014 In this study, the therapeutic index of recombinant human interferon alpha 2b anti-HPIV was 1476.63, the therapeutic index of recombinant human interferon alpha 2b anti-RSV was 141.37, the therapeutic index of recombinant human interferon alpha 2b anti-coronavirus was more than 2820.76, and the antiviral effect of recombinant human interferon alpha 2b was better than ribavirin (RBV). Ribavirin 381-384 interferon alpha 2 Homo sapiens 144-163 25355997-6 2014 The IFNalpha was the most active compound, with an average IC50 (50% inhibitory concentration) value lower than the IC50 of the RBV. Ribavirin 128-131 interferon alpha 1 Homo sapiens 4-12 25705565-15 2014 Collectively, our study led to identification of important correlates of IFN/RBV treatment response in HIV-1/HCV co-infected individuals. Ribavirin 77-80 interferon alpha 1 Homo sapiens 73-76 24700342-0 2014 Ribavirin improves the IFN-gamma response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Ribavirin 0-9 interferon alpha 1 Homo sapiens 69-72 24700342-1 2014 UNLABELLED: Ribavirin (RBV) is an important component of interferon (IFN)-based and direct antiviral treatment regimens for hepatitis C virus (HCV) infection. Ribavirin 12-21 interferon alpha 1 Homo sapiens 69-72 24700342-1 2014 UNLABELLED: Ribavirin (RBV) is an important component of interferon (IFN)-based and direct antiviral treatment regimens for hepatitis C virus (HCV) infection. Ribavirin 23-26 interferon alpha 1 Homo sapiens 69-72 24119110-1 2014 Erythropoietin is widely used in the USA and some other Western countries to maintain doses of ribavirin during peginterferon/ribavirin-based treatment for chronic hepatitis C virus (HCV) infection. Ribavirin 95-104 erythropoietin Homo sapiens 0-14 24119110-1 2014 Erythropoietin is widely used in the USA and some other Western countries to maintain doses of ribavirin during peginterferon/ribavirin-based treatment for chronic hepatitis C virus (HCV) infection. Ribavirin 126-135 erythropoietin Homo sapiens 0-14 23841718-0 2014 Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. AIM: The objective of the current study was to find baseline predictive factors of response to therapy with pegylated interferon and ribavirin (PEG-IFN/RBV therapy) in children and adolescents with chronic hepatitis C. METHODS: IL28B genotype and mutations in the core of hepatitis C virus (HCV) were analyzed in 30 patients treated with PEG-IFN/RBV for HCV infection. Ribavirin 82-91 interferon lambda 3 Homo sapiens 15-20 24700342-2 2014 Immunomodulation, in particular improvement of the host IFN response, has been proposed as RBV"s mechanism of action. Ribavirin 91-94 interferon alpha 1 Homo sapiens 56-59 23841718-0 2014 Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. AIM: The objective of the current study was to find baseline predictive factors of response to therapy with pegylated interferon and ribavirin (PEG-IFN/RBV therapy) in children and adolescents with chronic hepatitis C. METHODS: IL28B genotype and mutations in the core of hepatitis C virus (HCV) were analyzed in 30 patients treated with PEG-IFN/RBV for HCV infection. Ribavirin 287-296 interferon lambda 3 Homo sapiens 15-20 23841718-0 2014 Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. AIM: The objective of the current study was to find baseline predictive factors of response to therapy with pegylated interferon and ribavirin (PEG-IFN/RBV therapy) in children and adolescents with chronic hepatitis C. METHODS: IL28B genotype and mutations in the core of hepatitis C virus (HCV) were analyzed in 30 patients treated with PEG-IFN/RBV for HCV infection. Ribavirin 306-309 interferon lambda 3 Homo sapiens 15-20 23841718-0 2014 Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. AIM: The objective of the current study was to find baseline predictive factors of response to therapy with pegylated interferon and ribavirin (PEG-IFN/RBV therapy) in children and adolescents with chronic hepatitis C. METHODS: IL28B genotype and mutations in the core of hepatitis C virus (HCV) were analyzed in 30 patients treated with PEG-IFN/RBV for HCV infection. Ribavirin 500-503 interferon lambda 3 Homo sapiens 15-20 24119110-3 2014 Here, we report the cases of three Japanese ribavirin-intolerant relapsed patients with HCV genotype 2 who achieved SVR from retreatment by adding erythropoietin. Ribavirin 44-53 erythropoietin Homo sapiens 147-161 24119110-8 2014 Until the next-generation antiviral treatments for HCV genotype 2 become available, the addition of erythropoietin to dual therapy can be a treatment of choice for ribavirin-intolerant relapsed patients. Ribavirin 164-173 erythropoietin Homo sapiens 100-114 24700342-0 2014 Ribavirin improves the IFN-gamma response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Ribavirin 0-9 interferon alpha 1 Homo sapiens 23-26 24700342-6 2014 During RBV pretreatment, both the frequency of CD56(dim) NK cells with cytotoxic effector functions and the frequency of CD56(bright) NK cells with the capacity to produce IFN-gamma decreased (P = 0.049 and P = 0.001, respectively). Ribavirin 7-10 neural cell adhesion molecule 1 Homo sapiens 47-51 24700342-6 2014 During RBV pretreatment, both the frequency of CD56(dim) NK cells with cytotoxic effector functions and the frequency of CD56(bright) NK cells with the capacity to produce IFN-gamma decreased (P = 0.049 and P = 0.001, respectively). Ribavirin 7-10 neural cell adhesion molecule 1 Homo sapiens 121-125 24700342-6 2014 During RBV pretreatment, both the frequency of CD56(dim) NK cells with cytotoxic effector functions and the frequency of CD56(bright) NK cells with the capacity to produce IFN-gamma decreased (P = 0.049 and P = 0.001, respectively). Ribavirin 7-10 interferon gamma Homo sapiens 172-181 24700342-7 2014 In vitro or in vivo exposure of NK cells to RBV improved the pSTAT4 (P < 0.01) but not pSTAT1 response of NK cells to subsequent stimulation with IFN-alpha. Ribavirin 44-47 interferon alpha 1 Homo sapiens 149-158 23957840-2 2014 We investigated whether erythropoietin (EPO) could alleviate RBV-induced anemia to help maintain the RBV dose during the first 12 weeks, the triple therapy phase. Ribavirin 61-64 erythropoietin Homo sapiens 24-38 24700342-10 2014 CONCLUSION: RBV enhances the pSTAT4 and IFN-gamma response of NK cells to IFN-alpha-stimulation. Ribavirin 12-15 interferon gamma Homo sapiens 40-49 23957840-2 2014 We investigated whether erythropoietin (EPO) could alleviate RBV-induced anemia to help maintain the RBV dose during the first 12 weeks, the triple therapy phase. Ribavirin 61-64 erythropoietin Homo sapiens 40-43 24700342-10 2014 CONCLUSION: RBV enhances the pSTAT4 and IFN-gamma response of NK cells to IFN-alpha-stimulation. Ribavirin 12-15 interferon alpha 1 Homo sapiens 74-83 23957840-2 2014 We investigated whether erythropoietin (EPO) could alleviate RBV-induced anemia to help maintain the RBV dose during the first 12 weeks, the triple therapy phase. Ribavirin 101-104 erythropoietin Homo sapiens 24-38 24905490-3 2014 RESULTS: Plasma apolipoprotein H (ApoH) levels were significantly higher in patients who achieved spontaneous clearance or responded to pegylated-interferon/ribavirin therapy. Ribavirin 157-166 apolipoprotein H Homo sapiens 16-32 23957840-2 2014 We investigated whether erythropoietin (EPO) could alleviate RBV-induced anemia to help maintain the RBV dose during the first 12 weeks, the triple therapy phase. Ribavirin 101-104 erythropoietin Homo sapiens 40-43 25130512-1 2014 BACKGROUND: Recent studies in chronic hepatitis C patients have shown that rs368234815 polymorphism nearby IL28B is a better predictor of response to antiviral treatment with pegylated interferon and ribavirin than IL28B polymorphisms (rs12979860 and rs8099917). Ribavirin 200-209 interferon lambda 3 Homo sapiens 107-112 25130512-1 2014 BACKGROUND: Recent studies in chronic hepatitis C patients have shown that rs368234815 polymorphism nearby IL28B is a better predictor of response to antiviral treatment with pegylated interferon and ribavirin than IL28B polymorphisms (rs12979860 and rs8099917). Ribavirin 200-209 interferon lambda 3 Homo sapiens 215-220 24974131-1 2014 BACKGROUND/PURPOSE: Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC). Ribavirin 116-125 insulin Homo sapiens 20-27 24905490-3 2014 RESULTS: Plasma apolipoprotein H (ApoH) levels were significantly higher in patients who achieved spontaneous clearance or responded to pegylated-interferon/ribavirin therapy. Ribavirin 157-166 apolipoprotein H Homo sapiens 34-38 25387553-1 2014 INTRODUCTION: Interferon-g-inducible protein-10 (IP-10) serum levels are associated with IL28B genotype and may predict response to interferon/ribavirin-based therapy in chronic hepatitis C patients. Ribavirin 143-152 C-X-C motif chemokine ligand 10 Homo sapiens 49-54 25283962-1 2014 BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin. Ribavirin 353-362 interferon lambda 3 Homo sapiens 192-204 25283962-1 2014 BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin. Ribavirin 353-362 interferon lambda 3 Homo sapiens 261-266 25278709-0 2014 IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. Ribavirin 94-103 interferon lambda 3 Homo sapiens 0-5 25198668-14 2014 IL-18 -607AA and OPN -442TT genotypes can be used as positive predictive markers of interferon plus ribavirin treatment of HCV infection in the Pakistani population. Ribavirin 100-109 interleukin 18 Homo sapiens 0-5 24845459-1 2014 Autoantibodies to inosine monophosphate dehydrogenase-2 (IMPDH2), an enzyme involved in de novo biosynthesis of guanine nucleotides, are observed in a subset of hepatitis C virus (HCV) patients receiving interferon alpha (IFN-alpha) plus ribavirin. Ribavirin 238-247 inosine monophosphate dehydrogenase 2 Homo sapiens 57-63 24845459-9 2014 In conclusion, this study showed that the temporal kinetics of IFN-alpha + ribavirin-induced humoral autoimmune response to IMPDH2 exhibited a considerably delayed pace of increase in antibody levels and avidity as well as in isotype class switch in comparison with a conventional humoral response to infectious agents. Ribavirin 75-84 interferon alpha 1 Homo sapiens 63-72 24845459-9 2014 In conclusion, this study showed that the temporal kinetics of IFN-alpha + ribavirin-induced humoral autoimmune response to IMPDH2 exhibited a considerably delayed pace of increase in antibody levels and avidity as well as in isotype class switch in comparison with a conventional humoral response to infectious agents. Ribavirin 75-84 inosine monophosphate dehydrogenase 2 Homo sapiens 124-130 25356124-9 2014 RBV significantly decreased (P < 0.05) the erythrocyte count, haemoglobin and EPO levels in kidney and serum, either individually (R group) or combined with Peg-INF-alpha (PR group), compared to "Control" and "P" groups. Ribavirin 0-3 erythropoietin Rattus norvegicus 81-84 25232239-1 2014 Interleukin (IL) 28B genetic polymorphism is significantly associated with the sustained virological response rate in patients with chronic hepatitis C treated with pegylated interferon-alpha (PEG-IFN) plus ribavirin and with spontaneous hepatitis C virus clearance. Ribavirin 207-216 interferon lambda 3 Homo sapiens 0-20 25227310-10 2014 Multivariate analysis revealed that besides age, ribavirin starting dose and baseline Hb also EPO rs1617640 G homozygosity associates with Hb reduction at week 4 (p = 0.025) and 12 (p = 0.029), while ITPA C homozygotes are at risk for Hb decline particularly early during treatment. Ribavirin 49-58 erythropoietin Homo sapiens 94-97 25227310-11 2014 Furthermore, EPO rs1617640 G homozygotes were more frequently in need for blood transfusion, epoetin-alpha supplementation, or ribavirin dose reduction (p < 0.001). Ribavirin 127-136 erythropoietin Homo sapiens 13-16 25356124-12 2014 CONCLUSION: VitD could have a potential beneficial role in the prevention of ribavirin-induced anaemia by promoting endogenous EPO. Ribavirin 77-86 erythropoietin Rattus norvegicus 127-130 25132781-9 2014 CONCLUSION: The IL28B genotype was linked to an impact on early viral kinetics in response to PEG-IFN/RBV therapy in HCV-6 infected patients. Ribavirin 102-105 interferon lambda 3 Homo sapiens 16-21 25059552-2 2014 Daclatasvir combined with peginterferon alpha-2a and ribavirin in Japanese patients infected with genotype 1b HCV achieved sustained virological response (SVR) in 100% of treatment-naive patients, due to high rates of favorable IL28B allele and genotype 1b. Ribavirin 53-62 interferon lambda 3 Homo sapiens 228-233 24400682-0 2014 Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan. Ribavirin 54-63 interferon lambda 3 Homo sapiens 0-15 24889558-1 2014 This study tested whether differential expression of an important ISG with antiviral properties, tripartite motif 22 (TRIM22), correlates with a response to Peg-IFNalpha-2a/RBV combination therapy in treatment-naive patients with chronic hepatitis C. A total of 32 patients with chronic hepatitis C were enrolled in this study and received standard Peg-IFNalpha-2a/RBV combination therapy. Ribavirin 365-368 tripartite motif containing 22 Homo sapiens 97-116 24889558-1 2014 This study tested whether differential expression of an important ISG with antiviral properties, tripartite motif 22 (TRIM22), correlates with a response to Peg-IFNalpha-2a/RBV combination therapy in treatment-naive patients with chronic hepatitis C. A total of 32 patients with chronic hepatitis C were enrolled in this study and received standard Peg-IFNalpha-2a/RBV combination therapy. Ribavirin 365-368 tripartite motif containing 22 Homo sapiens 118-124 24889558-9 2014 This study showed that pretreatment upregulation of TRIM22 may be associated with responsiveness to Peg-IFNalpha-2a/RBV combination therapy. Ribavirin 116-119 tripartite motif containing 22 Homo sapiens 52-58 24957263-0 2014 Ribavirin uptake into human hepatocyte HHL5 cells is enhanced by interferon-alpha via up-regulation of the human concentrative nucleoside transporter (hCNT2). Ribavirin 0-9 solute carrier family 28 member 2 Homo sapiens 151-156 24957263-1 2014 Ribavirin is a broad spectrum antiviral that increases the response rate in chronic hepatitis C patients when administered in combination with IFNalpha. Ribavirin 0-9 interferon alpha 1 Homo sapiens 143-151 24957263-3 2014 hCNT2 is the best candidate to mediate ribavirin uptake into hepatocytes due to its high-affinity for purines and its capacity to concentrate its substrates intracellularly. Ribavirin 39-48 solute carrier family 28 member 2 Homo sapiens 0-5 24957263-6 2014 hCNT2 activity up-regulation was associated with increased ribavirin accumulation into cells. Ribavirin 59-68 solute carrier family 28 member 2 Homo sapiens 0-5 24848437-4 2014 However, an IFN-free combination (sofosbuvir and ribavirin) has been recently approved for genotypes 2 and 3 patients with many other drugs in preclinical and clinical development. Ribavirin 49-58 interferon alpha 1 Homo sapiens 12-15 24889558-0 2014 Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNalpha-2a and ribavirin in Iranian patients with chronic hepatitis C. Interferons are able to exert an antiviral effect against hepatitis C virus (HCV) infection via induction of interferon-stimulated genes (ISGs). Ribavirin 115-124 tripartite motif containing 22 Homo sapiens 27-33 24889558-1 2014 This study tested whether differential expression of an important ISG with antiviral properties, tripartite motif 22 (TRIM22), correlates with a response to Peg-IFNalpha-2a/RBV combination therapy in treatment-naive patients with chronic hepatitis C. A total of 32 patients with chronic hepatitis C were enrolled in this study and received standard Peg-IFNalpha-2a/RBV combination therapy. Ribavirin 173-176 tripartite motif containing 22 Homo sapiens 97-116 24889558-1 2014 This study tested whether differential expression of an important ISG with antiviral properties, tripartite motif 22 (TRIM22), correlates with a response to Peg-IFNalpha-2a/RBV combination therapy in treatment-naive patients with chronic hepatitis C. A total of 32 patients with chronic hepatitis C were enrolled in this study and received standard Peg-IFNalpha-2a/RBV combination therapy. Ribavirin 173-176 tripartite motif containing 22 Homo sapiens 118-124 24929144-0 2014 KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C. Natural killer cells play a key role in the immune control of viral infections. Ribavirin 83-92 killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 Homo sapiens 0-7 25337144-0 2014 The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Ribavirin 130-139 interferon lambda 3 Homo sapiens 12-27 25337144-1 2014 BACKGROUND: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) rs8099917 has been described to be associated with response to treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) in patients with chronic hepatitis C from the North America, Europe, Asia countries like Japan and Taiwan. Ribavirin 176-185 interferon lambda 3 Homo sapiens 12-27 25337144-1 2014 BACKGROUND: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) rs8099917 has been described to be associated with response to treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) in patients with chronic hepatitis C from the North America, Europe, Asia countries like Japan and Taiwan. Ribavirin 176-185 interferon lambda 3 Homo sapiens 29-34 25337144-1 2014 BACKGROUND: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) rs8099917 has been described to be associated with response to treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) in patients with chronic hepatitis C from the North America, Europe, Asia countries like Japan and Taiwan. Ribavirin 195-198 interferon lambda 3 Homo sapiens 12-27 25337144-1 2014 BACKGROUND: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) rs8099917 has been described to be associated with response to treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) in patients with chronic hepatitis C from the North America, Europe, Asia countries like Japan and Taiwan. Ribavirin 195-198 interferon lambda 3 Homo sapiens 29-34 25132867-2 2014 She subsequently completed 72 weeks of natural IFN-beta plus ribavirin therapy without remarkable adverse effects and achieved a sustained viral response, suggesting differences in the pharmacological properties and biological effects of IFN-alpha and IFN-beta. Ribavirin 61-70 interferon beta 1 Homo sapiens 252-260 25132867-3 2014 Thus, natural IFN-beta plus ribavirin therapy may be a treatment option for patients with poor tolerance to IFN-alpha or pegIFN-alpha treatments. Ribavirin 28-37 interferon alpha 1 Homo sapiens 108-117 24994464-0 2014 Low IL10 serum levels as key factor for predicting the sustained virological response to IFNalpha/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype. Ribavirin 98-107 interleukin 10 Homo sapiens 4-8 24994464-0 2014 Low IL10 serum levels as key factor for predicting the sustained virological response to IFNalpha/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype. Ribavirin 98-107 interferon lambda 3 Homo sapiens 148-153 24994464-1 2014 PROPOSE: IL28B polymorphisms rs12979860 CC genotype was associated to protection of HCV infection and sustained virological response (SVR) in HCV infected patients treated with pegIFNalpha/ribavirin (IFNalpha/RIB), however, this polymorphism frequency varies depending on genetic components. Ribavirin 189-198 interferon lambda 3 Homo sapiens 9-14 24994464-1 2014 PROPOSE: IL28B polymorphisms rs12979860 CC genotype was associated to protection of HCV infection and sustained virological response (SVR) in HCV infected patients treated with pegIFNalpha/ribavirin (IFNalpha/RIB), however, this polymorphism frequency varies depending on genetic components. Ribavirin 189-198 interferon alpha 1 Homo sapiens 180-188 24929144-6 2014 In conclusion, IL28B and KIR3DL1/HLA-Bw4 are independent predictors of an SVR in Japanese patients infected with genotype 1b HCV receiving TVR/PEG-IFN/RBV or PEG-IFN/RBV therapy. Ribavirin 151-154 interferon lambda 3 Homo sapiens 15-20 24929144-6 2014 In conclusion, IL28B and KIR3DL1/HLA-Bw4 are independent predictors of an SVR in Japanese patients infected with genotype 1b HCV receiving TVR/PEG-IFN/RBV or PEG-IFN/RBV therapy. Ribavirin 151-154 killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 Homo sapiens 25-32 24929144-6 2014 In conclusion, IL28B and KIR3DL1/HLA-Bw4 are independent predictors of an SVR in Japanese patients infected with genotype 1b HCV receiving TVR/PEG-IFN/RBV or PEG-IFN/RBV therapy. Ribavirin 166-169 interferon lambda 3 Homo sapiens 15-20 24857619-7 2014 CONCLUSION: Interferon-beta plus ribavirin therapy was safe in elderly patients, with lower proportions of patients with a dose reduction of interferon-beta or ribavirin and treatment discontinuation. Ribavirin 33-42 interferon beta 1 Homo sapiens 141-156 24857619-0 2014 Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C. AIM: This study aims to evaluate the efficacy and safety of interferon-beta plus ribavirin therapy in older Japanese patients. Ribavirin 21-30 interferon beta 1 Homo sapiens 188-203 24857619-0 2014 Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C. AIM: This study aims to evaluate the efficacy and safety of interferon-beta plus ribavirin therapy in older Japanese patients. Ribavirin 209-218 interferon beta 1 Homo sapiens 0-15 24768758-1 2014 BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) near the interferon lambda 3 (IFNL3, previously known as IL28B) region are the strongest baseline predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin therapy in hepatitis C virus (HCV) genotype 1 infection. Ribavirin 237-246 interferon lambda 3 Homo sapiens 92-97 24857619-7 2014 CONCLUSION: Interferon-beta plus ribavirin therapy was safe in elderly patients, with lower proportions of patients with a dose reduction of interferon-beta or ribavirin and treatment discontinuation. Ribavirin 160-169 interferon beta 1 Homo sapiens 12-27 25013899-11 2014 CONCLUSIONS: In HIV/HCV coinfected patients with HCV genotypes 1 or 4, RVR, mainly influenced by genotype IL28B and HCV-RNA levels, reliably predicted SVR after 4 weeks of therapy with Peg-IFN plus RBV. Ribavirin 198-201 nuclear receptor subfamily 1 group D member 2 Homo sapiens 71-74 25252446-4 2014 The paper presents a case of a patient with Hashimoto"s thyroiditis, in whom at the time of CHC therapy with pegylated interferon alfa and ribavirin hyperthyroidism episode evolved with an increased level of TSH receptor antibodies after introducing an antiviral treatment and its decrease after the use of antithyroid drugs. Ribavirin 139-148 thyroid stimulating hormone receptor Homo sapiens 208-220 25077851-7 2014 Presence of certain depressive symptoms i.e., presence of little interest or pleasure in doing things, feeling tired or having little energy, poor appetite, social withdrawal and work inhibition at the baseline were associated with development of depression during the course of pegylated IFN-alpha plus ribavirin therapy. Ribavirin 304-313 interferon alpha 1 Homo sapiens 289-298 25077851-8 2014 CONCLUSION: Depressive symptoms in patients with pegylated IFN-alpha and ribavirin induced MDE are influenced by the symptoms of depression prior to starting of pegylated IFN-alpha and ribavirin combination. Ribavirin 73-82 interferon alpha 1 Homo sapiens 171-180 25077851-8 2014 CONCLUSION: Depressive symptoms in patients with pegylated IFN-alpha and ribavirin induced MDE are influenced by the symptoms of depression prior to starting of pegylated IFN-alpha and ribavirin combination. Ribavirin 185-194 interferon alpha 1 Homo sapiens 59-68 24677184-1 2014 UNLABELLED: Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)-ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks. Ribavirin 304-313 interferon alpha 1 Homo sapiens 227-230 24870236-3 2014 Therapies are under development to improve outcomes and include targeting the eukaryotic translation initiation factor (eIF4E) with its inhibitor ribavirin. Ribavirin 146-155 eukaryotic translation initiation factor 4E Homo sapiens 120-125 24870236-8 2014 GLI1 alone is sufficient to drive UGT1A-dependent glucuronidation of ribavirin and Ara-C, and thus drug resistance. Ribavirin 69-78 GLI family zinc finger 1 Homo sapiens 0-4 24870236-8 2014 GLI1 alone is sufficient to drive UGT1A-dependent glucuronidation of ribavirin and Ara-C, and thus drug resistance. Ribavirin 69-78 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 34-39 24657484-10 2014 CONCLUSIONS: A higher percentage of patients with chronic HCV infection who received immunotherapy with TG4040 followed by TG4040 and PEG-IFNalpha/RBV achieved a cEVR compared with patients who received only PEG-IFNalpha/RBV therapy. Ribavirin 147-150 interferon alpha 1 Homo sapiens 138-146 23745758-3 2014 IFN-beta was administrated twice a day for 2 weeks followed by 24 or 48 weeks of PEG IFN/RBV. Ribavirin 89-92 interferon beta 1 Homo sapiens 0-8 24677184-1 2014 UNLABELLED: Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)-ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks. Ribavirin 319-322 interferon alpha 1 Homo sapiens 227-230 24793175-1 2014 CASE PRESENTATION: Here, we present a Japanese child with chronic hepatitis C with fibrosis, who did not respond to Peg-IFN alpha-2b but responded to Peg-IFN alpha-2a with ribavirin, accompanied with fluvastatin. Ribavirin 172-181 interferon alpha 1 Homo sapiens 154-157 24750345-1 2014 Inosine triphosphatase (ITPA) genetic variants are strongly associated with ribavirin (RBV)-induced anaemia during pegylated interferon (PEG-IFN) plus RBV therapy. Ribavirin 76-85 inosine triphosphatase Homo sapiens 24-28 24750345-1 2014 Inosine triphosphatase (ITPA) genetic variants are strongly associated with ribavirin (RBV)-induced anaemia during pegylated interferon (PEG-IFN) plus RBV therapy. Ribavirin 87-90 inosine triphosphatase Homo sapiens 24-28 24750345-1 2014 Inosine triphosphatase (ITPA) genetic variants are strongly associated with ribavirin (RBV)-induced anaemia during pegylated interferon (PEG-IFN) plus RBV therapy. Ribavirin 151-154 inosine triphosphatase Homo sapiens 24-28 24750345-10 2014 In conclusion, ITPA genetic variants were associated with severe RBV-induced anaemia and could influence the efficacy of PEG-IFN plus RBV treatment among elderly patients with IL28B favourable type. Ribavirin 65-68 inosine triphosphatase Homo sapiens 15-19 24750345-10 2014 In conclusion, ITPA genetic variants were associated with severe RBV-induced anaemia and could influence the efficacy of PEG-IFN plus RBV treatment among elderly patients with IL28B favourable type. Ribavirin 65-68 interferon lambda 3 Homo sapiens 176-181 24750345-10 2014 In conclusion, ITPA genetic variants were associated with severe RBV-induced anaemia and could influence the efficacy of PEG-IFN plus RBV treatment among elderly patients with IL28B favourable type. Ribavirin 134-137 inosine triphosphatase Homo sapiens 15-19 24750345-10 2014 In conclusion, ITPA genetic variants were associated with severe RBV-induced anaemia and could influence the efficacy of PEG-IFN plus RBV treatment among elderly patients with IL28B favourable type. Ribavirin 134-137 interferon lambda 3 Homo sapiens 176-181 24969847-1 2014 BACKGROUND: The aim of this study was to evaluate whether polymorphisms of the mannose receptor C type 1 (MRC-1) and interleukin 28B (IL-28B) genes are associated with the treatment outcome of patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2, respectively) who are treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV). Ribavirin 324-333 mannose receptor C-type 1 Homo sapiens 79-104 24102823-1 2014 BACKGROUND: A strong association between single nucleotide polymorphisms (SNPs) of IL28B and treatment outcomes of pegylated interferon-alpha (PEG IFNalpha) and ribavirin (RBV) has been shown in chronic hepatitis C (CHC) patients with genotype 1. Ribavirin 161-170 interferon lambda 3 Homo sapiens 83-88 24102823-1 2014 BACKGROUND: A strong association between single nucleotide polymorphisms (SNPs) of IL28B and treatment outcomes of pegylated interferon-alpha (PEG IFNalpha) and ribavirin (RBV) has been shown in chronic hepatitis C (CHC) patients with genotype 1. Ribavirin 172-175 interferon lambda 3 Homo sapiens 83-88 25071317-2 2014 Many studies in adults have demonstrated that genetic variation in IFNL3 is a strong predictor of the virological response in treatment-naive patients with HCV genotype 1 who were treated with Pegylated-IFN-alpha and ribavirin. Ribavirin 217-226 interferon lambda 3 Homo sapiens 67-72 24969847-1 2014 BACKGROUND: The aim of this study was to evaluate whether polymorphisms of the mannose receptor C type 1 (MRC-1) and interleukin 28B (IL-28B) genes are associated with the treatment outcome of patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2, respectively) who are treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV). Ribavirin 324-333 mannose receptor C-type 1 Homo sapiens 106-111 24969847-1 2014 BACKGROUND: The aim of this study was to evaluate whether polymorphisms of the mannose receptor C type 1 (MRC-1) and interleukin 28B (IL-28B) genes are associated with the treatment outcome of patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2, respectively) who are treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV). Ribavirin 324-333 interferon lambda 3 Homo sapiens 134-140 24367041-0 2014 IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. Ribavirin 128-137 interferon lambda 4 (gene/pseudogene) Homo sapiens 0-5 24415789-1 2014 BACKGROUND: The polymorphisms of IFNL4 are strongly associated with both spontaneous hepatitis C virus (HCV) clearance and response to peg-IFN-alpha/ribavirin treatment. Ribavirin 149-158 interferon lambda 4 (gene/pseudogene) Homo sapiens 33-38 25097047-8 2014 Moreover, chronic HCV patients treated with IFN and ribavirin had significantly lower levels of C3 and C4 compared with patients naive to IFN and ribavirin treatment. Ribavirin 52-61 interferon alpha 1 Homo sapiens 138-141 25097047-8 2014 Moreover, chronic HCV patients treated with IFN and ribavirin had significantly lower levels of C3 and C4 compared with patients naive to IFN and ribavirin treatment. Ribavirin 146-155 interferon alpha 1 Homo sapiens 44-47 24488144-4 2014 Population-wide resistance and presence of IFN-resistant variants were highly associated with pegylated IFN-alpha2a/ribavirin treatment outcome at week 12 (P = 3.78 x 10(-5) and 0.0114, respectively). Ribavirin 116-125 interferon alpha 1 Homo sapiens 43-46 24488144-4 2014 Population-wide resistance and presence of IFN-resistant variants were highly associated with pegylated IFN-alpha2a/ribavirin treatment outcome at week 12 (P = 3.78 x 10(-5) and 0.0114, respectively). Ribavirin 116-125 interferon alpha 2 Homo sapiens 104-114 24449403-0 2014 ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Ribavirin 63-72 inosine triphosphatase Homo sapiens 0-4 24449403-2 2014 Inosine triphosphatase (ITPA) variants causing ITPase deficiency have been shown to protect against RBV-induced anemia. Ribavirin 100-103 inosine triphosphatase Homo sapiens 0-22 24449403-2 2014 Inosine triphosphatase (ITPA) variants causing ITPase deficiency have been shown to protect against RBV-induced anemia. Ribavirin 100-103 inosine triphosphatase Homo sapiens 24-28 24726902-0 2014 Identification of naive HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. Ribavirin 88-97 interferon lambda 3 Homo sapiens 111-116 25032184-1 2014 BACKGROUND/AIMS: There are few available data regarding the association between the single nucleotide polymorphisms (SNPs) of the gene encoding interleukin 28B (IL28B) and a sustained virologic response (SVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy in Korean chronic hepatitis C patients. Ribavirin 241-250 interferon lambda 3 Homo sapiens 161-166 25032184-1 2014 BACKGROUND/AIMS: There are few available data regarding the association between the single nucleotide polymorphisms (SNPs) of the gene encoding interleukin 28B (IL28B) and a sustained virologic response (SVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy in Korean chronic hepatitis C patients. Ribavirin 252-255 interferon lambda 3 Homo sapiens 161-166 24519039-1 2014 UNLABELLED: The present study evaluated the impact of variations in the inosine triphosphate pyrophosphatase (ITPase) gene (ITPA) on treatment outcome in patients with hepatitis C virus (HCV) genotype 2/3 infection receiving peginterferon-alpha2a and lower, conventional 800 mg daily dose of ribavirin. Ribavirin 292-301 inosine triphosphatase Homo sapiens 72-108 24519039-1 2014 UNLABELLED: The present study evaluated the impact of variations in the inosine triphosphate pyrophosphatase (ITPase) gene (ITPA) on treatment outcome in patients with hepatitis C virus (HCV) genotype 2/3 infection receiving peginterferon-alpha2a and lower, conventional 800 mg daily dose of ribavirin. Ribavirin 292-301 inosine triphosphatase Homo sapiens 110-116 24519039-1 2014 UNLABELLED: The present study evaluated the impact of variations in the inosine triphosphate pyrophosphatase (ITPase) gene (ITPA) on treatment outcome in patients with hepatitis C virus (HCV) genotype 2/3 infection receiving peginterferon-alpha2a and lower, conventional 800 mg daily dose of ribavirin. Ribavirin 292-301 inosine triphosphatase Homo sapiens 124-128 24519039-2 2014 Previous studies using higher, weight-based ribavirin dosing report that patients carrying polymorphisms encoding reduced predicted ITPase activity show decreased risk of ribavirin-induced anemia but increased risk of thrombocytopenia, with no impact on elimination of virus. Ribavirin 44-53 inosine triphosphatase Homo sapiens 132-138 24519039-2 2014 Previous studies using higher, weight-based ribavirin dosing report that patients carrying polymorphisms encoding reduced predicted ITPase activity show decreased risk of ribavirin-induced anemia but increased risk of thrombocytopenia, with no impact on elimination of virus. Ribavirin 171-180 inosine triphosphatase Homo sapiens 132-138 24519039-6 2014 Gene variants predicting reduced predicted ITPase activity were also associated with decreased risk of anemia (P < 0.0001), increased risk of thrombocytopenia (P = 0.007), and lower ribavirin concentrations (P = 0.02). Ribavirin 185-194 inosine triphosphatase Homo sapiens 43-49 24519039-7 2014 CONCLUSION: These findings demonstrate a novel ribavirin-like association between polymorphisms at ITPA and treatment efficacy in chronic hepatitis C mediated by reduced relapse risk. Ribavirin 47-56 inosine triphosphatase Homo sapiens 99-103 24519039-8 2014 We hypothesize that patients (63%) being homozygous for both major alleles, leading to normal ITPase activity, may benefit more from the addition of ribavirin to present and future treatment regimens for HCV in spite of concomitant increased risk of anemia. Ribavirin 149-158 inosine triphosphatase Homo sapiens 94-100 24367041-1 2014 Response to pegylated interferon-alpha and ribavirin (IFN-alpha/RBV) treatment for chronic hepatitis C virus (HCV) infection is influenced by host genetic factors, but their role for IFN-alpha-free, direct-acting antiviral (DAA) regimens is unclear. Ribavirin 43-52 interferon alpha 1 Homo sapiens 54-63 24367041-1 2014 Response to pegylated interferon-alpha and ribavirin (IFN-alpha/RBV) treatment for chronic hepatitis C virus (HCV) infection is influenced by host genetic factors, but their role for IFN-alpha-free, direct-acting antiviral (DAA) regimens is unclear. Ribavirin 43-52 interferon alpha 1 Homo sapiens 183-192 24367041-3 2014 We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies. Ribavirin 70-73 interferon lambda 4 (gene/pseudogene) Homo sapiens 75-80 24367041-3 2014 We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies. Ribavirin 70-73 interferon lambda 3 Homo sapiens 252-263 24367041-3 2014 We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies. Ribavirin 70-73 interferon alpha 1 Homo sapiens 267-276 24672032-1 2014 IFNL3 (lambda-3 interferon gene) polymorphisms and the expression of miR-122 have been associated with sustained virological response (SVR) to treatment with pegylated interferon plus ribavirin in patients with chronic hepatitis C (CHC). Ribavirin 184-193 interferon lambda 3 Homo sapiens 0-5 24672032-1 2014 IFNL3 (lambda-3 interferon gene) polymorphisms and the expression of miR-122 have been associated with sustained virological response (SVR) to treatment with pegylated interferon plus ribavirin in patients with chronic hepatitis C (CHC). Ribavirin 184-193 microRNA 122 Homo sapiens 69-76 24674023-14 2014 NS3/4A protease efficiency cleaving MAVS may be associated with virus transmission and response to pegIFN/RBV treatment. Ribavirin 106-109 mitochondrial antiviral signaling protein Homo sapiens 36-40 24286977-4 2014 In contrast, antiviral therapy (e.g. with pegylated interferon-alpha combined with ribavirin) raises hepcidin levels and reduces iron overload in patients with CHC. Ribavirin 83-92 hepcidin antimicrobial peptide Homo sapiens 101-109 24325603-2 2014 To compare binding mechanism and behavior of antiviral drugs with human serum albumin (HSA), we performed fluorescence spectroscopy and X-ray crystallography to investigate the interactions of ribavirin and lamivudine with HSA. Ribavirin 193-202 albumin Homo sapiens 72-85 25203700-13 2014 CONCLUSION: The genetic data reported here provides strong support for the role of NS2, NS3 and p7 in antagonizing the peg-IFN/RBV response during the treatment of HCV infections. Ribavirin 127-130 NS2 Homo sapiens 83-86 25203700-13 2014 CONCLUSION: The genetic data reported here provides strong support for the role of NS2, NS3 and p7 in antagonizing the peg-IFN/RBV response during the treatment of HCV infections. Ribavirin 127-130 KRAS proto-oncogene, GTPase Homo sapiens 88-91 24654629-4 2014 RESULTS: A landmark genome-wide association study (GWAS) identified polymorphisms in the IL28B gene on chromosome 19 (19q13.13) associated with response to therapy with pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV) and spontaneous viral clearance in acute hepatitis C. Furthermore, IL28B genotype is associated with changes of lipid metabolism and insulin resistance. Ribavirin 210-219 interferon lambda 3 Homo sapiens 89-94 24654629-4 2014 RESULTS: A landmark genome-wide association study (GWAS) identified polymorphisms in the IL28B gene on chromosome 19 (19q13.13) associated with response to therapy with pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV) and spontaneous viral clearance in acute hepatitis C. Furthermore, IL28B genotype is associated with changes of lipid metabolism and insulin resistance. Ribavirin 221-224 interferon lambda 3 Homo sapiens 89-94 24654629-5 2014 A further GWAS demonstrated that ITPA genetic variants protect HCV genotype 1 patients from RBV-induced anaemia. Ribavirin 92-95 inosine triphosphatase Homo sapiens 33-37 24654629-10 2014 CONCLUSIONS: The determination of IL28B polymorphisms may be useful to individualise treatment options when using PEG/RBV based therapies for chronic hepatitis C infection. Ribavirin 118-121 interferon lambda 3 Homo sapiens 34-39 24752298-6 2014 The analysis of liver biopsies of patients with CHC revealed a strong association of high IFN-lambdaR1 expression with elevated ISG expression, with IFN-lambda3 minor alleles, and with nonresponse to pegylated IFN-alpha and ribavirin. Ribavirin 224-233 interferon lambda receptor 1 Homo sapiens 90-102 24325603-2 2014 To compare binding mechanism and behavior of antiviral drugs with human serum albumin (HSA), we performed fluorescence spectroscopy and X-ray crystallography to investigate the interactions of ribavirin and lamivudine with HSA. Ribavirin 193-202 albumin Homo sapiens 87-90 24325603-2 2014 To compare binding mechanism and behavior of antiviral drugs with human serum albumin (HSA), we performed fluorescence spectroscopy and X-ray crystallography to investigate the interactions of ribavirin and lamivudine with HSA. Ribavirin 193-202 albumin Homo sapiens 223-226 24325603-4 2014 Our results further demonstrated that ribavirin and lamivdudine interaction with HSA could be affected by the presence of other compounds, including the non-steroidal anti-inflammatory drugs, indometacin. Ribavirin 38-47 albumin Homo sapiens 81-84 24325603-5 2014 X-ray structures revealed that ribavirin and lamivudine bind in IIA subdomain of HSA mainly by forming hydrogen bond and hydrophobic interactions forces. Ribavirin 31-40 albumin Homo sapiens 81-84 24325603-8 2014 Our results reveal the key biochemical and structural characteristics of the HSA interaction with ribavirin and lamivudine, providing guidance for future development of ribavirin- and lamivudine-based compounds and a drug-HSA delivery system. Ribavirin 98-107 albumin Homo sapiens 77-80 24325603-8 2014 Our results reveal the key biochemical and structural characteristics of the HSA interaction with ribavirin and lamivudine, providing guidance for future development of ribavirin- and lamivudine-based compounds and a drug-HSA delivery system. Ribavirin 98-107 albumin Homo sapiens 222-225 24325603-8 2014 Our results reveal the key biochemical and structural characteristics of the HSA interaction with ribavirin and lamivudine, providing guidance for future development of ribavirin- and lamivudine-based compounds and a drug-HSA delivery system. Ribavirin 169-178 albumin Homo sapiens 77-80 24431103-8 2014 Furthermore, we evaluated HSP27 levels in placentae exposed to ribavirin, which triggers EVT differentiation. Ribavirin 63-72 heat shock protein family B (small) member 1 Homo sapiens 26-31 24424305-5 2014 For treatment-naive patients treated with peginterferon-alfa and ribavirin a lower rate of undetectable HCV-RNA at week 4 (RVR) was observed for ART (9%) vs. CAP (16%). Ribavirin 65-74 nuclear receptor subfamily 1 group D member 2 Homo sapiens 123-126 24792632-1 2014 OBJECTIVE: Recent genome-wide association studies performed in adults correlated single-nucleotide polymorphisms (SNPs rs12979860 and rs8099917) located on chromosome 19, upstream of the interleukin 28B gene, with spontaneous clearance of hepatitis C virus and with response to treatment with paginated interferon and ribavirin. Ribavirin 318-327 interferon lambda 3 Homo sapiens 187-202 24431103-11 2014 Induction of EVT differentiation by ribavirin elevated HSP27 levels. Ribavirin 36-45 heat shock protein family B (small) member 1 Homo sapiens 55-60 24462955-10 2014 The baseline LDL-C level exerted a potent influence on the SVR of treatment-experienced patients treated with TVR-based triple therapy, especially for prior partial and null responders to PEG-IFNalpha and RBV. Ribavirin 205-208 component of oligomeric golgi complex 2 Homo sapiens 13-18 24822024-4 2014 Clinical trials in HCV genotype 2/3 patients have demonstrated optimal efficacy in HCV-2, where the combination SOF/ribavirin (Rbv) for 12 weeks resulted in >90% sustained virological response (SVR) rates, while HCV-3 patients with advanced liver fibrosis and previous failure to PegIFN plus Rbv therapy still require individualized and optimized treatment strategies. Ribavirin 116-125 BMP binding endothelial regulator Homo sapiens 83-88 24822024-4 2014 Clinical trials in HCV genotype 2/3 patients have demonstrated optimal efficacy in HCV-2, where the combination SOF/ribavirin (Rbv) for 12 weeks resulted in >90% sustained virological response (SVR) rates, while HCV-3 patients with advanced liver fibrosis and previous failure to PegIFN plus Rbv therapy still require individualized and optimized treatment strategies. Ribavirin 127-130 BMP binding endothelial regulator Homo sapiens 83-88 24822024-4 2014 Clinical trials in HCV genotype 2/3 patients have demonstrated optimal efficacy in HCV-2, where the combination SOF/ribavirin (Rbv) for 12 weeks resulted in >90% sustained virological response (SVR) rates, while HCV-3 patients with advanced liver fibrosis and previous failure to PegIFN plus Rbv therapy still require individualized and optimized treatment strategies. Ribavirin 295-298 BMP binding endothelial regulator Homo sapiens 83-88 24760000-2 2014 Inosine triphosphatase (ITPA) genetic variants are associated with RBV- induced anemia and dose reduction. Ribavirin 67-70 inosine triphosphatase Homo sapiens 0-22 24760000-2 2014 Inosine triphosphatase (ITPA) genetic variants are associated with RBV- induced anemia and dose reduction. Ribavirin 67-70 inosine triphosphatase Homo sapiens 24-28 24462955-1 2014 Elevated serum low-density lipoprotein cholesterol (LDL-C) level has been associated with sustained virological response (SVR) by chronic hepatitis C patients treated with pegylated-interferon (PEG-IFN) alpha and ribavirin (RBV). Ribavirin 213-222 component of oligomeric golgi complex 2 Homo sapiens 52-57 24462955-1 2014 Elevated serum low-density lipoprotein cholesterol (LDL-C) level has been associated with sustained virological response (SVR) by chronic hepatitis C patients treated with pegylated-interferon (PEG-IFN) alpha and ribavirin (RBV). Ribavirin 224-227 component of oligomeric golgi complex 2 Homo sapiens 52-57 24495847-0 2014 Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 DeltaG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. Ribavirin 193-202 interferon lambda 4 (gene/pseudogene) Homo sapiens 48-53 24164926-8 2014 A 48-hr exposure to ribavirin (>=8 mug/ml) was followed by a significant increase in [Ca2+]i, a significant decrease in forward scatter and a significant increase in annexin V binding. Ribavirin 20-29 annexin A5 Homo sapiens 169-178 24164926-9 2014 The annexin V binding after ribavirin treatment was significantly blunted but not abolished in the nominal absence of extracellular Ca2+. Ribavirin 28-37 annexin A5 Homo sapiens 4-13 24642705-13 2014 CONCLUSIONS: The favorable IL-28B rs12979860 genotype is a statistically significant predictor of SVR, RVR and ETR in HCV-4 monoinfected patients treated with Peg-IFN plus Rbv. Ribavirin 172-175 interferon lambda 3 Homo sapiens 27-33 24415442-4 2014 The association of IL28b polymorphism with virological response was studied in 356 patients with genotype 3 chronic HCV undergoing treatment with peg-interferon and ribavirin and was compared with matched controls. Ribavirin 165-174 interferon lambda 3 Homo sapiens 19-24 23981197-12 2014 On the other hand, detection of serum CYC at baseline may be negatively associated with treatment response to pegylated interferon plus ribavirin in CHC. Ribavirin 136-145 cytochrome c, somatic Homo sapiens 38-41 25173222-2 2014 METHODS: One-hundred-and-eighty-eight treatment of the CHC patients who were administered combination therapy of ribavirin with IFNa from 2010 to 2012. Ribavirin 113-122 interferon alpha 2 Homo sapiens 128-132 24532585-3 2014 IL-28B is a type III IFN, and genetic polymorphisms upstream of its gene are strongly associated with the efficacy of polyethylene glycol-IFN and ribavirin therapy. Ribavirin 146-155 interferon lambda 3 Homo sapiens 0-6 24325405-1 2014 Genome-wide association studies recently revealed that certain interleukin-28B (IL28B) polymorphisms are strongly associated with responses to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients chronically infected with hepatitis C virus (HCV) genotype 1, as well as with spontaneous clearance of HCV. Ribavirin 178-187 interferon lambda 3 Homo sapiens 63-78 24236455-8 2014 Taken together, our data suggest that BST-2 is a host restriction factor against HCV, and induction of BST-2 in hepatocytes could be one of the mechanisms by which current HCV standard therapy (IFN-alpha plus ribavirin) achieves a sustained virological response (SVR). Ribavirin 209-218 bone marrow stromal cell antigen 2 Homo sapiens 103-108 24566281-4 2014 The results showed that a 50% cytotoxic concentration (CC50) of EGCG, EGCG palmitate, and ribavirin was achieved at 2,359.71, 431.42, and 94.06 muM, respectively. Ribavirin 90-99 latexin Homo sapiens 144-147 24621321-0 2014 Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-alpha-2a with ribavirin therapy: a case report. Ribavirin 135-144 interferon alpha 1 Homo sapiens 104-126 24485784-5 2014 The anti-HCV activities demonstrated by this unusual class of compounds were superior to that of ribavirin (EC50=81.9 muM). Ribavirin 97-106 latexin Homo sapiens 118-121 24861285-4 2014 An association between IL-18 gene promoter polymorphisms and pegylated interferon (PEG-IFN) and ribavirin treatment outcomes has been reported for individuals with chronic hepatitis C virus genotype 1 (HCV-1). Ribavirin 96-105 interleukin 18 Homo sapiens 23-28 24325405-1 2014 Genome-wide association studies recently revealed that certain interleukin-28B (IL28B) polymorphisms are strongly associated with responses to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients chronically infected with hepatitis C virus (HCV) genotype 1, as well as with spontaneous clearance of HCV. Ribavirin 178-187 interferon lambda 3 Homo sapiens 80-85 24325405-1 2014 Genome-wide association studies recently revealed that certain interleukin-28B (IL28B) polymorphisms are strongly associated with responses to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients chronically infected with hepatitis C virus (HCV) genotype 1, as well as with spontaneous clearance of HCV. Ribavirin 189-192 interferon lambda 3 Homo sapiens 63-78 24325405-1 2014 Genome-wide association studies recently revealed that certain interleukin-28B (IL28B) polymorphisms are strongly associated with responses to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients chronically infected with hepatitis C virus (HCV) genotype 1, as well as with spontaneous clearance of HCV. Ribavirin 189-192 interferon lambda 3 Homo sapiens 80-85 24782254-2 2014 Recent approval of telaprevir and boceprevir, targeting the protease residing in nonstructural protein 3 (NS3) of the HCV genome, increased therapy success when given in combination with pegylated IFN and ribavirin, but side effects are more frequent and the management of treatment is complex. Ribavirin 205-214 KRAS proto-oncogene, GTPase Homo sapiens 106-109 24338811-7 2014 HCV genotype 1 patients with the TT allele of IL28B and with a low Vs value (<1.40 m/sec) who were treated with peg-IFN plus ribavirin therapy achieved a sustained virologic response at a rate of 79% (15/19), while all patients with the TG/GG allele of IL28B and a high Vs value (>=1.40 m/sec) experienced a non-virologic response (6/6). Ribavirin 128-137 interferon lambda 3 Homo sapiens 46-51 24338811-7 2014 HCV genotype 1 patients with the TT allele of IL28B and with a low Vs value (<1.40 m/sec) who were treated with peg-IFN plus ribavirin therapy achieved a sustained virologic response at a rate of 79% (15/19), while all patients with the TG/GG allele of IL28B and a high Vs value (>=1.40 m/sec) experienced a non-virologic response (6/6). Ribavirin 128-137 interferon lambda 3 Homo sapiens 256-261 24338811-9 2014 It is concluded that the combination of ARFI at cut off of 1.4 m/sec and IL28B may be useful for patients with chronic hepatitis C with genotype 1 treated with peg-IFN/ribavirin combination therapy. Ribavirin 168-177 interferon lambda 3 Homo sapiens 73-78 24022240-5 2014 In 2009, genome-wide association studies found the single-nucleotide polymorphisms, located near the host interleukin-28B (IL28B) gene that encodes IFN-lambda3, to be the best pretreatment predictor of virologic response to Peg-IFN and RBV therapy in chronic hepatitis C genotype 1 patients. Ribavirin 236-239 interferon lambda 3 Homo sapiens 123-128 24022240-5 2014 In 2009, genome-wide association studies found the single-nucleotide polymorphisms, located near the host interleukin-28B (IL28B) gene that encodes IFN-lambda3, to be the best pretreatment predictor of virologic response to Peg-IFN and RBV therapy in chronic hepatitis C genotype 1 patients. Ribavirin 236-239 interferon alpha 1 Homo sapiens 148-151 24022240-5 2014 In 2009, genome-wide association studies found the single-nucleotide polymorphisms, located near the host interleukin-28B (IL28B) gene that encodes IFN-lambda3, to be the best pretreatment predictor of virologic response to Peg-IFN and RBV therapy in chronic hepatitis C genotype 1 patients. Ribavirin 236-239 interferon alpha 1 Homo sapiens 228-231 24022240-6 2014 Additionally, inosine triphosphatase (ITPA) gene variants were found to be associated with RBV-induced hemolytic anemia, which could affect treatment dose for selected patients. Ribavirin 91-94 inosine triphosphatase Homo sapiens 14-36 24022240-6 2014 Additionally, inosine triphosphatase (ITPA) gene variants were found to be associated with RBV-induced hemolytic anemia, which could affect treatment dose for selected patients. Ribavirin 91-94 inosine triphosphatase Homo sapiens 38-42 24670522-7 2014 The ICER of "PEG/RBV trial" compared with "dual therapy" was $37 500/QALY. Ribavirin 17-20 cAMP responsive element modulator Homo sapiens 4-8 24670522-9 2014 In sensitivity analyses, IFN-free treatment attaining 90% SVR had an ICER less than $100 000/QALY compared with "PEG/RBV trial" when its cost was $109 000 or less (125% of the cost of PEG/RBV/TVR). Ribavirin 188-191 interferon alpha 1 Homo sapiens 25-28 25369007-11 2014 The analysis of results from TaqMan SNP Genotyping has been shown that two SNPs (Ex4-30G>C and Ivs1-4640 G>A) of IFNAR1 and IFNAR2 didn"t show any relationship with response to combined therapy in subjects affected with chronic hepatitis C who have treated with peg-IFN-alpha and Ribavirin. Ribavirin 286-295 interferon alpha and beta receptor subunit 1 Homo sapiens 119-125 24398031-1 2014 BACKGROUND: Previous studies have shown that single nucleotide polymorphisms (SNP) in IL28B and IL10R are associated with sustained virological response (SVR) in chronic hepatitis C patients treated with pegilated interferon plus ribavirin (P/R). Ribavirin 230-239 interferon lambda 3 Homo sapiens 86-91 24398031-1 2014 BACKGROUND: Previous studies have shown that single nucleotide polymorphisms (SNP) in IL28B and IL10R are associated with sustained virological response (SVR) in chronic hepatitis C patients treated with pegilated interferon plus ribavirin (P/R). Ribavirin 230-239 interleukin 10 receptor subunit alpha Homo sapiens 96-101 25369007-11 2014 The analysis of results from TaqMan SNP Genotyping has been shown that two SNPs (Ex4-30G>C and Ivs1-4640 G>A) of IFNAR1 and IFNAR2 didn"t show any relationship with response to combined therapy in subjects affected with chronic hepatitis C who have treated with peg-IFN-alpha and Ribavirin. Ribavirin 286-295 interferon alpha and beta receptor subunit 2 Homo sapiens 130-136 25369007-11 2014 The analysis of results from TaqMan SNP Genotyping has been shown that two SNPs (Ex4-30G>C and Ivs1-4640 G>A) of IFNAR1 and IFNAR2 didn"t show any relationship with response to combined therapy in subjects affected with chronic hepatitis C who have treated with peg-IFN-alpha and Ribavirin. Ribavirin 286-295 interferon alpha 1 Homo sapiens 119-122 24205831-0 2014 Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. BACKGROUND: The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC). Ribavirin 92-101 interferon lambda 4 (gene/pseudogene) Homo sapiens 17-35 24205831-0 2014 Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. BACKGROUND: The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC). Ribavirin 92-101 interferon lambda 3 Homo sapiens 40-45 24205831-0 2014 Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. BACKGROUND: The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC). Ribavirin 92-101 interferon lambda 3 Homo sapiens 156-161 24205831-0 2014 Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. BACKGROUND: The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC). Ribavirin 219-228 interferon lambda 3 Homo sapiens 156-161 24205831-0 2014 Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. BACKGROUND: The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC). Ribavirin 234-237 interferon lambda 3 Homo sapiens 156-161 24523350-1 2014 BACKGROUND: In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported. Ribavirin 214-223 interferon lambda 3 Homo sapiens 75-80 24342953-2 2014 METHODS: A total of 148 treatment-naive HIV-HCV-GT1 who received antiviral therapy with pegylated interferon/ribavirin were included in this multinational, retrospective analysis. Ribavirin 109-118 beta-1,4-galactosyltransferase 1 Homo sapiens 48-51 24145541-3 2014 IFN-alpha showed a moderate but significant synergism with ribavirin. Ribavirin 59-68 interferon alpha 1 Homo sapiens 0-9 24162072-11 2014 CONCLUSIONS: Evaluations of viral reduction at 2 weeks or both IL-28B and ISDR are useful to predict SVR to low-dose PEG-IFN-alpha2a plus ribavirin therapy for elderly and/or cirrhotic patients. Ribavirin 138-147 interferon lambda 3 Homo sapiens 63-69 24523350-1 2014 BACKGROUND: In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported. Ribavirin 225-228 interferon lambda 3 Homo sapiens 75-80 24584067-1 2014 BACKGROUND: Amino acid variations in several HCV genomic regions have been reported to be associated with response to interferon (IFN)-alpha plus ribavirin (RBV) combination therapy. Ribavirin 157-160 interferon alpha 1 Homo sapiens 118-140 24173146-2 2014 Soluble LDLR can inhibit HCV infectivity; greater plasma low-density lipoprotein levels are associated with treatment success; LDLR genotypes have a synergistic impact on the likelihood of achieving SVR with Peg-IFN plus RBV, as well as on viral kinetics after starting treatment. Ribavirin 221-224 low density lipoprotein receptor Homo sapiens 127-131 24107682-0 2014 Functional analysis of purine nucleoside phosphorylase as a key enzyme in ribavirin metabolism. Ribavirin 74-83 purine nucleoside phosphorylase Homo sapiens 23-54 24107682-3 2014 Furthermore, no pharmacogenomic studies related to PNP-mediated ribavirin phosphorolysis have previously been conducted. Ribavirin 64-73 purine nucleoside phosphorylase Homo sapiens 51-54 25236666-5 2014 METHODS: rs153109, corresponding to position c.-964A>G of the IL-27 locus, was amplified from genomic DNA extracted from 15 patients with chronic hepatitis C stratified by sustained viral response (SVR), relapser and non-responder, after treatment with peginterferon-alpha (PegIFN- alpha) combined with ribavirin (RBV). Ribavirin 306-315 interleukin 27 Homo sapiens 65-70 25236666-5 2014 METHODS: rs153109, corresponding to position c.-964A>G of the IL-27 locus, was amplified from genomic DNA extracted from 15 patients with chronic hepatitis C stratified by sustained viral response (SVR), relapser and non-responder, after treatment with peginterferon-alpha (PegIFN- alpha) combined with ribavirin (RBV). Ribavirin 317-320 interleukin 27 Homo sapiens 65-70 24107682-4 2014 In this study, we sought to identify the role of PNP in ribavirin phosphorolysis in the human small intestine, and to clarify the effect of the single nucleotide polymorphism (rs1049564) on PNP"s ribavirin phosphorolysis activity. Ribavirin 56-65 purine nucleoside phosphorylase Homo sapiens 49-52 24107682-5 2014 The results of our investigations show that PNP is abundantly expressed in the human small intestine, and that intestinal ribavirin phosphorolysis is severely inhibited by ganciclovir, a PNP-inhibitor. Ribavirin 122-131 purine nucleoside phosphorylase Homo sapiens 44-47 24107682-5 2014 The results of our investigations show that PNP is abundantly expressed in the human small intestine, and that intestinal ribavirin phosphorolysis is severely inhibited by ganciclovir, a PNP-inhibitor. Ribavirin 122-131 purine nucleoside phosphorylase Homo sapiens 187-190 24107682-6 2014 Therefore, PNP is likely to play a primary role in the ribavirin phosphorolysis in the human small intestine. Ribavirin 55-64 purine nucleoside phosphorylase Homo sapiens 11-14 24107682-8 2014 We believe that the present study will facilitate further pharmacogenomic and biochemical characterization of PNP as a key metabolic enzyme of ribavirin. Ribavirin 143-152 purine nucleoside phosphorylase Homo sapiens 110-113 24895793-3 2014 METHODOLOGY: Concentrations of MCP-1 in serum were determined in 165 patients with chronic hepatitis C (CHC) treated with interferon and ribavirin by enzyme linked immunosorbent assay before and 48 weeks after cessation of therapy. Ribavirin 137-146 C-C motif chemokine ligand 2 Homo sapiens 31-36 23396509-8 2014 Ribavirin monotherapy lowered serum IP-10 levels but had no effect on ISG expression in PBMC. Ribavirin 0-9 C-X-C motif chemokine ligand 10 Homo sapiens 36-41 25328696-6 2014 In conclusion, evaluation of viral reduction at 2 weeks or the combination of IL28B polymorphism and amino acid substitution at core 70 are useful for predicting SVR to telaprevir with PEG-IFN and ribavirin therapy. Ribavirin 197-206 interferon lambda 3 Homo sapiens 78-83 25548683-11 2014 IFNL4 ss469415590 variant and HCV viral loads or IFNL4 ss469415590 variant and early virological response were better predictors of SVR in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. Ribavirin 174-183 interferon lambda 4 (gene/pseudogene) Homo sapiens 0-5 25548683-11 2014 IFNL4 ss469415590 variant and HCV viral loads or IFNL4 ss469415590 variant and early virological response were better predictors of SVR in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. Ribavirin 174-183 interferon lambda 4 (gene/pseudogene) Homo sapiens 49-54 25548683-11 2014 IFNL4 ss469415590 variant and HCV viral loads or IFNL4 ss469415590 variant and early virological response were better predictors of SVR in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. Ribavirin 174-183 interferon alpha 1 Homo sapiens 0-3 24171456-1 2014 Enhanced endogenous interferon (IFN) stimulated gene (ISG) signature has been associated with nonresponsiveness to hepatitis C treatment using pegylated-IFNalpha (pegIFNalpha) and ribavirin (RBV) in human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. Ribavirin 180-189 interferon alpha 1 Homo sapiens 32-35 23591768-0 2014 Ex vivo induction of IFN-lambda3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients. Ribavirin 82-91 interferon lambda 3 Homo sapiens 21-32 23591768-0 2014 Ex vivo induction of IFN-lambda3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients. Ribavirin 82-91 toll like receptor 7 Homo sapiens 38-42 23591768-1 2014 BACKGROUND: Genetic variation around interleukin-28B (IL28B), encoding IFN-lambda3, predict non-responders to pegylated interferon-alpha/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC). Ribavirin 137-146 interferon lambda 3 Homo sapiens 54-59 23591768-1 2014 BACKGROUND: Genetic variation around interleukin-28B (IL28B), encoding IFN-lambda3, predict non-responders to pegylated interferon-alpha/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC). Ribavirin 137-146 interferon lambda 3 Homo sapiens 71-82 23591768-1 2014 BACKGROUND: Genetic variation around interleukin-28B (IL28B), encoding IFN-lambda3, predict non-responders to pegylated interferon-alpha/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC). Ribavirin 156-159 interferon lambda 3 Homo sapiens 54-59 23591768-1 2014 BACKGROUND: Genetic variation around interleukin-28B (IL28B), encoding IFN-lambda3, predict non-responders to pegylated interferon-alpha/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC). Ribavirin 156-159 interferon lambda 3 Homo sapiens 71-82 23591768-6 2014 Detectable levels of IFN-lambdas were inducible even in a small amount of PBMC, and IFN-lambda3 was more robustly up-regulated by R-837 in PBMC of CHC patients with favorable genotype for the response to Peg-IFN/RBV (TT in rs8099917) than those with TG/GG. Ribavirin 212-215 interferon lambda 3 Homo sapiens 84-95 23591768-7 2014 Importantly, the protein levels of IFN-lambda3 induced by R-837 clearly differentiated the response to Peg-IFN/RBV treatment (p = 1.0 x 10(-10)), including cases that IL28B genotyping failed to predict the treatment response. Ribavirin 111-114 interferon lambda 3 Homo sapiens 35-46 24171456-1 2014 Enhanced endogenous interferon (IFN) stimulated gene (ISG) signature has been associated with nonresponsiveness to hepatitis C treatment using pegylated-IFNalpha (pegIFNalpha) and ribavirin (RBV) in human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. Ribavirin 191-194 interferon alpha 1 Homo sapiens 32-35 23829453-0 2014 Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. Ribavirin 141-150 interferon lambda 3 Homo sapiens 9-24 24171456-1 2014 Enhanced endogenous interferon (IFN) stimulated gene (ISG) signature has been associated with nonresponsiveness to hepatitis C treatment using pegylated-IFNalpha (pegIFNalpha) and ribavirin (RBV) in human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. Ribavirin 191-194 interferon alpha Mus musculus 153-161 24171456-2 2014 Using a proteomic approach, we identified high levels of IFNalpha receptor 2a (IFNalphaR2a) in the serum of null responders to pegIFNalpha/RBV. Ribavirin 139-142 interferon alpha Mus musculus 57-65 24329856-1 2014 Ribavirin amplifies the interferon-alpha (IFN) signalling cascade. Ribavirin 0-9 interferon alpha 1 Homo sapiens 42-45 24329856-2 2014 As ribavirin needs 4 weeks to reach steady state, ribavirin priming may optimize hepatic IFN sensitivity before starting a pegylated (PEG)-IFN/ribavirin combination therapy. Ribavirin 50-59 interferon alpha 1 Homo sapiens 89-92 24496160-12 2014 CONCLUSION: Overexpression of COX-2 and TGF-beta1 is an independent predictor for poor outcome of interferon and ribavirin therapy and these might be useful markers for the response to treatment. Ribavirin 113-122 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 24329856-2 2014 As ribavirin needs 4 weeks to reach steady state, ribavirin priming may optimize hepatic IFN sensitivity before starting a pegylated (PEG)-IFN/ribavirin combination therapy. Ribavirin 50-59 interferon alpha 1 Homo sapiens 89-92 24496160-12 2014 CONCLUSION: Overexpression of COX-2 and TGF-beta1 is an independent predictor for poor outcome of interferon and ribavirin therapy and these might be useful markers for the response to treatment. Ribavirin 113-122 transforming growth factor beta 1 Homo sapiens 40-49 24379617-2 2013 Several studies have shown that, in patients with genotype 1 (GT-1), rs12979860 C/C and rs8099917 T/T substitutions are associated with a more than twofold increase in sustained virological response rate to Peg-IFN and RBV treatment. Ribavirin 219-222 beta-1,4-galactosyltransferase 1 Homo sapiens 62-66 24355007-0 2014 Genetic polymorphism in IFNL4 and response to pegylated interferon-alpha and ribavirin in Japanese chronic hepatitis C patients. Ribavirin 77-86 interferon lambda 4 (gene/pseudogene) Homo sapiens 24-29 25674609-5 2014 We found that in groups with HPS who were treated with ribavirin, there was no significant reduction in mortality (RR 0.99, 95 % CI 0.60-1.61, I(2) = 0 %). Ribavirin 55-64 HPS1 biogenesis of lysosomal organelles complex 3 subunit 1 Homo sapiens 29-32 25674609-10 2014 Additionally, the results of the application of ribavirin in the population with HPS could not be determined, particularly in patients in the end stage of this disease. Ribavirin 48-57 HPS1 biogenesis of lysosomal organelles complex 3 subunit 1 Homo sapiens 81-84 24349500-8 2013 In conclusion, combinations of KIR3DL1/HLA-Bw4, KIR2DL2/HLA-C1, and a genetic variant of the IL28B gene are predictive of the response to PEG-IFN and ribavirin therapy in Japanese patients infected with genotype 1b HCV. Ribavirin 150-159 killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 Homo sapiens 31-38 24349500-8 2013 In conclusion, combinations of KIR3DL1/HLA-Bw4, KIR2DL2/HLA-C1, and a genetic variant of the IL28B gene are predictive of the response to PEG-IFN and ribavirin therapy in Japanese patients infected with genotype 1b HCV. Ribavirin 150-159 killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 Homo sapiens 48-55 24349500-8 2013 In conclusion, combinations of KIR3DL1/HLA-Bw4, KIR2DL2/HLA-C1, and a genetic variant of the IL28B gene are predictive of the response to PEG-IFN and ribavirin therapy in Japanese patients infected with genotype 1b HCV. Ribavirin 150-159 interferon lambda 3 Homo sapiens 93-98 23942001-2 2013 The aim of our study was retrospective evaluation of treatment efficacy using pegylated interferon (IFN)-alpha2b with ribavirin in children and adolescents with chronic hepatitis C, both treatment naive and re-treated. Ribavirin 118-127 interferon alpha 1 Homo sapiens 88-110 24254131-6 2013 In particular, an IFN sparing regimen of sofosbuvir/RBV may become available in 2014. Ribavirin 52-55 interferon alpha 1 Homo sapiens 18-21 23867320-9 2013 In the transplantation setting, adding a protease inhibitor to PegIFN/RBV results in a significant increase in the incidence and severity of anemia and, as a consequence, a greater need for epoetin, transfusions, and ribavirin dose reductions. Ribavirin 70-73 erythropoietin Homo sapiens 190-197 23942546-8 2013 A univariate logistic regression analysis indicated that a plasma RBV concentration of <1960 ng/mL at the end of the treatment was strongly associated with relapse (odds ratio, 55; 95% confidence interval, 7.24- ; P = 0.0001) independently of age, body weight, RBV dose, baseline viral load, the interleukin-28B genotype, and response to previous courses of treatment. Ribavirin 66-69 interferon lambda 3 Homo sapiens 299-314 24304455-3 2013 Inosine triphosphatase (ITPA) genetic variants are associated with ribavirin-induced anaemia and dose reduction; however, their impact in real-life clinic patient cohorts remains to be defined. Ribavirin 67-76 inosine triphosphatase Homo sapiens 0-22 24304455-3 2013 Inosine triphosphatase (ITPA) genetic variants are associated with ribavirin-induced anaemia and dose reduction; however, their impact in real-life clinic patient cohorts remains to be defined. Ribavirin 67-76 inosine triphosphatase Homo sapiens 24-28 24304455-9 2013 More severe ITPA deficiency was associated with less reduction in haemoglobin level (P <0.001; R(2) = 0.34), less ribavirin dose reduction (OR 0.42; (95% CI = 0.23-0.77); P = 0.005) and less EPO use [OR 0.53; (0.30-0.94); P = 0.029]. Ribavirin 117-126 inosine triphosphatase Homo sapiens 12-16 24304455-11 2013 In this clinical cohort, ITPA deficiency helped predict the risk of on-treatment anaemia, ribavirin dose reduction, need for EPO support and was associated with SVR. Ribavirin 90-99 inosine triphosphatase Homo sapiens 25-29 24304455-12 2013 For patients on HCV regimens including peginterferon/ribavirin, testing for ITPA deficiency may have clinical utility. Ribavirin 53-62 inosine triphosphatase Homo sapiens 76-80 24348648-0 2013 Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4. Ribavirin 75-84 interferon lambda 3 Homo sapiens 15-20 23664070-2 2013 CASE REPORT: A 40-year-old, HIV and hepatitis C virus co-infected woman was treated with interferon and ribavirine and developed a TTP confirmed by the presence of anti-ADAMTS 13 antibodies. Ribavirin 104-114 ADAM metallopeptidase with thrombospondin type 1 motif 13 Homo sapiens 169-178 24348648-10 2013 CONCLUSIONS: IL-28B polymorphisms were the strongest pretreatment predictors of response to pegylated interferon and ribavirin in Polish patients chronically infected with HCV genotype 1 and 4. Ribavirin 117-126 interferon lambda 3 Homo sapiens 13-19 24579307-5 2013 The results showed that single nucleotide polymorphisms (SNPs) of the IL28B gene, which encodes protein IFN-lambda3, are associated with viral clearance and treatment effectiveness of HCV patients who were cured by PEG-IFNalpha combined with ribavirin (RBV). Ribavirin 253-256 interferon alpha 1 Homo sapiens 219-227 24244641-1 2013 BACKGROUND AND AIMS: Recently, several genome-wide association studies have revealed that single nucleotide polymorphisms (SNPs) in proximity to IL28B predict spontaneous clearance of hepatitis C virus (HCV) infection as well as outcome following pegylated interferon and ribavirin therapy among genotype 1 infected patients. Ribavirin 272-281 interferon lambda 3 Homo sapiens 145-150 23850877-0 2013 Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. Ribavirin 43-52 inosine triphosphatase Homo sapiens 21-25 23850877-1 2013 BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) in the inosine triphosphate pyrophosphatase (ITPA) gene protect patients from ribavirin induced anemia. Ribavirin 140-149 inosine triphosphatase Homo sapiens 69-105 23850877-1 2013 BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) in the inosine triphosphate pyrophosphatase (ITPA) gene protect patients from ribavirin induced anemia. Ribavirin 140-149 inosine triphosphatase Homo sapiens 107-111 24168256-1 2013 The IL-28 gene is associated with sustained viral response (SVR) after treatment with peg-IFN and ribavirin in liver transplant recipients with chronic hepatitis C genotype 1 infection. Ribavirin 98-107 interferon lambda 3 Homo sapiens 4-9 24579307-5 2013 The results showed that single nucleotide polymorphisms (SNPs) of the IL28B gene, which encodes protein IFN-lambda3, are associated with viral clearance and treatment effectiveness of HCV patients who were cured by PEG-IFNalpha combined with ribavirin (RBV). Ribavirin 242-251 interferon lambda 3 Homo sapiens 104-115 24579307-5 2013 The results showed that single nucleotide polymorphisms (SNPs) of the IL28B gene, which encodes protein IFN-lambda3, are associated with viral clearance and treatment effectiveness of HCV patients who were cured by PEG-IFNalpha combined with ribavirin (RBV). Ribavirin 242-251 interferon alpha 1 Homo sapiens 219-227 24579307-5 2013 The results showed that single nucleotide polymorphisms (SNPs) of the IL28B gene, which encodes protein IFN-lambda3, are associated with viral clearance and treatment effectiveness of HCV patients who were cured by PEG-IFNalpha combined with ribavirin (RBV). Ribavirin 253-256 interferon lambda 3 Homo sapiens 104-115 24240045-0 2013 Endogenous IFNgamma in chronic HCV genotype 4 patients treated with PEG-IFNalpha and ribavirin. Ribavirin 85-94 interferon gamma Homo sapiens 11-19 24240045-4 2013 The role of endogenous interferon gamma (IFNgamma) in Egyptian patients infected with chronic HCV and treated with PEG-IFN/ribavirin is uncertain. Ribavirin 123-132 interferon gamma Homo sapiens 23-50 24240045-5 2013 The goal of this study was to evaluate the association of IFNgamma and chronic HCV infection among patients treated with combination therapy of PEG-IFN/ribavirin. Ribavirin 152-161 interferon gamma Homo sapiens 58-66 23842134-1 2013 OBJECTIVE: To identify genetic factors that predict sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin (RBV) in HIV/hepatitis C virus (HCV) genotype 1 or 4-coinfected patients and that enhance the predictive capacity of IL28B genotype in this population. Ribavirin 123-132 interferon lambda 3 Homo sapiens 250-255 23842134-1 2013 OBJECTIVE: To identify genetic factors that predict sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin (RBV) in HIV/hepatitis C virus (HCV) genotype 1 or 4-coinfected patients and that enhance the predictive capacity of IL28B genotype in this population. Ribavirin 134-137 interferon lambda 3 Homo sapiens 250-255 23939236-2 2013 Analysing 206 HCV(+)/HIV(+) and 162 HCV(+)/HIV(-) patients, we found that compared with IL28B rs12979860, IFNL4 ss469415590 was strongly associated with response to interferon/ribavirin therapy in HCV(+)/HIV(-) individuals but not in HIV(+)/HCV(+) patients. Ribavirin 176-185 interferon lambda 4 (gene/pseudogene) Homo sapiens 106-111 23715768-8 2013 There is a complementary effect between the IL28B and LDLR genotypes on the probability of achieving SVR after Peg-IFN/RBV therapy in patients with HCV 1 or 4. Ribavirin 119-122 interferon lambda 3 Homo sapiens 44-49 23715768-8 2013 There is a complementary effect between the IL28B and LDLR genotypes on the probability of achieving SVR after Peg-IFN/RBV therapy in patients with HCV 1 or 4. Ribavirin 119-122 low density lipoprotein receptor Homo sapiens 54-58 23924660-1 2013 BACKGROUND & AIMS: Treatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. Ribavirin 106-115 erythropoietin Homo sapiens 193-207 30534284-0 2013 Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. The therapeutic effect of interferon (IFN) on chronic hepatitis C and its adverse effects have been well documented. Ribavirin 46-55 interferon alpha 1 Homo sapiens 129-139 24204676-1 2013 BACKGROUND: Antidepressants are effective in treating interferon-alpha/ribavirin (IFN-alpha/RBV)-associated depression during or after treatment of chronic hepatitis C (CHC). Ribavirin 71-80 interferon alpha 1 Homo sapiens 82-91 30534284-0 2013 Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. The therapeutic effect of interferon (IFN) on chronic hepatitis C and its adverse effects have been well documented. Ribavirin 46-55 interferon alpha 1 Homo sapiens 141-144 24205298-5 2013 The RBV has a natural polymorphism at residue 170 of the PrP-encoding gene (N/N, S/S, and S/N). Ribavirin 4-7 prion protein Homo sapiens 57-60 24205298-11 2013 These observations suggest that macaque PrP(TSE) was more permissive than human PrP(TSE) in selecting the competent RBV substrate. Ribavirin 116-119 prion protein Homo sapiens 40-43 24205298-11 2013 These observations suggest that macaque PrP(TSE) was more permissive than human PrP(TSE) in selecting the competent RBV substrate. Ribavirin 116-119 prion protein Homo sapiens 80-83 24205298-14 2013 This is the first report showing PrP(TSE) from vCJD-infected human and macaque brains efficiently amplified with RBV brain as the substrate. Ribavirin 113-116 prion protein Homo sapiens 33-36 23553458-2 2013 Traditional treatment with pegylated interferon plus ribavirin (peg-IFN + RBV) is very expensive and has a low rate of sustained virological response in coinfected patients, especially if they are infected with HCV genotype 1. Ribavirin 53-62 interferon alpha 1 Homo sapiens 68-71 24113185-7 2013 Accordingly, TRAP1 silencing sensitizes cells to apoptosis induced by novel antitumoral drugs that inhibit cap-dependent translation, such as ribavirin or 4EGI-1, and reduces the ability of cells to migrate through the pores of transwell filters. Ribavirin 142-151 TNF receptor associated protein 1 Homo sapiens 13-18 23532970-0 2013 Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. Ribavirin 67-76 adenosine kinase Homo sapiens 0-16 23532970-4 2013 We found that the expression of adenosine kinase (ADK) in ORL8 cells was significantly higher than that in RBV-resistant OR6 cells harboring HCV RNA. Ribavirin 107-110 adenosine kinase Homo sapiens 32-48 23532970-4 2013 We found that the expression of adenosine kinase (ADK) in ORL8 cells was significantly higher than that in RBV-resistant OR6 cells harboring HCV RNA. Ribavirin 107-110 adenosine kinase Homo sapiens 50-53 23532970-5 2013 Ectopic ADK expression in OR6 cells converted them from an RBV-resistant to an RBV-sensitive phenotype, and inhibition of ADK abolished the activity of RBV. Ribavirin 59-62 adenosine kinase Homo sapiens 8-11 23532970-5 2013 Ectopic ADK expression in OR6 cells converted them from an RBV-resistant to an RBV-sensitive phenotype, and inhibition of ADK abolished the activity of RBV. Ribavirin 79-82 adenosine kinase Homo sapiens 8-11 23532970-5 2013 Ectopic ADK expression in OR6 cells converted them from an RBV-resistant to an RBV-sensitive phenotype, and inhibition of ADK abolished the activity of RBV. Ribavirin 79-82 adenosine kinase Homo sapiens 8-11 23532970-9 2013 CONCLUSION: These results indicate that ADK acts as a determinant for the activity of RBV and provide new insight into the molecular mechanism underlying differential drug sensitivity. Ribavirin 86-89 adenosine kinase Homo sapiens 40-43 24073221-0 2013 Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C. BACKGROUND AND AIMS: Vitamin D exerts immunomodulatory effects on the host response against infection with hepatitis C virus (HCV). Ribavirin 97-106 vitamin D receptor Homo sapiens 62-65 24073221-2 2013 METHODS: Single nucleotide polymorphisms (SNPs) in CYP27B-1260 gene promoter (rs10877012AC) and in vitamin D receptor (VDR) gene rs2228570TC, rs1544410CT, rs7975232AC and rs731236AT were analyzed in a cohort of 238 Caucasian CHC patients treated with pegylated interferon (Peg-IFN) plus ribavirin (RBV). Ribavirin 287-296 vitamin D receptor Homo sapiens 99-117 24073221-2 2013 METHODS: Single nucleotide polymorphisms (SNPs) in CYP27B-1260 gene promoter (rs10877012AC) and in vitamin D receptor (VDR) gene rs2228570TC, rs1544410CT, rs7975232AC and rs731236AT were analyzed in a cohort of 238 Caucasian CHC patients treated with pegylated interferon (Peg-IFN) plus ribavirin (RBV). Ribavirin 298-301 vitamin D receptor Homo sapiens 99-117 24073221-10 2013 CONCLUSION: VDR gene polymorphisms are independently related to the response to Peg-IFN+RBV therapy in chronic hepatitis C and could be used as complementary biomarkers of response when included in a prediction algorithm in association with demographic, virologic, biochemical and genetic traits. Ribavirin 88-91 vitamin D receptor Homo sapiens 12-15 24984327-12 2013 IL-28 genotype is an important predictor of SVR in patients treated with a combination of interferon-alpha and ribavirin as well as in patients with HCV genotype 1 receiving triple therapy. Ribavirin 111-120 interferon lambda 3 Homo sapiens 0-5 23553458-6 2013 In order to elucidate whether sequence heterogeneity in the PKR-binding domain of HCV NS5A genotype 1 could influence the antiviral activity of either NTZ monotherapy or peg-IFN + RBV, baseline and end-of-therapy plasma samples from two groups of eleven non-responder HIV/HCV-coinfected patients that had received NTZ or peg-IFN + RBV were studied. Ribavirin 180-183 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 60-63 23553458-6 2013 In order to elucidate whether sequence heterogeneity in the PKR-binding domain of HCV NS5A genotype 1 could influence the antiviral activity of either NTZ monotherapy or peg-IFN + RBV, baseline and end-of-therapy plasma samples from two groups of eleven non-responder HIV/HCV-coinfected patients that had received NTZ or peg-IFN + RBV were studied. Ribavirin 331-334 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 60-63 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 278-287 interferon lambda 3 Homo sapiens 99-114 23770441-5 2013 Additionally, certain variations in the human ITPA gene have been linked to adverse reactions to the immunosuppressive prodrugs azathioprine and 6-mercaptopurine and protection against ribavirin-induced hemolytic anemia. Ribavirin 185-194 inosine triphosphatase Homo sapiens 46-50 24055394-2 2013 This study aims to provide a systematic literature review with meta-analysis, in order to evaluate if insulin resistance interferes with sustained virologic response in patients infected by the HCV genotype 1 versus HCV genotypes 2 and 3, undergoing treatment with interferon and ribavirin or pegylated interferon and ribavarin. Ribavirin 280-289 insulin Homo sapiens 102-109 24055394-2 2013 This study aims to provide a systematic literature review with meta-analysis, in order to evaluate if insulin resistance interferes with sustained virologic response in patients infected by the HCV genotype 1 versus HCV genotypes 2 and 3, undergoing treatment with interferon and ribavirin or pegylated interferon and ribavarin. Ribavirin 318-327 insulin Homo sapiens 102-109 24055394-10 2013 CONCLUSION: This meta-analysis provides evidence that elevated Homeostasis Model Assessment of Insulin Resistance is associated with a lower sustained virologic response rate in patients with hepatitis C treated with interferon and ribavirin or pegylated interferon and ribavarin, regardless of their genotype. Ribavirin 232-241 insulin Homo sapiens 95-102 24055394-10 2013 CONCLUSION: This meta-analysis provides evidence that elevated Homeostasis Model Assessment of Insulin Resistance is associated with a lower sustained virologic response rate in patients with hepatitis C treated with interferon and ribavirin or pegylated interferon and ribavarin, regardless of their genotype. Ribavirin 270-279 insulin Homo sapiens 95-102 23135762-1 2013 OBJECTIVE: Recent studies have demonstrated that genetic polymorphisms near the IL28B gene are associated with the clinical outcome of pegylated interferon alpha (peg-IFN-alpha) plus ribavirin therapy for patients with chronic hepatitis C virus (HCV). Ribavirin 183-192 interferon lambda 3 Homo sapiens 80-85 23135762-6 2013 RESULTS: There were significant differences in the reduction of HCV-RNA levels after peg-IFN-alpha plus ribavirin therapy based on the IL28B SNP rs8099917 between TT (favourable) and TG/GG (unfavourable) genotypes in patients; the first-phase viral decline slope per day and second-phase slope per week in TT genotype were significantly higher than in TG/GG genotype. Ribavirin 104-113 interferon lambda 3 Mus musculus 135-140 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 278-287 interferon alpha 1 Homo sapiens 264-272 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 289-292 interferon lambda 3 Homo sapiens 99-114 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 289-292 interferon lambda 3 Homo sapiens 121-126 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 289-292 interferon alpha 1 Homo sapiens 164-167 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 289-292 interferon alpha 1 Homo sapiens 250-258 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 289-292 interferon alpha 1 Homo sapiens 264-272 23281610-0 2013 Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C. AIM: Interleukin (IL)-28B gene polymorphism is closely linked with treatment response to peginterferon plus ribavirin combination therapy for hepatitis C virus genotype 1. Ribavirin 70-79 interferon lambda 3 Homo sapiens 11-17 23281610-9 2013 CONCLUSION: In genotype 2 patients treated with peginterferon plus ribavirin combination therapy, IL-28B gene polymorphism was a significant independent predictor of SVR as well as RVR. Ribavirin 67-76 interferon lambda 3 Homo sapiens 98-104 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 278-287 interferon lambda 3 Homo sapiens 121-126 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 278-287 interferon alpha 1 Homo sapiens 164-167 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 278-287 interferon alpha 1 Homo sapiens 250-258 23919217-0 2013 Association of ITPA polymorphism with outcomes of peginterferon-alpha plus ribavirin combination therapy. Ribavirin 75-84 inosine triphosphatase Homo sapiens 15-19 24009705-11 2013 RBV also blocked polyribosome loading of HCV-IRES mRNA through the inhibition of cellular IMPDH activity, and induced PKR and eIF2alpha phosphorylation. Ribavirin 0-3 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 118-121 24009705-12 2013 Knockdown of PKR or IMPDH prevented RBV induced HCV IRES-GFP translation. Ribavirin 36-39 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 13-16 23916907-11 2013 Pegylated interferon plus ribavirin treated patients with the IL28B CC genotype achieved higher sustained virological response rate than those with the CT genotype (58.6% vs 40.8%, OR 2.057, p = 0.002), and those who carried the T allele (41.8%, OR1.976, p = 0.002). Ribavirin 26-35 interferon lambda 3 Homo sapiens 62-67 23916907-14 2013 The IL28B CC polymorphism is associated with increased Th1 cytokine production of activated peripheral blood monocytes and lymphocytes, which may play a role in interferon-induced rapid immune control and sustained virological response of pegylated interferon plus ribavirin treated patients. Ribavirin 265-274 interferon lambda 3 Homo sapiens 4-9 23916907-14 2013 The IL28B CC polymorphism is associated with increased Th1 cytokine production of activated peripheral blood monocytes and lymphocytes, which may play a role in interferon-induced rapid immune control and sustained virological response of pegylated interferon plus ribavirin treated patients. Ribavirin 265-274 negative elongation factor complex member C/D Homo sapiens 55-58 23919217-1 2013 AIM: To analyzed the association between inosine triphosphatase (ITPA) (rs1127354) genotypes and sustained virological response (SVR) rates in peginterferon (Peg-IFN)alpha + ribavirin (RBV) treatment. Ribavirin 174-183 inosine triphosphatase Homo sapiens 41-63 23919217-1 2013 AIM: To analyzed the association between inosine triphosphatase (ITPA) (rs1127354) genotypes and sustained virological response (SVR) rates in peginterferon (Peg-IFN)alpha + ribavirin (RBV) treatment. Ribavirin 174-183 inosine triphosphatase Homo sapiens 65-69 23919217-1 2013 AIM: To analyzed the association between inosine triphosphatase (ITPA) (rs1127354) genotypes and sustained virological response (SVR) rates in peginterferon (Peg-IFN)alpha + ribavirin (RBV) treatment. Ribavirin 185-188 inosine triphosphatase Homo sapiens 65-69 23919217-4 2013 RESULTS: In patients with ITPA CC genotype, hemoglobin decline was significantly greater and the percentage of patients in whom total RBV dose was < 60% of standard and/or treatment was withdrawn was significantly higher compared with CA/AA genotype. Ribavirin 134-137 inosine triphosphatase Homo sapiens 26-30 23919217-6 2013 CONCLUSION: ITPA CC genotype was a disadvantageous factor for Peg-IFNalpha + RBV treatment in relation to completion rates and RBV dose. Ribavirin 77-80 inosine triphosphatase Homo sapiens 12-16 23919217-6 2013 CONCLUSION: ITPA CC genotype was a disadvantageous factor for Peg-IFNalpha + RBV treatment in relation to completion rates and RBV dose. Ribavirin 127-130 inosine triphosphatase Homo sapiens 12-16 23790339-10 2013 Elevated CD3(+) CD8(+) percentages and declined CD4(+)/CD8(+) ratios can be observed in the low dose group and ribavirin group (P<0.05). Ribavirin 111-120 Cd4 molecule Rattus norvegicus 48-51 23790339-11 2013 Moreover, the CD3(+) CD4(+) percentage of ribavirin group was lower than in the control group (P<0.05). Ribavirin 42-51 Cd4 molecule Rattus norvegicus 21-24 23359491-11 2013 CONCLUSION: A 24-week response-guided combination regimen of mericitabine 1,000 mg BID plus Peg-IFNalpha-2a/RBV is well tolerated and more effective than a standard 48-week course of Peg-IFNalpha-2a/RBV. Ribavirin 108-111 interferon alpha 1 Homo sapiens 187-195 23600803-7 2013 This indicated that ribavirin reversed the gene expression, including that of humoral factors, in the OCT4-expressing PCA cells selected using the EOS system. Ribavirin 20-29 POU class 5 homeobox 1 Homo sapiens 102-106 23279319-0 2013 Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C. AIM: Prediction of treatment responses to pegylated interferon (PEG IFN) plus ribavirin (RBV) therapy is uncertain for genotype 1b chronic hepatitis C. METHODS: In this study, 96 patients were investigated for the correlation between 36 pretreatment serum chemokine/cytokine levels and PEG IFN/RBV treatment efficacy by a sandwich enzyme-linked immunoassay (ELISA) and a bead array. Ribavirin 71-80 C-C motif chemokine ligand 5 Homo sapiens 6-12 23279319-0 2013 Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C. AIM: Prediction of treatment responses to pegylated interferon (PEG IFN) plus ribavirin (RBV) therapy is uncertain for genotype 1b chronic hepatitis C. METHODS: In this study, 96 patients were investigated for the correlation between 36 pretreatment serum chemokine/cytokine levels and PEG IFN/RBV treatment efficacy by a sandwich enzyme-linked immunoassay (ELISA) and a bead array. Ribavirin 191-200 C-C motif chemokine ligand 5 Homo sapiens 6-12 23359491-11 2013 CONCLUSION: A 24-week response-guided combination regimen of mericitabine 1,000 mg BID plus Peg-IFNalpha-2a/RBV is well tolerated and more effective than a standard 48-week course of Peg-IFNalpha-2a/RBV. Ribavirin 199-202 BH3 interacting domain death agonist Homo sapiens 83-86 23279319-0 2013 Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C. AIM: Prediction of treatment responses to pegylated interferon (PEG IFN) plus ribavirin (RBV) therapy is uncertain for genotype 1b chronic hepatitis C. METHODS: In this study, 96 patients were investigated for the correlation between 36 pretreatment serum chemokine/cytokine levels and PEG IFN/RBV treatment efficacy by a sandwich enzyme-linked immunoassay (ELISA) and a bead array. Ribavirin 202-205 C-C motif chemokine ligand 5 Homo sapiens 6-12 23279319-0 2013 Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C. AIM: Prediction of treatment responses to pegylated interferon (PEG IFN) plus ribavirin (RBV) therapy is uncertain for genotype 1b chronic hepatitis C. METHODS: In this study, 96 patients were investigated for the correlation between 36 pretreatment serum chemokine/cytokine levels and PEG IFN/RBV treatment efficacy by a sandwich enzyme-linked immunoassay (ELISA) and a bead array. Ribavirin 407-410 C-C motif chemokine ligand 5 Homo sapiens 6-12 23359491-11 2013 CONCLUSION: A 24-week response-guided combination regimen of mericitabine 1,000 mg BID plus Peg-IFNalpha-2a/RBV is well tolerated and more effective than a standard 48-week course of Peg-IFNalpha-2a/RBV. Ribavirin 199-202 interferon alpha 1 Homo sapiens 96-104 23279319-5 2013 CONCLUSION: The serum RANTES level is an important determinant influencing the virological response to PEG IFN/RBV therapy in chronic hepatitis C. Ribavirin 111-114 C-C motif chemokine ligand 5 Homo sapiens 22-28 23813140-0 2013 Pegylated interferon-alpha2b and ribavirin decrease claudin-1 and E-cadherin expression in HepG2 and Huh-7.5 cells. Ribavirin 33-42 claudin 1 Homo sapiens 52-61 23281009-5 2013 Sequence analysis revealed that Gln at position 70 of the core protein (core-Gln(70) ), Tyr at position 1082 plus Gln at 1112 of NS3 (NS3-Tyr(1082) /Gln(1112) ), and six or more mutations in the interferon/ribavirin resistance-determining region of NS5A (NS5A-IRRDR>=6) were significantly associated with development of HCC. Ribavirin 206-215 KRAS proto-oncogene, GTPase Homo sapiens 129-132 23281009-5 2013 Sequence analysis revealed that Gln at position 70 of the core protein (core-Gln(70) ), Tyr at position 1082 plus Gln at 1112 of NS3 (NS3-Tyr(1082) /Gln(1112) ), and six or more mutations in the interferon/ribavirin resistance-determining region of NS5A (NS5A-IRRDR>=6) were significantly associated with development of HCC. Ribavirin 206-215 KRAS proto-oncogene, GTPase Homo sapiens 134-137 23702664-0 2013 SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin. Ribavirin 114-123 suppressor of cytokine signaling 1 Homo sapiens 0-6 23702664-2 2013 The purpose of this study was to investigate the relationship between methylation of SOCS-1 and sustained virologic response (SVR) in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN)-alpha and ribavirin (RBV). Ribavirin 223-232 suppressor of cytokine signaling 1 Homo sapiens 85-91 23702664-2 2013 The purpose of this study was to investigate the relationship between methylation of SOCS-1 and sustained virologic response (SVR) in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN)-alpha and ribavirin (RBV). Ribavirin 234-237 suppressor of cytokine signaling 1 Homo sapiens 85-91 23808991-3 2013 Here, we investigated miR-122 serum levels in patients with chronic hepatitis C virus (HCV) genotype 1 infection during antiviral therapy with pegylated interferon and ribavirin. Ribavirin 168-177 microRNA 122 Homo sapiens 22-29 23808991-10 2013 We conclude that the serum level of miR-122 well reflects the success of interferon/ribavirin therapy in patients with chronic HCV infection. Ribavirin 84-93 microRNA 122 Homo sapiens 36-43 24065997-0 2013 The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis. Ribavirin 113-122 interferon lambda 3 Homo sapiens 14-29 23813140-0 2013 Pegylated interferon-alpha2b and ribavirin decrease claudin-1 and E-cadherin expression in HepG2 and Huh-7.5 cells. Ribavirin 33-42 cadherin 1 Homo sapiens 66-76 23813140-0 2013 Pegylated interferon-alpha2b and ribavirin decrease claudin-1 and E-cadherin expression in HepG2 and Huh-7.5 cells. Ribavirin 33-42 MIR7-3 host gene Homo sapiens 101-106 23813140-9 2013 Claudin-1 and E-cadherin cell membrane expression diminished after exposure to PEGIFNalpha2b (50 ng) + RBV(50 mug); the maximal decrease was observed with 200 ng of PEG-IFNalpha2b + 200 mug of RBV. Ribavirin 103-106 claudin 1 Homo sapiens 0-9 23813140-9 2013 Claudin-1 and E-cadherin cell membrane expression diminished after exposure to PEGIFNalpha2b (50 ng) + RBV(50 mug); the maximal decrease was observed with 200 ng of PEG-IFNalpha2b + 200 mug of RBV. Ribavirin 103-106 cadherin 1 Homo sapiens 14-24 23813140-9 2013 Claudin-1 and E-cadherin cell membrane expression diminished after exposure to PEGIFNalpha2b (50 ng) + RBV(50 mug); the maximal decrease was observed with 200 ng of PEG-IFNalpha2b + 200 mug of RBV. Ribavirin 193-196 claudin 1 Homo sapiens 0-9 23813140-9 2013 Claudin-1 and E-cadherin cell membrane expression diminished after exposure to PEGIFNalpha2b (50 ng) + RBV(50 mug); the maximal decrease was observed with 200 ng of PEG-IFNalpha2b + 200 mug of RBV. Ribavirin 193-196 cadherin 1 Homo sapiens 14-24 23813140-11 2013 The inhibition of claudin-1 and E-cadherin expression in Huh-7 and Huh-7.5 cells was only observed with 200 ng of PEG-IFNalpha2b + 200 mug of RBV. Ribavirin 142-145 claudin 1 Homo sapiens 18-27 23813140-11 2013 The inhibition of claudin-1 and E-cadherin expression in Huh-7 and Huh-7.5 cells was only observed with 200 ng of PEG-IFNalpha2b + 200 mug of RBV. Ribavirin 142-145 cadherin 1 Homo sapiens 32-42 23813140-11 2013 The inhibition of claudin-1 and E-cadherin expression in Huh-7 and Huh-7.5 cells was only observed with 200 ng of PEG-IFNalpha2b + 200 mug of RBV. Ribavirin 142-145 MIR7-3 host gene Homo sapiens 57-62 23813140-11 2013 The inhibition of claudin-1 and E-cadherin expression in Huh-7 and Huh-7.5 cells was only observed with 200 ng of PEG-IFNalpha2b + 200 mug of RBV. Ribavirin 142-145 MIR7-3 host gene Homo sapiens 67-72 23813140-14 2013 CONCLUSION: The increased therapeutic efficacy of the PEG-IFNalpha2b plus RBV treatment could be secondary to the inhibition of claudin-1 and E-cadherin cell membrane expression. Ribavirin 74-77 claudin 1 Homo sapiens 128-137 23813140-14 2013 CONCLUSION: The increased therapeutic efficacy of the PEG-IFNalpha2b plus RBV treatment could be secondary to the inhibition of claudin-1 and E-cadherin cell membrane expression. Ribavirin 74-77 cadherin 1 Homo sapiens 142-152 26201921-8 2013 Moreover, TIPE2 mRNA expression was upregulated, whereas that of TLR2 and TLR4 was downregulated after treatment of patients with interferon-alpha and ribavirin. Ribavirin 151-160 TNF alpha induced protein 8 like 2 Homo sapiens 10-15 23589118-4 2013 Furthermore, longitudinal analyses indicated that upregulated OX40L expression on monocytes is closely associated with rapid or early virological responses in patients receiving pegylated IFN-alpha/ribavirin treatment. Ribavirin 198-207 TNF superfamily member 4 Homo sapiens 62-67 23216931-0 2013 Serum peptides, represented by complement 3f des-arginine, are useful for prediction of the response to pegylated interferon-alpha plus ribavirin in patients with chronic hepatitis C. AIM: Biomarkers predicting sustained virological response (SVR) to pegylated interferon-alpha plus ribavirin (PEG IFN-alpha/RBV) were investigated. Ribavirin 136-145 interferon alpha 1 Homo sapiens 298-307 26201921-8 2013 Moreover, TIPE2 mRNA expression was upregulated, whereas that of TLR2 and TLR4 was downregulated after treatment of patients with interferon-alpha and ribavirin. Ribavirin 151-160 toll like receptor 2 Homo sapiens 65-69 26201921-8 2013 Moreover, TIPE2 mRNA expression was upregulated, whereas that of TLR2 and TLR4 was downregulated after treatment of patients with interferon-alpha and ribavirin. Ribavirin 151-160 toll like receptor 4 Homo sapiens 74-78 23389758-11 2013 CONCLUSION: Postoperative pegylated interferon plus ribavirin is associated with reduced recurrence of HCC in patients with HCV infection. Ribavirin 52-61 HCC Homo sapiens 103-106 23439262-0 2013 A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. Ribavirin 111-120 interferon lambda 3 Homo sapiens 124-129 23439262-2 2013 The goal of this study was to evaluate the safety, tolerability, and efficacy of the peginterferon-free combination of ABT-450/r and ABT-072 with ribavirin in treatment-naive patients with IL28B CC genotype, infected with HCV genotype 1. Ribavirin 146-155 interferon lambda 3 Homo sapiens 189-194 23637397-8 2013 IFN-alpha-resistant populations displayed decreased sensitivity to a combination of IFN-alpha and ribavirin. Ribavirin 98-107 interferon alpha 1 Homo sapiens 0-9 23918534-11 2013 Most patients (67%) possess the ITPA genotype associated with susceptibility to ribavirin-induced hemolysis. Ribavirin 80-89 inosine triphosphatase Homo sapiens 32-36 23918536-0 2013 Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. Ribavirin 104-113 apolipoprotein B Homo sapiens 6-26 23918536-2 2013 Polymorphisms in the human IL28B gene and amino acid substitutions in the core and interferon sensitivity-determining region (ISDR) in NS5A of HCV genotype 1b (G1b) were also shown to strongly affect the outcome of Peg-IFN plus RBV therapy. Ribavirin 228-231 interferon lambda 3 Homo sapiens 27-32 23918536-3 2013 In this study, an observational cohort study was performed in 247 HCV G1b-infected patients to investigate whether the response to Peg-IFN and RBV combination therapy in these patients is independently associated with the level of lipid factors, especially apolipoprotein B-100 (apoB-100), an obligatory structural component of very low density lipoprotein and low density lipoprotein. Ribavirin 143-146 apolipoprotein B Homo sapiens 257-277 23918536-6 2013 Together, we conclude that serum apoB-100 concentrations could predict virological response to Peg-IFN plus RBV combination therapy in patients infected with HCV G1b, especially in those with the rs8099917 hetero/minor genotype. Ribavirin 108-111 apolipoprotein B Homo sapiens 33-41 23918539-0 2013 Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese. Ribavirin 101-110 nitric oxide synthase 2 Homo sapiens 21-26 23918539-1 2013 This study aimed to evaluate whether genetic polymorphisms of the inducible nitric oxide synthase (iNOS) gene NOS2A could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV). Ribavirin 304-313 nitric oxide synthase 2 Homo sapiens 66-97 23918539-1 2013 This study aimed to evaluate whether genetic polymorphisms of the inducible nitric oxide synthase (iNOS) gene NOS2A could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV). Ribavirin 304-313 nitric oxide synthase 2 Homo sapiens 99-103 23918539-1 2013 This study aimed to evaluate whether genetic polymorphisms of the inducible nitric oxide synthase (iNOS) gene NOS2A could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV). Ribavirin 304-313 nitric oxide synthase 2 Homo sapiens 110-115 23542783-0 2013 Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. Ribavirin 26-35 interferon lambda 3 Homo sapiens 53-58 23542783-1 2013 OBJECTIVE: Some experts consider that hepatitis C virus (HCV) genotype 1-infected patients harboring IL28B genotype CC should be treated with interferon (Peg-IFN) plus ribavirin (RBV). Ribavirin 168-177 interferon lambda 3 Homo sapiens 101-106 23542783-1 2013 OBJECTIVE: Some experts consider that hepatitis C virus (HCV) genotype 1-infected patients harboring IL28B genotype CC should be treated with interferon (Peg-IFN) plus ribavirin (RBV). Ribavirin 179-182 interferon lambda 3 Homo sapiens 101-106 23542783-11 2013 SUMMARY: Some experts consider that hepatitis C virus (HCV) genotype 1-infected patients harboring the favorable IL28B genotype CC should be treated with interferon plus ribavirin. Ribavirin 170-179 interferon lambda 3 Homo sapiens 113-118 23730840-1 2013 IL28B and inosine triphosphatase (ITPA) polymorphisms are able to predict treatment response and degree of ribavirin-related anaemia, respectively, in the treatment of chronic hepatitis C virus (HCV) infection. Ribavirin 107-116 interferon lambda 3 Homo sapiens 0-5 23583759-8 2013 Moreover, we studied eight chronic HCV patients undergoing treatment with peg-IFN and ribavirin, who were administered EPO for treatment-induced anemia. Ribavirin 86-95 erythropoietin Homo sapiens 119-122 23621358-1 2013 Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors, that is, ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate. Ribavirin 62-71 asialoglycoprotein receptor 1 Homo sapiens 147-152 23621358-1 2013 Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors, that is, ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate. Ribavirin 73-76 asialoglycoprotein receptor 1 Homo sapiens 147-152 23621358-4 2013 Liver-targeted RBV tripalmitate-loaded micelles were obtained in aqueous media at low PHEA-EDA-PLA-GAL copolymer concentration value with nanometric size. Ribavirin 15-18 ectodysplasin A Homo sapiens 91-94 23621358-5 2013 By in vitro experiments, the specificity of RBV tripalmitate-loaded PHEA-EDA-PLA-GAL micelles toward HepG2 was demonstrated by using a competitive inhibition assay in the presence of free GAL. Ribavirin 44-47 ectodysplasin A Homo sapiens 73-76 23816271-11 2013 CONCLUSION: Serum levels of CXCL13 and E-Cadherin could be used as surrogate markers to predict response of combined PEG IFN-alpha/RBV therapy, especially at week 12. Ribavirin 131-134 C-X-C motif chemokine ligand 13 Homo sapiens 28-34 23816271-11 2013 CONCLUSION: Serum levels of CXCL13 and E-Cadherin could be used as surrogate markers to predict response of combined PEG IFN-alpha/RBV therapy, especially at week 12. Ribavirin 131-134 cadherin 1 Homo sapiens 39-49 23826153-0 2013 Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection. Ribavirin 77-86 interferon lambda 3 Homo sapiens 18-23 23826153-0 2013 Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection. Ribavirin 77-86 killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 3 Homo sapiens 28-35 23801888-0 2013 Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment. Ribavirin 82-91 glutamic--pyruvic transaminase Homo sapiens 0-24 23801888-1 2013 Alanine aminotransferase (ALT) elevation was occassionally observed during the treatment with combination peginterferon alpha plus ribavirin. Ribavirin 131-140 glutamic--pyruvic transaminase Homo sapiens 0-24 23321318-1 2013 BACKGROUND & AIMS: Nucleotide polymorphisms upstream of the interleukin 28B (IL28B) gene are strongly associated with hepatitis C virus (HCV) clearance in treatment-naive patients treated with peginterferon/ribavirin (PegIFN/RBV). Ribavirin 211-220 interferon lambda 3 Homo sapiens 81-86 24396987-2 2013 Genome-wide association studies have shown that single nucleotide polymorphisms (SNPs) near IL 28B gene on chromosome 19 are strong predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin. Ribavirin 209-218 interferon lambda 3 Homo sapiens 92-98 23741313-2 2013 A genome-wide association study identified a single nucleotide polymorphism near the IL-28B gene that strongly predicts response to hepatitis C treatment with interferon and ribavirin. Ribavirin 174-183 interferon lambda 3 Homo sapiens 85-91 23967025-3 2013 However, after the discovery of single nucleotide polymorphisms near the IL28B gene (rs8099917 and rs12979860) as potent predictive factors affecting the response to peg-IFN plus RBV, lipid factors are thought to be confounding factors. Ribavirin 179-182 interferon lambda 3 Homo sapiens 73-78 23717463-9 2013 The activities of the Th1 response were compared between subjects treated with 1(OH) vitamin D3/Peg-IFN/RBV and those treated with Peg-IFN/RBV therapy alone. Ribavirin 104-107 negative elongation factor complex member C/D Homo sapiens 22-25 23717463-10 2013 RESULTS: 1(OH) vitamin D3/Peg-IFN/RBV treatment could induce rapid viral reduction, especially in IL28B T/T polymorphism. Ribavirin 34-37 interferon lambda 3 Homo sapiens 98-103 23717463-12 2013 Th1 responses in the subjects treated with 1(OH) vitamin D3/Peg-IFN/RBV were significantly higher than those treated with Peg-IFN/RBV at 12 weeks after Peg-IFN/RBV therapy (p<0.05). Ribavirin 68-71 negative elongation factor complex member C/D Homo sapiens 0-3 23314745-0 2013 Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Ribavirin 60-69 interferon lambda 3 Homo sapiens 10-16 23314745-3 2013 We determined three SNPs of IL-28B (rs12979860, rs12980275, and rs8099917) in 82 patients with chronic HCV infection treated with pegylated interferon alpha and ribavirin (peg-IFNalpha/RBV). Ribavirin 161-170 interferon lambda 3 Homo sapiens 28-34 23314745-3 2013 We determined three SNPs of IL-28B (rs12979860, rs12980275, and rs8099917) in 82 patients with chronic HCV infection treated with pegylated interferon alpha and ribavirin (peg-IFNalpha/RBV). Ribavirin 185-188 interferon lambda 3 Homo sapiens 28-34 23314745-11 2013 In children and adolescents chronically infected with HCV genotypes 1 and 4, IL-28B rs12979860 and rs8099917 polymorphisms were the only predictors of response to peg-IFN/RBV. Ribavirin 171-174 interferon lambda 3 Homo sapiens 77-83 23858977-1 2013 In this paper, we describe the preparation of liver-targeted nanoparticles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors in the liver (i.e., ASGPR in hepatocytes). Ribavirin 118-127 asialoglycoprotein receptor 1 Homo sapiens 213-218 23858977-1 2013 In this paper, we describe the preparation of liver-targeted nanoparticles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors in the liver (i.e., ASGPR in hepatocytes). Ribavirin 129-132 asialoglycoprotein receptor 1 Homo sapiens 213-218 23858977-5 2013 RBV tripalmitate-loaded nanoparticles were obtained starting from PHEA-EDA-DPPE-GAL copolymer by using the dialysis method. Ribavirin 0-3 ectodysplasin A Homo sapiens 71-74 23647954-2 2013 The aim of this meta-analysis was to obtain a pooled odds ratio (OR) of the impact of IL-28B genotype on achieving sustained virologic response (SVR) in patients with HCV genotype 2/3 infection treated with pegIFN and ribavirin. Ribavirin 218-227 interferon lambda 3 Homo sapiens 86-92 23647954-5 2013 In Caucasians, the pooled OR of SVR with the favourable IL-28B genotype was 1.36 (95%CI: 0.98-1.88, P = 0.07) in all patients and 1.55 (95%CI: 1.10-2.18, P = 0.01) in patients treated with pegIFN and ribavirin for >=24 weeks. Ribavirin 200-209 interferon lambda 3 Homo sapiens 56-62 23647954-8 2013 The favourable IL-28B genotype is a statistically significant predictor of SVR and RVR in Caucasian patients treated with pegIFN and ribavirin for 24 weeks. Ribavirin 133-142 interferon lambda 3 Homo sapiens 15-21 23583375-2 2013 A potential anticancer agent, ribavirin, targets eIF4E activity in AML patients corresponding to clinical responses. Ribavirin 30-39 eukaryotic translation initiation factor 4E Homo sapiens 49-54 23583375-3 2013 To date, ribavirin is the only direct inhibitor of eIF4E to reach clinical trials. Ribavirin 9-18 eukaryotic translation initiation factor 4E Homo sapiens 51-56 23583375-4 2013 We showed that ribavirin acts as a competitive inhibitor of the methyl 7-guanosine (m(7)G) cap, the natural ligand of eIF4E. Ribavirin 15-24 eukaryotic translation initiation factor 4E Homo sapiens 118-123 23583375-5 2013 Here we examine the conformational changes occurring in human eIF4E upon binding the active metabolite of ribavirin, ribavirin triphosphate (RTP). Ribavirin 106-115 eukaryotic translation initiation factor 4E Homo sapiens 62-67 23651608-2 2013 This study aimed to evaluate whether genetic polymorphisms of the signal transducer and activator of transcription 6 gene (STAT6) could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV). Ribavirin 318-327 signal transducer and activator of transcription 6 Homo sapiens 66-116 23651608-2 2013 This study aimed to evaluate whether genetic polymorphisms of the signal transducer and activator of transcription 6 gene (STAT6) could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV). Ribavirin 318-327 signal transducer and activator of transcription 6 Homo sapiens 123-128 23403428-2 2013 Viral RNA declines have been observed in the clinic for both alpha interferon-ribavirin (IFN-alpha-RBV) and IFN-RBV-free regimens that include DCV. Ribavirin 99-102 interferon alpha 1 Homo sapiens 89-98 23321318-1 2013 BACKGROUND & AIMS: Nucleotide polymorphisms upstream of the interleukin 28B (IL28B) gene are strongly associated with hepatitis C virus (HCV) clearance in treatment-naive patients treated with peginterferon/ribavirin (PegIFN/RBV). Ribavirin 229-232 interferon lambda 3 Homo sapiens 81-86 23449803-7 2013 Furthermore, miR-27a enhanced in vitro interferon (IFN) signaling, and patients who expressed high levels of miR-27a in the liver showed a more favorable response to pegylated IFN and ribavirin combination therapy. Ribavirin 184-193 microRNA 27a Homo sapiens 13-20 23449803-7 2013 Furthermore, miR-27a enhanced in vitro interferon (IFN) signaling, and patients who expressed high levels of miR-27a in the liver showed a more favorable response to pegylated IFN and ribavirin combination therapy. Ribavirin 184-193 interferon alpha 1 Homo sapiens 33-55 23449803-7 2013 Furthermore, miR-27a enhanced in vitro interferon (IFN) signaling, and patients who expressed high levels of miR-27a in the liver showed a more favorable response to pegylated IFN and ribavirin combination therapy. Ribavirin 184-193 microRNA 27a Homo sapiens 109-116 23274935-13 2013 CONCLUSIONS: IL28B genotype, pretreatment CXCL10, and HCV RNA levels have very good capacity to predict pegylated interferon/ribavirin-treatment outcome in both HIV/HCV coinfected and HCV monoinfected patients. Ribavirin 125-134 interferon lambda 3 Homo sapiens 13-18 23449803-7 2013 Furthermore, miR-27a enhanced in vitro interferon (IFN) signaling, and patients who expressed high levels of miR-27a in the liver showed a more favorable response to pegylated IFN and ribavirin combination therapy. Ribavirin 184-193 interferon alpha 1 Homo sapiens 51-54 23195617-2 2013 Recent studies reported associations between RBV-induced anemia and genetic polymorphisms of concentrative nucleoside transporters such as CNT3 (encoded by SLC28A3) and inosine triphosphatase (encoded by ITPA). Ribavirin 45-48 solute carrier family 28 member 3 Homo sapiens 139-143 23613999-10 2013 CONCLUSION: Our results show that the KIR3DS1 genotype has a positive effect on HCV viral clearance during the first weeks of Peg-IFN/RBV treatment in HCV/HCV co-infected patients bearing genotype 1, and higher RVR and SVR rates. Ribavirin 134-137 killer cell immunoglobulin like receptor, three Ig domains and short cytoplasmic tail 1 Homo sapiens 38-45 23613999-10 2013 CONCLUSION: Our results show that the KIR3DS1 genotype has a positive effect on HCV viral clearance during the first weeks of Peg-IFN/RBV treatment in HCV/HCV co-infected patients bearing genotype 1, and higher RVR and SVR rates. Ribavirin 134-137 nuclear receptor subfamily 1 group D member 2 Homo sapiens 211-214 23195617-2 2013 Recent studies reported associations between RBV-induced anemia and genetic polymorphisms of concentrative nucleoside transporters such as CNT3 (encoded by SLC28A3) and inosine triphosphatase (encoded by ITPA). Ribavirin 45-48 solute carrier family 28 member 3 Homo sapiens 156-163 23195617-2 2013 Recent studies reported associations between RBV-induced anemia and genetic polymorphisms of concentrative nucleoside transporters such as CNT3 (encoded by SLC28A3) and inosine triphosphatase (encoded by ITPA). Ribavirin 45-48 inosine triphosphatase Homo sapiens 204-208 23195617-7 2013 RESULTS: Patients with SLC28A2 rs11854484 genotype TT had higher dosage- and body weight-adjusted RBV levels than those with genotypes TC or CC (p=0.02 and p=0.06 at weeks 4 and 8, respectively). Ribavirin 98-101 solute carrier family 28 member 2 Homo sapiens 23-30 23195617-10 2013 CONCLUSIONS: The newly identified association between RBV serum levels and SLC28A2 rs11854484 genotype, as well as the replicated association of ITPA and SLC28A3 genetic polymorphisms with RBV-induced anemia and treatment response, may support individualized treatment of chronic hepatitis C and warrant further investigation in larger studies. Ribavirin 54-57 solute carrier family 28 member 2 Homo sapiens 75-82 23195617-10 2013 CONCLUSIONS: The newly identified association between RBV serum levels and SLC28A2 rs11854484 genotype, as well as the replicated association of ITPA and SLC28A3 genetic polymorphisms with RBV-induced anemia and treatment response, may support individualized treatment of chronic hepatitis C and warrant further investigation in larger studies. Ribavirin 189-192 inosine triphosphatase Homo sapiens 145-149 23195617-10 2013 CONCLUSIONS: The newly identified association between RBV serum levels and SLC28A2 rs11854484 genotype, as well as the replicated association of ITPA and SLC28A3 genetic polymorphisms with RBV-induced anemia and treatment response, may support individualized treatment of chronic hepatitis C and warrant further investigation in larger studies. Ribavirin 189-192 solute carrier family 28 member 3 Homo sapiens 154-161 24021786-13 2013 CONCLUSION: The standard Peg-IFNa-2a + RBV combination antiviral therapy reduces PD-1 expression on CD4+ and CD8+ T lymphocytes and increases PD-L1 expression on CD8+ T lymphocytes in peripheral blood. Ribavirin 39-42 programmed cell death 1 Homo sapiens 81-85 23471078-9 2013 Blockade of eIF4E by ribavirin or overexpression of the promyelocytic leukemia protein (PML) decreased iNOS expression due to reduced iNOS mRNA export from the nucleus. Ribavirin 21-30 eukaryotic translation initiation factor 4E Homo sapiens 12-17 23490373-1 2013 Genetic variation in the IL-28B (interleukin-28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C treated with peginterferon-alpha and ribavirin. Ribavirin 220-229 interferon lambda 3 Homo sapiens 25-31 23490373-1 2013 Genetic variation in the IL-28B (interleukin-28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C treated with peginterferon-alpha and ribavirin. Ribavirin 220-229 interferon lambda 3 Homo sapiens 33-69 23490380-1 2013 SNPs of the inosine triphosphatase (ITPA) gene are associated with reduced haemoglobin levels during treatment with ribavirin. Ribavirin 116-125 inosine triphosphatase Homo sapiens 12-34 23490380-1 2013 SNPs of the inosine triphosphatase (ITPA) gene are associated with reduced haemoglobin levels during treatment with ribavirin. Ribavirin 116-125 inosine triphosphatase Homo sapiens 36-40 23399035-2 2013 Hepatitis C genotype 2a virus (HCV2a) has been shown to induce PKR activation to suppress the translation of antiviral interferon stimulated genes (ISGs), suggesting that PKR inhibitor can be beneficial for treating chronically HCV-infected patients in conjunction with interferon alpha and ribavirin. Ribavirin 291-300 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 63-66 23399035-2 2013 Hepatitis C genotype 2a virus (HCV2a) has been shown to induce PKR activation to suppress the translation of antiviral interferon stimulated genes (ISGs), suggesting that PKR inhibitor can be beneficial for treating chronically HCV-infected patients in conjunction with interferon alpha and ribavirin. Ribavirin 291-300 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 171-174 24021786-13 2013 CONCLUSION: The standard Peg-IFNa-2a + RBV combination antiviral therapy reduces PD-1 expression on CD4+ and CD8+ T lymphocytes and increases PD-L1 expression on CD8+ T lymphocytes in peripheral blood. Ribavirin 39-42 CD4 molecule Homo sapiens 100-103 24021786-13 2013 CONCLUSION: The standard Peg-IFNa-2a + RBV combination antiviral therapy reduces PD-1 expression on CD4+ and CD8+ T lymphocytes and increases PD-L1 expression on CD8+ T lymphocytes in peripheral blood. Ribavirin 39-42 CD8a molecule Homo sapiens 109-112 24021786-13 2013 CONCLUSION: The standard Peg-IFNa-2a + RBV combination antiviral therapy reduces PD-1 expression on CD4+ and CD8+ T lymphocytes and increases PD-L1 expression on CD8+ T lymphocytes in peripheral blood. Ribavirin 39-42 CD274 molecule Homo sapiens 142-147 24021786-13 2013 CONCLUSION: The standard Peg-IFNa-2a + RBV combination antiviral therapy reduces PD-1 expression on CD4+ and CD8+ T lymphocytes and increases PD-L1 expression on CD8+ T lymphocytes in peripheral blood. Ribavirin 39-42 CD8a molecule Homo sapiens 162-165 23410505-0 2013 Interferon alpha and ribavirin collaboratively regulate p38 mitogen-activated protein kinase signaling in hepatoma cells. Ribavirin 21-30 mitogen-activated protein kinase 14 Homo sapiens 56-59 23333419-0 2013 Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against "rings and rods"-associated inosine-5"-monophosphate dehydrogenase 2 in viral hepatitis C. BACKGROUND AND AIMS: Autoantibodies against so-called "rings and rods" structures, as determined by indirect immunofluorescence assay (IFA) using the human cell line HEp-2, have been described in chronic hepatitis C virus (HCV) infected patients treated with interferon/ribavirin. Ribavirin 492-501 inosine monophosphate dehydrogenase 2 Homo sapiens 159-199 23333419-1 2013 Recently, cytidine triphosphate synthase (CTPS) and inosine-5"-monophosphate dehydrogenase 2 (IMPDH2), the enzyme inhibited by ribavirin, were proposed as the target antigens. Ribavirin 127-136 CTP synthase 1 Homo sapiens 10-40 23333419-1 2013 Recently, cytidine triphosphate synthase (CTPS) and inosine-5"-monophosphate dehydrogenase 2 (IMPDH2), the enzyme inhibited by ribavirin, were proposed as the target antigens. Ribavirin 127-136 CTP synthase 1 Homo sapiens 42-46 23333419-1 2013 Recently, cytidine triphosphate synthase (CTPS) and inosine-5"-monophosphate dehydrogenase 2 (IMPDH2), the enzyme inhibited by ribavirin, were proposed as the target antigens. Ribavirin 127-136 inosine monophosphate dehydrogenase 2 Homo sapiens 52-92 23333419-1 2013 Recently, cytidine triphosphate synthase (CTPS) and inosine-5"-monophosphate dehydrogenase 2 (IMPDH2), the enzyme inhibited by ribavirin, were proposed as the target antigens. Ribavirin 127-136 inosine monophosphate dehydrogenase 2 Homo sapiens 94-100 23650781-5 2013 They were treated with ribavirin-pegylated interferon alpha 2a. Ribavirin 23-32 interferon alpha 2 Homo sapiens 43-62 23410505-3 2013 Effects of IFN-alpha and ribavirin on p38 MAPK signaling were investigated in human hepatoma cells. Ribavirin 25-34 mitogen-activated protein kinase 14 Homo sapiens 38-41 23410505-5 2013 Also, p38 MAPK phosphorylation was enhanced by ribavirin. Ribavirin 47-56 mitogen-activated protein kinase 14 Homo sapiens 6-9 23410505-6 2013 Treatment for 48 h with a combination of IFN-alpha and ribavirin increased p38 MAPK phosphorylation, whereas the treatment for 72 h reduced p38 MAPK phosphorylation. Ribavirin 55-64 mitogen-activated protein kinase 14 Homo sapiens 75-78 23410505-7 2013 Cell culture-derived HCV (HCVcc) infection dramatically increased p38 MAPK phosphorylation and such phosphorylation was inhibited by IFN-alpha or ribavirin. Ribavirin 146-155 mitogen-activated protein kinase 14 Homo sapiens 66-69 23410505-8 2013 Moreover, siRNA-mediated knockdown of p38 MAPK resulted in enhancement of ribavirin-dependent HCV RNA replication. Ribavirin 74-83 mitogen-activated protein kinase 14 Homo sapiens 38-41 23410505-9 2013 These results suggest that regulation of p38 MAPK signaling by IFN-alpha and ribavirin might contribute to anti-HCV action. Ribavirin 77-86 mitogen-activated protein kinase 14 Homo sapiens 41-44 23328301-0 2013 IL28B in the era of direct-acting antivirals for hepatitis C. The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-alpha and ribavirin. Ribavirin 180-189 interferon lambda 3 Homo sapiens 0-5 26201629-0 2013 Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. BACKGROUND: Genetic variation leading to inosine triphosphatase (ITPA) deficiency protects chronic hepatitis C patients receiving ribavirin against hemolytic anemia. Ribavirin 152-161 inosine triphosphatase Homo sapiens 15-19 26201629-0 2013 Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. BACKGROUND: Genetic variation leading to inosine triphosphatase (ITPA) deficiency protects chronic hepatitis C patients receiving ribavirin against hemolytic anemia. Ribavirin 152-161 inosine triphosphatase Homo sapiens 15-19 26201629-1 2013 The relationship between ITPA gene variation and serum ribavirin concentration was analyzed in association with a reduction in blood cells and dose reduction of pegylated interferon (PEG-IFN) or ribavirin. Ribavirin 55-64 inosine triphosphatase Homo sapiens 25-29 26201629-1 2013 The relationship between ITPA gene variation and serum ribavirin concentration was analyzed in association with a reduction in blood cells and dose reduction of pegylated interferon (PEG-IFN) or ribavirin. Ribavirin 195-204 inosine triphosphatase Homo sapiens 25-29 23328301-0 2013 IL28B in the era of direct-acting antivirals for hepatitis C. The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-alpha and ribavirin. Ribavirin 180-189 interferon lambda 3 Homo sapiens 66-71 23328301-1 2013 In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-alpha and ribavirin, and boceprevir and telaprevir attenuate the association between the IL28B genotype and treatment response. Ribavirin 114-123 interferon lambda 3 Homo sapiens 193-198 23173698-0 2013 Lead-in treatment with interferon-beta/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Ribavirin 130-139 interferon lambda 3 Homo sapiens 194-199 23280583-7 2013 In conclusion, the data indicate that immune cells of responders and non-responders to IFN/RBV therapy exhibited significantly different virological and host gene expression profiles. Ribavirin 91-94 interferon alpha 1 Homo sapiens 87-90 23297176-0 2013 Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C. This study aimed to develop a model for predicting anemia using the inosine triphosphatase (ITPA) genotype and to evaluate its relationship with treatment outcome. Ribavirin 134-143 inosine triphosphatase Homo sapiens 24-28 23383658-1 2013 The IL28 gene is highly associated with sustained viral response (SVR) in patients infected with genotype 1 after standard of care (SOC) treatment with peg-IFN and ribavirin. Ribavirin 164-173 interferon lambda 3 Homo sapiens 4-8 23173698-0 2013 Lead-in treatment with interferon-beta/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Ribavirin 39-48 interferon lambda 3 Homo sapiens 194-199 23173698-1 2013 BACKGROUND AND AIM: The most important factor influencing the effect of pegylated interferon (PEG-IFN)/ribavirin therapy (PEG) for chronic hepatitis C genotype 1b with high viral load is the interleukin 28B (IL28B) genotype. Ribavirin 103-112 progestagen associated endometrial protein Homo sapiens 122-125 23173698-1 2013 BACKGROUND AND AIM: The most important factor influencing the effect of pegylated interferon (PEG-IFN)/ribavirin therapy (PEG) for chronic hepatitis C genotype 1b with high viral load is the interleukin 28B (IL28B) genotype. Ribavirin 103-112 interferon lambda 3 Homo sapiens 208-213 23173698-9 2013 CONCLUSION: It was suggested that lead-in twice-daily IFN-beta/ribavirin treatment followed by PEG-IFN/ribavirin combination therapy may modify the HCV-RNA dynamics compared with that by PEG-IFN/ribavirin therapy, and it is particularly useful for the IL28B minor genotype. Ribavirin 63-72 interferon lambda 3 Homo sapiens 252-257 23173698-9 2013 CONCLUSION: It was suggested that lead-in twice-daily IFN-beta/ribavirin treatment followed by PEG-IFN/ribavirin combination therapy may modify the HCV-RNA dynamics compared with that by PEG-IFN/ribavirin therapy, and it is particularly useful for the IL28B minor genotype. Ribavirin 103-112 progestagen associated endometrial protein Homo sapiens 95-98 23173698-9 2013 CONCLUSION: It was suggested that lead-in twice-daily IFN-beta/ribavirin treatment followed by PEG-IFN/ribavirin combination therapy may modify the HCV-RNA dynamics compared with that by PEG-IFN/ribavirin therapy, and it is particularly useful for the IL28B minor genotype. Ribavirin 103-112 interferon lambda 3 Homo sapiens 252-257 23173698-9 2013 CONCLUSION: It was suggested that lead-in twice-daily IFN-beta/ribavirin treatment followed by PEG-IFN/ribavirin combination therapy may modify the HCV-RNA dynamics compared with that by PEG-IFN/ribavirin therapy, and it is particularly useful for the IL28B minor genotype. Ribavirin 103-112 progestagen associated endometrial protein Homo sapiens 95-98 23173698-9 2013 CONCLUSION: It was suggested that lead-in twice-daily IFN-beta/ribavirin treatment followed by PEG-IFN/ribavirin combination therapy may modify the HCV-RNA dynamics compared with that by PEG-IFN/ribavirin therapy, and it is particularly useful for the IL28B minor genotype. Ribavirin 103-112 interferon lambda 3 Homo sapiens 252-257 23967741-10 2013 During the course of peg-IFNalpha-2a plus RBV combination therapy, the expression ratios of PD-1 and TLR4 on PBMCs showed a decreasing trend, while TLR3 expression showed an increasing trend. Ribavirin 42-45 toll like receptor 4 Homo sapiens 101-105 23967741-10 2013 During the course of peg-IFNalpha-2a plus RBV combination therapy, the expression ratios of PD-1 and TLR4 on PBMCs showed a decreasing trend, while TLR3 expression showed an increasing trend. Ribavirin 42-45 toll like receptor 3 Homo sapiens 148-152 23967741-13 2013 Peg-IFNalpha-2a plus RBV treatment-induced suppression of HCV replication results in a significant reduction in PD-1 and TLR4 expression on the surface of PBMCs, but a remarkably elevated level of TLR3 expression. Ribavirin 21-24 toll like receptor 4 Homo sapiens 121-125 23967741-13 2013 Peg-IFNalpha-2a plus RBV treatment-induced suppression of HCV replication results in a significant reduction in PD-1 and TLR4 expression on the surface of PBMCs, but a remarkably elevated level of TLR3 expression. Ribavirin 21-24 toll like receptor 3 Homo sapiens 197-201 23386076-8 2013 The use of erythropoietin-stimulating agents has been shown to be effective for anemia caused by peginterferon and ribavirin without compromising SVR rates. Ribavirin 115-124 erythropoietin Homo sapiens 11-25 23409973-0 2013 Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Ribavirin 189-198 KRAS proto-oncogene, GTPase Homo sapiens 36-39 23559897-1 2013 Ribavirin is an antiviral drug used in combination with pegylated interferon-alpha (IFN-alpha) for the treatment of hepatitis C virus (HCV) infection. Ribavirin 0-9 interferon alpha 1 Homo sapiens 84-93 23219017-4 2013 The aim of the study was to evaluate the association of of IL28B rs12979860, TGF-beta1-509, TNF-alpha 308, and IL-10-1082 polymorphisms with the susceptibility to hepatitis C virus genotype 4 infection and response to pegylated interferon-alpha and ribavirin therapy. Ribavirin 249-258 interferon lambda 3 Homo sapiens 59-64 23559897-3 2013 In the present study, we re-evaluated the effect of ribavirin on Foxp3(+)CD4(+)CD25(+) Treg cells from normal donors. Ribavirin 52-61 forkhead box P3 Homo sapiens 65-70 23559897-3 2013 In the present study, we re-evaluated the effect of ribavirin on Foxp3(+)CD4(+)CD25(+) Treg cells from normal donors. Ribavirin 52-61 interferon stimulated exonuclease gene 20 Homo sapiens 79-83 23100146-1 2013 PURPOSE: Autoantibodies to cytoplasmic structures called rods and rings (RR) are primarily specific to patients with hepatitis C virus (HCV) infection treated with pegylated interferon-alpha/ribavirin (IFN/R). Ribavirin 191-200 interferon production regulator Homo sapiens 202-207 23286844-6 2013 On the other hand on-treatment HCV RNA kinetics are fundamental for individualized treatment regimens because achieving negative HCV RNA at week 4 (rapid virological response, RVR) is the key factor when the duration of PEG-IFN/RBV is tailored in HCV-2 patients. Ribavirin 228-231 nuclear receptor subfamily 1 group D member 2 Homo sapiens 176-179 23201294-1 2013 Recently, genome-wide association studies (GWAS) in patients with chronic hepatitis C virus (HCV) infection have identified two functional single nucleotide polymorphisms (SNPs) in the inosine triphosphatase (ITPA) gene, that are associated strongly and independently with hemolytic anemia in patients exposed to pegylated-interferon (Peg-IFN) plus ribavirin (RBV) combined therapy. Ribavirin 349-358 inosine triphosphatase Homo sapiens 209-213 23201294-1 2013 Recently, genome-wide association studies (GWAS) in patients with chronic hepatitis C virus (HCV) infection have identified two functional single nucleotide polymorphisms (SNPs) in the inosine triphosphatase (ITPA) gene, that are associated strongly and independently with hemolytic anemia in patients exposed to pegylated-interferon (Peg-IFN) plus ribavirin (RBV) combined therapy. Ribavirin 360-363 inosine triphosphatase Homo sapiens 209-213 23190183-0 2013 Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI). Ribavirin 49-58 interferon gamma Homo sapiens 0-16 23121166-2 2013 AIM: To determine, in a cohort of Spanish patients with chronic hepatitis C treated with peginterferon plus ribavirin (P+R), whether insulin resistance predicts SVR independently of interleukin-28B rs12979860 polymorphism. Ribavirin 108-117 insulin Homo sapiens 133-140 23142377-0 2013 Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. Ribavirin 136-139 interferon lambda 3 Homo sapiens 21-26 23142377-1 2013 Recently, genome-wide associated studies (GWAS) have identified that host genetics IL28B SNPs rs12979860 and rs8099917 were significantly associated with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy. Ribavirin 218-221 interferon lambda 3 Homo sapiens 83-88 23142377-9 2013 The IL-28B SNPs rs12979860 genotype CC and rs8099917 genotype TT significantly positive associated with SVR in patients infected chronic HCV genotype 1 to PEG-INF/RBV therapy (OR=4.473, 95% CI=3.814-5.246, OR=5.171, 95% CI=4.372-6.117 respectively). Ribavirin 163-166 interferon lambda 3 Homo sapiens 4-10 23440114-8 2013 Thus, the IL28B genotype appears to be a strong predictor of SVR following PEG-IFN/RBV therapy in treatment-naive Brazilian patients infected with HCV genotype 1. Ribavirin 83-86 interferon lambda 3 Homo sapiens 10-15 24282816-3 2013 Two NS3-4A protease inhibitors (telaprevir and boceprevir) have been recently approved for the treatment of hepatitis C in combination with standard of care (pegylated interferon plus ribavirin). Ribavirin 184-193 KRAS proto-oncogene, GTPase Homo sapiens 4-7 23300158-4 2013 RESULTS: Ribavirin decreased the virus load and dose-dependently inhibited the accumulation of RANTES messenger RNA in Andes-virus (ANDV)-infected human endothelial cells, but failed to suppress TNF-alpha-induced activation of RANTES and interleukin-6 in ANDV-inoculated cultures. Ribavirin 9-18 C-C motif chemokine ligand 5 Homo sapiens 95-101 23300158-4 2013 RESULTS: Ribavirin decreased the virus load and dose-dependently inhibited the accumulation of RANTES messenger RNA in Andes-virus (ANDV)-infected human endothelial cells, but failed to suppress TNF-alpha-induced activation of RANTES and interleukin-6 in ANDV-inoculated cultures. Ribavirin 9-18 C-C motif chemokine ligand 5 Homo sapiens 227-233 23300158-4 2013 RESULTS: Ribavirin decreased the virus load and dose-dependently inhibited the accumulation of RANTES messenger RNA in Andes-virus (ANDV)-infected human endothelial cells, but failed to suppress TNF-alpha-induced activation of RANTES and interleukin-6 in ANDV-inoculated cultures. Ribavirin 9-18 interleukin 6 Homo sapiens 238-251 23300158-5 2013 This report also shows, for the first time, that the deleterious over-stimulation by TNF-alpha is mediated by nuclear factor-kappaB, and describes the effect of ribavirin on cytokine production following ANDV infection. Ribavirin 161-170 tumor necrosis factor Homo sapiens 85-94 23411358-3 2013 HCV-1g NS3 sequences show some similarities to HCV-4 and are poorly responsive to interferon/ribavirin and to boceprevir/telaprevir; this patient was also a null-responder to boceprevir treatment. Ribavirin 93-102 KRAS proto-oncogene, GTPase Homo sapiens 7-10 23050902-0 2013 Ribavirin-induced intracellular GTP depletion activates transcription elongation in coagulation factor VII gene expression. Ribavirin 0-9 coagulation factor VII Homo sapiens 84-106 23050902-6 2013 Ribavirin unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation. Ribavirin 0-9 elongation factor for RNA polymerase II Homo sapiens 22-25 23050902-7 2013 We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation. Ribavirin 17-26 elongation factor for RNA polymerase II 3 Homo sapiens 36-40 23050902-7 2013 We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation. Ribavirin 97-106 elongation factor for RNA polymerase II 3 Homo sapiens 81-85 23050902-8 2013 Ribavirin also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to F7. Ribavirin 0-9 cyclin dependent kinase 9 Homo sapiens 39-43 23050902-8 2013 Ribavirin also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to F7. Ribavirin 0-9 cyclin dependent kinase 9 Homo sapiens 45-70 23050902-8 2013 Ribavirin also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to F7. Ribavirin 0-9 AF4/FMR2 family member 4 Homo sapiens 76-80 23050902-9 2013 These data suggest that ribavirin-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation. Ribavirin 24-33 AF4/FMR2 family member 4 Homo sapiens 125-129 23050902-9 2013 These data suggest that ribavirin-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation. Ribavirin 24-33 elongation factor for RNA polymerase II 3 Homo sapiens 134-138 23459628-1 2013 Ribavirin (RBV), a guanosine analog for treatment of hepatitis C, is a substrate of a nucleoside transporter, solute carrier family 29 member 1 (SLC29A1). Ribavirin 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 145-152 23936821-0 2013 Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients. Ribavirin 63-72 interferon lambda 3 Homo sapiens 110-115 23936821-1 2013 BACKGROUND: The rs12979860 CC genotype of the interleukin 28B (IL28B) polymorphism is associated with high rates of sustained virological response (SVR) to peginterferon (PegIFN) and ribavirin (Rbv) in hepatitis C virus genotype-1 (HCV-1) patients. Ribavirin 183-192 interferon lambda 3 Homo sapiens 63-68 23936821-1 2013 BACKGROUND: The rs12979860 CC genotype of the interleukin 28B (IL28B) polymorphism is associated with high rates of sustained virological response (SVR) to peginterferon (PegIFN) and ribavirin (Rbv) in hepatitis C virus genotype-1 (HCV-1) patients. Ribavirin 194-197 interferon lambda 3 Homo sapiens 63-68 23936821-12 2013 However, in IL28B CC cirrhotics, the achievement of RVR identifies those patients who still have high rates of SVR to Peg-IFN/Rbv therapy. Ribavirin 126-129 nuclear receptor subfamily 1 group D member 2 Homo sapiens 52-55 24281015-8 2013 High serum levels of IFN-lambda1 may be conducive to effective PEG-IFN/RBV combination therapy because of the immunomodulatory system. Ribavirin 71-74 interferon lambda 1 Homo sapiens 21-32 24281016-7 2013 CONCLUSION: The NS5A sequence heterogeneity and IL28B SNP are useful factors to predict the sensitivity to PEG-IFN/RBV therapy in HCV-2a and HCV-2b infections. Ribavirin 115-118 interferon lambda 3 Homo sapiens 48-53 24281016-7 2013 CONCLUSION: The NS5A sequence heterogeneity and IL28B SNP are useful factors to predict the sensitivity to PEG-IFN/RBV therapy in HCV-2a and HCV-2b infections. Ribavirin 115-118 interferon alpha 1 Homo sapiens 111-114 24223458-3 2013 Several viral and host factors have been proved to affect response to the treatment PEG-IFN and ribavirin; the strongest of them is polymorphisms near IL28B; nonetheless, nonresponse in patients with favorable IL28B is still unexplained, which implies the importance of studying other immunological factors that may correlate with response. Ribavirin 96-105 interferon lambda 3 Homo sapiens 151-156 24223458-3 2013 Several viral and host factors have been proved to affect response to the treatment PEG-IFN and ribavirin; the strongest of them is polymorphisms near IL28B; nonetheless, nonresponse in patients with favorable IL28B is still unexplained, which implies the importance of studying other immunological factors that may correlate with response. Ribavirin 96-105 interferon lambda 3 Homo sapiens 210-215 23459628-1 2013 Ribavirin (RBV), a guanosine analog for treatment of hepatitis C, is a substrate of a nucleoside transporter, solute carrier family 29 member 1 (SLC29A1). Ribavirin 11-14 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 145-152 23459628-9 2013 These results suggest that RBV/DP coadministration reduces the concentration of RBV in blood by inhibiting an important role of SLC29A1 in gastrointestinal absorption of RBV. Ribavirin 27-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-135 23459628-9 2013 These results suggest that RBV/DP coadministration reduces the concentration of RBV in blood by inhibiting an important role of SLC29A1 in gastrointestinal absorption of RBV. Ribavirin 80-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-135 23459628-9 2013 These results suggest that RBV/DP coadministration reduces the concentration of RBV in blood by inhibiting an important role of SLC29A1 in gastrointestinal absorption of RBV. Ribavirin 80-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-135 23080496-0 2012 A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. Ribavirin 125-134 interferon lambda 3 Homo sapiens 36-41 24490062-4 2013 Relative mRNA expression of TLR3/RIG-I signaling genes involved in IFN- beta production was correlated with positive- and negative-strand HCV RNAs in pretreatment liver tissues responsive and nonresponsive to peginterferon and ribavirin for chronic hepatitis C genotype 1. Ribavirin 227-236 toll like receptor 3 Homo sapiens 28-32 24490062-4 2013 Relative mRNA expression of TLR3/RIG-I signaling genes involved in IFN- beta production was correlated with positive- and negative-strand HCV RNAs in pretreatment liver tissues responsive and nonresponsive to peginterferon and ribavirin for chronic hepatitis C genotype 1. Ribavirin 227-236 DExD/H-box helicase 58 Homo sapiens 33-38 24490062-4 2013 Relative mRNA expression of TLR3/RIG-I signaling genes involved in IFN- beta production was correlated with positive- and negative-strand HCV RNAs in pretreatment liver tissues responsive and nonresponsive to peginterferon and ribavirin for chronic hepatitis C genotype 1. Ribavirin 227-236 interferon alpha 1 Homo sapiens 67-70 23859951-6 2013 Interleukin 28B (IL28B) genotype was recently and convincingly associated with response to pegIFN and RBV therapy. Ribavirin 102-105 interferon lambda 3 Homo sapiens 0-15 23859951-6 2013 Interleukin 28B (IL28B) genotype was recently and convincingly associated with response to pegIFN and RBV therapy. Ribavirin 102-105 interferon lambda 3 Homo sapiens 17-22 22954804-14 2012 GENERAL SIGNIFICANCE: These data suggest that both CyPA and CyPB are excellent targets for the treatment of HCV 1b, which shows the greatest resistance to interferon and ribavirin combination therapy. Ribavirin 170-179 peptidylprolyl isomerase A Homo sapiens 51-55 22954804-14 2012 GENERAL SIGNIFICANCE: These data suggest that both CyPA and CyPB are excellent targets for the treatment of HCV 1b, which shows the greatest resistance to interferon and ribavirin combination therapy. Ribavirin 170-179 peptidylprolyl isomerase B Homo sapiens 60-64 23359634-0 2012 Evolution of viral RNA in a Chinese patient to interferon/ribavirin therapy for hepatitis C. OBJECTIVE: The combination of interferon (IFN) and ribavirin (RBV) is the standard therapy for hepatitis C virus (HCV) infection. Ribavirin 58-67 interferon alpha 1 Homo sapiens 135-138 23359634-9 2012 In addition, each different response of chimeric replicon to IFN is most likely related to amino acid changes in or near the IFN-sensitivity determining region (ISDR) of NS5A during chronic infection and IFN/RBV therapy. Ribavirin 208-211 interferon alpha 1 Homo sapiens 61-64 23423835-0 2012 Changes in serum Interleukin-33 concentration before and after treatment with pegylated interferon alfa-2a plus ribavirin in patients with chronic hepatitis C genotype 1b infection. Ribavirin 112-121 interleukin 33 Homo sapiens 17-31 23423835-3 2012 OBJECTIVES: To evaluate serum IL-33 levels in a group of patients with chronic hepatitis C (CHC) genotype 1b at enrolment and after a course of pegylated (PEG)-IFN plus ribavirin. Ribavirin 169-178 interleukin 33 Homo sapiens 30-35 23306941-1 2013 OBJECTIVES: The aim of this study was to evaluate rapid virologic response (RVR) rate after peginterferon (PegIFN) and ribavirin (RBV) dual combination therapy in Korean hepatitis C virus (HCV) genotype 1 patients whose IL28B polymorphism is generally favorable. Ribavirin 119-128 interferon lambda 3 Homo sapiens 220-225 23306941-1 2013 OBJECTIVES: The aim of this study was to evaluate rapid virologic response (RVR) rate after peginterferon (PegIFN) and ribavirin (RBV) dual combination therapy in Korean hepatitis C virus (HCV) genotype 1 patients whose IL28B polymorphism is generally favorable. Ribavirin 130-133 interferon lambda 3 Homo sapiens 220-225 22814486-7 2013 Our findings demonstrate that, although ribavirin does not lead to a viral load decline, in vivo treatment with ribavirin affects the activation of pDC and mDC in chronic HBV patients. Ribavirin 112-121 chemokine (C-C motif) ligand 22 Mus musculus 156-159 23323251-0 2012 Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. BACKGROUND/AIMS: Sustained virologic response (SVR) for the treatment of chronic hepatitis C (CHC) may differ with ethnicity due to differences in genetic traits. Ribavirin 30-39 interferon lambda 3 Homo sapiens 63-68 23073135-0 2012 Insulin resistance and response to telaprevir plus pegylated interferon and ribavirin: a requiem for the HOMA score? Ribavirin 76-85 insulin Homo sapiens 0-7 22588246-12 2012 Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-gamma-secreting cells were also increased during Peg-IFN/RBV-therapy. Ribavirin 143-146 CD4 molecule Homo sapiens 10-13 22588246-12 2012 Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-gamma-secreting cells were also increased during Peg-IFN/RBV-therapy. Ribavirin 143-146 interferon gamma Homo sapiens 82-91 23020144-0 2012 Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. Ribavirin 178-187 interleukin 10 Homo sapiens 17-31 23020144-0 2012 Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. Ribavirin 178-187 interferon lambda 3 Homo sapiens 36-51 23020144-1 2012 BACKGROUND AND AIM: Recently, it has been suggested that single nucleotide polymorphisms (SNPs) in some cytokine genes may influence the production of the associated cytokines that affect the host immune response to pegylated interferon-alpha (Peg-IFN-alpha) with ribavirin (RBV) in hepatitis C virus (HCV) patients. Ribavirin 264-273 interferon alpha 1 Homo sapiens 248-257 23020144-1 2012 BACKGROUND AND AIM: Recently, it has been suggested that single nucleotide polymorphisms (SNPs) in some cytokine genes may influence the production of the associated cytokines that affect the host immune response to pegylated interferon-alpha (Peg-IFN-alpha) with ribavirin (RBV) in hepatitis C virus (HCV) patients. Ribavirin 275-278 interferon alpha 1 Homo sapiens 248-257 23080496-1 2012 Interleukin-28B (IL28B) polymorphisms are associated with viral response to peginterferon and ribavirin (RBV) in chronic hepatitis C (HCV). Ribavirin 94-103 interferon lambda 3 Homo sapiens 17-22 23080496-1 2012 Interleukin-28B (IL28B) polymorphisms are associated with viral response to peginterferon and ribavirin (RBV) in chronic hepatitis C (HCV). Ribavirin 105-108 interferon lambda 3 Homo sapiens 17-22 23080496-4 2012 The IL-28B variants are hypothesized to have a differential impact on HCV quasispecies evolution during treatment with pegylated interferon (PEG-IFN) and RBV. Ribavirin 154-157 interferon lambda 3 Homo sapiens 4-10 23139603-0 2012 Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C. AIM: To construct formulae for predicting the likelihood of ribavirin-induced anemia in pegylated interferon alpha plus ribavirin for chronic hepatitis C. METHODS: Five hundred and sixty-one Japanese patients with hepatitis C virus genotype 1b who had received combination treatment were enrolled and assigned randomly to the derivation and confirmatory groups. Ribavirin 54-63 inosine triphosphatase Homo sapiens 26-30 23031183-9 2012 CONCLUDING SUGGESTIONS: The new era for antiviral drugs like protease and polymerase inhibitors that seem to be more efficacious and less toxic than Ribavirin, may open the possibility to verify, when administered during the early phase of HCV infection (eventually helped by an immune-stimulant cytokine as IL-2), whether a precocious significant reduction of viral load (threshold) may allow the host to sustain his strong reactions and clear the virus within the due time, confirming the hypothesis about the crucial role of this tool which may be extended to all the cited infections. Ribavirin 149-158 interleukin 2 Homo sapiens 308-312 23149444-0 2012 Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. Ribavirin 70-73 progestagen associated endometrial protein Homo sapiens 118-129 29702891-7 2012 RESULTS: The total direct cost of hepatitis C treatment per patient with interferon alpha (IFN) plus ribavirin (RBV) was US $982.25, with peginterferon alpha (PEG) 2a 180 mug plus RBV was US $10,658.08, and with PEG 2b 120 mug plus RBV was US $12,597.63, taking into account entire treatment according to Brazilian guidelines and assuming that all patients completed full treatment. Ribavirin 180-183 interferon alpha 1 Homo sapiens 91-94 29702891-7 2012 RESULTS: The total direct cost of hepatitis C treatment per patient with interferon alpha (IFN) plus ribavirin (RBV) was US $982.25, with peginterferon alpha (PEG) 2a 180 mug plus RBV was US $10,658.08, and with PEG 2b 120 mug plus RBV was US $12,597.63, taking into account entire treatment according to Brazilian guidelines and assuming that all patients completed full treatment. Ribavirin 180-183 interferon alpha 1 Homo sapiens 91-94 23171003-0 2012 Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan. Ribavirin 78-87 G protein subunit beta 1 Homo sapiens 37-41 23171003-1 2012 BACKGROUND: The aim of this study was to evaluate whether polymorphisms in the guanine nucleotide binding (G protein), beta polypeptide 1 (GNB1) gene are associated with a rapid virological response (RVR) among HCV genotype 1 (HCV-1) and 2 (HCV-2) infected patients receiving peginterferon plus ribavirin treatment (PEG-IFNalpha-RBV). Ribavirin 295-304 G protein subunit beta 1 Homo sapiens 139-143 23139603-0 2012 Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C. AIM: To construct formulae for predicting the likelihood of ribavirin-induced anemia in pegylated interferon alpha plus ribavirin for chronic hepatitis C. METHODS: Five hundred and sixty-one Japanese patients with hepatitis C virus genotype 1b who had received combination treatment were enrolled and assigned randomly to the derivation and confirmatory groups. Ribavirin 163-172 inosine triphosphatase Homo sapiens 26-30 23139603-0 2012 Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C. AIM: To construct formulae for predicting the likelihood of ribavirin-induced anemia in pegylated interferon alpha plus ribavirin for chronic hepatitis C. METHODS: Five hundred and sixty-one Japanese patients with hepatitis C virus genotype 1b who had received combination treatment were enrolled and assigned randomly to the derivation and confirmatory groups. Ribavirin 163-172 inosine triphosphatase Homo sapiens 26-30 23109451-3 2012 Our aim was to establish an association between three IL28B SNPs (rs8099917, rs12979860, and rs8103142) and the peg-IFNalpha/RBV treatment response in a Mexican population cohort with chronic HCV. Ribavirin 125-128 interferon lambda 3 Homo sapiens 54-59 23109451-3 2012 Our aim was to establish an association between three IL28B SNPs (rs8099917, rs12979860, and rs8103142) and the peg-IFNalpha/RBV treatment response in a Mexican population cohort with chronic HCV. Ribavirin 125-128 interferon alpha 1 Homo sapiens 116-124 22577043-4 2012 Those NS5A regions nearly coincided with the interferon (IFN) sensitivity-determining region (NS5A aa.2209-2248) and the IFN/RBV resistance-determining region (NS5A aa.2339-2379). Ribavirin 125-128 interferon alpha 1 Homo sapiens 121-124 22985631-5 2012 Ribavirin reduced phosphorylation of Raf, MEK, ERK, Tyk2, and STAT1, but selectively increased STAT3 phosphorylation. Ribavirin 0-9 zinc fingers and homeoboxes 2 Homo sapiens 37-40 22985631-5 2012 Ribavirin reduced phosphorylation of Raf, MEK, ERK, Tyk2, and STAT1, but selectively increased STAT3 phosphorylation. Ribavirin 0-9 mitogen-activated protein kinase kinase 7 Homo sapiens 42-45 22985631-5 2012 Ribavirin reduced phosphorylation of Raf, MEK, ERK, Tyk2, and STAT1, but selectively increased STAT3 phosphorylation. Ribavirin 0-9 mitogen-activated protein kinase 1 Homo sapiens 47-50 22985631-5 2012 Ribavirin reduced phosphorylation of Raf, MEK, ERK, Tyk2, and STAT1, but selectively increased STAT3 phosphorylation. Ribavirin 0-9 tyrosine kinase 2 Homo sapiens 52-56 22985631-5 2012 Ribavirin reduced phosphorylation of Raf, MEK, ERK, Tyk2, and STAT1, but selectively increased STAT3 phosphorylation. Ribavirin 0-9 signal transducer and activator of transcription 1 Homo sapiens 62-67 22985631-5 2012 Ribavirin reduced phosphorylation of Raf, MEK, ERK, Tyk2, and STAT1, but selectively increased STAT3 phosphorylation. Ribavirin 0-9 signal transducer and activator of transcription 3 Homo sapiens 95-100 22985631-6 2012 IFN-alpha synergistically regulated ERK and STAT3 phosphorylation with ribavirin, and up-regulated expression and phosphorylation of STAT1. Ribavirin 71-80 interferon alpha 1 Homo sapiens 0-9 22985631-6 2012 IFN-alpha synergistically regulated ERK and STAT3 phosphorylation with ribavirin, and up-regulated expression and phosphorylation of STAT1. Ribavirin 71-80 mitogen-activated protein kinase 1 Homo sapiens 36-39 22985631-6 2012 IFN-alpha synergistically regulated ERK and STAT3 phosphorylation with ribavirin, and up-regulated expression and phosphorylation of STAT1. Ribavirin 71-80 signal transducer and activator of transcription 3 Homo sapiens 44-49 22985631-9 2012 ERK and STAT pathways were down-regulated by ribavirin following HCV infection. Ribavirin 45-54 mitogen-activated protein kinase 1 Homo sapiens 0-3 22985631-10 2012 These results suggest that ribavirin may mediate anti-HCV activity through interference with ERK and STAT pathways. Ribavirin 27-36 mitogen-activated protein kinase 1 Homo sapiens 93-96 22619107-0 2012 Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. UNLABELLED: Hepatitis C virus (HCV) infection is associated with insulin resistance (IR), which is a condition known to influence the progression of liver fibrosis and the response to pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. Ribavirin 331-340 insulin Homo sapiens 59-66 22619107-0 2012 Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. UNLABELLED: Hepatitis C virus (HCV) infection is associated with insulin resistance (IR), which is a condition known to influence the progression of liver fibrosis and the response to pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. Ribavirin 331-340 insulin Homo sapiens 181-188 22619107-0 2012 Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. UNLABELLED: Hepatitis C virus (HCV) infection is associated with insulin resistance (IR), which is a condition known to influence the progression of liver fibrosis and the response to pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. Ribavirin 342-345 insulin Homo sapiens 59-66 22619107-0 2012 Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. UNLABELLED: Hepatitis C virus (HCV) infection is associated with insulin resistance (IR), which is a condition known to influence the progression of liver fibrosis and the response to pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. Ribavirin 342-345 insulin Homo sapiens 181-188 22891772-0 2012 Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Ribavirin 0-9 CD4 molecule Homo sapiens 44-47 22891772-0 2012 Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Ribavirin 0-9 interleukin 2 receptor subunit alpha Homo sapiens 52-56 22891772-0 2012 Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Ribavirin 0-9 CD4 molecule Homo sapiens 71-74 22891772-0 2012 Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Ribavirin 0-9 interleukin 2 receptor subunit alpha Homo sapiens 79-83 22891772-0 2012 Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Ribavirin 0-9 forkhead box P3 Homo sapiens 88-93 22891772-0 2012 Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Ribavirin 0-9 interleukin 10 Homo sapiens 121-135 22891772-4 2012 To confirm this hypothesis, we investigated whether RBV modulates the inhibitory activity of human peripheral CD4(+) CD25(+) CD127(-) T cells in vitro. Ribavirin 52-55 CD4 molecule Homo sapiens 110-113 22891772-4 2012 To confirm this hypothesis, we investigated whether RBV modulates the inhibitory activity of human peripheral CD4(+) CD25(+) CD127(-) T cells in vitro. Ribavirin 52-55 interleukin 2 receptor subunit alpha Homo sapiens 118-122 22891772-5 2012 CD4(+) CD25(+) CD127(-) T cells pre-incubated with RBV lose their ability to inhibit the proliferation of CD4(+) CD25(-) T cells. Ribavirin 54-57 CD4 molecule Homo sapiens 0-3 22891772-5 2012 CD4(+) CD25(+) CD127(-) T cells pre-incubated with RBV lose their ability to inhibit the proliferation of CD4(+) CD25(-) T cells. Ribavirin 54-57 interleukin 2 receptor subunit alpha Homo sapiens 8-12 22891772-5 2012 CD4(+) CD25(+) CD127(-) T cells pre-incubated with RBV lose their ability to inhibit the proliferation of CD4(+) CD25(-) T cells. Ribavirin 54-57 CD4 molecule Homo sapiens 109-112 22891772-5 2012 CD4(+) CD25(+) CD127(-) T cells pre-incubated with RBV lose their ability to inhibit the proliferation of CD4(+) CD25(-) T cells. Ribavirin 54-57 interleukin 2 receptor subunit alpha Homo sapiens 117-121 22891772-6 2012 Expression of Forkhead box P3 (FOXP3) in CD4(+) CD25(-) T cells was down-modulated when they were incubated with CD4(+) CD25(+) CD127(-) T cells pre-incubated with RBV without down-modulating CD45RO on their surface. Ribavirin 169-172 forkhead box P3 Homo sapiens 14-29 22891772-6 2012 Expression of Forkhead box P3 (FOXP3) in CD4(+) CD25(-) T cells was down-modulated when they were incubated with CD4(+) CD25(+) CD127(-) T cells pre-incubated with RBV without down-modulating CD45RO on their surface. Ribavirin 169-172 forkhead box P3 Homo sapiens 31-36 22891772-6 2012 Expression of Forkhead box P3 (FOXP3) in CD4(+) CD25(-) T cells was down-modulated when they were incubated with CD4(+) CD25(+) CD127(-) T cells pre-incubated with RBV without down-modulating CD45RO on their surface. Ribavirin 169-172 CD4 molecule Homo sapiens 41-44 22891772-6 2012 Expression of Forkhead box P3 (FOXP3) in CD4(+) CD25(-) T cells was down-modulated when they were incubated with CD4(+) CD25(+) CD127(-) T cells pre-incubated with RBV without down-modulating CD45RO on their surface. Ribavirin 169-172 interleukin 2 receptor subunit alpha Homo sapiens 49-53 22891772-6 2012 Expression of Forkhead box P3 (FOXP3) in CD4(+) CD25(-) T cells was down-modulated when they were incubated with CD4(+) CD25(+) CD127(-) T cells pre-incubated with RBV without down-modulating CD45RO on their surface. Ribavirin 169-172 CD4 molecule Homo sapiens 115-118 22891772-6 2012 Expression of Forkhead box P3 (FOXP3) in CD4(+) CD25(-) T cells was down-modulated when they were incubated with CD4(+) CD25(+) CD127(-) T cells pre-incubated with RBV without down-modulating CD45RO on their surface. Ribavirin 169-172 interleukin 2 receptor subunit alpha Homo sapiens 123-127 22891772-8 2012 These results indicated that RBV might inhibit the conversion of CD4(+) CD25(-) FOXP3(-) naive T cells into CD4(+) CD25(+) FOXP3(+) adaptive Treg cells by down-modulating the IL-10-producing Treg 1 cells to prevent these effector T cells from entering anergy and to maintain Th1 cell activity. Ribavirin 29-32 CD4 molecule Homo sapiens 65-68 22891772-8 2012 These results indicated that RBV might inhibit the conversion of CD4(+) CD25(-) FOXP3(-) naive T cells into CD4(+) CD25(+) FOXP3(+) adaptive Treg cells by down-modulating the IL-10-producing Treg 1 cells to prevent these effector T cells from entering anergy and to maintain Th1 cell activity. Ribavirin 29-32 interleukin 2 receptor subunit alpha Homo sapiens 73-77 22891772-8 2012 These results indicated that RBV might inhibit the conversion of CD4(+) CD25(-) FOXP3(-) naive T cells into CD4(+) CD25(+) FOXP3(+) adaptive Treg cells by down-modulating the IL-10-producing Treg 1 cells to prevent these effector T cells from entering anergy and to maintain Th1 cell activity. Ribavirin 29-32 forkhead box P3 Homo sapiens 82-87 22891772-8 2012 These results indicated that RBV might inhibit the conversion of CD4(+) CD25(-) FOXP3(-) naive T cells into CD4(+) CD25(+) FOXP3(+) adaptive Treg cells by down-modulating the IL-10-producing Treg 1 cells to prevent these effector T cells from entering anergy and to maintain Th1 cell activity. Ribavirin 29-32 CD4 molecule Homo sapiens 111-114 22899224-0 2012 Mutations in non-structural 5A and rapid viral response to pegylated interferon-alpha-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. For patients chronically infected with hepatitis C virus (HCV), mutations in the non-structural 5A (NS5A) gene are important predictive factors for the response to interferon (IFN) therapy. Ribavirin 106-115 interferon alpha 1 Homo sapiens 403-406 22891772-8 2012 These results indicated that RBV might inhibit the conversion of CD4(+) CD25(-) FOXP3(-) naive T cells into CD4(+) CD25(+) FOXP3(+) adaptive Treg cells by down-modulating the IL-10-producing Treg 1 cells to prevent these effector T cells from entering anergy and to maintain Th1 cell activity. Ribavirin 29-32 interleukin 2 receptor subunit alpha Homo sapiens 119-123 22891772-8 2012 These results indicated that RBV might inhibit the conversion of CD4(+) CD25(-) FOXP3(-) naive T cells into CD4(+) CD25(+) FOXP3(+) adaptive Treg cells by down-modulating the IL-10-producing Treg 1 cells to prevent these effector T cells from entering anergy and to maintain Th1 cell activity. Ribavirin 29-32 forkhead box P3 Homo sapiens 128-133 22891772-8 2012 These results indicated that RBV might inhibit the conversion of CD4(+) CD25(-) FOXP3(-) naive T cells into CD4(+) CD25(+) FOXP3(+) adaptive Treg cells by down-modulating the IL-10-producing Treg 1 cells to prevent these effector T cells from entering anergy and to maintain Th1 cell activity. Ribavirin 29-32 interleukin 10 Homo sapiens 181-186 22536875-1 2012 AIM: IL28B polymorphisms serve to predict response to pegylated interferon plus ribavirin therapy (PEG IFN/RBV) in Japanese patients with chronic hepatitis C (CHC) very reliably. Ribavirin 82-91 interferon lambda 3 Homo sapiens 7-12 22842190-2 2012 This meta-analysis aimed to derive a more precise estimation of the effects of IL-28B SNPs locus (rs12979860 and rs8099917) on SVR in naive CHC patients receiving pegylated interferon alpha (PEG-IFN-alpha) plus ribavirin. Ribavirin 211-220 interferon lambda 3 Homo sapiens 79-85 23241183-5 2012 Recently, however, a randomized trial has reported significantly better response at all time-points during therapy with pegylated interferon plus ribavirin, if such therapy was combined with vitamin B12. Ribavirin 146-155 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 199-202 22931407-0 2012 HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-alpha and ribavirin. Ribavirin 119-128 major histocompatibility complex, class I, B Homo sapiens 0-5 22931407-9 2012 HLA-B*15:02 is associated with treatment-induced anemia in Taiwanese CHC patients receiving combination therapy with PEG-IFN-alpha plus RBV. Ribavirin 136-139 major histocompatibility complex, class I, B Homo sapiens 0-5 22536875-1 2012 AIM: IL28B polymorphisms serve to predict response to pegylated interferon plus ribavirin therapy (PEG IFN/RBV) in Japanese patients with chronic hepatitis C (CHC) very reliably. Ribavirin 109-112 interferon lambda 3 Homo sapiens 7-12 22536875-2 2012 However, the prediction by the IL28B polymorphism contradicted the virological response to PEG IFN/RBV in some patients. Ribavirin 99-102 interferon lambda 3 Homo sapiens 31-36 22612669-11 2012 CONCLUSION: The reduction therapy of IFN-beta and ribavirin in elderly HCV patients with genotype 1b, high viral load, IL28B gene (rs8099917) of TT who had complications of anemia, low bodyweight, diabetes mellitus and/or hypertension is one possible selection of treatment. Ribavirin 52-61 interferon lambda 3 Homo sapiens 121-126 22930507-0 2012 Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy. Ribavirin 100-109 interferon lambda 3 Homo sapiens 15-20 22387529-0 2012 Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatment-naive patients infected with HCV genotype 1. Ribavirin 75-84 insulin Homo sapiens 0-7 22387529-1 2012 OBJECTIVE: Insulin resistance is a predictor of poor response to peginterferon/ribavirin in patients infected with the chronic hepatitis C virus (HCV). Ribavirin 79-88 insulin Homo sapiens 11-18 22450877-0 2012 An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Ribavirin 22-31 interferon alpha 2 Homo sapiens 121-140 22836041-0 2012 Single-nucleotide polymorphism in the promoter region of the osteopontin gene at nucleotide -443 as a marker predicting the efficacy of pegylated interferon/ribavirin-therapy in Egyptians patients with chronic hepatitis C. Osteopontin (OPN) is an extracellular matrix glycophosphoprotein produced by several types of cells including the immune system. Ribavirin 157-166 secreted phosphoprotein 1 Homo sapiens 61-72 22836041-1 2012 The present study examined the possibility that single-nucleotide polymorphisms (SNP) in the promoter region of the OPN at nt -443 is a marker predicting the therapeutic efficacy of pegylated interferon (peg-IFN-alpha2b)-ribavirin combination therapy in Egyptian patients with chronic hepatitis C. Blood was collected from 95 patients with chronic hepatitis C who had received peg-IFN-alpha2b-ribavirin combination therapy and 100 age and sex matched controls. Ribavirin 221-230 secreted phosphoprotein 1 Homo sapiens 116-119 22836041-1 2012 The present study examined the possibility that single-nucleotide polymorphisms (SNP) in the promoter region of the OPN at nt -443 is a marker predicting the therapeutic efficacy of pegylated interferon (peg-IFN-alpha2b)-ribavirin combination therapy in Egyptian patients with chronic hepatitis C. Blood was collected from 95 patients with chronic hepatitis C who had received peg-IFN-alpha2b-ribavirin combination therapy and 100 age and sex matched controls. Ribavirin 393-402 secreted phosphoprotein 1 Homo sapiens 116-119 22836041-6 2012 It can be concluded that SNP in the promoter region of OPN at nt -443 and serum OPN protein level are predictors of response to the efficacy of peg-IFN-alpha2b-ribavirin therapy in Egyptian patients with chronic hepatitis C. Ribavirin 160-169 secreted phosphoprotein 1 Homo sapiens 55-58 22836041-6 2012 It can be concluded that SNP in the promoter region of OPN at nt -443 and serum OPN protein level are predictors of response to the efficacy of peg-IFN-alpha2b-ribavirin therapy in Egyptian patients with chronic hepatitis C. Ribavirin 160-169 secreted phosphoprotein 1 Homo sapiens 80-83 22967098-1 2012 IL28B genotype has been shown to be the strongest pretreatment predictor of sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C infection (CHC) treated with pegylated interferon (peg-IFN) and ribavirin (RBV). Ribavirin 225-234 interferon lambda 3 Homo sapiens 0-5 22967098-1 2012 IL28B genotype has been shown to be the strongest pretreatment predictor of sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C infection (CHC) treated with pegylated interferon (peg-IFN) and ribavirin (RBV). Ribavirin 236-239 interferon lambda 3 Homo sapiens 0-5 22782948-0 2012 Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection. Ribavirin 120-129 Fc gamma receptor IIIa Homo sapiens 36-40 22824093-1 2012 The addition of the broad-spectrum antiviral agent ribavirin (RBV), a synthetic guanosine analog, to interferon-alpha (IFNalpha) monotherapy has been a major breakthrough in the treatment of patients with hepatitis C virus (HCV), as it greatly improved treatment response rates. Ribavirin 51-60 interferon alpha 1 Homo sapiens 119-127 22824093-1 2012 The addition of the broad-spectrum antiviral agent ribavirin (RBV), a synthetic guanosine analog, to interferon-alpha (IFNalpha) monotherapy has been a major breakthrough in the treatment of patients with hepatitis C virus (HCV), as it greatly improved treatment response rates. Ribavirin 62-65 interferon alpha 1 Homo sapiens 119-127 22824093-2 2012 Although several mechanisms of action have been proposed for RBV"s antiviral activity, each with some experimental evidence, the precise mechanism by which it acts synergistically with IFNalpha has remained elusive. Ribavirin 61-64 interferon alpha 1 Homo sapiens 185-193 22824093-8 2012 Eukaryotic eIF5B is a ribosome-dependent GTPase that is responsible for 80S complex formation in translation initiation but shows much lower affinities for GTP than to other GTPases, thus suggesting that it may mis-incorporate the RBV triphosphate (RTP) in place of GTP even at the RBV concentrations achieved in clinical use. Ribavirin 231-234 eukaryotic translation initiation factor 5B Homo sapiens 11-16 22812541-7 2012 Perfusions without sodium drastically reduced the intestinal loss of ribavirin in both wild-type and Ent1(-/-) mice. Ribavirin 69-78 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 101-105 22812541-8 2012 After 20 muM ribavirin perfusions, Ent1(-/-) intestinal tissue contained 8-fold greater ribavirin than wild-type mice (p < 0.01). Ribavirin 88-97 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 35-39 22812541-10 2012 Ribavirin plasma concentrations were significantly higher in wild-type mice (2.7-fold) vs Ent1(-/-) mice at 30 min after the 20 muM perfusion (p < 0.01). Ribavirin 0-9 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 90-94 22727259-0 2012 Different impact of IL28B polymorphisms on response to peginterferon-alpha plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. Ribavirin 80-89 interferon lambda 3 Homo sapiens 20-25 22220723-0 2012 Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. Ribavirin 157-166 CD4 molecule Homo sapiens 62-65 22220723-1 2012 The long-term impact of pegylated-interferon plus ribavirin (Peg-IFN-RBV) treatment outcome on CD4 T cell course in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is unknown. Ribavirin 50-59 CD4 molecule Homo sapiens 95-98 22524382-1 2012 Identification of the relationship between the interleukin (IL)-28B genotype and the effect of peginterferon plus ribavirin treatment has had a great impact on the study of antiviral therapy for patients with chronic hepatitis C virus (HCV) infection. Ribavirin 114-123 interferon lambda 3 Homo sapiens 47-67 22639111-7 2012 These findings suggest that optimization of ribavirin plasma concentrations during the first week of ribavirin dosing is most critical in AA patients in order to increase the rate of SVR, especially those with the IL-28B TT genotype. Ribavirin 44-53 interferon lambda 3 Homo sapiens 214-220 22639111-7 2012 These findings suggest that optimization of ribavirin plasma concentrations during the first week of ribavirin dosing is most critical in AA patients in order to increase the rate of SVR, especially those with the IL-28B TT genotype. Ribavirin 101-110 interferon lambda 3 Homo sapiens 214-220 23139898-1 2012 The standard treatment for CH-C, pegylated interferon-alpha and ribavirin (PEG-IFN + RBV), is associated with depression. Ribavirin 64-73 solute carrier family 4 member 1 (Diego blood group) Homo sapiens 27-31 23139898-1 2012 The standard treatment for CH-C, pegylated interferon-alpha and ribavirin (PEG-IFN + RBV), is associated with depression. Ribavirin 85-88 solute carrier family 4 member 1 (Diego blood group) Homo sapiens 27-31 23139898-4 2012 We included 67 CH-C patients being treated with PEG-IFN+RBV. Ribavirin 56-59 solute carrier family 4 member 1 (Diego blood group) Homo sapiens 15-19 22487191-5 2012 By induction with IFN-beta, even in refractory cases, the high virus negative conversion rate in the early treatment phase and actions of pegylated IFN-alpha-2b and ribavirin in the maintenance treatment phase led to an additive effect. Ribavirin 165-174 interferon beta 1 Homo sapiens 18-26 22727259-12 2012 CONCLUSIONS: The rate of SVR to pegIFN/RBV therapy tends to be lower in HIV-infected patients with chronic hepatitis C due to HCV-1a than HCV-1b; being the impact of IL28B variants significantly stronger on HCV-1a than HCV-1b. Ribavirin 39-42 interferon lambda 3 Homo sapiens 166-171 22613000-0 2012 Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. Ribavirin 108-117 insulin Homo sapiens 0-7 22432893-0 2012 Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation. Ribavirin 123-132 interferon lambda 3 Homo sapiens 0-15 22432893-1 2012 BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT). Ribavirin 292-301 interferon lambda 3 Homo sapiens 20-35 22432893-1 2012 BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT). Ribavirin 292-301 interferon lambda 3 Homo sapiens 37-42 22432893-1 2012 BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT). Ribavirin 292-301 interferon alpha 1 Homo sapiens 127-130 22432893-1 2012 BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT). Ribavirin 310-313 interferon lambda 3 Homo sapiens 20-35 22432893-1 2012 BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT). Ribavirin 310-313 interferon lambda 3 Homo sapiens 37-42 22613000-8 2012 CONCLUSIONS: For HCV genotype 1, both IL28B and baseline HOMA-IR are independent pretreatment predictors of SVR in patients treated with PegIFNalpha-2b and RBV. Ribavirin 156-159 interferon lambda 3 Homo sapiens 38-43 22432893-1 2012 BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT). Ribavirin 310-313 interferon alpha 1 Homo sapiens 127-130 22432893-9 2012 CONCLUSION: Measurement of donors" and recipients" IL28B SNP can predict the response to PEGIFN/RBV therapy, and the donors" IL28B SNP might be a more significant predictor than that of the recipients. Ribavirin 96-99 interferon lambda 3 Homo sapiens 51-56 22634340-0 2012 Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. BACKGROUND & AIMS: Insulin resistance, fibrosis and steatosis are established predictors of response to peg-interferon/ribavirin therapy in chronic hepatitis C (CHC). Ribavirin 219-228 interferon lambda 3 Homo sapiens 19-24 22613675-1 2012 A single nucleotide polymorphism (SNP) upstream of the IL28 gene (rs12979860) has been reported to predict sustained virological response to peginterferon-ribavirin therapy in chronic HCV patients. Ribavirin 155-164 interferon lambda 3 Homo sapiens 55-59 22634340-11 2012 CONCLUSIONS: Insulin resistance is more common in carriers of the T allele of SNP rs12979860 than in CC homozygotes and may partly explain the poor outcome of peginterferon/ribavirin therapy in these patients. Ribavirin 173-182 insulin Homo sapiens 13-20 22863266-10 2012 Haemoglobin reductions <10 g/dL were less frequent with albIFN 900 and 1200 mug vs 1500 mug and Peg-IFNalpha-2a (P = 0.02), leading to fewer ribavirin dose reductions. Ribavirin 144-153 interferon alpha 1 Homo sapiens 103-111 22554247-1 2012 BACKGROUND AND AIM: The inosine triphosphatase (ITPA) genotype is associated with ribavirin-induced anemia and pegylated interferon alpha (PEG IFN-alpha)-induced platelet reduction during PEG IFN-alpha plus ribavirin combination therapy. Ribavirin 82-91 interferon alpha 1 Homo sapiens 192-201 22554247-1 2012 BACKGROUND AND AIM: The inosine triphosphatase (ITPA) genotype is associated with ribavirin-induced anemia and pegylated interferon alpha (PEG IFN-alpha)-induced platelet reduction during PEG IFN-alpha plus ribavirin combination therapy. Ribavirin 207-216 interferon alpha 1 Homo sapiens 143-152 22613675-2 2012 In addition, two functionally deficient variants (rs1127354 and rs7270101) of inosine triphosphatase (ITPA) were shown to protect against ribavirin (RBV) - induced hemolytic anemia during early stages of treatment. Ribavirin 138-147 inosine triphosphatase Homo sapiens 102-106 22613675-2 2012 In addition, two functionally deficient variants (rs1127354 and rs7270101) of inosine triphosphatase (ITPA) were shown to protect against ribavirin (RBV) - induced hemolytic anemia during early stages of treatment. Ribavirin 149-152 inosine triphosphatase Homo sapiens 102-106 23199501-4 2012 Genome-wide association studies have recently identified several clinically important host determinants of the outcomes of peginterferon-alpha and ribavirin treatment outcome: IL28B polymorphism is associated with spontaneous clearance and treatment responsiveness; ITPA polymorphism protects against ribavirin-induced anaemia and dose reductions; genetic determinants of liver fibrosis progression rate have been proposed. Ribavirin 147-156 interferon lambda 3 Homo sapiens 176-181 22943620-2 2012 RBV acts as a prodrug and exerts its broad antiviral activity primarily through its active phosphorylated metabolite ribavirin 5 -triphosphate (RTP), and also possibly through ribavirin 5 -monophosphate (RMP). Ribavirin 0-3 URI1 prefoldin like chaperone Homo sapiens 176-208 23289278-9 2012 CONCLUSION: Combination therapy of recombinant pegylated interferon alpha 2a with ribavirin leads to SVR in the majority of treated patients (70.5%). Ribavirin 82-91 interferon alpha 2 Homo sapiens 57-76 22683884-1 2012 BACKGROUND: The rate of non-response to pegylated interferon plus ribavirin (peg-IFN+RBV) in HCV/HIV coinfected patients is higher than in HCV-monoinfected patients. Ribavirin 66-75 interferon alpha 1 Homo sapiens 81-84 23199501-4 2012 Genome-wide association studies have recently identified several clinically important host determinants of the outcomes of peginterferon-alpha and ribavirin treatment outcome: IL28B polymorphism is associated with spontaneous clearance and treatment responsiveness; ITPA polymorphism protects against ribavirin-induced anaemia and dose reductions; genetic determinants of liver fibrosis progression rate have been proposed. Ribavirin 301-310 interferon lambda 3 Homo sapiens 176-181 22943620-4 2012 In a recombinant human UGT1A1 assay, the assay buffer components uridine and its phosphorylated derivatives are isobaric with RBV and its phosphorylated metabolites, leading to significant interference when analyzed by LC-MS with the nominal mass resolution mode. Ribavirin 126-129 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 23-29 22928901-2 2012 Following these studies, ITPA gene variants were reported to affect ribavirin-induced anemia and therapeutic outcomes of CHC patients. Ribavirin 68-77 inosine triphosphatase Homo sapiens 25-29 22943620-6 2012 CONCLUSION: The developed LC-high-resolution accurate MS method allows for quantitation of RBV and its phosphorylated metabolites, eliminating the interferences from uridine and its phosphorylated derivatives in recombinant human UGT1A1 assays. Ribavirin 91-94 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 230-236 22584257-0 2012 Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Ribavirin 51-60 inosine triphosphatase Homo sapiens 24-28 22584257-1 2012 OBJECTIVES: Two functional genetic variants in the inosine triphosphatase (ITPA) gene have been shown to be strongly associated with protection from ribavirin (RBV)-induced hemolysis. Ribavirin 149-158 inosine triphosphatase Homo sapiens 51-73 22584257-1 2012 OBJECTIVES: Two functional genetic variants in the inosine triphosphatase (ITPA) gene have been shown to be strongly associated with protection from ribavirin (RBV)-induced hemolysis. Ribavirin 149-158 inosine triphosphatase Homo sapiens 75-79 22584257-1 2012 OBJECTIVES: Two functional genetic variants in the inosine triphosphatase (ITPA) gene have been shown to be strongly associated with protection from ribavirin (RBV)-induced hemolysis. Ribavirin 160-163 inosine triphosphatase Homo sapiens 51-73 22584257-1 2012 OBJECTIVES: Two functional genetic variants in the inosine triphosphatase (ITPA) gene have been shown to be strongly associated with protection from ribavirin (RBV)-induced hemolysis. Ribavirin 160-163 inosine triphosphatase Homo sapiens 75-79 22584257-9 2012 CONCLUSION: We have confirmed a strong association between functional ITPA variants and RBV-induced hemolysis and showed protection from RBV dose reduction, although this did not translate into increased rapid viral response or sustained viral response. Ribavirin 88-91 inosine triphosphatase Homo sapiens 70-74 22584257-9 2012 CONCLUSION: We have confirmed a strong association between functional ITPA variants and RBV-induced hemolysis and showed protection from RBV dose reduction, although this did not translate into increased rapid viral response or sustained viral response. Ribavirin 137-140 inosine triphosphatase Homo sapiens 70-74 23012624-0 2012 Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Ribavirin 98-107 inosine triphosphatase Homo sapiens 9-13 23087747-1 2012 BACKGROUND: Single nucleotide polymorphism in the interleukin28B (IL28B) gene was recently shown to be associated with a significant increase in response to interferon-alpha and ribavirin treatment in patients with chronic hepatitis C. Similarly, thyroid disease (TD) occurring during treatment confer an improved sustained virologic response (SVR). Ribavirin 178-187 interferon lambda 3 Homo sapiens 50-64 23087747-1 2012 BACKGROUND: Single nucleotide polymorphism in the interleukin28B (IL28B) gene was recently shown to be associated with a significant increase in response to interferon-alpha and ribavirin treatment in patients with chronic hepatitis C. Similarly, thyroid disease (TD) occurring during treatment confer an improved sustained virologic response (SVR). Ribavirin 178-187 interferon lambda 3 Homo sapiens 66-71 22284614-0 2012 Influence of HLA alleles in response to treatment with pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C. The objective of this study was to analyse the possible role of HLA polymorphism of chronically infected hepatitis C virus patients in the response outcome to treatment with pegylated interferon-alpha plus ribavirin. Ribavirin 86-95 major histocompatibility complex, class II, DQ beta 1 Homo sapiens 13-16 22711348-11 2012 This finding may help to early identify responders to standard PEG-IFN-alpha and ribavirin treatment even within those with unfavorable IL28B genotype. Ribavirin 81-90 interferon lambda 3 Homo sapiens 136-141 22521237-3 2012 Recent studies indicate association of several single nucleotide polymorphisms near IL28B gene and response of hepatitis C patients to combined interferon/ribavirin treatment. Ribavirin 155-164 interferon lambda 3 Homo sapiens 84-89 23012624-1 2012 It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients. Ribavirin 86-95 interferon lambda 3 Homo sapiens 156-161 23012624-1 2012 It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients. Ribavirin 231-240 inosine triphosphatase Homo sapiens 26-48 23012624-1 2012 It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients. Ribavirin 231-240 inosine triphosphatase Homo sapiens 50-54 23012624-1 2012 It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients. Ribavirin 231-240 interferon lambda 3 Homo sapiens 156-161 23012624-6 2012 ITPA rs1127354 major type leads to significantly greater ribavirin-induced anemia than ITPA rs1127354 minor type between days 0 and 84. Ribavirin 57-66 inosine triphosphatase Homo sapiens 0-4 23012624-8 2012 ITPA rs1127354 is useful for the prediction of ribavirin-induced anemia in the early phase after the commencement of peginterferon plus ribavirin treatment and IL28B rs8099917 is useful for the prediction of sustained virological response. Ribavirin 47-56 inosine triphosphatase Homo sapiens 0-4 23012624-8 2012 ITPA rs1127354 is useful for the prediction of ribavirin-induced anemia in the early phase after the commencement of peginterferon plus ribavirin treatment and IL28B rs8099917 is useful for the prediction of sustained virological response. Ribavirin 136-145 inosine triphosphatase Homo sapiens 0-4 22331604-1 2012 UNLABELLED: Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin-28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (PEG-IFN)/ribavirin. Ribavirin 264-273 interferon lambda 3 Homo sapiens 109-114 22331604-1 2012 UNLABELLED: Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin-28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (PEG-IFN)/ribavirin. Ribavirin 264-273 interferon alpha 1 Homo sapiens 259-262 22334369-2 2012 Coadministration of pioglitazone with peginterferon/ribavirin improves insulin sensitivity and increases virologic response rates in insulin-resistant HCV genotype 4 patients, but it is unclear whether this finding applies to genotype 1 patients. Ribavirin 52-61 insulin Homo sapiens 71-78 22334369-2 2012 Coadministration of pioglitazone with peginterferon/ribavirin improves insulin sensitivity and increases virologic response rates in insulin-resistant HCV genotype 4 patients, but it is unclear whether this finding applies to genotype 1 patients. Ribavirin 52-61 insulin Homo sapiens 133-140 22334369-7 2012 CONCLUSION: Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone. Ribavirin 101-110 insulin Homo sapiens 197-204 22284614-0 2012 Influence of HLA alleles in response to treatment with pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C. The objective of this study was to analyse the possible role of HLA polymorphism of chronically infected hepatitis C virus patients in the response outcome to treatment with pegylated interferon-alpha plus ribavirin. Ribavirin 340-349 major histocompatibility complex, class II, DQ beta 1 Homo sapiens 198-201 22284614-7 2012 HLA class II antigens can positively influence the response to treatment with pegylated interferon-alpha and ribavirin. Ribavirin 109-118 major histocompatibility complex, class II, DQ beta 1 Homo sapiens 0-3 22799464-0 2012 Chemokine CXCL10 at week 4 of treatment predicts sustained virological response in patients with chronic hepatitis C. The aim of this study was to analyze the predictive value of CXCL9, CXCL10, and CXCL11 concentrations before and after 4 and 12 weeks of treatment with pegylated interferon-alpha2b and ribavirin in patients with chronic hepatitis C infected with the hepatitis C virus genotype 1. Ribavirin 303-312 C-X-C motif chemokine ligand 10 Homo sapiens 10-16 23012624-0 2012 Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Ribavirin 98-107 interferon lambda 3 Homo sapiens 18-23 23012624-1 2012 It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients. Ribavirin 86-95 inosine triphosphatase Homo sapiens 26-48 23012624-1 2012 It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients. Ribavirin 86-95 inosine triphosphatase Homo sapiens 50-54 22612303-1 2012 BACKGROUND: Polymorphisms in the IL-28B region are a strong predictor of sustained virologic response (SVR) in individual studies of HCV genotype 1 patients receiving peginterferon (pegIFN) and ribavirin. Ribavirin 194-203 interferon lambda 3 Homo sapiens 33-39 22783042-5 2012 Over the past 20 years, IFN therapy has improved to more effectively eliminate the virus, progressing from single IFN therapy to combination therapy with ribavirin (RBV) and finally to pegylated IFN (PEG-IFN) therapy. Ribavirin 154-163 interferon alpha 1 Homo sapiens 24-27 22783042-5 2012 Over the past 20 years, IFN therapy has improved to more effectively eliminate the virus, progressing from single IFN therapy to combination therapy with ribavirin (RBV) and finally to pegylated IFN (PEG-IFN) therapy. Ribavirin 165-168 interferon alpha 1 Homo sapiens 24-27 22612303-10 2012 CONCLUSIONS: IL-28B genotype is significantly associated with SVR in HCV genotype 1 patients of varying race, as well as in HIV co-infected patients, receiving pegIFN and ribavirin. Ribavirin 171-180 interferon lambda 3 Homo sapiens 13-19 22430973-0 2012 Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. Ribavirin 55-64 inosine triphosphatase Homo sapiens 15-19 22882858-1 2012 The aim of this research was to evaluate the role of IL-28B single nucleotide polymorphism (SNP) variations in Chinese patients undergoing pegylated interferon-alpha plus ribavirin (PEG-IFN-alpha/RBV) treatment. Ribavirin 171-180 interferon lambda 3 Homo sapiens 53-59 22530607-0 2012 Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Ribavirin 98-107 patatin like phospholipase domain containing 3 Homo sapiens 17-23 22350701-1 2012 BACKGROUND: Several single nucleotide polymorphisms (SNPs) within the interleukin 28B (IL28B) locus are associated with sustained viral response in chronic hepatitis C (HCV) patients who were treated with pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Ribavirin 241-250 interferon lambda 3 Homo sapiens 87-92 22350701-1 2012 BACKGROUND: Several single nucleotide polymorphisms (SNPs) within the interleukin 28B (IL28B) locus are associated with sustained viral response in chronic hepatitis C (HCV) patients who were treated with pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Ribavirin 252-255 interferon lambda 3 Homo sapiens 87-92 22585728-9 2012 In conclusion, this study identified amino acid substitution of the core region, alpha-fetoprotein level, and type of previous response as predictors of virological response to telaprevir/PEG-IFN/ribavirin in patients infected with HCV genotype 1b who had not responded to previous PEG-IFN/ribavirin therapy. Ribavirin 196-205 alpha fetoprotein Homo sapiens 81-98 22585729-1 2012 Published studies have described a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and ribavirin (RBV)-induced hemolytic anemia in HCV-infected patients receiving pegylated interferon (pegIFN) and RBV. Ribavirin 158-167 inosine triphosphatase Homo sapiens 105-141 22585729-1 2012 Published studies have described a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and ribavirin (RBV)-induced hemolytic anemia in HCV-infected patients receiving pegylated interferon (pegIFN) and RBV. Ribavirin 158-167 inosine triphosphatase Homo sapiens 143-147 22585729-1 2012 Published studies have described a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and ribavirin (RBV)-induced hemolytic anemia in HCV-infected patients receiving pegylated interferon (pegIFN) and RBV. Ribavirin 169-172 inosine triphosphatase Homo sapiens 105-141 22585729-1 2012 Published studies have described a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and ribavirin (RBV)-induced hemolytic anemia in HCV-infected patients receiving pegylated interferon (pegIFN) and RBV. Ribavirin 169-172 inosine triphosphatase Homo sapiens 143-147 22585729-1 2012 Published studies have described a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and ribavirin (RBV)-induced hemolytic anemia in HCV-infected patients receiving pegylated interferon (pegIFN) and RBV. Ribavirin 268-271 inosine triphosphatase Homo sapiens 105-141 22585729-1 2012 Published studies have described a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and ribavirin (RBV)-induced hemolytic anemia in HCV-infected patients receiving pegylated interferon (pegIFN) and RBV. Ribavirin 268-271 inosine triphosphatase Homo sapiens 143-147 22585729-11 2012 Determination of ITPA polymorphisms may allow prediction of RBV-induced anemia and earlier initiation of supportive care to ensure optimal therapeutic outcomes. Ribavirin 60-63 inosine triphosphatase Homo sapiens 17-21 22430973-11 2012 Polymorphisms at rs1127354 in the ITPA gene influence hemoglobin levels during combination HCV therapy and the need for RBV dose reduction and erythropoietin use in HIV/HCV-coinfected patients. Ribavirin 120-123 inosine triphosphatase Homo sapiens 34-38 22486858-11 2012 CONCLUSIONS: A combination of metformin, peginterferon alfa-2a, and ribavirin improved insulin sensitivity and increased the SVR rate of patients with hepatitis C genotype 1 and IR, with a good safety profile. Ribavirin 68-77 insulin Homo sapiens 87-94 22426896-0 2012 Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C. Evidence has shown that the p7, NS2 and NS3 genes affect the outcome of pegylated-IFN-alpha/ribavirin (PEG-IFN/RBV) combination therapy in different populations with HCV infections. Ribavirin 99-108 NS2 Homo sapiens 195-198 22426896-0 2012 Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C. Evidence has shown that the p7, NS2 and NS3 genes affect the outcome of pegylated-IFN-alpha/ribavirin (PEG-IFN/RBV) combination therapy in different populations with HCV infections. Ribavirin 99-108 KRAS proto-oncogene, GTPase Homo sapiens 203-206 22426896-0 2012 Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C. Evidence has shown that the p7, NS2 and NS3 genes affect the outcome of pegylated-IFN-alpha/ribavirin (PEG-IFN/RBV) combination therapy in different populations with HCV infections. Ribavirin 255-264 NS2 Homo sapiens 195-198 22426896-0 2012 Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C. Evidence has shown that the p7, NS2 and NS3 genes affect the outcome of pegylated-IFN-alpha/ribavirin (PEG-IFN/RBV) combination therapy in different populations with HCV infections. Ribavirin 255-264 KRAS proto-oncogene, GTPase Homo sapiens 203-206 22426896-0 2012 Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C. Evidence has shown that the p7, NS2 and NS3 genes affect the outcome of pegylated-IFN-alpha/ribavirin (PEG-IFN/RBV) combination therapy in different populations with HCV infections. Ribavirin 274-277 NS2 Homo sapiens 195-198 22426896-0 2012 Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C. Evidence has shown that the p7, NS2 and NS3 genes affect the outcome of pegylated-IFN-alpha/ribavirin (PEG-IFN/RBV) combination therapy in different populations with HCV infections. Ribavirin 274-277 KRAS proto-oncogene, GTPase Homo sapiens 203-206 22426896-4 2012 In conclusion, increased amino acid sequence diversity in the p7, NS2 and NS3 genes is associated with an SVR to PEG-IFN/RBV therapy in Chinese patients with genotype 1b chronic hepatitis C. Ribavirin 121-124 NS2 Homo sapiens 66-69 22426896-4 2012 In conclusion, increased amino acid sequence diversity in the p7, NS2 and NS3 genes is associated with an SVR to PEG-IFN/RBV therapy in Chinese patients with genotype 1b chronic hepatitis C. Ribavirin 121-124 KRAS proto-oncogene, GTPase Homo sapiens 74-77 22473525-2 2012 A highly sensitive and specific liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated, using ribavirin (CAS NO: 36791-04-5) as the internal standard (IS). Ribavirin 133-142 breast cancer anti-estrogen resistance 1 Mus musculus 144-147 22493491-1 2012 Insulin resistance is a risk factor for non-response to interferon/ribavirin therapy in patients with chronic hepatitis C. The aim of this study was to determine the role played by protein-tyrosine phosphatases (PTPs) in the absence of interferon-alpha (IFNalpha) response associated with insulin resistance. Ribavirin 67-76 insulin Homo sapiens 0-7 22396433-0 2012 Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV. Ribavirin 23-32 interferon alpha 2 Homo sapiens 124-143 22493491-14 2012 The use of PTP-1B inhibitors may improve the response to IFNalpha/ribavirin therapy. Ribavirin 66-75 protein tyrosine phosphatase non-receptor type 1 Homo sapiens 11-17 22098610-10 2012 CONCLUSIONS: The H63D mutation has little impact on the clinical characteristics of CHC, but is related to favorable response to PEG-IFN plus ribavirin therapy, particularly in patients with the TT allele in IL28B. Ribavirin 142-151 interferon lambda 3 Homo sapiens 208-213 22729189-12 2012 CONCLUSION: In patients with HCV genotypes 2 or 3 infection, a higher SVR was observed in patients receiving Peg-IFN plus RBV related to patients treated with biosimilar standard IFN plus RBV. Ribavirin 122-125 interferon alpha 1 Homo sapiens 179-182 22573217-3 2012 Moreover, recent genomewide association studies found a highly significant and strong association between genetic variants near the IFNlambda3 gene, designated the IL28B genotype, with spontaneous clearance of hepatitis C virus as well as with response to treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. Ribavirin 325-334 interferon lambda 3 Homo sapiens 164-169 25755419-1 2012 BACKGROUND: The single nucleotide polymorphism (SNP) of IL28B gene on chromosome 19, encoding for the interferon (IFN)-lambda-3 is strongly associated with treatment response to pegylated-IFN and ribavirin in patients infected with different genotypes of hepatitis C virus (HCV). Ribavirin 196-205 interferon lambda 3 Homo sapiens 56-61 25755419-1 2012 BACKGROUND: The single nucleotide polymorphism (SNP) of IL28B gene on chromosome 19, encoding for the interferon (IFN)-lambda-3 is strongly associated with treatment response to pegylated-IFN and ribavirin in patients infected with different genotypes of hepatitis C virus (HCV). Ribavirin 196-205 interferon lambda 3 Homo sapiens 102-127 25755419-1 2012 BACKGROUND: The single nucleotide polymorphism (SNP) of IL28B gene on chromosome 19, encoding for the interferon (IFN)-lambda-3 is strongly associated with treatment response to pegylated-IFN and ribavirin in patients infected with different genotypes of hepatitis C virus (HCV). Ribavirin 196-205 interferon alpha 1 Homo sapiens 114-117 22641049-1 2012 The IL28B locus attracted the attention of HCV researchers after a series of genome-wide association studies independently identified a strong association between common IL28B polymorphisms and the outcome of PEG-IFN-alpha plus ribavirin combination therapy in patients chronically infected with HCV genotype 1. Ribavirin 228-237 interferon lambda 3 Homo sapiens 4-9 22641049-1 2012 The IL28B locus attracted the attention of HCV researchers after a series of genome-wide association studies independently identified a strong association between common IL28B polymorphisms and the outcome of PEG-IFN-alpha plus ribavirin combination therapy in patients chronically infected with HCV genotype 1. Ribavirin 228-237 interferon lambda 3 Homo sapiens 170-175 22382144-0 2012 LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. Ribavirin 113-116 low density lipoprotein receptor Homo sapiens 0-4 22382144-0 2012 LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. Ribavirin 113-116 interferon lambda 3 Homo sapiens 37-42 22382144-10 2012 CONCLUSION: The LDLr genotype impacts on viral kinetics during the first days of starting treatment with PEG-IFN/RBV in HIV/HCV genotype 1 co-infected patients, and modifies the impact of IL28B on HCV viral decay. Ribavirin 113-116 low density lipoprotein receptor Homo sapiens 16-20 22729189-12 2012 CONCLUSION: In patients with HCV genotypes 2 or 3 infection, a higher SVR was observed in patients receiving Peg-IFN plus RBV related to patients treated with biosimilar standard IFN plus RBV. Ribavirin 188-191 interferon alpha 1 Homo sapiens 113-116 22294644-0 2012 Plasma IL-6 and IL-9 predict the failure of interferon-alpha plus ribavirin therapy in HIV/HCV-coinfected patients. Ribavirin 66-75 interleukin 6 Homo sapiens 7-11 22397984-4 2012 Similarly, pharmacologic inhibition of eIF4E with ribavirin also enhanced tumor cell radiosensitivity. Ribavirin 50-59 eukaryotic translation initiation factor 4E Homo sapiens 39-44 22294644-0 2012 Plasma IL-6 and IL-9 predict the failure of interferon-alpha plus ribavirin therapy in HIV/HCV-coinfected patients. Ribavirin 66-75 interleukin 9 Homo sapiens 16-20 22497812-1 2012 Low-density lipoprotein cholesterol (LDL-C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to peginterferon/ribavirin (pegIFN/RBV) for chronic hepatitis C (CHC) infection. Ribavirin 160-169 interferon lambda 3 Homo sapiens 72-77 22537149-1 2012 IL28B polymorphism is associated with the response to pegylated interferon-alpha with ribavirin (PEG-IFN-alpha/RBV) treatment in chronic hepatitis C patients. Ribavirin 86-95 interferon lambda 3 Homo sapiens 0-5 22497812-1 2012 Low-density lipoprotein cholesterol (LDL-C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to peginterferon/ribavirin (pegIFN/RBV) for chronic hepatitis C (CHC) infection. Ribavirin 178-181 interferon lambda 3 Homo sapiens 72-77 22497812-9 2012 LDL-C remains significantly associated with SVR for heterozygous IL28B genotype patients, where LDL-C and HCV RNA burden may identify those patients with high or low likelihood of cure with pegIFN/RBV therapy. Ribavirin 197-200 interferon lambda 3 Homo sapiens 65-70 22212648-2 2012 Equilibrative nucleoside transporter 1 (ENT1), encoded by SLC29A1 gene, is the main transporter that imports ribavirin into human hepatocytes. Ribavirin 109-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-38 22212648-2 2012 Equilibrative nucleoside transporter 1 (ENT1), encoded by SLC29A1 gene, is the main transporter that imports ribavirin into human hepatocytes. Ribavirin 109-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-44 22212648-2 2012 Equilibrative nucleoside transporter 1 (ENT1), encoded by SLC29A1 gene, is the main transporter that imports ribavirin into human hepatocytes. Ribavirin 109-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-65 22537149-1 2012 IL28B polymorphism is associated with the response to pegylated interferon-alpha with ribavirin (PEG-IFN-alpha/RBV) treatment in chronic hepatitis C patients. Ribavirin 111-114 interferon lambda 3 Homo sapiens 0-5 22416920-0 2012 The expression kinetics of CD137 in chronic hepatitis C patients treated with pegylated-interferon and ribavirin. Ribavirin 103-112 TNF receptor superfamily member 9 Homo sapiens 27-32 32898985-0 2012 Erratum to: "Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin" [J Hepatol 2012;56:34-40]. Ribavirin 142-151 interferon lambda 3 Homo sapiens 13-28 22448788-4 2012 Recent times has seen a major breakthrough in the field with the description of the IL28B genotype as an independent association factor for pegylated IFN-alpha2b/ribavirin treatment response. Ribavirin 162-171 interferon lambda 3 Homo sapiens 84-89 22387386-1 2012 Recent studies showed that two single nucleotide polymorphisms (SNPs) (rs12979860 and rs8099917) near the gene IL28B coding for IFNlambda3 were associated with the antiviral treatment response of the combination therapy of pegIFN plus RBV. Ribavirin 235-238 interferon lambda 3 Homo sapiens 111-116 22387386-1 2012 Recent studies showed that two single nucleotide polymorphisms (SNPs) (rs12979860 and rs8099917) near the gene IL28B coding for IFNlambda3 were associated with the antiviral treatment response of the combination therapy of pegIFN plus RBV. Ribavirin 235-238 interferon lambda 3 Homo sapiens 128-138 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 161-164 CD4 molecule Homo sapiens 76-79 22248659-0 2012 Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. BACKGROUND & AIMS: Although interleukin 28B (interferon, lambda 3) (IL28B) genotype affects the response of patients with chronic hepatitis C to peginterferon and ribavirin, little is known regarding its effect on response to direct-acting antivirals in interferon-free combinations. Ribavirin 287-296 interferon lambda 3 Homo sapiens 152-190 22293330-4 2012 AIM: To correlate the expression of Met-enkephalin immunoreactivity (MEIR) in the liver of patients with chronic hepatitis C with their response to treatment with pegylated interferon and ribavirin. Ribavirin 188-197 proopiomelanocortin Homo sapiens 36-50 21871023-0 2012 Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance. Ribavirin 0-9 inducible T cell co-stimulator Mus musculus 24-46 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 161-164 inducible T cell costimulator Homo sapiens 145-149 21871023-0 2012 Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance. Ribavirin 0-9 CD4 molecule Homo sapiens 50-53 21871023-0 2012 Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance. Ribavirin 0-9 interleukin 10 Homo sapiens 73-87 21871023-1 2012 BACKGROUND AND AIM: The immunological mechanism by which ribavirin (RBV) polarizes the T-helper (Th) 1/2 balance toward Th1 predominancy is not fully understood. Ribavirin 57-66 negative elongation factor complex member C/D Homo sapiens 87-104 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 161-164 interleukin 10 Homo sapiens 206-211 21871023-1 2012 BACKGROUND AND AIM: The immunological mechanism by which ribavirin (RBV) polarizes the T-helper (Th) 1/2 balance toward Th1 predominancy is not fully understood. Ribavirin 57-66 negative elongation factor complex member C/D Homo sapiens 120-123 21871023-1 2012 BACKGROUND AND AIM: The immunological mechanism by which ribavirin (RBV) polarizes the T-helper (Th) 1/2 balance toward Th1 predominancy is not fully understood. Ribavirin 68-71 negative elongation factor complex member C/D Homo sapiens 87-104 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 161-164 heart and neural crest derivatives expressed 2 Mus musculus 265-268 21871023-1 2012 BACKGROUND AND AIM: The immunological mechanism by which ribavirin (RBV) polarizes the T-helper (Th) 1/2 balance toward Th1 predominancy is not fully understood. Ribavirin 68-71 negative elongation factor complex member C/D Homo sapiens 120-123 21871023-2 2012 We therefore examined whether RBV affects costimulatory signaling, which is known to be essential for regulating the Th1/2 balance. Ribavirin 30-33 negative elongation factor complex member C/D Homo sapiens 117-122 21871023-4 2012 RESULTS: In CD4(+) T cells, RBV selectively downmodulates the expression of inducible costimulator (ICOS), a ligand for B7-H2 on dendritic cells, which mainly differentiates Th0 into Th2 cells. Ribavirin 28-31 CD4 antigen Mus musculus 12-15 22351942-5 2012 Baseline CD16(+)56(-) NK IFN-alphaR expression was associated with IFN-alpha-induced pSTAT1, and both were associated with magnitude of HCV decrease during pegylated IFN-alpha plus ribavirin therapy. Ribavirin 181-190 Fc gamma receptor IIIa Homo sapiens 9-13 22351942-5 2012 Baseline CD16(+)56(-) NK IFN-alphaR expression was associated with IFN-alpha-induced pSTAT1, and both were associated with magnitude of HCV decrease during pegylated IFN-alpha plus ribavirin therapy. Ribavirin 181-190 interferon alpha 1 Homo sapiens 25-34 21871023-6 2012 An analysis of the association between ICOS kinetics and hepatitis C virus (HCV) elimination in hepatitis C patients receiving combined pegylated interferon and RBV indicated that HCV elimination tended to occur more frequently in patients showing ICOS downmodulation with RBV treatment. Ribavirin 161-164 inducible T cell costimulator Homo sapiens 39-43 21871023-4 2012 RESULTS: In CD4(+) T cells, RBV selectively downmodulates the expression of inducible costimulator (ICOS), a ligand for B7-H2 on dendritic cells, which mainly differentiates Th0 into Th2 cells. Ribavirin 28-31 inducible T cell co-stimulator Mus musculus 76-98 21871023-4 2012 RESULTS: In CD4(+) T cells, RBV selectively downmodulates the expression of inducible costimulator (ICOS), a ligand for B7-H2 on dendritic cells, which mainly differentiates Th0 into Th2 cells. Ribavirin 28-31 inducible T cell co-stimulator Mus musculus 100-104 21871023-6 2012 An analysis of the association between ICOS kinetics and hepatitis C virus (HCV) elimination in hepatitis C patients receiving combined pegylated interferon and RBV indicated that HCV elimination tended to occur more frequently in patients showing ICOS downmodulation with RBV treatment. Ribavirin 161-164 inducible T cell costimulator Homo sapiens 248-252 21871023-4 2012 RESULTS: In CD4(+) T cells, RBV selectively downmodulates the expression of inducible costimulator (ICOS), a ligand for B7-H2 on dendritic cells, which mainly differentiates Th0 into Th2 cells. Ribavirin 28-31 heart and neural crest derivatives expressed 2 Mus musculus 183-186 22357660-0 2012 Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8. Ribavirin 0-9 C-X-C motif chemokine ligand 8 Homo sapiens 100-113 21871023-6 2012 An analysis of the association between ICOS kinetics and hepatitis C virus (HCV) elimination in hepatitis C patients receiving combined pegylated interferon and RBV indicated that HCV elimination tended to occur more frequently in patients showing ICOS downmodulation with RBV treatment. Ribavirin 273-276 inducible T cell costimulator Homo sapiens 39-43 22357660-6 2012 Such enhancement depended on autocrine IFN-beta being enhanced by RBV. Ribavirin 66-69 interferon beta 1 Homo sapiens 39-47 22357660-7 2012 RBV upregulated interleukin 8 (IL-8) in the absence of IFN-alpha. Ribavirin 0-3 C-X-C motif chemokine ligand 8 Homo sapiens 16-29 22357660-7 2012 RBV upregulated interleukin 8 (IL-8) in the absence of IFN-alpha. Ribavirin 0-3 C-X-C motif chemokine ligand 8 Homo sapiens 31-35 22357660-8 2012 The IL-8 upregulation induced by RBV was responsible for the activation of activator protein 1 (AP-1). Ribavirin 33-36 C-X-C motif chemokine ligand 8 Homo sapiens 4-8 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 61-64 interleukin 10 Homo sapiens 24-38 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 61-64 interleukin 10 Homo sapiens 40-45 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 61-64 CD4 molecule Homo sapiens 76-79 22357660-8 2012 The IL-8 upregulation induced by RBV was responsible for the activation of activator protein 1 (AP-1). Ribavirin 33-36 JunB proto-oncogene, AP-1 transcription factor subunit Homo sapiens 75-94 21871023-6 2012 An analysis of the association between ICOS kinetics and hepatitis C virus (HCV) elimination in hepatitis C patients receiving combined pegylated interferon and RBV indicated that HCV elimination tended to occur more frequently in patients showing ICOS downmodulation with RBV treatment. Ribavirin 273-276 inducible T cell costimulator Homo sapiens 248-252 22357660-8 2012 The IL-8 upregulation induced by RBV was responsible for the activation of activator protein 1 (AP-1). Ribavirin 33-36 JunB proto-oncogene, AP-1 transcription factor subunit Homo sapiens 96-100 22357660-9 2012 CONCLUSIONS: Ribavirin augments the anti-HCV effects of IFN-alpha induced by ISGs through enhancing autocrine IFN-beta. Ribavirin 13-22 interferon alpha 1 Homo sapiens 56-65 21871023-8 2012 CONCLUSIONS: The downmodulation of ICOS in correlation with a reduction in IL-10 produced by CD4(+) T cells is possibly the immunological mechanism of action of RBV, which polarizes the Th1/2 balance toward a Th1 cytokine profile, thus contributing to the elimination of cells chronically infected with HCV. Ribavirin 161-164 inducible T cell costimulator Homo sapiens 35-39 22357660-9 2012 CONCLUSIONS: Ribavirin augments the anti-HCV effects of IFN-alpha induced by ISGs through enhancing autocrine IFN-beta. Ribavirin 13-22 interferon beta 1 Homo sapiens 110-118 21871023-8 2012 CONCLUSIONS: The downmodulation of ICOS in correlation with a reduction in IL-10 produced by CD4(+) T cells is possibly the immunological mechanism of action of RBV, which polarizes the Th1/2 balance toward a Th1 cytokine profile, thus contributing to the elimination of cells chronically infected with HCV. Ribavirin 161-164 interleukin 10 Homo sapiens 75-80 22357660-10 2012 Moreover, RBV can enhance IL-8 through activating AP-1. Ribavirin 10-13 C-X-C motif chemokine ligand 8 Homo sapiens 26-30 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 61-64 inducible T cell costimulator Homo sapiens 145-149 22357660-10 2012 Moreover, RBV can enhance IL-8 through activating AP-1. Ribavirin 10-13 JunB proto-oncogene, AP-1 transcription factor subunit Homo sapiens 50-54 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 61-64 interleukin 10 Homo sapiens 206-211 21871023-8 2012 CONCLUSIONS: The downmodulation of ICOS in correlation with a reduction in IL-10 produced by CD4(+) T cells is possibly the immunological mechanism of action of RBV, which polarizes the Th1/2 balance toward a Th1 cytokine profile, thus contributing to the elimination of cells chronically infected with HCV. Ribavirin 161-164 CD4 molecule Homo sapiens 93-96 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 61-64 heart and neural crest derivatives expressed 2 Mus musculus 265-268 21871023-8 2012 CONCLUSIONS: The downmodulation of ICOS in correlation with a reduction in IL-10 produced by CD4(+) T cells is possibly the immunological mechanism of action of RBV, which polarizes the Th1/2 balance toward a Th1 cytokine profile, thus contributing to the elimination of cells chronically infected with HCV. Ribavirin 161-164 negative elongation factor complex member C/D Homo sapiens 186-191 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 161-164 interleukin 10 Homo sapiens 24-38 21871023-5 2012 Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. Ribavirin 161-164 interleukin 10 Homo sapiens 40-45 21871023-8 2012 CONCLUSIONS: The downmodulation of ICOS in correlation with a reduction in IL-10 produced by CD4(+) T cells is possibly the immunological mechanism of action of RBV, which polarizes the Th1/2 balance toward a Th1 cytokine profile, thus contributing to the elimination of cells chronically infected with HCV. Ribavirin 161-164 negative elongation factor complex member C/D Homo sapiens 186-189 22324288-8 2012 Treatment with PEG-IFN-alfa and ribavirin resulted in increases in the expression of CD11b and CD18, and decreases of CD16 and CD62L. Ribavirin 32-41 integrin subunit alpha M Homo sapiens 85-90 22404724-3 2012 This study evaluated durability of virologic response over 5 years in children previously treated with interferon alfa-2b plus ribavirin (IFN/R). Ribavirin 127-136 interferon production regulator Homo sapiens 138-143 22324288-8 2012 Treatment with PEG-IFN-alfa and ribavirin resulted in increases in the expression of CD11b and CD18, and decreases of CD16 and CD62L. Ribavirin 32-41 integrin subunit beta 2 Homo sapiens 95-99 22483497-6 2012 The preemptive IFN/RBV protocol initiated treatment promptly after improvement in the patient"s general condition with a low-dose IFN alpha2b and RBV (400 mg/d) followed by a gradual increase in the INFalpha2b dosage. Ribavirin 19-22 interferon alpha 1 Homo sapiens 130-133 22324288-8 2012 Treatment with PEG-IFN-alfa and ribavirin resulted in increases in the expression of CD11b and CD18, and decreases of CD16 and CD62L. Ribavirin 32-41 Fc gamma receptor IIIa Homo sapiens 118-122 22483497-6 2012 The preemptive IFN/RBV protocol initiated treatment promptly after improvement in the patient"s general condition with a low-dose IFN alpha2b and RBV (400 mg/d) followed by a gradual increase in the INFalpha2b dosage. Ribavirin 146-149 interferon alpha 1 Homo sapiens 15-18 22324288-8 2012 Treatment with PEG-IFN-alfa and ribavirin resulted in increases in the expression of CD11b and CD18, and decreases of CD16 and CD62L. Ribavirin 32-41 selectin L Homo sapiens 127-132 22269828-7 2012 Ribavirin treatment leads to a Th1 cytokine response while oseltamivir leads to a Th2 cytokine response with significant increase in the levels of the anti-inflammatory cytokine IL-10. Ribavirin 0-9 negative elongation factor complex member C/D, Th1l Mus musculus 31-34 22232287-0 2012 ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system. Ribavirin 8-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 22616502-5 2012 Additionally, the study of variants of IL28 helps in the identification of patients with more chances of response to the treatment of hepatitis C with interferon and ribavirin. Ribavirin 166-175 interferon lambda 3 Homo sapiens 39-43 22232287-2 2012 However, because the role of this transporter in the antiviral mechanism of the drug remains unclear, the present study aimed to elucidate the role of ENT1 in ribavirin antiviral action. Ribavirin 159-168 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 151-155 22232287-5 2012 Nitrobenzylmercaptopurine riboside (NBMPR) and micro-RNA targeted to ENT1 mRNA (miR-ENT1) were used to reduce the ribavirin uptake level in OR6 cells. Ribavirin 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-73 22232287-5 2012 Nitrobenzylmercaptopurine riboside (NBMPR) and micro-RNA targeted to ENT1 mRNA (miR-ENT1) were used to reduce the ribavirin uptake level in OR6 cells. Ribavirin 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-88 22232287-7 2012 It was found that the primary ribavirin transporter in OR6 cells was ENT1 and that inhibition of ENT1-mediated ribavirin uptake by NBMPR significantly attenuated the antiviral activity of the drug as well as its accumulation in OR6 cells. Ribavirin 30-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-73 22232287-7 2012 It was found that the primary ribavirin transporter in OR6 cells was ENT1 and that inhibition of ENT1-mediated ribavirin uptake by NBMPR significantly attenuated the antiviral activity of the drug as well as its accumulation in OR6 cells. Ribavirin 30-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-101 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 73-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 59-63 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 73-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-127 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 73-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-127 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 225-234 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 59-63 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 225-234 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-127 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 225-234 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-127 22232287-9 2012 In conclusion, our results show that by facilitating its uptake and accumulation in OR6 cells, ENT1 plays a pivotal role in the antiviral effectiveness of ribavirin and therefore provides an important insight into the efficacy of the drug in anti-HCV therapy. Ribavirin 155-164 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-99 22594992-2 2012 We investigate the effect of IL4 C-590T and C-33T polymorphisms on the response to combination therapy with interferon and ribavirin in chronic HCV patients. Ribavirin 123-132 interleukin 4 Homo sapiens 29-32 22181672-1 2012 AIM: A genetic polymorphism of inosine triphosphate pyrophosphatase (ITPA) has been associated with pegylated-interferon/ribavirin (PEG-IFN/RBV)-induced anemia in chronic hepatitis C patients. Ribavirin 123-132 inosine triphosphatase Homo sapiens 71-75 22154462-1 2012 The combination of pegylated interferon-alpha2b (PEG-IFNalpha) and ribavirin (RBV) is a standard treatment for chronic hepatitis C. The case of a patient with chronic hepatitis C who developed Hashitoxicosis followed by type 1 diabetes mellitus (T1DM) with PEG-IFNalpha plus RBV combination therapy, but not IFNalpha alone, is presented. Ribavirin 275-278 interferon alpha 2 Homo sapiens 29-47 22181672-1 2012 AIM: A genetic polymorphism of inosine triphosphate pyrophosphatase (ITPA) has been associated with pegylated-interferon/ribavirin (PEG-IFN/RBV)-induced anemia in chronic hepatitis C patients. Ribavirin 142-145 inosine triphosphatase Homo sapiens 71-75 22168813-4 2012 A correlated set of polymorphisms in the region of the interleukin-28B (IL-28B) gene on chromosome 19, coding for interferon (IFN)-lambda3 were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with PEG-IFN-alpha and RBV. Ribavirin 251-254 interferon lambda 3 Homo sapiens 72-78 22298085-1 2012 BACKGROUND AND AIM: Data concerning the influence of insulin resistance (IR) and ethnicity on early phases of viral kinetics after initiation of peginterferon plus ribavirin in treatment-naive, chronic hepatitis C (CHC) patients are limited. Ribavirin 164-173 insulin Homo sapiens 53-60 21951981-0 2012 IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections. Ribavirin 250-259 interferon lambda 3 Homo sapiens 0-5 21951981-0 2012 IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections. Ribavirin 250-259 interferon lambda 3 Homo sapiens 164-183 22027585-1 2012 BACKGROUND & AIMS: We studied the relationship between IL28B gene-related SNP rs12979860 and early viral kinetics (day 0-28) during peginterferon and ribavirin treatment, in 173 African Americans (AA) and 188 Caucasian Americans (CA) with HCV genotype 1. Ribavirin 154-163 interferon lambda 3 Homo sapiens 59-64 22511902-0 2012 Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients. Ribavirin 106-115 glutamic--pyruvic transaminase Homo sapiens 23-47 22457865-2 2012 We report the case of a 55-year old woman under treatment with Pegylated alpha 2a interferon (IFN) and Ribavirin for chronic viral C hepatitis, who developed a progressive severe haemorrhagic syndrome diagnosed as acquired haemophilia based on supplementary laboratory data (prolonged activated partial thromboplastin time, extremely low factor VIII level - 1%, high titre of factor VIII inhibitor - 30 Bethesda U/ml).The onset was insidious, about three months before presenting to our unit. Ribavirin 103-112 cytochrome c oxidase subunit 8A Homo sapiens 345-349 22457865-2 2012 We report the case of a 55-year old woman under treatment with Pegylated alpha 2a interferon (IFN) and Ribavirin for chronic viral C hepatitis, who developed a progressive severe haemorrhagic syndrome diagnosed as acquired haemophilia based on supplementary laboratory data (prolonged activated partial thromboplastin time, extremely low factor VIII level - 1%, high titre of factor VIII inhibitor - 30 Bethesda U/ml).The onset was insidious, about three months before presenting to our unit. Ribavirin 103-112 cytochrome c oxidase subunit 8A Homo sapiens 383-387 22246829-0 2012 Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin. Ribavirin 235-244 interferon lambda 3 Homo sapiens 139-154 22158703-0 2012 Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. Ribavirin 42-51 inosine triphosphatase Homo sapiens 16-20 22313623-0 2012 The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. Ribavirin 141-150 interferon lambda 3 Homo sapiens 14-19 22313623-1 2012 BACKGROUND: Recent studies of CH-C patients have demonstrated a strong association between IL28B CC genotype and sustained virologic response (SVR) after PEG-IFN/RBV treatment. Ribavirin 162-165 interferon lambda 3 Homo sapiens 91-96 22313623-2 2012 We aimed to assess whether IL28B alleles rs12979860 genotype influences gene expression in response to PEG-IFN/RBV in CH-C patients. Ribavirin 111-114 interferon lambda 3 Homo sapiens 27-32 22313623-16 2012 These data may provide some mechanistic explanation for higher rate of SVR in IL28B CC patients who are treated with PEG-IFN/RBV. Ribavirin 125-128 interferon lambda 3 Homo sapiens 78-83 21932415-0 2012 Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Ribavirin 64-73 interferon lambda 3 Homo sapiens 0-15 21932415-1 2012 UNLABELLED: Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection. Ribavirin 200-209 interferon lambda 3 Homo sapiens 60-75 21932415-1 2012 UNLABELLED: Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection. Ribavirin 200-209 interferon lambda 3 Homo sapiens 77-82 21932415-1 2012 UNLABELLED: Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection. Ribavirin 211-214 interferon lambda 3 Homo sapiens 60-75 21932415-1 2012 UNLABELLED: Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection. Ribavirin 211-214 interferon lambda 3 Homo sapiens 77-82 21932415-3 2012 The aim was to investigate the predictive power of the rs12979860 IL28B SNP for a response to Peg-IFN and Rbv in HCV-4 patients. Ribavirin 106-109 interferon lambda 3 Homo sapiens 66-71 21932415-11 2012 CONCLUSION: The IL28B rs12979860 SNP may have an added value in the treatment algorithm of HCV-4 patients because it is the strongest predictor of an SVR to PegIFN/Rbv therapy. Ribavirin 164-167 interferon lambda 3 Homo sapiens 16-21 22475143-5 2012 RESULTS: Fifty-two (26.80%) of 194 peg-IFNa-2a/RBV-treated patients developed thyroid dysfunction. Ribavirin 47-50 interferon alpha 2 Homo sapiens 39-43 22038554-3 2012 This drug has few side effects and reinforces the effect of IFN when administered in combination with peg-IFN and ribavirin. Ribavirin 114-123 interferon alpha 1 Homo sapiens 60-63 22158703-1 2012 BACKGROUND: A recent genome-wide association study reported a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate (ITPA) gene and hemolytic anemia in patients infected with hepatitis C virus (HCV) receiving pegylated interferon and ribavirin. Ribavirin 271-280 inosine triphosphatase Homo sapiens 154-158 22158703-12 2012 CONCLUSIONS: This study confirms that polymorphisms in the ITPA gene are associated with protection from RBV-induced anemia in HIV/HCV-coinfected patients but not improved clinical outcomes. Ribavirin 105-108 inosine triphosphatase Homo sapiens 59-63 22129484-6 2012 The transcription of Lin28B is promoted by NF-kappaB and by Myc; hence, practical measures which antagonize NF-kappaB or Myc activity may complement the utility of metformin for boosting let-7 expression and controlling cancer stemness; salsalate, antioxidants, tyrosine kinase and cox-2 inhibitors, ribavirin, vitamin D, gamma-secretase inhibitors (when available), and parenteral curcumin may have some utility in this regard. Ribavirin 300-309 lin-28 homolog B Mus musculus 21-27 22212565-5 2012 Furthermore, the important role of host polymorphisms of the IL28B gene on virological response to treatment with pegylated interferon (PEG-IFN) alpha and ribavirin (RBV) has recently been clearly demonstrated. Ribavirin 155-164 interferon lambda 3 Homo sapiens 61-66 22212570-4 2012 Although data sets were not complete, patients with IL28B CT and TT genotype appear to significantly improve when these agents are combined with PEG-INF and RBV. Ribavirin 157-160 interferon lambda 3 Homo sapiens 52-57 22212576-1 2012 An association between variations at the IL28B gene locus and HCV clearance (spontaneous recovery or sustained virological response under pegylated interferon (PEG-IFN) and ribavirin (RBV) has been extensively described. Ribavirin 173-182 interferon lambda 3 Homo sapiens 41-46 22239497-4 2012 Recent evidence points to a beneficial role of recombinant erythropoietin (EPO) in alleviating ribavirin-induced anaemia thereby improving quality of life, enabling higher ribavirin dosage and consequently improving SVR. Ribavirin 95-104 erythropoietin Homo sapiens 59-73 22239497-4 2012 Recent evidence points to a beneficial role of recombinant erythropoietin (EPO) in alleviating ribavirin-induced anaemia thereby improving quality of life, enabling higher ribavirin dosage and consequently improving SVR. Ribavirin 95-104 erythropoietin Homo sapiens 75-78 22239497-4 2012 Recent evidence points to a beneficial role of recombinant erythropoietin (EPO) in alleviating ribavirin-induced anaemia thereby improving quality of life, enabling higher ribavirin dosage and consequently improving SVR. Ribavirin 172-181 erythropoietin Homo sapiens 59-73 22239497-4 2012 Recent evidence points to a beneficial role of recombinant erythropoietin (EPO) in alleviating ribavirin-induced anaemia thereby improving quality of life, enabling higher ribavirin dosage and consequently improving SVR. Ribavirin 172-181 erythropoietin Homo sapiens 75-78 22239497-7 2012 A consensus was reached recommending the use of EPO for patients infected with viral genotype 1 developing significant anaemia below 100 g/L haemoglobin and a haematocrit of <30% during standard therapy to improve quality of life and sustain optimal ribavirin dose. Ribavirin 253-262 erythropoietin Homo sapiens 48-51 22239498-0 2012 Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis. Ribavirin 80-89 erythropoietin Homo sapiens 10-24 22239499-12 2012 We developed a model that could identify non-RVR patients at high risk for relapse after 48 weeks of peginterferon alfa-2a plus ribavirin and who may benefit from intensified therapy to reduce this risk of relapse. Ribavirin 128-137 nuclear receptor subfamily 1 group D member 2 Homo sapiens 45-48 22239510-0 2012 Serum PAI-1 is a novel predictor for response to pegylated interferon-alpha-2b plus ribavirin therapy in chronic hepatitis C virus infection. Ribavirin 84-93 serpin family E member 1 Homo sapiens 6-11 22212576-1 2012 An association between variations at the IL28B gene locus and HCV clearance (spontaneous recovery or sustained virological response under pegylated interferon (PEG-IFN) and ribavirin (RBV) has been extensively described. Ribavirin 184-187 interferon lambda 3 Homo sapiens 41-46 22212576-2 2012 In genotype 1-infected patients, the new direct antiviral agents (DAA) including the two approved protease inhibitors boceprevir and telaprevir, in association with the PEG-IFN/RBV combination is the new standard of care making it necessary to redefine the interest of the IL28B genotype in the decision to treat and how to treat genotype 1-infected patients. Ribavirin 177-180 interferon lambda 3 Homo sapiens 273-278 22212579-4 2012 However, early clinical studies provide strong evidence for a benefit of RBV in combination with DAAs for both IFN containing and sparing regimens. Ribavirin 73-76 interferon alpha 1 Homo sapiens 111-114 22212584-10 2012 The role of the IL28B polymorphism as a predictor of response to the current standard of care (SoC), PEG-IFN and RBV treatment is the subject of debate, but this mainly seems to be because of the small size of the samples in the studies performed so far. Ribavirin 113-116 interferon lambda 3 Homo sapiens 16-21 22052088-0 2012 Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection. Ribavirin 86-95 interferon lambda 3 Homo sapiens 0-15 22052088-2 2012 The present study investigated the relationship between IL-28 genotypes and the virological response to PEG-IFN/RBV therapy at 24 and 48 weeks. Ribavirin 112-115 interferon lambda 3 Homo sapiens 56-61 22052088-10 2012 The IL-28B genotype is a significant pre-treatment predictor of the response to PEG-IFN/RBV therapy at 48 weeks in patients with HCV infection. Ribavirin 88-91 interferon lambda 3 Homo sapiens 4-10 22052220-2 2012 In the present study, we investigated the association of inosine triphosphate pyrophosphatase (ITPA) genotypes with RBV-induced hemoglobin (Hb) reduction in HCV patients treated with PEG-IFN/RBV therapy. Ribavirin 116-119 inosine triphosphatase Homo sapiens 95-99 22052220-11 2012 In conclusion, the ITPA genotypes may be a useful marker for prediction of RBV-induced anemia. Ribavirin 75-78 inosine triphosphatase Homo sapiens 19-23 22129484-6 2012 The transcription of Lin28B is promoted by NF-kappaB and by Myc; hence, practical measures which antagonize NF-kappaB or Myc activity may complement the utility of metformin for boosting let-7 expression and controlling cancer stemness; salsalate, antioxidants, tyrosine kinase and cox-2 inhibitors, ribavirin, vitamin D, gamma-secretase inhibitors (when available), and parenteral curcumin may have some utility in this regard. Ribavirin 300-309 myelocytomatosis oncogene Mus musculus 121-124 22924160-0 2012 Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin. Ribavirin 151-160 interferon lambda 3 Homo sapiens 33-38 22924160-9 2012 CONCLUSIONS: These data suggest that age, HCV genotype and IL28B polymorphism are useful for prediction of the response to treatment with Peg-IFN-alpha and ribavirin. Ribavirin 156-165 interferon lambda 3 Homo sapiens 59-64 22536498-9 2012 For example, patients infected with HCV genotype 2/3 with a certain IL-28B polymorphism can be treated with a shorter course of interferon and ribavirin which can also help reduce costs. Ribavirin 143-152 interferon lambda 3 Homo sapiens 68-74 22809728-2 2012 Polymorphisms in the ITPA gene protect against ribavirin-induced anaemia. Ribavirin 47-56 inosine triphosphatase Homo sapiens 21-25 22300892-3 2012 The aims of the study were to assess safety, tolerability and virological response in patients who were previous PEG-IFN-alpha/ribavirin non-responders. Ribavirin 127-136 interferon alpha 1 Homo sapiens 117-120 22809728-3 2012 The maximum dosage of ribavirin that can be tolerated by patients with different ITPA polymorphisms remains unknown. Ribavirin 22-31 inosine triphosphatase Homo sapiens 81-85 22898703-0 2012 Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. Ribavirin 161-170 interferon lambda 3 Homo sapiens 0-15 22809728-10 2012 Patients with moderate ITPA deficiency are predicted to tolerate twice the ribavirin dosage as patients with wild-type ITPA. Ribavirin 75-84 inosine triphosphatase Homo sapiens 23-27 22481965-3 2012 In this study, we investigated the association between serum B-cell-activating factor belonging to the TNF family (BAFF) levels and the presence of antithyroid peroxidase antibody (anti-TPO) in CHC patients treated with pegylated interferon alpha and ribavirin combination therapy. Ribavirin 251-260 TNF superfamily member 13b Homo sapiens 61-85 22951364-8 2012 RESULTS: In our assay, the degree of haemolysis is dependent on the ribavirin concentration used and can be inhibited by the addition of dipyridamole (50% inhibitory concentration [IC(50)] 30 muM), ATP or glutathione (IC(50) 1.63 mM and 767 muM, respectively). Ribavirin 68-77 latexin Homo sapiens 192-195 22951364-8 2012 RESULTS: In our assay, the degree of haemolysis is dependent on the ribavirin concentration used and can be inhibited by the addition of dipyridamole (50% inhibitory concentration [IC(50)] 30 muM), ATP or glutathione (IC(50) 1.63 mM and 767 muM, respectively). Ribavirin 68-77 latexin Homo sapiens 241-244 22481680-8 2012 CONCLUSION: Heterozigozity for H63D and/or C282Y HFE gene mutation predicts absence of sustained virological response to combination treatment with interferon and ribavirin in patients with chronic hepatitis C, non-1 genotype and serum ferritin levels above 500 ng/mL. Ribavirin 163-172 homeostatic iron regulator Homo sapiens 49-52 21933670-1 2012 OBJECTIVES: To explore the impact of response to interferon and ribavirin antiviral therapy on human growth hormone (hGH) levels in Egyptian chronic hepatitis C genotype-4 infected patients. Ribavirin 64-73 growth hormone 1 Homo sapiens 101-115 21933670-8 2012 Besides, we found that response to interferon/ribavirin treatment has an impact on growth hormone levels. Ribavirin 46-55 growth hormone 1 Homo sapiens 83-97 22300961-0 2012 The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. Ribavirin 93-102 bile acid-CoA:amino acid N-acyltransferase Homo sapiens 28-31 22300961-11 2012 CONCLUSIONS: NR1I1 vitamin D receptor polymorphisms influence response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C and exert an additive genetic predisposition to previously described low 25-OH vitamin D serum levels. Ribavirin 95-104 vitamin D receptor Homo sapiens 13-18 22301466-0 2012 Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Ribavirin 145-154 interferon lambda 3 Homo sapiens 0-15 22301466-1 2012 BACKGROUND: Interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and viral factors can predict sustained virological response (SVR) in HCV genotype-1 (HCV-1) patients receiving 48 weeks of pegylated interferon and ribavirin. Ribavirin 232-241 interferon lambda 3 Homo sapiens 12-27 22301466-1 2012 BACKGROUND: Interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and viral factors can predict sustained virological response (SVR) in HCV genotype-1 (HCV-1) patients receiving 48 weeks of pegylated interferon and ribavirin. Ribavirin 232-241 interferon lambda 3 Homo sapiens 29-34 22481965-3 2012 In this study, we investigated the association between serum B-cell-activating factor belonging to the TNF family (BAFF) levels and the presence of antithyroid peroxidase antibody (anti-TPO) in CHC patients treated with pegylated interferon alpha and ribavirin combination therapy. Ribavirin 251-260 TNF superfamily member 13b Homo sapiens 115-119 23258094-4 2012 This retrospective study examined the efficacy of retreatment with PEG-IFNalpha-2a + RBV by evaluating the time to eradication of hepatitis C virus RNA, early virological response (EVR), and SVR. Ribavirin 83-88 interferon alpha 1 Homo sapiens 71-79 22103907-0 2012 Pegylated interferon alpha-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase. Ribavirin 35-44 glutamic--pyruvic transaminase Homo sapiens 99-123 22126968-0 2012 Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C. INTRODUCTION: Combination therapy with pegylated interferon alpha (Peg-interferon) and ribavirin is currently the cornerstone of antiviral therapy for chronic hepatitis C. Monotherapy with Peg-interferon still is important for the treatment of chronic hepatitis B. Ribavirin 207-216 interferon alpha 2 Homo sapiens 19-38 21898478-2 2012 Recently, single nucleotide polymorphisms (SNPs) of IL28B and host response to peginterferon alpha (PEG-IFNalpha) and ribavirin (RBV) were shown to be strongly associated. Ribavirin 118-127 interferon lambda 3 Homo sapiens 52-57 21932410-1 2012 UNLABELLED: Pegylated interferon-alpha2/ribavirin (peg-IFN/RBV) is the standard of care (SOC) for patients with chronic hepatitis C (CHC) infection. Ribavirin 40-49 interferon alpha 1 Homo sapiens 55-58 21932410-1 2012 UNLABELLED: Pegylated interferon-alpha2/ribavirin (peg-IFN/RBV) is the standard of care (SOC) for patients with chronic hepatitis C (CHC) infection. Ribavirin 59-62 interferon alpha 2 Homo sapiens 22-39 21564352-2 2012 To our knowledge, this is the first case report of a patient who developed simultaneously subacute cutaneous lupus erythematosus and a small CD20+ B-cell clone because of chronic HCV infection and relapse after standard of care therapy (pegylated interferon plus ribavirin). Ribavirin 263-272 keratin 20 Homo sapiens 141-145 22989839-0 2012 New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C. A 60-year-old woman developed type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis during type 1 interferon therapies for chronic hepatitis C. The diabetes mellitus was elicited by interferon-alpha plus ribavirin therapy, while the optic neuritis was induced after interferon-beta treatment, followed by interferon-alpha and ribavirin therapy. Ribavirin 385-394 aquaporin 4 Homo sapiens 44-55 22989839-0 2012 New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C. A 60-year-old woman developed type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis during type 1 interferon therapies for chronic hepatitis C. The diabetes mellitus was elicited by interferon-alpha plus ribavirin therapy, while the optic neuritis was induced after interferon-beta treatment, followed by interferon-alpha and ribavirin therapy. Ribavirin 507-516 aquaporin 4 Homo sapiens 44-55 21898478-2 2012 Recently, single nucleotide polymorphisms (SNPs) of IL28B and host response to peginterferon alpha (PEG-IFNalpha) and ribavirin (RBV) were shown to be strongly associated. Ribavirin 129-132 interferon lambda 3 Homo sapiens 52-57 21898478-11 2012 CONCLUSION: Gene expression involving innate immunity is strongly associated with IL28B genotype and response to PEG-IFNalpha/RBV. Ribavirin 126-129 interferon lambda 3 Homo sapiens 82-87 21898478-11 2012 CONCLUSION: Gene expression involving innate immunity is strongly associated with IL28B genotype and response to PEG-IFNalpha/RBV. Ribavirin 126-129 interferon alpha 1 Homo sapiens 117-125 21293098-1 2012 OBJECTIVE: Hepatitis C virus (HCV genome) polymorphisms are thought to influence the outcome of pegylated-interferon/ribavirin (PEG-IFN/RBV) therapy. Ribavirin 117-126 interferon alpha 1 Homo sapiens 132-139 21325786-0 2012 Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Ribavirin 144-153 interferon lambda 3 Homo sapiens 74-79 21325786-1 2012 OBJECTIVES: Genetic variation near the IL28B gene and substitution of aa 70 and 91 in the core region of HCV-1b are useful as predictors of treatment efficacy to telaprevir/pegylated interferon (PEG-IFN)/ribavirin, but its impact on viral dynamics is not clear. Ribavirin 204-213 interferon lambda 3 Homo sapiens 39-44 21734353-0 2012 Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Ribavirin 131-140 interferon lambda 3 Homo sapiens 75-80 21734353-10 2012 CONCLUSION: aa substitution in core/NS5A region and genetic variation near IL28B were important predictors of treatment efficacy to IFN/ribavirin. Ribavirin 136-145 interferon lambda 3 Homo sapiens 75-80 21734353-10 2012 CONCLUSION: aa substitution in core/NS5A region and genetic variation near IL28B were important predictors of treatment efficacy to IFN/ribavirin. Ribavirin 136-145 interferon alpha 1 Homo sapiens 132-135 21703176-0 2012 Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. Ribavirin 129-138 interferon lambda 3 Homo sapiens 0-15 21703176-3 2012 METHODS: Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks peginterferon/ribavirin. Ribavirin 109-118 interferon lambda 3 Homo sapiens 9-24 21934116-3 2012 CASE: Peginterferon-alpha and ribavirin (RBV) were initiated to treat hepatitis C virus (HCV) infection in an HIV-infected patient with high CD4 counts having discontinued antiretroviral therapy (ART). Ribavirin 30-39 CD4 molecule Homo sapiens 141-144 21934116-3 2012 CASE: Peginterferon-alpha and ribavirin (RBV) were initiated to treat hepatitis C virus (HCV) infection in an HIV-infected patient with high CD4 counts having discontinued antiretroviral therapy (ART). Ribavirin 41-44 CD4 molecule Homo sapiens 141-144 22095536-0 2012 Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b. Ribavirin 66-75 interferon lambda 3 Homo sapiens 136-141 21990051-10 2012 CONCLUSIONS: The IL-28B genotype impacts on viral kinetics during the first week of treatment with PEG-IFN/RBV in patients with HCV genotype 1/4. Ribavirin 107-110 interferon lambda 3 Homo sapiens 17-23 21879313-1 2012 Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection. Ribavirin 103-106 interferon lambda 3 Homo sapiens 179-194 22785017-9 2012 At the end of the disease, we have observed reactive GFAP(+) and vimentin(+) astrocytes in both immunized and ribavirin-treated groups, accompanied by increased level of GFAP mRNA. Ribavirin 110-119 glial fibrillary acidic protein Rattus norvegicus 53-57 22785017-9 2012 At the end of the disease, we have observed reactive GFAP(+) and vimentin(+) astrocytes in both immunized and ribavirin-treated groups, accompanied by increased level of GFAP mRNA. Ribavirin 110-119 vimentin Rattus norvegicus 65-73 22785017-9 2012 At the end of the disease, we have observed reactive GFAP(+) and vimentin(+) astrocytes in both immunized and ribavirin-treated groups, accompanied by increased level of GFAP mRNA. Ribavirin 110-119 glial fibrillary acidic protein Rattus norvegicus 170-174 22635082-2 2012 CASE PRESENTATION: We present a 38-year-old woman who has been treated with combined pegylated interferon alpha (INF-alpha) and Ribavirin for chronic hepatitis C. Destructive thyrotoxicosis appeared after four months of continuous IFN-alpha therapy and a beta blocker was prescribed. Ribavirin 128-137 interferon alpha 1 Homo sapiens 231-240 21879313-1 2012 Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection. Ribavirin 326-329 interferon lambda 3 Homo sapiens 179-194 23284866-11 2012 CONCLUSIONS: Sequential rapid stopping rules using on-treatment virological responses and interleukin-28B genotype can rapidly identify additional peginterferon/ribavirin non-responders. Ribavirin 161-170 interferon lambda 3 Homo sapiens 90-105 23133602-15 2012 CONCLUSIONS: In HCV-HIV coinfected patients treated with PegIFNalpha and ribavirin, SVR is associated with IL28B rs8099917 polymorphism. Ribavirin 73-82 interferon lambda 3 Homo sapiens 107-112 23173032-1 2012 BACKGROUND & AIMS: A combination of pegylated interferon-alpha and ribavirin (PR) is the standard therapy for patients with chronic hepatitis C. The impact of polymorphism of interleukin-28B (IL28B) on sustained virological response (SVR) to PR has been well documented in patients with CHC genotype-1 (GT1), but it is controversial in genotype-2 (GT2) CHC patients. Ribavirin 71-80 interferon lambda 3 Homo sapiens 179-194 23133528-2 2012 Insulin resistance seems to interact with hepatitis C promoting fibrosis progression and impairing sustained virological response to peginterferon and ribavirin. Ribavirin 151-160 insulin Homo sapiens 0-7 22962590-0 2012 Ribavirin enhances the action of interferon-alpha against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway. Ribavirin 0-9 tumor protein p53 Homo sapiens 93-96 23029188-0 2012 Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. Ribavirin 84-93 interferon lambda 3 Homo sapiens 8-13 23029188-1 2012 BACKGROUND: Many studies have been published on the association between single nucleotide polymorphisms (SNP) near the IL28B gene and response to the combined treatments of pegylated-interferon (PegIFN) and ribavirin (RBV) in chronic HCV-infected patients, but without identical conclusions. Ribavirin 207-216 interferon lambda 3 Homo sapiens 119-124 23029188-1 2012 BACKGROUND: Many studies have been published on the association between single nucleotide polymorphisms (SNP) near the IL28B gene and response to the combined treatments of pegylated-interferon (PegIFN) and ribavirin (RBV) in chronic HCV-infected patients, but without identical conclusions. Ribavirin 218-221 interferon lambda 3 Homo sapiens 119-124 23029188-10 2012 CONCLUSION: Polymorphisms of rs12979860 and rs8099917 near IL28B only associate with the treatment response to PegIFN/RBV in patients infected with HCV genotype 1 or 4 but not with genotype 2 or 3, irrespective of the previous treatment history or HIV co-infected status. Ribavirin 118-121 interferon lambda 3 Homo sapiens 59-64 22962590-9 2012 Compared to either ribavirin or IFN-alpha alone, ribavirin plus IFN-alpha resulted in greater p53 activation and HCV suppression. Ribavirin 49-58 tumor protein p53 Homo sapiens 94-97 22962590-0 2012 Ribavirin enhances the action of interferon-alpha against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway. Ribavirin 0-9 mitogen-activated protein kinase 3 Homo sapiens 118-124 22962590-10 2012 We further identified ERK1/2 that linked ribavirin signals to p53 activation. Ribavirin 41-50 mitogen-activated protein kinase 3 Homo sapiens 22-28 22962590-10 2012 We further identified ERK1/2 that linked ribavirin signals to p53 activation. Ribavirin 41-50 tumor protein p53 Homo sapiens 62-65 22962590-3 2012 We, therefore, decided to investigate whether and how ribavirin inhibits the replication of HCV by promoting the activity of p53. Ribavirin 54-63 tumor protein p53 Homo sapiens 125-128 22962590-11 2012 More importantly, knockdown of ERK1/2 and p53 partially mitigated the inhibitory effects of ribavirin on the HCV replication, indicating that ERK1/2-p53 pathway was involved in the anti-HCV effects of ribavirin. Ribavirin 92-101 mitogen-activated protein kinase 3 Homo sapiens 31-37 22962590-4 2012 METHODS: HepG2 and HCV replicons (JFH1/HepG2) were utilized to study the relationship between ribavirin and p53. Ribavirin 94-103 tumor protein p53 Homo sapiens 108-111 22962590-11 2012 More importantly, knockdown of ERK1/2 and p53 partially mitigated the inhibitory effects of ribavirin on the HCV replication, indicating that ERK1/2-p53 pathway was involved in the anti-HCV effects of ribavirin. Ribavirin 92-101 tumor protein p53 Homo sapiens 42-45 22962590-7 2012 By knocking down ERK1/ERK2 and p53 utilizing RNA interference strategy, we further assessed the role of ERK1/2 and p53 in the suppression of HCV replication by ribavirin in a HCV replicon system. Ribavirin 160-169 mitogen-activated protein kinase 3 Homo sapiens 104-110 22962590-11 2012 More importantly, knockdown of ERK1/2 and p53 partially mitigated the inhibitory effects of ribavirin on the HCV replication, indicating that ERK1/2-p53 pathway was involved in the anti-HCV effects of ribavirin. Ribavirin 92-101 mitogen-activated protein kinase 3 Homo sapiens 142-148 22962590-11 2012 More importantly, knockdown of ERK1/2 and p53 partially mitigated the inhibitory effects of ribavirin on the HCV replication, indicating that ERK1/2-p53 pathway was involved in the anti-HCV effects of ribavirin. Ribavirin 92-101 tumor protein p53 Homo sapiens 149-152 22962590-11 2012 More importantly, knockdown of ERK1/2 and p53 partially mitigated the inhibitory effects of ribavirin on the HCV replication, indicating that ERK1/2-p53 pathway was involved in the anti-HCV effects of ribavirin. Ribavirin 201-210 mitogen-activated protein kinase 3 Homo sapiens 31-37 22962590-11 2012 More importantly, knockdown of ERK1/2 and p53 partially mitigated the inhibitory effects of ribavirin on the HCV replication, indicating that ERK1/2-p53 pathway was involved in the anti-HCV effects of ribavirin. Ribavirin 201-210 tumor protein p53 Homo sapiens 42-45 22962590-11 2012 More importantly, knockdown of ERK1/2 and p53 partially mitigated the inhibitory effects of ribavirin on the HCV replication, indicating that ERK1/2-p53 pathway was involved in the anti-HCV effects of ribavirin. Ribavirin 201-210 mitogen-activated protein kinase 3 Homo sapiens 142-148 22962590-7 2012 By knocking down ERK1/ERK2 and p53 utilizing RNA interference strategy, we further assessed the role of ERK1/2 and p53 in the suppression of HCV replication by ribavirin in a HCV replicon system. Ribavirin 160-169 tumor protein p53 Homo sapiens 115-118 22962590-8 2012 RESULTS: Using HepG2 and HCV replicons, we demonstrated that ribavirin caused the cell cycle arrest at G1 phase and stabilized and activated p53, which was associated with the antiviral activity of ribavirin. Ribavirin 61-70 tumor protein p53 Homo sapiens 141-144 22962590-8 2012 RESULTS: Using HepG2 and HCV replicons, we demonstrated that ribavirin caused the cell cycle arrest at G1 phase and stabilized and activated p53, which was associated with the antiviral activity of ribavirin. Ribavirin 198-207 tumor protein p53 Homo sapiens 141-144 22328925-5 2012 Haplotypes carrying the major alleles at IL28B SNPs were highly associated with sustained virological responses (SVRs) after treatment with peg-IFN-alpha and RBV [odds ratio (OR) = 2.5, 95% confidence interval (CI) = 1.6-4.0, 4.0x10(-5)]. Ribavirin 158-161 interferon lambda 3 Homo sapiens 41-46 22962590-11 2012 More importantly, knockdown of ERK1/2 and p53 partially mitigated the inhibitory effects of ribavirin on the HCV replication, indicating that ERK1/2-p53 pathway was involved in the anti-HCV effects of ribavirin. Ribavirin 201-210 tumor protein p53 Homo sapiens 149-152 22962590-12 2012 CONCLUSION: Ribavirin stimulates ERK1/2 and subsequently promotes p53 activity which at least partly contributes to the enhanced antiviral response of IFN-alpha plus ribavirin against HCV. Ribavirin 12-21 mitogen-activated protein kinase 3 Homo sapiens 33-39 22962590-12 2012 CONCLUSION: Ribavirin stimulates ERK1/2 and subsequently promotes p53 activity which at least partly contributes to the enhanced antiviral response of IFN-alpha plus ribavirin against HCV. Ribavirin 12-21 tumor protein p53 Homo sapiens 66-69 22962590-12 2012 CONCLUSION: Ribavirin stimulates ERK1/2 and subsequently promotes p53 activity which at least partly contributes to the enhanced antiviral response of IFN-alpha plus ribavirin against HCV. Ribavirin 166-175 mitogen-activated protein kinase 3 Homo sapiens 33-39 22962590-12 2012 CONCLUSION: Ribavirin stimulates ERK1/2 and subsequently promotes p53 activity which at least partly contributes to the enhanced antiviral response of IFN-alpha plus ribavirin against HCV. Ribavirin 166-175 tumor protein p53 Homo sapiens 66-69 22848715-0 2012 Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C. Ribavirin improves outcomes of therapy in chronic hepatitis C but its mode of action has still remained unclear. Ribavirin 0-9 CD4 molecule Homo sapiens 54-57 22848715-0 2012 Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C. Ribavirin improves outcomes of therapy in chronic hepatitis C but its mode of action has still remained unclear. Ribavirin 0-9 negative elongation factor complex member C/D Homo sapiens 59-62 22848715-0 2012 Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C. Ribavirin improves outcomes of therapy in chronic hepatitis C but its mode of action has still remained unclear. Ribavirin 114-123 CD4 molecule Homo sapiens 54-57 22848715-0 2012 Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C. Ribavirin improves outcomes of therapy in chronic hepatitis C but its mode of action has still remained unclear. Ribavirin 114-123 negative elongation factor complex member C/D Homo sapiens 59-62 22848715-4 2012 Ribavirin enhanced proliferation of T effector cells and increased production of IFN-gamma in TH1 clones, but had only little effect on IL-10 secretion in TH2 clones. Ribavirin 0-9 interferon gamma Homo sapiens 81-90 22848715-4 2012 Ribavirin enhanced proliferation of T effector cells and increased production of IFN-gamma in TH1 clones, but had only little effect on IL-10 secretion in TH2 clones. Ribavirin 0-9 negative elongation factor complex member C/D Homo sapiens 94-97 22848715-5 2012 However, ribavirin markedly inhibited IL-10 release in Treg clones in a dose dependent fashion. Ribavirin 9-18 interleukin 10 Homo sapiens 38-43 22848715-7 2012 Our in vitro data suggest that--in addition to its immunostimulatory effects on TH1 cells--ribavirin can inhibit functions of HCV-specific Tregs and thus reverses Treg-mediated suppression of T effector cells in chronic hepatitis C. Ribavirin 91-100 negative elongation factor complex member C/D Homo sapiens 80-83 22649509-1 2012 BACKGROUND: The interleukin-28B gene (IL28B) locus has been associated with host resistance to hepatitis C virus (HCV) infection and response to PEG-IFN/RBV treatment in western populations. Ribavirin 153-156 interferon lambda 3 Homo sapiens 38-43 22649509-9 2012 CONCLUSIONS: Thus, the rs12979860-CC variant upstream of IL28B gene is associated with spontaneous clearance of HCV, susceptible to IFN/RBV treatment and increased IL-28B levels in this Chinese population. Ribavirin 136-139 interferon lambda 3 Homo sapiens 57-62 22253847-1 2012 Several SNPs located in or around the IL28B gene are associated with response of patients infected with Hepatitis C virus to treatment with pegylated interferon-alpha +/- ribavirin or with spontaneous clearance of the virus. Ribavirin 171-180 interferon lambda 3 Homo sapiens 38-43 22253715-1 2012 BACKGROUND AND AIMS: Recently, several genome-wide association studies have revealed that single nucleotide polymorphisms (SNPs) in proximity to IL28B predict spontaneous clearance of HCV infection as well as outcome following peginterferon and ribavirin therapy among HCV genotype 1 infected patients. Ribavirin 245-254 interferon lambda 3 Homo sapiens 145-150 22328925-9 2012 These results demonstrate that rs12979860, compared to rs8099917, may be a better predictor of response to the peg-IFN/RBV treatment among HCV/HIV-1 coinfected patients. Ribavirin 119-122 interferon alpha 1 Homo sapiens 115-118 21796793-6 2012 Recently, specific targeting of the eIF4E-dependent mRNA export pathway in a phase II proof-of-principle trial with ribavirin led to impaired eIF4E-dependent mRNA export correlating with clinical responses including remissions in leukemia patients. Ribavirin 116-125 eukaryotic translation initiation factor 4E Homo sapiens 36-41 21796793-6 2012 Recently, specific targeting of the eIF4E-dependent mRNA export pathway in a phase II proof-of-principle trial with ribavirin led to impaired eIF4E-dependent mRNA export correlating with clinical responses including remissions in leukemia patients. Ribavirin 116-125 eukaryotic translation initiation factor 4E Homo sapiens 142-147 21934619-3 2011 RECENT FINDINGS: In the HIV/HCV coinfection setting, insulin resistance seems to be associated with a reduction in rapid virological response and SVR to pegylated interferon and ribavirin, both in naive and treatment experienced patients. Ribavirin 178-187 insulin Homo sapiens 53-60 21951389-9 2011 CONCLUSIONS: Re-treatment with PEG-IFN alpha2a plus ribavirin therapy is effective in patients who relapse after a course of PEG-IFN alpha2b plus ribavirin therapy. Ribavirin 148-157 interferon alpha 2 Homo sapiens 37-47 21907615-0 2011 Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. Ribavirin 112-121 interferon lambda 3 Homo sapiens 22-27 21907615-2 2011 OBJECTIVES: The aim of this study was to investigate the association between genetic variation near the IL28B gene and treatment outcome prediction in Korean patients receiving peg-interferon (PEG-IFN) plus ribavirin therapy. Ribavirin 207-216 interferon lambda 3 Homo sapiens 104-109 22075738-1 2011 OBJECTIVE: To prospectively evaluate depressive symptoms and risk factors for depression in patients with chronic hepatitis C (CHC) treated with pegylated interferon alpha therapy combined with oral ribavirin (PEG-IFN-alpha+RBV) and to analyze self-rating scale for depression in comparison to observer-based scale in the given population. Ribavirin 199-208 progestagen associated endometrial protein Homo sapiens 210-213 21993426-1 2011 The achievement of response to the current standard of care-pegylated interferon plus ribavirin-has recently been described to be associated with single-nucleotide polymorphisms (SNPs) near the IL-28B gene. Ribavirin 86-95 interferon lambda 3 Homo sapiens 194-200 21918436-4 2011 IL28B variations are strongly associated with response to pegylated-IFN plus ribavirin (Peg-IFN/RBV) in patients with chronic infection by HCV genotype 1 or 4. Ribavirin 77-86 interferon lambda 3 Homo sapiens 0-5 21918436-4 2011 IL28B variations are strongly associated with response to pegylated-IFN plus ribavirin (Peg-IFN/RBV) in patients with chronic infection by HCV genotype 1 or 4. Ribavirin 77-86 interferon alpha 1 Homo sapiens 92-95 21918436-4 2011 IL28B variations are strongly associated with response to pegylated-IFN plus ribavirin (Peg-IFN/RBV) in patients with chronic infection by HCV genotype 1 or 4. Ribavirin 96-99 interferon lambda 3 Homo sapiens 0-5 21918436-10 2011 SUMMARY: IL28B genotyping can aid in Peg-IFN/RBV clinical decision-making, and it may be useful in the selection of candidates for triple therapy with Peg-IFN/RBV plus direct-acting antiviral drugs. Ribavirin 45-48 interferon lambda 3 Homo sapiens 9-14 22006276-1 2011 UNLABELLED: The IL28B genotype is the most important pretreatment predictor of treatment outcome in patients with chronic hepatitis C. The impact of the rs12979860 genotype on relapse was retrospectively evaluated in genotype 1/4 patients who received response-guided therapy with peginterferon alpha-2a 180 mug/week plus ribavirin 1,000/1,200 mg/day in a large, randomized, multicenter study. Ribavirin 322-331 interferon lambda 3 Homo sapiens 16-21 22414275-0 2011 Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines. Ribavirin 0-9 estrogen receptor 1 Homo sapiens 19-23 22414275-0 2011 Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines. Ribavirin 0-9 estrogen receptor 1 Homo sapiens 69-73 22414275-3 2011 The ESR1 gene re-expression through epigenetic modulators such as DNA methyltransferase inhibitors and/or histone deacetylase inhibitors restores tamoxifen sensitivity in ESR1 negative breast cancer cell lines and opens new treatment horizons in patients who were previously associated with a poor prognosis.In the study presented herein, we tested the ability of ribavirin, which shares some structural similarities with the DNA-methyltransferase inhibitor 5-azacytidine and which is widely known as an anti-viral agent in the treatment of hepatitis C, to restore ESR1 gene re-expression in ESR1 negative breast cancer cell lines.In our study we identified ribavirin to restore ESR1 gene re-expression alone and even more in combination with suberoylanilide hydroxamic acid (SAHA - up to 276 fold induction).Ribavirin and analogs could pave the way to novel translational research projects that aim to restore ESR1 gene re-expression and thus the susceptibility to tamoxifen-based endocrine treatment strategies. Ribavirin 364-373 estrogen receptor 1 Homo sapiens 4-8 22414275-3 2011 The ESR1 gene re-expression through epigenetic modulators such as DNA methyltransferase inhibitors and/or histone deacetylase inhibitors restores tamoxifen sensitivity in ESR1 negative breast cancer cell lines and opens new treatment horizons in patients who were previously associated with a poor prognosis.In the study presented herein, we tested the ability of ribavirin, which shares some structural similarities with the DNA-methyltransferase inhibitor 5-azacytidine and which is widely known as an anti-viral agent in the treatment of hepatitis C, to restore ESR1 gene re-expression in ESR1 negative breast cancer cell lines.In our study we identified ribavirin to restore ESR1 gene re-expression alone and even more in combination with suberoylanilide hydroxamic acid (SAHA - up to 276 fold induction).Ribavirin and analogs could pave the way to novel translational research projects that aim to restore ESR1 gene re-expression and thus the susceptibility to tamoxifen-based endocrine treatment strategies. Ribavirin 658-667 estrogen receptor 1 Homo sapiens 4-8 22414275-3 2011 The ESR1 gene re-expression through epigenetic modulators such as DNA methyltransferase inhibitors and/or histone deacetylase inhibitors restores tamoxifen sensitivity in ESR1 negative breast cancer cell lines and opens new treatment horizons in patients who were previously associated with a poor prognosis.In the study presented herein, we tested the ability of ribavirin, which shares some structural similarities with the DNA-methyltransferase inhibitor 5-azacytidine and which is widely known as an anti-viral agent in the treatment of hepatitis C, to restore ESR1 gene re-expression in ESR1 negative breast cancer cell lines.In our study we identified ribavirin to restore ESR1 gene re-expression alone and even more in combination with suberoylanilide hydroxamic acid (SAHA - up to 276 fold induction).Ribavirin and analogs could pave the way to novel translational research projects that aim to restore ESR1 gene re-expression and thus the susceptibility to tamoxifen-based endocrine treatment strategies. Ribavirin 809-818 estrogen receptor 1 Homo sapiens 4-8 22129918-3 2011 The role of eIF4E in oncogenic transformation and the development of a means to directly target its activity with ribavirin are discussed here. Ribavirin 114-123 eukaryotic translation initiation factor 4E Homo sapiens 12-17 22044696-0 2011 Suppressor of cytokine signal 3 and IL28 genetic variation predict the viral response to peginterferon and ribavirin. Ribavirin 107-116 interferon lambda 3 Homo sapiens 36-40 21703195-0 2011 Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. Ribavirin 105-114 insulin Homo sapiens 10-17 22023039-1 2011 PURPOSE: This work was carried out to study the level of pretreatment hepatic expression of Toll like receptor 3 (TLR3) among chronic HCV patients, aiming to determine if there are consistent differences in gene expression, between those who show complete early virological response (cEVR) at week-12 of Pegylated-Interferon alpha-2a plus ribavirin treatment and others who are not responding to this combination, also if this could be used to predict treatment outcomes. Ribavirin 339-348 toll like receptor 3 Homo sapiens 114-118 21596633-2 2011 In the complex network of interacting factors determining sustained virological response independently of known predictive factors related to host and virus, two modern tools are emerging: polymorphisms in the IL28B gene and very early exposure to ribavirin. Ribavirin 248-257 interferon lambda 3 Homo sapiens 210-215 22189977-5 2011 ITPA is a gene on chromosome 20, coding for inosine triphosphatase, and polymorphisms on this gene have been associated with ribavirin-induced hemolytic anemia. Ribavirin 125-134 inosine triphosphatase Homo sapiens 0-4 21354446-0 2011 IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) associated with IL28B influence the outcome of peginterferon-alpha/ribavirin therapy of chronic hepatitis C virus (HCV) infection. Ribavirin 232-241 interferon lambda 3 Homo sapiens 0-5 21354446-0 2011 IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) associated with IL28B influence the outcome of peginterferon-alpha/ribavirin therapy of chronic hepatitis C virus (HCV) infection. Ribavirin 232-241 interferon lambda 3 Homo sapiens 181-186 21354446-7 2011 CONCLUSIONS: Polymorphisms in IL28B are strongly associated with the first phase viral decline during peginterferon-alpha/ribavirin therapy of chronic HCV infection, irrespective of HCV genotype. Ribavirin 122-131 interferon lambda 3 Homo sapiens 30-35 21623851-0 2011 Meta-analysis: insulin resistance and sustained virological response in hepatitis C. BACKGROUND: A higher baseline homeostasis model assessment of insulin resistance (HOMA-IR) score has sometimes predicted a poorer sustained virological response (SVR) rate to peginterferon/ribavirin therapy in treatment-naive chronic hepatitis C patients. Ribavirin 274-283 insulin Homo sapiens 15-22 21911885-1 2011 BACKGROUND AND AIMS: Genetic variations in the interleukin 28B (IL28B) gene have been associated with viral response to PEG-interferon-alpha/ribavirin (PR) therapy in hepatitis C virus (HCV) genotype 1 infected patients from North America, Europe and Asia. Ribavirin 141-150 interferon lambda 3 Homo sapiens 64-69 21914076-11 2011 IL-28B genotype is a potentially useful marker for the response to PEGIFN/RBV therapy administered after curative treatment of HCV-related HCC. Ribavirin 74-77 interferon lambda 3 Homo sapiens 0-6 21659334-0 2011 Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hematologic abnormalities during current therapy with pegylated interferon and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC) often necessitate dose reduction and premature withdrawal from therapy. Ribavirin 118-127 inosine triphosphatase Homo sapiens 41-45 21659334-0 2011 Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hematologic abnormalities during current therapy with pegylated interferon and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC) often necessitate dose reduction and premature withdrawal from therapy. Ribavirin 118-127 DDRGK domain containing 1 Homo sapiens 46-52 21659334-0 2011 Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hematologic abnormalities during current therapy with pegylated interferon and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC) often necessitate dose reduction and premature withdrawal from therapy. Ribavirin 240-249 inosine triphosphatase Homo sapiens 41-45 21659334-0 2011 Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hematologic abnormalities during current therapy with pegylated interferon and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC) often necessitate dose reduction and premature withdrawal from therapy. Ribavirin 240-249 DDRGK domain containing 1 Homo sapiens 46-52 21659334-0 2011 Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hematologic abnormalities during current therapy with pegylated interferon and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC) often necessitate dose reduction and premature withdrawal from therapy. Ribavirin 259-262 inosine triphosphatase Homo sapiens 41-45 21659334-0 2011 Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hematologic abnormalities during current therapy with pegylated interferon and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC) often necessitate dose reduction and premature withdrawal from therapy. Ribavirin 259-262 DDRGK domain containing 1 Homo sapiens 46-52 21659334-3 2011 One SNP (rs11697186) located on DDRGK1 gene on chromosome 20 showed strong associations in the minor-allele-dominant model with the decrease of platelet counts in response to PEG-IFN/RBV therapy [P = 8.17 x 10(-9); odds ratio (OR) = 4.6]. Ribavirin 183-186 DDRGK domain containing 1 Homo sapiens 32-38 21820962-4 2011 We also discuss the recent discovery of single nucleotide polymorphisms (SNPs) near the human IFN-lambda3 gene, IL28B, that correlate strongly with the ability to achieve a sustained virological response to therapy with pegylated IFN-alpha plus ribavirin in patients with chronic hepatitis C. Ribavirin 245-254 interferon lambda 3 Homo sapiens 94-105 21820962-4 2011 We also discuss the recent discovery of single nucleotide polymorphisms (SNPs) near the human IFN-lambda3 gene, IL28B, that correlate strongly with the ability to achieve a sustained virological response to therapy with pegylated IFN-alpha plus ribavirin in patients with chronic hepatitis C. Ribavirin 245-254 interferon lambda 3 Homo sapiens 112-117 21745312-0 2011 Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Ribavirin 130-139 interferon lambda 3 Homo sapiens 15-30 21884341-0 2011 Early detection of interstitial pneumonia by monitoring KL-6 in a chronic hepatitis C patient undergoing pegylated interferon and ribavirin therapy. Ribavirin 130-139 mucin 1, cell surface associated Homo sapiens 56-60 21884341-4 2011 The patient successfully recovered from her early-stage pneumonia by immediate discontinuation of therapy, which indicates that regular monitoring of serum KL-6 may be effective for avoidance of IP progression induced by PEG IFN and RBV therapy. Ribavirin 233-236 mucin 1, cell surface associated Homo sapiens 156-160 21739446-1 2011 An association has been reported between genetic polymorphism near IL28B gene and the prevalence of mutation of hepatitis C virus (HCV) core region residue 70, both of which have been associated with a lack of virologic response to antiviral combination therapy with peginterferon (PEG-IFN) and ribavirin. Ribavirin 295-304 interferon lambda 3 Homo sapiens 67-72 20659305-1 2011 Recently, genome-wide association studies in patients affected by HCV infection have identified a strong association between sustained virological response to peg-interferon/ribavirin and spontaneous viral clearance and common single nucleotide polymorphisms (SNPs) near the IL28B gene, encoding for interferon-lambda-3. Ribavirin 174-183 interferon lambda 3 Homo sapiens 275-280 20659305-1 2011 Recently, genome-wide association studies in patients affected by HCV infection have identified a strong association between sustained virological response to peg-interferon/ribavirin and spontaneous viral clearance and common single nucleotide polymorphisms (SNPs) near the IL28B gene, encoding for interferon-lambda-3. Ribavirin 174-183 interferon lambda 3 Homo sapiens 300-319 21623851-0 2011 Meta-analysis: insulin resistance and sustained virological response in hepatitis C. BACKGROUND: A higher baseline homeostasis model assessment of insulin resistance (HOMA-IR) score has sometimes predicted a poorer sustained virological response (SVR) rate to peginterferon/ribavirin therapy in treatment-naive chronic hepatitis C patients. Ribavirin 274-283 insulin Homo sapiens 147-154 21867935-2 2011 Recent data have demonstrated promise for the NS3 protease inhibitor boceprevir, which, when added to the standard of care peginterferon and ribavirin, improves sustained virological response while shortening duration of therapy in genotype-1-infected individuals. Ribavirin 141-150 KRAS proto-oncogene, GTPase Homo sapiens 46-49 21538438-1 2011 UNLABELLED: Insulin resistance (IR) is common in chronic hepatitis C (CHC) and associates with reduced virological response to pegylated-interferon (PEG-IFN)/ribavirin therapy, but the underlying mechanisms are still unclear. Ribavirin 158-167 insulin Homo sapiens 12-19 21554996-3 2011 Therefore, the current study was aimed to prospectively utilize the baseline IL-8 levels in the HCV infected serum and predicts its role in sustained virological response (SVR) to IFN-alpha+ribavirin therapy, in chronic HCV patients in Pakistan. Ribavirin 190-199 C-X-C motif chemokine ligand 8 Homo sapiens 77-81 21554996-10 2011 Results of this study suggest that increased levels of IL-8 in HCV infection might be involved in pathogenesis, persistence and resistance to IFN-alpha+ribavirin combination therapy. Ribavirin 152-161 C-X-C motif chemokine ligand 8 Homo sapiens 55-59 21147186-2 2011 METHODS: Donor and recipient genotypes of IL28B rs12979860C>T single nucleotide polymorphism were determined in 91 patients with HCV liver graft reinfection, 47 of whom were treated with pegylated interferon-alpha (PEG-IFN-alpha) and ribavirin. Ribavirin 237-246 interferon lambda 3 Homo sapiens 42-47 21147186-6 2011 More important, donor IL28B rs12979860 CC vs. CT/TT genotypes were associated with rapid, complete early, and sustained virologic response (RVR, cEVR, SVR) to treatment with PEG-IFN-alpha and ribavirin (p=0.003, 0.0012, 0.008, respectively), but weaker associations of recipient genotypes with RVR, cEVR, and SVR were observed as well (p=0.0046, 0.115, 0.118, respectively). Ribavirin 192-201 interferon lambda 3 Homo sapiens 22-27 21147189-3 2011 Recently, several single-nucleotide polymorphisms (SNPs) near the IL28B locus, also known as IFNlambda3, were identified to be strong predictors of SVR in patients receiving PEG-IFN and RBV. Ribavirin 186-189 interferon lambda 3 Homo sapiens 66-71 21147189-3 2011 Recently, several single-nucleotide polymorphisms (SNPs) near the IL28B locus, also known as IFNlambda3, were identified to be strong predictors of SVR in patients receiving PEG-IFN and RBV. Ribavirin 186-189 interferon lambda 3 Homo sapiens 93-103 21670772-0 2011 Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Ribavirin 103-112 major histocompatibility complex, class II, DQ beta 1 Homo sapiens 35-38 21742841-0 2011 IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. Ribavirin 69-78 interferon lambda 3 Homo sapiens 0-5 21572301-1 2011 OBJECTIVE: The aims of this study were to appraise the predictive value of variations in a single-nucleotide polymorphism (SNP) in the low-density lipoprotein receptor (LDLR) gene for sustained virological response (SVR) to pegylated interferon (Peg-IFN) and ribavirin (RBV), as well as to analyze the relationship between LDLR genotype and other predictors of SVR, particularly IL28B genotype, in patients coinfected with HIV and hepatitis C virus (HCV). Ribavirin 259-268 low density lipoprotein receptor Homo sapiens 135-167 21572301-1 2011 OBJECTIVE: The aims of this study were to appraise the predictive value of variations in a single-nucleotide polymorphism (SNP) in the low-density lipoprotein receptor (LDLR) gene for sustained virological response (SVR) to pegylated interferon (Peg-IFN) and ribavirin (RBV), as well as to analyze the relationship between LDLR genotype and other predictors of SVR, particularly IL28B genotype, in patients coinfected with HIV and hepatitis C virus (HCV). Ribavirin 259-268 low density lipoprotein receptor Homo sapiens 169-173 21572301-1 2011 OBJECTIVE: The aims of this study were to appraise the predictive value of variations in a single-nucleotide polymorphism (SNP) in the low-density lipoprotein receptor (LDLR) gene for sustained virological response (SVR) to pegylated interferon (Peg-IFN) and ribavirin (RBV), as well as to analyze the relationship between LDLR genotype and other predictors of SVR, particularly IL28B genotype, in patients coinfected with HIV and hepatitis C virus (HCV). Ribavirin 270-273 low density lipoprotein receptor Homo sapiens 135-167 21572301-1 2011 OBJECTIVE: The aims of this study were to appraise the predictive value of variations in a single-nucleotide polymorphism (SNP) in the low-density lipoprotein receptor (LDLR) gene for sustained virological response (SVR) to pegylated interferon (Peg-IFN) and ribavirin (RBV), as well as to analyze the relationship between LDLR genotype and other predictors of SVR, particularly IL28B genotype, in patients coinfected with HIV and hepatitis C virus (HCV). Ribavirin 270-273 low density lipoprotein receptor Homo sapiens 169-173 21670772-0 2011 Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Ribavirin 103-112 interferon lambda 3 Homo sapiens 43-48 21628662-0 2011 IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. BACKGROUND: Pegylated interferon, ribavirin, and telaprevir triple therapy is a new strategy expected to eradicate the hepatitis C virus (HCV) even in patients infected with difficult-to-treat genotype 1 strains, although adverse effects, such as anemia and rash, are frequent. Ribavirin 199-208 interferon lambda 3 Homo sapiens 0-5 22977564-6 2011 Multivariate analysis showed that IL-28B TT homozygosity (P=0.014) and the platelets number (P=0.030) was associated with the early suppression of HCV-RNA at 12 weeks after the start of PEG-IFN/RBV therapy. Ribavirin 194-197 interferon lambda 3 Homo sapiens 34-40 22977564-7 2011 The IL-28B polymorphism was a significant pre-treatment predictor of the response to PEG-IFN/RBV therapy in patients with HCV infection. Ribavirin 93-96 interferon lambda 3 Homo sapiens 4-10 21628662-0 2011 IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. BACKGROUND: Pegylated interferon, ribavirin, and telaprevir triple therapy is a new strategy expected to eradicate the hepatitis C virus (HCV) even in patients infected with difficult-to-treat genotype 1 strains, although adverse effects, such as anemia and rash, are frequent. Ribavirin 83-92 interferon lambda 3 Homo sapiens 0-5 21439960-8 2011 CONCLUSIONS: High-dose pegylated IFN-alpha with standard or high doses of ribavirin induces a potent antiviral response in a substantial number of patients who did not respond to standard therapy. Ribavirin 74-83 interferon alpha 1 Homo sapiens 33-42 21628662-6 2011 Patients with the anemia-susceptible ITPA SNP rs1127354 genotype typically required ribavirin dose reduction earlier than did patients with other genotypes. Ribavirin 84-93 inosine triphosphatase Homo sapiens 37-41 21692944-0 2011 IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. Ribavirin 109-118 interferon lambda 3 Homo sapiens 0-5 21567425-10 2011 The results suggest that low CD83 expression and high IL-10 production of DCs at the baseline may predict a poor virologic response to 24-week PEG-IFN plus ribavirin therapy in HCV genotype 1 patients. Ribavirin 156-165 CD83 molecule Homo sapiens 29-33 21567425-10 2011 The results suggest that low CD83 expression and high IL-10 production of DCs at the baseline may predict a poor virologic response to 24-week PEG-IFN plus ribavirin therapy in HCV genotype 1 patients. Ribavirin 156-165 interleukin 10 Homo sapiens 54-59 21543469-6 2011 When Huh7.5 cells were exposed to RBV, resistance developed through reduced RBV uptake via the ENT1 nucleoside transporter and antiviral efficacy was reduced. Ribavirin 34-37 MIR7-3 host gene Homo sapiens 5-9 21543469-6 2011 When Huh7.5 cells were exposed to RBV, resistance developed through reduced RBV uptake via the ENT1 nucleoside transporter and antiviral efficacy was reduced. Ribavirin 34-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-99 21543469-6 2011 When Huh7.5 cells were exposed to RBV, resistance developed through reduced RBV uptake via the ENT1 nucleoside transporter and antiviral efficacy was reduced. Ribavirin 76-79 MIR7-3 host gene Homo sapiens 5-9 21543469-6 2011 When Huh7.5 cells were exposed to RBV, resistance developed through reduced RBV uptake via the ENT1 nucleoside transporter and antiviral efficacy was reduced. Ribavirin 76-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-99 21543469-7 2011 The uptake defect in RBV-resistant cells was specific to RBV, since transport of another ENT1 substrate, cytidine, was unaffected. Ribavirin 21-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 89-93 21692944-8 2011 We conclude that the IL28B variability influences the antiviral efficiency of interferon/ribavirin therapy and has a strong impact on SVR, independently of traditional response predictors. Ribavirin 89-98 interferon lambda 3 Homo sapiens 21-26 21346780-0 2011 IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infection. Ribavirin 112-121 interferon lambda 3 Homo sapiens 0-5 21615225-1 2011 The aim of this study was to prospectively investigate CD81 expression on PBMC for early discrimination between sustained virologic response (SVR) and relapse (REL) to pegylated interferon alfa-2b and ribavirin treatment. Ribavirin 201-210 CD81 molecule Homo sapiens 55-59 21861317-3 2011 It is a matter of ongoing debate how to incorporate the IL28B data into the current treatment algorithms with pegylated interferon-alpha and ribavirin. Ribavirin 141-150 interferon lambda 3 Homo sapiens 56-61 21869868-1 2011 Genome-wide association studies have recently identified single nucleotide polymorphisms in proximity to the interleukin-28B (IL-28B) gene that can predict sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection who are undergoing therapy with pegylated interferon (IFN) a and ribavirin. Ribavirin 315-324 interferon lambda 3 Homo sapiens 126-132 21455212-0 2011 Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Ribavirin 25-34 eukaryotic translation initiation factor 4E Homo sapiens 14-19 21529139-1 2011 OBJECTIVE: Several studies recently revealed that single nucleotide polymorphisms (SNPs) in the interleukin28B (IL28B) region are associated with the response to pegylated interferon-alfa (PEG-IFN-alfa) and ribavirin (RBV) treatment among hepatitis C virus (HCV)-infected individuals of European, African and Asian ancestry. Ribavirin 207-216 interferon lambda 3 Homo sapiens 112-117 21529139-1 2011 OBJECTIVE: Several studies recently revealed that single nucleotide polymorphisms (SNPs) in the interleukin28B (IL28B) region are associated with the response to pegylated interferon-alfa (PEG-IFN-alfa) and ribavirin (RBV) treatment among hepatitis C virus (HCV)-infected individuals of European, African and Asian ancestry. Ribavirin 218-221 interferon lambda 3 Homo sapiens 112-117 21748625-4 2011 About 13 months after the initiation of antiviral therapy, in the form of type 2b peg-IFN with ribavirin, a negative serum hepatitis C virus (HCV)-RNA titer was confirmed. Ribavirin 95-104 interferon alpha 1 Homo sapiens 86-89 21606538-1 2011 INTRODUCTION: The impact of highly active antiretroviral therapy (HAART) on CD4+ cell course during treatment with pegylated interferon plus ribavirin (PegIFN-RBV) in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is unknown. Ribavirin 141-150 CD4 molecule Homo sapiens 76-79 21869868-1 2011 Genome-wide association studies have recently identified single nucleotide polymorphisms in proximity to the interleukin-28B (IL-28B) gene that can predict sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection who are undergoing therapy with pegylated interferon (IFN) a and ribavirin. Ribavirin 315-324 interferon lambda 3 Homo sapiens 109-124 20487258-3 2011 This study was conducted to assess the effect of pegylated interferon-alpha2a (pegIFN-alpha2a) and ribavirin treatment on peripheral blood lymphocytes, mainly on CD81 expression on B cells and CD4(+) CD25(+) CD127(low/-) FoxP3(+) regulatory T cells (Tregs) in patients with chronic HCV infection. Ribavirin 99-108 CD4 molecule Homo sapiens 193-196 21504519-7 2011 CONCLUSION: Serum MIP-1beta levels may predict the response to HCV treatment with pegylated interferon and ribavirin and are associated with amino acid substitutions in the ISDR. Ribavirin 109-118 C-C motif chemokine ligand 4 Homo sapiens 20-29 21503910-1 2011 Variation at the IL-28B locus was recently reported to be a significant predictive factor of viral response to pegylated-interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL-28B polymorphism rs8099917 and viral and clinical factors were investigated. Ribavirin 137-146 interferon lambda 3 Homo sapiens 17-23 21503919-0 2011 Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. Ribavirin 49-58 inosine triphosphatase Homo sapiens 31-35 21503919-0 2011 Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. Ribavirin 108-117 inosine triphosphatase Homo sapiens 31-35 21503919-1 2011 An association between a single nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and reduction of hemoglobin during peg-interferon plus ribavirin combination therapy for patients with chronic hepatitis C virus (HCV) infection has been reported. Ribavirin 173-182 inosine triphosphatase Homo sapiens 69-105 21503919-1 2011 An association between a single nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and reduction of hemoglobin during peg-interferon plus ribavirin combination therapy for patients with chronic hepatitis C virus (HCV) infection has been reported. Ribavirin 173-182 inosine triphosphatase Homo sapiens 107-111 21145800-0 2011 IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. Ribavirin 88-97 interferon lambda 3 Homo sapiens 0-4 21145800-1 2011 BACKGROUND & AIMS: Common genetic variation within the IL28 locus has been found to influence the effect of peg-interferon and ribavirin combination therapy against chronic hepatitis C virus (HCV) infection. Ribavirin 131-140 interferon lambda 3 Homo sapiens 59-63 21145800-7 2011 Among patients treated with peg-interferon plus ribavirin therapy, liver mRNA levels of IL28, MxA, PKR, OAS1, and ISG15 were significantly or marginally lower in responders who became negative for HCV RNA (p=0.001, 0.004, 0.014, 0.051, and 0.015, respectively). Ribavirin 48-57 interferon lambda 3 Homo sapiens 88-92 21145800-7 2011 Among patients treated with peg-interferon plus ribavirin therapy, liver mRNA levels of IL28, MxA, PKR, OAS1, and ISG15 were significantly or marginally lower in responders who became negative for HCV RNA (p=0.001, 0.004, 0.014, 0.051, and 0.015, respectively). Ribavirin 48-57 MX dynamin like GTPase 1 Homo sapiens 94-97 21145800-7 2011 Among patients treated with peg-interferon plus ribavirin therapy, liver mRNA levels of IL28, MxA, PKR, OAS1, and ISG15 were significantly or marginally lower in responders who became negative for HCV RNA (p=0.001, 0.004, 0.014, 0.051, and 0.015, respectively). Ribavirin 48-57 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 99-102 21145800-7 2011 Among patients treated with peg-interferon plus ribavirin therapy, liver mRNA levels of IL28, MxA, PKR, OAS1, and ISG15 were significantly or marginally lower in responders who became negative for HCV RNA (p=0.001, 0.004, 0.014, 0.051, and 0.015, respectively). Ribavirin 48-57 2'-5'-oligoadenylate synthetase 1 Homo sapiens 104-108 21145800-7 2011 Among patients treated with peg-interferon plus ribavirin therapy, liver mRNA levels of IL28, MxA, PKR, OAS1, and ISG15 were significantly or marginally lower in responders who became negative for HCV RNA (p=0.001, 0.004, 0.014, 0.051, and 0.015, respectively). Ribavirin 48-57 ISG15 ubiquitin like modifier Homo sapiens 114-119 21430053-9 2011 Interestingly, TSC inhibited BVDV replication in cell culture synergistically with RBV. Ribavirin 83-86 TSC complex subunit 1 Homo sapiens 15-18 21430053-10 2011 In conclusion, TSC emerges as a new nonnucleoside inhibitor of BVDV RdRp that is synergistic with RBV, a feature that turns it into a potential compound to be evaluated against hepatitis C virus (HCV). Ribavirin 98-101 TSC complex subunit 1 Homo sapiens 15-18 20487258-3 2011 This study was conducted to assess the effect of pegylated interferon-alpha2a (pegIFN-alpha2a) and ribavirin treatment on peripheral blood lymphocytes, mainly on CD81 expression on B cells and CD4(+) CD25(+) CD127(low/-) FoxP3(+) regulatory T cells (Tregs) in patients with chronic HCV infection. Ribavirin 99-108 interleukin 2 receptor subunit alpha Homo sapiens 200-204 20487258-3 2011 This study was conducted to assess the effect of pegylated interferon-alpha2a (pegIFN-alpha2a) and ribavirin treatment on peripheral blood lymphocytes, mainly on CD81 expression on B cells and CD4(+) CD25(+) CD127(low/-) FoxP3(+) regulatory T cells (Tregs) in patients with chronic HCV infection. Ribavirin 99-108 forkhead box P3 Homo sapiens 221-226 20487258-10 2011 Our results suggest that immunomodulation fluctuates during antiviral treatment and that percentage CD81 expression levels on B cells and Tregs might be useful as an immunological prognostic factor for pegIFN-alpha2a and ribavirin treatment response in chronic HCV infection. Ribavirin 221-230 CD81 molecule Homo sapiens 100-104 21628814-0 2011 Sequence variation of the HVR1 region of Hepatitis C virus in response to interferon-alpha and ribavirin treatment. Ribavirin 95-104 vasoactive intestinal peptide receptor 1 Homo sapiens 26-30 21628814-2 2011 The aim of this study was to examine sequence variations within the HVR1 region of HCV genotype 4 in infected Saudi patients treated with a combination therapy of interferon-alpha and ribavirin. Ribavirin 184-193 vasoactive intestinal peptide receptor 1 Homo sapiens 68-72 21505315-0 2011 IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. Ribavirin 127-136 interferon lambda 3 Homo sapiens 0-5 21505315-1 2011 BACKGROUND: A single nucleotide polymorphism (SNP) upstream of the IL28B gene (rs12979860) predicts sustained virological response (SVR) to peginterferon-ribavirin therapy in chronic hepatitis C patients. Ribavirin 154-163 interferon lambda 3 Homo sapiens 67-72 21830408-0 2011 Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C. BACKGROUND/AIM: To investigate the early effects of peginterferon alpha-2b plus ribavirin therapy on blood pressure and related cardiovascular risk parameters, and also insulin resistance in patients with chronic hepatitis C virus (HCV) infection. Ribavirin 44-53 insulin Homo sapiens 86-93 21537116-0 2011 Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse. Ribavirin 63-72 interferon lambda 3 Homo sapiens 10-15 21415224-0 2011 Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 61-66 21415224-3 2011 EXPERIMENTAL DESIGN: Breast cancer cells were treated with ribavirin, an inhibitor of eIF4E, and effects on cell proliferation and on known mRNA targets of eIF4E were determined. Ribavirin 59-68 eukaryotic translation initiation factor 4E Homo sapiens 86-91 21415224-3 2011 EXPERIMENTAL DESIGN: Breast cancer cells were treated with ribavirin, an inhibitor of eIF4E, and effects on cell proliferation and on known mRNA targets of eIF4E were determined. Ribavirin 59-68 eukaryotic translation initiation factor 4E Homo sapiens 156-161 21415224-6 2011 RESULTS: At clinically relevant concentrations, ribavirin reduced cell proliferation and suppressed clonogenic potential, correlating with reduced mRNA export and protein expression of important eIF4E targets. Ribavirin 48-57 eukaryotic translation initiation factor 4E Homo sapiens 195-200 21575275-1 2011 BACKGROUND: Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN alpha/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). Ribavirin 128-137 interferon alpha 1 Homo sapiens 159-168 21575275-2 2011 PegIFN/ribavirin has increased rate of sustained virological response than standard IFN alpha/ribavirin therapy. Ribavirin 7-16 interferon alpha 1 Homo sapiens 84-93 21228123-3 2011 Through a genome-wide scan, we found two variants (rs8099917 and rs12979860) in the IL-28B locus that affect the outcome of PEG-IFN and ribavirin combination therapy, consistent with recent studies (P = 6.52x10(-8); odds ratio 2.46 and P = 8.63x10(-8), odds ratio 2.40, respectively). Ribavirin 136-145 interferon lambda 3 Homo sapiens 84-90 21389156-0 2011 The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. Ribavirin 142-151 interferon lambda 3 Homo sapiens 240-255 21393126-0 2011 Ribavirin concentration in the later stages of 48 week pegylated interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. Ribavirin 0-9 interferon alpha 2 Homo sapiens 65-83 21393126-3 2011 PATIENTS AND METHODS: Serum ribavirin concentration of 183 chronic hepatitis C patients (genotype 1) treated with pegylated interferon-alpha2b plus ribavirin for 48 weeks was prospectively measured by HPLC at weeks 4, 12, 24, 36 and 48. Ribavirin 28-37 interferon alpha 2 Homo sapiens 124-142 21145807-0 2011 Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. Ribavirin 136-145 interferon lambda 3 Homo sapiens 29-34 21145807-11 2011 CONCLUSIONS: IL28B polymorphisms modulate early virologic response to peginterferon/ribavirin treatment. Ribavirin 84-93 interferon lambda 3 Homo sapiens 13-18 21382156-7 2011 The set of odds ratios of studies demonstrated an association between SNP (rs12987960/rs8099917) in the IL28B and SVR in CHC treated with peginterferon plus ribavirin (OR: 4.6; 95% CI: 2.9-7.3). Ribavirin 157-166 interferon lambda 3 Homo sapiens 104-109 21360545-0 2011 Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. Ribavirin 79-88 interferon lambda 3 Homo sapiens 15-20 21360545-1 2011 Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Ribavirin 135-144 interferon lambda 3 Homo sapiens 29-44 21360545-1 2011 Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Ribavirin 135-144 interferon lambda 3 Homo sapiens 46-51 21360545-1 2011 Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Ribavirin 146-149 interferon lambda 3 Homo sapiens 29-44 21360545-1 2011 Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Ribavirin 146-149 interferon lambda 3 Homo sapiens 46-51 21360545-11 2011 IL28B polymorphism was predictive of PEG-IFN plus RBV combination treatment outcomes in patients infected with genotype 2 and, especially, with genotype 2b. Ribavirin 50-53 interferon lambda 3 Homo sapiens 0-5 21398397-8 2011 CONCLUSION: Serum IL-10, IL-12, and IL-18 levels are predictive of the response to HCV treatment with pegylated interferon and ribavirin and are associated with amino acid substitutions in the ISDR and core region. Ribavirin 127-136 interleukin 10 Homo sapiens 18-23 21398397-8 2011 CONCLUSION: Serum IL-10, IL-12, and IL-18 levels are predictive of the response to HCV treatment with pegylated interferon and ribavirin and are associated with amino acid substitutions in the ISDR and core region. Ribavirin 127-136 interleukin 18 Homo sapiens 36-41 21538279-9 2011 The use of IL-28B genotyping to predict the response to pegylated interferon and ribavirin may also find its way into clinical practice. Ribavirin 81-90 interferon lambda 3 Homo sapiens 11-17 21199653-0 2011 Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Ribavirin 38-47 adenylosuccinate synthase 2 Homo sapiens 87-112 21572662-11 2011 Naranjo causality assessment scale revealed probable association with IFN-alpha and ribavirin. Ribavirin 84-93 interferon alpha 1 Homo sapiens 70-79 20849436-9 2011 Among patients treated with peginterferon plus RBV in routine clinical practice, genotype, baseline viral load, age, GGT level and platelet levels all predict the likelihood of treatment success. Ribavirin 47-50 inactive glutathione hydrolase 2 Homo sapiens 117-120 21159314-3 2011 This study examined the correlation of BCL-2 gene polymorphism with the response to treatment with pegylated-IFN-alfa2b and ribavirin. Ribavirin 124-133 BCL2 apoptosis regulator Homo sapiens 39-44 21320556-1 2011 Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. Ribavirin 0-9 interferon alpha 1 Homo sapiens 42-52 21320556-1 2011 Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. Ribavirin 0-9 interferon alpha 1 Homo sapiens 54-57 21320556-1 2011 Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. Ribavirin 11-14 interferon alpha 1 Homo sapiens 42-52 21320556-1 2011 Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. Ribavirin 11-14 interferon alpha 1 Homo sapiens 54-57 21479134-1 2011 BACKGROUND: Single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) have received considerable interest for their association with sustained virological response (SVR) when treating patients of genotype-1 hepatitis C virus (GT1-HCV) chronic infection with pegylated interferon and ribavirin (PegIFN/RBV). Ribavirin 291-300 interferon lambda 3 Homo sapiens 54-69 21479134-1 2011 BACKGROUND: Single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) have received considerable interest for their association with sustained virological response (SVR) when treating patients of genotype-1 hepatitis C virus (GT1-HCV) chronic infection with pegylated interferon and ribavirin (PegIFN/RBV). Ribavirin 291-300 interferon lambda 3 Homo sapiens 71-76 21479134-1 2011 BACKGROUND: Single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) have received considerable interest for their association with sustained virological response (SVR) when treating patients of genotype-1 hepatitis C virus (GT1-HCV) chronic infection with pegylated interferon and ribavirin (PegIFN/RBV). Ribavirin 309-312 interferon lambda 3 Homo sapiens 54-69 21479134-1 2011 BACKGROUND: Single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) have received considerable interest for their association with sustained virological response (SVR) when treating patients of genotype-1 hepatitis C virus (GT1-HCV) chronic infection with pegylated interferon and ribavirin (PegIFN/RBV). Ribavirin 309-312 interferon lambda 3 Homo sapiens 71-76 21159314-8 2011 We conclude that BCL-2 gene polymorphism at codon 43 (127G/A) is a new biological marker to potentially identify responders and non-responders of HCV genotype 4 patients to achieving a sustained virological response to treatment with IFN in combination with ribavirin. Ribavirin 258-267 BCL2 apoptosis regulator Homo sapiens 17-22 21159314-8 2011 We conclude that BCL-2 gene polymorphism at codon 43 (127G/A) is a new biological marker to potentially identify responders and non-responders of HCV genotype 4 patients to achieving a sustained virological response to treatment with IFN in combination with ribavirin. Ribavirin 258-267 interferon alpha 1 Homo sapiens 234-237 22087138-0 2011 Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Ribavirin 133-142 interferon lambda 3 Homo sapiens 39-44 21374656-1 2011 UNLABELLED: Polymorphisms near the IL28B gene, which code for interferon (IFN)-lambda3, predict response to pegylated interferon-alpha (PEG-IFN) and ribavirin treatment in hepatitis C virus (HCV) genotype 1 infected patients. Ribavirin 149-158 interferon lambda 3 Homo sapiens 35-40 21111740-1 2011 Preactivation of this endogenous IFN system is associated with nonresponse to pegylated IFN-alpha (pegIFN-alpha) and ribavirin. Ribavirin 117-126 interferon alpha 1 Homo sapiens 33-36 21111740-9 2011 CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2. Ribavirin 133-142 interferon lambda 3 Homo sapiens 13-18 21111740-9 2011 CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2. Ribavirin 133-142 interferon alpha inducible protein 27 Homo sapiens 271-276 21111740-9 2011 CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2. Ribavirin 133-142 ISG15 ubiquitin like modifier Homo sapiens 278-283 21111740-9 2011 CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2. Ribavirin 133-142 radical S-adenosyl methionine domain containing 2 Homo sapiens 285-290 21111740-9 2011 CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2. Ribavirin 133-142 HIV-1 Tat interactive protein 2 Homo sapiens 296-303 21374656-7 2011 Furthermore, we show that IL28B polymorphisms are associated with relapse in patients who achieve rapid viral response to PEG-IFN/ribavirin therapy. Ribavirin 130-139 interferon lambda 3 Homo sapiens 26-31 22087138-5 2011 OBJECTIVES: To assess the associations of single nucleotide polymorphisms (SNP) of the IL28B and sustained virologic response (SVR) of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy. Ribavirin 187-196 interferon lambda 3 Homo sapiens 87-92 21418737-0 2011 Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin. Ribavirin 168-177 coagulation factor VIII Homo sapiens 0-11 22087138-7 2011 Then we performed a meta-analysis comparing the SVR rate at SNP of the IL28B in individuals with PEG-interferon/ribavirin therapy. Ribavirin 112-121 interferon lambda 3 Homo sapiens 71-76 21418737-4 2011 We report a rare case of acquired FVIII and factor IX (FIX) inhibitors in a single, non-haemophilic patient with chronic hepatitis C virus (HCV) infection who was receiving antiviral treatment with pegylated interferon plus ribavirin. Ribavirin 224-233 coagulation factor VIII Homo sapiens 34-39 22087138-12 2011 CONCLUSIONS: IL28B is significantly associated with response to PEG-interferon/ribavirin therapy of patients with chronic HCV infection. Ribavirin 79-88 interferon lambda 3 Homo sapiens 13-18 21418737-4 2011 We report a rare case of acquired FVIII and factor IX (FIX) inhibitors in a single, non-haemophilic patient with chronic hepatitis C virus (HCV) infection who was receiving antiviral treatment with pegylated interferon plus ribavirin. Ribavirin 224-233 coagulation factor IX Homo sapiens 44-53 20667172-5 2011 For this purpose, 17 hepatitis C patients received IFN-alpha treatment with ribavirin. Ribavirin 76-85 interferon alpha 1 Homo sapiens 51-60 20830599-8 2011 CONCLUSIONS: A decision tree model that includes age, gender, AFP, platelet counts, and GGT is useful for predicting the probability of response to therapy with peg-interferon plus ribavirin and has the potential to support clinical decisions regarding the selection of patients for therapy. Ribavirin 181-190 alpha fetoprotein Homo sapiens 62-65 21129805-0 2011 Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. Ribavirin 66-75 interferon lambda 3 Homo sapiens 130-135 21129805-11 2011 CONCLUSIONS: The IL28B polymorphism and mutations in the ISDR of HCV were significant pre-treatment predictors of response to PEG-IFN/RBV. Ribavirin 134-137 interferon lambda 3 Homo sapiens 17-22 21112657-1 2011 BACKGROUND & AIMS: Genetic variation in the interleukin 28B (IL28B) gene has been associated with the response to interferon-alfa/ribavirin therapy in hepatitis C virus (HCV) genotype 1-infected patients. Ribavirin 134-143 interferon lambda 3 Homo sapiens 65-70 21304937-10 2011 Further, model predictions estimate the threshold ribavirin exposure beyond which anemia becomes intolerable and suggest guidelines for the usage of growth hormones, such as erythropoietin, that stimulate erythrocyte production and avert the reduction of ribavirin dosage, thereby improving treatment response. Ribavirin 255-264 erythropoietin Homo sapiens 174-188 21112657-3 2011 METHODS: In patients with chronic hepatitis C genotype 2/3 (n=267), IL28B host genotypes (rs8099917, rs12980275 and rs12979860) were analyzed for associations with sustained virologic response (SVR) to antiviral therapy with (pegylated) interferon-alfa and ribavirin and with respect to epidemiological, biochemical, and virological parameters. Ribavirin 257-266 interferon lambda 3 Homo sapiens 68-73 21553652-8 2011 In contrast, the absorption rate of ribavirin (a CNT2 substrate) remained unchanged. Ribavirin 36-45 solute carrier family 28 member 2 Rattus norvegicus 49-53 21091911-8 2011 Successful HCV treatment with pegylated interferon/ribavirin or blocking PD-1/PDL-1 engagement ex vivo led to reduced PD-1 expression and improved IL-12 production as well as STAT-1 activation in M/Mphi from HCV-infected individuals. Ribavirin 51-60 programmed cell death 1 Homo sapiens 118-122 21390311-1 2011 BACKGROUND: High baseline levels of IP-10 predict a slower first phase decline in HCV RNA and a poor outcome following interferon/ribavirin therapy in patients with chronic hepatitis C. Several recent studies report that single nucleotide polymorphisms (SNPs) adjacent to IL28B predict spontaneous resolution of HCV infection and outcome of treatment among HCV genotype 1 infected patients. Ribavirin 130-139 C-X-C motif chemokine ligand 10 Homo sapiens 36-41 21390311-1 2011 BACKGROUND: High baseline levels of IP-10 predict a slower first phase decline in HCV RNA and a poor outcome following interferon/ribavirin therapy in patients with chronic hepatitis C. Several recent studies report that single nucleotide polymorphisms (SNPs) adjacent to IL28B predict spontaneous resolution of HCV infection and outcome of treatment among HCV genotype 1 infected patients. Ribavirin 130-139 interferon lambda 3 Homo sapiens 272-277 21143041-6 2011 The results of these studies suggested that the addition of this specific protease inhibitor to PEG IFN alfa-2a and RBV can significantly improve the results of treatment in patients affected with chronic HCV infection with genotype 1, when compared with the standard treatment, PEG IFN alfa-2a and RBV alone. Ribavirin 116-119 interferon alpha 1 Homo sapiens 283-286 20219081-1 2011 The present study aimed to characterize the baseline serum concentrations and the initial beta-chemokine response to treatment with interferon-alpha and ribavirin with respect to the final clinical outcome of virological response to treatment. Ribavirin 153-162 C-C motif chemokine ligand 5 Homo sapiens 90-104 21143041-6 2011 The results of these studies suggested that the addition of this specific protease inhibitor to PEG IFN alfa-2a and RBV can significantly improve the results of treatment in patients affected with chronic HCV infection with genotype 1, when compared with the standard treatment, PEG IFN alfa-2a and RBV alone. Ribavirin 299-302 interferon alpha 1 Homo sapiens 100-103 21143041-10 2011 RBV remains an essential component of treatment with protease inhibitors combined with PEG IFN. Ribavirin 0-3 interferon alpha 1 Homo sapiens 91-94 21274861-1 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). Ribavirin 145-154 inosine triphosphatase Homo sapiens 43-65 21246582-1 2011 UNLABELLED: Polymorphisms of the inosine triphosphatase (ITPA) gene influence anemia during pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with PEG-IFN, RBV, and telaprevir are not known. Ribavirin 127-136 inosine triphosphatase Homo sapiens 33-55 21246582-1 2011 UNLABELLED: Polymorphisms of the inosine triphosphatase (ITPA) gene influence anemia during pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with PEG-IFN, RBV, and telaprevir are not known. Ribavirin 127-136 inosine triphosphatase Homo sapiens 57-61 21068134-0 2011 HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Ribavirin 76-85 interferon lambda 3 Homo sapiens 22-27 21068134-1 2011 BACKGROUND AND AIMS: A number of recent studies have shown that human polymorphisms near the IL28B type III interferon (IFNlambda) gene influence the response to peg-interferon plus ribavirin combination therapy for infection with chronic hepatitis C virus (HCV). Ribavirin 182-191 interferon lambda 3 Homo sapiens 93-98 21068134-8 2011 CONCLUSIONS: IL28B polymorphisms and HCV core amino acid 70 substitutions contribute independently to an SVR to peg-interferon plus ribavirin combination therapy. Ribavirin 132-141 interferon lambda 3 Homo sapiens 13-18 21070775-0 2011 Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. BACKGROUND & AIMS: Chronic hepatitis C is associated with an increased prevalence of insulin resistance, which might result from liver disease, metabolic factors, or the hepatitis C virus (HCV) itself. Ribavirin 82-91 insulin Homo sapiens 11-18 21070775-0 2011 Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. BACKGROUND & AIMS: Chronic hepatitis C is associated with an increased prevalence of insulin resistance, which might result from liver disease, metabolic factors, or the hepatitis C virus (HCV) itself. Ribavirin 82-91 insulin Homo sapiens 206-213 21070775-2 2011 We evaluated changes in insulin resistance and weight in patients with hepatitis C during and after peginterferon and ribavirin therapy. Ribavirin 118-127 insulin Homo sapiens 24-31 21070775-9 2011 CONCLUSIONS: In patients with HCV genotype 1 infections, therapy with peginterferon and ribavirin is associated with decreases in body weight and insulin resistance. Ribavirin 88-97 insulin Homo sapiens 146-153 21246582-1 2011 UNLABELLED: Polymorphisms of the inosine triphosphatase (ITPA) gene influence anemia during pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with PEG-IFN, RBV, and telaprevir are not known. Ribavirin 138-141 inosine triphosphatase Homo sapiens 33-55 21246582-1 2011 UNLABELLED: Polymorphisms of the inosine triphosphatase (ITPA) gene influence anemia during pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with PEG-IFN, RBV, and telaprevir are not known. Ribavirin 138-141 inosine triphosphatase Homo sapiens 57-61 21274861-1 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). Ribavirin 145-154 inosine triphosphatase Homo sapiens 67-71 21246582-1 2011 UNLABELLED: Polymorphisms of the inosine triphosphatase (ITPA) gene influence anemia during pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with PEG-IFN, RBV, and telaprevir are not known. Ribavirin 206-209 inosine triphosphatase Homo sapiens 33-55 21246582-1 2011 UNLABELLED: Polymorphisms of the inosine triphosphatase (ITPA) gene influence anemia during pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with PEG-IFN, RBV, and telaprevir are not known. Ribavirin 206-209 inosine triphosphatase Homo sapiens 57-61 21274861-1 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). Ribavirin 145-154 inosine triphosphatase Homo sapiens 86-117 21274861-1 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). Ribavirin 156-159 inosine triphosphatase Homo sapiens 43-65 21269381-0 2011 Characterization of elevated alanine aminotransferase levels during pegylated-interferon alpha-2b plus ribavirin treatment for chronic hepatitis C. AIM: Elevation of alanine aminotransferase (ALT) levels during pegylated-interferon (peg-IFN) plus ribavirin therapy in patients with chronic hepatitis C [CHC] is a problem that cannot be disregarded. Ribavirin 103-112 glutamic--pyruvic transaminase Homo sapiens 29-53 21274861-1 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). Ribavirin 156-159 inosine triphosphatase Homo sapiens 67-71 21269381-0 2011 Characterization of elevated alanine aminotransferase levels during pegylated-interferon alpha-2b plus ribavirin treatment for chronic hepatitis C. AIM: Elevation of alanine aminotransferase (ALT) levels during pegylated-interferon (peg-IFN) plus ribavirin therapy in patients with chronic hepatitis C [CHC] is a problem that cannot be disregarded. Ribavirin 249-258 glutamic--pyruvic transaminase Homo sapiens 29-53 21274861-1 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). Ribavirin 156-159 inosine triphosphatase Homo sapiens 86-117 21269381-0 2011 Characterization of elevated alanine aminotransferase levels during pegylated-interferon alpha-2b plus ribavirin treatment for chronic hepatitis C. AIM: Elevation of alanine aminotransferase (ALT) levels during pegylated-interferon (peg-IFN) plus ribavirin therapy in patients with chronic hepatitis C [CHC] is a problem that cannot be disregarded. Ribavirin 249-258 glutamic--pyruvic transaminase Homo sapiens 168-192 21274861-1 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). Ribavirin 203-206 inosine triphosphatase Homo sapiens 43-65 21269387-9 2011 CONCLUSION: Potent combination therapy with PEG-IFN and ribavirin is likely associated with the increase in IFN-related type 1 diabetes. Ribavirin 58-67 interferon alpha 1 Homo sapiens 110-113 21274861-1 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). Ribavirin 203-206 inosine triphosphatase Homo sapiens 67-71 21274861-1 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). Ribavirin 203-206 inosine triphosphatase Homo sapiens 86-117 20924369-3 2011 Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)-lambda-3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV. Ribavirin 207-216 interferon lambda 3 Homo sapiens 53-58 20196801-0 2011 Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection. Ribavirin 67-76 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 6-9 20196801-17 2011 S-B12 > 360 pm is independently correlated to ETR in HCV patients treated with interferon and ribavirin. Ribavirin 97-106 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 2-5 20196808-0 2011 Are FoxP3(+) cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C? Ribavirin 64-73 forkhead box P3 Homo sapiens 4-9 21340353-10 2011 Pretreatment CXCL10 levels were predictive of both EVR and SVR to IFN-alpha and ribavirin and may be useful in the evaluation of candidates for therapy. Ribavirin 80-89 C-X-C motif chemokine ligand 10 Homo sapiens 13-19 20924369-3 2011 Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)-lambda-3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV. Ribavirin 207-216 interferon lambda 3 Homo sapiens 97-122 20924369-3 2011 Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)-lambda-3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV. Ribavirin 207-216 interferon lambda 3 Homo sapiens 126-131 20924369-3 2011 Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)-lambda-3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV. Ribavirin 207-216 interferon alpha 1 Homo sapiens 109-112 21376259-9 2011 CONCLUSIONS: IFI27, IFIT1, IFI6, ISG15, and CXCL10 genes are potential biological markers useful for predicting response to Peg-IFNalpha 2b/RBV therapy in HCV-1 patients. Ribavirin 140-143 interferon alpha inducible protein 27 Homo sapiens 13-18 21817190-0 2011 Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. Ribavirin 139-148 inosine triphosphatase Homo sapiens 42-64 21817190-1 2011 BACKGROUND: A genome-wide association study revealed an association between variants of the inosine triphosphatase (ITPA) gene and ribavirin (RBV)-induced anaemia. Ribavirin 131-140 inosine triphosphatase Homo sapiens 92-114 21817190-1 2011 BACKGROUND: A genome-wide association study revealed an association between variants of the inosine triphosphatase (ITPA) gene and ribavirin (RBV)-induced anaemia. Ribavirin 131-140 inosine triphosphatase Homo sapiens 116-120 21817190-1 2011 BACKGROUND: A genome-wide association study revealed an association between variants of the inosine triphosphatase (ITPA) gene and ribavirin (RBV)-induced anaemia. Ribavirin 142-145 inosine triphosphatase Homo sapiens 92-114 21817190-1 2011 BACKGROUND: A genome-wide association study revealed an association between variants of the inosine triphosphatase (ITPA) gene and ribavirin (RBV)-induced anaemia. Ribavirin 142-145 inosine triphosphatase Homo sapiens 116-120 21817190-4 2011 RESULTS: Variants of the ITPA gene protected against severe anaemia throughout the 48-week treatment period and were associated with lower incidence of anaemia-related RBV dose reduction. Ribavirin 168-171 inosine triphosphatase Homo sapiens 25-29 22024523-7 2011 CONCLUSIONS: Serum IL-10 and IL-12p40 levels in combination with IL28B genotype, especially G-allele carriage, are strong predictive markers of an NVR to HCV treatment with pegylated interferon and ribavirin. Ribavirin 198-207 interleukin 10 Homo sapiens 19-24 22024524-3 2011 In this study, we investigated the association of serum IL-6 levels with outcomes of pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Ribavirin 121-130 interleukin 6 Homo sapiens 56-60 22024524-3 2011 In this study, we investigated the association of serum IL-6 levels with outcomes of pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Ribavirin 132-135 interleukin 6 Homo sapiens 56-60 22024524-8 2011 In male patients with SVR, serum IL-6 levels decreased significantly at 4 weeks of treatment (P=0.029) and remained significantly lower than those of non-SVR patients after 4, 8 and 12 weeks of PEG-IFN plus RBV therapy. Ribavirin 207-210 interleukin 6 Homo sapiens 33-37 22024524-9 2011 CONCLUSIONS: Our results suggest that baseline levels of IL-6, as well as their decrease during treatment, are correlated to outcomes of PEG-IFN plus RBV therapy in male patients. Ribavirin 150-153 interleukin 6 Homo sapiens 57-61 22155905-0 2011 Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients. Ribavirin 0-9 matrix metallopeptidase 9 Homo sapiens 31-36 21817190-6 2011 Among a subset of patients with the IL28B genotype of TT at rs8099917, patients with variants of the ITPA gene were associated with a higher rate of receiving >80% of the expected RBV dose, a higher rate of sustained virological response (SVR), and a lower rate of relapse. Ribavirin 183-186 interferon lambda 3 Homo sapiens 36-41 21817190-6 2011 Among a subset of patients with the IL28B genotype of TT at rs8099917, patients with variants of the ITPA gene were associated with a higher rate of receiving >80% of the expected RBV dose, a higher rate of sustained virological response (SVR), and a lower rate of relapse. Ribavirin 183-186 inosine triphosphatase Homo sapiens 101-105 21376259-9 2011 CONCLUSIONS: IFI27, IFIT1, IFI6, ISG15, and CXCL10 genes are potential biological markers useful for predicting response to Peg-IFNalpha 2b/RBV therapy in HCV-1 patients. Ribavirin 140-143 interferon induced protein with tetratricopeptide repeats 1 Homo sapiens 20-25 21817190-7 2011 CONCLUSIONS: The variants of the ITPA gene, which could protect against haemolytic anaemia and RBV dose reduction, were associated with a high rate of SVR by standard PEG-IFN and RBV therapy in a subset of Japanese patients with the favourable TT genotype at rs8099917 of IL28B. Ribavirin 95-98 inosine triphosphatase Homo sapiens 33-37 21817190-7 2011 CONCLUSIONS: The variants of the ITPA gene, which could protect against haemolytic anaemia and RBV dose reduction, were associated with a high rate of SVR by standard PEG-IFN and RBV therapy in a subset of Japanese patients with the favourable TT genotype at rs8099917 of IL28B. Ribavirin 95-98 interferon lambda 3 Homo sapiens 272-277 21817190-7 2011 CONCLUSIONS: The variants of the ITPA gene, which could protect against haemolytic anaemia and RBV dose reduction, were associated with a high rate of SVR by standard PEG-IFN and RBV therapy in a subset of Japanese patients with the favourable TT genotype at rs8099917 of IL28B. Ribavirin 179-182 inosine triphosphatase Homo sapiens 33-37 21817190-7 2011 CONCLUSIONS: The variants of the ITPA gene, which could protect against haemolytic anaemia and RBV dose reduction, were associated with a high rate of SVR by standard PEG-IFN and RBV therapy in a subset of Japanese patients with the favourable TT genotype at rs8099917 of IL28B. Ribavirin 179-182 interferon lambda 3 Homo sapiens 272-277 21900721-6 2011 Cells were treated for 24 h with ribavirin (0, 10 and 50 muM) plus abacavir, tenofovir or lamivudine at doses of 0, 10 and 50 muM and HCV RNA production was quantified by real-time PCR in triplicate assays. Ribavirin 33-42 latexin Homo sapiens 57-60 22155905-3 2011 METHODS: THP-1 and LX-2 cells were treated with ribavirin (RBV)/interferon-alpha (IFN-alpha) and select HIV antivirals. Ribavirin 48-57 GLI family zinc finger 2 Homo sapiens 9-14 22155905-3 2011 METHODS: THP-1 and LX-2 cells were treated with ribavirin (RBV)/interferon-alpha (IFN-alpha) and select HIV antivirals. Ribavirin 59-62 GLI family zinc finger 2 Homo sapiens 9-14 22155905-7 2011 Decreases in MMP-9 activity were mediated by IFN-alpha, which also attenuated RBV induction of MMP-9 activity and protein expression in THP-1 cells. Ribavirin 78-81 matrix metallopeptidase 9 Homo sapiens 13-18 22155905-7 2011 Decreases in MMP-9 activity were mediated by IFN-alpha, which also attenuated RBV induction of MMP-9 activity and protein expression in THP-1 cells. Ribavirin 78-81 interferon alpha 1 Homo sapiens 45-54 22155905-7 2011 Decreases in MMP-9 activity were mediated by IFN-alpha, which also attenuated RBV induction of MMP-9 activity and protein expression in THP-1 cells. Ribavirin 78-81 matrix metallopeptidase 9 Homo sapiens 95-100 21900721-6 2011 Cells were treated for 24 h with ribavirin (0, 10 and 50 muM) plus abacavir, tenofovir or lamivudine at doses of 0, 10 and 50 muM and HCV RNA production was quantified by real-time PCR in triplicate assays. Ribavirin 33-42 latexin Homo sapiens 126-129 21376259-9 2011 CONCLUSIONS: IFI27, IFIT1, IFI6, ISG15, and CXCL10 genes are potential biological markers useful for predicting response to Peg-IFNalpha 2b/RBV therapy in HCV-1 patients. Ribavirin 140-143 interferon alpha inducible protein 6 Homo sapiens 27-31 22155905-7 2011 Decreases in MMP-9 activity were mediated by IFN-alpha, which also attenuated RBV induction of MMP-9 activity and protein expression in THP-1 cells. Ribavirin 78-81 GLI family zinc finger 2 Homo sapiens 136-141 21376259-9 2011 CONCLUSIONS: IFI27, IFIT1, IFI6, ISG15, and CXCL10 genes are potential biological markers useful for predicting response to Peg-IFNalpha 2b/RBV therapy in HCV-1 patients. Ribavirin 140-143 ISG15 ubiquitin like modifier Homo sapiens 33-38 22155905-11 2011 RBV/pegylated IFN-alpha decreased plasma MMP-9 abundance in HIV-HCV patients. Ribavirin 0-3 interferon alpha 1 Homo sapiens 14-23 22155905-11 2011 RBV/pegylated IFN-alpha decreased plasma MMP-9 abundance in HIV-HCV patients. Ribavirin 0-3 matrix metallopeptidase 9 Homo sapiens 41-46 21376259-9 2011 CONCLUSIONS: IFI27, IFIT1, IFI6, ISG15, and CXCL10 genes are potential biological markers useful for predicting response to Peg-IFNalpha 2b/RBV therapy in HCV-1 patients. Ribavirin 140-143 C-X-C motif chemokine ligand 10 Homo sapiens 44-50 20438578-0 2011 Antiviral re-treatment of IFN-ribavirin non-responders for recurrent post-transplantation hepatitis C. BACKGROUND: The aim of the study was to compare the efficacy and tolerability of pegylated interferon (PEG-IFN) plus ribavirin (RIB) and PEG-IFN monotherapy after unsuccessful initial therapy with interferon-alpha2b (IFN) plus RIB after recurrent post-transplantation hepatitis C. METHODS: Twenty-four patients with either no response (n = 10) or relapse (n = 14) after treatment with IFN plus RIB were prospectively randomized in the two treatment arms: 1) PEG-IFN monotherapy at a dosage of 0.8 mug/kg per week (n = 12) and 2) PEG-IFN (0.8 mug/kg per week) plus RIB (800-1200 mg/d) (n = 12). Ribavirin 30-39 interferon alpha 1 Homo sapiens 26-29 22879793-1 2011 Combined pegylated interferon (PEG-IFN)+ribavirin (RBV) therapy has been used as a primary treatment for chronic hepatitis C. However, IFN-induced autoimmune disease, including type 1 diabetes mellitus, has been highlighted as one of the problems with this therapy. Ribavirin 40-49 interferon alpha 1 Homo sapiens 135-138 22879793-1 2011 Combined pegylated interferon (PEG-IFN)+ribavirin (RBV) therapy has been used as a primary treatment for chronic hepatitis C. However, IFN-induced autoimmune disease, including type 1 diabetes mellitus, has been highlighted as one of the problems with this therapy. Ribavirin 51-54 interferon alpha 1 Homo sapiens 135-138 21734383-3 2011 RESULTS: Single nucleotide polymorphisms near the IL28B gene location which encode for interferon (IFN)-lambda3 have a large effect in determining the likelihood of patients obtaining a cure from pegylated IFN-alpha and ribavirin combination therapy or spontaneous clearance of the HCV. Ribavirin 220-229 interferon lambda 3 Homo sapiens 50-55 22156478-1 2011 Combination therapy of pegylated interferon-alpha with ribavirin (PEG-IFN/RBV) is a standard of care for chronic hepatitis C (CHC). Ribavirin 55-64 interferon alpha 1 Homo sapiens 70-73 21734383-3 2011 RESULTS: Single nucleotide polymorphisms near the IL28B gene location which encode for interferon (IFN)-lambda3 have a large effect in determining the likelihood of patients obtaining a cure from pegylated IFN-alpha and ribavirin combination therapy or spontaneous clearance of the HCV. Ribavirin 220-229 interferon lambda 3 Homo sapiens 87-111 21691112-4 2011 On the other hand, the common BSEP polymorphism V444A (c.1331T>C; allele frequency 65%) emerged as an independent predictor of the success rate in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Ribavirin 218-227 ATP binding cassette subfamily B member 11 Homo sapiens 30-34 21734383-3 2011 RESULTS: Single nucleotide polymorphisms near the IL28B gene location which encode for interferon (IFN)-lambda3 have a large effect in determining the likelihood of patients obtaining a cure from pegylated IFN-alpha and ribavirin combination therapy or spontaneous clearance of the HCV. Ribavirin 220-229 interferon alpha 1 Homo sapiens 206-215 21254158-1 2011 UNLABELLED: Polymorphisms of the IL28B gene are highly associated with sustained virological response (SVR) in patients with chronic hepatitis C treated with peginterferon and ribavirin. Ribavirin 176-185 interferon lambda 3 Homo sapiens 33-38 22156487-2 2011 A common genetic variation near the IL28B gene has been found to affect the response to PEG-IFN plus ribavirin therapy for CHC. Ribavirin 101-110 interferon lambda 3 Homo sapiens 36-41 21254160-1 2011 UNLABELLED: The combination of pegylated interferon (PEG-IFN) and ribavirin is the standard treatment for chronic hepatitis C. Our recent clinical study suggests that ribavirin augments the induction of interferon-stimulated genes (ISGs) in patients treated for hepatitis C virus (HCV) infection. Ribavirin 167-176 interferon alpha 1 Homo sapiens 57-60 21254160-8 2011 Direct up-regulation of these antiviral genes by ribavirin is mediated by a novel mechanism different from those associated with IFN signaling and intracellular double-stranded RNA sensing pathways such as RIG-I and MDA5. Ribavirin 49-58 interferon induced with helicase C domain 1 Homo sapiens 216-220 21254160-10 2011 CONCLUSION: Our study suggests that ribavirin, acting by way of a novel innate mechanism, potentiates the anti-HCV effect of IFN. Ribavirin 36-45 interferon alpha 1 Homo sapiens 125-128 22220215-6 2011 CTPS1 enzyme inhibitors 6-diazo-5-oxo-L-norleucine and Acivicin as well as the IMPDH2 inhibitor Ribavirin exhibited dose-dependent induction of RR in >95% of cells in all cancer cell lines tested as well as mouse primary cells. Ribavirin 96-105 inosine monophosphate dehydrogenase 2 Mus musculus 79-85 20809700-0 2011 Evaluation of interleukin-8 in hepatitis C virus infection: relation to combined peg-interferon ribavirin response and genotype 4. Ribavirin 96-105 C-X-C motif chemokine ligand 8 Homo sapiens 14-27 20809700-3 2011 The aim of the present study was to investigate the relationship among levels of IL-8 in serum of subjects with past exposure to HCV indicated by positive IgG to HCV and negative PCR, patients with chronic HCV infections and in responder to combined alfa IFN and ribavirin therapy. Ribavirin 263-272 C-X-C motif chemokine ligand 8 Homo sapiens 81-85 20809700-8 2011 The present study highlights the kinetic of serum levels of interleukin-8 in patients with chronic hepatitis C genotype 4 before and after therapy with combined alfa interferon and ribavirin. Ribavirin 181-190 C-X-C motif chemokine ligand 8 Homo sapiens 60-73 21532235-4 2011 However, the titers of anti-CCP antibodies and BAFF levels were elevated by the IFN plus ribavirin therapy. Ribavirin 89-98 TNF superfamily member 13b Homo sapiens 47-51 20974502-0 2011 Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HIV/HCV co-infected patients. Ribavirin 100-109 insulin Homo sapiens 0-7 21576995-4 2011 In contrast to IL-17, IFN-gamma showed significant reduction after 12 weeks of treatment with pegylated IFN plus ribavirin. Ribavirin 113-122 interferon gamma Homo sapiens 22-31 21576995-4 2011 In contrast to IL-17, IFN-gamma showed significant reduction after 12 weeks of treatment with pegylated IFN plus ribavirin. Ribavirin 113-122 interferon alpha 1 Homo sapiens 22-25 21576995-6 2011 CONCLUSION: Our findings suggest that the combined treatment with pegylated IFN-alpha and ribavirin downmodulates the secretion of key cytokine IFN-gamma as early as 12 weeks after treatment in infected patients. Ribavirin 90-99 interferon gamma Homo sapiens 144-153 22220215-7 2011 RR formation by lower concentration of Ribavirin was enhanced in IMPDH2-knockdown HeLa cells whereas it was inhibited in GFP-IMPDH2 overexpressed HeLa cells. Ribavirin 39-48 inosine monophosphate dehydrogenase 2 Homo sapiens 65-71 22220215-7 2011 RR formation by lower concentration of Ribavirin was enhanced in IMPDH2-knockdown HeLa cells whereas it was inhibited in GFP-IMPDH2 overexpressed HeLa cells. Ribavirin 39-48 inosine monophosphate dehydrogenase 2 Homo sapiens 125-131 22114715-0 2011 Ribavirin enhances IFN-alpha signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. Ribavirin 0-9 interferon alpha 1 Homo sapiens 19-28 22174846-6 2011 It was also revealed that IL28B and STAT1-nuclear translocation in hepatocytes are independent predictors of response to treatment with peginterferon and ribavirin in chronic hepatitis C patients. Ribavirin 154-163 interferon lambda 3 Homo sapiens 26-31 22174846-6 2011 It was also revealed that IL28B and STAT1-nuclear translocation in hepatocytes are independent predictors of response to treatment with peginterferon and ribavirin in chronic hepatitis C patients. Ribavirin 154-163 signal transducer and activator of transcription 1 Homo sapiens 36-41 22114715-0 2011 Ribavirin enhances IFN-alpha signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. Ribavirin 0-9 MX dynamin like GTPase 1 Homo sapiens 44-47 22114715-1 2011 The nucleoside analogue Ribavirin significantly increases patient response to IFN-alpha treatment of HCV, by directly inhibiting viral replication. Ribavirin 24-33 interferon alpha 1 Homo sapiens 78-87 22114715-2 2011 Recent studies indicate that Ribavirin also regulates immunity and we propose that Ribavirin enhances specific interferon sensitive gene (ISG) expression by amplifying the IFN-alpha-JAK/STAT pathway. Ribavirin 29-38 interferon alpha 1 Homo sapiens 172-181 22114715-2 2011 Recent studies indicate that Ribavirin also regulates immunity and we propose that Ribavirin enhances specific interferon sensitive gene (ISG) expression by amplifying the IFN-alpha-JAK/STAT pathway. Ribavirin 83-92 interferon alpha 1 Homo sapiens 172-181 22114715-3 2011 We found that IFN-alpha-induced STAT1 and STAT3 phosphorylation was increased in hepatocytes co-treated with Ribavirin and IFN-alpha, compared to IFN-alpha alone. Ribavirin 109-118 interferon alpha 1 Homo sapiens 14-23 22114715-3 2011 We found that IFN-alpha-induced STAT1 and STAT3 phosphorylation was increased in hepatocytes co-treated with Ribavirin and IFN-alpha, compared to IFN-alpha alone. Ribavirin 109-118 signal transducer and activator of transcription 1 Homo sapiens 32-37 22114715-3 2011 We found that IFN-alpha-induced STAT1 and STAT3 phosphorylation was increased in hepatocytes co-treated with Ribavirin and IFN-alpha, compared to IFN-alpha alone. Ribavirin 109-118 signal transducer and activator of transcription 3 Homo sapiens 42-47 22114715-4 2011 Ribavirin specifically enhanced IFN-alpha induced mRNA and protein of the anti-viral mediator MxA, which co-localised with HCV core protein. Ribavirin 0-9 interferon alpha 1 Homo sapiens 32-41 22114715-4 2011 Ribavirin specifically enhanced IFN-alpha induced mRNA and protein of the anti-viral mediator MxA, which co-localised with HCV core protein. Ribavirin 0-9 MX dynamin like GTPase 1 Homo sapiens 94-97 22114715-5 2011 These novel findings indicate for the first time that Ribavirin, in addition to its viral incorporation, also enhances IFN-alpha-JAK/STAT signalling, leading to a novel MxA-mediated immuno-modulatory mechanism that may enhance IFN-alpha anti-viral activity against HCV. Ribavirin 54-63 interferon alpha 1 Homo sapiens 119-128 22114715-5 2011 These novel findings indicate for the first time that Ribavirin, in addition to its viral incorporation, also enhances IFN-alpha-JAK/STAT signalling, leading to a novel MxA-mediated immuno-modulatory mechanism that may enhance IFN-alpha anti-viral activity against HCV. Ribavirin 54-63 MX dynamin like GTPase 1 Homo sapiens 169-172 22114715-5 2011 These novel findings indicate for the first time that Ribavirin, in addition to its viral incorporation, also enhances IFN-alpha-JAK/STAT signalling, leading to a novel MxA-mediated immuno-modulatory mechanism that may enhance IFN-alpha anti-viral activity against HCV. Ribavirin 54-63 interferon alpha 1 Homo sapiens 227-236 21750736-0 2011 Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C. INTRODUCTION: Polymorphisms near the IL28B gene (e.g. rs12979860) encoding interferon lambda3 have recently been associated with both spontaneous clearance and treatment response to pegIFN/RBV in chronic hepatitis C (CHC) patients. Ribavirin 296-299 interferon lambda 3 Homo sapiens 144-149 22003405-0 2011 IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. Ribavirin 116-125 interferon lambda 3 Homo sapiens 0-5 22003405-1 2011 BACKGROUND: Genetic studies have demonstrated a strong association between single nucleotide polymorphisms (SNPs) at IL28B and response to treatment with peginterferon (PEG) and ribavirin (RBV) in HCV monoinfected persons. Ribavirin 178-187 interferon lambda 3 Homo sapiens 117-122 22003405-1 2011 BACKGROUND: Genetic studies have demonstrated a strong association between single nucleotide polymorphisms (SNPs) at IL28B and response to treatment with peginterferon (PEG) and ribavirin (RBV) in HCV monoinfected persons. Ribavirin 189-192 interferon lambda 3 Homo sapiens 117-122 22003405-9 2011 CONCLUSIONS: IL28B SNPs have an additive allele dose effect in predicting HCV treatment outcomes in HCV/HIV coinfected persons and can be incorporated into a simple pretreatment prediction score that could minimize the risk of exposure to PEG/RBV therapy for persons with unfavorable scores. Ribavirin 243-246 interferon lambda 3 Homo sapiens 13-18 21760886-0 2011 An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. BACKGROUND: Genetic variation in IL28B and other factors are associated with sustained virological response (SVR) after pegylated-interferon/ribavirin treatment for chronic hepatitis C (CHC). Ribavirin 229-238 interferon lambda 3 Homo sapiens 3-8 21760886-0 2011 An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. BACKGROUND: Genetic variation in IL28B and other factors are associated with sustained virological response (SVR) after pegylated-interferon/ribavirin treatment for chronic hepatitis C (CHC). Ribavirin 229-238 interferon lambda 3 Homo sapiens 121-126 21760886-7 2011 IL28B rs12979860-CC genotype was the strongest predictor of SVR (aOR, 7.56; p<.0001); the model also included HCV RNA (log10 IU/ml), AST:ALT ratio, Ishak fibrosis score and prior ribavirin treatment. Ribavirin 182-191 interferon lambda 3 Homo sapiens 0-5 21603632-0 2011 Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. BACKGROUND: Despite being expensive, the standard combination of pegylated interferon (Peg-IFN)-alpha and ribavirin used to treat chronic hepatitis C (CH) results in a moderate clearance rate and a plethora of side effects. Ribavirin 82-91 interferon alpha 1 Homo sapiens 17-20 21677781-7 2011 Remarkably, ongoing protein synthesis and viral replication are required to maintain repression of the IFNbeta gene in persistently infected cells, as the gene can be activated by the protein synthesis inhibitor cycloheximide, or by the antiviral drug ribavirin. Ribavirin 252-261 interferon beta 1 Homo sapiens 103-110 21603632-0 2011 Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. BACKGROUND: Despite being expensive, the standard combination of pegylated interferon (Peg-IFN)-alpha and ribavirin used to treat chronic hepatitis C (CH) results in a moderate clearance rate and a plethora of side effects. Ribavirin 230-239 interferon alpha 1 Homo sapiens 17-20 20861007-0 2010 Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. BACKGROUND/AIM: Insulin resistance (IR) is a major predictor of treatment failure in patients with hepatitis C virus (HCV) infection treated with peginterferon/ribavirin. Ribavirin 284-293 insulin Homo sapiens 140-147 22303600-5 2011 Recently all interest has been turned towards the demonstration of the host polymorphism located upstream of the IL-28B gene and which is associated with sustained virological response to treatment with pegylated interferon Alfa in combination with ribavirin. Ribavirin 249-258 interferon lambda 3 Homo sapiens 113-119 20822376-1 2011 OBJECTIVE: Several treatment strategies for patients with chronic hepatitis C have been compared mainly in terms of their efficacy, and it has been found that pegylated interferon (IFN) plus ribavirin has become the standard therapy, but aged patients may not tolerate ribavirin and the cost-effectiveness of treatment should also be further considered. Ribavirin 269-278 interferon alpha 1 Homo sapiens 181-184 20950615-5 2010 The IL28B genotype can be considered, along with other factors, in predicting patient responses to therapy with pegylated IFN-alpha and ribavirin. Ribavirin 136-145 interferon lambda 3 Homo sapiens 4-9 20729740-0 2010 Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment. Ribavirin 85-94 erythropoietin Homo sapiens 22-36 20931559-0 2010 IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. UNLABELLED: Genetic variation in the IL28B (interleukin 28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC) who were treated with peginterferon-alpha and ribavirin. Ribavirin 386-395 interferon lambda 3 Homo sapiens 0-5 20931559-0 2010 IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. UNLABELLED: Genetic variation in the IL28B (interleukin 28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC) who were treated with peginterferon-alpha and ribavirin. Ribavirin 386-395 interferon lambda 3 Homo sapiens 177-182 20931559-0 2010 IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. UNLABELLED: Genetic variation in the IL28B (interleukin 28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC) who were treated with peginterferon-alpha and ribavirin. Ribavirin 386-395 interferon lambda 3 Homo sapiens 184-220 20637200-1 2010 BACKGROUND & AIMS: A single nucleotide polymorphism (SNP) upstream of the IL28B gene has been associated with response of patients with chronic hepatitis C to therapy with pegylated interferon and ribavirin and also with spontaneous clearance of acute hepatitis C in a heterogeneous population. Ribavirin 201-210 interferon lambda 3 Homo sapiens 78-83 20002306-3 2010 This study examined the correlation of gene expression of MxA with the response to treatment with pegylated-IFN-alfa2b and ribavirin. Ribavirin 123-132 MX dynamin like GTPase 1 Homo sapiens 58-61 20708617-0 2010 Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. BACKGROUND & AIMS: Patients with hepatitis C virus (HCV)-related liver disease frequently undergo orthotopic liver transplantation, but recurrent hepatitis C is still a major cause of morbidity. Ribavirin 95-104 interferon lambda 3 Homo sapiens 12-17 20708617-4 2010 Liver recipient and donor DNA samples were screened for single nucleotide polymorphisms near the IL28B genes (rs12980275 and rs8099917) that affect sensitivity to PEG-IFN/RBV. Ribavirin 171-174 interferon lambda 3 Homo sapiens 97-102 20708617-9 2010 CONCLUSIONS: In patients with recurrent HCV infection after orthotopic liver transplantation, combination analyses of single nucleotide polymorphisms of IL28B in recipient and donor tissues and mutations in HCV RNA allow prediction of SVR to PEG-IFN/RBV therapy. Ribavirin 250-253 interferon lambda 3 Homo sapiens 153-158 20889274-1 2010 A SNP has been identified (rs12979860) located in chromosome 19,3 kb upstream of the IL28B gene that encodes IFN-lambda3, which was strongly associated with the sustained virological response (SVR) to pegIFN and ribavirin in more than 1000 patients with genotype 1 chronic hepatitis C. In patients of European ancestry, as well as in African-American and Hispanic patients, the CC genotype was associated with a two-fold greater SVR rate than the TT genotype, CT being closer to TT than to CC. Ribavirin 212-221 interferon lambda 3 Homo sapiens 85-90 20889274-1 2010 A SNP has been identified (rs12979860) located in chromosome 19,3 kb upstream of the IL28B gene that encodes IFN-lambda3, which was strongly associated with the sustained virological response (SVR) to pegIFN and ribavirin in more than 1000 patients with genotype 1 chronic hepatitis C. In patients of European ancestry, as well as in African-American and Hispanic patients, the CC genotype was associated with a two-fold greater SVR rate than the TT genotype, CT being closer to TT than to CC. Ribavirin 212-221 interferon lambda 3 Homo sapiens 109-120 20002306-9 2010 These results highlight the importance of the detection of MxA expression at the start of therapy as a factor for assessing the likelihood of HCV genotype 4 patients to achieving a sustained virological response to treatment with IFN-alpha2 in combination with ribavirin. Ribavirin 261-270 MX dynamin like GTPase 1 Homo sapiens 59-62 20609558-0 2010 [Thrombotic thrombocytopenic purpura mediated by an ADAMTS13-inhibitor related to a treatment with pegylated-interferon alpha-2a and ribavirine in a patient with chronic hepatitis C]. Ribavirin 133-143 ADAM metallopeptidase with thrombospondin type 1 motif 13 Homo sapiens 52-60 21048934-0 2010 IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. Ribavirin 79-88 interferon lambda 3 Homo sapiens 0-5 21048934-1 2010 Recent genome-wide association studies report that the SNP rs8099917, located 8.9 kb upstream of the start codon of IL28B, is associated with both disease chronicity and therapeutic response to pegIFN-alpha and RBV in patients infected with genotype 1 HCV. Ribavirin 211-214 interferon lambda 3 Homo sapiens 116-121 20804372-0 2010 Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Ribavirin 52-61 interferon lambda 3 Homo sapiens 65-70 20812847-1 2010 The equilibrative nucleoside transporter 1 (ENT1) is the main protein involved in ribavirin cellular uptake. Ribavirin 82-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-42 20812847-1 2010 The equilibrative nucleoside transporter 1 (ENT1) is the main protein involved in ribavirin cellular uptake. Ribavirin 82-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 20812847-2 2010 Polymorphisms at the ENT1 gene may influence ribavirin activity as part of hepatitis C virus (HCV) therapy. Ribavirin 45-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-25 20812847-9 2010 In summary, a SNP rs760370A G at the ENT1 gene influences the chance of rapid virological response to pegIFN-ribavirin therapy in HIV-infected patients with chronic HCV infection due to HCV genotypes 1 or 4, most likely modulating intracellular ribavirin exposure within hepatocytes. Ribavirin 109-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-41 20812847-9 2010 In summary, a SNP rs760370A G at the ENT1 gene influences the chance of rapid virological response to pegIFN-ribavirin therapy in HIV-infected patients with chronic HCV infection due to HCV genotypes 1 or 4, most likely modulating intracellular ribavirin exposure within hepatocytes. Ribavirin 245-254 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-41 20555268-0 2010 The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C. BACKGROUND: Conflicting results have been reported in studies evaluating the relationship between serum markers of iron overload, liver iron deposits, and HFE mutations (C282Y and H63D) in chronic hepatitis C patients, and also their impact on the response to therapy in these patients. Ribavirin 117-126 homeostatic iron regulator Homo sapiens 32-35 20804372-1 2010 BACKGROUND: Variation in the IL28B gene is associated with sustained virologic response (SVR) to pegylated interferon plus ribavirin in hepatitis C virus (HCV)-monoinfected patients with genotype 1. Ribavirin 123-132 interferon lambda 3 Homo sapiens 29-34 20547162-1 2010 BACKGROUND & AIMS: In a genome-wide association study of patients being treated for chronic hepatitis C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to protect against ribavirin (RBV)-induced hemolytic anemia during early stages of treatment. Ribavirin 223-232 inosine triphosphatase Homo sapiens 174-180 20547162-1 2010 BACKGROUND & AIMS: In a genome-wide association study of patients being treated for chronic hepatitis C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to protect against ribavirin (RBV)-induced hemolytic anemia during early stages of treatment. Ribavirin 234-237 inosine triphosphatase Homo sapiens 174-180 20547162-11 2010 The ITPase deficiency variable was associated with lower rates of anemia over the entire treatment period (48 weeks), as well as a lower rate of anemia-related RBV dose reduction (hazard ratio, 0.52; P = .0037). Ribavirin 160-163 inosine triphosphatase Homo sapiens 4-10 20547162-13 2010 CONCLUSIONS: Two polymorphisms that cause ITPase deficiency are strongly associated with protection from RBV-induced hemolytic anemia and decrease the need for RBV dose reduction. Ribavirin 105-108 inosine triphosphatase Homo sapiens 42-48 20547162-13 2010 CONCLUSIONS: Two polymorphisms that cause ITPase deficiency are strongly associated with protection from RBV-induced hemolytic anemia and decrease the need for RBV dose reduction. Ribavirin 160-163 inosine triphosphatase Homo sapiens 42-48 21076689-6 2010 For the first time, the case reports below highlight the same immunological adverse event secondary to PEG IFN-alpha 2a/ribavirin combination therapy and explain, in part, the complex interaction between host immune response and viral genotype. Ribavirin 120-129 interferon alpha 1 Homo sapiens 107-116 20577091-0 2010 Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus. Ribavirin 55-64 insulin Homo sapiens 0-7 20576307-1 2010 BACKGROUND & AIMS: A common genetic variation at the IL28 locus has been found to affect the response of peg-interferon and ribavirin combination therapy against chronic hepatitis C virus (HCV) infection. Ribavirin 128-137 interferon lambda 3 Homo sapiens 57-61 20887330-1 2010 AIM: Recent human genome-wide association studies (GWAS) revealed a strong association between IL28B gene variation and the pegylated interferon-alpha with ribavirin (PEG-IFN-alpha/RBV) treatment response in chronic hepatitis C patients. Ribavirin 158-167 interferon lambda 3 Homo sapiens 97-102 20887330-1 2010 AIM: Recent human genome-wide association studies (GWAS) revealed a strong association between IL28B gene variation and the pegylated interferon-alpha with ribavirin (PEG-IFN-alpha/RBV) treatment response in chronic hepatitis C patients. Ribavirin 158-167 interferon alpha 1 Homo sapiens 173-182 20629523-3 2010 In this case, ribavirin targets an oncogene, the eukaryotic translation initiation factor eIF4E, elevated in approximately 30% of cancers including many leukemias and lymphomas. Ribavirin 14-23 eukaryotic translation initiation factor 4E Homo sapiens 90-95 20629523-4 2010 Specifically, ribavirin impedes eIF4E mediated oncogenic transformation by acting as an inhibitor of eIF4E. Ribavirin 14-23 eukaryotic translation initiation factor 4E Homo sapiens 32-37 20629523-4 2010 Specifically, ribavirin impedes eIF4E mediated oncogenic transformation by acting as an inhibitor of eIF4E. Ribavirin 14-23 eukaryotic translation initiation factor 4E Homo sapiens 101-106 20206412-1 2010 Insulin resistance is a predictive factor of response to treatment with peginterferon and ribavirin in patients with hepatitis C. Insulin resistance impairs sensitivity to interferon and can block its intracellular signalling. Ribavirin 90-99 insulin Homo sapiens 0-7 20550548-10 2010 Our data show that NKG2A expression is dysregulated in chronic HCV infection and that NKG2A-positive NK cells are associated with a beneficial response to pegylated interferon and ribavirin therapy. Ribavirin 180-189 killer cell lectin-like receptor subfamily C, member 1 Mus musculus 86-91 21063486-0 2010 Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. Ribavirin 80-89 C-reactive protein Homo sapiens 9-12 21063486-9 2010 Hs-CRP level was significantly decreased in 83 patients after peginterferon/ribavirin combination therapy (0.24 vs. 0.62 mg/L, P < 0.001), particularly in 68 patients achieving a sustained virological response (0.25 vs. 0.64 mg/L, P < 0.001). Ribavirin 76-85 C-reactive protein Homo sapiens 3-6 21063486-10 2010 CONCLUSION: CHC patients had a higher hs-CRP level than healthy controls which could be ameliorated after peginterferon/ribavirin combination therapy. Ribavirin 120-129 C-reactive protein Homo sapiens 41-44 20206412-1 2010 Insulin resistance is a predictive factor of response to treatment with peginterferon and ribavirin in patients with hepatitis C. Insulin resistance impairs sensitivity to interferon and can block its intracellular signalling. Ribavirin 90-99 insulin Homo sapiens 130-137 20639253-6 2010 Triple therapy consisting of ISG15 knockdown, interferon alpha (IFNalpha) and ribavirin led to complete suppression of the HCV NS5A protein, corresponding to 99% suppression of HCV-RNA compared to 75% suppression by IFNalpha and ribavirin only. Ribavirin 229-238 ISG15 ubiquitin like modifier Homo sapiens 29-34 20639253-11 2010 Furthermore, analysis of ISG15 prior to therapy may be useful to predict short-term and long-term outcome and thus tailor antiviral therapy with pegIFN and ribavirin. Ribavirin 156-165 ISG15 ubiquitin like modifier Homo sapiens 25-30 20683942-0 2010 Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. UNLABELLED: The Major Depression Inventory (MDI) was used to estimate the value of routine medical interviews in diagnosing major depression among patients receiving peginterferon alfa-2a and ribavirin therapy for chronic hepatitis C virus (HCV) infection (n = 325). Ribavirin 280-289 MAFD2 Homo sapiens 132-135 20648473-1 2010 UNLABELLED: Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG-IFN/ribavirin is not clear. Ribavirin 213-222 interferon lambda 3 Homo sapiens 39-44 20648473-1 2010 UNLABELLED: Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG-IFN/ribavirin is not clear. Ribavirin 299-308 interferon lambda 3 Homo sapiens 39-44 20648473-9 2010 CONCLUSION: This study identified genetic variation near the IL28B gene and aa substitution of the core region as predictors of sustained virological response to a triple therapy of telaprevir/PEG-IFN/ribavirin in Japanese patients infected with HCV genotype 1b. Ribavirin 201-210 interferon lambda 3 Homo sapiens 61-66 20627191-7 2010 It is suggested that the interferon (IFN)-alpha/ribavirin therapy starting 2 months may be an effective option and now is undertaken. Ribavirin 48-57 interferon alpha 1 Homo sapiens 25-47 20399780-1 2010 BACKGROUND & AIMS: We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic hepatitis C virus genotype 1 (HCV-1) infection. Ribavirin 213-222 interferon lambda 3 Homo sapiens 73-93 20646277-15 2010 CONCLUSIONS: PEG-IFN alpha-2b plus weight-based ribavirin is effective in re-treating previous interferon-alpha plus RBV failure; 22.2% of the patients with genotype 1 HCV and 40% of patients with genotype 3 HCV achieved SVR. Ribavirin 117-120 interferon alpha 1 Homo sapiens 17-20 20399780-10 2010 CONCLUSIONS: In treatment-naive HCV-1 patients treated with pegylated interferon and ribavirin, a polymorphism upstream of IL-28B is associated with increased on-treatment and sustained virologic response and effectively predicts treatment outcome. Ribavirin 85-94 interferon lambda 3 Homo sapiens 123-129 20478857-7 2010 RESULTS: Hyperaemic septal rBV differed significantly between the groups and was highest in controls: d-TGA 0.141+/-0.060 ml/ml, TOF 0.134+/-0.080 ml/ml, controls 0.189+/-0.074 ml/ml, p=0.005. Ribavirin 27-30 T-box transcription factor 1 Homo sapiens 104-107 20303352-11 2010 IP10-induction correlated with first- and second-phase kinetics and with ribavirin serum concentrations on day 3. Ribavirin 73-82 C-X-C motif chemokine ligand 10 Homo sapiens 0-4 19878535-1 2010 Insulin resistance (IR) reduces response to pegylated-interferon (PEG-IFN)/ribavirin in chronic hepatitis C (CHC), but the mechanisms are still undefined. Ribavirin 75-84 insulin Homo sapiens 0-7 20390327-0 2010 Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy. Ribavirin 133-142 toll like receptor 7 Homo sapiens 14-18 21055076-11 2010 Th1/Th2 type cells in state of equilibrium (means IFN-gamma/IL-4) were: 2.02 +- 0.19, 2.38 +- 0.10, 2.36 +- 0.14, 2.22 +- 0.17 and 2.07 +- 0.15; and complex model group Haoqin Qingdan decoction group and virazole group were decreased, and there was no significant difference observed (t = 0.587, F = 3.684, P > 0.05). Ribavirin 204-212 negative elongation factor complex member C/D, Th1l Mus musculus 0-3 21161001-10 2010 CONCLUSION: These results suggest the possibilities of shortening the duration of Peg-IFN plus RBV combination therapy by actively reducing HCV-RNA levels using the IFN-beta induction regimen. Ribavirin 95-98 interferon beta 1 Homo sapiens 165-173 20428788-0 2010 Effect of ribavirin and interferon beta on miRNA profile in the hepatitis C virus subgenomic replicon-bearing Huh7 cells. Ribavirin 10-19 MIR7-3 host gene Homo sapiens 110-114 20483710-0 2010 Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin. Ribavirin 158-167 negative elongation factor complex member C/D Homo sapiens 10-13 20483710-8 2010 Combined treatment with pegylated interferon-alpha plus ribavirin down-modulated the secretion of key Th1 and Th17 pro-inflammatory mediators, and pro-fibrotic growth factors as early as 12 weeks after treatment initiation. Ribavirin 56-65 negative elongation factor complex member C/D Homo sapiens 102-105 20222909-2 2010 AIM: To explore the relationship between starting ribavirin doses, expressed as mg/kg body weight and both rapid viral response at treatment week 4 (RVR) and sustained virological response (SVR) in patients treated for 12-14 weeks with peg-interferon alpha-2b and ribavirin. Ribavirin 50-59 nuclear receptor subfamily 1 group D member 2 Homo sapiens 149-152 20222909-6 2010 RESULTS: A nonlinear relationship was ascertained between ribavirin dose and RVR, but not SVR. Ribavirin 58-67 nuclear receptor subfamily 1 group D member 2 Homo sapiens 77-80 20222909-8 2010 Regression analysis identified low baseline viraemia, genotype 2 and high ribavirin dose as independent prognostic factors for RVR. Ribavirin 74-83 nuclear receptor subfamily 1 group D member 2 Homo sapiens 127-130 20222909-10 2010 CONCLUSIONS: Starting high ribavirin doses appears capable of increasing the rate of RVR in patients with HCV genotypes 2 and 3 undergoing short treatment. Ribavirin 27-36 nuclear receptor subfamily 1 group D member 2 Homo sapiens 85-88 20176026-0 2010 Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Ribavirin 106-115 interferon lambda 3 Homo sapiens 34-39 20428788-7 2010 It was found that IFN beta and/or RBV suppressed miR-122 expression marginally, with a synergetic anti-HCV effect between IFN beta and RBV. Ribavirin 34-37 interferon beta 1 Homo sapiens 122-130 20028490-12 2010 In LDLT for HCV, pre-emptive IFN-RBV-based treatment with the application of no-stopping approach is feasible and effective. Ribavirin 33-36 interferon alpha 1 Homo sapiens 29-32 20070395-0 2010 Advantage of IFN-beta/alpha2b same-day administration for ribavirin-intolerant patients with chronic hepatitis C. AIM: Although interferon (IFN)/ribavirin is the mainstream combination treatment for chronic hepatitis C in patients with a high viral load, ribavirin is problematic for women of childbearing age and patients with anemia. Ribavirin 58-67 interferon beta 1 Homo sapiens 13-21 20377423-9 2010 Extensive intraerythrocyte accumulation of RBV following boosted production of red blood cells by EPO could explain these findings. Ribavirin 43-46 erythropoietin Homo sapiens 98-101 20546329-4 2010 Recent genome-wide association studies (GWAS) of the human whole genome revealed several single nucleotide polymorphism sites (SNP) strongly associated with the response to pegylated IFN-alpha (PEG-IFN) plus ribavirin (RBV) treatment in chronic hepatitis C patients. Ribavirin 219-222 interferon alpha 1 Homo sapiens 183-192 20546329-4 2010 Recent genome-wide association studies (GWAS) of the human whole genome revealed several single nucleotide polymorphism sites (SNP) strongly associated with the response to pegylated IFN-alpha (PEG-IFN) plus ribavirin (RBV) treatment in chronic hepatitis C patients. Ribavirin 219-222 interferon alpha 1 Homo sapiens 183-186 18521089-6 2010 Compared to no treatment, IFN-alpha/ribavirin administration was associated with significant flattening of the diurnal ACTH and cortisol slope and increased evening plasma ACTH and cortisol concentrations. Ribavirin 36-45 proopiomelanocortin Homo sapiens 119-123 18521089-6 2010 Compared to no treatment, IFN-alpha/ribavirin administration was associated with significant flattening of the diurnal ACTH and cortisol slope and increased evening plasma ACTH and cortisol concentrations. Ribavirin 36-45 proopiomelanocortin Homo sapiens 172-176 20070395-0 2010 Advantage of IFN-beta/alpha2b same-day administration for ribavirin-intolerant patients with chronic hepatitis C. AIM: Although interferon (IFN)/ribavirin is the mainstream combination treatment for chronic hepatitis C in patients with a high viral load, ribavirin is problematic for women of childbearing age and patients with anemia. Ribavirin 58-67 interferon alpha 1 Homo sapiens 13-16 20070395-4 2010 among 138 patients who underwent IFN treatment after ribavirin release. Ribavirin 53-62 interferon alpha 1 Homo sapiens 33-36 20166183-0 2010 Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy. Ribavirin 149-158 neural cell adhesion molecule 1 Homo sapiens 28-32 20185188-5 2010 RESULTS: Equilibrative nucleoside transporter 1 (ENT1)-mediated uptake was exclusively involved in ribavirin uptake in HH268 and HH283 and was responsible for the largest ribavirin uptake fraction in HH291. Ribavirin 99-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-47 20185188-5 2010 RESULTS: Equilibrative nucleoside transporter 1 (ENT1)-mediated uptake was exclusively involved in ribavirin uptake in HH268 and HH283 and was responsible for the largest ribavirin uptake fraction in HH291. Ribavirin 99-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-53 20185188-5 2010 RESULTS: Equilibrative nucleoside transporter 1 (ENT1)-mediated uptake was exclusively involved in ribavirin uptake in HH268 and HH283 and was responsible for the largest ribavirin uptake fraction in HH291. Ribavirin 171-180 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-47 20185188-5 2010 RESULTS: Equilibrative nucleoside transporter 1 (ENT1)-mediated uptake was exclusively involved in ribavirin uptake in HH268 and HH283 and was responsible for the largest ribavirin uptake fraction in HH291. Ribavirin 171-180 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-53 20185188-10 2010 CONCLUSIONS: ENT1, but not ENT2 or CNTs, is a major ribavirin uptake transporter in human hepatocytes. Ribavirin 52-61 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-17 20185188-11 2010 The different ENT1-mediated ribavirin uptake levels in different hepatocyte lines are associated with different expression levels of specific isoforms of ENT1 mRNAs. Ribavirin 28-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-18 20185188-11 2010 The different ENT1-mediated ribavirin uptake levels in different hepatocyte lines are associated with different expression levels of specific isoforms of ENT1 mRNAs. Ribavirin 28-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 20207653-0 2010 Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection. Ribavirin 65-74 insulin Homo sapiens 0-7 20423829-8 2010 The level of HMGB1 in the BALF significantly increased in the RSV group as compared with that in the control group (P<0.05), but was lowered by ribavirin treatment (P<0.05). Ribavirin 147-156 high mobility group box 1 Mus musculus 13-18 20423829-9 2010 The expression of the HMGB1 in the lung tissue significantly increased in the RSV group in comparison with that in the control group (P<0.05), and was not significantly decreased by ribavirin treatment (P>0.05). Ribavirin 185-194 high mobility group box 1 Mus musculus 22-27 20096989-0 2010 Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes. Ribavirin 28-37 solute carrier family 28 member 3 Homo sapiens 57-62 20096989-0 2010 Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes. Ribavirin 28-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-72 20163278-1 2010 IMPORTANCE OF THE FIELD: Ribavirin is a broad spectrum antiviral agent that is used with pegylated IFN (Peg-IFN) for HCV treatment. Ribavirin 25-34 interferon alpha 1 Homo sapiens 99-111 19758279-0 2010 Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome. Ribavirin 10-19 ribonuclease L Homo sapiens 40-47 19780859-0 2010 CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients. Ribavirin 95-104 CD81 molecule Homo sapiens 0-4 20101190-1 2010 BACKGROUND: This study aimed to assess the relationship between interferon (IFN)-related adverse effects and Hepatitis C virus (HCV) virologic response in HIV/HCV-coinfected individuals treated with pegylated interferon and ribavirin. Ribavirin 224-233 interferon alpha 1 Homo sapiens 76-79 20190684-0 2010 The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. BACKGROUND: Iron overload observed in chronic hepatitis C (CHC) has been suggested to be one of the negative prognostic factors influencing liver disease progression and failure of treatment with recombinant interferon in monotherapy or in combination with ribavirin. Ribavirin 88-97 homeostatic iron regulator Homo sapiens 30-33 20190684-9 2010 The lack of sustained viral response after treatment with pegylated interferon and ribavirin was observed more frequently in carriers of HFE mutations. Ribavirin 83-92 homeostatic iron regulator Homo sapiens 137-140 19961845-6 2010 Coadministration of adenosine, inosine and mizoribine, but not thymidine and gemcitabine, significantly suppressed the intestinal absorption of ribavirin, indicating that ribavirin absorption is mediated by CNT2 in rats. Ribavirin 144-153 solute carrier family 28 member 2 Rattus norvegicus 207-211 19690915-1 2010 BACKGROUND: This study aimed to evaluate whether laparoscopic splenectomy (Lap-Sp) contributes to the completion and curability of combined peginterferon and ribavirin (peg-IFN + RIB) therapy for cirrhotic patients with pancytopenia due to hypersplenism. Ribavirin 158-167 interferon alpha 1 Homo sapiens 173-176 20332289-3 2010 METHOD: The authors examined whether a functional polymorphism (5-HTTLPR) in the gene encoding the serotonin transporter moderates IFN-alpha-induced depressive symptoms in 1,015 patients with chronic hepatitis C (CHC) receiving pegylated IFN-alpha and ribavirin. Ribavirin 252-261 solute carrier family 6 member 4 Homo sapiens 99-120 19961845-6 2010 Coadministration of adenosine, inosine and mizoribine, but not thymidine and gemcitabine, significantly suppressed the intestinal absorption of ribavirin, indicating that ribavirin absorption is mediated by CNT2 in rats. Ribavirin 171-180 solute carrier family 28 member 2 Rattus norvegicus 207-211 19674283-10 2010 Low hepatic TLR3 expression is a novel predictor of response to peginterferon plus ribavirin in genotype 1 patients. Ribavirin 83-92 toll like receptor 3 Homo sapiens 12-16 20016018-0 2010 Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients. Ribavirin 101-110 C-C motif chemokine ligand 11 Homo sapiens 37-44 20016018-11 2010 CONCLUSIONS: Our preliminary data suggest that plasma eotaxin levels prior to HCV antiviral therapy may be useful in predicting virological response to HCV treatment with IFN-alpha + ribavirin in HIV/HCV co-infected patients. Ribavirin 183-192 C-C motif chemokine ligand 11 Homo sapiens 54-61 19846672-1 2010 Upregulation of interferon (IFN)-stimulated genes (ISGs), including IFN-stimulated gene 15 (ISG15) and other members of the ISG15 pathway, in pre-treatment liver tissue of patients chronically infected with hepatitis C virus (HCV) is associated with subsequent treatment failure (pegylated IFN-alpha/ribavirin). Ribavirin 300-309 ISG15 ubiquitin like modifier Homo sapiens 68-90 19846672-1 2010 Upregulation of interferon (IFN)-stimulated genes (ISGs), including IFN-stimulated gene 15 (ISG15) and other members of the ISG15 pathway, in pre-treatment liver tissue of patients chronically infected with hepatitis C virus (HCV) is associated with subsequent treatment failure (pegylated IFN-alpha/ribavirin). Ribavirin 300-309 ISG15 ubiquitin like modifier Homo sapiens 92-97 20006403-0 2010 Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin: some issues. Ribavirin 151-160 insulin Homo sapiens 0-7 20006404-0 2010 Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients. Ribavirin 80-89 interferon alpha 1 Homo sapiens 70-73 20006404-0 2010 Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients. Ribavirin 91-94 interferon alpha 1 Homo sapiens 70-73 20460925-1 2010 Insulin resistance has been found to be an independent factor predicting sustained response to peginterferon plus ribavirin in patients with chronic hepatitis C. Insulin resistance seems to be involved in decreased sensitivity to interferon and could block interferon intracellular signaling. Ribavirin 114-123 insulin Homo sapiens 0-7 19665449-6 2010 Conversely, ribavirin dose-dependently inhibited lysis of target cells by up to 66% and impaired interferon gamma production when IL-15-activated NK cells were used. Ribavirin 12-21 interleukin 15 Homo sapiens 130-135 20713999-7 2010 Ribavirin (PEG IFNa-RBV), at the moment, is the standard of care of patients with chronic hepatitis C and compensated cirrhosis. Ribavirin 0-9 interferon alpha 2 Homo sapiens 15-19 20713999-12 2010 The SVR in chronic hepatitis C patients who were treated with PEG IFNa-RBV in registration trials was 54 to 61%. Ribavirin 71-74 interferon alpha 2 Homo sapiens 66-70 20713999-15 2010 Results obtained from the association of PEG IFNa - RBV - Amantadine in chronic hepatitis C patients are controversial. Ribavirin 52-55 interferon alpha 2 Homo sapiens 45-49 19184426-0 2010 Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Ribavirin 123-132 insulin Homo sapiens 11-18 19184426-1 2010 Insulin resistance is a candidate predictive factor for virological response to peginterferon plus ribavirin (PEG/RBV) therapy in chronic hepatitis C patients. Ribavirin 99-108 insulin Homo sapiens 0-7 19184426-1 2010 Insulin resistance is a candidate predictive factor for virological response to peginterferon plus ribavirin (PEG/RBV) therapy in chronic hepatitis C patients. Ribavirin 114-117 insulin Homo sapiens 0-7 20814156-5 2010 The trans-stimulated uptake of [3H]uridine at ICT was inhibited by ENT1 inhibitors/substrates such as NBMPR, dipyridamole, adenosine, and ribavirin in a concentration-dependent manner. Ribavirin 138-147 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-71 20460925-1 2010 Insulin resistance has been found to be an independent factor predicting sustained response to peginterferon plus ribavirin in patients with chronic hepatitis C. Insulin resistance seems to be involved in decreased sensitivity to interferon and could block interferon intracellular signaling. Ribavirin 114-123 insulin Homo sapiens 162-169 20068341-1 2010 We investigated whether sustained virological response (SVR) and non-SVR by chronic hepatitis C patients to pegylated interferon plus ribavirin (PEG-IFN/RBV) combination therapy are distinguishable by viral factors such as the IFN/RBV resistance-determining region (IRRDR) and by on-treatment factors through new indices such as the rebound index (RI). Ribavirin 134-143 interferon alpha 1 Homo sapiens 149-156 21151503-7 2010 The DeltaHb at week 4 was significantly greater in patients with RBV levels of >=800 muM (-25.5 +- 10.1%) than in patients with RBV levels <800 muM (-15.6 +- 7.7%). Ribavirin 65-68 latexin Homo sapiens 88-91 21151503-9 2010 Thus the optimal levels of erythrocyte phosphorylated RBV at week 2 of therapy in order to achieve EVR without anemia seemed to be 600-800 muM. Ribavirin 54-57 latexin Homo sapiens 139-142 21152181-2 2010 Treatment with IFN-alpha is more efficient when it complemented by the antiviral ribavirin and the IFN-alpha is conjugated with polyethylene glycol to form peginterferon. Ribavirin 81-90 interferon alpha 1 Homo sapiens 15-24 20625493-2 2010 Currently, HCV-infected patients could undergo antiviral therapy by giving pegylated IFN-alpha with ribavirin. Ribavirin 100-109 interferon alpha 1 Homo sapiens 85-94 19671541-0 2009 Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Ribavirin 113-122 insulin Homo sapiens 0-7 20104263-8 2010 The results suggest that retinol supplement increases the antiviral effect of interferon alpha-2b plus ribavirin only during the administration of IFN alpha-2b, ribavirin and retinol in patients with chronic hepatitis C. Ribavirin 161-170 interferon alpha 2 Homo sapiens 78-97 19853271-9 2009 Ribavirin, UDA, and Ampligen decreased IL-6 expression. Ribavirin 0-9 interleukin 6 Mus musculus 39-43 19671541-10 2009 CONCLUSION: Insulin resistance and geographical origin are major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4 patients. Ribavirin 128-137 insulin Homo sapiens 12-19 19602549-2 2009 Ribavirin is a substrate of several nucleoside transporters, including the equilibrative nucleoside transporter (Ent) and the concentrative nucleoside transporter 2. Ribavirin 0-9 solute carrier family 28 (sodium-coupled nucleoside transporter), member 2 Mus musculus 126-164 18458677-0 2009 Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Ribavirin 138-147 interleukin 6 Homo sapiens 32-45 18458677-0 2009 Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Ribavirin 138-147 solute carrier family 6 member 4 Homo sapiens 50-71 19846870-0 2009 Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. Ribavirin 148-157 neural cell adhesion molecule 1 Homo sapiens 33-37 19846870-7 2009 Interestingly, pretreatment levels of CD56(-) NK cells correlated with the outcome of pegylated IFN-alpha and ribavirin treatment. Ribavirin 110-119 neural cell adhesion molecule 1 Homo sapiens 38-42 19877200-2 2009 This study investigated the association between KIR genetic diversity and sustained virologic response (SVR) to Peginterferon and Ribavirin (Peg/RBV) therapy in liver transplant (LT) recipients with hepatitis C virus (HCV) recurrence. Ribavirin 130-139 killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4 Homo sapiens 48-51 19877200-9 2009 Absence of KIR2DS2 and/or KIR2DL2 is associated with failure of Peg/RBV therapy in patients with recurrent HCV after LT. Ribavirin 68-71 killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 2 Homo sapiens 11-18 19859993-13 2009 Steatosis and insulin resistance have been associated with fibrosis progression and a reduced rate of sustained response to peginterferon plus ribavirin. Ribavirin 143-152 insulin Homo sapiens 14-21 26192611-7 2009 The patient had received IFN therapy twice previously (IFN-alpha 2a and IFN-alpha 2b with ribavirin therapy); however, no adverse side effects were observed. Ribavirin 90-99 interferon alpha 1 Homo sapiens 25-28 19845037-0 2009 Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Ribavirin 133-142 insulin Homo sapiens 13-20 19845037-10 2009 CONCLUSION: Adding metformin to peginterferon and ribavirin was safe and improved insulin sensitivity. Ribavirin 50-59 insulin Homo sapiens 82-89 19695729-0 2009 Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. Ribavirin 151-160 insulin Homo sapiens 0-7 19682316-2 2009 We analysed the mutational frequency in the PKR-binding domain (PKR-BD) of NS5A and PePHD of E2 protein pre- and post-treatment with peginterferon-alfa-2b and ribavirin in children chronically infected with HCV genotype 1. Ribavirin 159-168 ubiquitin conjugating enzyme E2 B Homo sapiens 93-103 19881314-3 2009 Intracellular ribavirin was accumulated in erythrocytes with the concentration of 1361 muM, which corresponds to the blood level in patients receiving ribavirin. Ribavirin 14-23 latexin Homo sapiens 87-90 19881314-3 2009 Intracellular ribavirin was accumulated in erythrocytes with the concentration of 1361 muM, which corresponds to the blood level in patients receiving ribavirin. Ribavirin 151-160 latexin Homo sapiens 87-90 19881314-4 2009 Dipyridamole reduced ribavirin accumulation by 40.7% (807 muM) via inhibiting es-type nucleoside transporter on erythrocytes. Ribavirin 21-30 latexin Homo sapiens 58-61 19602549-6 2009 After oral administration of three different doses, 0.024, 0.24, and 6.1 mg/kg, we found that the dose-normalized plasma AUC(0-12 h) of ribavirin was 69.7 +/- 12.0, 20.7 +/- 1.5, and 18.3 +/- 2.7 min/l, respectively, in the Ent1(+/+) mice and 18.9 +/- 2.8, 13.0 +/- 0.5, and 12.2 +/- 1.0 min/l, respectively, in the Ent1(-/-) mice. Ribavirin 136-145 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 224-228 19602549-6 2009 After oral administration of three different doses, 0.024, 0.24, and 6.1 mg/kg, we found that the dose-normalized plasma AUC(0-12 h) of ribavirin was 69.7 +/- 12.0, 20.7 +/- 1.5, and 18.3 +/- 2.7 min/l, respectively, in the Ent1(+/+) mice and 18.9 +/- 2.8, 13.0 +/- 0.5, and 12.2 +/- 1.0 min/l, respectively, in the Ent1(-/-) mice. Ribavirin 136-145 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 316-320 19602549-9 2009 Our findings indicate that Ent1 plays a significant role in the oral absorption and erythrocyte distribution of ribavirin. Ribavirin 112-121 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 27-31 19555400-2 2009 Given that interindividual variations in IL-10 production are influenced by functional polymorphisms in the IL-10 gene promoter, we determined the frequencies of common (-1082, -819 and -592) IL-10 promoter polymorphisms in chronic HCV patients with and without S. mansoni co-infection and healthy controls, and investigated their association with the degree of histological activity index (HAI) and response to interferon-ribavirin therapy. Ribavirin 423-432 interleukin 10 Homo sapiens 108-113 19555400-2 2009 Given that interindividual variations in IL-10 production are influenced by functional polymorphisms in the IL-10 gene promoter, we determined the frequencies of common (-1082, -819 and -592) IL-10 promoter polymorphisms in chronic HCV patients with and without S. mansoni co-infection and healthy controls, and investigated their association with the degree of histological activity index (HAI) and response to interferon-ribavirin therapy. Ribavirin 423-432 interleukin 10 Homo sapiens 108-113 19749757-0 2009 Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. The recommended treatment for patients with chronic hepatitis C, pegylated interferon-alpha (PEG-IFN-alpha) plus ribavirin (RBV), does not provide sustained virologic response (SVR) in all patients. Ribavirin 81-90 interferon lambda 3 Homo sapiens 27-32 19749758-0 2009 IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Ribavirin 78-87 interferon lambda 3 Homo sapiens 0-5 19592135-1 2009 A 50-year-old diabetic man receiving insulin, and suffering from chronic hepatitis C treated with interferon alfa and ribavirin presented with an acute peripheral scotoma and retinopathy associated with interferon therapy. Ribavirin 118-127 insulin Homo sapiens 37-44 19302338-10 2009 After peginterferon plus ribavirin therapy, only patients who had achieved clearance of hepatitis C virus had higher post-treatment RBP4 levels. Ribavirin 25-34 retinol binding protein 4 Homo sapiens 132-136 19619545-0 2009 Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. Ribavirin 0-9 interferon alpha 1 Homo sapiens 19-29 19619545-0 2009 Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. Ribavirin 0-9 mechanistic target of rapamycin kinase Homo sapiens 59-63 19619545-0 2009 Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. Ribavirin 0-9 tumor protein p53 Homo sapiens 68-71 19619545-1 2009 Cellular mechanisms involving the enhancement of interferon (IFN) signaling by ribavirin remain poorly understood. Ribavirin 79-88 interferon alpha 1 Homo sapiens 49-59 19619545-1 2009 Cellular mechanisms involving the enhancement of interferon (IFN) signaling by ribavirin remain poorly understood. Ribavirin 79-88 interferon alpha 1 Homo sapiens 61-64 19619545-2 2009 Here, we identified a novel role of ribavirin in the communication between p53 and the mammalian target of rapamycin (mTOR) signaling. Ribavirin 36-45 tumor protein p53 Homo sapiens 75-78 19619545-2 2009 Here, we identified a novel role of ribavirin in the communication between p53 and the mammalian target of rapamycin (mTOR) signaling. Ribavirin 36-45 mechanistic target of rapamycin kinase Homo sapiens 87-116 19619545-2 2009 Here, we identified a novel role of ribavirin in the communication between p53 and the mammalian target of rapamycin (mTOR) signaling. Ribavirin 36-45 mechanistic target of rapamycin kinase Homo sapiens 118-122 19619545-3 2009 Ribavirin activates p53 by stimulating mTOR and promoting the interaction between mTOR and p53. Ribavirin 0-9 tumor protein p53 Homo sapiens 20-23 19619545-3 2009 Ribavirin activates p53 by stimulating mTOR and promoting the interaction between mTOR and p53. Ribavirin 0-9 mechanistic target of rapamycin kinase Homo sapiens 39-43 19619545-3 2009 Ribavirin activates p53 by stimulating mTOR and promoting the interaction between mTOR and p53. Ribavirin 0-9 mechanistic target of rapamycin kinase Homo sapiens 82-86 19619545-3 2009 Ribavirin activates p53 by stimulating mTOR and promoting the interaction between mTOR and p53. Ribavirin 0-9 tumor protein p53 Homo sapiens 91-94 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 13-22 mechanistic target of rapamycin kinase Homo sapiens 45-49 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 13-22 tumor protein p53 Homo sapiens 54-57 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 13-22 interferon alpha 1 Homo sapiens 67-70 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 13-22 interferon alpha 1 Homo sapiens 99-108 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 109-118 mechanistic target of rapamycin kinase Homo sapiens 45-49 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 109-118 tumor protein p53 Homo sapiens 54-57 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 109-118 interferon alpha 1 Homo sapiens 67-70 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 109-118 interferon alpha 1 Homo sapiens 99-108 19619545-6 2009 We conclude that ribavirin enhances activities of mTOR and p53, which may account for its antiviral and antitumor effects. Ribavirin 17-26 mechanistic target of rapamycin kinase Homo sapiens 50-54 19619545-6 2009 We conclude that ribavirin enhances activities of mTOR and p53, which may account for its antiviral and antitumor effects. Ribavirin 17-26 tumor protein p53 Homo sapiens 59-62 19262360-8 2009 These preliminary experiences evidenced that combination treatment of PEG-IFN-alpha2b with ribavirin shows encouraging results and was well tolerated in children and adolescents with chronic hepatitis C. Ribavirin 91-100 interferon alpha 1 Homo sapiens 74-77 19753589-0 2009 Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C. Lung toxicity related to interferon (IFN) alpha typically takes a form of interstitial pneumonitis, granulomatous inflammation, or organizing pneumonia. Ribavirin 64-73 interferon alpha 1 Homo sapiens 134-156 19131283-7 2009 Sustained virological response during pegylated interferon plus ribavirine treatment was achieved by 97% and 49% patients with normal and elevated gamma-glutamyltranspeptidase, respectively (p=0.0001). Ribavirin 64-74 inactive glutathione hydrolase 2 Homo sapiens 147-175 19433856-0 2009 Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Ribavirin 116-125 eukaryotic translation initiation factor 4E Homo sapiens 36-41 19552663-0 2009 Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. Ribavirin 191-200 interferon alpha 2 Homo sapiens 10-29 19433856-3 2009 We tested the clinical efficacy of targeting eIF4E in M4/M5 AML patients with a physical mimic of the m(7)G cap, ribavirin. Ribavirin 113-122 eukaryotic translation initiation factor 4E Homo sapiens 45-50 19433856-5 2009 Ribavirin-induced relocalization of nuclear eIF4E to the cytoplasm and reduction of eIF4E levels were associated with clinical response. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 44-49 19433856-5 2009 Ribavirin-induced relocalization of nuclear eIF4E to the cytoplasm and reduction of eIF4E levels were associated with clinical response. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 84-89 19193669-1 2009 BACKGROUND: Dendritic cell (DC) defects may contribute to chronicity in hepatitis C virus (HCV) infection and determine response to PEG-interferon and ribavirin therapy via poor T cell stimulation. Ribavirin 151-160 chemokine (C-C motif) ligand 22 Mus musculus 28-30 19830190-5 2009 CASE PRESENTATION: This report describes a 65-year-old Asian-American woman who developed pure red cell aplasia from high titer neutralizing anti-epoetin antibodies after epoetin-alfa therapy during ribavirin and peg-interferon treatment for chronic hepatitis C virus infection. Ribavirin 199-208 erythropoietin Homo sapiens 146-153 19830190-5 2009 CASE PRESENTATION: This report describes a 65-year-old Asian-American woman who developed pure red cell aplasia from high titer neutralizing anti-epoetin antibodies after epoetin-alfa therapy during ribavirin and peg-interferon treatment for chronic hepatitis C virus infection. Ribavirin 199-208 erythropoietin Homo sapiens 171-178 19841506-4 2009 Of note, both patients recovered from their initial unconjugated hyperbilirubinemia despite continuation of ribavirin therapy, which indicates that compensatory mechanisms leading to a normalization of UGT1A1 activity are likely. Ribavirin 108-117 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 202-208 19423402-3 2009 CD4+ T cell surface CCR5 and CXCR3 densities increased after 6 months of treatment with pegylated interferon-alpha and ribavirin. Ribavirin 119-128 CD4 molecule Homo sapiens 0-3 19423402-3 2009 CD4+ T cell surface CCR5 and CXCR3 densities increased after 6 months of treatment with pegylated interferon-alpha and ribavirin. Ribavirin 119-128 C-C motif chemokine receptor 5 Homo sapiens 20-24 19423402-3 2009 CD4+ T cell surface CCR5 and CXCR3 densities increased after 6 months of treatment with pegylated interferon-alpha and ribavirin. Ribavirin 119-128 C-X-C motif chemokine receptor 3 Homo sapiens 29-34 19345260-1 2009 The current FDA-approved treatment for HCV (pegylated interferon-alpha (IFNalpha) with ribavirin) is effective in only about 50% of patients. Ribavirin 87-96 interferon alpha 1 Homo sapiens 72-80 19428584-4 2009 The system has been validated using interferon (IFN), which is still the only consensual antiviral agent against HCV infection, associated with ribavirin. Ribavirin 144-153 interferon alpha 1 Homo sapiens 36-52 19392865-0 2009 Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Ribavirin 180-189 apolipoprotein B Homo sapiens 0-16 19482597-2 2009 The addition of ribavirin to IFN therapy has increased the response rate dramatically. Ribavirin 16-25 interferon alpha 1 Homo sapiens 29-32 20431732-0 2009 Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance. Ribavirin 77-86 insulin Homo sapiens 96-103 20431732-10 2009 CONCLUSIONS: The clearance of HCV by the combination therapy of pegylated interferon alpha-2a and ribavirin improves insulin resistance by reducing fasting serum insulin and glucose levels. Ribavirin 98-107 insulin Homo sapiens 117-124 20431732-10 2009 CONCLUSIONS: The clearance of HCV by the combination therapy of pegylated interferon alpha-2a and ribavirin improves insulin resistance by reducing fasting serum insulin and glucose levels. Ribavirin 98-107 insulin Homo sapiens 162-169 19369574-1 2009 Ribavirin is found to be absorbed in the intestine through the human concentrative nucleoside transporter 2 (hCNT2). Ribavirin 0-9 solute carrier family 28 member 2 Homo sapiens 69-107 19369574-1 2009 Ribavirin is found to be absorbed in the intestine through the human concentrative nucleoside transporter 2 (hCNT2). Ribavirin 0-9 solute carrier family 28 member 2 Homo sapiens 109-114 19200137-1 2009 Interferon (IFN)-based combination therapy with ribavirin has become the gold standard for the treatment of chronic hepatitis C virus infection. Ribavirin 48-57 interferon alpha 1 Homo sapiens 12-15 20191195-9 2009 Peginterferon alpha-2b with ribavirin is a cost-effective therapy for the treatment of naive CHC adult patients compared to the interferon alpha-2b and ribavirin regime, irrespective of the viral genotype. Ribavirin 28-37 interferon alpha 2 Homo sapiens 3-22 19578615-1 2009 CONTEXT: It has been suggested that coinfected patients HCV/HIV must be treated with pegylated interferon associated to ribavirin (PEG+RBV), because of better taxes of sustained virological response when compared to those treated with conventional interferon associated to ribavirin (IFN+RBV). Ribavirin 120-129 interferon alpha 1 Homo sapiens 248-291 19671341-0 2009 [Effect of ribavirin upon secretion of thymic stromal lymphopoietin in respiratory syncytial virus-induced asthma exacerbation of mice]. Ribavirin 11-20 thymic stromal lymphopoietin Mus musculus 39-67 19671341-12 2009 CONCLUSION: Ribavirin can inhibit the elevated production of TSLP after RSV infection and relieve RSV-induced asthma exacerbation in mice. Ribavirin 12-21 thymic stromal lymphopoietin Mus musculus 61-65 19164483-6 2009 Xenopus oocytes expressing NH2-terminal-deleted hENT3 (expressed at the cell surface) showed pH-dependent interaction with several classes of nucleosides (anti-HIV ddNs, gemcitabine, fialuridine, ribavirin) that produce mitochondrial toxicity. Ribavirin 196-205 solute carrier family 29 member 3 Homo sapiens 48-53 19581773-0 2009 Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C. A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC). Ribavirin 65-74 interferon alpha 2 Homo sapiens 202-227 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 123-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-56 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 123-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-62 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 123-126 solute carrier family 28 member 3 Homo sapiens 67-105 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 123-126 solute carrier family 28 member 3 Homo sapiens 107-111 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-56 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-62 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 28 member 3 Homo sapiens 67-105 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 28 member 3 Homo sapiens 107-111 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-56 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-62 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 28 member 3 Homo sapiens 67-105 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 28 member 3 Homo sapiens 107-111 19244331-9 2009 Taken together, these results indicate that RBV uptake is restricted primarily to ENT1 in the cell lines examined. Ribavirin 44-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 19244331-10 2009 Interestingly, some RBV-resistant cell lines may compensate for reduced ENT1-mediated nucleoside uptake by increasing the activity of an alternative nucleoside transporter, ENT2. Ribavirin 20-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-76 19244331-10 2009 Interestingly, some RBV-resistant cell lines may compensate for reduced ENT1-mediated nucleoside uptake by increasing the activity of an alternative nucleoside transporter, ENT2. Ribavirin 20-23 solute carrier family 29 member 2 Homo sapiens 173-177 19578615-1 2009 CONTEXT: It has been suggested that coinfected patients HCV/HIV must be treated with pegylated interferon associated to ribavirin (PEG+RBV), because of better taxes of sustained virological response when compared to those treated with conventional interferon associated to ribavirin (IFN+RBV). Ribavirin 135-138 interferon alpha 1 Homo sapiens 248-291 19164463-0 2009 The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. Ribavirin 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 16-54 19637783-4 2009 We report the case of an African woman, heterozygote for sickle cell anaemia mutation and for glucose-6-phosphate-deshydrogenase (G6PD) deficiency, who developed a multisystemic sarcoidosis (skin, lungs, liver, salivary and lachrymal glands, peripheral nerves), confirmed by biopsies, in the course of a second treatment with pegylated interferon and ribavirine for hepatitis C. The antiviral treatment was discontinued and all symptoms regressed spontaneously within some weeks. Ribavirin 351-361 glucose-6-phosphate dehydrogenase Homo sapiens 94-128 20524482-0 2009 Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy. Ribavirin 60-69 glutamic--pyruvic transaminase Homo sapiens 124-148 19164463-0 2009 The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. Ribavirin 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-60 19164463-0 2009 The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. Ribavirin 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 19164463-2 2009 The human equilibrative nucleoside transporter (ENT) 1 transports ribavirin into erythrocytes where it is phosphorylated. Ribavirin 66-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-54 19164463-4 2009 Here, we examined the in vitro and ex vivo transport and metabolism of ribavirin by erythrocytes isolated from humans and Ent1-null mice. Ribavirin 71-80 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 122-126 19164463-5 2009 Ribavirin (2.4 microM) uptake was significantly higher (1044 +/- 255 amol/microg/10 s) into erythrocytes from Ent1(+/+) mice compared with that from Ent1(-/-) mice (76.48 +/- 11.20 amol/microg/10 s). Ribavirin 0-9 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 110-114 19164463-9 2009 Our modeling of ribavirin in erythrocytes on long-term administration of ribavirin suggests that the accumulation of ribavirin inside the cells is dependent on ENT1/Ent1 transport and the rates of intracellular phosphorylation and the degradation of the phosphorylated metabolites. Ribavirin 16-25 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 160-164 19164463-9 2009 Our modeling of ribavirin in erythrocytes on long-term administration of ribavirin suggests that the accumulation of ribavirin inside the cells is dependent on ENT1/Ent1 transport and the rates of intracellular phosphorylation and the degradation of the phosphorylated metabolites. Ribavirin 16-25 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 165-169 19164463-9 2009 Our modeling of ribavirin in erythrocytes on long-term administration of ribavirin suggests that the accumulation of ribavirin inside the cells is dependent on ENT1/Ent1 transport and the rates of intracellular phosphorylation and the degradation of the phosphorylated metabolites. Ribavirin 73-82 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 160-164 19164463-9 2009 Our modeling of ribavirin in erythrocytes on long-term administration of ribavirin suggests that the accumulation of ribavirin inside the cells is dependent on ENT1/Ent1 transport and the rates of intracellular phosphorylation and the degradation of the phosphorylated metabolites. Ribavirin 73-82 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 165-169 19164463-9 2009 Our modeling of ribavirin in erythrocytes on long-term administration of ribavirin suggests that the accumulation of ribavirin inside the cells is dependent on ENT1/Ent1 transport and the rates of intracellular phosphorylation and the degradation of the phosphorylated metabolites. Ribavirin 73-82 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 160-164 19164463-9 2009 Our modeling of ribavirin in erythrocytes on long-term administration of ribavirin suggests that the accumulation of ribavirin inside the cells is dependent on ENT1/Ent1 transport and the rates of intracellular phosphorylation and the degradation of the phosphorylated metabolites. Ribavirin 73-82 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 165-169 19164463-10 2009 We predict that Ent1(+/+) and Ent1(-/-) mice will serve as excellent models to investigate the contribution of Ent1 to the pharmacokinetics and toxicity of ribavirin in vivo. Ribavirin 156-165 solute carrier family 29 (nucleoside transporters), member 1 Mus musculus 16-20 19289328-1 2009 OBJECTIVE: To report a rare case of diabetes caused by type B insulin resistance due to development of insulin receptor autoantibodies during treatment of hepatitis C with interferon-alpha and ribavirin. Ribavirin 193-202 insulin Homo sapiens 62-69 19289328-1 2009 OBJECTIVE: To report a rare case of diabetes caused by type B insulin resistance due to development of insulin receptor autoantibodies during treatment of hepatitis C with interferon-alpha and ribavirin. Ribavirin 193-202 insulin Homo sapiens 103-110 19375037-3 2009 The randomised controlled RIBAVIC ANRS HC02 trial comparing the combination ribavirin-pegylated interferon-alpha2b versus ribavirine-standard interferon-alpha2b as first treatment in HIV-HCV co-infected patients allowed an analysis of 205 paired (pre- and post-treatment) biopsies using the Metavir and Ishak scores. Ribavirin 76-85 interferon alpha 2 Homo sapiens 96-114 19166653-2 2009 A small-molecule thrombopoietin mimetic, eltrombo-pag, has demonstrated a dose-response associated increase in platelet count in a phase 2 study, allowing initiation and completion of a 12-week course of peginterferon plus ribavirin in 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, or 75 mg of eltrombopag daily, respectively, compared with 6% in the placebo arm. Ribavirin 223-232 thrombopoietin Homo sapiens 17-31 19068241-9 2009 CONCLUSIONS: Pretreatment YKL-40 levels are an independent predictor of initial virologic response to peginterferon and ribavirin treatment. Ribavirin 120-129 chitinase 3 like 1 Homo sapiens 26-32 18680550-0 2009 Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Ribavirin 157-166 insulin Homo sapiens 0-7 19072829-3 2009 RVR patients received pegylated interferon (Peg-IFN) alfa-2b (1.5 microg/kg) and ribavirin (1000-1200 mg/day) for 12 weeks; those who relapsed were re-treated with the same drug doses but for the extended standard duration of 24 weeks. Ribavirin 81-90 nuclear receptor subfamily 1 group D member 2 Homo sapiens 0-3 18680550-10 2009 CONCLUSIONS: Insulin resistance is a major determinant of SVR in genotype 1 CHC patients receiving peginterferon alpha-2b/ribavirin. Ribavirin 122-131 insulin Homo sapiens 13-20 19033352-3 2009 As there is no previous data to fully characterize the entity of IFN-related thyroiditis, the aim of this study is to document in detail its evolution in a cohort of hepatitis C patients treated with pegylated IFN-alpha2b and Ribavirin (RBV). Ribavirin 226-235 interferon alpha 1 Homo sapiens 65-68 19033352-3 2009 As there is no previous data to fully characterize the entity of IFN-related thyroiditis, the aim of this study is to document in detail its evolution in a cohort of hepatitis C patients treated with pegylated IFN-alpha2b and Ribavirin (RBV). Ribavirin 237-240 interferon alpha 1 Homo sapiens 65-68 19687584-0 2009 Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C. Interferon (IFN) therapies, including IFN, peginterferon (PEG-IFN) and ribavirin (RBV) plus PEG-IFN combination, are widely used for patients with chronic hepatitis C. We encountered a patient with chronic hepatitis C in whom previous IFN or PEG-IFN alone had not induced type 1 diabetes (T1D), while the addition of RBV to PEG-IFN did induce T1D. Ribavirin 29-38 interferon alpha 1 Homo sapiens 165-175 20049173-4 2009 We describe several strategies that have been suggested for eIF4E targeting in the clinic: the use of a small molecule antagonist of eIF4E (ribavirin), siRNA or antisense oligonucleotide strategies, suicide gene therapy, and the use of a tissue-targeting 4EBP fusion peptide. Ribavirin 140-149 eukaryotic translation initiation factor 4E Homo sapiens 60-65 20049173-5 2009 The first clinical trial targeting eIF4E indicates that ribavirin effectively targets eIF4E in poor prognosis leukemia patients and more importantly leads to striking clinical responses including complete and partial remissions. Ribavirin 56-65 eukaryotic translation initiation factor 4E Homo sapiens 35-40 20049173-5 2009 The first clinical trial targeting eIF4E indicates that ribavirin effectively targets eIF4E in poor prognosis leukemia patients and more importantly leads to striking clinical responses including complete and partial remissions. Ribavirin 56-65 eukaryotic translation initiation factor 4E Homo sapiens 86-91 18761603-0 2009 Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin. Ribavirin 25-34 BMP binding endothelial regulator Homo sapiens 38-43 18761603-1 2009 Guidelines for the treatment of patients infected with hepatitis C virus of genotypes 2 and 3 (HCV-2 and HCV-3, respectively) recommend a 24-week course of Peg-interferon (Peg-IFN) alpha-2a combined with ribavirin, despite 50% of patients in registration trials attaining a sustained virologic response (SVR) following Peg-IFN alpha-2a monotherapy. Ribavirin 204-213 BMP binding endothelial regulator Homo sapiens 95-100 20446436-4 2009 The growth rate of the serum erythropoietin in the first few weeks of treatment is correlated with the necessity of decreasing the doses or even to stop the treatment with ribavirin. Ribavirin 172-181 erythropoietin Homo sapiens 29-43 18844579-10 2008 Western analysis revealed that HCV serum increased p-c-Jun levels, which were decreased with Ribavirin and PTX. Ribavirin 93-102 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 53-58 19117241-3 2009 Depending on the weight-based ribavirin dose, patients with >105 kg reach a maximum of 13.2 mg/kg body-weight ribavirin in the peg-IFN alfa-2b regimen as opposed to only 11.3 mg/kg in the peg-IFN alfa-2a regimen. Ribavirin 113-122 interferon alpha 1 Homo sapiens 134-137 18620776-0 2008 Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. Ribavirin 98-107 hepcidin antimicrobial peptide Homo sapiens 138-146 18620776-6 2008 This relative impairment of hepcidin production was fully reversible after successful HCV eradication by PEG-IFN plus ribavirin, concomitantly with the improvement of the iron overload condition. Ribavirin 118-127 hepcidin antimicrobial peptide Homo sapiens 28-36 20001276-8 2009 For patients with difficult-to-treat disease and with pronounced anaemia, erythropoietin can be used to maintain the ribavirin dose. Ribavirin 117-126 erythropoietin Homo sapiens 74-88 19249526-3 2009 We have reported herein the efficacy of divided administration of interferon (IFN) beta plus cyclosporine for chronic hepatitis C patients who failed pegylated (Peg)-IFN or IFN combined ribavirin treatment. Ribavirin 186-195 interferon alpha 1 Homo sapiens 78-81 18928375-8 2008 Reduction of RF1 viral load was observed in response to 3 injections of 3 microg/kg pegylated-interferon alpha-2a alone or in combination with 50 mg/kg of ribavirin (0.5 or 1.4 log-copies/mL). Ribavirin 155-164 mitochondrial translation release factor 1 Homo sapiens 13-16 19061675-1 2008 OBJECTIVE: This study was designed to determine the effect of 12-week pegylated IFNalpha plus ribavirin (peg-IFNalpha/RBV) treatment on cognitive performance in chronic hepatitis C (CHC) patients. Ribavirin 94-103 interferon alpha 1 Homo sapiens 109-117 19061675-8 2008 CONCLUSION: The findings suggest that peg-IFNalpha/RBV therapy of CHC patients is related to cognitive performance decline and is a result of IFNalpha-induced neurotransmission abnormalities in the limbic system, dorsolateral prefrontal cortex and anterior cingulate cortex. Ribavirin 51-54 interferon alpha 1 Homo sapiens 42-50 19061675-8 2008 CONCLUSION: The findings suggest that peg-IFNalpha/RBV therapy of CHC patients is related to cognitive performance decline and is a result of IFNalpha-induced neurotransmission abnormalities in the limbic system, dorsolateral prefrontal cortex and anterior cingulate cortex. Ribavirin 51-54 interferon alpha 1 Homo sapiens 142-150 18844579-14 2008 In conclusion, Ribavirin decreased HSC proliferation and may act by decreasing p-c-Jun levels in HSCs. Ribavirin 15-24 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 81-86 19441669-1 2008 UNLABELLED: Chronic hepatitis C (CHC) patients treated with peg-interferon alpha and ribavirin (peg-IFNalpha/RBV) complain of irritability, attention and memory disturbances which may indicate cognitive impairment associated with treatment. Ribavirin 85-94 interferon alpha 1 Homo sapiens 100-108 19441669-1 2008 UNLABELLED: Chronic hepatitis C (CHC) patients treated with peg-interferon alpha and ribavirin (peg-IFNalpha/RBV) complain of irritability, attention and memory disturbances which may indicate cognitive impairment associated with treatment. Ribavirin 109-112 interferon alpha 1 Homo sapiens 100-108 19441669-10 2008 CONCLUSIONS: The findings suggest that peg-IFNalpha/RBV therapy of CHC patients is connected with the deterioration in cognitive functioning including attention, auditory verbal memory and visuo-spatial skills. Ribavirin 52-55 interferon alpha 1 Homo sapiens 43-51 18706892-0 2008 Ribavirin targets eIF4E dependent Akt survival signaling. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 18-23 18706892-0 2008 Ribavirin targets eIF4E dependent Akt survival signaling. Ribavirin 0-9 AKT serine/threonine kinase 1 Homo sapiens 34-37 18706892-4 2008 We demonstrate that a physical mimic of the m(7)G cap, ribavirin, inhibits eIF4E dependent Akt survival signaling. Ribavirin 55-64 eukaryotic translation initiation factor 4E Homo sapiens 75-80 18706892-4 2008 We demonstrate that a physical mimic of the m(7)G cap, ribavirin, inhibits eIF4E dependent Akt survival signaling. Ribavirin 55-64 AKT serine/threonine kinase 1 Homo sapiens 91-94 18706892-5 2008 Specifically, ribavirin impairs eIF4E mediated Akt activation via inhibiting the production of an upstream activator of Akt, NBS1. Ribavirin 14-23 eukaryotic translation initiation factor 4E Homo sapiens 32-37 18706892-5 2008 Specifically, ribavirin impairs eIF4E mediated Akt activation via inhibiting the production of an upstream activator of Akt, NBS1. Ribavirin 14-23 AKT serine/threonine kinase 1 Homo sapiens 47-50 18706892-5 2008 Specifically, ribavirin impairs eIF4E mediated Akt activation via inhibiting the production of an upstream activator of Akt, NBS1. Ribavirin 14-23 AKT serine/threonine kinase 1 Homo sapiens 120-123 18706892-5 2008 Specifically, ribavirin impairs eIF4E mediated Akt activation via inhibiting the production of an upstream activator of Akt, NBS1. Ribavirin 14-23 nibrin Homo sapiens 125-129 18706892-6 2008 Consequently, ribavirin impairs eIF4E dependent apoptotic rescue. Ribavirin 14-23 eukaryotic translation initiation factor 4E Homo sapiens 32-37 18706892-8 2008 Ribavirin represents a first-in-class strategy to inhibit eIF4E dependent cancers, through competition for m(7)G cap binding. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 58-63 18706892-9 2008 Thus, ribavirin coordinately impairs eIF4E dependent pathways and thereby, potently inhibits its biological effects. Ribavirin 6-15 eukaryotic translation initiation factor 4E Homo sapiens 37-42 18602075-2 2008 Administration of ribavirin to EAE rats markedly affected the production of pro-inflammatory cytokines IFN-gamma, IL-1beta and TNF-alpha in DLN and spinal cord, thus shifting the balance towards the anti-inflammatory cytokines IL-10 and TGF-beta. Ribavirin 18-27 interferon gamma Rattus norvegicus 103-112 19028630-6 2008 Our case report provides new significant insight on the histopathological changes occurring in bone marrow of HCV-infected cirrhotic patients during peg-IFN alpha-2a plus RBV treatment, providing also additional information on potential bone marrow toxicity in the course of IFN-based treatments. Ribavirin 171-174 interferon alpha 1 Homo sapiens 275-278 18619701-8 2008 CONCLUSIONS: Among non-Hispanic Caucasian patients treated with peginterferon and ribavirin after failing previous treatment with interferon, homozygosity for the ACC IL10 promoter diplotype was associated with SVR. Ribavirin 82-91 interleukin 10 Homo sapiens 167-171 19102366-6 2008 The increase in interferon-gamma following ribavirin monotherapy was significantly higher for patients with sustained viral response. Ribavirin 43-52 interferon gamma Homo sapiens 16-32 19102366-7 2008 CONCLUSIONS: The sustained viral response rate of this pilot study using ribavirin priming and reduced peginterferon dosage is in line with previous trials using standard treatment regimens for chronic hepatitis C. Our data stress the positive impact of the ribavirin-induced TH2-TH1 cytokine shift at least in patients with normal ALT. Ribavirin 73-82 negative elongation factor complex member C/D Homo sapiens 280-283 19102366-7 2008 CONCLUSIONS: The sustained viral response rate of this pilot study using ribavirin priming and reduced peginterferon dosage is in line with previous trials using standard treatment regimens for chronic hepatitis C. Our data stress the positive impact of the ribavirin-induced TH2-TH1 cytokine shift at least in patients with normal ALT. Ribavirin 258-267 negative elongation factor complex member C/D Homo sapiens 280-283 18602075-2 2008 Administration of ribavirin to EAE rats markedly affected the production of pro-inflammatory cytokines IFN-gamma, IL-1beta and TNF-alpha in DLN and spinal cord, thus shifting the balance towards the anti-inflammatory cytokines IL-10 and TGF-beta. Ribavirin 18-27 interleukin 1 beta Rattus norvegicus 114-122 18602075-2 2008 Administration of ribavirin to EAE rats markedly affected the production of pro-inflammatory cytokines IFN-gamma, IL-1beta and TNF-alpha in DLN and spinal cord, thus shifting the balance towards the anti-inflammatory cytokines IL-10 and TGF-beta. Ribavirin 18-27 tumor necrosis factor Rattus norvegicus 127-136 18602075-2 2008 Administration of ribavirin to EAE rats markedly affected the production of pro-inflammatory cytokines IFN-gamma, IL-1beta and TNF-alpha in DLN and spinal cord, thus shifting the balance towards the anti-inflammatory cytokines IL-10 and TGF-beta. Ribavirin 18-27 interleukin 10 Rattus norvegicus 227-232 18602075-2 2008 Administration of ribavirin to EAE rats markedly affected the production of pro-inflammatory cytokines IFN-gamma, IL-1beta and TNF-alpha in DLN and spinal cord, thus shifting the balance towards the anti-inflammatory cytokines IL-10 and TGF-beta. Ribavirin 18-27 transforming growth factor, beta 1 Rattus norvegicus 237-245 18258414-4 2008 Compared to control subjects, patients treated with IFN-alpha/ribavirin exhibited significant decreases in motor speed as measured in the simple and five-choice movement segments of the CANTAB reaction time task and slower response times in the rapid visual information processing task, a task of sustained attention. Ribavirin 62-71 interferon alpha 1 Homo sapiens 52-61 18790241-11 2008 Two of 4 patients who underwent combination therapy with IFN and ribavirin during treatment with CsA and MMF obtained an HCV-negative status for over 24 weeks. Ribavirin 65-74 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 97-100 18514579-4 2008 CD4+ T cell responses appear to protect against liver injury and may be important to clearance during interferon and ribavirin based therapy. Ribavirin 117-126 CD4 molecule Homo sapiens 0-3 18248380-0 2008 Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. BACKGROUND AND AIM: It has been reported that immunological factors, such as the T-helper cell (Th)1/Th2 ratio, play a part in the mechanisms for the antihepatitis C virus (HCV) effect of the interferon (IFN) alpha-2b plus ribavirin combination therapy. Ribavirin 84-93 negative elongation factor complex member C/D Homo sapiens 15-18 18248380-0 2008 Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. BACKGROUND AND AIM: It has been reported that immunological factors, such as the T-helper cell (Th)1/Th2 ratio, play a part in the mechanisms for the antihepatitis C virus (HCV) effect of the interferon (IFN) alpha-2b plus ribavirin combination therapy. Ribavirin 84-93 interferon alpha 1 Homo sapiens 345-361 18585970-7 2008 Studies are under way to determine whether improving insulin sensitivity results in better outcomes in patients receiving pegylated interferon alfa plus ribavirin therapy for chronic hepatitis C. Ribavirin 153-162 insulin Homo sapiens 53-60 18391043-11 2008 These results suggest that NS3 can limit the incorporation of ribavirin into viral RNA, thus reducing its inhibitory or mutagenic effects. Ribavirin 62-71 KRAS proto-oncogene, GTPase Homo sapiens 27-30 18551609-1 2008 Previous studies identified amino acid (aa) substitutions of the hepatitis C virus core region of genotype 1b (HCV-1b core region) and elevated serum alpha-fetoprotein (AFP) levels as predictors of poor virologic response to pegylated interferon (PEG-IFN) plus ribavirin (RBV), and also as risk factors for hepatocarcinogenesis. Ribavirin 261-270 alpha fetoprotein Homo sapiens 169-172 18551609-1 2008 Previous studies identified amino acid (aa) substitutions of the hepatitis C virus core region of genotype 1b (HCV-1b core region) and elevated serum alpha-fetoprotein (AFP) levels as predictors of poor virologic response to pegylated interferon (PEG-IFN) plus ribavirin (RBV), and also as risk factors for hepatocarcinogenesis. Ribavirin 272-275 alpha fetoprotein Homo sapiens 169-172 18551609-6 2008 In 49 patients with abnormal AFP levels and substitutions at aa 70 who were treated with PEG-IFN + RBV, the rate of normalization of AFP was significantly lower in non-virological responders (28.6%) than in transient (71.4%) and sustained (100%) virological responders. Ribavirin 99-102 alpha fetoprotein Homo sapiens 29-32 18551609-6 2008 In 49 patients with abnormal AFP levels and substitutions at aa 70 who were treated with PEG-IFN + RBV, the rate of normalization of AFP was significantly lower in non-virological responders (28.6%) than in transient (71.4%) and sustained (100%) virological responders. Ribavirin 99-102 alpha fetoprotein Homo sapiens 133-136 18551610-1 2008 The efficacy of interferon (IFN) monotherapy for non-responders to pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy is still unclear. Ribavirin 103-112 interferon alpha 1 Homo sapiens 28-31 18551610-9 2008 The results suggest that low-dose intermittent IFN monotherapy is an efficacious therapeutic regimen for patients unsuitable for PEG-IFN plus RBV, including non-responders, because it can lead to ALT normalization and thus a reduced risk of hepatocarcinogenesis. Ribavirin 142-145 interferon alpha 1 Homo sapiens 47-50 18495540-0 2008 Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin. Ribavirin 124-133 neural cell adhesion molecule 1 Homo sapiens 13-17 18495540-3 2008 Interestingly, this expansion of unconventional CD56(-) NK cells rapidly reverted when HCV was suppressed by IFNalpha and ribavirin treatment, and was not seen in mono-infected control groups. Ribavirin 122-131 neural cell adhesion molecule 1 Homo sapiens 48-52 18248380-0 2008 Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. BACKGROUND AND AIM: It has been reported that immunological factors, such as the T-helper cell (Th)1/Th2 ratio, play a part in the mechanisms for the antihepatitis C virus (HCV) effect of the interferon (IFN) alpha-2b plus ribavirin combination therapy. Ribavirin 376-385 negative elongation factor complex member C/D Homo sapiens 15-18 18248380-0 2008 Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. BACKGROUND AND AIM: It has been reported that immunological factors, such as the T-helper cell (Th)1/Th2 ratio, play a part in the mechanisms for the antihepatitis C virus (HCV) effect of the interferon (IFN) alpha-2b plus ribavirin combination therapy. Ribavirin 376-385 interferon alpha 2 Homo sapiens 59-78 18248380-8 2008 CONCLUSIONS: The significant changes in the Th2 level correlated with the therapeutic effect during the IFN alpha-2b plus ribavirin combination therapy. Ribavirin 122-131 interferon alpha 1 Homo sapiens 104-107 18636675-8 2008 After LS, since her platelet count immediately increased to 225,000/microL 14 d after operation, IFN therapy was restarted and we could convert the combination therapy of IFN and ribavirin, resulting in no detectable viral marker. Ribavirin 179-188 interferon alpha 1 Homo sapiens 97-100 19198574-12 2008 CONCLUSION: Daily weight based interferon alpha-2b dosing and PEG interferon alpha-2b weighed based dosing once weekly both in combination with Ribavirin offer the same efficacy and safety rates. Ribavirin 144-153 interferon alpha 2 Homo sapiens 66-85 18508296-8 2008 Multivariate analysis in all patients showed that RVR was the strongest independent factor associated with an SVR, followed by treatment duration, mean weight-based exposure of ribavirin, and baseline viral load. Ribavirin 177-186 nuclear receptor subfamily 1 group D member 2 Homo sapiens 50-53 18508296-9 2008 CONCLUSION: HCV-1 patients derive a significantly better SVR from 48 weeks versus 24 weeks of peginterferon/ribavirin even if they attain an RVR. Ribavirin 108-117 nuclear receptor subfamily 1 group D member 2 Homo sapiens 141-144 17916116-6 2008 At Mount Sinai Medical Center, protocol biopsies have been performed for the last 2 years in patients receiving pegylated interferon-alpha2b and ribavirin (PEG) for recurrent HCV. Ribavirin 145-154 progestagen associated endometrial protein Homo sapiens 156-159 18428145-0 2008 Therapy with interferon-alpha and ribavirin for chronic hepatitis C virus infection upregulates membrane HLA-ABC, CD86, and CD28 on peripheral blood mononuclear cells. Ribavirin 34-43 CD86 molecule Homo sapiens 114-118 18428145-0 2008 Therapy with interferon-alpha and ribavirin for chronic hepatitis C virus infection upregulates membrane HLA-ABC, CD86, and CD28 on peripheral blood mononuclear cells. Ribavirin 34-43 CD28 molecule Homo sapiens 124-128 18622147-0 2008 [Association between raised IL-8 serum levels and resistance to combined peg-interferon plus ribavirin therapy in HCV+ active chronic hepatitis]. Ribavirin 93-102 C-X-C motif chemokine ligand 8 Homo sapiens 28-32 18622147-7 2008 Serum IL-8 can be considered and proposed as a non-invasive and predictive marker of response to combined PEG IFN alpha2b + Ribavirin in CAH HCV +. Ribavirin 124-133 C-X-C motif chemokine ligand 8 Homo sapiens 6-10 18702333-1 2008 UNLABELLED: The aim of the study was to describe describe the frequency of depressive symptoms and episodes accompanying peg-interferon alpha and ribavirin (peg-IFN-alpha/RBV) treatment of chronic hepatitis C patients (CHC). Ribavirin 146-155 interferon alpha 1 Homo sapiens 161-170 18358726-3 2008 Then regioselective acylation of ribavirin and cytarabine with pyrimidine vinyl ester was catalyzed by CAL-B (immobilized lipase from Candida antarctica) in anhydrous acetone. Ribavirin 33-42 PAN0_003d1715 Moesziomyces antarcticus 122-128 18371949-6 2008 Gemcitabine (a pyrimidine nucleoside analogue, a CNT1 substrate) and ribavirin (a purine nucleoside analog, a CNT2 substrate) also significantly suppressed the mizoribine intestinal absorption. Ribavirin 69-78 solute carrier family 28 member 2 Rattus norvegicus 110-114 18646554-0 2008 Influence of interferon-alpha and ribavirin on the transcription of interferon-gamma and IFN-gamma receptor genes in Jurkat cells. Ribavirin 34-43 interferon gamma Homo sapiens 68-84 18646554-0 2008 Influence of interferon-alpha and ribavirin on the transcription of interferon-gamma and IFN-gamma receptor genes in Jurkat cells. Ribavirin 34-43 interferon gamma Homo sapiens 89-98 18646554-3 2008 In the presented study, using Jurkat cell line as an in vitro model for interferon-gamma synthesis, influence of interferon-alpha and ribavirin on the expressions of IFN-gamma and its receptor subunits (IFNgR1 and IFNgR2) were studied. Ribavirin 134-143 interferon gamma Homo sapiens 166-175 18646554-3 2008 In the presented study, using Jurkat cell line as an in vitro model for interferon-gamma synthesis, influence of interferon-alpha and ribavirin on the expressions of IFN-gamma and its receptor subunits (IFNgR1 and IFNgR2) were studied. Ribavirin 134-143 interferon gamma receptor 1 Homo sapiens 203-209 18646554-3 2008 In the presented study, using Jurkat cell line as an in vitro model for interferon-gamma synthesis, influence of interferon-alpha and ribavirin on the expressions of IFN-gamma and its receptor subunits (IFNgR1 and IFNgR2) were studied. Ribavirin 134-143 interferon gamma receptor 2 Homo sapiens 214-220 18646554-5 2008 Results indicate that both drugs, IFN-alpha and ribavirin, induced changes in IFN-gamma and its receptor expressions. Ribavirin 48-57 interferon gamma Homo sapiens 78-87 18646554-7 2008 The inhibitory effect of ribavirin dominated IFN-alpha action and was responsible for the decrease in the mRNA levels of IFN-gamma and the receptor of IFN-gamma. Ribavirin 25-34 interferon alpha 1 Homo sapiens 45-54 18646554-7 2008 The inhibitory effect of ribavirin dominated IFN-alpha action and was responsible for the decrease in the mRNA levels of IFN-gamma and the receptor of IFN-gamma. Ribavirin 25-34 interferon gamma Homo sapiens 121-130 18646554-7 2008 The inhibitory effect of ribavirin dominated IFN-alpha action and was responsible for the decrease in the mRNA levels of IFN-gamma and the receptor of IFN-gamma. Ribavirin 25-34 interferon gamma Homo sapiens 151-160 18646554-8 2008 This phenomenon observed at in vitro model may be responsible for the IFN-gamma decrease during hepatitis C therapy with IFN-alpha and ribavirin which was suggested by some authors. Ribavirin 135-144 interferon gamma Homo sapiens 70-79 18081733-0 2008 Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. BACKGROUND: Treatment options are limited for patients with hepatitis C virus who do not experience sustained viral eradication with pegylated interferon and ribavirin therapy. Ribavirin 288-297 interferon alpha 2 Homo sapiens 16-35 18336595-8 2008 Furthermore, MBL2 genotypes containing X or O mutations were found to be associated with non-responsiveness to pginterferon and ribavirin treatment (P = 0.023). Ribavirin 128-137 mannose binding lectin 2 Homo sapiens 13-17 17939042-7 2008 CONCLUSIONS: Combined treatment with L: -carnitine, ribavirin and IFN alpha resulted in greater antihyperlipidaemic effects and than with ribavirin and IFN alpha alone. Ribavirin 52-61 interferon alpha 1 Homo sapiens 152-161 17939042-7 2008 CONCLUSIONS: Combined treatment with L: -carnitine, ribavirin and IFN alpha resulted in greater antihyperlipidaemic effects and than with ribavirin and IFN alpha alone. Ribavirin 138-147 interferon alpha 1 Homo sapiens 66-75 18215704-6 2008 INTERVENTION: IFN-based treatment, including PEG-IFN with and without ribavirin. Ribavirin 70-79 interferon alpha 1 Homo sapiens 14-17 18080217-5 2008 Human uridine-cytidine kinase-1 (UCK-1) was used for ribavirin phosphorylation to its monophosphate form. Ribavirin 53-62 uridine-cytidine kinase 1 Homo sapiens 6-31 18080217-5 2008 Human uridine-cytidine kinase-1 (UCK-1) was used for ribavirin phosphorylation to its monophosphate form. Ribavirin 53-62 uridine-cytidine kinase 1 Homo sapiens 33-38 18080217-8 2008 Our findings show that ribavirin is a potential substrate of UCK-1, and RMP formed could be chemically coupled to AsOR to form a conjugate for liver specific targeting. Ribavirin 23-32 uridine-cytidine kinase 1 Homo sapiens 61-66 18310007-0 2008 Artificially low HbA1c associated with treatment with ribavirin. Ribavirin 54-63 hemoglobin subunit alpha 1 Homo sapiens 17-21 18720164-0 2008 Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in HCV chronic patients. Ribavirin 87-96 galectin 3 binding protein Homo sapiens 33-40 18211540-2 2008 METHOD OF STUDY: We used a rapid genotyping method based on melting temperature assay to search for three single nucleotide polymorphisms (SNPs) located in the first exon of the MBL2 gene and we also measured MBL serum levels in patients with recurrent bacterial vaginosis (rBV) and recurrent vulvovaginal candidiasis (rVVC). Ribavirin 274-277 mannose binding lectin 2 Homo sapiens 178-182 18211540-2 2008 METHOD OF STUDY: We used a rapid genotyping method based on melting temperature assay to search for three single nucleotide polymorphisms (SNPs) located in the first exon of the MBL2 gene and we also measured MBL serum levels in patients with recurrent bacterial vaginosis (rBV) and recurrent vulvovaginal candidiasis (rVVC). Ribavirin 274-277 mannose binding lectin 2 Homo sapiens 178-181 18610555-8 2008 For the triple combinations of IFN-alpha2b plus RBV with either 2"-C-MeC or 2"-F-C-MeC, the Cl(wt) values at 1:1:1 ratio tested were 0.5 and 0.8, respectively, indicating synergistic antiviral effects. Ribavirin 48-51 C-C motif chemokine ligand 28 Homo sapiens 69-72 18672537-2 2008 A single test dose of IFN was useful to identify non-responders to IFN-alpha2b/ribavirin (RBV) or likely non-responders to pegylated (PEG)-IFN-alpha2a/RBV therapy in genotype 1 patients. Ribavirin 79-88 interferon alpha 1 Homo sapiens 22-25 18672537-2 2008 A single test dose of IFN was useful to identify non-responders to IFN-alpha2b/ribavirin (RBV) or likely non-responders to pegylated (PEG)-IFN-alpha2a/RBV therapy in genotype 1 patients. Ribavirin 90-93 interferon alpha 1 Homo sapiens 22-25 18672537-2 2008 A single test dose of IFN was useful to identify non-responders to IFN-alpha2b/ribavirin (RBV) or likely non-responders to pegylated (PEG)-IFN-alpha2a/RBV therapy in genotype 1 patients. Ribavirin 151-154 interferon alpha 1 Homo sapiens 22-25 18672537-10 2008 A 24 h log10 change after 10 MU IFN-alpha2b is an excellent predictor of SVR on PEG-IFNalpha2a/RBV combination therapy. Ribavirin 95-98 interferon alpha 1 Homo sapiens 32-35 18067241-2 2008 The ambiguous incorporation of 5"-triphosphate of ribavirin (RTP, 8) by a viral RNA-dependent RNA polymerase (RdRp) is a key step of the mutation induction. Ribavirin 50-59 MORN repeat containing 4 Homo sapiens 61-64 18510050-10 2008 Ribavirin and corticosteroids are usually suggested for the treatment of SARS. Ribavirin 0-9 seryl-tRNA synthetase 1 Homo sapiens 73-77 18510050-11 2008 However, the ribavirin therapy increases the risk of teratogenic effects in newborns of pregnant women with SARS. Ribavirin 13-22 seryl-tRNA synthetase 1 Homo sapiens 108-112 17662475-5 2007 The replicon cells were subjected to treatment with several antiviral compounds and inhibition of the replicon was observed in treatment with known nucleoside analog inhibitors of NS5 such as 2"-C-methyladenosine (EC(50)=2.42 +/- 0.59 microM), or ribavirin (EC(50)=6.77 +/- 1.33 microM), mycophenolic acid (EC(50)=1.31 +/- 0.27 microM) and siRNA against NS3. Ribavirin 247-256 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 180-183 18156991-2 2008 Our objective was to determine if a baseline CD4 count >/=350 cells/mm predicts a sustained HCV response to pegylated interferon plus ribavirin. Ribavirin 137-146 CD4 molecule Homo sapiens 45-48 18652518-3 2008 METHODS: Using single nucleotide polymorphisms (SNPs) and viral genotype, we applied the support vector machine (SVM) algorithm to build a tool to predict responsiveness to IFNalpha-ribavirin combination therapy. Ribavirin 182-191 interferon alpha 1 Homo sapiens 173-181 17852932-6 2008 To conclude, we found that utilizing a low initial daily RBV dose, later increased due to tolerance in combination with peg-IFN alpha-2a 180 microg weekly, was successful. Ribavirin 57-60 interferon alpha 1 Homo sapiens 124-127 18265628-0 2007 High dose of erythropoietin in management of interferon/ribavirin induced anemia. Ribavirin 56-65 erythropoietin Homo sapiens 13-27 17845853-2 2007 Ribavirin has also been reported to inhibit human S-adenosyl-L-homocysteine hydrolase (Hs-SAHH), which catalyzes the conversion of S-adenosyl-L-homocysteine to adenosine and homocysteine. Ribavirin 0-9 adenosylhomocysteinase Homo sapiens 90-94 17845853-3 2007 We now report that ribavirin, which is structurally similar to adenosine, produces time-dependent inactivation of Hs-SAHH and Trypanosoma cruzi SAHH (Tc-SAHH). Ribavirin 19-28 adenosylhomocysteinase Homo sapiens 117-121 17845853-3 2007 We now report that ribavirin, which is structurally similar to adenosine, produces time-dependent inactivation of Hs-SAHH and Trypanosoma cruzi SAHH (Tc-SAHH). Ribavirin 19-28 adenosylhomocysteinase Homo sapiens 144-148 17845853-5 2007 The reversible binding step of ribavirin to Hs-SAHH and Tc-SAHH has similar K(I) values (266 and 194 microM), but the slow inactivation step is 5-fold faster with Tc-SAHH. Ribavirin 31-40 adenosylhomocysteinase Homo sapiens 47-51 17845853-5 2007 The reversible binding step of ribavirin to Hs-SAHH and Tc-SAHH has similar K(I) values (266 and 194 microM), but the slow inactivation step is 5-fold faster with Tc-SAHH. Ribavirin 31-40 adenosylhomocysteinase Homo sapiens 59-63 17845853-5 2007 The reversible binding step of ribavirin to Hs-SAHH and Tc-SAHH has similar K(I) values (266 and 194 microM), but the slow inactivation step is 5-fold faster with Tc-SAHH. Ribavirin 31-40 adenosylhomocysteinase Homo sapiens 59-63 17845853-6 2007 Ribavirin may provide a structural lead for design of more selective inhibitors of Tc-SAHH as potential anti-parasitic drugs. Ribavirin 0-9 adenosylhomocysteinase Homo sapiens 86-90 18265628-1 2007 Accumulating evidence now supports the use of recombinant human erythropoietin (rHuEPO) to manage anemia in PEG-IFN/RBV treated patients, with the objective of maintaining the RBV dose, but currently no official guidelines exist. Ribavirin 116-119 erythropoietin Homo sapiens 64-78 18265628-1 2007 Accumulating evidence now supports the use of recombinant human erythropoietin (rHuEPO) to manage anemia in PEG-IFN/RBV treated patients, with the objective of maintaining the RBV dose, but currently no official guidelines exist. Ribavirin 176-179 erythropoietin Homo sapiens 64-78 17927614-1 2007 Many patients with chronic hepatitis C (HCV) infection undergoing treatment with pegylated interferon-alpha (PEG-IFN-alpha) and ribavirin develop neutropenia requiring dose reduction or granulocyte colony-stimulating factor (G-CSF) supplement. Ribavirin 128-137 colony stimulating factor 3 Homo sapiens 186-223 17968840-12 2007 CONCLUSIONS: In patients with symptomatic DILI, treatment with IFN-ribavirin (RBV) led to decreases in aminotransferase levels, which enabled the reinitiation of ART. Ribavirin 67-76 interferon alpha 1 Homo sapiens 63-66 17968840-12 2007 CONCLUSIONS: In patients with symptomatic DILI, treatment with IFN-ribavirin (RBV) led to decreases in aminotransferase levels, which enabled the reinitiation of ART. Ribavirin 78-81 interferon alpha 1 Homo sapiens 63-66 17914965-7 2007 Multiple regression analysis showed that TIS was the only independent variable associated with resistance to IFN/ribavirin (P = 0.0277). Ribavirin 113-122 interferon alpha 1 Homo sapiens 109-112 17699579-5 2007 While all four drugs resulted in a decrease in the GTP levels and infectious virus, only RBV increased the mutation frequency of viral RNA (vRNA). Ribavirin 89-92 vault RNA 1-1 Homo sapiens 140-144 17675168-2 2007 The current treatment with IFN-alpha given alone or in combination with ribavirin is ineffective in eliminating the virus in a large proportion of individuals with chronic hepatitis C. Recent data suggest that HCV blocks IFN-alpha signalling, an effect that facilitates viral persistence. Ribavirin 72-81 interferon alpha 1 Homo sapiens 221-230 17929300-11 2007 The patients pretreated with ribavirin had heightened induction of IFN-related genes and down-regulation of genes involved in IFN inhibition and hepatic stellate cell activation. Ribavirin 29-38 interferon alpha 1 Homo sapiens 67-70 17929300-11 2007 The patients pretreated with ribavirin had heightened induction of IFN-related genes and down-regulation of genes involved in IFN inhibition and hepatic stellate cell activation. Ribavirin 29-38 interferon alpha 1 Homo sapiens 126-129 17560677-11 2007 Treatment with PEG-interferon alpha-2b plus ribavirin increased CCR5(high)/CXCR3(high) expressing CD8+ cells frequency in peripheral blood and decreased CXCL10/CCL3 serum concentration. Ribavirin 44-53 C-C motif chemokine receptor 5 Homo sapiens 64-68 17560677-11 2007 Treatment with PEG-interferon alpha-2b plus ribavirin increased CCR5(high)/CXCR3(high) expressing CD8+ cells frequency in peripheral blood and decreased CXCL10/CCL3 serum concentration. Ribavirin 44-53 C-X-C motif chemokine receptor 3 Homo sapiens 75-80 17560677-11 2007 Treatment with PEG-interferon alpha-2b plus ribavirin increased CCR5(high)/CXCR3(high) expressing CD8+ cells frequency in peripheral blood and decreased CXCL10/CCL3 serum concentration. Ribavirin 44-53 CD8a molecule Homo sapiens 98-101 17560677-11 2007 Treatment with PEG-interferon alpha-2b plus ribavirin increased CCR5(high)/CXCR3(high) expressing CD8+ cells frequency in peripheral blood and decreased CXCL10/CCL3 serum concentration. Ribavirin 44-53 C-X-C motif chemokine ligand 10 Homo sapiens 153-159 17560677-11 2007 Treatment with PEG-interferon alpha-2b plus ribavirin increased CCR5(high)/CXCR3(high) expressing CD8+ cells frequency in peripheral blood and decreased CXCL10/CCL3 serum concentration. Ribavirin 44-53 C-C motif chemokine ligand 3 Homo sapiens 160-164 17927614-1 2007 Many patients with chronic hepatitis C (HCV) infection undergoing treatment with pegylated interferon-alpha (PEG-IFN-alpha) and ribavirin develop neutropenia requiring dose reduction or granulocyte colony-stimulating factor (G-CSF) supplement. Ribavirin 128-137 colony stimulating factor 3 Homo sapiens 225-230 17958644-3 2007 Better results have recently been reported with pegylated IFN both in IFN-naive and in previous nonresponders to standard IFN, suggesting the use of pegylated IFN as a first-line therapy in chronic hepatitis D. Nucleoside analogues that inhibit hepatitis B virus (HBV) are ineffective against HDV and combination therapy with lamivudine or ribavirin has not shown significant advantages over monotherapy with either standard or pegylated IFN. Ribavirin 340-349 interferon alpha 1 Homo sapiens 58-61 19190694-8 2007 Considering all patients with chronic HCV-infection, bcl-2 rearrangement was slightly more frequent in the non treated group than in those who underwent treatment with interferon plus ribavirin but the difference was not statistically significant, although treated patients showed biochemical and virologic response at the end of 6 months of antiviral therapy. Ribavirin 184-193 BCL2 apoptosis regulator Homo sapiens 53-58 17724740-0 2007 Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. PURPOSE: Administration of pegylated interferon-alpha (IFN-alpha) and ribavirin in adults with chronic hepatitis C (CHC) is a recommended therapeutic standard. Ribavirin 67-76 interferon alpha 1 Homo sapiens 170-179 17823081-3 2007 In this paper, we investigated the distribution of two variants of the IFNAR1 gene, G17470C and L168V, in two patient groups having received IFN-alpha alone or in combination with ribavirin. Ribavirin 180-189 interferon alpha and beta receptor subunit 1 Homo sapiens 71-77 18007553-7 2007 PEG-IFN + ribavirin reduced the total bilirubin concentration by 27%, alanine amino transferase (ALT) activity by 75% and gamma-glutamyl transpeptidase (gamma-GTP) activity by 74% (P < 0.05). Ribavirin 10-19 gamma-glutamyltransferase 1 Rattus norvegicus 122-151 18007553-7 2007 PEG-IFN + ribavirin reduced the total bilirubin concentration by 27%, alanine amino transferase (ALT) activity by 75% and gamma-glutamyl transpeptidase (gamma-GTP) activity by 74% (P < 0.05). Ribavirin 10-19 gamma-glutamyltransferase 1 Rattus norvegicus 153-162 18007553-8 2007 In contrast, danazol + PEG-IFN + ribavirin reduced total bilirubin levels by 61%, alkaline phosphatase activity by 45%, ALT activity by 76%, and gamma-GTP activity by 74% (P < 0.05). Ribavirin 33-42 gamma-glutamyltransferase 1 Rattus norvegicus 145-154 18007553-9 2007 The only treatment that increased interleukin 10 (IL-10) mRNA in fibrotic rats was PEG-IFN + ribavirin. Ribavirin 93-102 interleukin 10 Rattus norvegicus 34-48 18007553-9 2007 The only treatment that increased interleukin 10 (IL-10) mRNA in fibrotic rats was PEG-IFN + ribavirin. Ribavirin 93-102 interleukin 10 Rattus norvegicus 50-55 18007553-10 2007 However, danazol + PEG-IFN + ribavirin reduced the expression of IL-6, IL-10, tumor necrosis factor alpha and transforming growth factor ss. Ribavirin 29-38 interleukin 6 Rattus norvegicus 65-69 18007553-10 2007 However, danazol + PEG-IFN + ribavirin reduced the expression of IL-6, IL-10, tumor necrosis factor alpha and transforming growth factor ss. Ribavirin 29-38 interleukin 10 Rattus norvegicus 71-76 18007553-10 2007 However, danazol + PEG-IFN + ribavirin reduced the expression of IL-6, IL-10, tumor necrosis factor alpha and transforming growth factor ss. Ribavirin 29-38 tumor necrosis factor Rattus norvegicus 78-105 17629590-9 2007 CONCLUSIONS: In conclusion, PEG-IFN-alpha2b and RBV combined with 50 mg MMPD q12h was well tolerated and induced virological response with undetectable HCV RNA in IFN-alpha and RBV nonresponders. Ribavirin 48-51 interferon alpha 1 Homo sapiens 32-35 17629590-9 2007 CONCLUSIONS: In conclusion, PEG-IFN-alpha2b and RBV combined with 50 mg MMPD q12h was well tolerated and induced virological response with undetectable HCV RNA in IFN-alpha and RBV nonresponders. Ribavirin 48-51 interferon alpha 1 Homo sapiens 163-166 17700367-6 2007 Expression of these variants in U-251 cells revealed that all except E385K can uptake various substrates of hCNT2: inosine, ribavirin and uridine. Ribavirin 124-133 solute carrier family 28 member 2 Homo sapiens 108-113 17897248-5 2007 There are only limited data about pegylated IFN alone or in association with ribavirin for hepatitis C in dialysis population. Ribavirin 77-86 interferon alpha 1 Homo sapiens 44-47 17654600-7 2007 In the IFN beta-1a/ribavirin group, 73 of 127 patients (57.5%) achieved an SVR [P < 0.001 versus IFN beta-1a; the adjusted odds ratio was 4.54 (95% confidence interval: 2.53, 8.13)]. Ribavirin 19-28 interferon beta 1 Homo sapiens 7-15 17654600-7 2007 In the IFN beta-1a/ribavirin group, 73 of 127 patients (57.5%) achieved an SVR [P < 0.001 versus IFN beta-1a; the adjusted odds ratio was 4.54 (95% confidence interval: 2.53, 8.13)]. Ribavirin 19-28 interferon beta 1 Homo sapiens 100-108 17654600-10 2007 The addition of ribavirin to IFN beta-1a significantly increased the proportion of patients who achieved an SVR versus IFN beta-1a monotherapy. Ribavirin 16-25 interferon beta 1 Homo sapiens 119-127 17559739-4 2007 The secondary objective was to calculate the incremental cost of using epoetin versus no epoetin to treat RIA, per ribavirin dose reduction/discontinuation averted. Ribavirin 115-124 erythropoietin Homo sapiens 71-78 17597457-3 2007 This study investigated whether PKR is a mediator of the effectiveness of ribavirin, used either alone or in combination with interferon (IFN)- alpha , against hepatitis C virus (HCV) infection. Ribavirin 74-83 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 32-35 17597457-6 2007 A pulse-chase assay of the half-life of PKR protein was performed to study whether ribavirin decreases PKR degradation. Ribavirin 83-92 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 103-106 17597457-8 2007 RESULTS: Ribavirin was able to up-regulate the levels of phosphorylated PKR and phosphorylated eIF2 alpha , leading to suppression of HCV-RNA replication. Ribavirin 9-18 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 72-75 17597457-9 2007 The effects that treatment with ribavirin plus IFN- alpha had on PKR activity were greater than those observed for treatment with either ribavirin alone or IFN- alpha alone. Ribavirin 32-41 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 65-68 17597457-9 2007 The effects that treatment with ribavirin plus IFN- alpha had on PKR activity were greater than those observed for treatment with either ribavirin alone or IFN- alpha alone. Ribavirin 32-41 interferon alpha 1 Homo sapiens 156-166 17597457-11 2007 The pulse-chase experiment showed that ribavirin can reduce the degradation rate of PKR protein. Ribavirin 39-48 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 84-87 17597457-12 2007 CONCLUSION: These results suggest that the anti-HCV action of ribavirin is partly attributable to its ability to up-regulate PKR activity. Ribavirin 62-71 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 125-128 17663735-8 2007 RESULTS: Among human immunodeficiency virus (HIV) negative patients (n = 235), SVR was 29% (29/101) for IFN monotherapy, 44% (32/72) for IFN with ribavirin, and 63% (39/62) for pegylated IFN (PegIFN) with ribavirin. Ribavirin 146-155 interferon alpha 1 Homo sapiens 137-140 17663735-8 2007 RESULTS: Among human immunodeficiency virus (HIV) negative patients (n = 235), SVR was 29% (29/101) for IFN monotherapy, 44% (32/72) for IFN with ribavirin, and 63% (39/62) for pegylated IFN (PegIFN) with ribavirin. Ribavirin 146-155 interferon alpha 1 Homo sapiens 137-140 17596864-9 2007 Finally, the enhanced third phase in patients treated with IFN-alpha in combination with RBV versus patients treated with IFN-alpha alone can be explained by a mutagenic effect of RBV against HCV. Ribavirin 180-183 interferon alpha 1 Homo sapiens 59-68 17596864-9 2007 Finally, the enhanced third phase in patients treated with IFN-alpha in combination with RBV versus patients treated with IFN-alpha alone can be explained by a mutagenic effect of RBV against HCV. Ribavirin 180-183 interferon alpha 1 Homo sapiens 122-131 17414926-6 2007 Plasma IP-10 levels of 400 pg/mL before treatment and on days 7 and 14 could be used to identify likely coinfected PEG-IFN/ribavirin nonresponders. Ribavirin 123-132 C-X-C motif chemokine ligand 10 Homo sapiens 7-12 17589934-0 2007 Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. We report a panel of severe inflammatory and vascular intraocular disorders occurring during interferon-alpha (IFN-alpha) treatment in eight hepatitis C virus (HCV)-infected patients. Ribavirin 43-52 interferon alpha 1 Homo sapiens 216-225 17379518-1 2007 The conversion of ribavirin to the monophosphate by adenosine kinase is the rate-limiting step in activation of this broad spectrum antiviral drug. Ribavirin 18-27 adenosine kinase Homo sapiens 52-68 17559739-2 2007 Studies have shown that the use of epoetin decreases the need for ribavirin dose reduction or discontinuation. Ribavirin 66-75 erythropoietin Homo sapiens 35-42 17663735-10 2007 SVR increased with genotype 2 and 3 [OR 11.0, 95% CI: 5.8-20.5], and combination therapy (IFN and ribavirin OR 3.7, 95% CI: 1.7-8.4), PegIFN and ribavirin (OR 4.2, 95% CI: 1.8-9.5). Ribavirin 145-154 interferon alpha 1 Homo sapiens 90-93 17539990-11 2007 CONCLUSION: Low dose long-term interferon monotherapy to prevent carcinogenesis of HCC was considered useful in aged patients for whom peg-interferon and ribavirin combination therapy is difficult. Ribavirin 154-163 interferon alpha 1 Homo sapiens 31-41 17559739-9 2007 Using one-way sensitivity analyses, the cost of using epoetin per ribavirin dose reduction/discontinuation averted was $39,579-$52,023. Ribavirin 66-75 erythropoietin Homo sapiens 54-61 17559739-12 2007 The cost of using epoetin per ribavirin dose reduction/discontinuation averted is substantial in patients with genotypes 1, 2, or 3; and varies with the probability of response to epoetin. Ribavirin 30-39 erythropoietin Homo sapiens 18-25 17660602-0 2007 IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C. The aim of the study was to observe the frequency of neutropenia during Pegylated Interferon/Ribavirin therapy in patient with chronic hepatitis C; to compare the efficacy of two strategies of management of neutropenia--with Interferon dose modification and with Neupogen administration; to compare the effectiveness rate of sustained viral response (SVR) in patients with Pegylated Interferon dose modification and in patients treated by using granulocyte colony-stimulating factor G-CSF-filgrastim. Ribavirin 194-203 interferon alpha 1 Homo sapiens 0-3 17140564-4 2007 In Xenopus oocytes, influxes of ribavirin mediated by hCNT2 (concentrative nucleoside transporter 2), hCNT3 (concentrative nucleoside transporter 3), hENT1 (equilibrative nucleoside transporter 1) and hENT2 (equilibrative nucleoside transporter 2) were saturable, and apparent K(m) values were 18.0 microM, 14.2 microM, 3.46 mM and 3.71 mM, respectively. Ribavirin 32-41 solute carrier family 28 member 2 Homo sapiens 54-59 17501760-0 2007 Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. Ribavirin 127-136 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 30-33 17441804-0 2007 Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. AIMS: We previously reported the potential effect of combination therapy of an initial high-dose interferon (IFN) and amantadine on the eradication of HCV-RNA in patients with chronic hepatitis C. The additive effects of amantadine on interferon and ribavirin combination therapy remain controversial. Ribavirin 52-61 interferon alpha 1 Homo sapiens 203-229 17441804-0 2007 Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. AIMS: We previously reported the potential effect of combination therapy of an initial high-dose interferon (IFN) and amantadine on the eradication of HCV-RNA in patients with chronic hepatitis C. The additive effects of amantadine on interferon and ribavirin combination therapy remain controversial. Ribavirin 52-61 interferon alpha 1 Homo sapiens 213-223 17441804-0 2007 Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. AIMS: We previously reported the potential effect of combination therapy of an initial high-dose interferon (IFN) and amantadine on the eradication of HCV-RNA in patients with chronic hepatitis C. The additive effects of amantadine on interferon and ribavirin combination therapy remain controversial. Ribavirin 366-375 interferon alpha 1 Homo sapiens 36-46 17441804-0 2007 Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. AIMS: We previously reported the potential effect of combination therapy of an initial high-dose interferon (IFN) and amantadine on the eradication of HCV-RNA in patients with chronic hepatitis C. The additive effects of amantadine on interferon and ribavirin combination therapy remain controversial. Ribavirin 366-375 interferon alpha 1 Homo sapiens 203-229 17441804-0 2007 Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. AIMS: We previously reported the potential effect of combination therapy of an initial high-dose interferon (IFN) and amantadine on the eradication of HCV-RNA in patients with chronic hepatitis C. The additive effects of amantadine on interferon and ribavirin combination therapy remain controversial. Ribavirin 366-375 interferon alpha 1 Homo sapiens 213-223 17441804-7 2007 CONCLUSION: Triple therapy with an initial high dose of IFN with ribavirin and amantadine may be effective, especially for chronic hepatitis C IFN-retreatment patients with a high viral load of genotype 1b. Ribavirin 65-74 interferon alpha 1 Homo sapiens 56-59 17441804-7 2007 CONCLUSION: Triple therapy with an initial high dose of IFN with ribavirin and amantadine may be effective, especially for chronic hepatitis C IFN-retreatment patients with a high viral load of genotype 1b. Ribavirin 65-74 interferon alpha 1 Homo sapiens 143-146 17444850-8 2007 CONCLUSION: In Japanese patients, peg-IFNalpha-2a plus ribavirin provided significant improvement in SVR rates compared with peg-IFNalpha-2a alone in treatment-naive patients, and was effective as re-treatment for non-responders or relapsers to previous treatment with interferon monotherapy. Ribavirin 55-64 interferon alpha 1 Homo sapiens 129-137 17444854-2 2007 The change in AFP levels after treatment with pegylated interferon and ribavirin (Peg-IFN/RBV) combination therapy is still unknown. Ribavirin 71-80 alpha fetoprotein Homo sapiens 14-17 17444854-2 2007 The change in AFP levels after treatment with pegylated interferon and ribavirin (Peg-IFN/RBV) combination therapy is still unknown. Ribavirin 90-93 alpha fetoprotein Homo sapiens 14-17 17444854-3 2007 The aim of this study was to investigate the predictors of elevated serum AFP in patients with CHC, and its change after Peg-IFN/RBV therapy. Ribavirin 129-132 alpha fetoprotein Homo sapiens 74-77 17444854-14 2007 After Peg-IFN/RBV combination therapy, a higher platelet count and HCV viral eradication were determinants of normal AFP at EOF. Ribavirin 14-17 alpha fetoprotein Homo sapiens 117-120 17397412-4 2007 Administering erythropoietin can improve anemia caused by peginterferon and ribavirin therapy and is more effective than dose reduction at improving QOL during treatment. Ribavirin 76-85 erythropoietin Homo sapiens 14-28 17376035-1 2007 BACKGROUND: Interferon (IFN) has been well documented to cause thyroid dysfunction, especially in high risk patients and when combined with ribavirin (RBV). Ribavirin 140-149 interferon alpha 1 Homo sapiens 12-28 17376035-1 2007 BACKGROUND: Interferon (IFN) has been well documented to cause thyroid dysfunction, especially in high risk patients and when combined with ribavirin (RBV). Ribavirin 151-154 interferon alpha 1 Homo sapiens 12-28 17381375-8 2007 In the primary logistic regression analysis, ribavirin use was strongly associated with anemia (odds ratio [OR] 3.0, 99% confidence interval [CI] 1.5-6.1, p<0.0001), hypomagnesemia (OR 21, 99% CI 5.8-73, p<0.0001), and bradycardia (OR 2.3, 99% CI 1.0-5.1, p=0.007). Ribavirin 45-54 olfactory receptor family 6 subfamily B member 2 Homo sapiens 185-190 17547292-10 2007 Moreover, recent data strongly suggest that insulin resistance is an important predictor of poor response to antiviral therapy in chronic hepatitis patients treated with peginterferon plus ribavirin. Ribavirin 189-198 insulin Homo sapiens 44-51 17397001-0 2007 CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance. Ribavirin 84-93 CD4 molecule Homo sapiens 0-3 17962866-3 2007 DATA SYNTHESIS: In the last years several published papers have demonstrated an important relationship between insulin resistance and chronic hepatitis C. Increased prevalence of type 2 diabetes mellitus, the development of hepatic steatosis (specially in non-3 genotype), a more rapid progression of hepatic disease and reduction in the sustained virological response to treatment with pegylated interferon plus ribavirin have been associated with insulin resistance in patients infected with HCV. Ribavirin 413-422 insulin Homo sapiens 111-118 17962866-7 2007 CONCLUSIONS: Diagnosing and treating insulin resistance in patients with chronic hepatitis C could not only avoid complications but also prevent disease progression and increased the sustained virological rate to treatment with pegylated interferon plus ribavarin. Ribavirin 254-263 insulin Homo sapiens 37-44 17140564-4 2007 In Xenopus oocytes, influxes of ribavirin mediated by hCNT2 (concentrative nucleoside transporter 2), hCNT3 (concentrative nucleoside transporter 3), hENT1 (equilibrative nucleoside transporter 1) and hENT2 (equilibrative nucleoside transporter 2) were saturable, and apparent K(m) values were 18.0 microM, 14.2 microM, 3.46 mM and 3.71 mM, respectively. Ribavirin 32-41 solute carrier family 28 member 3 Homo sapiens 102-107 17140564-4 2007 In Xenopus oocytes, influxes of ribavirin mediated by hCNT2 (concentrative nucleoside transporter 2), hCNT3 (concentrative nucleoside transporter 3), hENT1 (equilibrative nucleoside transporter 1) and hENT2 (equilibrative nucleoside transporter 2) were saturable, and apparent K(m) values were 18.0 microM, 14.2 microM, 3.46 mM and 3.71 mM, respectively. Ribavirin 32-41 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-155 17140564-4 2007 In Xenopus oocytes, influxes of ribavirin mediated by hCNT2 (concentrative nucleoside transporter 2), hCNT3 (concentrative nucleoside transporter 3), hENT1 (equilibrative nucleoside transporter 1) and hENT2 (equilibrative nucleoside transporter 2) were saturable, and apparent K(m) values were 18.0 microM, 14.2 microM, 3.46 mM and 3.71 mM, respectively. Ribavirin 32-41 solute carrier family 29 member 2 Homo sapiens 201-206 17140564-5 2007 These data indicate that hCNT2 and hCNT3 have higher affinity for ribavirin than do hENT1 and hENT2. Ribavirin 66-75 solute carrier family 28 member 2 Homo sapiens 25-30 17140564-5 2007 These data indicate that hCNT2 and hCNT3 have higher affinity for ribavirin than do hENT1 and hENT2. Ribavirin 66-75 solute carrier family 28 member 3 Homo sapiens 35-40 17140564-7 2007 These results suggest that ribavirin is taken up by BeWo cells via both the high-affinity Na(+)-dependent transporter hCNT3 and the low-affinity Na(+)-independent transporters hENT1 and hENT2. Ribavirin 27-36 solute carrier family 28 member 3 Homo sapiens 118-123 17140564-7 2007 These results suggest that ribavirin is taken up by BeWo cells via both the high-affinity Na(+)-dependent transporter hCNT3 and the low-affinity Na(+)-independent transporters hENT1 and hENT2. Ribavirin 27-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 176-181 17140564-7 2007 These results suggest that ribavirin is taken up by BeWo cells via both the high-affinity Na(+)-dependent transporter hCNT3 and the low-affinity Na(+)-independent transporters hENT1 and hENT2. Ribavirin 27-36 solute carrier family 29 member 2 Homo sapiens 186-191 17173661-1 2007 We conducted a study to evaluate the efficacy of pegylated interferon/ribavirin in patients who did not respond to previous posttransplant recurrent HCV treatment with IFN/ribavirin combination. Ribavirin 70-79 interferon alpha 1 Homo sapiens 168-171 17060520-7 2007 Treatment with both MPA and RBV resulted in increased reduction of vRNA levels but did not result in enhanced depression of GTP levels. Ribavirin 28-31 vault RNA 1-1 Homo sapiens 67-71 16909305-0 2007 Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE/RANKL. Ribavirin 0-9 TNF superfamily member 11 Homo sapiens 81-87 16909305-0 2007 Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE/RANKL. Ribavirin 0-9 TNF superfamily member 11 Homo sapiens 88-93 16909305-3 2007 Ribavirin enhances osteoclast formation through osteoblasts by up-regulation of TRANCE/RANKL gene expression, whereas it has no significant effect on either osteoblast differentiation or on bone formation. Ribavirin 0-9 TNF superfamily member 11 Homo sapiens 80-86 16909305-3 2007 Ribavirin enhances osteoclast formation through osteoblasts by up-regulation of TRANCE/RANKL gene expression, whereas it has no significant effect on either osteoblast differentiation or on bone formation. Ribavirin 0-9 TNF superfamily member 11 Homo sapiens 87-92 17299014-4 2007 Studies using epoetin alfa 40 000 units subcutaneously once weekly have demonstrated efficacy in maintaining hemoglobin, ribavirin dose, and quality of life scores, but clear benefit shown with sustained virologic response (SVR) is lacking. Ribavirin 121-130 erythropoietin Homo sapiens 14-21 17300707-4 2007 Furthermore, administering IFN-beta once or twice one day before combination treatment using ribavirin and IFN-alpha was more effective than administering IFN-alpha once or twice one day before the combination treatment using ribavirin and IFN-alpha. Ribavirin 93-102 interferon beta 1, fibroblast Mus musculus 27-35 17300707-5 2007 CONCLUSION: These data indicate that this MHV-infection system is a good animal model to assess anti-HCV activity for therapy using IFN and ribavirin, and suggest that administering IFN-beta before the start of combination therapy with ribavirin and IFN-alpha promotes the therapeutic effects of combination treatment with ribavirin and IFN-alpha ?in chronic hepatitis C patients. Ribavirin 236-245 interferon beta 1, fibroblast Mus musculus 182-190 17300707-5 2007 CONCLUSION: These data indicate that this MHV-infection system is a good animal model to assess anti-HCV activity for therapy using IFN and ribavirin, and suggest that administering IFN-beta before the start of combination therapy with ribavirin and IFN-alpha promotes the therapeutic effects of combination treatment with ribavirin and IFN-alpha ?in chronic hepatitis C patients. Ribavirin 236-245 interferon beta 1, fibroblast Mus musculus 182-190 17060520-5 2007 Increasing the RBV concentration from 10 to 40 mug/ml resulted in a decrease in viral RNA (vRNA) levels and an increase in RBV-TP formation. Ribavirin 15-18 vault RNA 1-1 Homo sapiens 91-95 17060520-8 2007 Although guanosine prevented the depression in GTP levels caused by RBV, guanosine only partially prevented the effect of RBV on vRNA levels. Ribavirin 122-125 vault RNA 1-1 Homo sapiens 129-133 17060520-9 2007 These results suggest that the inhibition of IMP dehydrogenase by RBV is of secondary importance to the inhibition of vRNA replication by RBV and that the interaction of RBV-TP with the viral polymerase is the primary action of RBV. Ribavirin 66-69 vault RNA 1-1 Homo sapiens 118-122 17060520-9 2007 These results suggest that the inhibition of IMP dehydrogenase by RBV is of secondary importance to the inhibition of vRNA replication by RBV and that the interaction of RBV-TP with the viral polymerase is the primary action of RBV. Ribavirin 138-141 vault RNA 1-1 Homo sapiens 118-122 17060520-9 2007 These results suggest that the inhibition of IMP dehydrogenase by RBV is of secondary importance to the inhibition of vRNA replication by RBV and that the interaction of RBV-TP with the viral polymerase is the primary action of RBV. Ribavirin 138-141 vault RNA 1-1 Homo sapiens 118-122 17713164-11 2007 Furthermore, ribavirin treatment modified the efficacy of interferon (IFN) treatment. Ribavirin 13-22 interferon alpha 1 Homo sapiens 70-73 17803064-3 2007 In 8 of 18 patients, HCV RNA became undetectable, and 3 of 8 interferon/ribavirin treatment failure patients showed undetectable HCV load following HEP1 treatment. Ribavirin 72-81 DNL-type zinc finger Homo sapiens 148-152 17713164-12 2007 The IFN half-inhibition concentration (IC50) was significantly lower for viruses obtained after 1 month"s exposure to 50 microM ribavirin than for viruses cultured in the absence of ribavirin. Ribavirin 128-137 interferon alpha 1 Homo sapiens 4-7 17713164-12 2007 The IFN half-inhibition concentration (IC50) was significantly lower for viruses obtained after 1 month"s exposure to 50 microM ribavirin than for viruses cultured in the absence of ribavirin. Ribavirin 182-191 interferon alpha 1 Homo sapiens 4-7 17803064-9 2007 Thus, oral HEP1 therapy matches the efficacy results for injectable peginterferon/oral ribavirin therapy with the advantages of more rapid action and less side effects. Ribavirin 87-96 DNL-type zinc finger Homo sapiens 11-15 17803064-10 2007 HEP1 therapy should be used in patients where either peginterferon/ribavirin therapy fails or is contraindicated. Ribavirin 67-76 DNL-type zinc finger Homo sapiens 0-4 17675762-0 2007 Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin. Ribavirin 114-123 mucin 1, cell surface associated Homo sapiens 6-10 17370474-6 2007 In addition to its antiviral action, ribavirin also enhanced the TH-1 response. Ribavirin 37-46 negative elongation factor complex member C/D Homo sapiens 65-69 17477035-0 2007 Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Pulmonary toxicity is a rare but potentially fatal side effect occurring during interferon (IFN) alpha treatment for chronic hepatitis C. We present a 47-year-old woman who had chronic hepatitis C and was treated with pegylated IFN alpha-2b in combination with ribavirin, with a good virological response by week 10 of therapy. Ribavirin 90-99 interferon alpha 1 Homo sapiens 217-220 17477035-0 2007 Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Pulmonary toxicity is a rare but potentially fatal side effect occurring during interferon (IFN) alpha treatment for chronic hepatitis C. We present a 47-year-old woman who had chronic hepatitis C and was treated with pegylated IFN alpha-2b in combination with ribavirin, with a good virological response by week 10 of therapy. Ribavirin 90-99 interferon alpha 1 Homo sapiens 353-356 17477035-5 2007 Based on a MEDLINE search up to 2004, we believe that this is the first reported case of a patient recovering from interstitial pneumonitis associated with pegylated IFN alpha-2b for chronic hepatitis C. Physicians should keep in mind the possibility of this complication when treating chronic hepatitis C patients with pegylated IFN alpha-2b and ribavirin combinational therapy. Ribavirin 347-356 interferon alpha 1 Homo sapiens 166-169 17477035-5 2007 Based on a MEDLINE search up to 2004, we believe that this is the first reported case of a patient recovering from interstitial pneumonitis associated with pegylated IFN alpha-2b for chronic hepatitis C. Physicians should keep in mind the possibility of this complication when treating chronic hepatitis C patients with pegylated IFN alpha-2b and ribavirin combinational therapy. Ribavirin 347-356 interferon alpha 1 Homo sapiens 330-333 21901059-3 2007 The administration of ribavirin decreased the elevations in serum alanine aminotransferase (ALT) by 78.5, 82.1, 75.1%, aspartate aminotransferase (AST) 47.5, 37.4, 38.8%, and alkaline phosphatase (ALP) by 23.4, 16, 21.6%, respectively and also pre-vented the development of hepatic necrosis caused by CCl(4). Ribavirin 22-31 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 119-145 21901059-3 2007 The administration of ribavirin decreased the elevations in serum alanine aminotransferase (ALT) by 78.5, 82.1, 75.1%, aspartate aminotransferase (AST) 47.5, 37.4, 38.8%, and alkaline phosphatase (ALP) by 23.4, 16, 21.6%, respectively and also pre-vented the development of hepatic necrosis caused by CCl(4). Ribavirin 22-31 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 147-150 21901059-5 2007 When silymarin was combined with ribavirin, the serum activities of AST and ALP were further decreased, indicating a beneficial additive effect. Ribavirin 33-42 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 68-71 17675762-4 2007 RESULTS: The average serum KL-6 levels in patients treated with combination therapy of pegylated IFN and ribavirin increased by 21% at 12 weeks after the start, 23% at 24 weeks, and 28% at 48 weeks. Ribavirin 105-114 mucin 1, cell surface associated Homo sapiens 27-31 17675762-5 2007 In patients treated with combination therapy of pegylated IFN and ribavirin, the serum KL-6 level significantly increased during treatment. Ribavirin 66-75 mucin 1, cell surface associated Homo sapiens 87-91 17064957-0 2007 Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Ribavirin 44-53 interferon alpha 1 Homo sapiens 27-30 17702435-6 2007 Retreatment with PEG IFN alpha-2a and RBV in patients who fail to achieve SVR in the treatment with PEG IFN alpha-2b+RBV revealed high early viral response, in patients with advanced liver histology too. Ribavirin 38-41 interferon alpha 1 Homo sapiens 104-107 17133546-6 2007 Multivariate analysis revealed that factors associated with SVR were IFN dose and the number of amino acid substitutions in ISDR but not with subtypes J and W. The correlation between the number of substitutions in ISDR and responses to IFN-ribavirin combination therapy was restricted to patients with J-type HCV 1b. Ribavirin 241-250 interferon alpha 1 Homo sapiens 69-72 17133546-6 2007 Multivariate analysis revealed that factors associated with SVR were IFN dose and the number of amino acid substitutions in ISDR but not with subtypes J and W. The correlation between the number of substitutions in ISDR and responses to IFN-ribavirin combination therapy was restricted to patients with J-type HCV 1b. Ribavirin 241-250 interferon alpha 1 Homo sapiens 237-240 17133546-7 2007 The ISDR is a useful predictive marker for response to IFN-ribavirin combination therapy in J-type HCV. Ribavirin 59-68 interferon alpha 1 Homo sapiens 55-58 17702435-5 2007 In the work the data of efficacy of retherapy with PEG IFN alfa-2a+RBV administered during 72 weeks were present. Ribavirin 67-70 interferon alpha 1 Homo sapiens 55-58 17702435-6 2007 Retreatment with PEG IFN alpha-2a and RBV in patients who fail to achieve SVR in the treatment with PEG IFN alpha-2b+RBV revealed high early viral response, in patients with advanced liver histology too. Ribavirin 117-120 interferon alpha 1 Homo sapiens 21-24 17702435-6 2007 Retreatment with PEG IFN alpha-2a and RBV in patients who fail to achieve SVR in the treatment with PEG IFN alpha-2b+RBV revealed high early viral response, in patients with advanced liver histology too. Ribavirin 117-120 interferon alpha 1 Homo sapiens 104-107 17100715-7 2006 RESULTS: In patients treated with ribavirin alone (n = 8), mean alanine aminotransferase (ALT) levels before and after treatment were significantly different (198.4 +/- 147.6 and 104.8 +/- 66.5 IU/L respectively; p < 0.05). Ribavirin 34-43 glutamic--pyruvic transaminase Homo sapiens 64-88 18572508-0 2007 [Interferon alpha, gamma, omega before and during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin]. Ribavirin 119-128 interferon gamma Homo sapiens 1-31 17131467-7 2006 Insulin resistance together with fibrosis and genotype has been found to be independently associated with impaired response rate to peginterferon plus ribavirin. Ribavirin 151-160 insulin Homo sapiens 0-7 18087178-4 2007 Both IFN monotherapy and IFN-ribavirin combination therapy were shown to reduce significantly the complications of liver disease, in terms of development of cirrhosis, HCC and liver-related mortality. Ribavirin 29-38 interferon alpha 1 Homo sapiens 25-28 18333370-3 2007 The adipokines-leptin, adiponectin, TNF-alpha-, which are modified in obesity, have been proposed as determinant factors of non-responsiveness to the IFN-alpha/Ribavirin treatment and of liver fibrosis extension in patients with CHC and obesity. Ribavirin 160-169 adiponectin, C1Q and collagen domain containing Homo sapiens 23-34 18333370-3 2007 The adipokines-leptin, adiponectin, TNF-alpha-, which are modified in obesity, have been proposed as determinant factors of non-responsiveness to the IFN-alpha/Ribavirin treatment and of liver fibrosis extension in patients with CHC and obesity. Ribavirin 160-169 tumor necrosis factor Homo sapiens 36-45 17074015-0 2006 Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. BACKGROUND: Clearance of hepatitis C virus (HCV) is attributed to host cellular immune responses, in which T helper cells play a critical role. Ribavirin 83-92 dipeptidyl peptidase 4 Homo sapiens 19-23 17074015-0 2006 Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. BACKGROUND: Clearance of hepatitis C virus (HCV) is attributed to host cellular immune responses, in which T helper cells play a critical role. Ribavirin 83-92 TNF receptor superfamily member 8 Homo sapiens 28-32 17074015-1 2006 The purpose of the present paper was therefore to study the serial changes of serum soluble markers released from T helper 1 (Th1) and 2 (Th2) and their correlations with treatment responses in chronic hepatitis C patients receiving interferon-alpha plus ribavirin for 24 weeks. Ribavirin 255-264 negative elongation factor complex member C/D Homo sapiens 126-129 17075881-7 2006 Compared with patients treated with IFN alfa-2b plus ribavirin, those receiving PEG-IFN alfa-2b plus ribavirin had a higher sustained clinical (67.5% versus 56.3%), virologic (62.5% versus 53.1%), and immunologic (57.5% versus 31.3%) response, regardless of HCV genotype and viral load. Ribavirin 101-110 interferon alpha 1 Homo sapiens 84-87 16998879-0 2006 Peripheral insulin resistance during treatment of chronic hepatitis C with peguilated interferon plus ribavirin. Ribavirin 102-111 insulin Homo sapiens 11-18 17032416-1 2006 Ribavirin, an antiviral agent, potentiates IFN activity when added to it. Ribavirin 0-9 interferon alpha 1 Homo sapiens 43-46 17066158-0 2006 Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Rare cases of ischemic colitis associated with interferon-alpha (IFN-alpha) treatment for chronic hepatitis C (HCV) infection and metastatic cancer have been reported. Ribavirin 55-64 interferon alpha 1 Homo sapiens 163-172 17032193-5 2006 RESULTS: EPO alleviated the decrease in hemoglobin during combination antiviral therapy with ribavirin (10%vs 20%, p < 0.0001). Ribavirin 93-102 erythropoietin Homo sapiens 9-12 16960776-2 2006 METHODS: Plasma IP-10 was monitored before, during, and after treatment with pegylated IFN- alpha 2a and ribavirin in 265 HCV-infected patients. Ribavirin 105-114 C-X-C motif chemokine ligand 10 Homo sapiens 16-21 16950651-0 2006 First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. The aim of the present study was to assess parameters in early phase HCV dynamics for predicting the outcome of interferon (IFN)/ribavirin combination therapy in patients with chronic hepatitis C (CH-C). Ribavirin 87-96 interferon alpha 1 Homo sapiens 267-283 16950651-8 2006 These results demonstrate that parameters of HCV kinetics 24h after the start of therapy are useful for the early prediction of outcome in response to IFN alpha-2b/ribavirin combination therapy. Ribavirin 164-173 interferon alpha 1 Homo sapiens 151-154 16958821-0 2006 2"-,5"-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. OBJECTIVE: Although all the mechanisms of elimination of hepatitis C virus (HCV) by Interferon (IFN) have not been fully elucidated, the 2"-5"-oligoadenylate (2-5A) system is one of the mechanisms of the antiviral effect of IFN. Ribavirin 111-120 interferon alpha 1 Homo sapiens 263-266 16958821-0 2006 2"-,5"-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. OBJECTIVE: Although all the mechanisms of elimination of hepatitis C virus (HCV) by Interferon (IFN) have not been fully elucidated, the 2"-5"-oligoadenylate (2-5A) system is one of the mechanisms of the antiviral effect of IFN. Ribavirin 111-120 interferon alpha 1 Homo sapiens 391-394 16919076-9 2006 Re-treatment with IFN and ribavirin of those who failed to respond to previous IFN monotherapy was successful in 33%. Ribavirin 26-35 interferon alpha 1 Homo sapiens 79-82 16621037-7 2006 In addition, ribavirin treatment seemed also to promote the production of pro-inflammatory cytokines 4 days after cessation of treatment, although after 3 days of treatment ribavirin inhibited pro-inflammatory cytokine production in infected mice, significantly reducing the levels of the cytokines IL-1alpha, interleukin-5 (IL-5), monocyte chemotactic protein-1 (MCP-1), and granulocyte-macrophage colony stimulating factor (GM-CSF). Ribavirin 13-22 interleukin 1 alpha Mus musculus 299-308 16780556-1 2006 OBJECTIVES: To evaluate whether in chronic hepatitis C-positive patients who failed to respond to interferon (IFN) monotherapy a sustained response obtained with retreatment using the combination therapy of IFN + ribavirin can be safely considered to reflect eradication of the infection. Ribavirin 213-222 interferon alpha 1 Homo sapiens 110-113 16780556-9 2006 CONCLUSIONS: Nonresponders to IFN monotherapy who achieve a sustained virologic response after retreatment with IFN + ribavirin stand a discrete risk of HCV reactivation within 2 yr after therapy. Ribavirin 118-127 interferon alpha 1 Homo sapiens 30-33 16621037-7 2006 In addition, ribavirin treatment seemed also to promote the production of pro-inflammatory cytokines 4 days after cessation of treatment, although after 3 days of treatment ribavirin inhibited pro-inflammatory cytokine production in infected mice, significantly reducing the levels of the cytokines IL-1alpha, interleukin-5 (IL-5), monocyte chemotactic protein-1 (MCP-1), and granulocyte-macrophage colony stimulating factor (GM-CSF). Ribavirin 13-22 interleukin 5 Mus musculus 310-323 16621037-7 2006 In addition, ribavirin treatment seemed also to promote the production of pro-inflammatory cytokines 4 days after cessation of treatment, although after 3 days of treatment ribavirin inhibited pro-inflammatory cytokine production in infected mice, significantly reducing the levels of the cytokines IL-1alpha, interleukin-5 (IL-5), monocyte chemotactic protein-1 (MCP-1), and granulocyte-macrophage colony stimulating factor (GM-CSF). Ribavirin 13-22 interleukin 5 Mus musculus 325-329 16621037-7 2006 In addition, ribavirin treatment seemed also to promote the production of pro-inflammatory cytokines 4 days after cessation of treatment, although after 3 days of treatment ribavirin inhibited pro-inflammatory cytokine production in infected mice, significantly reducing the levels of the cytokines IL-1alpha, interleukin-5 (IL-5), monocyte chemotactic protein-1 (MCP-1), and granulocyte-macrophage colony stimulating factor (GM-CSF). Ribavirin 13-22 chemokine (C-C motif) ligand 2 Mus musculus 332-362 16621037-7 2006 In addition, ribavirin treatment seemed also to promote the production of pro-inflammatory cytokines 4 days after cessation of treatment, although after 3 days of treatment ribavirin inhibited pro-inflammatory cytokine production in infected mice, significantly reducing the levels of the cytokines IL-1alpha, interleukin-5 (IL-5), monocyte chemotactic protein-1 (MCP-1), and granulocyte-macrophage colony stimulating factor (GM-CSF). Ribavirin 13-22 chemokine (C-C motif) ligand 2 Mus musculus 364-369 16621037-7 2006 In addition, ribavirin treatment seemed also to promote the production of pro-inflammatory cytokines 4 days after cessation of treatment, although after 3 days of treatment ribavirin inhibited pro-inflammatory cytokine production in infected mice, significantly reducing the levels of the cytokines IL-1alpha, interleukin-5 (IL-5), monocyte chemotactic protein-1 (MCP-1), and granulocyte-macrophage colony stimulating factor (GM-CSF). Ribavirin 13-22 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 376-424 16621037-7 2006 In addition, ribavirin treatment seemed also to promote the production of pro-inflammatory cytokines 4 days after cessation of treatment, although after 3 days of treatment ribavirin inhibited pro-inflammatory cytokine production in infected mice, significantly reducing the levels of the cytokines IL-1alpha, interleukin-5 (IL-5), monocyte chemotactic protein-1 (MCP-1), and granulocyte-macrophage colony stimulating factor (GM-CSF). Ribavirin 13-22 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 426-432 16980747-0 2006 Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. The aim of the 18 months follow up study was to assess the frequency of anemia during IFN/RBV therapy in patients with chronic hepatitis C; to manage anemia either with recombinant human erythropoietin (rHuEPO)--epoetin alpha or with RBV dose reduction and to compare the rate of SVR in patients with RBV dose reduction and with administration of epoetin alpha. Ribavirin 191-194 interferon alpha 1 Homo sapiens 0-3 16980747-0 2006 Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. The aim of the 18 months follow up study was to assess the frequency of anemia during IFN/RBV therapy in patients with chronic hepatitis C; to manage anemia either with recombinant human erythropoietin (rHuEPO)--epoetin alpha or with RBV dose reduction and to compare the rate of SVR in patients with RBV dose reduction and with administration of epoetin alpha. Ribavirin 335-338 interferon alpha 1 Homo sapiens 0-3 16980747-0 2006 Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. The aim of the 18 months follow up study was to assess the frequency of anemia during IFN/RBV therapy in patients with chronic hepatitis C; to manage anemia either with recombinant human erythropoietin (rHuEPO)--epoetin alpha or with RBV dose reduction and to compare the rate of SVR in patients with RBV dose reduction and with administration of epoetin alpha. Ribavirin 335-338 interferon alpha 1 Homo sapiens 0-3 16980747-13 2006 In anemic HCV-infected patients on RBV/PEG-IFN therapy, EPO maintains RBV dose and significantly improves anemia and QOL. Ribavirin 35-38 erythropoietin Homo sapiens 56-59 16864957-0 2006 Vitamin B12 reduces ribavirin-induced genotoxicity in phytohemaglutinin-stimulated human lymphocytes. Ribavirin 20-29 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 8-11 17048997-13 2006 The treatment of insulin resistance by decreasing hyperinsulinemia could improve sustained response rates in patients with chronic hepatitis C treated with peginterferon plus ribavirin. Ribavirin 175-184 insulin Homo sapiens 17-24 16735696-3 2006 CD81 was analyzed by flow cytometry in CD8(+), CD4(+), CD19(+), and CD56(+) lymphocyte subtypes from 20 patients with chronic hepatitis C before, during, and after antiviral treatment with pegylated interferon-alpha (IFN-alpha) and ribavirin. Ribavirin 232-241 CD81 molecule Homo sapiens 0-4 16735696-3 2006 CD81 was analyzed by flow cytometry in CD8(+), CD4(+), CD19(+), and CD56(+) lymphocyte subtypes from 20 patients with chronic hepatitis C before, during, and after antiviral treatment with pegylated interferon-alpha (IFN-alpha) and ribavirin. Ribavirin 232-241 CD8a molecule Homo sapiens 0-3 16699498-5 2006 Combination therapy with interferon and ribavirin affects the tissue expression of TGF-beta-1 and NF-kappaB and favors metalloproteinase activity, and may thereby modulate hepatic fibrogenetic events. Ribavirin 40-49 transforming growth factor beta 1 Homo sapiens 83-93 16699498-5 2006 Combination therapy with interferon and ribavirin affects the tissue expression of TGF-beta-1 and NF-kappaB and favors metalloproteinase activity, and may thereby modulate hepatic fibrogenetic events. Ribavirin 40-49 nuclear factor kappa B subunit 1 Homo sapiens 98-107 16864957-8 2006 The results showed that supplementation with vitamin B12 lowered the frequency of micronuclei (Z = 2.02, p < 0.04) and recovered the proliferation potential of the treated cells for each treatment period, except for the conditions with the highest concentration of ribavirin and the shortest time. Ribavirin 268-277 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 53-56 16864957-10 2006 The mechanism by which vitamin B12 reduces ribavirin-induced genotoxicity is related to de novo synthesis of nucleotides, and is worthy of further investigation. Ribavirin 43-52 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 31-34 16858501-0 2006 Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Ribavirin 127-136 erythropoietin Homo sapiens 58-72 16803610-0 2006 Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response. Ribavirin 53-62 negative elongation factor complex member C/D Homo sapiens 138-141 16858501-8 2006 Accumulating evidence now supports the use of recombinant human erythropoietin (rHuEpo) to manage anemia in these patients, with the objective of maintaining the RBV dose, but clinical standards are lacking. Ribavirin 162-165 erythropoietin Homo sapiens 64-78 16618404-0 2006 Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 66-76 16838649-4 2006 The most effective initial IFN therapy is the combination of pegylated IFN alpha-2b plus ribavirin. Ribavirin 89-98 interferon alpha 1 Homo sapiens 27-30 16556654-6 2006 Renal vascular resistance index (RVR units) was calculated by dividing MAP by RBV. Ribavirin 78-81 nuclear receptor subfamily 1 group D member 2 Homo sapiens 33-36 17364060-3 2006 Combination of IFN preparation with some nucleosides, including ribavirin, proved to be highly effective towards drug-resistant herpes virus. Ribavirin 64-73 interferon alpha 1 Homo sapiens 15-18 16629641-7 2006 Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages. Ribavirin 57-66 erythropoietin Homo sapiens 18-32 16637862-8 2006 Ribavirin-induced anaemia was treated with high doses of erythropoietin and low doses of iron. Ribavirin 0-9 erythropoietin Homo sapiens 57-71 16733374-16 2006 Late secondary adjunction of ribavirin to IFN-alpha for 6 months in HCV-RNA negative patients after 6 months of IFN-alpha significantly decreases the relapse rate in patients with HCV genotype 2 or 3, but not in patients with genotypes 1, 4 or 5. Ribavirin 29-38 interferon alpha 1 Homo sapiens 112-121 16618404-0 2006 Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Ribavirin 77-86 interferon alpha 1 Homo sapiens 10-20 16618404-0 2006 Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Ribavirin 77-86 interferon alpha 1 Homo sapiens 66-76 16633105-6 2006 Consideration is also given to evidence showing that treatment with ribavirin may contribute to IFN-induced depression. Ribavirin 68-77 interferon alpha 1 Homo sapiens 96-99 16584394-11 2006 CONCLUSIONS: CIFN and ribavirin treatment induced considerable SVR rates in patients with non-response or relapse to IFNalpha+/-ribavirin. Ribavirin 22-31 interferon alpha 1 Homo sapiens 117-125 16611188-0 2006 Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. Ribavirin 148-157 interleukin 10 Homo sapiens 36-50 16556180-0 2006 Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Ribavirin 93-102 glutamic--pyruvic transaminase Homo sapiens 188-212 16611188-0 2006 Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. Ribavirin 148-157 interleukin 18 Homo sapiens 71-76 16611188-10 2006 Treatment with interferon and ribavirin induced a significant decrease of IL-18 concentration independently of the viral response. Ribavirin 30-39 interleukin 18 Homo sapiens 74-79 16536487-6 2006 A molar drug ratio of six to eight RBV molecules per Hb tetramer was obtained with near complete haptoglobin (Hp) binding of the drug modified Hb maintained. Ribavirin 35-38 haptoglobin Homo sapiens 97-108 16706076-9 2006 The mutation of the gen HFE in our patient and the hemolysis caused by ribavirin can be related to the development of the disease, but the iron overload because of ribavirin use is also controversial. Ribavirin 164-173 homeostatic iron regulator Homo sapiens 24-27 16462544-0 2006 Resolution of diabetes in type 2 diabetic patient treated with IFN-alpha and ribavirin for hepatitis C. We report on a patient whose type 2 diabetes mellitus resolved during IFN-alpha therapy for hepatitis C virus (HCV). Ribavirin 77-86 interferon alpha 1 Homo sapiens 174-183 16496340-3 2006 The aim of this study was to evaluate the efficacy of a hemoglobin-ribavirin conjugate (HRC 203) in murine hepatitis virus strain 3 (MHV-3) induced viral hepatitis. Ribavirin 67-76 histidine rich calcium binding protein Homo sapiens 88-91 16150856-0 2006 Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. BACKGROUND: Increased serum and intrahepatic interferon gamma inducible protein 10 (IP-10) levels in patients with chronic hepatitis C (CHC) have been described. Ribavirin 137-146 C-X-C motif chemokine ligand 10 Homo sapiens 34-71 16150856-9 2006 CONCLUSION: Pretreatment serum IP-10 behaves as a predictive factor of SVR to peginterferon plus ribavirin therapy in genotype 1 infected patients. Ribavirin 97-106 C-X-C motif chemokine ligand 10 Homo sapiens 31-36 16498048-1 2006 Autoimmune thyroid disease is a common side-effect of interferon-alpha (IFN-alpha) treatment of viral hepatitis C. We have described three patients with hepatitis C for whom IFN-alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves" disease. Ribavirin 188-197 interferon alpha 1 Homo sapiens 72-81 16496340-4 2006 HRC 203 had greater anti-viral activity on both isolated hepatocytes and macrophages, whereas both ribavirin and HRC 203 inhibited production of the pro-inflammatory cytokines interferon gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) by macrophages. Ribavirin 99-108 interferon gamma Homo sapiens 176-203 16496340-4 2006 HRC 203 had greater anti-viral activity on both isolated hepatocytes and macrophages, whereas both ribavirin and HRC 203 inhibited production of the pro-inflammatory cytokines interferon gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) by macrophages. Ribavirin 99-108 tumor necrosis factor Homo sapiens 209-236 16496340-7 2006 In contrast, survival was enhanced in both ribavirin- and HRC 203-treated mice with a marked reduction in biochemical [ALT(max) 964 +/- 128 IU/L (ribavirin); 848 +/- 212 IU/L (HRC 203)] and histological evidence of hepatic necrosis (<10% in ribavirin/HRC 203 vs. 90% in untreated controls). Ribavirin 43-52 histidine rich calcium binding protein Homo sapiens 176-179 16496340-7 2006 In contrast, survival was enhanced in both ribavirin- and HRC 203-treated mice with a marked reduction in biochemical [ALT(max) 964 +/- 128 IU/L (ribavirin); 848 +/- 212 IU/L (HRC 203)] and histological evidence of hepatic necrosis (<10% in ribavirin/HRC 203 vs. 90% in untreated controls). Ribavirin 43-52 histidine rich calcium binding protein Homo sapiens 176-179 16496340-7 2006 In contrast, survival was enhanced in both ribavirin- and HRC 203-treated mice with a marked reduction in biochemical [ALT(max) 964 +/- 128 IU/L (ribavirin); 848 +/- 212 IU/L (HRC 203)] and histological evidence of hepatic necrosis (<10% in ribavirin/HRC 203 vs. 90% in untreated controls). Ribavirin 146-155 histidine rich calcium binding protein Homo sapiens 58-61 16527653-2 2006 Similarly, relapsers after combination standard IFN and RBV therapy have higher SVR rates than combination of therapy nonresponders when treated with pegylated interferon and ribavirin. Ribavirin 175-184 interferon alpha 1 Homo sapiens 48-51 16496340-7 2006 In contrast, survival was enhanced in both ribavirin- and HRC 203-treated mice with a marked reduction in biochemical [ALT(max) 964 +/- 128 IU/L (ribavirin); 848 +/- 212 IU/L (HRC 203)] and histological evidence of hepatic necrosis (<10% in ribavirin/HRC 203 vs. 90% in untreated controls). Ribavirin 146-155 histidine rich calcium binding protein Homo sapiens 58-61 16377237-0 2006 Th1 response during ribavirin and interferon-alpha combination therapy in chronic hepatitis C. Ribavirin and interferon-alpha induce Th1 polarization of human CD4+ T cells. Ribavirin 20-29 negative elongation factor complex member C/D Homo sapiens 0-3 16475995-7 2006 These results suggest that ribavirin may modulate the humoral immune response against HCV and trigger a favourable response to IFN. Ribavirin 27-36 interferon alpha 1 Homo sapiens 127-130 16538590-2 2006 The introduction of therapy with intraventricular interferon alpha (IFN-alpha) and its later association with ribavirin aroused new expectations. Ribavirin 110-119 interferon alpha 1 Homo sapiens 50-77 16565651-3 2006 This review is focused on complementary treatments (erythropoietin, G-CSF, vitamin E, glutathion, ursodeoxycholic acid and antidepressants) likely to bring a benefit in maintaining adequate interferon and ribavirin dosages and in improving quality of life. Ribavirin 205-214 erythropoietin Homo sapiens 52-66 16377237-0 2006 Th1 response during ribavirin and interferon-alpha combination therapy in chronic hepatitis C. Ribavirin and interferon-alpha induce Th1 polarization of human CD4+ T cells. Ribavirin 20-29 negative elongation factor complex member C/D Homo sapiens 133-136 16377237-0 2006 Th1 response during ribavirin and interferon-alpha combination therapy in chronic hepatitis C. Ribavirin and interferon-alpha induce Th1 polarization of human CD4+ T cells. Ribavirin 95-104 negative elongation factor complex member C/D Homo sapiens 0-3 16377237-0 2006 Th1 response during ribavirin and interferon-alpha combination therapy in chronic hepatitis C. Ribavirin and interferon-alpha induce Th1 polarization of human CD4+ T cells. Ribavirin 95-104 negative elongation factor complex member C/D Homo sapiens 133-136 16377237-6 2006 In conclusion, the results of this study indicate that the increase of Th1 response is related to the inflammatory activity in the liver and possibly to ribavirin and interferon-alpha therapy. Ribavirin 153-162 negative elongation factor complex member C/D Homo sapiens 71-74 16476009-0 2006 Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Ribavirin 69-78 solute carrier family 6 member 4 Homo sapiens 0-21 16493487-0 2006 Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C. Interferon alpha (IFN-alpha) is used to treat haematological and solid malignancies and is the gold standard therapy for chronic hepatitis C infection in combination with ribavirin. Ribavirin 272-281 interferon alpha 1 Homo sapiens 119-128 16436132-1 2006 The aim of this randomized prospective study was to assess the efficacy and safety of a triple therapy with interferon-alpha (IFN-alpha)-ribavirin-interleukin-2 (IL-2) for the treatment of patients with genotype 1 infection and high viral load nonresponsive to primary IFN-ribavirin therapy. Ribavirin 137-146 interleukin 2 Homo sapiens 147-160 16436132-1 2006 The aim of this randomized prospective study was to assess the efficacy and safety of a triple therapy with interferon-alpha (IFN-alpha)-ribavirin-interleukin-2 (IL-2) for the treatment of patients with genotype 1 infection and high viral load nonresponsive to primary IFN-ribavirin therapy. Ribavirin 137-146 interleukin 2 Homo sapiens 162-166 16563475-6 2006 Further, the ribavirin induced antinociception was enhanced by D2 receptor antagonists haloperidol, sulpiride, clozapine or domperidone and by the dopamine D2 receptor agonist bromocryptine. Ribavirin 13-22 dopamine receptor D2 Mus musculus 63-74 16563475-6 2006 Further, the ribavirin induced antinociception was enhanced by D2 receptor antagonists haloperidol, sulpiride, clozapine or domperidone and by the dopamine D2 receptor agonist bromocryptine. Ribavirin 13-22 dopamine receptor D2 Mus musculus 147-167 16476009-6 2006 Treatment with either lamivudine or ribavirin reduced the 5-HTT mRNA expression, protein level and 5-HT uptake in T-cell line. Ribavirin 36-45 solute carrier family 6 member 4 Homo sapiens 58-63 16476009-9 2006 Mimicking clinical use by treating PBMC with a combination of IFN-alpha and ribavirin increased the 5-HTT mRNA expression level. Ribavirin 76-85 solute carrier family 6 member 4 Homo sapiens 100-105 16542004-0 2006 Conversion of viramidine to ribavirin in vivo by adenosine deaminase and its inhibition by 2"-deoxycoformycin. Ribavirin 28-37 adenosine deaminase Rattus norvegicus 49-68 16542004-1 2006 Previously we reported that viramidine is a prodrug of ribavirin and that adenosine deaminase catalyses viramidine deamination to ribavirin in vivo. Ribavirin 130-139 adenosine deaminase Rattus norvegicus 74-93 16518956-0 2006 Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection. Ribavirin 123-132 interferon alpha and beta receptor subunit 2 Homo sapiens 8-27 16542004-6 2006 These findings provide strong evidence that adenosine deaminase plays a major role in converting viramidine to ribavirin in vivo. Ribavirin 111-120 adenosine deaminase Rattus norvegicus 44-63 16518956-2 2006 We investigated the expression of hepatic IFN receptor alpha/beta (IFNAR2c) mRNA and its association with the effectiveness of IFN plus ribavirin (RBV) therapy and with the clinical features in patients with HCV genotype 1b (HCV-1b) infection. Ribavirin 136-145 interferon alpha 1 Homo sapiens 42-45 17168855-9 2006 The only proven effective prevention of RBV-induced anemia is the concomitant administration of erythropoietin. Ribavirin 40-43 erythropoietin Homo sapiens 96-110 16518956-2 2006 We investigated the expression of hepatic IFN receptor alpha/beta (IFNAR2c) mRNA and its association with the effectiveness of IFN plus ribavirin (RBV) therapy and with the clinical features in patients with HCV genotype 1b (HCV-1b) infection. Ribavirin 136-145 interferon alpha 1 Homo sapiens 67-70 16518956-2 2006 We investigated the expression of hepatic IFN receptor alpha/beta (IFNAR2c) mRNA and its association with the effectiveness of IFN plus ribavirin (RBV) therapy and with the clinical features in patients with HCV genotype 1b (HCV-1b) infection. Ribavirin 147-150 interferon alpha 1 Homo sapiens 42-45 16518956-2 2006 We investigated the expression of hepatic IFN receptor alpha/beta (IFNAR2c) mRNA and its association with the effectiveness of IFN plus ribavirin (RBV) therapy and with the clinical features in patients with HCV genotype 1b (HCV-1b) infection. Ribavirin 147-150 interferon alpha 1 Homo sapiens 67-70 17310824-1 2006 Patients with chronic infection with the 3a genotype of hepatitis C virus (HCV) are considered as "easy-to-treat" with interferon/ribavirin (IFN/RBV), independent of liver disease severity. Ribavirin 130-139 interferon alpha 1 Homo sapiens 141-144 16166793-9 2006 Our study has demonstrated that mutations in the IFN sensitivity-determining region, spanning nucleotides 2,209-2,248 in the NS5A region, correlate with the sustained virological response to combination therapy with IFN and ribavirin in patients with chronic HCV-1b infection in Taiwan. Ribavirin 224-233 interferon alpha 1 Homo sapiens 49-52 16293442-0 2006 Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C. AIM: This study was to investigate the immunomodulatory effects of ribavirin combined with interferon (IFN)-alpha 2b (R+IFN) compared with consensus IFN monotherapy (IFN-Con) in chronic hepatitis C (CHC) patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 203-206 16293442-0 2006 Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C. AIM: This study was to investigate the immunomodulatory effects of ribavirin combined with interferon (IFN)-alpha 2b (R+IFN) compared with consensus IFN monotherapy (IFN-Con) in chronic hepatitis C (CHC) patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 203-206 16293442-0 2006 Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C. AIM: This study was to investigate the immunomodulatory effects of ribavirin combined with interferon (IFN)-alpha 2b (R+IFN) compared with consensus IFN monotherapy (IFN-Con) in chronic hepatitis C (CHC) patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 203-206 16293442-0 2006 Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C. AIM: This study was to investigate the immunomodulatory effects of ribavirin combined with interferon (IFN)-alpha 2b (R+IFN) compared with consensus IFN monotherapy (IFN-Con) in chronic hepatitis C (CHC) patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 203-206 16325463-8 2006 The patients with higher levels of erythrocyte ribavirin (>/=1000muM) had greater Hb reduction compared to those with lower levels (<1000muM) (3.8+/-1.2g/dL versus 2.6+/-0.9g/dL, p<0.05). Ribavirin 47-56 latexin Homo sapiens 68-71 16166797-4 2006 Addition of ribavirin to IFN increases the sustained virological response (SVR). Ribavirin 12-21 interferon alpha 1 Homo sapiens 25-28 16166797-11 2006 Combination therapy with peg-IFN and ribavirin accomplished higher SVR than conventional IFN and ribavirin. Ribavirin 37-46 interferon alpha 1 Homo sapiens 89-92 16400748-13 2005 (7) The CD4 cell count fell by about 140/mm3 on average during peginterferon alfa-2a + ribavirin therapy. Ribavirin 87-96 CD4 molecule Homo sapiens 8-11 16433196-9 2005 IFN monotherapy seems reasonable for patients with thalassemia and chronic hepatitis C virus in whom ribavirin cannot be used. Ribavirin 101-110 interferon alpha 1 Homo sapiens 0-3 16758742-11 2006 Pegylated IFN alpha-2b with RBV seems to be effective in children with chronic hepatitis C previously non responded to therapy. Ribavirin 28-31 interferon alpha 1 Homo sapiens 10-13 16279900-5 2005 CONCLUSION: Combination therapy with PEG IFN alpha-2b plus RBV is more effective in patients who relapsed after combination standard IFN plus RBV than in nonresponders to either combination therapy or IFN monotherapy. Ribavirin 59-62 interferon alpha 1 Homo sapiens 41-44 16251386-0 2005 Further evidence that ribavirin interacts with eIF4E. Ribavirin 22-31 eukaryotic translation initiation factor 4E Homo sapiens 47-52 16251386-1 2005 This commentary discusses the recent reports in RNA by Yan and colleagues and Westman and colleagues of the apparent failure of ribavirin to bind to recombinant eIF4E and inhibit 7-methyl guanosine cap-dependent exogenous mRNA translation of cell extracts in vitro. Ribavirin 128-137 eukaryotic translation initiation factor 4E Homo sapiens 161-166 16251386-3 2005 Possible reasons for the discordant findings of Yan and colleagues and Westman and colleagues are suggested, and direct observation of the specific binding of ribavirin to eIF4E by using mass spectrometry is presented. Ribavirin 159-168 eukaryotic translation initiation factor 4E Homo sapiens 172-177 16425392-0 2005 Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C. AIM: To evaluate the effect of antiviral treatment on plasma levels of transforming growth factor-beta1 (TGF-beta1), metalloproteinase 1 (MMP-1), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with chronic hepatitis C. METHODS: TGF-beta1, MMP-1, and TIMP-1 plasma concentrations were measured by an enzyme immunoassay in 28 patients, during 48 wk of treatment with pegylated interferon-alpha 2b (PEG-IFN-alpha2b) plus ribavirin (RBV) and after 24 wk of follow-up. Ribavirin 45-54 transforming growth factor beta 1 Homo sapiens 75-107 16279900-5 2005 CONCLUSION: Combination therapy with PEG IFN alpha-2b plus RBV is more effective in patients who relapsed after combination standard IFN plus RBV than in nonresponders to either combination therapy or IFN monotherapy. Ribavirin 59-62 interferon alpha 1 Homo sapiens 133-136 16279900-5 2005 CONCLUSION: Combination therapy with PEG IFN alpha-2b plus RBV is more effective in patients who relapsed after combination standard IFN plus RBV than in nonresponders to either combination therapy or IFN monotherapy. Ribavirin 59-62 interferon alpha 1 Homo sapiens 133-136 16279900-5 2005 CONCLUSION: Combination therapy with PEG IFN alpha-2b plus RBV is more effective in patients who relapsed after combination standard IFN plus RBV than in nonresponders to either combination therapy or IFN monotherapy. Ribavirin 142-145 interferon alpha 1 Homo sapiens 41-44 16227297-2 2005 Patients are currently treated with alpha interferon (IFN-alpha) that is given alone or in combination with ribavirin. Ribavirin 108-117 interferon alpha 1 Homo sapiens 36-63 16084622-1 2005 BACKGROUND/AIMS: Differences in HCV-RNA clearance during therapy might explain the lower efficacy of peg-IFN/RBV in HIV/HCV-coinfection. Ribavirin 109-112 interferon alpha 1 Homo sapiens 105-108 24790244-9 2005 At baseline, the IFN + RBV treatment group (330 patients) had significantly higher percentages of black patients (22.1% vs 15.7%; P = 0.032) and patients with hepatic disease based on clinician-reported cirrhosis and liver dysfunction (18.8% vs 9.9%; P < 0.001), and a significantly lower percentage of white patients (60.3% vs 69.6%; P = 0.012) compared with the peg-IFN + RBV treatment group (345 patients). Ribavirin 23-26 interferon alpha 1 Homo sapiens 371-374 16131589-4 2005 2004) presented evidence that the antiviral nucleoside ribavirin and its phosphorylated derivatives were structural mimics of the mRNA cap, high-affinity ligands for eIF4E, and potent repressors of eIF4E-mediated cell transformation and tumor growth. Ribavirin 55-64 eukaryotic translation initiation factor 4E Homo sapiens 166-171 16131589-4 2005 2004) presented evidence that the antiviral nucleoside ribavirin and its phosphorylated derivatives were structural mimics of the mRNA cap, high-affinity ligands for eIF4E, and potent repressors of eIF4E-mediated cell transformation and tumor growth. Ribavirin 55-64 eukaryotic translation initiation factor 4E Homo sapiens 198-203 16131589-7 2005 Using a set of reporter mRNAs that are translated via either cap-dependent or viral internal ribosome entry sites (IRES)-dependent initiation, we found that these ribavirin-containing compounds did inhibit translation at high (millimolar) concentrations, but there was no correlation of this inhibition with an eIF4E requirement for translation. Ribavirin 163-172 eukaryotic translation initiation factor 4E Homo sapiens 311-316 16237717-6 2005 Treatment of recipients with histological recurrence is with pegylated IFN (+/- ribavirin). Ribavirin 80-89 interferon alpha 1 Homo sapiens 71-74 24790244-18 2005 CONCLUSIONS: In this retrospective data analysis of US office-based practicesconcerning HCV treatment, clinicians were observed to prescribe IFN + RBV at doses that differ from recommendations in the product information (PI), as well as prescribe the RBV component of peg-IFN + RBV at doses that differed from PI recommendations. Ribavirin 251-254 interferon alpha 1 Homo sapiens 141-144 24790244-9 2005 At baseline, the IFN + RBV treatment group (330 patients) had significantly higher percentages of black patients (22.1% vs 15.7%; P = 0.032) and patients with hepatic disease based on clinician-reported cirrhosis and liver dysfunction (18.8% vs 9.9%; P < 0.001), and a significantly lower percentage of white patients (60.3% vs 69.6%; P = 0.012) compared with the peg-IFN + RBV treatment group (345 patients). Ribavirin 377-380 interferon alpha 1 Homo sapiens 17-20 24790244-18 2005 CONCLUSIONS: In this retrospective data analysis of US office-based practicesconcerning HCV treatment, clinicians were observed to prescribe IFN + RBV at doses that differ from recommendations in the product information (PI), as well as prescribe the RBV component of peg-IFN + RBV at doses that differed from PI recommendations. Ribavirin 251-254 interferon alpha 1 Homo sapiens 141-144 16165397-0 2005 Alterations of soluble transferrin receptor level in children with chronic hepatitis C during treatment with recombinant interferon-alpha and ribavirin. Ribavirin 142-151 transferrin receptor Homo sapiens 23-43 16082285-0 2005 Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. Ribavirin 164-173 gamma-glutamyltransferase 1 Homo sapiens 28-31 16306034-3 2005 Given that TDF is an adenosine analogue, like didanosine, exposure to ribavirin might increase intracellular phosphorylated TDF metabolites, which could result in a higher risk of nephrotoxicity. Ribavirin 70-79 sex determining region Y Homo sapiens 11-14 16306034-3 2005 Given that TDF is an adenosine analogue, like didanosine, exposure to ribavirin might increase intracellular phosphorylated TDF metabolites, which could result in a higher risk of nephrotoxicity. Ribavirin 70-79 sex determining region Y Homo sapiens 124-127 16082285-2 2005 Therefore, this study aimed at evaluating GGT as an independent predictive factor for the response to treatment with interferon-alpha and ribavirin in hepatitis C virus (HCV)-infected patients. Ribavirin 138-147 gamma-glutamyltransferase 1 Homo sapiens 42-45 16019105-0 2005 GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. Ribavirin 56-65 G protein subunit beta 3 Homo sapiens 0-4 16136646-8 2005 Serum AFP levels decreased significantly during therapy with pegylated interferon alpha-2a and ribavirin. Ribavirin 95-104 alpha fetoprotein Homo sapiens 6-9 16002945-5 2005 MEASUREMENTS AND RESULTS: The mean peak C-reactive protein and lactate dehydrogenase levels were higher in SARS patients who were receiving ribavirin therapy than in SARS patients who were not receiving ribavirin therapy. Ribavirin 140-149 C-reactive protein Homo sapiens 40-58 15913800-0 2005 Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. The viral genotype and serum viral level influence the response to interferon (IFN) treatment in patients with chronic hepatitis C virus (HCV) viremia. Ribavirin 35-44 interferon alpha 1 Homo sapiens 221-231 15913800-0 2005 Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. The viral genotype and serum viral level influence the response to interferon (IFN) treatment in patients with chronic hepatitis C virus (HCV) viremia. Ribavirin 35-44 interferon alpha 1 Homo sapiens 233-236 15913800-0 2005 Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. The viral genotype and serum viral level influence the response to interferon (IFN) treatment in patients with chronic hepatitis C virus (HCV) viremia. Ribavirin 105-114 interferon alpha 1 Homo sapiens 221-231 15913800-0 2005 Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. The viral genotype and serum viral level influence the response to interferon (IFN) treatment in patients with chronic hepatitis C virus (HCV) viremia. Ribavirin 105-114 interferon alpha 1 Homo sapiens 233-236 15860662-7 2005 These results suggest that plasma concentrations of immunoreactive CXCL10 may be a predictor of responsiveness or nonresponsiveness to antiviral therapy with pegylated interferon (IFN) with or without ribavirin. Ribavirin 201-210 C-X-C motif chemokine ligand 10 Homo sapiens 67-73 16051377-0 2005 Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin. Ribavirin 141-150 interferon gamma Homo sapiens 21-37 16051377-1 2005 To investigate the influence of the T-to-A polymorphic sequence at position +874 in the interferon (IFN)-gamma gene (+874 IFN-gamma) on the response to combination therapy with high-dose interferon and ribavirin, the single nucleotide polymorphisms were determined by using a polymerase chain reaction sequence-specific primers approach in 150 histologically proved chronic hepatitis C (CHC) patients. Ribavirin 202-211 interferon gamma Homo sapiens 122-131 16108728-0 2005 Clinical role of serum and tissue matrix metalloprotease-9 expression in chronic HCV patients treated with pegylated IFN-alpha2b and ribavirin. Ribavirin 133-142 matrix metallopeptidase 9 Homo sapiens 34-58 16265606-7 2005 Drugs to replace or enhance ribavirin are being studied with IFN-based treatments. Ribavirin 28-37 interferon alpha 1 Homo sapiens 61-64 15917509-3 2005 The apparent Km for ribavirin is 540 microM, and k(cat) is 1.8 min-1. Ribavirin 20-29 CD59 molecule (CD59 blood group) Homo sapiens 63-68 15929778-0 2005 Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Anemia frequently complicates the treatment of chronic hepatitis C with interferon and ribavirin (RVN), requiring dose reduction and jeopardizing sustained virologic response. Ribavirin 207-210 erythropoietin Homo sapiens 47-54 15917509-8 2005 In phosphate-buffered saline plus ATP and 2,3-bisphosphoglycerate, the apparent Km for ribavirin is 88 microM, and k(cat) is 4.0 min-1. Ribavirin 87-96 CD59 molecule (CD59 blood group) Homo sapiens 129-134 15927905-7 2005 Treatment with epoetin alfa for this mixed anemia significantly improved hemoglobin levels and quality of life, and enabled adequate dosages of ribavirin to be maintained. Ribavirin 144-153 erythropoietin Homo sapiens 15-22 15896245-3 2005 We undertook this study to simultaneously evaluate the effect of interferon alpha 2b plus ribavirin therapy on TGF-beta1 daily serum levels and on mRNA TGF-beta1 expression in liver biopsy specimens from 60 patients with chronic hepatitis C. METHODS: Serum levels of TGF-beta1 were measured by ELISA. Ribavirin 90-99 transforming growth factor beta 1 Homo sapiens 111-120 16049740-1 2005 Lipase-catalyzed synthesis of potential multifunctional ribavirin derivatives was performed in acetone. Ribavirin 56-65 PAN0_003d1715 Moesziomyces antarcticus 0-6 15902734-0 2005 Expression of bcl-2 protein in chronic hepatitis C: effect of interferon alpha 2b with ribavirin therapy. Ribavirin 87-96 BCL2 apoptosis regulator Homo sapiens 14-19 15902734-8 2005 CONCLUSION: IFNalpha2b+RBV treatment, by bcl-2 protein expression decrease, enables apoptosis of hepatocytes and associated liver lymphocytes, which in turn eliminate hepatitis C viruses. Ribavirin 23-26 BCL2 apoptosis regulator Homo sapiens 41-46 24764593-9 2005 RESULTS: Although standard IFN monotherapy failed to achieve virologic and hematologic improvement, therapy with pegylated IFN alfa-2a plus ribavirin was associated with both virologic and hematologic improvement without any significant adverse effects. Ribavirin 140-149 interferon alpha 1 Homo sapiens 123-126 16161954-4 2005 In 25 cases treated with IFN ribavirin tests were repeated between 6-8 month of the therapy. Ribavirin 29-38 interferon alpha 1 Homo sapiens 25-28 15850468-9 2005 Daily 6 million units of IFN, six times/week for 2 weeks and then three times/week for 22 weeks were given with RBV (600-800 mg/day/patient). Ribavirin 112-115 interferon alpha 1 Homo sapiens 25-28 15778976-5 2005 The number of amino acid substitutions observed in the hypervariable region (HVR)-1 of the HCV genome between baseline and 1 year after ribavirin monotherapy was low, i.e., 3 (1-11) amino acid substitutions, suggesting the absence of a high selection pressure induced by ribavirin. Ribavirin 136-145 vasoactive intestinal peptide receptor 1 Homo sapiens 55-83 15778976-7 2005 Transferrin level and total iron-binding capacity decreased significantly during ribavirin monotherapy (P = 0.004). Ribavirin 81-90 transferrin Homo sapiens 0-11 16004522-0 2005 Treatment with pegylated interferon alpha-2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin. Ribavirin 164-173 interferon alpha 2 Homo sapiens 25-44 15847697-9 2005 HALT-C patients who were HCV positive or negative following 20 weeks of pegylated IFN plus ribavirin therapy had similar QS diversity scores for Taq and HF-2 samples, and there was a trend for higher complexity scores from Taq as compared with HF-2 samples. Ribavirin 91-100 complement factor H Homo sapiens 153-157 15847697-9 2005 HALT-C patients who were HCV positive or negative following 20 weeks of pegylated IFN plus ribavirin therapy had similar QS diversity scores for Taq and HF-2 samples, and there was a trend for higher complexity scores from Taq as compared with HF-2 samples. Ribavirin 91-100 complement factor H Homo sapiens 244-248 15865084-10 2005 Heterozygosityfor the C282Y mutation in HFE contributes to iron accumulation and fibrosis progression in chronic hepatitis C. Ribavirin could cause dose-dependent reversible haemolytic anaemia, which can be managed with dose reductions or with administration of epoetin alpha at 40,000 IU once weekly without sacrificing the optimal dosing of ribavarin. Ribavirin 126-135 erythropoietin Homo sapiens 262-269 15765399-0 2005 Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Ribavirin 73-82 insulin Homo sapiens 0-7 15765399-10 2005 CONCLUSIONS: Insulin resistance, fibrosis, and genotype are independent predictors of the response to antiviral therapy in chronic hepatitis C patients treated with peginterferon plus ribavirin. Ribavirin 184-193 insulin Homo sapiens 13-20 15699763-0 2005 Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. BACKGROUND: HCV reinfection after liver transplantation is universal and has an accelerated course with a high risk of progression to cirrhosis. Ribavirin 49-58 interferon alpha 1 Homo sapiens 45-48 15816475-0 2005 Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear. Ribavirin 46-55 interleukin 18 Homo sapiens 17-22 15816475-0 2005 Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear. Ribavirin 46-55 interferon alpha 1 Homo sapiens 237-259 15816475-0 2005 Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear. Ribavirin 260-269 interleukin 18 Homo sapiens 17-22 15816475-0 2005 Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear. Ribavirin 260-269 interferon alpha 1 Homo sapiens 237-259 15816475-0 2005 Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear. Ribavirin 260-269 interleukin 18 Homo sapiens 17-22 15816475-0 2005 Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear. Ribavirin 260-269 interferon alpha 1 Homo sapiens 237-259 15816475-7 2005 CONCLUSIONS: This study suggests that ribavirin may contribute to the antiviral effect through up-regulation of IL-18 in combination with IFN in patients with chronic hepatitis C. Ribavirin 38-47 interleukin 18 Homo sapiens 112-117 15756146-1 2005 In face of numerous benefits induced by therapy based on interferon (IFN) associated with ribavirin for the treatment of chronic hepatitis C, there is an increasing concern regarding its tolerance, which can, in some cases, reduce the quality of life as well as compliance of patients. Ribavirin 90-99 interferon alpha 1 Homo sapiens 57-67 15756146-1 2005 In face of numerous benefits induced by therapy based on interferon (IFN) associated with ribavirin for the treatment of chronic hepatitis C, there is an increasing concern regarding its tolerance, which can, in some cases, reduce the quality of life as well as compliance of patients. Ribavirin 90-99 interferon alpha 1 Homo sapiens 69-72 15699763-3 2005 We conducted a pilot study to determine the efficacy and safety of triple antiviral therapy in IFN-ribavirin nonresponders with recurrent chronic hepatitis C. METHODS: Twenty-four nonresponders to the IFN-ribavirin combination were enrolled in this pilot study. Ribavirin 99-108 interferon alpha 1 Homo sapiens 95-98 15699763-15 2005 CONCLUSION: Our results show that triple antiviral therapy for 48 weeks induced a sustained virological response in 33% of IFN-ribavirin nonresponders with recurrent hepatitis C. Ribavirin 127-136 interferon alpha 1 Homo sapiens 123-126 15647850-6 2005 Ribavirin that does not inhibit SARS-CoV replication in Vero cells inhibited SARS-CoV replication in Caco2 cells at therapeutical concentrations. Ribavirin 0-9 seryl-tRNA synthetase 1 Homo sapiens 77-81 15730926-0 2005 Hepatitis C virus genotypes, HLA-DRB alleles and their response to interferon-alpha and ribavirin in patients with chronic hepatitis C. BACKGROUND: Hepatitis C virus (HCV) is a worldwide common disease. Ribavirin 88-97 major histocompatibility complex, class II, DR beta 1 Homo sapiens 29-36 15730926-2 2005 The aim of this study was to study the associations between HCV genotypes, HLA-DRB alleles and their response to IFN-alpha and ribavirin in Chinese patients with chronic hepatitis C in Northeast China. Ribavirin 127-136 major histocompatibility complex, class II, DR beta 1 Homo sapiens 75-82 15730926-4 2005 Gene chips were used to analyze the frequency of HLA-DRB in 25 of these patients and their response to IFN-alpha and ribavirin. Ribavirin 117-126 major histocompatibility complex, class II, DR beta 1 Homo sapiens 49-56 15730926-5 2005 The associations of HCV genotypes, HLA-DRB alleles and their response to IFN-alpha and ribavirin were also studied. Ribavirin 87-96 major histocompatibility complex, class II, DR beta 1 Homo sapiens 35-42 15730926-7 2005 The response rates to IFN-alpha and ribavirin in patients with DRB1*07 were higher than those with DRB1*04. Ribavirin 36-45 major histocompatibility complex, class II, DR beta 1 Homo sapiens 63-67 15641150-9 2005 CONCLUSION: Combination regimen of interferon-alpha, ribavirin and amantadine can enhance sustained viral response on IFN-alpha and ribavirin non-responder patients with HCV. Ribavirin 53-62 interferon alpha 1 Homo sapiens 118-127 16381243-1 2005 The most important therapeutic advance in recent years considering chronic HCV infection has occurred with the introduction of pegylated interferon (PEG IFN) in the combination therapy with ribavirin, which results in better sustained virologic response (SVR). Ribavirin 190-199 interferon alpha 1 Homo sapiens 153-156 15601771-0 2004 Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 21-26 15581735-6 2005 In addition, a 20-point or greater increase in SDS Index score during IFN-alpha/ribavirin therapy significantly predicted failure to clear virus when considered alone [crude odds ratio (OR), 3.2; 95% confidence interval (CI), 1.3-8.0; p <0.01] or when controlling for other factors that affected IFN-alpha treatment response (adjusted OR, 3.6; 95% CI, 1.3-9.5; p=0.01). Ribavirin 80-89 interferon alpha 1 Homo sapiens 299-308 15597026-9 2005 Epoetin alfa and darbepoetin alfa are erythropoietic growth factors that effectively increase hemoglobin while maintaining the optimal ribavirin dose and improving patients" quality of life. Ribavirin 135-144 erythropoietin Homo sapiens 0-7 16190549-7 2005 IFNa2b+RBV therapy diminished bcl2 positive cell percentage, specifically in patients with eliminated HCV. Ribavirin 7-10 BCL2 apoptosis regulator Homo sapiens 30-34 16190549-8 2005 CONCLUSIONS: Tissue p53 protein expression increase and bcl-2 decrease can be a prognostic marker as far as a positive effect of IFNa2b+RBV treatment and HCV elimination are concerned. Ribavirin 136-139 tumor protein p53 Homo sapiens 20-23 15601771-3 2004 Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1. Ribavirin 55-64 eukaryotic translation initiation factor 4E Homo sapiens 74-79 15601771-3 2004 Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1. Ribavirin 55-64 eukaryotic translation initiation factor 4E Homo sapiens 179-184 15828854-0 2005 Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. BACKGROUND: Interferon (IFN)-alpha and ribavirin combination therapy is the standard treatment for patients with chronic hepatitis C. However, ribavirin induces anaemia, especially by haemolysis, an adverse effect that is dose-limiting. Ribavirin 60-69 interferon alpha 1 Homo sapiens 122-144 16060397-0 2005 Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) and ribavirin improves the rate of eradication of the virus by less than 20% in patients with genotype 1b and a high viral load. Ribavirin 187-196 interferon beta 1 Homo sapiens 0-15 16060397-0 2005 Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) and ribavirin improves the rate of eradication of the virus by less than 20% in patients with genotype 1b and a high viral load. Ribavirin 187-196 interferon alpha 2 Homo sapiens 26-44 15655043-5 2005 The combination of IFN plus ribavirin increases sustained virological response rates compared with IFN alone. Ribavirin 28-37 interferon alpha 1 Homo sapiens 99-102 15601771-3 2004 Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1. Ribavirin 55-64 eukaryotic translation initiation factor 4E Homo sapiens 179-184 15601771-3 2004 Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1. Ribavirin 55-64 eukaryotic translation initiation factor 4E Homo sapiens 179-184 15601771-3 2004 Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1. Ribavirin 55-64 cyclin D1 Homo sapiens 416-425 15601771-4 2004 Ribavirin potently suppresses eIF4E-mediated oncogenic transformation of murine cells in vitro, of tumor growth of a mouse model of eIF4E-dependent human squamous cell carcinoma in vivo, and of colony formation of eIF4E-dependent acute myelogenous leukemia cells derived from human patients. Ribavirin 0-9 eukaryotic translation initiation factor 4E Mus musculus 30-35 15681898-0 2004 Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Ribavirin has recently been demonstrated to be efficacious in combination with interferon (IFN) alpha-2b for the treatment of relapsed hepatitis C infections. Ribavirin 144-153 interferon alpha 2 Homo sapiens 86-105 15601771-4 2004 Ribavirin potently suppresses eIF4E-mediated oncogenic transformation of murine cells in vitro, of tumor growth of a mouse model of eIF4E-dependent human squamous cell carcinoma in vivo, and of colony formation of eIF4E-dependent acute myelogenous leukemia cells derived from human patients. Ribavirin 0-9 eukaryotic translation initiation factor 4E Mus musculus 132-137 15601771-4 2004 Ribavirin potently suppresses eIF4E-mediated oncogenic transformation of murine cells in vitro, of tumor growth of a mouse model of eIF4E-dependent human squamous cell carcinoma in vivo, and of colony formation of eIF4E-dependent acute myelogenous leukemia cells derived from human patients. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 132-137 15601771-7 2004 In all, ribavirin"s association with eIF4E may provide a pharmacologic means for the interruption of posttranscriptional networks of oncogenes that maintain and enhance neoplasia and malignancy in human cancer. Ribavirin 8-17 eukaryotic translation initiation factor 4E Homo sapiens 37-42 15534921-3 2004 In non-responders (NR), MCP-1 increased in the course of IFNalpha+RBV treatment, differences were statistically significant as compared to responders. Ribavirin 66-69 C-C motif chemokine ligand 2 Homo sapiens 24-29 15534921-9 2004 CONCLUSION: MCP-1 concentration may be a prognostic marker of the efficacy of IFN+RBV therapy in patients with chronic hepatitis C. Ribavirin 82-85 C-C motif chemokine ligand 2 Homo sapiens 12-17 15566510-1 2004 UNLABELLED: With the favorable result of interferon (IFN)-ribavirin combination therapy for 24 weeks among naive Taiwanese chronic hepatitis C (CHC) patients, the optimal regimens of re-treatment for CHC patients who failed initial IFN monotherapy is not well-established. Ribavirin 58-67 interferon alpha 1 Homo sapiens 53-56 15565613-2 2004 In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia, and improving HRQL in anemic (Hb < or = 12 g/dL) HCV-infected patients receiving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compared with placebo. Ribavirin 95-98 erythropoietin Homo sapiens 67-74 15565613-8 2004 In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy. Ribavirin 116-119 erythropoietin Homo sapiens 15-22 15566510-1 2004 UNLABELLED: With the favorable result of interferon (IFN)-ribavirin combination therapy for 24 weeks among naive Taiwanese chronic hepatitis C (CHC) patients, the optimal regimens of re-treatment for CHC patients who failed initial IFN monotherapy is not well-established. Ribavirin 58-67 interferon alpha 1 Homo sapiens 232-235 15505595-8 2004 Ribavirin inhibited TNF-alpha, IFN-gamma, and IL-10 in both PHA and TT-stimulated PBMC at 100 microM (p <0.05). Ribavirin 0-9 tumor necrosis factor Homo sapiens 20-29 15500548-5 2004 The HCV replication was inhibited by alpha-IFN 2b (7.39-13.2% at 10 U/mL, 3.29-6.12% at 100 U/mL, 1.3-4.86% at 1000 U/mL) and by ribavirin (4.36-13.9% at 100 microg/mL), but not by the other drugs at 24-72 h after treatment. Ribavirin 129-138 interferon alpha 1 Homo sapiens 43-46 15500555-0 2004 A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. Ribavirin 61-70 interferon alpha 1 Homo sapiens 113-123 15330905-3 2004 We sought to evaluate the efficacy of two doses of interferon alfa-2b (IFN) with ribavirin (RBV) in patients with normal ALT [correction]. Ribavirin 81-90 interferon alpha 1 Homo sapiens 71-74 15328100-11 2004 The suppression of IL-12(p70) and TNF-alpha in maturing DCs may explain the reduction in hepatic inflammation observed during ribavirin monotherapy. Ribavirin 126-135 annexin A6 Homo sapiens 25-28 15328100-11 2004 The suppression of IL-12(p70) and TNF-alpha in maturing DCs may explain the reduction in hepatic inflammation observed during ribavirin monotherapy. Ribavirin 126-135 tumor necrosis factor Homo sapiens 34-43 15328100-12 2004 Combination alpha interferon-ribavirin therapy may alter the cytokine profile of maturing DCs overall by suppressing IL-10 production but maintaining IL-12(p70) and TNF-alpha production, a pattern that would favor viral elimination through downstream effects on T cells. Ribavirin 29-38 interleukin 10 Homo sapiens 117-122 15328100-12 2004 Combination alpha interferon-ribavirin therapy may alter the cytokine profile of maturing DCs overall by suppressing IL-10 production but maintaining IL-12(p70) and TNF-alpha production, a pattern that would favor viral elimination through downstream effects on T cells. Ribavirin 29-38 annexin A6 Homo sapiens 156-159 15328100-12 2004 Combination alpha interferon-ribavirin therapy may alter the cytokine profile of maturing DCs overall by suppressing IL-10 production but maintaining IL-12(p70) and TNF-alpha production, a pattern that would favor viral elimination through downstream effects on T cells. Ribavirin 29-38 tumor necrosis factor Homo sapiens 165-174 15446477-6 2004 When ADG was regressed on supplemental lysine intake, the RBV of lysine in L-lysine sulfate was 99% of the RBV of lysine in L-lysine HCl. Ribavirin 58-61 ADG Sus scrofa 5-8 15446477-6 2004 When ADG was regressed on supplemental lysine intake, the RBV of lysine in L-lysine sulfate was 99% of the RBV of lysine in L-lysine HCl. Ribavirin 107-110 ADG Sus scrofa 5-8 15357651-10 2004 In patients with HCV genotype 1 and high viral loads, the effects of ribavirin with IFN-alpha appeared slowly, after the earliest days of treatment. Ribavirin 69-78 interferon alpha 1 Homo sapiens 84-93 15232364-0 2004 Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. OBJECTIVES: Anemia is a common complication during interferon-ribavirin therapy for hepatitis C. While normally a fall in hematocrit in results in an exponential compensatory rise in erythropoietin, such that the correlation between hematocrit and erythropoietin is sharply negative, the erythropoietin response during interferon-ribavirin combination therapy is not known. Ribavirin 70-79 erythropoietin Homo sapiens 18-32 15232364-0 2004 Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. OBJECTIVES: Anemia is a common complication during interferon-ribavirin therapy for hepatitis C. While normally a fall in hematocrit in results in an exponential compensatory rise in erythropoietin, such that the correlation between hematocrit and erythropoietin is sharply negative, the erythropoietin response during interferon-ribavirin combination therapy is not known. Ribavirin 179-188 erythropoietin Homo sapiens 18-32 15232364-0 2004 Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. OBJECTIVES: Anemia is a common complication during interferon-ribavirin therapy for hepatitis C. While normally a fall in hematocrit in results in an exponential compensatory rise in erythropoietin, such that the correlation between hematocrit and erythropoietin is sharply negative, the erythropoietin response during interferon-ribavirin combination therapy is not known. Ribavirin 179-188 erythropoietin Homo sapiens 18-32 15232364-7 2004 There was an approximate 2 log10 reduction in maximal achievable erythropoietin level in subjects exposed to interferon-ribavirin combination. Ribavirin 120-129 erythropoietin Homo sapiens 65-79 15254170-4 2004 We show here that ribavirin reduces mortality, from 100% to 10 and 30%, respectively, in gene-deleted CCR1(-/-) mice and in wild-type mice treated with the small-molecule chemokine receptor antagonist, Met-RANTES. Ribavirin 18-27 chemokine (C-C motif) receptor 1 Mus musculus 102-106 15254170-4 2004 We show here that ribavirin reduces mortality, from 100% to 10 and 30%, respectively, in gene-deleted CCR1(-/-) mice and in wild-type mice treated with the small-molecule chemokine receptor antagonist, Met-RANTES. Ribavirin 18-27 chemokine (C-C motif) ligand 5 Mus musculus 206-212 16265040-0 2004 Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy? Ribavirin 26-35 erythropoietin Homo sapiens 4-11 15535414-0 2004 PKR gene expression and response to pegylated interferon plus ribavirin therapy in chronic hepatitis C. Pegylated interferon (PEG-IFN) alpha combined with ribavirin is the current standard treatment for hepatitis C, but around 50% of patients do not respond for reasons that are not fully understood. Ribavirin 155-164 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 0-3 15535414-2 2004 Non-responders to PEG-IFN plus ribavirin had pre-treatment PKR mRNA levels in PBMCs (0.1+/-0.0074) and in liver (0.102+/-0.051) that were significantly higher than those of responders (PBMCs: 0.023+/-0.014, P=0.0005; liver: 0.034+/-0.020; P=0.0002). Ribavirin 31-40 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 59-62 15328100-8 2004 In contrast, ribavirin at physiological doses had no effect on DC maturation but markedly suppressed the production of TNF-alpha, IL-10, and IL-12(p70). Ribavirin 13-22 tumor necrosis factor Homo sapiens 119-128 15328100-8 2004 In contrast, ribavirin at physiological doses had no effect on DC maturation but markedly suppressed the production of TNF-alpha, IL-10, and IL-12(p70). Ribavirin 13-22 interleukin 10 Homo sapiens 130-135 15328100-8 2004 In contrast, ribavirin at physiological doses had no effect on DC maturation but markedly suppressed the production of TNF-alpha, IL-10, and IL-12(p70). Ribavirin 13-22 annexin A6 Homo sapiens 147-150 15324941-2 2004 Several studies have assessed the efficacy of pegylated interferon (IFN) and ribavirin (RBV) combination therapy in IFN and RBV therapy relapsers. Ribavirin 77-86 interferon alpha 1 Homo sapiens 116-119 15324941-2 2004 Several studies have assessed the efficacy of pegylated interferon (IFN) and ribavirin (RBV) combination therapy in IFN and RBV therapy relapsers. Ribavirin 88-91 interferon alpha 1 Homo sapiens 116-119 15324941-2 2004 Several studies have assessed the efficacy of pegylated interferon (IFN) and ribavirin (RBV) combination therapy in IFN and RBV therapy relapsers. Ribavirin 124-127 interferon alpha 1 Homo sapiens 56-66 15324941-2 2004 Several studies have assessed the efficacy of pegylated interferon (IFN) and ribavirin (RBV) combination therapy in IFN and RBV therapy relapsers. Ribavirin 124-127 interferon alpha 1 Homo sapiens 68-71 15148560-9 2004 In ribavirin treated cultures, concentrations higher than 2.5 microg/mL were associated with a decrease in ALP activity within 7 and 14 days (P < 0.01 and P < 0.001, respectively). Ribavirin 3-12 alkaline phosphatase, placental Homo sapiens 107-110 15232364-8 2004 CONCLUSION: There is a subnormal rise of erythropoietin after interferon-ribavirin combination therapy for hepatitis C. Ribavirin 73-82 erythropoietin Homo sapiens 41-55 15505595-8 2004 Ribavirin inhibited TNF-alpha, IFN-gamma, and IL-10 in both PHA and TT-stimulated PBMC at 100 microM (p <0.05). Ribavirin 0-9 interferon gamma Homo sapiens 31-40 15505595-8 2004 Ribavirin inhibited TNF-alpha, IFN-gamma, and IL-10 in both PHA and TT-stimulated PBMC at 100 microM (p <0.05). Ribavirin 0-9 interleukin 10 Homo sapiens 46-51 15505595-9 2004 At this concentration, ribavirin induced an increase of 124% in the production of IL-2 by PHA-stimulated PBMC (p <0.05). Ribavirin 23-32 interleukin 2 Homo sapiens 82-86 15505595-10 2004 CONCLUSIONS: The present data suggest that ribavirin may cause diverse effects on immunoregulatory cytokine secretion with changes in the Th1/Th2 balance. Ribavirin 43-52 negative elongation factor complex member C/D Homo sapiens 138-141 15230850-4 2004 The combination of pegylated IFNa and ribavirin seems to be a rational approach for patients who failed to respond to IFNa monotherapy. Ribavirin 38-47 interferon alpha 1 Homo sapiens 118-122 15230850-5 2004 Pegylated IFNa-based regimens appear to induce sustained responses in 40-68% of relapsers but in only 11% of nonresponders to previous therapy with standard IFNa plus ribavirin. Ribavirin 167-176 interferon alpha 1 Homo sapiens 10-14 15163430-1 2004 Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) and ribavirin improves the rate of eradication of HCV, but only about 13-14% of non-responders (NR) with HCV of genotype 1b previously treated with IFN achieve a sustained virological response (SVR). Ribavirin 81-90 interferon alpha 1 Homo sapiens 225-228 15350490-3 2004 The main aim of this pilot study was to assess the efficacy of combined alpha-interferon (alpha-IFN) and ribavirin treatment of HCV hemodialysis (HDx) patients, by comparing the sustained virological response to that obtained by local historical data on treatment with alpha-IFN alone. Ribavirin 105-114 interferon alpha 1 Homo sapiens 275-278 15350490-15 2004 CONCLUSION: This pilot study suggests that combination treatment for 24 weeks and 48 weeks with 3 MU alpha-IFN and 200 mg ribavirin three times a week, elicited a sustained virologic response in HDx patients with HCV infection better than IFN alone with minimal side effects. Ribavirin 122-131 interferon alpha 1 Homo sapiens 239-242 15309891-0 2004 Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Acute pancreatitis is a rare complication of interferon (IFN) and ribavirin (RBV) therapy. Ribavirin 50-59 interferon alpha 1 Homo sapiens 151-161 15309891-0 2004 Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Acute pancreatitis is a rare complication of interferon (IFN) and ribavirin (RBV) therapy. Ribavirin 50-59 interferon alpha 1 Homo sapiens 163-166 15309891-0 2004 Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Acute pancreatitis is a rare complication of interferon (IFN) and ribavirin (RBV) therapy. Ribavirin 172-181 interferon alpha 1 Homo sapiens 35-45 15309891-0 2004 Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Acute pancreatitis is a rare complication of interferon (IFN) and ribavirin (RBV) therapy. Ribavirin 183-186 interferon alpha 1 Homo sapiens 35-45 15251366-8 2004 In three patients anemia necessitated administration of erythropoietin and three patients received granulocyte-colony stimulating factor (G-CSF) due to leucopenia [corrected] In conclusion, we observed that daily IFN alpha-2b and subsequent PEG IFN alpha-2b therapy in combination with ribavirin provides biochemical and virological benefits in transplant recipients with established recurrent HCV infection. Ribavirin 286-295 interferon alpha 1 Homo sapiens 213-216 15158348-0 2004 Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed? Ribavirin 30-39 BMP binding endothelial regulator Homo sapiens 87-92 15086600-8 2004 In addition, 0.1 microg/mL ribavirin could upregulate the levels of IFN-gamma or IL-4 mRNA in some cases. Ribavirin 27-36 interferon gamma Homo sapiens 68-77 15131791-0 2004 Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Ribavirin 23-32 erythropoietin Homo sapiens 0-7 15131791-2 2004 This study assessed whether epoetin alfa could maintain RBV dose, improve quality of life (QOL), and increase hemoglobin (Hb) in anemic HCV-infected patients. Ribavirin 56-59 erythropoietin Homo sapiens 28-35 15131791-5 2004 RESULTS: At the end of the DBP, RBV doses were maintained in 88% of patients receiving epoetin alfa vs. 60% of patients receiving placebo (P < 0.001). Ribavirin 32-35 erythropoietin Homo sapiens 87-94 15131791-10 2004 CONCLUSIONS: Epoetin alfa maintained RBV dose and improved QOL and Hb in anemic HCV-infected patients receiving combination therapy. Ribavirin 37-40 erythropoietin Homo sapiens 13-20 15094232-0 2004 HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. Ribavirin 178-187 vasoactive intestinal peptide receptor 1 Homo sapiens 0-5 15086600-8 2004 In addition, 0.1 microg/mL ribavirin could upregulate the levels of IFN-gamma or IL-4 mRNA in some cases. Ribavirin 27-36 interleukin 4 Homo sapiens 81-85 15185728-9 2004 Since WNV-infected patients have already been treated with IFN and ribavirin and future clinical trials have been suggested, this first report of IFN alone or in combination with ribavirin in WNV-infected animal models might provide useful information for subsequent treatment of patients. Ribavirin 67-76 interferon alpha 1 Homo sapiens 146-149 15117320-8 2004 In a randomized placebo-controlled trial, treatment with epoetin alfa has been shown to raise Hb levels and maintain RBV doses. Ribavirin 117-120 erythropoietin Homo sapiens 57-64 15117320-10 2004 Anaemia in patients treated with interferon plus RBV combination therapy can be managed effectively and safely with once weekly epoetin alfa without sacrificing optimal dosing of RBV. Ribavirin 49-52 erythropoietin Homo sapiens 128-135 15117324-2 2004 We analysed amino acid sequences of the viral RNA-dependent RNA polymerase (RdRP) or nonstructural protein 5B (NS5B), responsible for ribavirin misincorporation into RNA products in patients with genotype 1b-related chronic hepatitis C and high viremia, and examined the relationship between such RdRp polymorphisms, and the initial decline in viral load induced by combination therapy with IFN-alpha and ribavirin. Ribavirin 134-143 interferon alpha 1 Homo sapiens 391-394 15031779-8 2004 Our results suggest that the direct effects of ribavirin on the genetic stability of the HCV subgenome and its synergistic action combined, with IFN-alpha, may explain the improved clinical responses to combination therapy. Ribavirin 47-56 interferon alpha 1 Homo sapiens 145-154 14988824-6 2004 Ribavirin antiviral effect partly reduced the rebound preceding the second IFN-alpha injection in patients receiving standard IFN-alpha 3 times per week plus ribavirin. Ribavirin 0-9 interferon alpha 1 Homo sapiens 75-84 14987324-6 2004 CONCLUSIONS: Circulating and intrahepatic T-helper-1-associated chemokines are abnormally elevated in patients with chronic hepatitis C. Increased baseline serum interferon-gamma-inducible protein-10 levels in genotype 1-infected patients are associated with virological non-response to peginterferon plus ribavirin combination therapy. Ribavirin 306-315 C-X-C motif chemokine ligand 10 Homo sapiens 162-199 15024445-0 2004 Ribavirin for SARS in children. Ribavirin 0-9 seryl-tRNA synthetase 1 Homo sapiens 14-18 14988824-6 2004 Ribavirin antiviral effect partly reduced the rebound preceding the second IFN-alpha injection in patients receiving standard IFN-alpha 3 times per week plus ribavirin. Ribavirin 0-9 interferon alpha 1 Homo sapiens 126-135 14988824-10 2004 CONCLUSIONS: Ribavirin exerts a significant, moderate, and transient antiviral effect in a significant proportion of patients with chronic hepatitis C. The antiviral effect of ribavirin correlates with ribavirin pharmacokinetics and is partly responsible for the improved efficacy of the combination of standard IFN-alpha and ribavirin compared with IFN-alpha monotherapy by increasing the incidence of the initial response. Ribavirin 13-22 interferon alpha 1 Homo sapiens 312-321 14988824-10 2004 CONCLUSIONS: Ribavirin exerts a significant, moderate, and transient antiviral effect in a significant proportion of patients with chronic hepatitis C. The antiviral effect of ribavirin correlates with ribavirin pharmacokinetics and is partly responsible for the improved efficacy of the combination of standard IFN-alpha and ribavirin compared with IFN-alpha monotherapy by increasing the incidence of the initial response. Ribavirin 13-22 interferon alpha 1 Homo sapiens 350-359 15081101-0 2004 Role of epoetin alfa in maintaining ribavirin dose. Ribavirin 36-45 erythropoietin Homo sapiens 8-15 14988824-10 2004 CONCLUSIONS: Ribavirin exerts a significant, moderate, and transient antiviral effect in a significant proportion of patients with chronic hepatitis C. The antiviral effect of ribavirin correlates with ribavirin pharmacokinetics and is partly responsible for the improved efficacy of the combination of standard IFN-alpha and ribavirin compared with IFN-alpha monotherapy by increasing the incidence of the initial response. Ribavirin 176-185 interferon alpha 1 Homo sapiens 312-321 15081101-7 2004 However, recent studies suggest that epoetin alfa can increase hemoglobin levels and facilitate maintenance of RBV dosage in patients with chronic hepatitis C who became anemic during standard combination therapy. Ribavirin 111-114 erythropoietin Homo sapiens 37-44 15081101-8 2004 Results of a randomized, randomized, double-blind, placebo-controlled trial suggest that epoetin alfa therapy can maintain RBV dosage, increase hemoglobin levels, and improve quality of life in this population. Ribavirin 123-126 erythropoietin Homo sapiens 89-96 14988824-10 2004 CONCLUSIONS: Ribavirin exerts a significant, moderate, and transient antiviral effect in a significant proportion of patients with chronic hepatitis C. The antiviral effect of ribavirin correlates with ribavirin pharmacokinetics and is partly responsible for the improved efficacy of the combination of standard IFN-alpha and ribavirin compared with IFN-alpha monotherapy by increasing the incidence of the initial response. Ribavirin 176-185 interferon alpha 1 Homo sapiens 350-359 15259856-4 2004 Pt-rib-1 is a ribavirin derivative. Ribavirin 14-23 ribonuclease, RNase A family, 1 (pancreatic) Mus musculus 3-8 14969836-14 2004 CONCLUSION: Daily IFN dosage with ribavirin is safe and can achieve response in up to 65% patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 18-21 15060691-0 2004 Soluble CD26/30 levels before and after treatment with interferon-alpha and ribavirin combination therapy in a pediatric hepatitis C patient. Ribavirin 76-85 dipeptidyl peptidase 4 Homo sapiens 8-12 15132871-8 2004 The Therapeutic index (TI = TC(50)/EC(50)) of AP3 was 116.12, much higher than the TI of herba patriniae (AP1) (TI = 59.26) and ribavirin (TI = 53.45). Ribavirin 128-137 adaptor-related protein complex 3, beta 1 subunit Mus musculus 46-49 15571424-12 2004 CONCLUSION: The combination of IL-2 and ribavirin seems to increase the probability of a sustained biochemical and virologic response in patients with chronic hepatitis C that is unresponsive to IFN. Ribavirin 40-49 interferon alpha 1 Homo sapiens 195-198 15069622-1 2004 BACKGROUND: Although pegylated interferon (IFN) is now used in many countries as a standard therapy for chronic hepatitis C, the efficacy and safety of combination therapy of high-dose interferon alpha-2b induction with ribavirin are not fully evaluated, especially in Japanese patients infected with hepatitis C virus (HCV) genotype 1b with a high viral load. Ribavirin 220-229 interferon alpha 2 Homo sapiens 185-204 14720084-8 2004 In the last 2 years, IFN plus ribavirin combination therapy has been the standard care for the treatment of chronic hepatitis C. Although information on the safety and efficacy of this dual therapy in HCV/HIV co-infected patients is scarce, recent trials have reported that the combination of IFN plus ribavirin is well tolerated and feasible in patients co-infected with HCV/HIV. Ribavirin 30-39 interferon alpha 1 Homo sapiens 293-296 14720084-8 2004 In the last 2 years, IFN plus ribavirin combination therapy has been the standard care for the treatment of chronic hepatitis C. Although information on the safety and efficacy of this dual therapy in HCV/HIV co-infected patients is scarce, recent trials have reported that the combination of IFN plus ribavirin is well tolerated and feasible in patients co-infected with HCV/HIV. Ribavirin 302-311 interferon alpha 1 Homo sapiens 21-24 14720084-8 2004 In the last 2 years, IFN plus ribavirin combination therapy has been the standard care for the treatment of chronic hepatitis C. Although information on the safety and efficacy of this dual therapy in HCV/HIV co-infected patients is scarce, recent trials have reported that the combination of IFN plus ribavirin is well tolerated and feasible in patients co-infected with HCV/HIV. Ribavirin 302-311 interferon alpha 1 Homo sapiens 293-296 15000873-6 2004 NAC was given as a single daily dose of 1000 mg/kg starting from 4 h after infection and until day 4 after infection, in association with ribavirin (100 mg/kg, i.p.). Ribavirin 138-147 NLR family, pyrin domain containing 1A Mus musculus 0-3 15279546-7 2004 Combination therapy with ribavirin does not seem to increase the response rate but could be proposed as a second choice to patients non responding to IFN monotherapy. Ribavirin 25-34 interferon alpha 1 Homo sapiens 150-153 15279549-0 2004 Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C. Combined therapy using Interferon alfa (IFN) and Ribavirin (RIB) represents the standard treatment in patients with chronic hepatitis C. However, the percentage of responders to this regimen is still low, while its cost and side effects are elevated. Ribavirin 77-86 interferon alpha 1 Homo sapiens 175-178 15192274-8 2004 CONCLUSIONS: In PEG-IFN alpha-2b and ribavirin combination therapy, elimination of infected cells may be pronounced following an increase in serum ribavirin concentration in chronic hepatitis C patients with genotype 1b infection and a high viral load. Ribavirin 147-156 interferon alpha 1 Homo sapiens 20-23 15069622-9 2004 CONCLUSIONS: The efficacy of 24-week combination therapy of high-dose IFN alpha-2b induction and ribavirin deserves attention in HCV genotype 1b patients with a high viral load, especially in nonresponders to previous IFN monotherapy and patients with a very high viral load. Ribavirin 97-106 interferon alpha 1 Homo sapiens 218-221 15671755-0 2004 Changes in TNF-alpha mRNA levels in the peripheral blood of patients with chronic hepatitis C virus (HCV) infection during alpha-interferon and ribavirin therapy. Ribavirin 144-153 tumor necrosis factor Homo sapiens 11-20 14717982-9 2004 We have also demonstrated that the ribavirin-treated CMK cells express PKC-alpha, -beta, -delta and -theta, and suggested that PKC-alpha and/or -beta appear to be responsible for PMA-induced activation of alpha IIb beta 3 in CMK cells. Ribavirin 35-44 cytidine/uridine monophosphate kinase 1 Homo sapiens 53-56 14717982-9 2004 We have also demonstrated that the ribavirin-treated CMK cells express PKC-alpha, -beta, -delta and -theta, and suggested that PKC-alpha and/or -beta appear to be responsible for PMA-induced activation of alpha IIb beta 3 in CMK cells. Ribavirin 35-44 protein kinase C alpha Homo sapiens 71-106 14717982-9 2004 We have also demonstrated that the ribavirin-treated CMK cells express PKC-alpha, -beta, -delta and -theta, and suggested that PKC-alpha and/or -beta appear to be responsible for PMA-induced activation of alpha IIb beta 3 in CMK cells. Ribavirin 35-44 protein kinase C alpha Homo sapiens 71-80 14717982-9 2004 We have also demonstrated that the ribavirin-treated CMK cells express PKC-alpha, -beta, -delta and -theta, and suggested that PKC-alpha and/or -beta appear to be responsible for PMA-induced activation of alpha IIb beta 3 in CMK cells. Ribavirin 35-44 cytidine/uridine monophosphate kinase 1 Homo sapiens 225-228 15488656-0 2004 S-adenosylhomocysteine hydrolase, S-adenosylmethionine, S-adenosylhomocysteine: correlations with ribavirin induced anemia. Ribavirin 98-107 adenosylhomocysteinase Homo sapiens 0-32 14974875-9 2004 RESULTS: In patients infected with HCV genotype 1, peginterferon alpha-2a plus ribavirin increased life-years (LYs) by 0.78 years and QALYs by 0.67 years, compared with interferon alpha-2b and ribavirin. Ribavirin 79-88 interferon alpha 2 Homo sapiens 169-188 15208476-2 2004 MATERIAL AND METHODS: One hundred thirty one patients with chronic hepatitis C were included and assigned to 24-week course of interferon alpha-2b with ribavirin. Ribavirin 152-161 interferon alpha 2 Homo sapiens 127-146 15015227-7 2004 In patients who were administered the combination of alpha-IFN and ribavirin this effect appeared in 4 from 7 cases without history of treatment with alpha-IFN (57%), one from 2 relapses and one from 3 non-responders. Ribavirin 67-76 interferon alpha 1 Homo sapiens 156-159 15015227-8 2004 The combination PEG-IFN and ribavirin was effective in the only one patient who relapsed after alpha-IFN and ribavirin and in one from the two non-responders to this combination. Ribavirin 28-37 interferon alpha 1 Homo sapiens 101-104 15015227-8 2004 The combination PEG-IFN and ribavirin was effective in the only one patient who relapsed after alpha-IFN and ribavirin and in one from the two non-responders to this combination. Ribavirin 109-118 interferon alpha 1 Homo sapiens 20-23 15671755-4 2004 In this study, we present the results of applying real-time RT-PCR for assessing the TNF-alpha mRNA level in the peripheral blood of patients treated with IFN-alpha and ribavirin. Ribavirin 169-178 tumor necrosis factor Homo sapiens 85-94 14662112-5 2003 Treatment with C-IFN lead to a higher response rate compared to that of recombinant IFN-alpha 2b in association with ribavirin. Ribavirin 117-126 interferon alpha 1 Homo sapiens 84-93 14760885-0 2003 Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Ribavirin 33-42 glutamic--pyruvic transaminase Homo sapiens 137-161 14988669-8 2003 In aged patients with chronic hepatitis C treatment with the more effective pegylated IFN should be taken into consideration, especially when association with ribavirin is at high risk of adverse events. Ribavirin 159-168 interferon alpha 1 Homo sapiens 86-89 14638410-1 2003 The approval of ribavirin in combination therapy regimens with interferon (IFN) dramatically improved therapy. Ribavirin 16-25 interferon alpha 1 Homo sapiens 75-78 14638354-0 2003 Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Ribavirin 72-81 erythropoietin Homo sapiens 12-19 14638354-0 2003 Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Ribavirin 138-147 erythropoietin Homo sapiens 12-19 14638354-1 2003 OBJECTIVE: The aim of this study was to determine the efficacy of epoetin alfa in alleviating anemia and minimizing ribavirin (RBV) dose reductions in patients with chronic hepatitis C virus (HCV) infection receiving combination RBV/interferon alfa (IFN) therapy. Ribavirin 116-125 erythropoietin Homo sapiens 66-73 14638354-1 2003 OBJECTIVE: The aim of this study was to determine the efficacy of epoetin alfa in alleviating anemia and minimizing ribavirin (RBV) dose reductions in patients with chronic hepatitis C virus (HCV) infection receiving combination RBV/interferon alfa (IFN) therapy. Ribavirin 127-130 erythropoietin Homo sapiens 66-73 14638354-1 2003 OBJECTIVE: The aim of this study was to determine the efficacy of epoetin alfa in alleviating anemia and minimizing ribavirin (RBV) dose reductions in patients with chronic hepatitis C virus (HCV) infection receiving combination RBV/interferon alfa (IFN) therapy. Ribavirin 229-232 erythropoietin Homo sapiens 66-73 14638354-5 2003 Based on intent-to-treat analysis, the mean changes from baseline Hb levels at week 16 were +2.8 g/dl for epoetin alfa versus +0.4 g/dl for SOC (p<0.0001), and the mean changes in RBV dosage were -34 mg/day for epoetin alfa versus -146 mg/day (p=0.060) for SOC. Ribavirin 183-186 erythropoietin Homo sapiens 106-113 14638354-8 2003 At study end, 83% of epoetin alfa-treated patients maintained RBV dosages of at least 800 mg/day, compared with 54% of patients receiving SOC (p=0.022). Ribavirin 62-65 erythropoietin Homo sapiens 21-28 14638354-10 2003 CONCLUSIONS: In anemic HCV-infected patients treated with RBV/IFN, epoetin alfa increases Hb levels and maintains RBV dosing. Ribavirin 58-61 erythropoietin Homo sapiens 67-74 14638354-10 2003 CONCLUSIONS: In anemic HCV-infected patients treated with RBV/IFN, epoetin alfa increases Hb levels and maintains RBV dosing. Ribavirin 114-117 erythropoietin Homo sapiens 67-74 14633177-0 2003 Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C. The efficacy and secondary effects of an induction dose of interferon-alpha2b (IFN-alpha2b) with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C infection were compared. Ribavirin 82-91 interferon alpha 2 Homo sapiens 58-76 14633182-1 2003 The complex immunological effects of interferon and ribavirin therapy (IFN/R) in hepatitis C virus (HCV) may also exacerbate or trigger the de novo development of autoimmunity. Ribavirin 52-61 interferon alpha 1 Homo sapiens 71-74 12970428-4 2003 In the present study, we assessed the effects of combination antiviral therapy (alfa interferon and ribavirin) on peripheral B-cell CD81 expression and CD5 expansion and the presence of autoimmune markers. Ribavirin 100-109 CD81 molecule Homo sapiens 132-136 12970428-4 2003 In the present study, we assessed the effects of combination antiviral therapy (alfa interferon and ribavirin) on peripheral B-cell CD81 expression and CD5 expansion and the presence of autoimmune markers. Ribavirin 100-109 CD5 molecule Homo sapiens 152-155 14603150-7 2003 In contrast to non-HCV-infected recipients, treatment for acute cellular rejection is associated with attenuated patient survival among recipients with hepatitis C. Therapy with pegylated IFN (+/- ribavirin), although less efficacious than in immunocompetent patients, should be considered in recipients with histologically apparent recurrence of hepatitis C before jaundice develops. Ribavirin 197-206 interferon alpha 1 Homo sapiens 188-191 14568602-0 2003 [Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C]. Ribavirin 61-70 erythropoietin Homo sapiens 8-22 14568602-13 2003 In conclusion, in our patients with chronic hepatitis C treated with interferon/ribavirin combination therapy, erythropoietin was beneficial in the treatment of ribavirin-induced anemia. Ribavirin 80-89 erythropoietin Homo sapiens 111-125 14568602-13 2003 In conclusion, in our patients with chronic hepatitis C treated with interferon/ribavirin combination therapy, erythropoietin was beneficial in the treatment of ribavirin-induced anemia. Ribavirin 161-170 erythropoietin Homo sapiens 111-125 12969190-6 2003 Combination of IFN/ribavirin for 48 weeks is more effective when IFN is administered daily for the first 24 weeks in naive patients with CHC. Ribavirin 19-28 interferon alpha 1 Homo sapiens 65-68 12950173-2 2003 recently proposed the primary antiviral action of ribavirin to be that of a potent RNA mutagen [Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y., Hong, Z., Andino, R., and Cameron, C. E. (2000) Nat. Ribavirin 50-59 bromodomain containing 2 Homo sapiens 204-207 12941656-6 2003 The data showed that ribavirin and ODN 1826 increased interleukin-12 synthesis and inhibited interleukin-10 production. Ribavirin 21-30 interleukin 10 Mus musculus 93-107 12941656-8 2003 Furthermore, the DCs modulated by ribavirin and ODN 1826 could downregulate the Th2-type immune response in vivo and could alleviate airway inflammation. Ribavirin 34-43 heart and neural crest derivatives expressed 2 Mus musculus 80-83 12760867-12 2003 IFN and ribavirin also enhance CD95-mediated caspase activation, which might in part be responsible for the apoptosis-promoting effect of these antiviral compounds. Ribavirin 8-17 Fas cell surface death receptor Homo sapiens 31-35 15156609-0 2003 Assessment of selected clinical factors as predictors of response to combined interferon-alpha plus ribavirin therapy among patients with chronic hepatitis C. BACKGROUND: Combined interferon-alpha (IFN) plus ribavirin therapy is recommended as first-line regimen treatment of chronic hepatitis C (CHC) patients. Ribavirin 100-109 interferon alpha 1 Homo sapiens 198-201 15156609-1 2003 The aim of the study was to evaluate the selected clinical factors in the prediction of response to IFN with ribavirin for initial therapy and retreatment of CHC. Ribavirin 109-118 interferon alpha 1 Homo sapiens 100-103 12873822-1 2003 METHODS: We determined CCR5 genotypes in patients with hepatitis C treated with either interferon-alpha (N=78) or interferon and ribavirin (N=78). Ribavirin 129-138 C-C motif chemokine receptor 5 Homo sapiens 23-27 12873822-6 2003 In interferon/ribavirin treated patients CCR-Delta32 carriers and CCR5 wildtype patients had similar ETR rates [19.2% vs. 23.1%] and SVR rates [20.0% vs. 21.2%]. Ribavirin 14-23 C-C motif chemokine receptor 5 Homo sapiens 66-70 12873822-8 2003 However, interferon/ribavirin combination treatment may overcome this negative effect of CCR5-Delta32. Ribavirin 20-29 C-C motif chemokine receptor 5 Homo sapiens 89-93 12875209-10 2003 Early administration of intraventricular ribavirin and IFN might be considered especially to IFN in non-responders. Ribavirin 41-50 interferon alpha 1 Homo sapiens 93-96 12760867-4 2003 In the present study, we have asked whether the antiviral substances IFN and ribavirin could support CD95-mediated apoptosis by interfering with the activation of caspases, a family of proteases known for their essential role in apoptosis. Ribavirin 77-86 Fas cell surface death receptor Homo sapiens 101-105 12760867-4 2003 In the present study, we have asked whether the antiviral substances IFN and ribavirin could support CD95-mediated apoptosis by interfering with the activation of caspases, a family of proteases known for their essential role in apoptosis. Ribavirin 77-86 caspase 8 Homo sapiens 163-171 12760867-8 2003 IFN and ribavirin sensitized HepG2 cells for CD95-mediated apoptosis. Ribavirin 8-17 Fas cell surface death receptor Homo sapiens 45-49 12760867-12 2003 IFN and ribavirin also enhance CD95-mediated caspase activation, which might in part be responsible for the apoptosis-promoting effect of these antiviral compounds. Ribavirin 8-17 caspase 8 Homo sapiens 45-52 12734046-7 2003 However, published reports describe treatment with IFN monotherapy and combination therapy with IFN and ribavirin. Ribavirin 104-113 interferon alpha 1 Homo sapiens 51-54 12760867-10 2003 Furthermore, the positive effect on CD95-mediated caspase activation by IFN and ribavirin was confirmed by immunocytochemistry for activated caspase-3 and by immunoblot detection of activated caspase-3, caspase-7, and caspase-8. Ribavirin 80-89 Fas cell surface death receptor Homo sapiens 36-40 12760867-10 2003 Furthermore, the positive effect on CD95-mediated caspase activation by IFN and ribavirin was confirmed by immunocytochemistry for activated caspase-3 and by immunoblot detection of activated caspase-3, caspase-7, and caspase-8. Ribavirin 80-89 caspase 8 Homo sapiens 50-57 12760867-10 2003 Furthermore, the positive effect on CD95-mediated caspase activation by IFN and ribavirin was confirmed by immunocytochemistry for activated caspase-3 and by immunoblot detection of activated caspase-3, caspase-7, and caspase-8. Ribavirin 80-89 caspase 3 Homo sapiens 141-150 12760867-10 2003 Furthermore, the positive effect on CD95-mediated caspase activation by IFN and ribavirin was confirmed by immunocytochemistry for activated caspase-3 and by immunoblot detection of activated caspase-3, caspase-7, and caspase-8. Ribavirin 80-89 caspase 3 Homo sapiens 192-201 12760867-10 2003 Furthermore, the positive effect on CD95-mediated caspase activation by IFN and ribavirin was confirmed by immunocytochemistry for activated caspase-3 and by immunoblot detection of activated caspase-3, caspase-7, and caspase-8. Ribavirin 80-89 caspase 7 Homo sapiens 203-212 12760867-10 2003 Furthermore, the positive effect on CD95-mediated caspase activation by IFN and ribavirin was confirmed by immunocytochemistry for activated caspase-3 and by immunoblot detection of activated caspase-3, caspase-7, and caspase-8. Ribavirin 80-89 caspase 8 Homo sapiens 218-227 12760867-11 2003 Our data demonstrate that the antiviral substances IFN and ribavirin are able to sensitize for CD95-mediated apoptosis. Ribavirin 59-68 Fas cell surface death receptor Homo sapiens 95-99 12637521-6 2003 Reovirus-induced inhibition of NF-kappaB activation occurs by a mechanism that prevents IkappaBalpha degradation and that is blocked in the presence of the viral RNA synthesis inhibitor, ribavirin. Ribavirin 187-196 nuclear factor kappa B subunit 1 Homo sapiens 31-40 12637521-8 2003 Herein we show that ribavirin inhibits reovirus-induced apoptosis in TRAIL-resistant HEK293 cells and prevents the ability of reovirus infection to sensitize TRAIL-resistant cells to TRAIL-induced apoptosis. Ribavirin 20-29 TNF superfamily member 10 Homo sapiens 69-74 12637521-8 2003 Herein we show that ribavirin inhibits reovirus-induced apoptosis in TRAIL-resistant HEK293 cells and prevents the ability of reovirus infection to sensitize TRAIL-resistant cells to TRAIL-induced apoptosis. Ribavirin 20-29 TNF superfamily member 10 Homo sapiens 158-163 12637521-8 2003 Herein we show that ribavirin inhibits reovirus-induced apoptosis in TRAIL-resistant HEK293 cells and prevents the ability of reovirus infection to sensitize TRAIL-resistant cells to TRAIL-induced apoptosis. Ribavirin 20-29 TNF superfamily member 10 Homo sapiens 158-163 12700452-12 2003 CONCLUSION: Treatment with peg-IFN and ribavirin is relatively well-tolerated in HIV/HCV-co-infected patients, although new side-effects, including pancreatitis and severe weight loss, may result from the interaction of ribavirin with antiretroviral drugs. Ribavirin 220-229 interferon alpha 1 Homo sapiens 31-34 12743076-0 2003 Ribavirin in the treatment of SARS: A new trick for an old drug? Ribavirin 0-9 seryl-tRNA synthetase 1 Homo sapiens 30-34 12772791-10 2003 Interferon (IFN) ribavirin combination therapy is effective in patients with normal ALTs and appears superior to IFN monotherapy. Ribavirin 17-26 interferon alpha 1 Homo sapiens 12-15 12910808-5 2003 Later, it started the experimentations with IFN associated to other substances, for example IFN-ribavirin combination therapy. Ribavirin 96-105 interferon alpha 1 Homo sapiens 44-47 12910808-5 2003 Later, it started the experimentations with IFN associated to other substances, for example IFN-ribavirin combination therapy. Ribavirin 96-105 interferon alpha 1 Homo sapiens 92-95 12910808-6 2003 The treatment IFN-Ribavirin eradicates the infection in 30% of the patients with the genotype 1b and in 60% with the genotype 2 or 3, while this treatment is less efficacious in the patients with the genotype 4. Ribavirin 18-27 interferon alpha 1 Homo sapiens 14-17 12753337-7 2003 In conclusion, re-treatment of patients not responding to previous IFN monotherapy with a combination of high daily dose of IFN with ribavirin may be beneficial for genotype 1 infected patients. Ribavirin 133-142 interferon alpha 1 Homo sapiens 67-70 12719586-10 2003 In a second group, ribavirin further up-regulated a set of RSV- and IFN-stimulated response genes (ISGs) encoding antiviral proteins (MxA and p56), complement products, acute-phase response factors, and the STAT and IRF transcription factors. Ribavirin 19-28 interferon alpha 1 Homo sapiens 68-71 12719586-10 2003 In a second group, ribavirin further up-regulated a set of RSV- and IFN-stimulated response genes (ISGs) encoding antiviral proteins (MxA and p56), complement products, acute-phase response factors, and the STAT and IRF transcription factors. Ribavirin 19-28 MX dynamin like GTPase 1 Homo sapiens 134-137 12691700-1 2003 The combined interferon-alpha (IFN-alpha) and ribavirin (IFN-alpha/ribavirin) therapy for chronic hepatitis C virus (HCV) infection results in sustained viral eradication in 31%-64% of the patients. Ribavirin 46-55 interferon alpha 1 Homo sapiens 57-66 12691700-3 2003 The objective of this study was to further define the effect of IFN-alpha/ribavirin therapy on type 1 and type 2 HCV-specific CD4(+) and CD8(+) T-cell responses during IFN-alpha/ribavirin therapy. Ribavirin 74-83 interferon alpha 1 Homo sapiens 168-177 12691700-3 2003 The objective of this study was to further define the effect of IFN-alpha/ribavirin therapy on type 1 and type 2 HCV-specific CD4(+) and CD8(+) T-cell responses during IFN-alpha/ribavirin therapy. Ribavirin 178-187 interferon alpha 1 Homo sapiens 64-73 12691700-7 2003 These results indicate that enhancement of HCV-specific CD4(+) and CD8(+) T-cell responses is an important factor in determining the response to the IFN-alpha/ribavirin therapy and the outcome of the HCV infection. Ribavirin 159-168 interferon alpha 1 Homo sapiens 149-158 12753341-13 2003 In low viraemic patients who relapsed to a previous IFN treatment, combination therapy using high-dose IFN and low-dose ribavirin is better than high-dose IFN alone. Ribavirin 120-129 interferon alpha 1 Homo sapiens 52-55 12719586-11 2003 Because IFN-beta expression itself was reduced in the ribavirin-treated cells, we further investigated the mechanism for up-regulation of the IFN-signaling pathway. Ribavirin 54-63 interferon beta 1 Homo sapiens 8-16 12719586-11 2003 Because IFN-beta expression itself was reduced in the ribavirin-treated cells, we further investigated the mechanism for up-regulation of the IFN-signaling pathway. Ribavirin 54-63 interferon alpha 1 Homo sapiens 8-11 12753337-7 2003 In conclusion, re-treatment of patients not responding to previous IFN monotherapy with a combination of high daily dose of IFN with ribavirin may be beneficial for genotype 1 infected patients. Ribavirin 133-142 interferon alpha 1 Homo sapiens 124-127 12753338-1 2003 Interferon-alpha (IFN) monotherapy results in sustained virological clearance in a minority of patients with chronic hepatitis C. The aim of this study was to assess the effect of a reinforced regimen combining ribavirin and high-dose IFN for 48 weeks compared with a nonreinforced regimen combining a standard IFN regimen and ribavirin for 24 weeks in nonresponders with chronic hepatitis C. A total of 231 patients with chronic hepatitis C and previous nonresponse to IFN monotherapy were randomized. Ribavirin 211-220 interferon alpha 1 Homo sapiens 18-21 12753338-9 2003 Hence in nonresponders, a high-dose 48-week regimen of IFN and ribavirin combination was more effective than a regimen with interferon at lower dose and ribavirin for 24 weeks only. Ribavirin 153-162 interferon alpha 1 Homo sapiens 55-58 12753339-1 2003 Chronic hepatitis C patients with genotype 1 infection, liver cirrhosis, high viral load, or those who have not responded to anti-viral treatment in the past have limited chances of clearing the virus, even with pegylated interferon-ribavirin therapy. Ribavirin 233-242 interferon alpha 1 Homo sapiens 222-232 12719586-13 2003 Ribavirin-enhanced TAP-1-LMP2 expression was a transcriptional event where site mutations of the IFN-stimulated response element (ISRE) blocked RSV and ribavirin-inducible promoter activity. Ribavirin 0-9 transporter 1, ATP binding cassette subfamily B member Homo sapiens 19-24 12696006-0 2003 Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. Ribavirin 77-86 cytotoxic T-lymphocyte associated protein 4 Homo sapiens 15-20 12719586-13 2003 Ribavirin-enhanced TAP-1-LMP2 expression was a transcriptional event where site mutations of the IFN-stimulated response element (ISRE) blocked RSV and ribavirin-inducible promoter activity. Ribavirin 0-9 proteasome 20S subunit beta 9 Homo sapiens 25-29 12719586-13 2003 Ribavirin-enhanced TAP-1-LMP2 expression was a transcriptional event where site mutations of the IFN-stimulated response element (ISRE) blocked RSV and ribavirin-inducible promoter activity. Ribavirin 0-9 interferon alpha 1 Homo sapiens 97-100 12719586-13 2003 Ribavirin-enhanced TAP-1-LMP2 expression was a transcriptional event where site mutations of the IFN-stimulated response element (ISRE) blocked RSV and ribavirin-inducible promoter activity. Ribavirin 152-161 transporter 1, ATP binding cassette subfamily B member Homo sapiens 19-24 12719586-13 2003 Ribavirin-enhanced TAP-1-LMP2 expression was a transcriptional event where site mutations of the IFN-stimulated response element (ISRE) blocked RSV and ribavirin-inducible promoter activity. Ribavirin 152-161 proteasome 20S subunit beta 9 Homo sapiens 25-29 12719586-13 2003 Ribavirin-enhanced TAP-1-LMP2 expression was a transcriptional event where site mutations of the IFN-stimulated response element (ISRE) blocked RSV and ribavirin-inducible promoter activity. Ribavirin 152-161 interferon alpha 1 Homo sapiens 97-100 12719586-16 2003 We conclude that ribavirin potentiates virus-induced ISRE signaling to enhance the expression of antiviral ISGs, suggesting a mechanism for the efficacy of combined treatment with ribavirin and IFN in other chronic viral diseases. Ribavirin 17-26 interferon alpha 1 Homo sapiens 194-197 12749244-8 2003 CONCLUSIONS: In conclusion, interferon-alpha 2b and ribavirin combination therapy could induce earlier loss of hepatitis G virus RNA than interferon-alpha 2b alone. Ribavirin 52-61 interferon alpha 2 Homo sapiens 138-157 12702132-1 2003 OBJECTIVE: The effects on T-lymphocyte populations of two interferon-alfa-2a (IFN) regimens associated with ribavirin were evaluated in 36 HCV-HIV co-infected patients with chronic hepatitis C, T-CD4 cell count > 250 cells/ micro L and a plasma viral load of < 10 000 HIV RNA copies/mL. Ribavirin 108-117 interferon alpha 1 Homo sapiens 78-81 14518716-11 2003 In conclusion, this study shows that HVR-1 heterogeneity may be involved in the early response to combined IFN-RBV therapy. Ribavirin 111-114 vasoactive intestinal peptide receptor 1 Homo sapiens 37-42 12757175-0 2003 Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. Ribavirin 128-137 interferon alpha 2 Homo sapiens 25-44 12614467-1 2003 Retreatment of relapser patients with chronic hepatitis C with the standard dose of interferon (IFN) of 3 million units (MU) thrice weekly (tiw) plus ribavirin for 24 weeks achieves a sustained response in 30 and 73% of patients with genotype 1 and 2 or 3, respectively. Ribavirin 150-159 interferon alpha 1 Homo sapiens 84-94 12669220-6 2003 REGIONAL BLOOD VOLUME: Another parameter of microcirculation is the regional intracapillary myocardial blood volume (RBV) that almost represents the whole intramyocardial blood volume due to its dominating volume fraction. Ribavirin 117-120 CD1b molecule Homo sapiens 9-14 12669220-6 2003 REGIONAL BLOOD VOLUME: Another parameter of microcirculation is the regional intracapillary myocardial blood volume (RBV) that almost represents the whole intramyocardial blood volume due to its dominating volume fraction. Ribavirin 117-120 CD1b molecule Homo sapiens 103-108 12669220-6 2003 REGIONAL BLOOD VOLUME: Another parameter of microcirculation is the regional intracapillary myocardial blood volume (RBV) that almost represents the whole intramyocardial blood volume due to its dominating volume fraction. Ribavirin 117-120 CD1b molecule Homo sapiens 171-176 12669220-33 2003 A linear response range of Delta R1(myo) on Delta R1(blood) was estimated which, in future studies, will allow the determination of RBV with intravascular CA (Figure 2). Ribavirin 132-135 CD1b molecule Homo sapiens 50-59 12614467-1 2003 Retreatment of relapser patients with chronic hepatitis C with the standard dose of interferon (IFN) of 3 million units (MU) thrice weekly (tiw) plus ribavirin for 24 weeks achieves a sustained response in 30 and 73% of patients with genotype 1 and 2 or 3, respectively. Ribavirin 150-159 interferon alpha 1 Homo sapiens 96-99 12606760-0 2003 Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets. Ribavirin 41-50 cytidine/uridine monophosphate kinase 2 Homo sapiens 62-72 12606760-0 2003 Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets. Ribavirin 96-105 cytidine/uridine monophosphate kinase 2 Homo sapiens 62-72 12618532-0 2003 A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. The purpose of this study was to systematically describe the neuropsychiatric side effects of treatment with interferon-alpha-2b (INF-alpha) and ribavirin in patients with chronic hepatitis C as well as to compare different instruments used to measure these side effects. Ribavirin 89-98 interferon alpha 2 Homo sapiens 255-274 12618532-0 2003 A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. The purpose of this study was to systematically describe the neuropsychiatric side effects of treatment with interferon-alpha-2b (INF-alpha) and ribavirin in patients with chronic hepatitis C as well as to compare different instruments used to measure these side effects. Ribavirin 291-300 interferon alpha 2 Homo sapiens 255-274 12656650-2 2003 In treatment-naive patients with chronic hepatitis C, the sustained virological response rate (assessed 24 weeks after the end of a 48-week treatment period) was significantly higher in peginterferon-alpha-2a (40kD) plus ribavirin recipients than in peginterferon-alpha-2a (40kD) plus placebo recipients or interferon-alpha-2b plus ribavirin recipients (56% vs 29% and 44%). Ribavirin 221-230 interferon alpha 2 Homo sapiens 307-326 12713065-0 2003 Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia. Ribavirin 68-77 erythropoietin Homo sapiens 7-21 12713065-2 2003 In a pilot study, the exogenous administration of erythropoietin has been shown to be beneficial, reducing the rate of ribavirin dose reduction. Ribavirin 119-128 erythropoietin Homo sapiens 50-64 12713065-3 2003 How ribavirin administration affects normal erythropoietin production has not been determined. Ribavirin 4-13 erythropoietin Homo sapiens 44-58 12713065-4 2003 AIM: To investigate the endogenous erythropoietin response in hepatitis C patients with ribavirin-induced anaemia. Ribavirin 88-97 erythropoietin Homo sapiens 35-49 12713065-6 2003 Mathematical analysis and modelling were applied to compare the degree of erythropoietin increase in HCV-positive and in otherwise healthy anaemic patients, and estimate the endogenous excess erythropoietin production in response to ribavirin-induced anaemia. Ribavirin 233-242 erythropoietin Homo sapiens 192-206 12713065-7 2003 RESULTS: Erythropoietin concentration increased significantly in response to anaemia caused by ribavirin. Ribavirin 95-104 erythropoietin Homo sapiens 9-23 12713065-8 2003 The physiological erythropoietin response to the ribavirin-induced anaemia was as adequate in HCV-positive subjects as it is in anaemic subjects without liver disease. Ribavirin 49-58 erythropoietin Homo sapiens 18-32 12713065-11 2003 While the rationale for erythropoietin treatment of ribavirin-induced anaemia is not straightforward, the currently recommended dosing regimen should be reassessed. Ribavirin 52-61 erythropoietin Homo sapiens 24-38 12499231-3 2003 The conversion of viramidine to ribavirin, and of ribavirin to an inactive metabolite through adenosine deaminase, is reported. Ribavirin 50-59 adenosine deaminase Homo sapiens 94-113 14582000-6 2003 Epoetin alfa administration to HCV-infected patients with IFN-RBV-related anemia can significantly increase hemoglobin levels and maintain significantly higher RBV doses compared with patients treated with RBV dose reduction alone. Ribavirin 62-65 erythropoietin Homo sapiens 0-7 14582000-6 2003 Epoetin alfa administration to HCV-infected patients with IFN-RBV-related anemia can significantly increase hemoglobin levels and maintain significantly higher RBV doses compared with patients treated with RBV dose reduction alone. Ribavirin 160-163 erythropoietin Homo sapiens 0-7 14582000-6 2003 Epoetin alfa administration to HCV-infected patients with IFN-RBV-related anemia can significantly increase hemoglobin levels and maintain significantly higher RBV doses compared with patients treated with RBV dose reduction alone. Ribavirin 160-163 erythropoietin Homo sapiens 0-7 14582000-8 2003 Maintenance of RBV dose with epoetin alfa may improve adherence, thereby affecting SVR. Ribavirin 15-18 erythropoietin Homo sapiens 29-36 12949432-0 2003 Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism. Ribavirin 60-69 tumor necrosis factor Homo sapiens 108-117 12659664-1 2003 Either ribavirin (RBV) or cyclophosphamide (CY) can shift an immune response from Th2 toward a Th1 cytokine profile. Ribavirin 7-16 negative elongation factor complex member C/D Homo sapiens 95-98 12436477-5 2003 The effect of ribavirin on IFN-gamma and IL-1beta release in the supernatant of unstimulated and phytohemagglutinin (PHA) stimulated PBMCs was investigated by enzyme linked immunosorbent assay (ELISA). Ribavirin 14-23 interferon gamma Homo sapiens 27-36 12436477-5 2003 The effect of ribavirin on IFN-gamma and IL-1beta release in the supernatant of unstimulated and phytohemagglutinin (PHA) stimulated PBMCs was investigated by enzyme linked immunosorbent assay (ELISA). Ribavirin 14-23 interleukin 1 beta Homo sapiens 41-49 12436477-7 2003 Ribavirin led to a dose-dependent decrease of the IFN-gamma but an increase of IL-1beta release into the supernatant of PHA-stimulated PBMCs. Ribavirin 0-9 interferon gamma Homo sapiens 50-59 12436477-7 2003 Ribavirin led to a dose-dependent decrease of the IFN-gamma but an increase of IL-1beta release into the supernatant of PHA-stimulated PBMCs. Ribavirin 0-9 interleukin 1 beta Homo sapiens 79-87 12436477-11 2003 Our data suggest that ribavirin administration to chronically HCV-infected patients could lead to a decrease of the synthesis of proinflammatory cytokines (e.g., IFN-gamma) by an inhibition of total DNA-, RNA-, and protein-synthesis and by induction of apoptosis in the cells of the inflammatory infiltrate. Ribavirin 22-31 interferon gamma Homo sapiens 162-171 12673448-5 2003 CONCLUSIONS: The efficacy of IFNalpha and ribavirin combination therapy for chronic hepatitis C is associated with a vigorous response of peripheral blood Th1 cells, whereas weak CTL responses at the end of the therapy might predict a further relapse of the disease. Ribavirin 42-51 negative elongation factor complex member C/D Homo sapiens 155-158 12723514-4 2003 Ribavirin monotherapy was associated with a significant decrease in AST, ALT and gamma glutamyl transpeptidase levels. Ribavirin 0-9 solute carrier family 17 member 5 Homo sapiens 68-71 12659664-1 2003 Either ribavirin (RBV) or cyclophosphamide (CY) can shift an immune response from Th2 toward a Th1 cytokine profile. Ribavirin 18-21 negative elongation factor complex member C/D Homo sapiens 95-98 12723514-4 2003 Ribavirin monotherapy was associated with a significant decrease in AST, ALT and gamma glutamyl transpeptidase levels. Ribavirin 0-9 inactive glutathione hydrolase 2 Homo sapiens 81-110 12659664-4 2003 RBV is used today mainly to augment interferon-alpha treatment of hepatitis C. RBV shifts an immune response from Th2 toward Th1 more effectively than CY and may be a safe and useful adjuvant for current cancer immunotherapeutic efforts. Ribavirin 0-3 negative elongation factor complex member C/D Homo sapiens 125-128 12659664-4 2003 RBV is used today mainly to augment interferon-alpha treatment of hepatitis C. RBV shifts an immune response from Th2 toward Th1 more effectively than CY and may be a safe and useful adjuvant for current cancer immunotherapeutic efforts. Ribavirin 79-82 negative elongation factor complex member C/D Homo sapiens 125-128 12934167-9 2003 Retreatment of nonresponders to standard IFN monotherapy using PEG-IFN and ribavirin has achieved SVR rates of 34 to 40%. Ribavirin 75-84 interferon alpha 1 Homo sapiens 41-44 12934167-11 2003 A SVR after retreatment of relapsers and nonresponders with PEG-IFN and ribavirin is more likely in patients previously treated with IFN monotherapy, those with HCV genotypes 2 or 3, patients with low viral load (<2 million copies/mL), and individuals who had a significant decrease in HCV RNA levels during the initial treatment. Ribavirin 72-81 interferon alpha 1 Homo sapiens 133-136 12427791-2 2002 METHODS: To assess the effectiveness and tolerability of IFN/ribavirin retreatment of non-responders to IFN and to identify predictors of complete (biochemical and virological) sustained response, we performed a meta-analysis of individual data on 581 patients from 10 centres. Ribavirin 61-70 interferon alpha 1 Homo sapiens 104-107 12471573-5 2002 Induction therapy and the dose of IFN should be evaluated in combination therapy with IFN and ribavirin. Ribavirin 94-103 interferon alpha 1 Homo sapiens 34-37 12643293-0 2002 Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C. BACKGROUND: Interferon a with ribavirin combination therapy is effective but still unsatisfactory in the treatment of patients with interferon-relapsed chronic hepatitis C. AIMS: To compare, in a randomized, double blind, placebo-controlled study, high-dose interferon-alpha2b with or without ribavirin in the treatment for interferon-relapsers. Ribavirin 166-175 interferon alpha 2 Homo sapiens 394-412 12643293-0 2002 Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C. BACKGROUND: Interferon a with ribavirin combination therapy is effective but still unsatisfactory in the treatment of patients with interferon-relapsed chronic hepatitis C. AIMS: To compare, in a randomized, double blind, placebo-controlled study, high-dose interferon-alpha2b with or without ribavirin in the treatment for interferon-relapsers. Ribavirin 166-175 interferon alpha 2 Homo sapiens 394-412 12643293-5 2002 At the end of the follow-up, a higher sustained virological response rate was seen in patients treated with interferon alpha2b/ribavirin than those treated with interferon alpha2b/placebo (69% vs 23%, p < 0.001). Ribavirin 127-136 interferon alpha 2 Homo sapiens 108-126 12210408-10 2002 It is concluded that pretreatment hepatocellular MxA expression may become a useful predictor of response to combination treatment with IFN-alpha and ribavirin. Ribavirin 150-159 MX dynamin like GTPase 1 Homo sapiens 49-52 12642684-1 2002 Either ribavirin, RBV, or cyclophosphamide, CY, can shift an immune response from Th2 towards a Th1 cytokine profile. Ribavirin 7-16 negative elongation factor complex member C/D Homo sapiens 96-99 12642684-1 2002 Either ribavirin, RBV, or cyclophosphamide, CY, can shift an immune response from Th2 towards a Th1 cytokine profile. Ribavirin 18-21 negative elongation factor complex member C/D Homo sapiens 96-99 12642684-4 2002 RBV is used today mainly to augment interferon-alpha treatment of hepatitis C. RBV shifts an immune response from Th2 towards Th1 more effectively than CY and may be a safe and useful adjuvant for current cancer immunotherapeutic efforts. Ribavirin 0-3 negative elongation factor complex member C/D Homo sapiens 126-129 12642684-4 2002 RBV is used today mainly to augment interferon-alpha treatment of hepatitis C. RBV shifts an immune response from Th2 towards Th1 more effectively than CY and may be a safe and useful adjuvant for current cancer immunotherapeutic efforts. Ribavirin 79-82 negative elongation factor complex member C/D Homo sapiens 126-129 12297844-0 2002 A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Ribavirin 64-73 interferon alpha 1 Homo sapiens 144-154 12390318-0 2002 Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo. Ribavirin 0-9 CD40 ligand Homo sapiens 63-68 12390318-0 2002 Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo. Ribavirin 0-9 CD4 molecule Homo sapiens 63-66 12390318-3 2002 In contrast, after stimulation with both HCV core antigen and phorbol myristate acetate (PMA) plus ionomycin (IO), the expression of CD40L on CD4 lymphocytes was significantly higher in the ribavirin group compared with controls. Ribavirin 190-199 CD40 ligand Homo sapiens 133-138 12390318-3 2002 In contrast, after stimulation with both HCV core antigen and phorbol myristate acetate (PMA) plus ionomycin (IO), the expression of CD40L on CD4 lymphocytes was significantly higher in the ribavirin group compared with controls. Ribavirin 190-199 CD4 molecule Homo sapiens 133-136 12390318-4 2002 In the ribavirin group, the increased expression of CD40L significantly correlated with reduction of HCV RNA levels with respect to pretreatment values. Ribavirin 7-16 CD40 ligand Homo sapiens 52-57 12390318-6 2002 In conclusion, these data indicate that ribavirin -upmodulates CD40L expression on CD4 T cells, a property which may account in part for its ability to enhance the antiviral activity of interferon-alpha in the treatment of chronic HCV infection. Ribavirin 40-49 CD40 ligand Homo sapiens 63-68 12390318-6 2002 In conclusion, these data indicate that ribavirin -upmodulates CD40L expression on CD4 T cells, a property which may account in part for its ability to enhance the antiviral activity of interferon-alpha in the treatment of chronic HCV infection. Ribavirin 40-49 CD4 molecule Homo sapiens 63-66 12410649-6 2002 Our study shows that IFN and ribavirin combination therapy is effective in HIV-negative chronically HCV-infected haemophiliacs who do not respond to a previous IFN treatment. Ribavirin 29-38 interferon alpha 1 Homo sapiens 160-163 12352634-12 2002 In our series, there is limited experience with IFN-ribavirin therapy, which was not well tolerated. Ribavirin 52-61 interferon alpha 1 Homo sapiens 48-51 12353832-0 2002 Retreatment of high-dose interferon (5 MU daily) nonresponders with high-dose IFN + ribavirin. Ribavirin 84-93 interferon alpha 1 Homo sapiens 25-35 12352634-16 2002 Experience with IFN-ribavirin in this entity is limited, but has shown promise in hepatic disease and has shown efficacy in HCV-associated cryoglobulinemia. Ribavirin 20-29 interferon alpha 1 Homo sapiens 16-19 12127430-1 2002 BACKGROUND/AIMS: Interferon (IFN) with ribavirin combination therapy (CT) was proposed for the treatment of hepatitis C recurring in liver transplants. Ribavirin 39-48 interferon alpha 1 Homo sapiens 29-32 12199910-7 2002 CONCLUSION: Although our results demonstrated a very poor outcome and a bad tolerance to interferon monotherapy, this approach should not be dropped out, mainly in patients at high risk for side effects and in those with cirrhosis who do not tolerate or are at increased risk for the use of ribavirin. Ribavirin 291-300 interferon alpha 1 Homo sapiens 89-99 12182756-0 2002 Non-transferrin-bound iron in untreated and ribavirin-treated chronic hepatitis C patients. Ribavirin 44-53 transferrin Homo sapiens 4-15 12172411-5 2002 ACE levels reverted to normal and the skin lesions resolved a few months after cessation of interferon/ribavirin therapy. Ribavirin 103-112 angiotensin I converting enzyme Homo sapiens 0-3 12172411-7 2002 In conclusion, interferon/ribavirin therapy can evoke a sarcoid-like response, with skin lesions, hepatic granuloma, and elevation of ACE levels. Ribavirin 26-35 angiotensin I converting enzyme Homo sapiens 134-137 12084032-17 2002 CONCLUSION: : Daily administration of IFN with ribavirin is well tolerated in the majority of patients. Ribavirin 47-56 interferon alpha 1 Homo sapiens 38-41 12052714-2 2002 Interferon alpha-2b (Intron A) combination therapy with ribavirin is the current standard of care for the treatment of chronic hepatitis C virus infection. Ribavirin 56-65 interferon alpha 2 Homo sapiens 0-19 12087352-1 2002 OBJECTIVES: The objectives are to determine whether IFN-alpha and ribavirin can alter pretreatment CYP1A2, CYP2D6, CYP3A4 and N-acetyltransferase-2 activities after 1 month of treatment. Ribavirin 66-75 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 99-105 12087352-1 2002 OBJECTIVES: The objectives are to determine whether IFN-alpha and ribavirin can alter pretreatment CYP1A2, CYP2D6, CYP3A4 and N-acetyltransferase-2 activities after 1 month of treatment. Ribavirin 66-75 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 107-113 12087352-1 2002 OBJECTIVES: The objectives are to determine whether IFN-alpha and ribavirin can alter pretreatment CYP1A2, CYP2D6, CYP3A4 and N-acetyltransferase-2 activities after 1 month of treatment. Ribavirin 66-75 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 115-121 12087352-1 2002 OBJECTIVES: The objectives are to determine whether IFN-alpha and ribavirin can alter pretreatment CYP1A2, CYP2D6, CYP3A4 and N-acetyltransferase-2 activities after 1 month of treatment. Ribavirin 66-75 N-acetyltransferase 2 Homo sapiens 126-147 12145664-4 2002 RESULTS: Using standard therapy in the presence and absence of ribavirin, the sustained responders had lower baseline tumor necrosis alpha (TNF-alpha) levels as compared to relapsed responders and non-responders. Ribavirin 63-72 tumor necrosis factor Homo sapiens 140-149 12145664-6 2002 In pegylated combination therapy with high dose ribavirin, lower levels of TNF-alpha, transforming growth factor beta (TGF-beta) and fibrosis scores were seen when comparing baseline with follow up. Ribavirin 48-57 tumor necrosis factor Homo sapiens 75-84 12145664-6 2002 In pegylated combination therapy with high dose ribavirin, lower levels of TNF-alpha, transforming growth factor beta (TGF-beta) and fibrosis scores were seen when comparing baseline with follow up. Ribavirin 48-57 transforming growth factor beta 1 Homo sapiens 86-117 12145664-6 2002 In pegylated combination therapy with high dose ribavirin, lower levels of TNF-alpha, transforming growth factor beta (TGF-beta) and fibrosis scores were seen when comparing baseline with follow up. Ribavirin 48-57 transforming growth factor beta 1 Homo sapiens 119-127 12001034-3 2002 With combination interferon (IFN)-alpha 2b/ribavirin or pegylated IFN-alpha 2b/ribavirin therapy, long-term remission is possible for HCV-infected patients. Ribavirin 79-88 interferon alpha 1 Homo sapiens 66-75 12001034-7 2002 Ribavirin-associated hemolytic anemia is a potential problem in a patient population that is already susceptible to anemia but is manageable with recombinant human erythropoietin (epoetin alfa). Ribavirin 0-9 erythropoietin Homo sapiens 164-178 12001034-7 2002 Ribavirin-associated hemolytic anemia is a potential problem in a patient population that is already susceptible to anemia but is manageable with recombinant human erythropoietin (epoetin alfa). Ribavirin 0-9 erythropoietin Homo sapiens 180-187 11870386-2 2002 All treatments known so far rely on the antiviral activity of interferon alfa (IFN-alpha) that is given alone or in combination with ribavirin. Ribavirin 133-142 interferon alpha 1 Homo sapiens 79-88 11966438-11 2002 Several other IMPDH inhibitors (TR, mycophenolic acid, and ribavirin) exhibit similar PARP inhibitory activity. Ribavirin 59-68 poly(ADP-ribose) polymerase 1 Homo sapiens 86-90 11843062-6 2002 RESULTS: The sustained virological response rates (26 weeks after end of treatment) were 54% and 47% for patients receiving IFN induction/ribavirin and standard IFN/ribavirin, respectively (P = 0.35). Ribavirin 138-147 interferon alpha 1 Homo sapiens 124-127 11903249-10 2002 In addition to its antiviral action, ribavirin also enhances the Th1 response. Ribavirin 37-46 negative elongation factor complex member C/D Homo sapiens 65-68 11903249-11 2002 Indeed, the superiority of the combination of interferon alfa and ribavirin in terms of antiviral action is corroborated by the enhancement of a Th1-type immune reaction by this combination. Ribavirin 66-75 negative elongation factor complex member C/D Homo sapiens 145-148 11952719-2 2002 Subsequently, a combination of IFN-alpha plus ribavirin showed a greater efficacy: up to 40% success with 3 MU of IFN-alpha three times weekly and 1000-1200 mg of ribavirin daily in naive patients and in those who had relapsed after a course of IFN-alpha therapy. Ribavirin 46-55 interferon alpha 1 Homo sapiens 114-123 11952719-2 2002 Subsequently, a combination of IFN-alpha plus ribavirin showed a greater efficacy: up to 40% success with 3 MU of IFN-alpha three times weekly and 1000-1200 mg of ribavirin daily in naive patients and in those who had relapsed after a course of IFN-alpha therapy. Ribavirin 46-55 interferon alpha 1 Homo sapiens 114-123 11952719-2 2002 Subsequently, a combination of IFN-alpha plus ribavirin showed a greater efficacy: up to 40% success with 3 MU of IFN-alpha three times weekly and 1000-1200 mg of ribavirin daily in naive patients and in those who had relapsed after a course of IFN-alpha therapy. Ribavirin 163-172 interferon alpha 1 Homo sapiens 31-40 11830340-0 2002 Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. Ribavirin 169-178 interleukin 10 Homo sapiens 21-35 11843062-8 2002 In patients infected with genotype 2b/3a IFN induction/ribavirin led to a sustained response rate of 80% as compared to 65% in the standard combination therapy group (P = 0.073). Ribavirin 55-64 interferon alpha 1 Homo sapiens 41-44 11945143-1 2002 Approximately 60% of all patients with chronic hepatitis C (C-HCV) treated with standard interferon (IFN) treatment, i.e. combination of recombinant alpha IFN and ribavirin (RBV), are refractory to treatment. Ribavirin 163-172 interferon alpha 1 Homo sapiens 101-104 11803170-9 2002 Lastly, triple therapy with IFN, ribavirin and amantadine has been studied in small clinical trials in nonresponders to IFN monotherapy, with controversial results since in some studies sustained response was up to 48% being less than 20% in other studies. Ribavirin 33-42 interferon alpha 1 Homo sapiens 120-123 11945143-1 2002 Approximately 60% of all patients with chronic hepatitis C (C-HCV) treated with standard interferon (IFN) treatment, i.e. combination of recombinant alpha IFN and ribavirin (RBV), are refractory to treatment. Ribavirin 174-177 interferon alpha 1 Homo sapiens 101-104 11937769-10 2002 Pharmacokinetic analysis of ribavirin provides information on its mechanism of action and for developing more rational treatment for IFN-resistant HCV. Ribavirin 28-37 interferon alpha 1 Homo sapiens 133-136 11827565-7 2002 CONCLUSIONS: Interferon-alpha-2b plus ribavirin is an efficacious first- and second-line therapy in adult patients with compensated chronic hepatitis C, significantly improving sustained virological and biochemical responses versus interferon-alpha-2b monotherapy. Ribavirin 38-47 interferon alpha 2 Homo sapiens 232-251 11602568-2 2001 Recently, we demonstrated that the antiviral activity of ribavirin can result from the ability of a viral RNA polymerase to utilize ribavirin triphosphate and to incorporate this nucleotide with reduced specificity, thereby mutagenizing the genome and decreasing the yield of infectious virus (Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y., Hong, Z., Andino, R., and Cameron, C. E. (2000) Nat. Ribavirin 57-66 bromodomain containing 2 Homo sapiens 402-405 11851906-1 2002 We report two patients with chronic hepatitis C, both nonresponders to a previous course of interferon (IFN), who developed or suffered an exacerbation of sarcoidosis while under treatment with IFN-alpha2a, ribavirin and amantadine. Ribavirin 207-216 interferon alpha 1 Homo sapiens 104-107 15553066-1 2002 There is a overview of actual regimens proposed for treatment of acute and chronic hepatitis C. The new formulations of interferon alpha obtained by pegylation--PEG-IFN-s have resulted in improved efficacy as monotherapy and in combination with ribavirin. Ribavirin 245-254 interferon alpha 1 Homo sapiens 165-168 11702012-0 2001 Ribavirin enhances interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha. Ribavirin 0-9 interferon gamma Homo sapiens 19-35 11794896-6 2001 A second patient with IFN alpha and ribavirin for 4 months because of chronic hepatitis C (after the failure of a first treatment with IFN alpha alone) was hospitalized for fever, arthralgias, erythema nodosa and modification of previous skin scars. Ribavirin 36-45 interferon alpha 1 Homo sapiens 135-144 11678522-4 2001 Combination therapy with IFN-alpha and ribavirin has been found to be more efficacious than IFN-alpha alone. Ribavirin 39-48 interferon alpha 1 Homo sapiens 92-101 11471097-1 2001 This study assessed the use of ribavirin monotherapy to enhance sustained virologic response in hepatitis C virus (HCV)-infected patients who achieved virologic response to interferon (IFN)-ribavirin combination therapy. Ribavirin 31-40 interferon alpha 1 Homo sapiens 185-188 11680575-10 2001 In conclusion, in previous nonresponders or relapsers to interferon done, combination therapy with interferon-alpha2b (3 MU thrice weekly) + 600 mg ribavirin/day is tolerated better and is as effective as interferon plus higher (standard) doses of ribavirin (1,000-1,200 mg/day). Ribavirin 248-257 interferon alpha 2 Homo sapiens 99-117 11569724-0 2001 A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. Ribavirin 65-74 erythropoietin Homo sapiens 23-37 12825459-1 2001 Ribavirin, a nucleoside analog, used in combination with interferon-alpha (IFN alpha) results in a substantial improvement in the sustained virologic response in chronic hepatitis C. Identified antiviral mechanisms of action for ribavirin include: (i) inhibition of viral encoded polymerases; (ii) inhibition of genomic RNA capping; and (iii) inhibition of cellular encoded enzymes that control de novo synthesis of purine nucleosides. Ribavirin 0-9 interferon alpha 1 Homo sapiens 75-84 12825459-1 2001 Ribavirin, a nucleoside analog, used in combination with interferon-alpha (IFN alpha) results in a substantial improvement in the sustained virologic response in chronic hepatitis C. Identified antiviral mechanisms of action for ribavirin include: (i) inhibition of viral encoded polymerases; (ii) inhibition of genomic RNA capping; and (iii) inhibition of cellular encoded enzymes that control de novo synthesis of purine nucleosides. Ribavirin 229-238 interferon alpha 1 Homo sapiens 75-84 12825459-2 2001 More recently, ribavirin has been shown to engender a bias toward helper T-cell (CD4+) type 1 (Th1) cytokine responses in models of immunity. Ribavirin 15-24 negative elongation factor complex member C/D Homo sapiens 95-98 11759109-4 2001 RESULTS: A decrease in ICAM-1 levels at 3 and 6 months of therapy, compared with pretreatment levels, was observed in responders to IFN + ribavirin therapy but this decrease in ICAM-1 levels was not evident following cessation of treatment. Ribavirin 138-147 intercellular adhesion molecule 1 Homo sapiens 23-29 11759109-8 2001 A decrease in ICAM-1 levels during IFN + ribavirin treatment is associated with response to therapy, and its efficacy in predicting long-term response should be further substantiated. Ribavirin 41-50 intercellular adhesion molecule 1 Homo sapiens 14-20 11471097-2 2001 Patients who had chronic HCV infection and prior relapse were retreated with IFN-ribavirin for 6 months. Ribavirin 81-90 interferon alpha 1 Homo sapiens 77-80 11431744-1 2001 To determine whether a higher dosage of interferon (IFN) associated with ribavirin and/or prolonged time of administration may improve therapeutic efficacy, we conducted a 4-arm randomized trial on patients with chronic hepatitis C not responding to one or more previous treatment courses with IFN monotherapy. Ribavirin 73-82 interferon alpha 1 Homo sapiens 40-50 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 276-285 interferon alpha 1 Homo sapiens 189-215 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 276-285 interferon alpha 1 Homo sapiens 211-214 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 287-295 interferon alpha 1 Homo sapiens 189-215 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 287-295 interferon alpha 1 Homo sapiens 211-214 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 372-381 interferon alpha 1 Homo sapiens 189-215 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 372-381 interferon alpha 1 Homo sapiens 211-214 11431744-1 2001 To determine whether a higher dosage of interferon (IFN) associated with ribavirin and/or prolonged time of administration may improve therapeutic efficacy, we conducted a 4-arm randomized trial on patients with chronic hepatitis C not responding to one or more previous treatment courses with IFN monotherapy. Ribavirin 73-82 interferon alpha 1 Homo sapiens 52-55 11494545-1 2001 Ribavirin is a purine nucleoside analog that inhibits the replication of a wide range of DNA and RNA viruses, although ribavirin treatment dose not significantly decrease serum virus load in patients with chronic hepatitis C. Several lines of evidence from the randomized large-scale studies of USA and Europe indicate that combination therapy with ribavirin significantly enhances the sustained response rate of IFN therapy in major patient types with chronic hepatitis C. A recent trial in Japan also proved that the combination therapy is superior to IFN monotherapy. Ribavirin 0-9 interferon alpha 1 Homo sapiens 413-416 11494545-1 2001 Ribavirin is a purine nucleoside analog that inhibits the replication of a wide range of DNA and RNA viruses, although ribavirin treatment dose not significantly decrease serum virus load in patients with chronic hepatitis C. Several lines of evidence from the randomized large-scale studies of USA and Europe indicate that combination therapy with ribavirin significantly enhances the sustained response rate of IFN therapy in major patient types with chronic hepatitis C. A recent trial in Japan also proved that the combination therapy is superior to IFN monotherapy. Ribavirin 0-9 interferon alpha 1 Homo sapiens 554-557 11494545-2 2001 Thus, IFN-ribavirin combination is likely to become the antiviral therapy of choice for chronic hepatitis C. Ribavirin 10-19 interferon alpha 1 Homo sapiens 6-9 11434597-11 2001 CONCLUSIONS: A combination of high-dose IFN with ribavirin induces a short-lasting complete response in about one-third of IFN-non-responders. Ribavirin 49-58 interferon alpha 1 Homo sapiens 123-126 11391542-1 2001 Regulation of CD81 expression by interferon alfa (IFN-alpha) and ribavirin could thereby affect the response to antiviral therapy. Ribavirin 65-74 CD81 molecule Homo sapiens 14-18 11391542-2 2001 In the present study, the effects of IFN-alpha and ribavirin on CD81 protein and CD81 mRNA were assessed in peripheral blood lymphocytes (PBL) and isolated human hepatocytes by fluorescence-activated cell sorter (FACS) analysis and real-time polymerase chain reaction (PCR), respectively. Ribavirin 51-60 CD81 molecule Homo sapiens 64-68 11391542-5 2001 Incubation with IFN-alpha with and without ribavirin (2.2 microg/mL) significantly reduced cell surface-associated CD81 protein (83.9 +/- 10.3% of control; P =.003). Ribavirin 43-52 interferon alpha 1 Homo sapiens 16-25 11391542-5 2001 Incubation with IFN-alpha with and without ribavirin (2.2 microg/mL) significantly reduced cell surface-associated CD81 protein (83.9 +/- 10.3% of control; P =.003). Ribavirin 43-52 CD81 molecule Homo sapiens 115-119 11391542-9 2001 In conclusion, IFN-alpha and ribavirin regulate CD81 expression in vitro and in vivo. Ribavirin 29-38 CD81 molecule Homo sapiens 48-52 11482039-0 2001 Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon. Ribavirin 38-47 interferon alpha 1 Homo sapiens 99-109 11298134-0 2001 Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C. Recent studies in vitro and in animals have suggested that ribavirin may potentiate the antihepatitis C virus (HCV) activity of interferon-alpha (IFN-alpha) by up-modulating the production of T cell-derived cytokines, such as interleukin (IL)-2 and IFN-gamma, which play a key role in the cellular immune response against HCV. Ribavirin 15-24 interferon gamma Homo sapiens 54-70 11336170-3 2001 The aim of this study was to investigate the different leptin components in serum of patients with hepatitis C before, during and after interferon alpha and ribavirin therapy and in controls. Ribavirin 157-166 leptin Homo sapiens 55-61 11396525-0 2001 A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. BACKGROUND: Combination of interferon (IFN) alpha and ribavirin is considered the standard treatment for patients with chronic hepatitis C. While combination therapy is more effective than IFN alone, the optimal management of combination treatment remains uncertain. Ribavirin 92-101 interferon alpha 1 Homo sapiens 171-193 11396525-0 2001 A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. BACKGROUND: Combination of interferon (IFN) alpha and ribavirin is considered the standard treatment for patients with chronic hepatitis C. While combination therapy is more effective than IFN alone, the optimal management of combination treatment remains uncertain. Ribavirin 92-101 interferon alpha 1 Homo sapiens 183-186 11298134-0 2001 Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C. Recent studies in vitro and in animals have suggested that ribavirin may potentiate the antihepatitis C virus (HCV) activity of interferon-alpha (IFN-alpha) by up-modulating the production of T cell-derived cytokines, such as interleukin (IL)-2 and IFN-gamma, which play a key role in the cellular immune response against HCV. Ribavirin 15-24 interferon alpha 1 Homo sapiens 266-275 11298134-0 2001 Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C. Recent studies in vitro and in animals have suggested that ribavirin may potentiate the antihepatitis C virus (HCV) activity of interferon-alpha (IFN-alpha) by up-modulating the production of T cell-derived cytokines, such as interleukin (IL)-2 and IFN-gamma, which play a key role in the cellular immune response against HCV. Ribavirin 15-24 interferon gamma Homo sapiens 369-378 11298134-0 2001 Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C. Recent studies in vitro and in animals have suggested that ribavirin may potentiate the antihepatitis C virus (HCV) activity of interferon-alpha (IFN-alpha) by up-modulating the production of T cell-derived cytokines, such as interleukin (IL)-2 and IFN-gamma, which play a key role in the cellular immune response against HCV. Ribavirin 179-188 interferon gamma Homo sapiens 54-70 11298134-0 2001 Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C. Recent studies in vitro and in animals have suggested that ribavirin may potentiate the antihepatitis C virus (HCV) activity of interferon-alpha (IFN-alpha) by up-modulating the production of T cell-derived cytokines, such as interleukin (IL)-2 and IFN-gamma, which play a key role in the cellular immune response against HCV. Ribavirin 179-188 interferon alpha 1 Homo sapiens 266-275 11298134-0 2001 Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C. Recent studies in vitro and in animals have suggested that ribavirin may potentiate the antihepatitis C virus (HCV) activity of interferon-alpha (IFN-alpha) by up-modulating the production of T cell-derived cytokines, such as interleukin (IL)-2 and IFN-gamma, which play a key role in the cellular immune response against HCV. Ribavirin 179-188 interferon gamma Homo sapiens 369-378 11298134-2 2001 After 16 weeks of treatment, both the expression of IFN-gamma by activated T cells and the blood levels of IFN-gamma, were significantly reduced with respect to pretreatment values in patients treated with ribavirin and IFN-alpha but not in those undergoing treatment with IFN-alpha alone. Ribavirin 206-215 interferon gamma Homo sapiens 52-61 11298134-2 2001 After 16 weeks of treatment, both the expression of IFN-gamma by activated T cells and the blood levels of IFN-gamma, were significantly reduced with respect to pretreatment values in patients treated with ribavirin and IFN-alpha but not in those undergoing treatment with IFN-alpha alone. Ribavirin 206-215 interferon gamma Homo sapiens 107-116 11298134-2 2001 After 16 weeks of treatment, both the expression of IFN-gamma by activated T cells and the blood levels of IFN-gamma, were significantly reduced with respect to pretreatment values in patients treated with ribavirin and IFN-alpha but not in those undergoing treatment with IFN-alpha alone. Ribavirin 206-215 interferon alpha 1 Homo sapiens 273-282 11298134-6 2001 In addition, our findings suggest that ribavirin may exert an anti-inflammatory effect and may help reducing IFN-gamma-driven T cell activation and liver damage. Ribavirin 39-48 interferon gamma Homo sapiens 109-118 11230751-10 2001 This study suggests that the combination of IFN and ribavirin is a useful modality of therapy in patients with chronic hepatitis C who did not respond to IFN alone. Ribavirin 52-61 interferon alpha 1 Homo sapiens 154-157 11322207-1 2001 BACKGROUND: In chronic hepatitis C the schedule of interferon (IFN), 3 MU thrice weekly (tiw) plus ribavirin (1000-1200 mg/daily) needs further evaluation, as IFN dosages >3 MU achieve better responses. Ribavirin 99-108 interferon alpha 1 Homo sapiens 159-162 11322207-6 2001 Using logistic regression analysis, IFN-ribavirin was the strongest predictor of response (X2 = 21.3; P = 0.0001). Ribavirin 40-49 interferon alpha 1 Homo sapiens 36-39 11151933-0 2000 Early decrease of interferon-gamma+ and interleukin-2+ T cells during combination treatment with interferon-alpha and ribavirin in patients with chronic hepatitis C. Ribavirin 118-127 interferon gamma Homo sapiens 18-53 11233844-5 2001 Four of these were HCV RNA-negative at week 4 of IFN-RBV therapy and two of them had a transient early virological response (RNA-negative at weeks 4-8) to IFN alone. Ribavirin 53-56 interferon alpha 1 Homo sapiens 49-52 11233844-7 2001 Thus, addition of RBV to IFN increased both viral clearance during the first 12 weeks of therapy and the rate of sustained response. Ribavirin 18-21 interferon alpha 1 Homo sapiens 25-28 11112228-10 2000 Interferon and ribavirin in combination are likely to become the therapy of choice, particularly in coinfected patients with higher CD4 counts, lower HCV viremia, and non-1 genotype. Ribavirin 15-24 CD4 molecule Homo sapiens 132-135 11244158-4 2001 The aim of this study is to review our experience in the treatment of moderate to severe HCV recurrence with combination interferon-alpha2b and ribavirin (IFN/RIB). Ribavirin 144-153 interferon alpha 1 Homo sapiens 155-162 11253505-0 2001 Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Ribavirin plus interferon-alpha (IFN alpha) combination has led to a marked advance in the treatment of IFN alpha-naive or relapser patients with chronic hepatitis C but was shown to be only marginally effective in IFN alpha-nonresponders. Ribavirin 80-89 interferon alpha 1 Homo sapiens 191-200 11253505-0 2001 Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Ribavirin plus interferon-alpha (IFN alpha) combination has led to a marked advance in the treatment of IFN alpha-naive or relapser patients with chronic hepatitis C but was shown to be only marginally effective in IFN alpha-nonresponders. Ribavirin 158-167 interferon alpha 1 Homo sapiens 262-271 11253505-0 2001 Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Ribavirin plus interferon-alpha (IFN alpha) combination has led to a marked advance in the treatment of IFN alpha-naive or relapser patients with chronic hepatitis C but was shown to be only marginally effective in IFN alpha-nonresponders. Ribavirin 158-167 interferon alpha 1 Homo sapiens 262-271 11130893-1 2001 Interferon (IFN) therapy (+/- ribavirin) is the only currently available treatment for chronic hepatitis C virus (HCV), but is not effective for a majority of patients. Ribavirin 30-39 interferon alpha 1 Homo sapiens 12-15 11015548-3 2000 Combining IFN-alpha and ribavirin (RBV) has been shown to significantly improve the response in adult patients with chronic hepatitis C. The aim of this pilot study was to evaluate the efficacy and safety of a combined virostatic treatment with IFN-alpha and RBV in a small cohort of children and adolescents with chronic hepatitis C and previous malignancy. Ribavirin 35-38 interferon alpha 1 Homo sapiens 245-254 11169057-7 2000 CONCLUSIONS: The results of this pilot study indicate that interferon beta-la administered subcutaneously is an effective therapy for some patients with chronic hepatitis C, and suggest that interferon beta-1a deserves further evaluations in larger trials especially in combination with ribavirin. Ribavirin 287-296 interferon beta 1 Homo sapiens 59-74 11132533-1 2000 Combination therapy with interferon-alpha (IFN alpha) plus Ribavirin has been shown to improve the response rate in patients with chronic hepatitis C as compared to IFN alpha alone. Ribavirin 59-68 interferon alpha 1 Homo sapiens 165-174 11015548-3 2000 Combining IFN-alpha and ribavirin (RBV) has been shown to significantly improve the response in adult patients with chronic hepatitis C. The aim of this pilot study was to evaluate the efficacy and safety of a combined virostatic treatment with IFN-alpha and RBV in a small cohort of children and adolescents with chronic hepatitis C and previous malignancy. Ribavirin 24-33 interferon alpha 1 Homo sapiens 245-254 11099064-13 2000 CONCLUSION: Our data suggest that serum level(s) of IL-6 and/or C5b-9 taken prior to the initiation of IFN treatment may serve as surrogate marker(s) in evaluating patients with chronic hepatitis C whether to get IFN alpha in monotherapy or to consider having combination therapy in the form of IFN alpha-ribavirin. Ribavirin 305-314 interleukin 6 Homo sapiens 52-56 10980262-0 2000 Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G(1). Ribavirin 0-9 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 66-71 11008222-4 2000 The results showed that the patients who received ribavirin showed a higher reduction in serum alanine aminotransferase (ALT) activity than patients in the placebo group. Ribavirin 50-59 glutamic--pyruvic transaminase Homo sapiens 95-119 11357999-4 2000 Both the replication of DV and the production of IL-6 and IL-8 by HUVEC after DV infection were inhibited by ribavirin, an antiviral synthetic guanosine analogue. Ribavirin 109-118 interleukin 6 Homo sapiens 49-53 11357999-4 2000 Both the replication of DV and the production of IL-6 and IL-8 by HUVEC after DV infection were inhibited by ribavirin, an antiviral synthetic guanosine analogue. Ribavirin 109-118 C-X-C motif chemokine ligand 8 Homo sapiens 58-62 11030438-3 2000 Numerous in vitro experiments demonstrate that ribavirin has a selective down-regulatory effect on TH2 cytokine release with, in some cases, a concomitant TH1 cytokine up-regulation. Ribavirin 47-56 negative elongation factor complex member C/D Homo sapiens 155-158 10846070-4 2000 After ribavirin treatment of H25 transgenic mice, the appearance of neutralization-resistant virus was prevented and virus was cleared. Ribavirin 6-15 histocompatibility 25 Mus musculus 29-32 16498353-4 2000 Important recent therapeutic progress that surpasses and advances the results obtained with single IFN therapy is the combination of IFN with ribavirin, with which overall rates of response have increased three times compared to IFN monotherapy. Ribavirin 142-151 interferon alpha 1 Homo sapiens 99-102 18034536-12 2000 CONCLUSIONS: These results suggest that patients with chronic hepatitis C unresponsive to IFNalpha monotherapy could benefit from combination therapy with IFNalpha + ribavirin. Ribavirin 166-175 interferon alpha 1 Homo sapiens 90-98 10839592-12 2000 CONCLUSION: Our results indicate that combination therapy with IFN and ribavirin is effective in 50% of cases in clearing serum HCV RNA and may thus provide effective means of therapy in HIV-HCV-coinfected patients as initial treatment or in patients who have previously failed IFN monotherapy. Ribavirin 71-80 interferon alpha 1 Homo sapiens 278-281 10921396-4 2000 For patients who cannot tolerate the side effects of ribavirin, such as anaemia, IFN-alpha at 3 MU three times weekly for 48 weeks is preferred as the initial therapy. Ribavirin 53-62 interferon alpha 1 Homo sapiens 81-90 10921400-1 2000 The preferred treatment for patients with chronic hepatitis C, either treatment-naive, relapsers or nonresponders to IFN monotherapy, is now IFN-ribavirin combination treatment. Ribavirin 145-154 interferon alpha 1 Homo sapiens 141-144 10722482-10 2000 Both VX-497 and ribavirin demonstrated additivity when coapplied with IFN-alpha, with VX-497 again being the more potent in this combination. Ribavirin 16-25 interferon alpha 1 Homo sapiens 70-79 10733558-9 2000 RBV-treated patients showed an increase in aggregated band 3, which was associated with a significantly increased binding of autologous antibodies and complement C3 fragments indicating an erithrophagocytic removal by reticuloendothelial system. Ribavirin 0-3 complement C3 Homo sapiens 151-164 10733558-1 2000 The antiviral drug ribavirin (RBV) is widely used in combination with interferon (IFN) in the treatment of chronic hepatitis C virus (HCV) infection. Ribavirin 19-28 interferon alpha 1 Homo sapiens 82-85 10648463-4 2000 The main difference in T-cell reactivity of patients treated with IFN plus ribavirin was a significantly lower production of IL-10, whereas lymphocyte proliferation was similar to that in patients receiving IFN monotherapy. Ribavirin 75-84 interleukin 10 Homo sapiens 125-130 10852385-4 2000 In the latter group of patients an association was found between a reduction in the beta2-mu-free HLA class I heavy chain serum level and response to therapy with interferon alpha and ribavirin. Ribavirin 184-193 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 84-89 10648463-6 2000 The greater efficacy of combination therapy with IFN-alpha plus ribavirin may be related to its ability to suppress HCV-specific IL-10 production. Ribavirin 64-73 interleukin 10 Homo sapiens 129-134 10613748-2 2000 UNLABELLED: Randomized trials have shown the enhancement of efficacy with interferon alfa-2b and ribavirin (IFN-R) in comparison with interferon monotherapy (IFN) as first line treatment of chronic hepatitis C. Further definition of response based on disease, patient, and treatment characteristics is needed to determine the degree of benefit for the various patient subgroups. Ribavirin 97-106 interferon alpha 1 Homo sapiens 108-111 10961691-1 2000 To enhance the inhibitory potential of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) vs hepatitis C virus (HCV) NTPase/helicase, ribavirin-5"-triphosphate (ribavirin-TP) was synthesized and investigated. Ribavirin 39-90 helicase for meiosis 1 Homo sapiens 137-145 10635046-26 2000 Patients intolerant to ribavirin should be considered for continuation of INF to complete a 12-month course, dependent upon the assessment of HCV PCR status at week 12 of therapy. Ribavirin 23-32 cobalamin binding intrinsic factor Homo sapiens 74-77 10581390-9 1999 The result of restoration was also confirmed by IFN-induced STAT-1 induction in persistently infected cells treated with ribavirin. Ribavirin 121-130 signal transducer and activator of transcription 1 Homo sapiens 60-66 10581390-8 1999 Furthermore, suppression of IFN-induced 2-5AS induction and MHC class-I expression was restored by treatment of persistently infected cells with ribavirin through inhibition of virus replication. Ribavirin 145-154 interferon alpha 1 Homo sapiens 28-31 11093071-7 2000 Under prophylactic treatment with low-dose trimipramine (50 mg) or nefazodone (200 mg/day) therapy with IFN-alpha 3 x 3 mio IE/week was re-established after several months and again 2 years later adding ribavirin 1200 mg/day, a virustaticum. Ribavirin 203-212 interferon alpha 1 Homo sapiens 104-113 10490966-0 1999 Contact hypersensitivity responses following ribavirin treatment in vivo are influenced by type 1 cytokine polarization, regulation of IL-10 expression, and costimulatory signaling. Ribavirin 45-54 interleukin 10 Mus musculus 135-140 10616260-3 1999 This report documents the preliminary findings of an investigative protocol to evaluate the efficacy of long-term (12 month), daily IFN alpha 2b and ribavirin combination therapy for chronic hepatitis C patients, who have either relapsed (relapsers) or not responded (non-responders) to previous IFN therapy. Ribavirin 149-158 interferon alpha 1 Homo sapiens 296-299 10616260-9 1999 CONCLUSION: Although further studies on larger patient populations are necessary, our preliminary data suggests that daily IFN alpha 2b and ribavirin treatment is highly effective, especially among patients who have relapsed from previous IFN treatment. Ribavirin 140-149 interferon alpha 1 Homo sapiens 123-126 10616260-9 1999 CONCLUSION: Although further studies on larger patient populations are necessary, our preliminary data suggests that daily IFN alpha 2b and ribavirin treatment is highly effective, especially among patients who have relapsed from previous IFN treatment. Ribavirin 140-149 interferon alpha 1 Homo sapiens 239-242 11291251-12 1999 Also, the effect of ribavirin on IFN-mediated changes in HCV RNA levels needs to be investigated in carefully performed kinetics studies to better determine its mechanism of action. Ribavirin 20-29 interferon alpha 1 Homo sapiens 33-36 10490966-9 1999 Altogether, these data showed that, although ribavirin treatment induced a type 1 cytokine bias in contact allergen-primed BALB/c and C57BL/6 mice, in vivo CHS responses were dependent on ribavirin-mediated regulation of both IL-10 and preferential costimulatory signaling. Ribavirin 45-54 interleukin 10 Mus musculus 226-231 10581390-9 1999 The result of restoration was also confirmed by IFN-induced STAT-1 induction in persistently infected cells treated with ribavirin. Ribavirin 121-130 interferon alpha 1 Homo sapiens 48-51 10490966-5 1999 Ribavirin-mediated suppression of IL-10 in BALB/c mice was associated with increased B7-2 expression and enhanced CHS responses, whereas enhanced IL-10 levels, following ribavirin administration, led to increased B7-1 expression and impaired CHS responses in C57BL/6 mice. Ribavirin 0-9 interleukin 10 Mus musculus 34-39 10490966-5 1999 Ribavirin-mediated suppression of IL-10 in BALB/c mice was associated with increased B7-2 expression and enhanced CHS responses, whereas enhanced IL-10 levels, following ribavirin administration, led to increased B7-1 expression and impaired CHS responses in C57BL/6 mice. Ribavirin 0-9 CD86 antigen Mus musculus 85-89 10490966-5 1999 Ribavirin-mediated suppression of IL-10 in BALB/c mice was associated with increased B7-2 expression and enhanced CHS responses, whereas enhanced IL-10 levels, following ribavirin administration, led to increased B7-1 expression and impaired CHS responses in C57BL/6 mice. Ribavirin 0-9 CD80 antigen Mus musculus 213-217 10490966-5 1999 Ribavirin-mediated suppression of IL-10 in BALB/c mice was associated with increased B7-2 expression and enhanced CHS responses, whereas enhanced IL-10 levels, following ribavirin administration, led to increased B7-1 expression and impaired CHS responses in C57BL/6 mice. Ribavirin 170-179 interleukin 10 Mus musculus 146-151 10490966-6 1999 The effect of ribavirin on the expression of B7 molecules and on CHS responses was neutralized by IL-10 administration in BALB/c and by anti-IL-10 Ab in C57BL/6. Ribavirin 14-23 interleukin 10 Mus musculus 98-103 10490966-6 1999 The effect of ribavirin on the expression of B7 molecules and on CHS responses was neutralized by IL-10 administration in BALB/c and by anti-IL-10 Ab in C57BL/6. Ribavirin 14-23 interleukin 10 Mus musculus 141-146 10490966-7 1999 Thus, ribavirin controlled CHS responses directly through the modulation of IL-10 expression, and in vivo outcome was dictated by the preferential expression of either B7-1, an inappropriate costimulatory molecule in CHS, or B7-2, the predominant costimulatory molecule in CHS. Ribavirin 6-15 interleukin 10 Mus musculus 76-81 10490966-8 1999 Replacing dinitrofluorobenzene priming with IFN-alpha stimulation, we showed that the ribavirin-regulated pathway could function independent of Ag priming. Ribavirin 86-95 interferon alpha Mus musculus 44-53 10460040-5 1999 RESULTS: At the end of the treatment period, normalization of serum alanine aminotransferase levels and absence of hepatitis C virus RNA were seen in 21% of nonresponders and in 39% of relapsers who were treated with interferon alpha-2b and ribavirin, compared with 5% of nonresponders (P = 0.001) and 9% of relapsers treated with interferon alpha-2b alone (P <0.001). Ribavirin 241-250 interferon alpha 2 Homo sapiens 217-236 10438811-0 1999 Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Alpha interferon (IFN-alpha) treatment is effective on a long-term basis in only 15 to 25% of patients with chronic hepatitis C. The results of recent trials indicate that response rates can be significantly increased when IFN-alpha is given in combination with ribavirin. Ribavirin 63-72 interferon alpha 1 Homo sapiens 174-201 10438811-0 1999 Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Alpha interferon (IFN-alpha) treatment is effective on a long-term basis in only 15 to 25% of patients with chronic hepatitis C. The results of recent trials indicate that response rates can be significantly increased when IFN-alpha is given in combination with ribavirin. Ribavirin 63-72 interferon alpha 1 Homo sapiens 192-201 10438811-0 1999 Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Alpha interferon (IFN-alpha) treatment is effective on a long-term basis in only 15 to 25% of patients with chronic hepatitis C. The results of recent trials indicate that response rates can be significantly increased when IFN-alpha is given in combination with ribavirin. Ribavirin 436-445 interferon alpha 1 Homo sapiens 174-201 10438811-0 1999 Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Alpha interferon (IFN-alpha) treatment is effective on a long-term basis in only 15 to 25% of patients with chronic hepatitis C. The results of recent trials indicate that response rates can be significantly increased when IFN-alpha is given in combination with ribavirin. Ribavirin 436-445 interferon alpha 1 Homo sapiens 192-201 10342322-1 1999 Ribavirin therapy was initiated at a median of 181 days after liver transplantation in 18 patients with persistent elevation of alanine aminotransferase values and biopsy-proven hepatitis, and continued for 23 months (12-44 months). Ribavirin 0-9 glutamic--pyruvic transaminase Homo sapiens 128-152 10760037-10 1999 These data indicate that a combination of high-dose IFN with ribavirin is effective in inducing a short-lasting complete response in one-third of IFN nonresponders. Ribavirin 61-70 interferon alpha 1 Homo sapiens 146-149 10405886-13 1999 RESULTS: Only recently clinical data revealed a greater benefit of combination therapy with IFN-alpha and ribavirin compared to IFN-alpha alone in patients with chronic hepatitis C. In 345 CHC patients relapsing after pretreatment with IFN-alpha monotherapy, sustained response was achieved in a 10-fold higher degree with a combination of IFN and ribavirin compared to patients retreated with IFN alone. Ribavirin 348-357 interferon alpha 1 Homo sapiens 92-101 10405886-17 1999 The consequences for treatment options with IFN are a combination with ribavirin in CHC and a graduated systemic treatment schedule in AIDS-KS starting with IFN-treatment in early disease followed by chemotherapy in advanced stages of KS. Ribavirin 71-80 interferon alpha 1 Homo sapiens 44-47 10419923-2 1999 BACKGROUND & AIMS: The aim of this study was to compare interferon (IFN)-ribavirin combination therapy with IFN monotherapy in chronic hepatitis C with particular focus on its efficacy in cirrhosis. Ribavirin 77-86 interferon alpha 1 Homo sapiens 72-75 10419923-3 1999 METHODS: A multivariate analysis of individual patient data of all randomized controlled trials using an IFN-ribavirin arm, reported between 1991 and March 1998, was performed. Ribavirin 109-118 interferon alpha 1 Homo sapiens 105-108 10419923-8 1999 RESULTS: Patients without cirrhosis treated with IFN-ribavirin had a significantly higher sustained response rate than those treated with IFN, approximately 3-fold for previously untreated patients (IFN-ribavirin: genotype 1, 33%; genotype 2/3, 65%; IFN: genotype 1, 8%; genotype 2/3, 24%). Ribavirin 53-62 interferon alpha 1 Homo sapiens 49-52 10419923-9 1999 In cirrhosis, sustained response rates with IFN-ribavirin (previously untreated: genotype 1, 7%; genotype 2/3, 24%) were also significantly higher than those with IFN (previously untreated: genotype 1, 1%; genotype 2/3, 5%). Ribavirin 48-57 interferon alpha 1 Homo sapiens 44-47 10419923-11 1999 Tolerance for IFN-ribavirin was similar for patients with or without cirrhosis. Ribavirin 18-27 interferon alpha 1 Homo sapiens 14-17 10419923-12 1999 CONCLUSIONS: Combination with ribavirin significantly enhances the sustained response rate of IFN therapy in major patient types (cirrhosis, genotype 1) with chronic hepatitis C. Thus, IFN-ribavirin combination is likely to become the antiviral therapy of choice for cirrhosis caused by hepatitis C. Ribavirin 30-39 interferon alpha 1 Homo sapiens 94-97 10419923-12 1999 CONCLUSIONS: Combination with ribavirin significantly enhances the sustained response rate of IFN therapy in major patient types (cirrhosis, genotype 1) with chronic hepatitis C. Thus, IFN-ribavirin combination is likely to become the antiviral therapy of choice for cirrhosis caused by hepatitis C. Ribavirin 189-198 interferon alpha 1 Homo sapiens 94-97 10419923-12 1999 CONCLUSIONS: Combination with ribavirin significantly enhances the sustained response rate of IFN therapy in major patient types (cirrhosis, genotype 1) with chronic hepatitis C. Thus, IFN-ribavirin combination is likely to become the antiviral therapy of choice for cirrhosis caused by hepatitis C. Ribavirin 189-198 interferon alpha 1 Homo sapiens 185-188 10494606-1 1999 The influence of ribavirin on IFN-antibody formation in combination therapy with IFN-alpha has not yet been studied. Ribavirin 17-26 interferon alpha 1 Homo sapiens 30-33 10494606-2 1999 Therefore we evaluated the relationship between IFN-antibodies and response to ribavirin/IFN-alpha combination therapy and IFN-alpha monotherapy. Ribavirin 79-88 interferon alpha 1 Homo sapiens 48-51 10494606-13 1999 The development of high-titer IFN-antibodies during IFN-alpha or ribavirin/IFN-alpha therapy of patients with chronic hepatitis C may account for the early occurrence of breakthrough in some patients, while other mechanisms seem to be responsible for this phenomenon in the majority of the afflicted patients. Ribavirin 65-74 interferon alpha 1 Homo sapiens 30-33 10607236-0 1999 Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C. Long-term virological and histological outcome following interferon-alpha2b (IFN-alpha2b) and ribavirin treatment for 24 weeks was studied in 20 patients with chronic hepatitis C who were without a lasting response to IFN as monotherapy. Ribavirin 95-104 interferon alpha 2 Homo sapiens 187-205 10190717-6 1999 RESULTS: Ribavirin enhanced a Type 1 (IL-2, IFNgamma, TNFalpha) while suppressing a Type 2 cytokine response (IL-4, IL-5 and IL-10), at the level of both protein and mRNA expression. Ribavirin 9-18 interleukin 2 Homo sapiens 38-42 10074163-9 1999 RANTES induction was decreased in infected cells treated with ribavirin, which inhibits measles virus transcription. Ribavirin 62-71 C-C motif chemokine ligand 5 Homo sapiens 0-6 10190717-6 1999 RESULTS: Ribavirin enhanced a Type 1 (IL-2, IFNgamma, TNFalpha) while suppressing a Type 2 cytokine response (IL-4, IL-5 and IL-10), at the level of both protein and mRNA expression. Ribavirin 9-18 interferon gamma Homo sapiens 44-52 10190717-6 1999 RESULTS: Ribavirin enhanced a Type 1 (IL-2, IFNgamma, TNFalpha) while suppressing a Type 2 cytokine response (IL-4, IL-5 and IL-10), at the level of both protein and mRNA expression. Ribavirin 9-18 tumor necrosis factor Homo sapiens 54-62 10190717-6 1999 RESULTS: Ribavirin enhanced a Type 1 (IL-2, IFNgamma, TNFalpha) while suppressing a Type 2 cytokine response (IL-4, IL-5 and IL-10), at the level of both protein and mRNA expression. Ribavirin 9-18 interleukin 4 Homo sapiens 110-114 10190717-6 1999 RESULTS: Ribavirin enhanced a Type 1 (IL-2, IFNgamma, TNFalpha) while suppressing a Type 2 cytokine response (IL-4, IL-5 and IL-10), at the level of both protein and mRNA expression. Ribavirin 9-18 interleukin 5 Homo sapiens 116-120 10190717-6 1999 RESULTS: Ribavirin enhanced a Type 1 (IL-2, IFNgamma, TNFalpha) while suppressing a Type 2 cytokine response (IL-4, IL-5 and IL-10), at the level of both protein and mRNA expression. Ribavirin 9-18 interleukin 10 Homo sapiens 125-130 10192200-12 1999 CONCLUSIONS: In a group of previous IFN-alpha2a-treated chronic HCV patients we obtained a similar sustained clearance of viremia when retreated either with IFN-alpha2a alone or with a combination of IFN-alpha2a and ribavirin for 6 months. Ribavirin 216-225 interferon alpha 1 Homo sapiens 36-39 10192200-12 1999 CONCLUSIONS: In a group of previous IFN-alpha2a-treated chronic HCV patients we obtained a similar sustained clearance of viremia when retreated either with IFN-alpha2a alone or with a combination of IFN-alpha2a and ribavirin for 6 months. Ribavirin 216-225 interferon alpha 2 Homo sapiens 36-46 9934693-5 1999 Furthermore, synthesis of the P protein increased when rBV containing the manipulated V gene was used to infect insect cells. Ribavirin 55-58 OCA2 melanosomal transmembrane protein Homo sapiens 30-39 9893037-4 1998 Furthermore, cRSV that had been rendered non-infectious by ultraviolet-irradiation (UV-cRSV) or ribavirin treatment also induced an increased production of IL-8 in fresh A549 cells, suggesting that RSV induced the synthesis of a soluble mediator(s) which in turn enhanced the synthesis of IL-8. Ribavirin 96-105 C-X-C motif chemokine ligand 8 Homo sapiens 156-160 10622579-7 1999 The potential mechanisms of action of ribavirin, although not yet fully understood, include inhibition of synthesis of GTP by an effect on inosine monophosphate dehydrogenase thereby limiting viral RNA synthesis, and enhancement of TH1 responses, which may assist viral clearance. Ribavirin 38-47 negative elongation factor complex member C/D Homo sapiens 232-235 9860407-1 1998 OBJECTIVE: The aim of the study was to assess the efficacy of interferon (IFN)-alpha-2b and ribavirin in combination in the treatment of chronic hepatitis C (CHC) patients unresponsive to a previous treatment with IFN-alpha-2b alone. Ribavirin 92-101 interferon alpha 1 Homo sapiens 214-223 9860407-9 1998 CONCLUSIONS: A 24-wk treatment course with IFN-alpha and ribavirin given to patients with a previous lack of response to IFN-alpha alone offers a chance of a sustained biochemical and virological response, at least in a subset of such patients. Ribavirin 57-66 interferon alpha 1 Homo sapiens 121-130 9862245-12 1998 IFN and ribavirin monotherapy produced characteristic changes in safety laboratory tests (IFN--reductions in white cells, neutrophils and platelets; ribavirin--reduced haemoglobin) and characteristic adverse event profiles (IFN--headache, flu-like symptoms, fatigue, anorexia, nausea, myalgia, and insomnia; ribavirin--headache, fatigue, myalgia, and pruritus). Ribavirin 149-158 interferon alpha 1 Homo sapiens 0-3 10622581-4 1999 Ribavirin in combination with alpha interferon, in standard doses for 6-12 months significantly improves the sustained biochemical and virological response rates 2-3 times compared with IFN alone for 12 months. Ribavirin 0-9 interferon alpha 1 Homo sapiens 186-189 10349692-0 1999 Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Interferon (IFN) results in normalization of the serum alanine aminotransferase (ALT), loss of detectable serum hepatitis C virus (HCV) RNA, and histologic improvement in approximately 40% of patients. Ribavirin 45-54 interferon alpha 1 Homo sapiens 73-83 10349692-0 1999 Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Interferon (IFN) results in normalization of the serum alanine aminotransferase (ALT), loss of detectable serum hepatitis C virus (HCV) RNA, and histologic improvement in approximately 40% of patients. Ribavirin 45-54 interferon alpha 1 Homo sapiens 116-126 10349692-0 1999 Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Interferon (IFN) results in normalization of the serum alanine aminotransferase (ALT), loss of detectable serum hepatitis C virus (HCV) RNA, and histologic improvement in approximately 40% of patients. Ribavirin 45-54 interferon alpha 1 Homo sapiens 128-131 10349692-0 1999 Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Interferon (IFN) results in normalization of the serum alanine aminotransferase (ALT), loss of detectable serum hepatitis C virus (HCV) RNA, and histologic improvement in approximately 40% of patients. Ribavirin 45-54 glutamic--pyruvic transaminase Homo sapiens 171-195 10349692-2 1999 Retreatment of IFN relapsers with the combination of IFN and oral ribavirin for 6 months results in end-of-treatment loss of detectable HCV RNA and normalization of the ALT level in over 80% of patients. Ribavirin 66-75 interferon alpha 1 Homo sapiens 15-18 9870320-8 1998 The antiviral efficacy of ZDV in combination with RBV (2 microM) was assessed by HIV p24 antigen measurements. Ribavirin 50-53 transmembrane p24 trafficking protein 2 Homo sapiens 85-88 9862245-9 1998 Ribavirin and IFN pharmacokinetic parameters for combined ribavirin and IFN were similar to those during monotherapy with either compound, although the power of this study to detect differences was low. Ribavirin 0-9 interferon alpha 1 Homo sapiens 72-75 9862245-9 1998 Ribavirin and IFN pharmacokinetic parameters for combined ribavirin and IFN were similar to those during monotherapy with either compound, although the power of this study to detect differences was low. Ribavirin 58-67 interferon alpha 1 Homo sapiens 14-17 9862245-12 1998 IFN and ribavirin monotherapy produced characteristic changes in safety laboratory tests (IFN--reductions in white cells, neutrophils and platelets; ribavirin--reduced haemoglobin) and characteristic adverse event profiles (IFN--headache, flu-like symptoms, fatigue, anorexia, nausea, myalgia, and insomnia; ribavirin--headache, fatigue, myalgia, and pruritus). Ribavirin 8-17 interferon alpha 1 Homo sapiens 90-93 9862245-12 1998 IFN and ribavirin monotherapy produced characteristic changes in safety laboratory tests (IFN--reductions in white cells, neutrophils and platelets; ribavirin--reduced haemoglobin) and characteristic adverse event profiles (IFN--headache, flu-like symptoms, fatigue, anorexia, nausea, myalgia, and insomnia; ribavirin--headache, fatigue, myalgia, and pruritus). Ribavirin 8-17 interferon alpha 1 Homo sapiens 90-93 9862245-12 1998 IFN and ribavirin monotherapy produced characteristic changes in safety laboratory tests (IFN--reductions in white cells, neutrophils and platelets; ribavirin--reduced haemoglobin) and characteristic adverse event profiles (IFN--headache, flu-like symptoms, fatigue, anorexia, nausea, myalgia, and insomnia; ribavirin--headache, fatigue, myalgia, and pruritus). Ribavirin 149-158 interferon alpha 1 Homo sapiens 0-3 9807989-11 1998 INTERPRETATION: An interferon alpha2b plus ribavirin combination is more effective than 48 weeks of interferon alpha2b monotherapy and has an acceptable safety profile. Ribavirin 43-52 interferon alpha 2 Homo sapiens 100-118 9780043-4 1998 Effects of ribavirin on human and murine phytohaemagglutinin (PHA)-activated T cells included inhibition of in vitro proliferation and modulation of IL-2, IL-4, IFN-gamma and TNF-alpha levels. Ribavirin 11-20 interleukin 2 Mus musculus 149-153 9780043-4 1998 Effects of ribavirin on human and murine phytohaemagglutinin (PHA)-activated T cells included inhibition of in vitro proliferation and modulation of IL-2, IL-4, IFN-gamma and TNF-alpha levels. Ribavirin 11-20 interferon gamma Mus musculus 161-170 9780043-4 1998 Effects of ribavirin on human and murine phytohaemagglutinin (PHA)-activated T cells included inhibition of in vitro proliferation and modulation of IL-2, IL-4, IFN-gamma and TNF-alpha levels. Ribavirin 11-20 tumor necrosis factor Mus musculus 175-184 9780043-5 1998 HBcAg- and HBeAg-specific IL-2 and IFN-gamma levels were > or = 25-fold higher in mice immunized with HBV core- or e-antigens (HBcAg, HBeAg) while receiving ribavirin compared to untreated mice, but IL-4 and IL-6 remained constant. Ribavirin 160-169 interleukin 2 Mus musculus 26-30 9780043-8 1998 In ribavirin-treated HBeAg-Tg mice anti-HBe IgG1 (positively regulated by Th2 cytokines) decreased simultaneously as both anti-HBe IgG2a (positively regulated by Th1 cytokines) levels and in vitro T-cell IFN-gamma production increased, indicating a change in the Th1/Th2 balance. Ribavirin 3-12 immunoglobulin heavy constant gamma 1 (G1m marker) Mus musculus 44-48 9780043-8 1998 In ribavirin-treated HBeAg-Tg mice anti-HBe IgG1 (positively regulated by Th2 cytokines) decreased simultaneously as both anti-HBe IgG2a (positively regulated by Th1 cytokines) levels and in vitro T-cell IFN-gamma production increased, indicating a change in the Th1/Th2 balance. Ribavirin 3-12 immunoglobulin heavy variable V1-9 Mus musculus 131-136 9780043-8 1998 In ribavirin-treated HBeAg-Tg mice anti-HBe IgG1 (positively regulated by Th2 cytokines) decreased simultaneously as both anti-HBe IgG2a (positively regulated by Th1 cytokines) levels and in vitro T-cell IFN-gamma production increased, indicating a change in the Th1/Th2 balance. Ribavirin 3-12 negative elongation factor complex member C/D, Th1l Mus musculus 162-165 9780043-8 1998 In ribavirin-treated HBeAg-Tg mice anti-HBe IgG1 (positively regulated by Th2 cytokines) decreased simultaneously as both anti-HBe IgG2a (positively regulated by Th1 cytokines) levels and in vitro T-cell IFN-gamma production increased, indicating a change in the Th1/Th2 balance. Ribavirin 3-12 interferon gamma Mus musculus 204-213 9780043-8 1998 In ribavirin-treated HBeAg-Tg mice anti-HBe IgG1 (positively regulated by Th2 cytokines) decreased simultaneously as both anti-HBe IgG2a (positively regulated by Th1 cytokines) levels and in vitro T-cell IFN-gamma production increased, indicating a change in the Th1/Th2 balance. Ribavirin 3-12 negative elongation factor complex member C/D, Th1l Mus musculus 263-266 9722937-5 1998 Higher ribavirin concentrations markedly inhibited IFN-gamma production, but augmented interleukins (IL) 2, 4, and 12 secretion. Ribavirin 7-16 interferon gamma Homo sapiens 51-60 9722937-5 1998 Higher ribavirin concentrations markedly inhibited IFN-gamma production, but augmented interleukins (IL) 2, 4, and 12 secretion. Ribavirin 7-16 interleukin 2 Homo sapiens 87-106 9722937-7 1998 Thus, ribavirin and IFN-alpha appear to cause diverse effects on immunoregulatory cytokine secretion, and when combined, counteracted for production of IL-2 and IL-12, while upregulated mononuclear cell secretion of IFN-gamma and that of the anti-inflammatory cytokine IL-10. Ribavirin 6-15 interleukin 2 Homo sapiens 152-156 9722937-7 1998 Thus, ribavirin and IFN-alpha appear to cause diverse effects on immunoregulatory cytokine secretion, and when combined, counteracted for production of IL-2 and IL-12, while upregulated mononuclear cell secretion of IFN-gamma and that of the anti-inflammatory cytokine IL-10. Ribavirin 6-15 interferon gamma Homo sapiens 216-225 9722937-7 1998 Thus, ribavirin and IFN-alpha appear to cause diverse effects on immunoregulatory cytokine secretion, and when combined, counteracted for production of IL-2 and IL-12, while upregulated mononuclear cell secretion of IFN-gamma and that of the anti-inflammatory cytokine IL-10. Ribavirin 6-15 interleukin 10 Homo sapiens 269-274 9696489-6 1998 RESULTS: In six of the 15 patients treated with ribavirin, but in none of the controls, serum alanine aminotransferase levels declined by at least 30%. Ribavirin 48-57 glutamic--pyruvic transaminase Homo sapiens 94-118 18020586-7 1998 The long term efficacy of interferon-alpha-2a in patients with chronic hepatitis C is improved by the concomitant administration of ribavirin. Ribavirin 132-141 interferon alpha 2 Homo sapiens 26-45 9672184-2 1998 METHODS/CASES: We report on three patients who were treated with recombinant interferon-alpha2a for chronic hepatitis C, two of them in combination with ribavirin. Ribavirin 153-162 interferon alpha 2 Homo sapiens 77-95 9658373-10 1998 In conclusion, our results suggest that long-term administration of ribavirin is well tolerated and may be beneficial in controlling the progression of chronic hepatitis C. This may represent an alternative therapy in patients who have contraindications for interferon therapy or as a palliative approach in non-responders to IFN. Ribavirin 68-77 interferon alpha 1 Homo sapiens 258-268 9658373-10 1998 In conclusion, our results suggest that long-term administration of ribavirin is well tolerated and may be beneficial in controlling the progression of chronic hepatitis C. This may represent an alternative therapy in patients who have contraindications for interferon therapy or as a palliative approach in non-responders to IFN. Ribavirin 68-77 interferon alpha 1 Homo sapiens 326-329 9782309-10 1998 Ribavirin, a synthetic guanosine analogue prolonged survival to MHV-3 infection, inhibited production and transcription of the macrophage pro-inflammatory cytokines IL-1 beta and TNF-alpha and Th2 cytokines while preserving Th1 cytokine production. Ribavirin 0-9 interleukin 1 beta Mus musculus 165-174 9458644-7 1998 Patients with higher pre-treatment HCV RNA levels (> or = 3 million Eq/mL) and patients manifesting unsustained response to earlier IFN treatment should receive combination treatment with ribavirin and IFN-alpha, as treatment with IFN alone is associated with poor chances of sustained response. Ribavirin 191-200 interferon alpha 1 Homo sapiens 135-138 9499112-5 1998 Addition of therapeutic concentrations of dexamethasone (1 microM) or ribavirin (90 microg/ml), an antiviral agent, also significantly inhibited the synthesis of IL-6. Ribavirin 70-79 interleukin 6 Homo sapiens 162-166 9499112-6 1998 Hence, in clinical settings, pharmacological agents such as the specific antagonists of IL-6-inducing cytokines, as well as dexamethasone and ribavirin, could be used to modulate IL-6 production. Ribavirin 142-151 interleukin 6 Homo sapiens 179-183 9782309-10 1998 Ribavirin, a synthetic guanosine analogue prolonged survival to MHV-3 infection, inhibited production and transcription of the macrophage pro-inflammatory cytokines IL-1 beta and TNF-alpha and Th2 cytokines while preserving Th1 cytokine production. Ribavirin 0-9 tumor necrosis factor Mus musculus 179-188 9782309-10 1998 Ribavirin, a synthetic guanosine analogue prolonged survival to MHV-3 infection, inhibited production and transcription of the macrophage pro-inflammatory cytokines IL-1 beta and TNF-alpha and Th2 cytokines while preserving Th1 cytokine production. Ribavirin 0-9 heart and neural crest derivatives expressed 2 Mus musculus 193-196 9782309-10 1998 Ribavirin, a synthetic guanosine analogue prolonged survival to MHV-3 infection, inhibited production and transcription of the macrophage pro-inflammatory cytokines IL-1 beta and TNF-alpha and Th2 cytokines while preserving Th1 cytokine production. Ribavirin 0-9 negative elongation factor complex member C/D, Th1l Mus musculus 224-227 9407357-9 1997 The combined use of ribavirin or corticosteroid priming may improve the effect of IFN therapy by enhancing the durability of the response. Ribavirin 20-29 interferon alpha 1 Homo sapiens 82-85 9186825-9 1997 The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). Ribavirin 68-77 interferon alpha 1 Homo sapiens 155-158 9305674-3 1997 Three randomized, placebo-controlled studies comprising more than 150 patients have shown that therapy with ribavirin alone for 24 to 48 weeks resulted in a significant reduction in serum alanine aminotransferase (ALT) levels during therapy. Ribavirin 108-117 glutamic--pyruvic transaminase Homo sapiens 188-212 9186825-9 1997 The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). Ribavirin 68-77 interferon alpha 1 Homo sapiens 167-170 9186825-9 1997 The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). Ribavirin 121-130 interferon alpha 1 Homo sapiens 155-158 9186825-9 1997 The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). Ribavirin 121-130 interferon alpha 1 Homo sapiens 167-170 9186825-10 1997 The estimated probability of sustained response following interferon-ribavirin combination therapy was 51% for patients without previous IFN therapy, 52% for patients with previous IFN therapy and response-relapse, and 16% for previous IFN non-responders. Ribavirin 69-78 interferon alpha 1 Homo sapiens 137-140 9186825-10 1997 The estimated probability of sustained response following interferon-ribavirin combination therapy was 51% for patients without previous IFN therapy, 52% for patients with previous IFN therapy and response-relapse, and 16% for previous IFN non-responders. Ribavirin 69-78 interferon alpha 1 Homo sapiens 181-184 9186825-10 1997 The estimated probability of sustained response following interferon-ribavirin combination therapy was 51% for patients without previous IFN therapy, 52% for patients with previous IFN therapy and response-relapse, and 16% for previous IFN non-responders. Ribavirin 69-78 interferon alpha 1 Homo sapiens 181-184 9181527-4 1997 In this study, we evaluated the efficacy of ribavirin and IFN-alpha combination therapy for IFN-alpha resistant chronic hepatitis C. Twenty-four IFN-alpha non-responders and 24 relapsers were randomized to receive either ribavirin (1000 mg per day) together with IFN-alpha (3-6 million units (MU) thrice weekly) or the same dose of IFN-alpha alone, for 6 months. Ribavirin 44-53 interferon alpha 1 Homo sapiens 92-101 9181527-4 1997 In this study, we evaluated the efficacy of ribavirin and IFN-alpha combination therapy for IFN-alpha resistant chronic hepatitis C. Twenty-four IFN-alpha non-responders and 24 relapsers were randomized to receive either ribavirin (1000 mg per day) together with IFN-alpha (3-6 million units (MU) thrice weekly) or the same dose of IFN-alpha alone, for 6 months. Ribavirin 44-53 interferon alpha 1 Homo sapiens 92-101 9181527-4 1997 In this study, we evaluated the efficacy of ribavirin and IFN-alpha combination therapy for IFN-alpha resistant chronic hepatitis C. Twenty-four IFN-alpha non-responders and 24 relapsers were randomized to receive either ribavirin (1000 mg per day) together with IFN-alpha (3-6 million units (MU) thrice weekly) or the same dose of IFN-alpha alone, for 6 months. Ribavirin 44-53 interferon alpha 1 Homo sapiens 92-101 9181527-4 1997 In this study, we evaluated the efficacy of ribavirin and IFN-alpha combination therapy for IFN-alpha resistant chronic hepatitis C. Twenty-four IFN-alpha non-responders and 24 relapsers were randomized to receive either ribavirin (1000 mg per day) together with IFN-alpha (3-6 million units (MU) thrice weekly) or the same dose of IFN-alpha alone, for 6 months. Ribavirin 44-53 interferon alpha 1 Homo sapiens 92-101 9265583-7 1997 Alternative treatment schedules or combination therapy with interferon/ribavirin should be considered in subjects with normalized alanine aminotransferase (ALT) levels, but who are still viremic after three months of therapy, as well as in relapsers and in non-responders. Ribavirin 71-80 glutamic--pyruvic transaminase Homo sapiens 130-154 9011471-5 1996 This meta-analysis of IFN-ribavirin combination therapy for chronic hepatitis C suggests that combination therapy results in a two- to threefold greater efficacy than IFN monotherapy, whereas side effects are similar to IFN monotherapy, with the exception of ribavirin-induced anemia. Ribavirin 26-35 interferon alpha 1 Homo sapiens 22-25 9492183-2 1997 Recombinant baculoviruses (rBVs) highly expressed the Gag precursor and p26 antigens in an rBV-infected Sf21 cell culture supernatant. Ribavirin 27-30 transmembrane p24 trafficking protein 3 Homo sapiens 72-75 7576697-4 1995 Treatment of the cells with noninfectious cRSV prepared by ultraviolet (UV) irradiation (UV-cRSV) or ribavirin treatment resulted in the expression of ICAM-1 to a similar extent as infectious cRSV. Ribavirin 101-110 intercellular adhesion molecule 1 Homo sapiens 151-157 9011471-0 1996 Interferon-ribavirin combination therapy for chronic hepatitis C. Following preliminary reports of small studies that suggested a clinically important enhanced benefit from combination therapy with interferon-alpha (IFN) and ribavirin over IFN monotherapy in chronic hepatitis C, a meta-analysis of data from these studies was performed to estimate the efficacy and tolerability of combination therapy in chronic hepatitis C. Records were obtained from 59 patients who had received combination therapy with IFN 3 MU three times weekly and ribavirin 1000-1200 mg daily for six months and were followed for six months after stopping combination therapy. Ribavirin 11-20 interferon alpha 1 Homo sapiens 216-219 8770057-8 1996 Both amiloride and ribavirin inhibited IL-8 mRNA induction. Ribavirin 19-28 C-X-C motif chemokine ligand 8 Homo sapiens 39-43 8771530-0 1996 The effects of ribavirin on the GTP level and the VIP receptor dynamic of human IGR39 cells. Ribavirin 15-24 vasoactive intestinal peptide Homo sapiens 50-53 7593232-1 1995 Differentiation of the megakaryocytic leukemia cells, CMK, was induced by long-term (12 day) treatment with the combination of IL-3 and the nucleoside analogue ribavirin (RV), which reduces cellular GTP levels. Ribavirin 160-169 cytidine/uridine monophosphate kinase 1 Homo sapiens 54-57 7593232-1 1995 Differentiation of the megakaryocytic leukemia cells, CMK, was induced by long-term (12 day) treatment with the combination of IL-3 and the nucleoside analogue ribavirin (RV), which reduces cellular GTP levels. Ribavirin 171-173 cytidine/uridine monophosphate kinase 1 Homo sapiens 54-57 7593232-1 1995 Differentiation of the megakaryocytic leukemia cells, CMK, was induced by long-term (12 day) treatment with the combination of IL-3 and the nucleoside analogue ribavirin (RV), which reduces cellular GTP levels. Ribavirin 171-173 interleukin 3 Homo sapiens 127-131 8021297-3 1994 We developed an alternative induction protocol for the megakaryocytic leukemic cell line CMK, which involved incubation of the cells with IL-3 and the nucleoside analog, ribavirin, for 1-2 weeks. Ribavirin 170-179 C-X-C motif chemokine ligand 9 Homo sapiens 89-92 7629562-3 1995 The objective of our study is to verify whether the combination ribavirin (R)+ IFN-alpha can lead to positive results in non-responders to treatment with IFN-alpha alone. Ribavirin 64-73 interferon alpha 1 Homo sapiens 154-163 7534082-4 1995 Ribavirin-induced haemolysis was clinically significant in three patients, necessitating a reduction in the daily dose of ribavirin from 1.2 g to 0.2 g. Comparison of the pre- and post-treatment biopsy specimens in the four patients who tolerated the full dose of ribavirin and who had normal AST levels at the end of 6 months of treatment showed significant histological improvement with reduction in either lobular or periportal inflammation in all of the patients and a reduction in periportal fibrosis in one patient. Ribavirin 0-9 solute carrier family 17 member 5 Homo sapiens 293-296 7865717-0 1994 Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. Ribavirin 119-128 glutamic--pyruvic transaminase Homo sapiens 33-57 7521308-0 1994 A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. BACKGROUND/AIMS: In chronic hepatitis C, interferon alfa (IFN-alpha) therapy fails to achieve a sustained response in approximately 75% of patients. Ribavirin 42-51 interferon alpha 1 Homo sapiens 182-191 7521308-2 1994 The aim of this study was to evaluate whether ribavirin and IFN-alpha in combination could be effective in IFN-alpha-resistant chronic hepatitis C. METHODS: Twenty patients with chronic hepatitis C resistant to a previous course of IFN-alpha were randomly assigned to receive either ribavirin combined with IFN-alpha or IFN-alpha alone for 6 months. Ribavirin 46-55 interferon alpha 1 Homo sapiens 107-116 7521308-2 1994 The aim of this study was to evaluate whether ribavirin and IFN-alpha in combination could be effective in IFN-alpha-resistant chronic hepatitis C. METHODS: Twenty patients with chronic hepatitis C resistant to a previous course of IFN-alpha were randomly assigned to receive either ribavirin combined with IFN-alpha or IFN-alpha alone for 6 months. Ribavirin 46-55 interferon alpha 1 Homo sapiens 107-116 7521308-2 1994 The aim of this study was to evaluate whether ribavirin and IFN-alpha in combination could be effective in IFN-alpha-resistant chronic hepatitis C. METHODS: Twenty patients with chronic hepatitis C resistant to a previous course of IFN-alpha were randomly assigned to receive either ribavirin combined with IFN-alpha or IFN-alpha alone for 6 months. Ribavirin 46-55 interferon alpha 1 Homo sapiens 107-116 7521308-2 1994 The aim of this study was to evaluate whether ribavirin and IFN-alpha in combination could be effective in IFN-alpha-resistant chronic hepatitis C. METHODS: Twenty patients with chronic hepatitis C resistant to a previous course of IFN-alpha were randomly assigned to receive either ribavirin combined with IFN-alpha or IFN-alpha alone for 6 months. Ribavirin 46-55 interferon alpha 1 Homo sapiens 107-116 7521308-6 1994 CONCLUSIONS: These findings suggest that ribavirin plus IFN-alpha combination therapy is able to induce a sustained biochemical and virological response in a significant proportion of patients with IFN-alpha-resistant chronic hepatitis C. Ribavirin 41-50 interferon alpha 1 Homo sapiens 198-207 15566819-10 1995 At the end of 4 weeks of ribavirin treatment, serum levels of alanine aminotransferase (ALT) decreased in all but 1 patient; only 1 patient normalized serum ALT at this time. Ribavirin 25-34 glutamic--pyruvic transaminase Homo sapiens 62-86 8363379-1 1993 The sialidase (neuraminidase) inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (4-guanidino-Neu5Ac2en) has been examined for the ability to inhibit the growth of a wide range of influenza A and B viruses in vitro in comparison with amantadine, rimantadine, and ribavirin. Ribavirin 282-291 neuraminidase 1 Homo sapiens 15-28 7949457-13 1994 Ribavirin, which has a significant antiviral effect on hepatitis C virus, might be useful in combination with IFN-alpha. Ribavirin 0-9 interferon alpha 1 Homo sapiens 110-113 8235082-3 1993 All kittens, including ribavirin-treated and untreated kittens, succumbed to FIP. Ribavirin 23-32 upstream transcription factor 2, c-fos interacting Homo sapiens 77-80 8384433-4 1993 Serum alanine aminotransferase (an indicator of liver damage) was also reduced in animals treated with the two compounds (ribavirin at 32 mg/kg; ribamidine at 100 and 320 mg/kg). Ribavirin 122-131 glutamic--pyruvic transaminase Homo sapiens 6-30 1916970-3 1991 Mean levels of ALT and AST were significantly lower in the ribavirin treated group as compared to the placebo group on days 5, 10 and 14; serum bilirubin levels were significantly lower in the ribavirin group on days 10 and 14. Ribavirin 59-68 solute carrier family 17 member 5 Homo sapiens 23-26 1677450-3 1991 In the present in vitro study, the formation in human T cells (MOLT-4, ATH8, and CCRF-CEM) of the pharmacologically active metabolite of ddIno and ddAdo, 2",3"-dideoxyadenosine-5"-triphosphate (ddATP), was found to be stimulated 2-4-fold by appropriate concentrations of inosinate dehydrogenase (IMPD) inhibitors such as ribavirin, tiazofurin, and mycophenolic acid. Ribavirin 321-330 inosine monophosphate dehydrogenase 1 Homo sapiens 296-300 1829439-4 1991 The PS membrane gave different results from the AN 69 membrane, RBV values on the HHR and aXa being lower on both the HHR and LHR, with FPA values being regularly lower on the LHR. Ribavirin 64-67 luteinizing hormone/choriogonadotropin receptor Homo sapiens 126-129 1826574-0 1991 Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Ribavirin 58-67 SH2 domain containing 3A Homo sapiens 118-122 11114411-6 2000 Proliferation was suppressed 57-99% (P<0.001) by IFN-2b (10(5)-10(7) IU/ml), 41-74% (P<0.001) by CIFN (1.5-150 ng/ml), and 10-94% (P<0.001) by RBV (0.5-50 microg/ml). Ribavirin 152-155 interferon alpha 1 Homo sapiens 52-55 33766591-6 2021 Afterwards, the clinical development of some NAs including Favipiravir, Sofosbuvir, Ribavirin, Tenofovir, and Remdesivir as potential inhibitors of RdRp, were surveyed. Ribavirin 84-93 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 148-152 26112013-0 2015 The effects of pegylated interferon-alpha and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report. Ribavirin 46-55 inhibin subunit beta A Rattus norvegicus 93-102 26112013-2 2015 AIMS: To measure the effects of treatment with pegylated-interferon-alpha (Peg-IFN-alpha) and ribavirin on the concentrations of mature activin-A and follistatin in serum and liver tissue homogenates in rats. Ribavirin 94-103 inhibin subunit beta A Rattus norvegicus 136-145 23560893-0 2013 Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. Ribavirin 137-146 interferon lambda 3 Homo sapiens 33-39 23560893-3 2013 METHODS: IL-28B rs8099917 genotype was determined in 70 HCV-1 treatment-experienced patients retreated with 48-week peginterferon/ribavirin. Ribavirin 130-139 interferon lambda 3 Homo sapiens 9-15 23560893-11 2013 CONCLUSIONS: Host IL-28B genetic variants played a role in Asian relapsers but not nonresponders retreated with peginterferon/ribavirin. Ribavirin 126-135 interferon lambda 3 Homo sapiens 18-24 22195237-4 2011 Telaprevir and boceprevir are both NS3/NS4a inhibitors that significantly improve sustained response when added to PegIFN and RBV. Ribavirin 126-129 KRAS proto-oncogene, GTPase Homo sapiens 35-38 20977565-0 2010 ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. AIM: Host genetic variants leading to inosine triphosphatase (ITPA) deficiency, a condition not thought to be clinically important, protect against hemolytic anemia in chronic hepatitis C patients receiving ribavirin. Ribavirin 84-93 inosine triphosphatase Homo sapiens 0-4 20977565-0 2010 ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. AIM: Host genetic variants leading to inosine triphosphatase (ITPA) deficiency, a condition not thought to be clinically important, protect against hemolytic anemia in chronic hepatitis C patients receiving ribavirin. Ribavirin 84-93 inosine triphosphatase Homo sapiens 212-216 20977565-0 2010 ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. AIM: Host genetic variants leading to inosine triphosphatase (ITPA) deficiency, a condition not thought to be clinically important, protect against hemolytic anemia in chronic hepatitis C patients receiving ribavirin. Ribavirin 357-366 inosine triphosphatase Homo sapiens 0-4 20977565-0 2010 ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. AIM: Host genetic variants leading to inosine triphosphatase (ITPA) deficiency, a condition not thought to be clinically important, protect against hemolytic anemia in chronic hepatitis C patients receiving ribavirin. Ribavirin 357-366 inosine triphosphatase Homo sapiens 212-216 20977565-1 2010 In this study, we evaluated the clinical significance of ITPA variants in Japanese hepatitis C patients who were treated with pegylated interferon plus ribavirin. Ribavirin 152-161 inosine triphosphatase Homo sapiens 57-61 20977565-8 2010 CONCLUSION: ITPA SNP, rs1127354, is confirmed to be a useful predictor of ribavirin-induced anemia in Japanese patients. Ribavirin 74-83 inosine triphosphatase Homo sapiens 12-16 20977565-9 2010 Patients with the ITPA minor variant A (~ 27%) have an advantage in pegylated interferon plus ribavirin-based therapies, due to expected adherence of ribavirin doses, resulting in a higher viral clearance rate. Ribavirin 94-103 inosine triphosphatase Homo sapiens 18-22 20977565-9 2010 Patients with the ITPA minor variant A (~ 27%) have an advantage in pegylated interferon plus ribavirin-based therapies, due to expected adherence of ribavirin doses, resulting in a higher viral clearance rate. Ribavirin 150-159 inosine triphosphatase Homo sapiens 18-22 34919946-0 2022 Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Ribavirin 0-9 coactivator-associated arginine methyltransferase 1 Mus musculus 113-118 34919946-0 2022 Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Ribavirin 0-9 protein arginine N-methyltransferase 5 Mus musculus 131-136 34919946-4 2022 Furthermore, ribavirin suppressed the growth of subcutaneous and orthotopic xenograft of HCC in mice, decreased vascular endothelial growth factor (VEGF) and peritoneal permeability to reduce ascites production, and prolonged the survival of mice in HCC ascites tumor models. Ribavirin 13-22 vascular endothelial growth factor A Mus musculus 112-146 34919946-4 2022 Furthermore, ribavirin suppressed the growth of subcutaneous and orthotopic xenograft of HCC in mice, decreased vascular endothelial growth factor (VEGF) and peritoneal permeability to reduce ascites production, and prolonged the survival of mice in HCC ascites tumor models. Ribavirin 13-22 vascular endothelial growth factor A Mus musculus 148-152 34919946-5 2022 Mechanistically, ribavirin potently down-regulated global protein expression of CARM1 and PRMT5, and concurrently decreased accumulation of H3R17me2a and H3R8me2s/H4R3me2s. Ribavirin 17-26 coactivator-associated arginine methyltransferase 1 Mus musculus 80-85 34919946-5 2022 Mechanistically, ribavirin potently down-regulated global protein expression of CARM1 and PRMT5, and concurrently decreased accumulation of H3R17me2a and H3R8me2s/H4R3me2s. Ribavirin 17-26 protein arginine N-methyltransferase 5 Mus musculus 90-95 34919946-7 2022 In addition, our ChIP results shown that ribavirin inhibited CARM1 which in turn decreased the H3R17me2a, binds to the eukaryotic translation initiation factor 4E (eIF4E) and VEGF promoter region, and reduced the relative mRNA expression level of eIF4E and VEGF in HCC cells. Ribavirin 41-50 coactivator-associated arginine methyltransferase 1 Mus musculus 61-66 34919946-7 2022 In addition, our ChIP results shown that ribavirin inhibited CARM1 which in turn decreased the H3R17me2a, binds to the eukaryotic translation initiation factor 4E (eIF4E) and VEGF promoter region, and reduced the relative mRNA expression level of eIF4E and VEGF in HCC cells. Ribavirin 41-50 eukaryotic translation initiation factor 4E Mus musculus 119-162 34919946-7 2022 In addition, our ChIP results shown that ribavirin inhibited CARM1 which in turn decreased the H3R17me2a, binds to the eukaryotic translation initiation factor 4E (eIF4E) and VEGF promoter region, and reduced the relative mRNA expression level of eIF4E and VEGF in HCC cells. Ribavirin 41-50 eukaryotic translation initiation factor 4E Mus musculus 164-169 34919946-7 2022 In addition, our ChIP results shown that ribavirin inhibited CARM1 which in turn decreased the H3R17me2a, binds to the eukaryotic translation initiation factor 4E (eIF4E) and VEGF promoter region, and reduced the relative mRNA expression level of eIF4E and VEGF in HCC cells. Ribavirin 41-50 vascular endothelial growth factor A Mus musculus 175-179 34919946-7 2022 In addition, our ChIP results shown that ribavirin inhibited CARM1 which in turn decreased the H3R17me2a, binds to the eukaryotic translation initiation factor 4E (eIF4E) and VEGF promoter region, and reduced the relative mRNA expression level of eIF4E and VEGF in HCC cells. Ribavirin 41-50 eukaryotic translation initiation factor 4E Mus musculus 247-252 34919946-7 2022 In addition, our ChIP results shown that ribavirin inhibited CARM1 which in turn decreased the H3R17me2a, binds to the eukaryotic translation initiation factor 4E (eIF4E) and VEGF promoter region, and reduced the relative mRNA expression level of eIF4E and VEGF in HCC cells. Ribavirin 41-50 vascular endothelial growth factor A Mus musculus 257-261 34307188-2 2021 In this context, single nucleotide polymorphisms (SNPs) in the locus of interferon lambda 3 and 4 genes (IFNL3/4) have been important genetic markers of responsiveness to CHC as prognostic markers for the pegylated-Interferon-alpha/ribavirin (Peg-IFN-alpha/RBV). Ribavirin 232-241 interferon lambda 3 Homo sapiens 105-110 34960758-5 2021 We also demonstrated that IFNalpha combinations with sofosbuvir, telaprevir, NITD008, ribavirin, pimodivir, or lamivudine were effective against HCV, HEV, FLuAV, or HIV at lower concentrations, compared to monotherapies. Ribavirin 86-95 interferon alpha 1 Homo sapiens 26-34 34885967-5 2021 In this work, the interaction mechanism of four HIV protease inhibitors Darunavir (DRV), Lopinavir (LPV), Nelfinavir (NFV), and Ritonavire (RTV) targeting SARS-CoV-2 Mpro was explored by applying docking, molecular dynamics (MD) simulations, and MM-GBSA methods using the broad-spectrum antiviral drug Ribavirin (RBV) as the negative and nonspecific control. Ribavirin 302-311 NEWENTRY Severe acute respiratory syndrome-related coronavirus 166-170 34885967-5 2021 In this work, the interaction mechanism of four HIV protease inhibitors Darunavir (DRV), Lopinavir (LPV), Nelfinavir (NFV), and Ritonavire (RTV) targeting SARS-CoV-2 Mpro was explored by applying docking, molecular dynamics (MD) simulations, and MM-GBSA methods using the broad-spectrum antiviral drug Ribavirin (RBV) as the negative and nonspecific control. Ribavirin 313-316 NEWENTRY Severe acute respiratory syndrome-related coronavirus 166-170 34562771-0 2021 Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment. Ribavirin 53-62 glycophorin C (Gerbich blood group) Homo sapiens 17-30 34562771-4 2021 RESULTS: We identified a novel association in the gene coding glycophorin C (rs6741425; OR:0.12, 95%CI:0.04-0.34, P = 2.94 x 10-6) that predicts protection against ribavirin-induced anemia. Ribavirin 164-173 glycophorin C (Gerbich blood group) Homo sapiens 62-75 34562771-5 2021 We also replicated the associations of ITPA and VDR genetic variants with the development of ribavirin-induced anemia (rs1127354; OR:0.13, 95%CI:0.04-0.41, P = 8.66 x10-5; and rs1544410; OR:1.65, 95%CI:1.01-2.70, P = 0.0437). Ribavirin 93-102 vitamin D receptor Homo sapiens 48-51 34562771-6 2021 CONCLUSIONS: GYPC variation affecting erythrocyte membrane strength is important in predicting risk for developing ribavirin-induced anemia. Ribavirin 115-124 glycophorin C (Gerbich blood group) Homo sapiens 13-17 34463218-3 2021 Here, we modeled and predicted the functional domains of RAP-1 and RAP-2, docked with a ligand library comprising 128 phytoalexins reported with broad-spectrum activity, determined their binding energies (BEs), molecular interactions, and inhibition constant (Ki), and compared with the reference plant antiviral compounds ribavirin, ningnanmycin, and benzothiadiazole (BTH). Ribavirin 323-332 RAP1A, member of RAS oncogene family Homo sapiens 57-62 34091342-0 2021 Transformation of antiviral ribavirin during ozone/PMS intensified disinfection amid COVID-19 pandemic. Ribavirin 28-37 proline rich protein BstNI subfamily 1 Homo sapiens 51-54 34091342-3 2021 In this study, the transformation of ribavirin, antiviral for COVID-19, during ozone/PMS-chlorine intensified disinfection process was investigated. Ribavirin 37-46 proline rich protein BstNI subfamily 1 Homo sapiens 85-88 34091342-5 2021 During the O3/PMS process, ribavirin was dehydrogenated at the hydroxyl groups first, then lost the amide or the methanol group. Ribavirin 27-36 proline rich protein BstNI subfamily 1 Homo sapiens 14-17 34681251-1 2021 Continuing the work developed by our research group, in the present manuscript, we performed a theoretical study of 10 new structures derived from the antivirals cidofovir and ribavirin, as inhibitor prototypes for the enzyme thymidylate kinase from Variola virus (VarTMPK). Ribavirin 176-185 deoxythymidylate kinase Homo sapiens 226-244 34681251-1 2021 Continuing the work developed by our research group, in the present manuscript, we performed a theoretical study of 10 new structures derived from the antivirals cidofovir and ribavirin, as inhibitor prototypes for the enzyme thymidylate kinase from Variola virus (VarTMPK). Ribavirin 176-185 deoxythymidylate kinase Homo sapiens 265-272 34216268-10 2021 Our meta-analysis results suggest that IL28B rs12979860 CC is a strong predictor for SC of hepatitis C infection in PEG IFN-a/RBV-treated patients. Ribavirin 126-129 interferon lambda 3 Homo sapiens 39-44 34216268-10 2021 Our meta-analysis results suggest that IL28B rs12979860 CC is a strong predictor for SC of hepatitis C infection in PEG IFN-a/RBV-treated patients. Ribavirin 126-129 IFN1@ Homo sapiens 120-125 34307188-2 2021 In this context, single nucleotide polymorphisms (SNPs) in the locus of interferon lambda 3 and 4 genes (IFNL3/4) have been important genetic markers of responsiveness to CHC as prognostic markers for the pegylated-Interferon-alpha/ribavirin (Peg-IFN-alpha/RBV). Ribavirin 232-241 interferon alpha 1 Homo sapiens 247-256 35636577-7 2022 However, improved proliferation and interferon-gamma production of HEV-specific CD8+ T cells and evolution of a memory-like phenotype was observed upon reduction of immunosuppression and/or ribavirin treatment and was associated with viral clearance. Ribavirin 190-199 interferon gamma Homo sapiens 36-52 34075374-7 2021 We confirmed the Nsp14-IMPDH2 protein interaction and found that IMPDH2 knockdown or chemical inhibition using ribavirin (RIB) and mycophenolic acid (MPA) abolishes Nsp14-mediated NF-kappaB activation and cytokine induction. Ribavirin 111-120 inosine monophosphate dehydrogenase 2 Homo sapiens 23-29 34075374-7 2021 We confirmed the Nsp14-IMPDH2 protein interaction and found that IMPDH2 knockdown or chemical inhibition using ribavirin (RIB) and mycophenolic acid (MPA) abolishes Nsp14-mediated NF-kappaB activation and cytokine induction. Ribavirin 111-120 nuclear factor kappa B subunit 1 Homo sapiens 180-189 34075374-7 2021 We confirmed the Nsp14-IMPDH2 protein interaction and found that IMPDH2 knockdown or chemical inhibition using ribavirin (RIB) and mycophenolic acid (MPA) abolishes Nsp14-mediated NF-kappaB activation and cytokine induction. Ribavirin 122-125 inosine monophosphate dehydrogenase 2 Homo sapiens 23-29 34075374-7 2021 We confirmed the Nsp14-IMPDH2 protein interaction and found that IMPDH2 knockdown or chemical inhibition using ribavirin (RIB) and mycophenolic acid (MPA) abolishes Nsp14-mediated NF-kappaB activation and cytokine induction. Ribavirin 122-125 nuclear factor kappa B subunit 1 Homo sapiens 180-189 34130467-9 2021 Ribavirin and tenofovir showed significant binding energy above -8 kcal/mol with seven HB interactions with the main protease and also spike protein. Ribavirin 0-9 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 135-140 35470570-0 2022 Ribavirin inhibits cell proliferation, metastasis and prolongs survival in soft tissue Sarcomas by down-regulating both type I PRMT1 and Type II PRMT5. Ribavirin 0-9 protein arginine N-methyltransferase 1 Mus musculus 127-132 35470570-0 2022 Ribavirin inhibits cell proliferation, metastasis and prolongs survival in soft tissue Sarcomas by down-regulating both type I PRMT1 and Type II PRMT5. Ribavirin 0-9 protein arginine N-methyltransferase 5 Mus musculus 145-150 35470570-3 2022 We showed that ribavirin inhibited growth and metastasis and prolonged survival in animals bearing soft tissue sarcoma (STS) cells by down-regulating the mRNA and protein levels of PRMT1/PRMT5 and attenuating the accumulation of asymmetric and symmetric di-methylation of arginine (ADMA and SDMA). Ribavirin 15-24 protein arginine N-methyltransferase 1 Mus musculus 181-186 35470570-3 2022 We showed that ribavirin inhibited growth and metastasis and prolonged survival in animals bearing soft tissue sarcoma (STS) cells by down-regulating the mRNA and protein levels of PRMT1/PRMT5 and attenuating the accumulation of asymmetric and symmetric di-methylation of arginine (ADMA and SDMA). Ribavirin 15-24 protein arginine N-methyltransferase 5 Mus musculus 187-192 35470570-3 2022 We showed that ribavirin inhibited growth and metastasis and prolonged survival in animals bearing soft tissue sarcoma (STS) cells by down-regulating the mRNA and protein levels of PRMT1/PRMT5 and attenuating the accumulation of asymmetric and symmetric di-methylation of arginine (ADMA and SDMA). Ribavirin 15-24 histocompatibility Y Mus musculus 291-295 35470570-4 2022 Furthermore, ribavirin lowered the permeability of the peritoneum in KM mice bearing S180 ascites via decreasing the level of VEGF. Ribavirin 13-22 vascular endothelial growth factor A Mus musculus 126-130 35470570-5 2022 Ribavirin was a potent inhibitor of cell proliferation and metastasis in STS cells through downregulation of both type I PRMT1 and type II PRMT5. Ribavirin 0-9 protein arginine N-methyltransferase 1 Mus musculus 121-126 35470570-5 2022 Ribavirin was a potent inhibitor of cell proliferation and metastasis in STS cells through downregulation of both type I PRMT1 and type II PRMT5. Ribavirin 0-9 protein arginine N-methyltransferase 5 Mus musculus 139-144 35510477-3 2022 The results reveal a comparable binding affinity of sofosbuvir, galidesivir, ribavirin and remdesivir compared with the physiological nucleotide triphosphates against R. oryzae RdRp as well as the SARS-CoV-2 RdRp as reported before. Ribavirin 77-86 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 177-181 35510477-3 2022 The results reveal a comparable binding affinity of sofosbuvir, galidesivir, ribavirin and remdesivir compared with the physiological nucleotide triphosphates against R. oryzae RdRp as well as the SARS-CoV-2 RdRp as reported before. Ribavirin 77-86 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 208-212 35636577-7 2022 However, improved proliferation and interferon-gamma production of HEV-specific CD8+ T cells and evolution of a memory-like phenotype was observed upon reduction of immunosuppression and/or ribavirin treatment and was associated with viral clearance. Ribavirin 190-199 CD8a molecule Homo sapiens 80-83 35339025-1 2022 OBJECTIVES: Ribavirin inhibits eukaryotic translation initiation factor 4E (eIF4E), thereby decreasing cap-dependent translation. Ribavirin 12-21 eukaryotic translation initiation factor 4E Homo sapiens 31-74 35185356-8 2022 The availability of FDA-approved anti-RdRp drugs (Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir) as potent drugs against SARS-CoV-2 that tightly bind to its RdRp may aid in the treatment of patients and reduce the risk of the mysterious new form of COVID-19 viral infection. Ribavirin 50-59 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 38-42 35185356-8 2022 The availability of FDA-approved anti-RdRp drugs (Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir) as potent drugs against SARS-CoV-2 that tightly bind to its RdRp may aid in the treatment of patients and reduce the risk of the mysterious new form of COVID-19 viral infection. Ribavirin 50-59 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 173-177 35524830-0 2022 hsa-miR-17-5p: A Possible Predictor of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir +- Ribavirin Therapy Efficacy in Hepatitis C Infection. Ribavirin 88-97 microRNA 17 Homo sapiens 0-10 35339025-1 2022 OBJECTIVES: Ribavirin inhibits eukaryotic translation initiation factor 4E (eIF4E), thereby decreasing cap-dependent translation. Ribavirin 12-21 eukaryotic translation initiation factor 4E Homo sapiens 76-81 35339025-3 2022 METHODS: In the pharmacodynamic study, ribavirin (400 mg BID for 14 days) was evaluated in 8 patients with HPV-positive localized oropharyngeal carcinoma with phosphorylated-eIF4E (p-eIF4E) >= 30%. Ribavirin 39-48 eukaryotic translation initiation factor 4E Homo sapiens 174-179 35339025-3 2022 METHODS: In the pharmacodynamic study, ribavirin (400 mg BID for 14 days) was evaluated in 8 patients with HPV-positive localized oropharyngeal carcinoma with phosphorylated-eIF4E (p-eIF4E) >= 30%. Ribavirin 39-48 eukaryotic translation initiation factor 4E Homo sapiens 183-188 35339025-8 2022 RESULTS: Six patients were evaluable in the pharmacodynamic study: 4 had decreased p-eIF4E after 14 days of ribavirin. Ribavirin 108-117 eukaryotic translation initiation factor 4E Homo sapiens 85-90 35339025-14 2022 CONCLUSION: Oral ribavirin decreases p-eIF4E levels and is well-tolerated. Ribavirin 17-26 eukaryotic translation initiation factor 4E Homo sapiens 39-44 35215955-10 2022 Conclusions: A trend of decline in eGFR at 1 year after SOF/VEL treatment was observed among diabetic patients with baseline eGFR >= 60 (mL/min/1.73 m2) and concomitant use of RBV. Ribavirin 176-179 small integral membrane protein 1 (Vel blood group) Homo sapiens 60-63 35240967-2 2022 Pegylated IFN-alpha-2a (PEG-IFN-alpha-2a) with ribavirin (RIB) therapy induces an array of cellular antiviral responses including dsRNA kinases (PKR), chemokines and cytokines to tackle the HCV infection. Ribavirin 47-56 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 145-148 35240967-2 2022 Pegylated IFN-alpha-2a (PEG-IFN-alpha-2a) with ribavirin (RIB) therapy induces an array of cellular antiviral responses including dsRNA kinases (PKR), chemokines and cytokines to tackle the HCV infection. Ribavirin 58-61 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 145-148 2833416-9 1988 When 1 mM virazole is added to the cell suspension to deplete the guanyl nucleotide pool, the resulting lipolysis due to IAP treatment is decreased by 85%, whereas GTP and cyclic AMP levels were decreased by 80 and 70%, respectively. Ribavirin 10-18 Cd47 molecule Rattus norvegicus 121-124 35211422-6 2022 A generalized additive mixed model (GAMM) was conducted to analyze the trending shift of aspartate aminotransferase/alanine transaminase-ratio (AST/ALT-ratio) and platelet (PLT) in SFTS patients treated with ribavirin. Ribavirin 208-217 solute carrier family 17 member 5 Homo sapiens 144-147 35211422-16 2022 Treatment with ribavirin could increase PLT count while decreasing AST/ALT-ratio within SFTS patients. Ribavirin 15-24 solute carrier family 17 member 5 Homo sapiens 67-70 2949069-5 1987 However, mast cells cultured in 1 to 20 microM ribavirin for 1 to 7 days exhibited dose- and time-dependent inhibitions of stimulated beta-hexosaminidase and leukotriene C4 releases without altering mast cell mediator content. Ribavirin 47-56 O-GlcNAcase Mus musculus 134-153 6660848-1 1983 Ribavirin, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxyamide (Virazole; Viratek, Inc., Covina, Calif. Ribavirin 0-9 CCR4-NOT transcription complex subunit 8 Homo sapiens 98-103 6703684-2 1984 Human interferon-alpha 2 interacted additively or synergistically with rimantadine hydrochloride or ribavirin in reducing the yield of clinical isolates of either H3N2 or H1N1 subtype influenza A viruses. Ribavirin 100-109 interferon alpha 2 Homo sapiens 6-24 169109-10 1975 A nonlethal, principally upper respiratory tract infection of hamsters induced by the HA-1 virus was inhibited by ribavirin therapy. Ribavirin 114-123 Rho GTPase activating protein 45 Homo sapiens 86-90 7370262-7 1980 The additional attractive interactions between the carboxamide and the phosphate groups favour the syn glycosyl conformation in the 5"-monophosphates of ribavirin as well as pyrazomycin smaller to guanosine 5"-monophosphate whereas the anti conformation is strongly favoured for the 5"-nucleotides of tetrazole and showdomycin similar to other common purine and pyrimidine nucleotides. Ribavirin 153-162 synemin Homo sapiens 99-102 210448-0 1978 Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Ribavirin 46-55 adenosine kinase Homo sapiens 0-16 210448-4 1978 Resistance to the effect of ribavirin on purine excretion was associated only with those cell lines deficient in adenosine kinase activity. Ribavirin 28-37 adenosine kinase Homo sapiens 113-129 210448-6 1978 Therefore, the nucleoside kinase activity responsible for ribavirin phosphorylation is adenosine kinase. Ribavirin 58-67 adenosine kinase Homo sapiens 87-103 646339-3 1978 One-hour treatment with 25 muM ribavirin or 18 h with 2 muM inhibited the deoxyribonucleic acid synthesis to 50%. Ribavirin 31-40 latexin Homo sapiens 27-30 169109-1 1975 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) had significant in vitro activity against type 1 parainfluenza (Sendai) and type 3 parainogenic (HA-1) viruses. Ribavirin 0-51 Rho GTPase activating protein 45 Homo sapiens 161-165 169109-1 1975 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) had significant in vitro activity against type 1 parainfluenza (Sendai) and type 3 parainogenic (HA-1) viruses. Ribavirin 53-62 Rho GTPase activating protein 45 Homo sapiens 161-165 6307139-2 1983 In its activity against vesicular stomatitis virus, parainfluenza virus, measles and reo virus, C-c3 Ado proved about 100 times more potent than other established broad-spectrum antiviraL agents such as ribavirin (virazole) and (S)-DHPA ((S)-9-(2,3-dihydroxypropyl)adenine). Ribavirin 203-212 caspase 3 Mus musculus 96-100 6307139-2 1983 In its activity against vesicular stomatitis virus, parainfluenza virus, measles and reo virus, C-c3 Ado proved about 100 times more potent than other established broad-spectrum antiviraL agents such as ribavirin (virazole) and (S)-DHPA ((S)-9-(2,3-dihydroxypropyl)adenine). Ribavirin 214-222 caspase 3 Mus musculus 96-100 6108911-5 1980 Enzymatic nucleotide analyses in cell and tissue extracts after treatment with ribavirin indicated that ribavirin 5"-triphosphate was an effective substrate for yeast hexokinase, yeast phosphoglycerate kinase, and nucleosidediphosphate kinase from yeast or bovine liver. Ribavirin 79-88 hexokinase Saccharomyces cerevisiae S288C 167-177 6108911-5 1980 Enzymatic nucleotide analyses in cell and tissue extracts after treatment with ribavirin indicated that ribavirin 5"-triphosphate was an effective substrate for yeast hexokinase, yeast phosphoglycerate kinase, and nucleosidediphosphate kinase from yeast or bovine liver. Ribavirin 79-88 phosphoglycerate kinase Saccharomyces cerevisiae S288C 185-208 1069980-1 1976 One of the factors required for the antiviral activity of the synthetic nucleoside, ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), is the ability of the molecule to adopt the substrate conformation specified by the enzyme for which it is a competitive inhibitor, inosine 5"-phosphate dehydrogenase (IMP:NAD+ oxidoreductase, EC 1.2.1.14). Ribavirin 84-93 hydroxysteroid 17-beta dehydrogenase 6 Homo sapiens 326-340 1069980-2 1976 The calculated glycosidic minimum for ribavirin is the high syn conformation, which is in agreement with experimental determinations of the molecule"s solution conformation. Ribavirin 38-47 synemin Homo sapiens 60-63 984798-1 1976 Virazole (Ribavirin, ICN 1229), a broad-spectrum, antiviral chemotherapeutic agent was used to treat two adult chronically hepatitis B surface antigen (HB(s) Ag)-seropositive chimpanzees. Ribavirin 0-8 S-antigen visual arrestin Pan troglodytes 123-160 33600068-8 2021 However, patients treated with ribavirin (RBV)-free DAA showed a significant decrease in CD8+ cells (-204.3 cells/mm3 , 95%CI -375.0;-33.4, p=0.019), while patients treated with RBV experienced CD8+ cell increase (+141.2 cells/mm3 , 95%CI 40.3;242.1, p=0.006). Ribavirin 31-40 CD8a molecule Homo sapiens 89-92 33980604-5 2021 Mizoribine and ribavirin mapped to the ENT1 substrate pharmacophore and proved to be substrates of the ENTs. Ribavirin 15-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-43 33980604-7 2021 NBMPR also decreased ribavirin accumulation in ENT1 and ENT2 cells (ENT1: ~50% decrease p = 0.0498; ENT2: ~30% decrease p = 0.0125). Ribavirin 21-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-51 33980604-7 2021 NBMPR also decreased ribavirin accumulation in ENT1 and ENT2 cells (ENT1: ~50% decrease p = 0.0498; ENT2: ~30% decrease p = 0.0125). Ribavirin 21-30 solute carrier family 29 member 2 Homo sapiens 56-60 32338164-6 2021 The results show the effectiveness of Sofosbuvir, Ribavirin, Galidesivir, Remdesivir, Favipiravir, Cefuroxime, Tenofovir, and Hydroxychloroquine, in binding to SARS-CoV-2 RdRp. Ribavirin 50-59 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 171-175 33755912-7 2021 Our results demonstrated that RSV-induced IFN-alpha excessive secretion was moderately inhibited by indole-3-carboxaldehyde through downregulation of mRNA expression in a dose-dependent manner, in comparison, the inhibitory effects of ribavirin were too strong. Ribavirin 235-244 interferon alpha Mus musculus 42-51 33961695-3 2021 beta-D-N 4-hydroxycytidine (NHC, the initial metabolite of molnupiravir) is more than 100-fold more active than ribavirin or favipiravir against SARS-CoV-2, with antiviral activity correlated to the level of mutagenesis in virion RNA. Ribavirin 112-121 high mobility group nucleosomal binding domain 4 Homo sapiens 28-31 33556871-4 2021 The present article provides an overview of these small-molecule therapeutics based on insights from medicinal chemistry research and focuses on RNA-dependent RNA polymerase (RdRp) inhibitors, such as the nucleoside analogues remdesivir, favipiravir and ribavirin. Ribavirin 254-263 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 175-179 33689451-0 2021 Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 In Vitro. Ribavirin 0-9 transmembrane serine protease 2 Homo sapiens 88-95 33689451-0 2021 Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 In Vitro. Ribavirin 0-9 angiotensin converting enzyme 2 Homo sapiens 118-122 33689451-5 2021 According to the detailed molecular techniques, Ribavirin was shown to decrease the expression of TMPRSS2 both at mRNA and protein levels 48 hours after treatment. Ribavirin 48-57 transmembrane serine protease 2 Homo sapiens 98-105 33689451-6 2021 The suppressive effect of Ribavirin in ACE2 protein expression was shown to be dependent on cell types. Ribavirin 26-35 angiotensin converting enzyme 2 Homo sapiens 39-43 33689451-7 2021 Finally, proteolytic activity assays showed that Ribavirin also showed an inhibitory effect on TMPRSS2 enzyme. Ribavirin 49-58 transmembrane serine protease 2 Homo sapiens 95-102 33689451-8 2021 Based on these results, we hypothesized that Ribavirin may inhibit the expression of TMPRSS2 by modulating the formation of inhibitory G-quadruplex structures at the TMPRSS2 promoter. Ribavirin 45-54 transmembrane serine protease 2 Homo sapiens 85-92 33689451-8 2021 Based on these results, we hypothesized that Ribavirin may inhibit the expression of TMPRSS2 by modulating the formation of inhibitory G-quadruplex structures at the TMPRSS2 promoter. Ribavirin 45-54 transmembrane serine protease 2 Homo sapiens 166-173 33689451-9 2021 As a conclusion, Ribavirin is a potential antiviral drug for the treatment against SARS-CoV-2, and it interferes with the effect of TMPRSS2 and ACE2 expression. Ribavirin 17-26 transmembrane serine protease 2 Homo sapiens 132-139 33689451-9 2021 As a conclusion, Ribavirin is a potential antiviral drug for the treatment against SARS-CoV-2, and it interferes with the effect of TMPRSS2 and ACE2 expression. Ribavirin 17-26 angiotensin converting enzyme 2 Homo sapiens 144-148 33600068-8 2021 However, patients treated with ribavirin (RBV)-free DAA showed a significant decrease in CD8+ cells (-204.3 cells/mm3 , 95%CI -375.0;-33.4, p=0.019), while patients treated with RBV experienced CD8+ cell increase (+141.2 cells/mm3 , 95%CI 40.3;242.1, p=0.006). Ribavirin 31-40 CD8a molecule Homo sapiens 194-197 33600068-8 2021 However, patients treated with ribavirin (RBV)-free DAA showed a significant decrease in CD8+ cells (-204.3 cells/mm3 , 95%CI -375.0;-33.4, p=0.019), while patients treated with RBV experienced CD8+ cell increase (+141.2 cells/mm3 , 95%CI 40.3;242.1, p=0.006). Ribavirin 42-45 CD8a molecule Homo sapiens 89-92 33600068-8 2021 However, patients treated with ribavirin (RBV)-free DAA showed a significant decrease in CD8+ cells (-204.3 cells/mm3 , 95%CI -375.0;-33.4, p=0.019), while patients treated with RBV experienced CD8+ cell increase (+141.2 cells/mm3 , 95%CI 40.3;242.1, p=0.006). Ribavirin 42-45 CD8a molecule Homo sapiens 194-197 33600068-8 2021 However, patients treated with ribavirin (RBV)-free DAA showed a significant decrease in CD8+ cells (-204.3 cells/mm3 , 95%CI -375.0;-33.4, p=0.019), while patients treated with RBV experienced CD8+ cell increase (+141.2 cells/mm3 , 95%CI 40.3;242.1, p=0.006). Ribavirin 178-181 CD8a molecule Homo sapiens 89-92 33600068-10 2021 However, a fast decline of CD8+ T cells has been observed in patients treated without RBV, suggesting a favorable effect of HCV clearance on the general state of immune activation. Ribavirin 86-89 CD8a molecule Homo sapiens 27-30 32839082-0 2021 Insulin resistance in children with chronic hepatitis C and its association with response to IFN-alpha and ribavirin. Ribavirin 107-116 insulin Homo sapiens 0-7 32839082-1 2021 OBJECTIVE: The aim of our study was to evaluate the association between insulin resistance and the response to IFN-alpha and ribavirin in pediatric patients with chronic hepatitis C. METHODS: Twenty-six patients with chronic hepatitis C (mean age: 12.5 +- 1.96 years, M/F:3.33) were included in the study. Ribavirin 125-134 insulin Homo sapiens 72-79 33577917-0 2021 Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation. Ribavirin 0-9 protein arginine N-methyltransferase 5 Mus musculus 62-67 33152425-13 2021 Further, the total expression of RIG-I, MyD88 and NF-kappaB proteins had increased significantly in the VC group but reduced obviously in the group treated with ribavirin or carvacrol. Ribavirin 161-170 DEAD/H box helicase 58 Mus musculus 33-38 33152425-13 2021 Further, the total expression of RIG-I, MyD88 and NF-kappaB proteins had increased significantly in the VC group but reduced obviously in the group treated with ribavirin or carvacrol. Ribavirin 161-170 myeloid differentiation primary response gene 88 Mus musculus 40-45 33577917-2 2021 Ribavirin, the only clinically approved drug known to target eIF4E, is an anti-viral molecule currently used in hepatitis C therapy. Ribavirin 0-9 eukaryotic translation initiation factor 4E Homo sapiens 61-66 33577917-4 2021 Ribavirin treatment in CRC cell lines drastically inhibited cell proliferation and colony formation, induced S phase arrest and reduced cyclin D1, cyclin A/E and proliferating cell nuclear antigen (PCNA) levels in vitro, and suppressed tumorigenesis in mouse model of colitis-associated CRC. Ribavirin 0-9 cyclin D1 Mus musculus 136-145 33577917-4 2021 Ribavirin treatment in CRC cell lines drastically inhibited cell proliferation and colony formation, induced S phase arrest and reduced cyclin D1, cyclin A/E and proliferating cell nuclear antigen (PCNA) levels in vitro, and suppressed tumorigenesis in mouse model of colitis-associated CRC. Ribavirin 0-9 cyclin A2 Mus musculus 147-157 33577917-4 2021 Ribavirin treatment in CRC cell lines drastically inhibited cell proliferation and colony formation, induced S phase arrest and reduced cyclin D1, cyclin A/E and proliferating cell nuclear antigen (PCNA) levels in vitro, and suppressed tumorigenesis in mouse model of colitis-associated CRC. Ribavirin 0-9 proliferating cell nuclear antigen Mus musculus 162-196 33577917-4 2021 Ribavirin treatment in CRC cell lines drastically inhibited cell proliferation and colony formation, induced S phase arrest and reduced cyclin D1, cyclin A/E and proliferating cell nuclear antigen (PCNA) levels in vitro, and suppressed tumorigenesis in mouse model of colitis-associated CRC. Ribavirin 0-9 proliferating cell nuclear antigen Mus musculus 198-202 33577917-5 2021 Mechanistically, Ribavirin treatment significantly reduced PRMT5 and eIF4E protein levels and the accumulation of symmetric dimethylation of histone 3 at arginine 8 (H3R8me2s) and that of histone 4 at arginine 3 (H4R3me2s). Ribavirin 17-26 protein arginine N-methyltransferase 5 Mus musculus 59-64 33577917-5 2021 Mechanistically, Ribavirin treatment significantly reduced PRMT5 and eIF4E protein levels and the accumulation of symmetric dimethylation of histone 3 at arginine 8 (H3R8me2s) and that of histone 4 at arginine 3 (H4R3me2s). Ribavirin 17-26 eukaryotic translation initiation factor 4E Mus musculus 69-74 33577917-6 2021 Importantly, inhibition of PRMT5 by ribavirin resulted in promoted H3R8 methylation in eIF4E promoter region. Ribavirin 36-45 protein arginine N-methyltransferase 5 Mus musculus 27-32 33577917-6 2021 Importantly, inhibition of PRMT5 by ribavirin resulted in promoted H3R8 methylation in eIF4E promoter region. Ribavirin 36-45 eukaryotic translation initiation factor 4E Mus musculus 87-92 33577917-7 2021 Our results demonstrate the anti-cancer efficacy of ribavirin in CRC and suggest that the anti-cancer efficacy of ribavirin may be mediated by downregulating PRMT5 levels but not its enzymatic activity. Ribavirin 114-123 protein arginine N-methyltransferase 5 Mus musculus 158-163 33376595-7 2020 In vivo, in patients with chronic hepatitis C, 2 days after starting pegIFN/ribavirin therapy, a stronger ISG15 inducibility correlates with a milder Treg depletion. Ribavirin 76-85 ISG15 ubiquitin like modifier Homo sapiens 106-111 33545678-0 2021 Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma. Ribavirin 24-33 sonic hedgehog signaling molecule Homo sapiens 37-40 33545678-2 2021 Recent drug repurposing efforts in multiple solid and hematologic malignancies have demonstrated that eIF4E and EZH2 are both pharmacologically inhibited by the FDA-approved antiviral drug ribavirin. Ribavirin 189-198 eukaryotic translation initiation factor 4E Homo sapiens 102-107 33545678-2 2021 Recent drug repurposing efforts in multiple solid and hematologic malignancies have demonstrated that eIF4E and EZH2 are both pharmacologically inhibited by the FDA-approved antiviral drug ribavirin. Ribavirin 189-198 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 112-116 33545678-10 2021 CONCLUSIONS: The authors demonstrate that ribavirin, a clinically used drug known to inhibit eIF4E and EZH2, has significant antitumor effects in multiple preclinical models of medulloblastoma, including an aggressive group 3 animal model. Ribavirin 42-51 eukaryotic translation initiation factor 4E Homo sapiens 93-98 33545678-10 2021 CONCLUSIONS: The authors demonstrate that ribavirin, a clinically used drug known to inhibit eIF4E and EZH2, has significant antitumor effects in multiple preclinical models of medulloblastoma, including an aggressive group 3 animal model. Ribavirin 42-51 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 103-107 33347311-5 2021 The inhibitors of the virus entry to cells and RdRp, such as Arbidol, remdesivir, favipiravir, EIDD-2081, and ribavirin, are in clinical trials, while most of the protease inhibitors are mainly calculated by molecular docking technology, which needs in vivo and in vitro experiments to prove the effect for SARS-CoV-2. Ribavirin 110-119 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 47-51 33421473-6 2021 In-silico screening, molecular mechanics, molecular dynamics simulation (MDS) analysis suggest ribavirin, and remdesivir have good interaction with the binding site of the RdRp protein as compared to other antiviral investigated. Ribavirin 95-104 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 172-176 32807688-2 2021 Lopinavir-interferon alpha2b boosted ribavirin following with lopinavir boosted budesonide might be a potent treatment for viral clearance. Ribavirin 37-46 interferon alpha 2 Homo sapiens 10-28 33087448-4 2021 We confirmed the functions of major intestinal uptake/efflux drug transporters in freshly-isolated human jejunum sections by demonstrating a significant decrease in the mucosal uptake of cefadroxil (PEPT1) and methotrexate (PCFT), mucosal-to-serosal permeability of ribavirin (CNTs/ENTs), and serosal-to-mucosal permeability of P-gp and BCRP substrates in the presence of their typical inhibitors. Ribavirin 266-275 solute carrier family 15 member 1 Homo sapiens 199-204 32885325-2 2020 The aim of this study was to investigate the effect of pegylated interferon alpha (IFNalpha) + ribavirin (PegIFNalpha+RVB) or sofosbuvir + NS5A inhibitor (SOF+InNS5A) on IR and the components of OS. Ribavirin 95-104 interferon alpha 1 Homo sapiens 106-117 33127459-0 2020 Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin. Ribavirin 141-150 interferon lambda 4 (gene/pseudogene) Homo sapiens 0-19 32656649-3 2020 Here, we report three patients with HCV NS5A-P32del infection who were treated with sofosbuvir, velpatasvir plus ribavirin (SOF/VEL + RBV) in a real-world setting. Ribavirin 113-122 small integral membrane protein 1 (Vel blood group) Homo sapiens 128-131 32816249-10 2020 Age > 65 years, baseline eGFR, and ribavirin-containing regimens were independent risk factors of eGFR decline during and after SOF-based treatment. Ribavirin 35-44 epidermal growth factor receptor Homo sapiens 98-102 33127459-2 2020 So, a single nucleotide polymorphisms (SNP) of IFNL4 gene genotypes and its relationship with Sofosbuvir (SOF) and Ribavirin (RBV) treatment response is under consideration. Ribavirin 115-124 interferon lambda 4 (gene/pseudogene) Homo sapiens 47-52 33127459-2 2020 So, a single nucleotide polymorphisms (SNP) of IFNL4 gene genotypes and its relationship with Sofosbuvir (SOF) and Ribavirin (RBV) treatment response is under consideration. Ribavirin 126-129 interferon lambda 4 (gene/pseudogene) Homo sapiens 47-52 33612760-3 2020 Several studies had demonstrated that baseline serum interferon-gamma-inducible-protein 10 (IP-10) levels and interleukin 28B polymorphisms were associated with the resistance to the standard of care pegylated interferon alpha and ribavirin (PEG-IFNalpha/RBV) therapy and development of post-treatment relapse. Ribavirin 231-240 C-X-C motif chemokine ligand 10 Homo sapiens 53-90 33612760-3 2020 Several studies had demonstrated that baseline serum interferon-gamma-inducible-protein 10 (IP-10) levels and interleukin 28B polymorphisms were associated with the resistance to the standard of care pegylated interferon alpha and ribavirin (PEG-IFNalpha/RBV) therapy and development of post-treatment relapse. Ribavirin 231-240 C-X-C motif chemokine ligand 10 Homo sapiens 92-97 33612760-3 2020 Several studies had demonstrated that baseline serum interferon-gamma-inducible-protein 10 (IP-10) levels and interleukin 28B polymorphisms were associated with the resistance to the standard of care pegylated interferon alpha and ribavirin (PEG-IFNalpha/RBV) therapy and development of post-treatment relapse. Ribavirin 231-240 interferon lambda 3 Homo sapiens 110-125 33260359-0 2020 The Aerogen Solo Is an Alternative to the Small Particle Aerosol Generator (SPAG-2) for Administration of Inhaled Ribavirin. Ribavirin 115-124 UDP-N-acetylglucosamine pyrophosphorylase 1 Homo sapiens 77-83 33260359-3 2020 The Small-Particle Aerosol Generator delivery system (SPAG-2) is the only FDA-cleared device to deliver inhaled ribavirin. Ribavirin 112-121 UDP-N-acetylglucosamine pyrophosphorylase 1 Homo sapiens 54-60 32933750-0 2020 Identification of ribavirin-responsive cis-elements for GPAM suppression in the GPAM genome. Ribavirin 18-27 glycerol-3-phosphate acyltransferase, mitochondrial Homo sapiens 56-60 32933750-0 2020 Identification of ribavirin-responsive cis-elements for GPAM suppression in the GPAM genome. Ribavirin 18-27 glycerol-3-phosphate acyltransferase, mitochondrial Homo sapiens 80-84 32933750-2 2020 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) reduces GPAM expression by downregulating CCAAT/enhancer-binding protein alpha (C/EBPalpha). Ribavirin 51-60 glycerol-3-phosphate acyltransferase, mitochondrial Homo sapiens 75-79 32933750-2 2020 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) reduces GPAM expression by downregulating CCAAT/enhancer-binding protein alpha (C/EBPalpha). Ribavirin 51-60 CCAAT enhancer binding protein alpha Homo sapiens 109-145 32933750-2 2020 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) reduces GPAM expression by downregulating CCAAT/enhancer-binding protein alpha (C/EBPalpha). Ribavirin 51-60 CCAAT enhancer binding protein alpha Homo sapiens 147-157 32933750-2 2020 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) reduces GPAM expression by downregulating CCAAT/enhancer-binding protein alpha (C/EBPalpha). Ribavirin 62-65 glycerol-3-phosphate acyltransferase, mitochondrial Homo sapiens 75-79 32933750-2 2020 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) reduces GPAM expression by downregulating CCAAT/enhancer-binding protein alpha (C/EBPalpha). Ribavirin 62-65 CCAAT enhancer binding protein alpha Homo sapiens 109-145 32933750-2 2020 Recently, we demonstrated that the anti-viral drug ribavirin (RBV) reduces GPAM expression by downregulating CCAAT/enhancer-binding protein alpha (C/EBPalpha). Ribavirin 62-65 CCAAT enhancer binding protein alpha Homo sapiens 147-157 33179586-6 2022 We have also performed docking of drugs Lopinavir, Ribavirin, and Azithromycin on SARS-CoV-2 Mpro. Ribavirin 51-60 NEWENTRY Severe acute respiratory syndrome-related coronavirus 93-97 33193695-7 2020 Ribavirin was predicted to be the best small molecular drug, with a higher molecular binding energy of -6.39 kcal/mol with human angiotensin-converting enzyme 2 (ACE2), followed by remdesivir (-7.4 kcal/mol), mycophenolic acid (-5.35 kcal/mol), and chloroquine (-6.29 kcal/mol). Ribavirin 0-9 angiotensin converting enzyme 2 Homo sapiens 129-160 32786685-7 2020 The drug repurposing study revealed the high potential of noscapine and proximal binding to the Mpro enzyme in a comparative binding pattern analyzed with chloroquine, ribavirin, and favipiravir. Ribavirin 168-177 NEWENTRY Severe acute respiratory syndrome-related coronavirus 96-100 32934745-5 2020 The combination of ribavirin with TMZ and IFN-beta displayed a significant cell growth inhibitory effect with a ribavirin dose-dependency, including a relatively low concentration of ribavirin, on not only TMZ-sensitive but also TMZ-resistant malignant glioma cells. Ribavirin 112-121 IFN1@ Homo sapiens 42-50 32934745-5 2020 The combination of ribavirin with TMZ and IFN-beta displayed a significant cell growth inhibitory effect with a ribavirin dose-dependency, including a relatively low concentration of ribavirin, on not only TMZ-sensitive but also TMZ-resistant malignant glioma cells. Ribavirin 112-121 IFN1@ Homo sapiens 42-50 33080900-7 2020 Our MD simulations suggest that the combination of caffeine with ribavirin shows a stronger interaction with 6VW1, while in case of favipiravir+nicotine, 6LZG shows potent efficacy of these interaction, proposing the potent efficacy of these combinations for blocking ACE2 receptor against SARS-CoV-2. Ribavirin 65-74 angiotensin converting enzyme 2 Homo sapiens 268-272 32878881-6 2020 In silico screening, molecular mechanics and molecular dynamics simulation (MDS) analysis suggest ribavirin, ascorbate, lopinavir and hydroxychloroquine have strong interaction at the RBD-hACE2 interface. Ribavirin 98-107 angiotensin converting enzyme 2 Homo sapiens 188-193 32750467-0 2020 Mutations on VEEV nsP1 relate RNA capping efficiency to ribavirin susceptibility. Ribavirin 56-65 SH2 domain containing 3A Homo sapiens 18-22 32750467-7 2020 In the current study we performed a mutational analysis on two nsP1 positions associated with Sindbis virus (SINV) ribavirin resistance in the Venezuelan equine encephalitis virus (VEEV) context through reverse genetics correlated to enzyme assays using purified recombinant VEEV nsP1 proteins. Ribavirin 115-124 SH2 domain containing 3A Homo sapiens 63-67 32750467-7 2020 In the current study we performed a mutational analysis on two nsP1 positions associated with Sindbis virus (SINV) ribavirin resistance in the Venezuelan equine encephalitis virus (VEEV) context through reverse genetics correlated to enzyme assays using purified recombinant VEEV nsP1 proteins. Ribavirin 115-124 SH2 domain containing 3A Homo sapiens 280-284 33193695-7 2020 Ribavirin was predicted to be the best small molecular drug, with a higher molecular binding energy of -6.39 kcal/mol with human angiotensin-converting enzyme 2 (ACE2), followed by remdesivir (-7.4 kcal/mol), mycophenolic acid (-5.35 kcal/mol), and chloroquine (-6.29 kcal/mol). Ribavirin 0-9 angiotensin converting enzyme 2 Homo sapiens 162-166 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 solute carrier organic anion transporter family member 1B1 Homo sapiens 241-248 32606016-7 2020 Modulation of EZH2, Snail, eIF4E, IMPDH, mTOR, and cyclin D1 were observed in western blots and enzymatic activity assays in response to ribavirin treatment. Ribavirin 137-146 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 14-18 32606016-7 2020 Modulation of EZH2, Snail, eIF4E, IMPDH, mTOR, and cyclin D1 were observed in western blots and enzymatic activity assays in response to ribavirin treatment. Ribavirin 137-146 snail family transcriptional repressor 1 Homo sapiens 20-25 32606016-7 2020 Modulation of EZH2, Snail, eIF4E, IMPDH, mTOR, and cyclin D1 were observed in western blots and enzymatic activity assays in response to ribavirin treatment. Ribavirin 137-146 eukaryotic translation initiation factor 4E Homo sapiens 27-32 32606016-7 2020 Modulation of EZH2, Snail, eIF4E, IMPDH, mTOR, and cyclin D1 were observed in western blots and enzymatic activity assays in response to ribavirin treatment. Ribavirin 137-146 mechanistic target of rapamycin kinase Homo sapiens 41-45 32606016-7 2020 Modulation of EZH2, Snail, eIF4E, IMPDH, mTOR, and cyclin D1 were observed in western blots and enzymatic activity assays in response to ribavirin treatment. Ribavirin 137-146 cyclin D1 Homo sapiens 51-60 32606016-10 2020 Our work suggests that NPC responds to ribavirin-mediated EZH2, Snail, eIF4E, IMPDH, and mTOR changes and positions ribavirin for clinical evaluation as a potential addition to our NPC treatment armamentarium. Ribavirin 39-48 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 58-62 32606016-10 2020 Our work suggests that NPC responds to ribavirin-mediated EZH2, Snail, eIF4E, IMPDH, and mTOR changes and positions ribavirin for clinical evaluation as a potential addition to our NPC treatment armamentarium. Ribavirin 39-48 snail family transcriptional repressor 1 Homo sapiens 64-69 32606016-10 2020 Our work suggests that NPC responds to ribavirin-mediated EZH2, Snail, eIF4E, IMPDH, and mTOR changes and positions ribavirin for clinical evaluation as a potential addition to our NPC treatment armamentarium. Ribavirin 39-48 eukaryotic translation initiation factor 4E Homo sapiens 71-76 32606016-10 2020 Our work suggests that NPC responds to ribavirin-mediated EZH2, Snail, eIF4E, IMPDH, and mTOR changes and positions ribavirin for clinical evaluation as a potential addition to our NPC treatment armamentarium. Ribavirin 39-48 mechanistic target of rapamycin kinase Homo sapiens 89-93 32736668-0 2020 Inhibition of eIF4E signaling by ribavirin selectively targets lung cancer and angiogenesis. Ribavirin 33-42 eukaryotic translation initiation factor 4E Homo sapiens 14-19 32736668-8 2020 The mechanism studies demonstrate that ribavirin acts on lung cancer cells via suppressing eIF4E and mTOR signaling, leading to the subsequent inhibition of eIF4E-mediated protein translation. Ribavirin 39-48 eukaryotic translation initiation factor 4E Homo sapiens 91-96 32736668-8 2020 The mechanism studies demonstrate that ribavirin acts on lung cancer cells via suppressing eIF4E and mTOR signaling, leading to the subsequent inhibition of eIF4E-mediated protein translation. Ribavirin 39-48 mechanistic target of rapamycin kinase Homo sapiens 101-105 32736668-8 2020 The mechanism studies demonstrate that ribavirin acts on lung cancer cells via suppressing eIF4E and mTOR signaling, leading to the subsequent inhibition of eIF4E-mediated protein translation. Ribavirin 39-48 eukaryotic translation initiation factor 4E Homo sapiens 157-162 32240711-0 2020 Successful ongoing retreatment with glecaprevir/pibrentasvir+sofosbuvir+ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance. Ribavirin 72-81 KRAS proto-oncogene, GTPase Homo sapiens 161-164 32294532-7 2020 In addition, pegIFN-alpha/ribavirin therapy induced C19orf66 expression in CHC patients. Ribavirin 26-35 shiftless antiviral inhibitor of ribosomal frameshifting Homo sapiens 52-60 33016015-9 2020 Ribavirin, a nucleotide analogue anti-viral agent, inhibits moderately the Korean CDV propagation in the Vero/dSLAM cells. Ribavirin 0-9 slow as molasses Drosophila melanogaster 110-115 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 112-118 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 120-126 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 solute carrier organic anion transporter family member 1A2 Homo sapiens 128-135 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 solute carrier organic anion transporter family member 1B1 Homo sapiens 141-148 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 ATP binding cassette subfamily B member 1 Homo sapiens 165-170 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 ATP binding cassette subfamily C member 2 Homo sapiens 250-255 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 184-191 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 solute carrier family 28 member 2 Homo sapiens 193-200 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 solute carrier family 28 member 3 Homo sapiens 206-213 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 257-262 32635975-6 2020 Ribavirin uptake was inhibited by nucleosides such as adenosine and uridine, and by inhibitors of equilibrative nucleoside transporter 1 (ENT1) such as S-(4-nitrobenzyl)-6-thioinosine and dipyridamole in a concentration-dependent manner. Ribavirin 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-136 32222463-0 2020 Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Ribavirin 0-9 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 111-115 32222463-6 2020 KEY FINDINGS: The results suggest the effectiveness of Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir as potent drugs against SARS-CoV-2 since they tightly bind to its RdRp. Ribavirin 55-64 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 183-187 28520373-5 2012 The FDA-approved drug label for simeprevir contains information regarding a genetic variant near the IFNL3 gene (a C to T change; rs12979860), which is a strong predictor of response to peginterferon alfa and ribavirin treatment. Ribavirin 209-218 interferon lambda 3 Homo sapiens 101-106 32635975-6 2020 Ribavirin uptake was inhibited by nucleosides such as adenosine and uridine, and by inhibitors of equilibrative nucleoside transporter 1 (ENT1) such as S-(4-nitrobenzyl)-6-thioinosine and dipyridamole in a concentration-dependent manner. Ribavirin 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 138-142 32635975-8 2020 On the other hand, Na+-dependence of ribavirin uptake was not observed, suggesting the involvement of ENT1, but not Na+-dependent concentrative nucleoside transporters, in ribavirin uptake in K562 cells. Ribavirin 172-181 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-106 32635975-10 2020 These results suggest that ribavirin uptake into K562 cells is mainly mediated by ENT1, which may have a pivotal role in anticancer effect of ribavirin. Ribavirin 27-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 32635975-10 2020 These results suggest that ribavirin uptake into K562 cells is mainly mediated by ENT1, which may have a pivotal role in anticancer effect of ribavirin. Ribavirin 142-151 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 32630479-0 2020 Changes in miR-122 and Cholesterol Expression in Chronic Hepatitis C Patients after PegIFN-Alpha/Ribavirin Treatment. Ribavirin 97-106 microRNA 122 Homo sapiens 11-18 32630479-5 2020 The purpose of this study was to investigate the impact of peginterferon alpha (pegIFN-alpha) and ribavirin treatments on the expression of miR-122 and the cholesterol level in the peripheral blood mononuclear cells (PBMCs) of CHC patients. Ribavirin 98-107 microRNA 122 Homo sapiens 140-147 32630479-8 2020 Consequently, it seems that the decrease of miR-122 expression in the PBMCs of CHC patients is one of the antiviral effects connected with the pegIFN-alpha/ribavirin treatments. Ribavirin 156-165 microRNA 122 Homo sapiens 44-51 32276399-5 2020 In addition, the IFNL4 genotype was the primary polymorphism responsible for a suboptimal treatment response to pegylated IFN-alpha and ribavirin. Ribavirin 136-145 interferon lambda 4 (gene/pseudogene) Homo sapiens 17-22 32568409-4 2020 During early treatment with peg-IFN-a2a plus ribavirin, the imbalance of these Tc17/IFN-gamma cells could be partially restored, together with normalized serum ALT but not AST. Ribavirin 45-54 interferon gamma Homo sapiens 84-93 32568409-4 2020 During early treatment with peg-IFN-a2a plus ribavirin, the imbalance of these Tc17/IFN-gamma cells could be partially restored, together with normalized serum ALT but not AST. Ribavirin 45-54 solute carrier family 17 member 5 Homo sapiens 172-175 32568409-5 2020 Also, we analyzed the dynamic change of the percentage of this T cells subset in patients with different outcome after 4-week course of treatment with peg-IFN-a2a plus ribavirin and found that the percentage of CD8+CD28+CD244+ T cells significantly decreased in recovered patients but not in non-recovered patients. Ribavirin 168-177 CD8a molecule Homo sapiens 211-214 32568409-5 2020 Also, we analyzed the dynamic change of the percentage of this T cells subset in patients with different outcome after 4-week course of treatment with peg-IFN-a2a plus ribavirin and found that the percentage of CD8+CD28+CD244+ T cells significantly decreased in recovered patients but not in non-recovered patients. Ribavirin 168-177 CD28 molecule Homo sapiens 215-219 32568409-5 2020 Also, we analyzed the dynamic change of the percentage of this T cells subset in patients with different outcome after 4-week course of treatment with peg-IFN-a2a plus ribavirin and found that the percentage of CD8+CD28+CD244+ T cells significantly decreased in recovered patients but not in non-recovered patients. Ribavirin 168-177 CD244 molecule Homo sapiens 220-225 32486887-0 2020 Peripheral Expression of CXCL10 Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, and Ribavirin. Ribavirin 111-120 C-X-C motif chemokine ligand 10 Homo sapiens 25-31 32486887-5 2020 This study aimed to examine the expression level of C-X-C motif chemokine ligand 10 (CXCL10) in the Peripheral blood mononuclear cells (PBMCs) of HCV infected patients treated with DAAs + Ribavirin. Ribavirin 188-197 C-X-C motif chemokine ligand 10 Homo sapiens 52-83 32486887-5 2020 This study aimed to examine the expression level of C-X-C motif chemokine ligand 10 (CXCL10) in the Peripheral blood mononuclear cells (PBMCs) of HCV infected patients treated with DAAs + Ribavirin. Ribavirin 188-197 C-X-C motif chemokine ligand 10 Homo sapiens 85-91 32486887-6 2020 In this study we analyzed the expression levels of CXCL10 mRNA in the 90 chronic HCV patients using quantitative PCR (qPCR) prior, after, and during therapy with sofosbuvir/ribavirin (SOF+RBV) and sofosbuvir/daclatasvir/ribavirin (SOF+DCV+RBV), and further, the results were analyzed relative to treatment response. Ribavirin 173-182 C-X-C motif chemokine ligand 10 Homo sapiens 51-57 32486887-10 2020 Comparing the 2 regimens, the reduction in peripheral CXCL10 expression was more pronounced in patients undergoing SOF+DCV+RBV therapy. Ribavirin 123-126 C-X-C motif chemokine ligand 10 Homo sapiens 54-60 32375574-2 2021 This study demonstrated the putative inhibitory potential of lopinavir, remdesivir, oseltamir, azithromycin, ribavirin, and chloroquine towards V-ATPase, protein kinase A, SARS-CoV spike glycoprotein/ACE-2 complex and viral proteases. Ribavirin 109-118 angiotensin converting enzyme 2 Homo sapiens 200-205 32346535-6 2020 Interferon-alpha (IFN-alpha) and its analogs, pegylated IFN-alpha (PEG-IFN-alpha) alone with ribavirin (RBV), have been the primary antiviral treatment of HCV for many years with a low cure rate. Ribavirin 93-102 interferon alpha 1 Homo sapiens 18-27 32346535-6 2020 Interferon-alpha (IFN-alpha) and its analogs, pegylated IFN-alpha (PEG-IFN-alpha) alone with ribavirin (RBV), have been the primary antiviral treatment of HCV for many years with a low cure rate. Ribavirin 104-107 interferon alpha 1 Homo sapiens 18-27 32112805-7 2020 In addition, ribavirin treatment (1, 5 and 10 muM) remarkably caused DNA damage which was shown by the increase of gammaH2AX-positive cells and upregulation of the p53 during the differentiation of hiPSCs from mesoderm to cardiac progenitor cells. Ribavirin 13-22 tumor protein p53 Homo sapiens 164-167 32112805-8 2020 Moreover, exposuring to ribavirin (5 and 10 muM) markedly upregulated the expression of lncRNAs Gas5 in both mid-phase and late phase of differentiation and HBL1 in the mid-phase. Ribavirin 24-33 growth arrest specific 5 Homo sapiens 96-100 32112805-9 2020 In conclusion, our results suggest that ribavirin is detrimental in cardiac differentiation of hiPSCs, which may be associated with DNA damage, upregulated p53 and increased Gas5. Ribavirin 40-49 tumor protein p53 Homo sapiens 156-159 32112805-9 2020 In conclusion, our results suggest that ribavirin is detrimental in cardiac differentiation of hiPSCs, which may be associated with DNA damage, upregulated p53 and increased Gas5. Ribavirin 40-49 growth arrest specific 5 Homo sapiens 174-178 31863490-4 2020 Expression of TRIM22 mRNA has been linked to outcome of PEG-IFN and ribavirin therapy, where its higher expression leads to rapid virus clearance. Ribavirin 68-77 tripartite motif containing 22 Homo sapiens 14-20 32034167-5 2020 Patients who received DAA in combination with Ribavirin maintained elevated levels of CXCL10, consistent with an immune-stimulatory role of Ribavirin. Ribavirin 46-55 C-X-C motif chemokine ligand 10 Homo sapiens 86-92 31980340-2 2020 The results showed compound c23 illustrates highly curative, protective and inactivating activities against TMV at 500 mg/L, with the values of 68.8%, 58.8%, 86.0% respectively, which were superior to that of Ribavirin (42.3%, 49.8%, 68.4%, respectively) and similar to that of Ningnanmycin (59.4%, 52.4%, 88.4%, respectively). Ribavirin 209-218 nucleolin Homo sapiens 28-31 31980340-3 2020 The EC50 value of inactivating activities of compound c23 is 9.3 mg/L, which was better than that of Ribavirin (135.2 mg/L), and equivalent to that of Ningnanmycin (8.8 mg/L). Ribavirin 101-110 nucleolin Homo sapiens 54-57 32091891-4 2020 The results showed that some antiviral molecules had strongly bound to ToCV mCP in vitro, including quinazoline derivatives 4a and 4b, Ningnanmycin, and Ribavirin. Ribavirin 153-162 CD46 antigen, complement regulatory protein Mus musculus 76-79 31810127-1 2020 PURPOSE: This study aimed to investigate the effect of single nucleotide polymorphisms (SNPs) of genes involved in ribavirin (RBV) transport (SLC28A2 gene, ABCB1 gene and ABCB11 gene) on the clinical outcome and pharmacokinetics of ribavirin in HCV- 4 Egyptian patients. Ribavirin 115-124 solute carrier family 28 member 2 Homo sapiens 142-149 32024338-0 2020 Thyroid disturbances in children treated with combined Pegylated Interferon alpha and Ribavirin for chronic hepatitis C. Background: Immunomodulatory properties of interferon (INF) have been documented. Ribavirin 86-95 cobalamin binding intrinsic factor Homo sapiens 164-180 32024338-10 2020 Conclusion: This study revealed an association between subclinical thyroid dysfunction and treatment with IFN-alpha and Ribavirin in children. Ribavirin 120-129 interferon alpha 1 Homo sapiens 106-115 31864069-6 2020 RESULTS: VA1 replication was inhibited 10-100-fold by both ribavirin (EC50 = 154 muM) and favipiravir (EC50 = 246 muM). Ribavirin 59-68 latexin Homo sapiens 81-84 31864069-6 2020 RESULTS: VA1 replication was inhibited 10-100-fold by both ribavirin (EC50 = 154 muM) and favipiravir (EC50 = 246 muM). Ribavirin 59-68 latexin Homo sapiens 114-117 31864069-7 2020 In contrast, ribavirin inhibited HAstV4 replication (EC50 = 268 muM) but favipiravir only reduced replication by 44% at the highest dose. Ribavirin 13-22 latexin Homo sapiens 64-67 31864069-8 2020 Mild reductions in ATP (17-31%) was only observed at the highest concentration of ribavirin (1000 muM) and no significant decrease in ATP was detected for any concentration of favipiravir. Ribavirin 82-91 latexin Homo sapiens 98-101 32475915-8 2020 Moreover, Ziyuglycoside II administration and ribavirin blocked toll-like receptor 4 (TLR4)/nuclear factor kappa-B (NF-kappaB) signaling pathway both in mRNA and protein level, which was paralleled with immunohistochemical assay. Ribavirin 46-55 toll like receptor 4 Homo sapiens 64-84 32475915-8 2020 Moreover, Ziyuglycoside II administration and ribavirin blocked toll-like receptor 4 (TLR4)/nuclear factor kappa-B (NF-kappaB) signaling pathway both in mRNA and protein level, which was paralleled with immunohistochemical assay. Ribavirin 46-55 toll like receptor 4 Homo sapiens 86-90 32475915-8 2020 Moreover, Ziyuglycoside II administration and ribavirin blocked toll-like receptor 4 (TLR4)/nuclear factor kappa-B (NF-kappaB) signaling pathway both in mRNA and protein level, which was paralleled with immunohistochemical assay. Ribavirin 46-55 nuclear factor kappa B subunit 1 Homo sapiens 116-125 31810127-1 2020 PURPOSE: This study aimed to investigate the effect of single nucleotide polymorphisms (SNPs) of genes involved in ribavirin (RBV) transport (SLC28A2 gene, ABCB1 gene and ABCB11 gene) on the clinical outcome and pharmacokinetics of ribavirin in HCV- 4 Egyptian patients. Ribavirin 115-124 ATP binding cassette subfamily B member 11 Homo sapiens 171-177 31810127-1 2020 PURPOSE: This study aimed to investigate the effect of single nucleotide polymorphisms (SNPs) of genes involved in ribavirin (RBV) transport (SLC28A2 gene, ABCB1 gene and ABCB11 gene) on the clinical outcome and pharmacokinetics of ribavirin in HCV- 4 Egyptian patients. Ribavirin 126-129 solute carrier family 28 member 2 Homo sapiens 142-149 31810127-1 2020 PURPOSE: This study aimed to investigate the effect of single nucleotide polymorphisms (SNPs) of genes involved in ribavirin (RBV) transport (SLC28A2 gene, ABCB1 gene and ABCB11 gene) on the clinical outcome and pharmacokinetics of ribavirin in HCV- 4 Egyptian patients. Ribavirin 126-129 ATP binding cassette subfamily B member 11 Homo sapiens 171-177 31810127-9 2020 CONCLUSION: SNP genotyping for ABCB1 and ABCB11 genes can help in better personalized medicine for maximizing response for ribavirin as explored by the significant association between polymorphism in ABCB1 and ABCB11 genes and ribavirin pharmacokinetics and the significant association of ABCB11 1331 T > C SNP with clinical response. Ribavirin 123-132 ATP binding cassette subfamily B member 1 Homo sapiens 31-36 31810127-9 2020 CONCLUSION: SNP genotyping for ABCB1 and ABCB11 genes can help in better personalized medicine for maximizing response for ribavirin as explored by the significant association between polymorphism in ABCB1 and ABCB11 genes and ribavirin pharmacokinetics and the significant association of ABCB11 1331 T > C SNP with clinical response. Ribavirin 123-132 ATP binding cassette subfamily B member 11 Homo sapiens 41-47 31810127-9 2020 CONCLUSION: SNP genotyping for ABCB1 and ABCB11 genes can help in better personalized medicine for maximizing response for ribavirin as explored by the significant association between polymorphism in ABCB1 and ABCB11 genes and ribavirin pharmacokinetics and the significant association of ABCB11 1331 T > C SNP with clinical response. Ribavirin 123-132 ATP binding cassette subfamily B member 1 Homo sapiens 41-46 31810127-9 2020 CONCLUSION: SNP genotyping for ABCB1 and ABCB11 genes can help in better personalized medicine for maximizing response for ribavirin as explored by the significant association between polymorphism in ABCB1 and ABCB11 genes and ribavirin pharmacokinetics and the significant association of ABCB11 1331 T > C SNP with clinical response. Ribavirin 123-132 ATP binding cassette subfamily B member 11 Homo sapiens 210-216 31810127-9 2020 CONCLUSION: SNP genotyping for ABCB1 and ABCB11 genes can help in better personalized medicine for maximizing response for ribavirin as explored by the significant association between polymorphism in ABCB1 and ABCB11 genes and ribavirin pharmacokinetics and the significant association of ABCB11 1331 T > C SNP with clinical response. Ribavirin 123-132 ATP binding cassette subfamily B member 11 Homo sapiens 210-216 31810127-9 2020 CONCLUSION: SNP genotyping for ABCB1 and ABCB11 genes can help in better personalized medicine for maximizing response for ribavirin as explored by the significant association between polymorphism in ABCB1 and ABCB11 genes and ribavirin pharmacokinetics and the significant association of ABCB11 1331 T > C SNP with clinical response. Ribavirin 227-236 ATP binding cassette subfamily B member 1 Homo sapiens 31-36 31810127-9 2020 CONCLUSION: SNP genotyping for ABCB1 and ABCB11 genes can help in better personalized medicine for maximizing response for ribavirin as explored by the significant association between polymorphism in ABCB1 and ABCB11 genes and ribavirin pharmacokinetics and the significant association of ABCB11 1331 T > C SNP with clinical response. Ribavirin 227-236 ATP binding cassette subfamily B member 11 Homo sapiens 41-47 31810127-9 2020 CONCLUSION: SNP genotyping for ABCB1 and ABCB11 genes can help in better personalized medicine for maximizing response for ribavirin as explored by the significant association between polymorphism in ABCB1 and ABCB11 genes and ribavirin pharmacokinetics and the significant association of ABCB11 1331 T > C SNP with clinical response. Ribavirin 227-236 ATP binding cassette subfamily B member 1 Homo sapiens 41-46 31810127-9 2020 CONCLUSION: SNP genotyping for ABCB1 and ABCB11 genes can help in better personalized medicine for maximizing response for ribavirin as explored by the significant association between polymorphism in ABCB1 and ABCB11 genes and ribavirin pharmacokinetics and the significant association of ABCB11 1331 T > C SNP with clinical response. Ribavirin 227-236 ATP binding cassette subfamily B member 11 Homo sapiens 210-216 31810127-9 2020 CONCLUSION: SNP genotyping for ABCB1 and ABCB11 genes can help in better personalized medicine for maximizing response for ribavirin as explored by the significant association between polymorphism in ABCB1 and ABCB11 genes and ribavirin pharmacokinetics and the significant association of ABCB11 1331 T > C SNP with clinical response. Ribavirin 227-236 ATP binding cassette subfamily B member 11 Homo sapiens 210-216 31602234-1 2019 Sustained virological response (SVR) in hepatitis C virus (HCV) patients treated with pegylated interferon alpha-2a and ribavirin is associated with reduced insulin resistance (IR), measured as a reduction of homeostasis model assessment (HOMA) scores after 24 weeks of therapy, and reduced fasting serum insulin and serum glucose levels. Ribavirin 120-129 insulin Homo sapiens 157-164 32129203-4 2020 Ribavirin monotherapy was given in most (n = 6) patients and was accompanied by erythropoietin therapy in all. Ribavirin 0-9 erythropoietin Homo sapiens 80-94 31520644-0 2019 Quantification of ENT1 and ENT2 Proteins at the Placental Barrier and Contribution of These Transporters to Ribavirin Uptake. Ribavirin 108-117 solute carrier family 29 member 1 Rattus norvegicus 18-22 31520644-8 2019 In conclusion, ENT1 protein expressed in placental MVMs appears to play a predominant role in the uptake of ribavirin. Ribavirin 108-117 solute carrier family 29 member 1 Rattus norvegicus 15-19 32749108-6 2020 We find that IL28B variants rs8099917 and rs12979860 strongly influence results of combined pegylated (PEG)-IFN/ribavirin (RBV) therapy. Ribavirin 123-126 interferon lambda 3 Homo sapiens 13-18 31355968-0 2019 Retreatment with elbasvir, grazoprevir, sofosbuvir +- ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse. Ribavirin 54-63 beta-1,4-galactosyltransferase 1 Homo sapiens 89-92 31602234-1 2019 Sustained virological response (SVR) in hepatitis C virus (HCV) patients treated with pegylated interferon alpha-2a and ribavirin is associated with reduced insulin resistance (IR), measured as a reduction of homeostasis model assessment (HOMA) scores after 24 weeks of therapy, and reduced fasting serum insulin and serum glucose levels. Ribavirin 120-129 insulin Homo sapiens 305-312 31337707-8 2019 Inhibition of IMPDH2 activity with ribavirin favors ANKRD9 binding to IMPDH2 rods. Ribavirin 35-44 inosine monophosphate dehydrogenase 2 Homo sapiens 14-20 31640596-3 2019 However, the current standard of care (SOC) in Botswana remains PEGylated interferon-alpha (IFN-alpha) with ribavirin. Ribavirin 108-117 interferon alpha 1 Homo sapiens 92-101 31357056-5 2019 In this trial, LF associated mortality is reduced for patients with elevated aspartate aminotransferase (AST) when treated with ribavirin (OR 0.41, 95% CI 0.23-0.73), while mortality is higher for patients without elevated AST (OR 2.37, 95% CI 1.07-5.25). Ribavirin 128-137 solute carrier family 17 member 5 Homo sapiens 77-103 31357056-5 2019 In this trial, LF associated mortality is reduced for patients with elevated aspartate aminotransferase (AST) when treated with ribavirin (OR 0.41, 95% CI 0.23-0.73), while mortality is higher for patients without elevated AST (OR 2.37, 95% CI 1.07-5.25). Ribavirin 128-137 solute carrier family 17 member 5 Homo sapiens 105-108 31357056-5 2019 In this trial, LF associated mortality is reduced for patients with elevated aspartate aminotransferase (AST) when treated with ribavirin (OR 0.41, 95% CI 0.23-0.73), while mortality is higher for patients without elevated AST (OR 2.37, 95% CI 1.07-5.25). Ribavirin 128-137 solute carrier family 17 member 5 Homo sapiens 223-226 31337707-8 2019 Inhibition of IMPDH2 activity with ribavirin favors ANKRD9 binding to IMPDH2 rods. Ribavirin 35-44 ankyrin repeat domain 9 Homo sapiens 52-58 31337707-8 2019 Inhibition of IMPDH2 activity with ribavirin favors ANKRD9 binding to IMPDH2 rods. Ribavirin 35-44 inosine monophosphate dehydrogenase 2 Homo sapiens 70-76 31484073-3 2019 Here, we find that ribavirin induces spermidine-spermine N1-acetyltransferase (SAT1), a polyamine catabolic enzyme. Ribavirin 19-28 spermidine/spermine N1-acetyltransferase 1 Homo sapiens 79-83 31636735-7 2019 Notably, an obvious elevation of serum GP73 was observed after patients received PEG-IFN and ribavirin treatment. Ribavirin 93-102 golgi membrane protein 1 Homo sapiens 39-43 31484073-6 2019 We show ribavirin depletes polyamines via SAT1, in conjunction with its known mechanisms. Ribavirin 8-17 spermidine/spermine N1-acetyltransferase 1 Homo sapiens 42-46 31484073-8 2019 Inhibition of SAT1 activity, pharmacologically or genetically, reduces ribavirin"s effectiveness against three virus infection models. Ribavirin 71-80 spermidine/spermine N1-acetyltransferase 1 Homo sapiens 14-18 31322273-1 2019 Ribavirin exhibits inhibitory effects on the epigenetic enzyme enhancer of zeste homolog 2 (EZH2), which participates in lymphomagenesis. Ribavirin 0-9 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 63-90 31322273-1 2019 Ribavirin exhibits inhibitory effects on the epigenetic enzyme enhancer of zeste homolog 2 (EZH2), which participates in lymphomagenesis. Ribavirin 0-9 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 92-96 31322273-6 2019 The transcriptional effects of ribavirin on Hut78 cells were analyzed by microarray expression and the results were validated by reverse transcription-quantitative polymerase chain reaction, western blotting and knockout of signal transducer and activator of transcription 1 (STAT1). Ribavirin 31-40 signal transducer and activator of transcription 1 Homo sapiens 224-274 31322273-6 2019 The transcriptional effects of ribavirin on Hut78 cells were analyzed by microarray expression and the results were validated by reverse transcription-quantitative polymerase chain reaction, western blotting and knockout of signal transducer and activator of transcription 1 (STAT1). Ribavirin 31-40 signal transducer and activator of transcription 1 Homo sapiens 276-281 31322273-11 2019 Depletion of STAT1, which was proposed as a key regulator of the aforementioned pathways, exerted growth inhibitory effects almost to the same extent as ribavirin. Ribavirin 153-162 signal transducer and activator of transcription 1 Homo sapiens 13-18 31404089-9 2019 CONCLUSIONS: Tracking HGB or TBP can be treated as equivalent for the purpose of estimating RBV changes during HD. Ribavirin 92-95 TATA-box binding protein Homo sapiens 29-32 31485460-6 2019 Pretreatment CXCL10 levels are predictive of early virological response and sustained virological response (SVR) to IFN-alpha and ribavirin and may be useful in the evaluation of candidates for therapy. Ribavirin 130-139 C-X-C motif chemokine ligand 10 Homo sapiens 13-19